-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

###### A “SHOT” HEARD
##### AROUND THE WORLD

###### 6Va\^

 4


-----

###### INTRODUCTION

 “A Shot Heard Around the World,” is a compilation of almost 500 references with citations predominately coming from original sources, scientific journals, medical journals, peer reviewed studies, lawsuit filings, original letters, and includes direct links to the CDC, FDA, clinical trials, and manufacturers’ own reports. In some categories, experts are warning there may be devastating problems with the mass inoculation policies. Because children are likely to be the next group authorized under the EUA, this stands as a warning to parents to be informed in your decision. It is extremely concerning for children to be next on the list in mass inoculation. For all medical decisions, informed consent is critical.

 Let this compilation of hundreds of links, sources, and references, serve as a summary and launching pad for everyone’s own thorough investigation and research into the covid injections. Regardless, if someone has gotten one shot, two, or none, this information matters for all. In a time where information is being deleted, censored, banned, canceled, and withheld, many do not know where to find information to answer their questions. This summary is an essential resource. This can be shared with elected officials, school officials, employers, and others.

 As an organization who watches over issues affecting children, we are greatly concerned. The heart of this project is driven by the sole purpose to share important, even critical information with family, friends, and loved ones. Many of them do not know. The goal is to provide original source information from sources those searching, would see as credible and have a resource all in one place. The ultimate goal is not to tell any one person what to think, but instead allow them to think for themselves.

 A “SHOT” heard around the world is symbolic for a historic global moment. A careful evaluation may give credence to the thousands of experts who have been censored, removed from online, targeted with removal of their licenses, as they lay it all on the line to get this information to the public. May we hear the “SHOT heard around the word” before our children are unnecessarily harmed.

**_***Medical_** **_disclaimer:_** _This_ _pdf,_ _information,_ _resource_ _list,_ _and_ _website_ _information_ _was_ _createdfor_
_informational_ _purposes_ _only_ _and_ _has_ _no_ _ties_ _to_ _any_ _drug_ _company_ _or_ _physician._ _The_ _content_ _is_ _not_ _intended_
_to_ _be_ _a_ _substitutefor_ _professional_ _medical_ _advice,_ _diagnosis,_ _or_ _treatment._ _Always_ _seek_ _the_ _advice_ _ofyour_
_physician_ _or_ _other_ _qualified_ _health_ _provider_ _with_ _any_ _questionsyou_ _may_ _have_ _regarding_ _a_ _medical_
_condition._ _Never_ _disregard_ _professional_ _medical_ _advice_ _or_ _delay_ _in_ _seeking_ _it_ _because_ _ofsomethingyou_ _have_
_read_ _on_ _this_ _website._ _In_ _addition,_ _no_ _one_ _involved_ _in_ _this_ _website_ _hasfinancial_ _ties_ _to_ _any_ _ofthe_ _suggested_
_therapies._ _We_ _are_ _merely_ _advocates_ _ofinformed_ _consent,_ _open_ _dialogue_ _on_ _all_ _sides_ _ofan_ _issue,_ _andfight_
_medical_ _censorship.***_

Copyright and intellectual property of Protection of the Educational Rights of Kids 2

[www.perk-group.com](http://www.perk-group.com)


-----

Copyright and intellectual property of Protection of the Educational Rights of Kids 3

[www.perk-group.com](http://www.perk-group.com)


-----

###### TABLE OF CONTENTS

**OPERATING** **UNDER** **EMERGENCY** **USE** **AUTHORIZATION** **6**

**FULL** **LICENSURE** **EXPECTED** **IN** **2022** **6**

**PREVIOUS** **APPROVAL** **PROBLEMS** **6**

**INJURY** **STORIES** **HERE** **7**

**UNDERREPORTING** **INJURIES** **8**

**LIABILITY** **REMOVED** **FROM** **COVID** **MANUFACTURES** **10**

**FAILURE** **IN** **PREVIOUS** **ANIMAL** **STUDIES** **11**

**ENHANCED** **IMMUNE** **RESPONSE** **(PATHOGENIC** **PRIMING,** **ALSO** **CALLED** **CYTOKINE** **STORM)**
**13**

**BLOOD** **CLOTS** **&** **HEART** **INFLAMMATION** **14**

**TOXICITY** **OVERLOAD,** **INSTABILITY** **IN** **THE** **BODY** **15**

**INCREASE** **IN** **AUTOIMMUNE** **DISEASES** **&** **CONTAMINANTS** **IN** **VACCINES** **14**

**HIV** **VECTOR** **INCREASE** **IN** **AIDS** **SUSCEPTIBILITY** **IN** **MEN** **15**

**SAFETY** **AND** **EFFECTIVENESS** **QUESTIONS** **AND** **CONCERNS** **15**

**TWO** **MONTHS** **OF** **IMMUNITY** **FROM** **SHOT** **16**

**UNKNOWNS:** **MUTATIONS,** **CO-INFECTION,** **TRANSMISSION,** **LONG-TERM** **EFFECT,** **STOPPING**
**DEATH** **16**

**WARNING:** **RED** **FLAGS** **INNOCULATING** **PEOPLE** **WHO** **ALREADY** **HAD** **COVID** **17**

**HEAVIER** **PERIODS** **IN** **WOMEN** **18**

**ABNORMAL** **PHENOMENON** **ALARMING** **WOMEN** **18**

**FERTILITY,** **BREAST** **FEEDING,** **PREGNANCY** **19**

**CONCERNS** **REGARDING** **THE** **FORMATION** **OF** **THE** **PLACENTA** **19**

**LOWER** **SPERM** **COUNT** **20**

**PFIZER** **CLINICAL** **TRIAL-** **DEFECTIVE** **DESIGN** **CLAIM** **20**

**GENEVA** **ETHICIST** **SOUND** **THE** **ALARM** **ABOUT** **THE** **MRNA** **22**

**GENETICALLY** **ENGINEERED** **RNA** **OR** **DNA,** **SEQUENCING** **IDENTIFIED** **22**

**LIPID** **MODEL** **PREVIOUSLY** **PROBLEMATIC** **24**

Copyright and intellectual property of Protection of the Educational Rights of Kids 4

[www.perk-group.com](http://www.perk-group.com)


-----

**LIPID** **MODEL** **RISKS** **25**

**PEG** **ANAPHYLACTIC** **REACTIONS** **25**

**ANTI-PEG** **ANTIBODIES** **25**

**IMMUNE** **ESCAPE,** **VIRAL** **VARIANTS** **26**

**VACCINE** **RESISTANT** **VIRUS** **27**

**LOSS** **OF** **INNATE** **IMMUNE** **SYSTEM** **28**

**WARNING** **FROM** **EXPERTS** **AROUND** **THE** **GLOBE** **29**

**FULLY** **VACCINATED** **BREAK** **OUTS** **32**

**PREVIOUS** **CRIMINAL** **HISTORY** **AND** **BEHAVIOR** **33**

**40** **BILLION** **IN** **PROFITS** **35**

**NOTEWORTHY** **LEGAL** **CASES** **36**

**REPORT** **SUBMITTED** **TO** **ISRAEL** **ATTORNEY** **GENERAL** **37**

**IVERMECTIN** **TREATMENT** **TESTIMONIES** **GIVEN** **TO** **HOMELAND** **SECURITY** **38**

**ADDENDUM** **1:** **DANGER** **INGREDIENT** **SM-102,** **MODERNA** **PATENT,** **SPIKE** **PROTEIN**
**INJURY,** **PRION'S** **DISEASES,** **AND** **DARPA** **(DEPARTMENT** **OF** **DEFENSE** **PROGRAM**
**FOCUSED** **ON** **BIOTECH** **40**

**CONCLUSION** **51**

**ADDITIONAL** **RESOURCE** **LINKS** **52**

Copyright and intellectual property of Protection of the Educational Rights of Kids 5

[www.perk-group.com](http://www.perk-group.com)


-----

###### OPERATING UNDER EMERGENCY USE AUTHORIZATION
Currently, no covid shots are approved or licensed, including Moderna, Pfizer, Johnson and Johnson,
AstraZeneca, and 70+ others. Current ones in use are under EUA: Emergency Use Authorization and have
specific conditions to adhere to under EUA.

**Moderna:** On December 18, 2020, the Moderna biological product was issued (EUA) status by the FDA.
Tills is the first product they have ever brought to market, (the FD&C Act or the Act) (21 U.S.C. 360bbb-
3). [https://www.fda.gov/media/144636/download](https://www.fda.gov/media/144636/download) Page 1 https://www.modernatx.com/covidl9vaccine-
###### eua/recipients/

**Pfizer:** On December 11, 2020, FDA issued an EUA for the unapproved **biological** product, Pfizer-
BioNTech COVID-19 Vaccine, for active immunization against COVID-19 in individuals 16 years of age and
older. (Pfizer fact sheet)
###### https://www.fda.gov/media/144412/download https://www.fda.gov/media/144413/download Page 1 https://www.fda.gov/media/144413/download?fbclid=IwAR00a48tUcKo-
owxjGKeTk7y SOjeryewJEZAVvBLv-3RYIlpnTLQFY5WtO

**Johnson** **and** **Johnson:** Although J&J has never brought a vaccine to market before, on February 27, 2021,
the FDA issued and Emergency Use Authorization for use ofJohnson and Johnson single dose vaccine.
###### https://www.fda.gov/media/146303/download https://www.fda.gov/media/146304/download https://www.fda.gov/media/146305/download

 FULL LICENSURE EXPECTED IN 2022
Currently, under EUA (Emergency Use Authorization), even if the FDA rushes approval the soonest the
Moderna and Pfizer/BioNTech experimental vaccines could be considered by FDA for full licensure (in
adults only) is when the trials are expected to conclude, on October 27, 2022 and January 31, 2023,
respectively. Neither Pfizer/BioNTech nor Moderna have completely disclosed everything in their vaccines,
nor is full disclosure required by the FDA. [22] See e.g., _Ijmllard_ _Tobacco_ _Co._ _v._ _Reilly,_ 533 U.S. 525, 570-71
(2001)

###### PREVIOUS APPROVAL PROBLEMS
Previously from Moderna,"No mRNA drug has been approved in this new potential category of medicines,
and may never be approved as a result of efforts by others or us. mRNA drug development has substantial
clinical development and regulatory risks due to the novel and unprecedented nature of this new category of
medicines." [https://www.statnews.com/2017/01](https://www.statnews.com/2017/01_/10/moderna-trouble-mrna/) /10/moderna-trouble-mrna/

“As a potential new category of medicines, no mRNA medicines have been approved to date by the FDA or
other regulators. Adverse events in clinical trials of our investigational medicines or in clinical trials of others
developing similar products and the resulting publicity, as well as any other adverse events in the field of
mRNA medicine, or other products that are perceived to be similar to mRNA medicines, such as those
related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of
our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in
our investigational medicines, and less demand for any product that we may develop. Our large pipeline of
development candidates and investigational medicines could result in a greater quantity of reportable adverse
###### events...”
[https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

Copyright and intellectual property of Protection of the Educational Rights of Kids 6

[www.perk-group.com](http://www.perk-group.com)


-----

###### BIOLOGICS APPLICATION REQUIRED

Currently, Pfizer, Moderna, J&J are under EUA. They are not FDA approved, nor licensed. J&J was just
paused in the US due to serious blood clotting reactions, but then reinstated after short condiseration. They
are required to apply for a biologic application for full approval. **“Some** **of** **our** **investigational** **medicines**
**are** **classified** **as** **gene** **therapies** **by** **the** **FDA** **and** **the** **EMA,** **and** **the** **FDA** **has** **indicated** **that** **our**
###### investigational medicines will be reviewed within its Center for Biologies Evaluation and Research,
**or** **CBER.”**
https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-
applications-bla-process-cber
https: / [/www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021-fda](https:_/_/_www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021_-fda)
###### https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473 6
**(Pg.26-27)**

###### EUA ONSITE VISITS NOT REQUIRED, ONLY 2 MONTHS OF DATA REQUIRED
FDA does NOT have to do an onsite visit to the vaccine manufacturing facility before approval of the
EUA. Also, it states that only 4 months of EUA may be required before full approval is given. Before
emergency approval, FDA required only two month’s of safety data.
[https://www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021-fda](https://www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021-fda)

###### SAFETY DATA ANAYLZED AFTER 100 MILLION DOSES- MAY NOT BE IN PLACE UNTIL AFTER LICENSURE
Currently, a passive reporting system through the CDC called VAERS is in place to monitor adverse events.
There are indications the system is overwhelmed with injury reports, backlogged, and not updated. It is not
live, reporting and monitoring of adverse reactions. An active monitoring of adverse reactions/events will
###### NOT be in place until AFTER licensure of products, AFTER approval, and likely after 100 million-1- people
have already received the doses. “In interviews, F.D.A. officials acknowledged that a promised monitoring
system, known as BEST, is still in its developmental stages. They expect it to start analyzing vaccine safety
data sometime _soon_ _—_ but likely not until _after_ the Biden administration reaches its goal of vaccinating _100_
_millionpeopled_
###### In other words, there is NOT a system in place now to accurately capture the adverse reactions. 22 Side
Effects listed in FDA documents. “Following authorization of the vaccine, use in large numbers of
individuals may reveal additional, potentially less frequent and/or more serious adverse events not detected in
the trial safety population”
[https://www.fda.gov/media/143557/download?fbclid=IwARlUxM](https://www.fda.gov/media/143557/download?fbc) ZwbMfzLFbFCMci DbUOfq-
fqylLJIEwxHpGkLTqN8kzl AaGx-hO8 (p. 8, 9)

https: [//www.openvaers.com/covid-data](https:_/_/_www.openvaers.com/covid-data)
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)
###### https:/ /www.nytimes.com/2021 /02/12/health/covid-vaccine-how-safe.html

 INJURY STORIES HERE
Evidence of Backlogging on reporting injuries to VAERS

US VAERS 5/21 262,521 (likely higher due to VAERS ID numbers skyrocketing)

###### UK Yellow Card 5/12 869,764 (suspected reactions)

Sweden 4/15 22,000

Israel 3/21 See report

*Note most people, including health care practitioners do not know about VAERS in the US. See note on

Harvard evaluation of VAERS passive reporting system.
https: / [/drive.google.com/file/d/luS4krGJX-7sa8fuRlH7mhod-Xa5ZBsXU/view](https:_/_/_drive.google.com/file/d/luS4krGJX-7sa8fuRlH7mhod-Xa5ZBsXU_/_view)
http: / [/covidvaccinevictims.com/](http:_/_/_covidvaccinevictims.com/)

Copyright and intellectual property of Protection of the Educational Rights of Kids 7

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.openvaers.com/covid-data https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-
reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
###### https:/ /raysahelian.com/covidvaccinesideeffects.html

**“EXPECTED** **HIGH** **VOLUME** **OF** **COVID-19** **VACCINE** **ADVERSE** **DRUG** **REACTION”**
###### UK-The MHRA contracted out an (AI) software tool to process the “expected high volume of Covid-19
vaccine Adverse Drug Reaction (ADRs).” 300,000 + Yellow Card Reported Injuries. (Pfizer, Moderna,
AstraZeneca) **UK** **yellow** **cards** **reporting** **hundreds** **of** **thousand** **injuries** **below.**
[https://ted.europa.eu/udl?uri=TED:NQTICE:506291-2020:TEXT:EN:HTML&src=0](https://ted.europa.eu/udl?uri=TED:NQTICE:506291-2020:TEXT:EN:HTML&src=0)
**https:** **/** **[/www.gov.uk/government/publications](https:_/_/_www.gov.uk/government/_publications_/_coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting)** **/coronavirus-covid-19-vaccine-adverse-**
**reactions/coronavirus-vaccine-summary-of-yellow-card-reporting**

###### EVIDENCE OF BACKLOGGING ON REPORTING INJURIES TO VAERS
Previous capacity of VAERS reporting system handled a few reported deaths a week and a few thousand a
month. Currently, VAERS ID (unique identification numbers) have skyrocketed from December to now.
Possibility of Hundreds of Thousand Adverse reactions in the US. Indicating 200,000 more injuries. GDIT
posted positions to hire additional staff and professionals to report and code VAERS injury reporting. On
March 8, CDC gave GD a budget supplement of SI 6 million; GD is now hiring more “service
representatives” to take reports and medical coders to review them... (Search job posting General Dynamics,
which manages VAERS)
###### https://twitter.com/alexberenson/status/1376280404513161227?s=21

**GOALS** **OF** **MANUFACTURERS** **TO** **GIVE** **THE** **MRNA** **VAX** **TO** **6** **MONTH** **OLD** **BABIES**
Beginning trials on 6month-12 year old’s now. https: / /www.statnews.com/2021 /03 /25/pfizer-and-biontech-
to-begin-testing-covid-19-vaccine-in-children/

**SEE** **REAL** **TIME,** **LIVE** **ADVERSE** **EVENTS** **HAPPENING** **HERE:**
(In the social media era, Put the link to injuries, real time, social media) **(100+** **PAGES** of live injury stories
have been removed twice from internet access.)
http: / [/covidvaccinevictims.com/](http:_/_/_covidvaccinevictims.com/)
###### https://drive.google.eom/file/d/lYKOJR lFy88Zu3rcC3L5NvL Xr3ib6z¥/view (Removed from Online)
**https:** **/** **[/www.openvaers.com/covid-data](https:_/_/_www.openvaers.com/covid-data)**

###### UNDERREPORTING INJURIES
VAERS Underreporting. Disputes 1 in a Million claims. Recent JAMA reports injuries 50-120 Times more
than VAERS and CDC reporting: 2.47/per 10,000 anaphylaxis reaction. Long discussed, but ignored, we
need to reform the reporting system as it may hinder identifying safety issues with the new vaccines.
Documented insufficient system post surveillance, 30+decades of underreporting issues (See Lazuraus
Harvard Report pg. 6), VAERS system inefficacies; public officials continue to promote the inaccurate
statement that “injuries are rare.” Red flags are emerging even without a real time reporting system in place.
https: / / j amanetwork. com /j ournals/jama/fullarticle/2777417
###### https:/ /digital.ahrq.gov/sites/default/tiles/docs/publication/rl 8hs017045-lazarus-tinal-report-2011 .pdf https://wvw.icandecide.org/wp-content/uploads/2020/12/Lazarus-report.pdf

**PHARMACO-VIGILANCE** **TRACKING** **SYSTEM**
Where is the data? The Department of Defense of the federal government has contracted with tech giants,
Google and Oracle to track vaccinated persons. In the document entided “From the Factory to the
Frontlines,” the Department of Health and Human Services (HHS) and the Department of Defense (DOD)
stated that, because Warp Speed vaccine candidates use new unlicensed technology, “The key objective... is
to determine each vaccine’s performance in real-life scenarios, to study efficacy, and to discover any

Copyright and intellectual property of Protection of the Educational Rights of Kids g

[www.perk-group.com](http://www.perk-group.com)


-----

infrequent and rare side effects not identified in clinical trials.. .Robust analytical tools will be used to leverage
large amounts of data and the benefits of using such data across the value chain, including regulatory
obligations.” Where are the real-life studies and reporting? All we have seen is VAERS backlogged reporting
system.
https: / /www.thelastamericanvagabond.com/google-oracle-monitor-americans-who-get-warp-speeds-
COVID-19-vaccine-for-two-years/

**INVESTIGATION** **OF** **ELDERLY** **DEATHS**
**Blood** **clots** **aren’t** **the** **only** **problem.** **Countries** **investigating** **elderly** **deaths** **after** **inoculation.**
Countries around the world and different states are investigating and pausing the administration of the
COVID vaccine, particularly to the elderly. Quick snapshot-

Norway (investigating 33+ deaths in elderly after getting vaccine)
Germany (investigating deaths after the vaccine)
China (at one point completely paused the vaccine for elderly)
###### UK (for a while paused on second dose after so many anaphylactic reactions)
Israel (see data on injuries)
Australia (health minister considering pause)
CA (about a month ago said there is a "hot batch" and are pausing 330,000 vials)
https: / [/www.theepochtimes.com/deaths-of-elderly-who-recovered-from-covid-19-but-died-after-vaccine-](http://www.theepochtimes.com/deaths-of-elderly-who-recovered-from-covid-19-but-died-aft)
raise-questions 3692259.html?utm source=newsnoe&utm medium=email&utm campaign=breaking-2021-
02-10-4

###### PRESCREENING REQUIREMENT
Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should
not receive the shot. A COVID-19 prevaccination questionnaire pdf icon[6 pages] is available to assist with
screening. CDC [https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf](https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf)
https: / [/www.cdc.gov/vaccines/covid-19](http://www.cdc.gov/vaccines/covid-19) /clinical-considerations/managing-anaphylaxis.html

**ALL** **VACCINES** **USED** **IN** **ISRAEL** **ARE** **FROM** **PFIZER:** **ISRAEL** **INJURY** **ANYALYSIS**
###### Dr Herve Seligmann works at the Emerging Infectious and Tropical Diseases Research Unit, Faculty of
Medicine, Aix-Marseille University, Marseille, France. He is of Israeli-Luxembourg nationality. He has a B. Sc.
###### In Biology from the Hebrew University ofJerusalem and has written over 100 scientific publications. Dr.
Herve Seligmann and engineer Haim Yativ through their research and data analysis claim that Pfizer's
experimental shot causes "mortality hundreds of times greater in young people compared to mortality from
coronavirus without the vaccine, and dozens of times more in the elderly, when the documented mortality
from coronavirus is in the vicinity of the vaccine dose, thus adding greater mortality from heart attack, stroke,
etc."

“Our analyses indicate orders of **magnitude** **increases** **in** **deaths** **rates** during the 5-week long vaccination
process, as compared to the unvaccinated and those after completing the vaccination process.”
"The data in the table, rather than indicating the vaccine efficacy, indicate the vaccine's adverse effects," the
authors conclude. There is a mismatch between the data published by the authorities and the reality on the
ground. Compared to other years, mortality is 40 times higher.” An independent legal body that calls itself
the Civilian Probe (CP)* published its finding regarding the catastrophic impact of the Pfizer vaccine on the
nation.
###### https:/ /archive.ph/jilVR https:/ / staticl. squarespace. Com/static/544680b5e4b0149c3cfddd3b/t/6059e7669fb7f95bb994f934/l616504
728303/%D7%9E0/oD70/o9B0/oD7%AA%D70/o91+%D7%AA%D7%950/oD70/oA4%D7%A2%D7%950/oD7

0/oAA+0/oD70/o940/oD70/o9C0/oD70/o950/oD70/o950/oD70/o900/oD70/o99+0/oD70/oA00/oD70/o950/oD70/oAl0/oD7%97
###### +o/oD7o/oAlo/oD7o/o95o/oD7o/oA4o/oD7o/o99+o/oD7o/o9Co/oD7o/o94o/oD7o/oA4o/oD7o/oA6o/oD7%94+-+22-3-
21.pdf

Copyright and intellectual property of Protection of the Educational Rights of Kids **9**

[www.perk-group.com](http://www.perk-group.com)


-----

###### ASTRAZENECA SAFETY SIGNALS IGNORED, NOT INCLUDED IN ADVERSE REACTION REPORTING
The AstraZeneca brand primarily being used in Europe and other countries was put on HOLD by up to 24
countries. WHY? In spite of the PR team for the manufacturing company saying it was safe and effective, the
results showed a different story. On March 16, 2021, Luxembourg, Estonia, Lithuania, were 3 more
countries added to the halt list. Other countries include Sweden, Norway, Denmark, Finland, and France
(who limit shots to 55 year old’s and above.) Safety concerns over AstraZeneca creating blood clots notable
in women 25 and under. The UK has not paused it but has stated if you have a headache continually for four
days post vaccination, they tell you to go get help. AstraZeneca is going to Africa and 92 other third world
countries by the end of 2021. Under the umbrella of COVA X, who partners with WHO, GAVI, at least 29
million doses are in Italy waiting for shipment. Despite safety warnings, the United States is gearing up to
authorize EUA status for the US. Even though officials have begun calling out AstraZeneca’s misleading
effective rate because they are using OLD data.

###### LIABII TY REMOVED FROM COVID MANUFACTURERS
The public has become increasingly aware that manufacturers of vaccines have not been liable for their
products since 1986 and that our very own tax dollars pay for our own injuries. On February 4, 2020,
according to the Centers for Disease Control (CDC) website, there were only 11 active CV cases, Yet the
U.S. quiedy pushed through Federal regulations giving coronavirus vaccine makers full immunity from
liability. Although, these are new, investigational, and long-term consequences unknown, ALL manufacturers
have indemnity. They are not liable for any harm, adverse reactions, death, etc. short-term or long-term.
###### https:/ /www.cnbc.com/2020/12/16/covid-vaccine-side-effects-compensation-lawsuit.html

 NO LIABILITY DUE TO THE PREP ACT
The PREP Act allows covid vaccine manufacturers to create, develop, and market vaccine^wd^er^iabiliE.
Manufacturers have been allowed to bypass animal studies and go directly to human trialMW^'Cf'i-’v        -

###### https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx

**EXPIRATION** **END** **OF** **2024,** **BEYOND** **LIABILITY**
This was put into the Federal Register in March of 2020 and “does not expire till the end of 2024. The
consequences surpass liability. It also means that anything, that is developed over the next four years that has
to do with a biological agent, such as a vaccine or drug or biotechnology, is protected from liability under the
umbrella of COVID-19.”
Federal Register :: Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act
for Medical Countermeasures Against COVID-19

###### BEFORE LIABILITY REMOVED LOSSES FOR MANUFACTURES
“We have incurred significant losses since our inception and anticipate that we will continue to incur
significant losses for the foreseeable future.” “Risks related to the research, development, regulatory review,
and approval of our existing and future pipeline.” “Preclinical development is lengthy and uncertain,
especially for a new category of medicines such as mRNA, and therefore our preclinical programs or
development candidates may be delayed, terminated, or may never advance to the clinic” “Clinical testing is
expensive and complex and can take many years to complete, and its outcome is inherently uncertain.”
pg. 24 (Moderna 2018 Report^

[https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

Copyright and intellectual property of Protection of the Educational Rights of Kids 10

[www.perk-group.com](http://www.perk-group.com)


-----

[https://-www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://-www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

###### COUNTERMEASURES INJURY COMPENSATION
The Countermeasures Injury Compensation Program (CICP) is a federal program [taxpayer funded] that has
been created to help pay for related costs of medical care and other specific expenses to compensate people
injured after use of certain medical countermeasures. Medical countermeasures are specific vaccines,
medications, devices, or other items used to prevent, diagnose, or treat the public during a public health
emergency or a security threat.
###### https://www.fda.gov/media/144434/download https://www.clinicaltrials.gov/ct2/show/study/NCT04665258:

 ANIMAL STUDIES BYPASSED
These inoculations bypassed animal studies. Previously, for decades, they were not able to pass the animal
studies due to pathogenic priming, cytokine storms, enhanced antibody dependence, and the inability to
survive (in one ferret study, all of the ferrets died in the challenge phase) after vaccination when exposed to
the wild virus (because of an altered immune system response.) Ferrets pg 17-18. Note the challenge results
in the previous animal trials, including accelerated autoimmune issues.
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335Q60/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335Q60/)
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115540/ (ferrets)
[https://www.jstage.jst.go.jp/article/jvms/advpub/O/advpub](https://www.jstage.jst.go.jp/article/jvms/advpub/O/advpub_18-0702/_pdf) 18-0702/ pdf
###### https:/ /jvi.asm.org/content/jvi/87/12/6551 .full,pdf
https: / /pubs.acs.org/doi/full/10.1021 /acsinfecdis.6b00006
###### https://www.sciencedirect.com/science/article/pii/Sl090023314001786
https: / [/www.ncbi.nlm.nih.gov/pmc/articles/PMC7115629/](https:_/_/_www.ncbi.nlm.nih.gov/pmc/articles/PMC7115629/)
https: / /jvi.asm.org/content/jvi/85 /23 /12201 .full.pdf

###### FAILURE IN PREVIOUS ANIMAL STUDIES
Previously, coronavirus trials failed in animals. When animal trials were skipped in 1960, infants post
vaccination got sicker when exposed to wild virus, including **80%** **of** **the** **vaccinated** **infants** **requiring**
**hospitalization.** Review of previous trial outcomes. Caution due to disease enhancement, sicker, death, and
lung diseases post vaccination in Ferrets, mice, civets, and other animals.

“the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly
given that each component of our investigational medicines and development candidates, may have a
dependent or independent effect on safety, tolerability, and efficacy, which may, among other tilings, be
species-dependent”
###### https://www.nature.com/articles/s41579-020-00462-y#Secll https:/ /www.frontiersin.org/articles/10.3389/fmicb.2018.02991 /full https://www.ncbinlm.nih.gov/pmc/articles/PMC525089/
https: / [/www.nature.com/news/2005](http://www.nature.com/news/2005) /050110/full/050110-3.html#ref-CRl
[https://www.sec.gOv/Arcliives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/Arcliives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6
###### https://www.pnas.Org/content/102/3/797 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/ https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1177688?scroll=top&needAccess=true& https://science, sciencemag.org/content/303/5660/944
https: / /www.reuters.com/article/us-rsv-shot/research-shows-why-1960s-rsv-shot-sickened-children-
idUSTRE4BM4SH200! 23
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/ https://pubmed.ncbi.nlm.nih.gov/12810865/ (ADE mice)
[https://www.ncbi.nlm.nih.gov/pubmed/28817732](https://www.ncbi.nlm.nih.gov/pubmed/28817732) (White rabbits)
###### https://pubmed.ncbi.nlni.nih.gov/19122397/ (feline)

Copyright and intellectual property of Protection of the Educational Rights of Kids | |

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://pubmed.ncbi.nlm.mh.gov/2154621 / (feline) https://pubmed.ncbi.nlm.nih.gov/6754243/ (feline in Dengue) https://pubmed.ncbi.nlm.nih.gov/17049691/ (hamsters)
[https://www.ncbi.nlm.nih.gov/pubmed/21937658](https://www.ncbi.nlm.nih.gov/pubmed/21937658) (Mice, increase lung inflammation on challenge)
###### https://pubmed.ncbi.nlm.nih.gov/29029938/ (vaccine enhanced disease)
Kusters IC, Matthews J, Saluzzo JF. Manufacturing vaccines for an emerging viral infection        - Specific issues
associated with the development of a prototype SAKS vaccine. In: Barrett ADT, Stanberry LR,
editors. Vaccines for biodefense and emerging and neglected diseases. City: Elsevier; 2009. pp. 147-156

###### NO INDI NTL ILISHED ANIMAL STUDIES FROM; TU IS

“Most other previous vaccines have performed and published results on animal studies prior to being giving
to humans. This is critical because deadly effects are often not seen until this step. Vaccines that have been
given to humans prior to animal trials have frequently resulted in deaths that caused the governments to yank
the vaccines. Most scientists believe that human death is inevitable if there are no prior peer-reviewed animal
studies. We learn about these studies only from the company itself.”
###### https:/ /www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-
preclinical-studies-mrna

[https://assets.website-files.com/606d3a50c62e44338008303d/6076e4fd8bde421370729e47](https://assets.website-files.com/606d3a50c62e44338008303d/6076e4fd8bde421370729e47) Vaccine-PP.pdf

###### Oi

 PROBLEM WITH DENGUE VIRUS, EBOLA VIRUS, HIV, RSV, AND THE FAMILY
**C** **COR** **)?** **U**
Virus amplification or enhancement of virus infection is a common problem in the coronavirus family. In
some viruses, if a person harbors a non-neutralizing antibody to the virus, a subsequent infection by the virus
can cause that person to elicit a more severe reaction to the virus due to the presence of the non-neutralizing
antibody. This is not true for all viruses, only particular ones. Tins is called Antibody Dependent
Enhancement (ADE), and is a common problem with Dengue Virus, Ebola Virus, HIV, RSV, and the family
###### of coronaviruses. The problem of ADE is a major reason why many previous vaccine trials for other
coronaviruses failed. Major safety concerns were observed in animal models. If ADE occurs in an individual,
their response to the virus can be worse than their response if they had never developed an antibody in the
first place.

“This can cause a hyperinflammatory response, a cytokine storm, and a general dysregulation of the immune
system that allows the virus to cause more damage to our lungs and other organs of our body. In addition,
new cell types throughout our body are now susceptible to viral infection due to the additional viral entry
pathway. There are many studies that demonstrate that ADE is a persistent problem with coronaviruses in
general, and in particular, with SARS-related viruses.”

###### https://pubmed.ncbi.nlm.nih.gov/24182427/
Antibody-dependent enhancement of virus infection and disease. Viral immunology, 16(1), 69-86.
https: / [/www.liebertpub.com/doi/abs](http://www.liebertpub.com/doi/abs) /10.1089 /088282403763635465

Copyright and intellectual property of Protection of the Educational Rights of Kids J 2

[www.perk-group.com](http://www.perk-group.com)


-----

"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications."
Reviews in medical virology 13, no. 6 (2003): 387-398.
###### https:/ /onlinelibrary.wiley.com/doi/abs/10.1002/rmv.405
Antibody-dependent SAKS coronavirus infection is mediated by antibodies against spike proteins.
Biochemical and biophysical research communications 451, no. 2 (2014): 208-214.
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092860/ https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=l075&context=vmpm pubs (Ebola) https://pubmed.ncbi.nlm.nih.gov/27339099/ (zika) https:/ /technology.inquirer.net/69907/pharma-firm-issues-caution-anti-dengue-vaccine-sanofi-dengvaxia-
vaccine-health-dengue (Pharma firm issues caution on use of anti-dengue)
###### https://pubmed.ncbi.nlm.nih.gov/30410732/
[https://www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018](https://www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018) (Dengue distrust
in free vaccines post scare of Dengue outcome.)
###### https:/ /www.telegraph.co.uk/news/2018/02/05/plulippines-immunisation-rates-plummet-amid-dengue-
vaccination/ (Philippines)

###### ADE (ANTIBODY ENHANCEMENT) MORE SEVERE DISEASE
ADE(Antibody enhancement is a very serious paradox. '1'lus could mean that people who are vaccinated
might, paradoxically, suffer more severe disease when exposed to the wild virus than if they hadn’t been
vaccinated. Direct from manufactures, “risk of vaccine-enhanced disease over time, potentially associated
with waning immunity, remains unknown and needs to be evaluated further.” The accurate incidence of ADE
may never be known, as many cases will likely just be falsely described as a “new strain,” “new variant,” or
“more severe strain” and new outbreaks attributed to those not vaccinated.
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311339/
https: / [/academic.oup.com/cid/article-abstract/19/3/500/459343](https:_/_/_academic.oup.com/cid/article-abstract/19/3/500/459343)
https: / [/academic.oup.com/cid/article-abstract/19/3/500/459343](https:_/_/_academic.oup.com/cid/article-abstract/19/3/500/459343)

###### ENHANCED IMMUNE RESPONSE (PATHOGENIC PRIMING, ALSO CALLED CYTOKINE STORM)
Outspoken vaccine advocate, Dr Peter Hotez previously warned of potentially fatal consequences from
skipping animal studies. “If there is immune enhancement in animals, that’s a show-stopper”. During the
past decade, previous Coronavirus vaccines DID NOT pass the animal trials. Prior to the Emergency Use
Authorization, Moderna was unable to bring to market through clinical trials an approved CV vaccine, despite
billions of dollars invested into it. The ferrets tested in previous coronavirus animal trials all DIED when
placed in a “challenge” round where they were exposed to the wild virus, after being vaccinated. ADE is

Copyright and intellectual property of Protection of the Educational Rights of Kids | 3

[www.perk-group.com](http://www.perk-group.com)


-----

unique because it is a delayed reaction. “It has mainly been observed with positive-strand RNA viruses.”
Initially everything seems tine with the person having a great immune response but then becomes deadly
when the person is exposed to the virus in the wild. The paradox is the inoculation is what AMPLIFIES the
infection, possibly within months or years. Tins is why it must be ruled out in animal trials. Unfortunately,
###### ADE is well known to be a risk for coronavirus-mediated infections, as well as dengue.
https: / [/www.liebertpub.com/doi/abs](http://www.liebertpub.com/doi/abs) /10.1089 /088282403763635465
###### https:/ /onlinelibrary.wiley.com/doi/abs/10.1002/rmv.405 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092860/
https: / /bmcproc.biomedcentral.com/track/pdf/10.1186/1753-6561 -5-S1          -
P62?site=http: //bmcproc.biomedcentral.com
###### https://europepmc.org/article/PMC/3837288 https://www.sciencedirect.com/science/article/pii/Sl074761319303334 https://muse.ihu.edu/article/459161/pdf https://ivi.asm.org/content/ivi/77/13/7539.full.pdf
Takada, Ayato, Shinji Watanabe, Katsunori Okazaki, Hiroslai Kida, and Yoshihiro Kawaoka. "Infectivity­
enhancing antibodies to Ebola virus glycoprotein." Journal of virology 75, no. 5 (2001): 2324-2330.
###### https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=l075&context=vmpm pubs

Journal of General Virology 97, no. 7 (2016): 1489-1499.

https: / /www.microbiologyresearch.org/docserver/fulltext/jgv/97/7/1489 vir000468.pdf?expires=l 591728
###### 632&id=id&accname=guest&checksum=5007EAF2DlFCFBElC2DD06ED7DlC8FFE

 BLOOD CLOTS
 J&J was just paused in the US (4/13/2021), resumed (4/23/2021) for this very reason. The UK and 23+
other countries are seeing strong indicators of blood clotting (particularly in younger women). So much so,
almost 24 countries at one point have paused the administration of the AstraZeneca vaccine, (while
simultaneously still authorizing it to be sent to 3rd world countries!)
###### https://www.researchgate.net/protile/Andreas Hocke/publication/6259977 Extracellular RNA Mediates
Endothelial Cell Permeability via Vascular Endothelial Growth Factor/links/00463523c326a4024e00000
O/Extracellular-RNA-Mediates-Endothelial-Cell-Permeability-via-Vascular-Endothelial-Growth-Factor.pdf
"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation."
###### https://www.pnas.org/content/pnas/104/15/6388. full.pdf

 HEART INFLAMMATION, HEADACHES, NEUROLOGICAL SYMPTOMS
A recent leaked report from the Israeli Health Ministry is investigating cases of “Myocarditis”, heart
inflammation in predominately men following their second dose of the Pfizer shot. In addition, a recent
peer-reviewed journal reported other side effects/symptoms after receiving the shot.
###### https://pubmed.ncbi.nlm.nih.gov/33053430/
https: / /www.health.com/condition/infectious-diseases/coronavirus/pfizer-vaccine-heart-inflammation-
myocarditis

###### POSSIBLE INCREASE ON AUTOIMMUNE DISEASES & CONTAMINANTS IN VACCINES

 AUTOIMMUNITY LINK, CONTAMINANTS IN VACCINES
Dr. Vanessa Schmidt-Kruger, a Cell Biologist with over 20 years’ experience in molecular medicine working
at the Max Delbriick Center for Molecular Medicine gave a report on contaminants in the vaccines (which is
in the EMA’s Open Assessment Report), problems in the dosage of clinical trials, risks of LPNS, and long­
term consequences of autoimmune disease.

Copyright and intellectual property of Protection of the Educational Rights of Kids 14

[www.perk-group.com](http://www.perk-group.com)


-----

“The BioNTech vaccine that is currently already being used is not highly purified, it contains contaminants of
certain components.. .And finally if we have time I would like to talk about the long-term consequences
relating to immune disease, that is an aspect that has not yet been discussed in public at all.”
###### http://enformtk.u-aizu.ac.jp/howard/gcep dr vanessa schmidt krueger/ https:/ /www.mdc-berlin.de/person/dr-vanessa-schmidt-kruger

Potential Autoimmunity increase. Do COVID-19 RNA-based vaccines put at risk of immune-mediated
diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a
possible link to an increase in autoimmune diseases.”
Clin Immunol. 2021 Mar; 224: 108665. Published online 2021 Jan 8. doi: 10.1016/j.clim.2021.108665
PMCID: PMC7833091, PMID: 33429060
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246018/

 TOXICITY OVERLOAD, INSTABILITY IN THE BODY Dr Suhab Siddiqi, Moderna’s Ex-Director of Chemistry, told CNN, “I would not let the [vaccine] be injected
in my body. I would demand: Where is the toxicity data?” Potential toxicity is a problem.

###### BNT 162 B2 study had 78% CLASS 3 adverse events. It was an anti-cancer study that all studies were quoting
as their "proof" that it was safe, despite that terrible result- of liver toxicity. The conclusion of the study was
"generally safe,” in spite of the study including terrible statistics as well as being a poorly powered study. In a
cancer immunotherapy study, before covid, lots of toxicities are noted-especially when synthetic nucleosides
are used. It’s particularly alarming that no blood is being drawn after a few months into the study. How will
they detect immunological dyscrasias, or liver toxicity if no blood is drawn for abnormalities? They are
testing antibody levels, but no longer a cbc, cmp or crp. after 60-80 days. Tins is likely a problem with a shot
###### that already has precedence for liver toxicity.

 HIV VECTOR INCREASE IN AIDS SUSCEPTIBILITY IN MEN
Liability free manufacturers claim DNA of a viral vector vaccine is carried within a harmless adenovirus.
Veteran researchers raise a warning flag that it may not be “harmless.” This is very concerning for men in
particular. 4 Veteran Researchers are raising a warning flag about COVID vaccines containing the Ad5 vector
carrier and the correlation leaving people more vulnerable to the AIDS virus. “Additional exploratory studies
suggest that Ad5 immune complexes activate the dendritic cell—T cell axis, which might enhance HIV-1
replication in CD4 T cells. Additionally, Ad5-specific CD4 T cells could have an increased susceptibility to
###### HIV infection.” These are important red flags and indicators to watch for.
**Lancet** **link:** https://w w u t [.thelancet.com/iournals/lancet/article/PIISOl40-6736(20)32156-](https://wwut.thelancet.com/iournals/lancet/article/PIISOl40-6736(20)32156-)
###### 5/fulltext?fbclid=IwAR3NknTJTMJgrLHqvK96hJqsi56nzH37QrzOuslJddmeDGetiSFpEOssiEU

**Another** **summary:** **[https://www.sciencemag.org/.../could-certain-covid-19](https://www.sciencemag.org/.../could-certain-covid-19)** **...**
###### https://www.cnn.com/2020/12/10/australia/australia-vaccine-hiv-mtl-hnk/index.html

 TY TESTING NOT PROPERLY DONE

**After** **decades** **of** **failed** **animal** **trials,** **current** **trials** **have** **been** **conducted** **without** **an** **inert** **double-**
**blind** **placebo-controlled** **environment,** **insufficient** **time** **to** **observe** **effects** **on** **the** **human** **subjects,**
**numerous** **unknowns,** **no** **long-term** **studies,** **lead** **to** **serious** **safety** **concerns.**

###### SAFETY AND EFFECTIVENESS QUESTIONS AND CONCERNS
“Vaccine safety requires proper animal trials and peer-reviewed data, neither of which has occurred during
operation warp speed. Tins is especially concerning considering the fatal failure of prior coronavirus vaccine
attempts such as SARS-CoV-1, the virus that is 78% identical to SARS-CoV-2 (COVID-19). Prior
coronavirus (and other respiratory) vaccines have failed due to the scientific phenomena known as pathogenic
priming that makes the vaccine recipient more likely to suffer a sudden fatal outcome due to massive cytokine

Copyright and intellectual property of Protection of the Educational Rights of Kids **15**

[www.perk-group.com](http://www.perk-group.com)


-----

storm when exposed to the wild virus. In addition to pathogenic priming there are three other potential safety
issues that are being minimized. While we are hopeful that the vaccine is both effective and safe, hope is not
science. Because these experimental shots have not been tested in accordance with the usual standards, we
have serious concerns about safety.” Moderna and J&J have never brought a vaccine to market before covid.
###### https://raypeatforum.com/commiinity/threads/implications-for-possible-consequences-of-covid-
**19-vaccines.38726/**

###### NO SAFETY FOR CHILDREN UNDER 18 YEARS OLD, ELDERLY OVER 85, OR IMMUNOCOMPROMISED No data in clinical trials. “There are currently insufficient data to make conclusions about the safety of
**the** **vaccine** **in** **subpopulations** **such** **as** **children** **less** **than** **18** **years** **of** **age”** **“subgroups** **not** **yet** **studied**
**in** **the** **clinical** **trial** **such** **as** **pregnant,** **immunocompromised** **and** **very** **elderly** **(>85** **years** **of** **age)**
**persons.** **”**
###### https://www.fda.gov/media/144434/download https://www.clinicaltrials.gov/ct2/show/study/NCT0466525< :
https: / [/www.fda.gov/media/144246/download](https:_/_/_www.fda.gov/media/144246/download)
###### https://www.fda.gov/media/144413/download

 SHORT TERM SAFETY DATA WITHOUT A ROBUST MONITORING SYSTEM
With only limited short term safety data and absolutely no long-term safety studies, the proper length of
safety study has not been done to ensure that any of these injections do not cause cancer, seizures, pathogenic
priming, heart disease, reverse transcription, immune escape, fertility issues, allergies, and autoimmune
diseases, as observed in earlier coronavirus animal studies. Because animal studies were bypassed, millions of
humans are now the primary test animal. With only a passive injury reporting system, using a completely new
mRNA technology that has never been licensed for human use, since viruses mutate frequently, we have
absolutely no long-term knowledge of what to expect from these new injections. Previously rushed Dengue
imprudence is noteworthy.
**https:** **/** **[/www.biologicalmedicineinstitute.com/post/covid-19-mma-vaccines](https:_/_/_www.biologicalmedicineinstitute.com/post/covid-19-mma-vaccines)**
**[https://www.sciencemag.org/news/2019/04/dengue-vaccine-fiasco-leads-criminal-charges-](http://www.sciencemag.org/news)**
**researcher-** **Philippines**

###### TWO MONTHS OF IMMUNITY FROM SHOT
“We only have data to support 2 months.”
CDC notes that "observed outcome of vaccine efficacy at two months does not directiy inform vaccine
efficacy for any duration longer than two months." In other words, there is no way to know whether the
vaccine is effective for any period longer than the time period it has been given to patients. CDC information
on Pfizer vaccine: Fauci describes no long term immunity, does not prevent transmission, may lessen
symptoms. From the clinical trials “As the interim and final analyses have a limited length of follow-up, it is
not possible to assess sustained efficacy over a period longer than 2 months.”
###### https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/05-COVID-Clark-
508.pdf
###### https://www. dailymail, co.uk/news/article-8884031 /Dr-Fauci-warns-early-COVID-19-vaccines-prevent-
symptoms-not-block-infection.html
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258](https://www.clinicaltrials.gov/ct2/show/_study/NCT04665258)
https: / [/www.fda.gov/media/144246/download](https:_/_/_www.fda.gov/media/144246/download)
###### https://www.fda.gov/media/144413/download
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)

###### UNKNOWNS: MUTATIONS, CO-INFECTION, TRANSMISSION, LONG-TERM EFFECT, STOPPING DEATH

Copyright and intellectual property of Protection of the Educational Rights of Kids 16

[www.perk-group.com](http://www.perk-group.com)


-----

###### UNKNOWN EFFECTIVENESS ON MUTATIONS OR CO-INFECTIONS
Tliis has not been studied. “Additional evaluations will be needed to assess the effect of the vaccine in
preventing asymptomatic infection” **Future** **vaccine** **effectiveness** **if** **there** **are** **mutations/changes** **in** **the**
**virus,** **and/or** **potential** **effects** **of** **co-infections?** “Continued evaluation of vaccine effectiveness following
issuance of an EUA and/or licensure will be critical to address these uncertainties.”
###### https://www.fda.gov/media/144434/download https://www.clinicaltrials.gov/ct2/show/study/NCT04665258: https://www.fda.gov/media/144246/download
https: / [/www.fda.gov/media/144413](https:_/_/_www.fda.gov/media/144413_/_download) /download
###### https://www.clinicaltrials.gov/ct2/show/study/NCT04665258

**EFFECT** **ON** **TRANSMISSION** **UNKOWN**
See statements from Moderna and Pfizer’s own words. NIH..“the studies **aren’t** designed to assess
transmission. They don’t ask that question and there’s really no information on this at this point in time.”
“Data are limited to assess the effect of the vaccine against transmission of SARS-CoV-2 from individuals
who are infected despite vaccination.. ..data from clinical trials and from vaccine use post-authorization will
be needed to assess the effect of the vaccine in preventing virus shedding and transmission, in particular in
individuals with asymptomatic infection.”
###### https://www.fda.gov/media/144434/download https://www.clinicaltrials.gov/ct2/show/study/NCT04665258: https://www.fda.gov/media/144246/download
https: / [/www.fda.gov/media/144413](https:_/_/_www.fda.gov/media/144413_/_download) /download
[https://www.medscape.com/viewarticle/941388](https://www.medscape.com/viewarticle/941388)

###### UNKNOWN EFFECTIVENESS AGAINST LONG-TERM EFFECTS OF COVID-19 DISEASE
There are only 2 months of data. “COVID-19 disease may have long-term effects on certain organs, and at
present it is not possible to assess whether the vaccine will have an impact on specific long-term sequelae of
COVID-19 disease in individuals who are infected despite vaccination.”
https: / [/www.fda.gov/media/144434/download](https:_/_/_www.fda.gov/media/144434/download)
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258:](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)
###### https://www.fda.gov/media/144246/download https://www.fda.gov/media/144413/download

 UNKNOWN EFFECTIVENESS IN STOPPING DEATHS FROM COVID-19 DISEASE
“A larger number of individuals at lugli risk of COVID-19 and higher attack rates would be needed to
confirm efficacy of the vaccine against mortality.” “The protocol had prespecified stopping rules that
included monitoring of severe COVTD-19 cases, and these stopping criteria were not met.”
https: / [/www.fda.gov/media/144434/download](https:_/_/_www.fda.gov/media/144434/download)
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258:](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)
https: / [/www.fda.gov/media/144246/download](https:_/_/_www.fda.gov/media/144246/download)
###### https://www.fda.gov/media/144413/download

 WARNING: RED FLAGS INNOCULATING PEOPLE WHO ALREADY HAD COVID

**PREVIOUSLY** **HAVING** **COVID-CLINICAL** **TRIALS-** **NO** **DATA**
**Will** **the** **vaccine** **protect** **individuals** **previously** **infected** **with** **SARS-CoV-2?** **UNKNOWN**
“Regarding the benefit of the mRNA-1273 for individuals with prior infection with SARS-CoV2, participants
with a known history of SARSCoV-2 infection **were** **excluded** **from** **the** **Phase** **3** **study...Thus,** the study
was not designed to assess the benefit in individuals with prior SARS-CoV-2 infection.”
###### https://www.fda.gov/media/144434/download
[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)

Copyright and intellectual property of Protection of the Educational Rights of Kids | 7

[www.perk-group.com](http://www.perk-group.com)


-----

https: / [/www.fda.gov/media/144246/download](https:_/_/_www.fda.gov/media/144246/download)
###### https://www.fda.gov/media/144413/download

**WARNING:** **RED** **FLAGS** **INNOCULATING** **PEOPLE** **WHO** **ALREADY** **HAD** **COVID:**
The clinical studies _excluded_ participants who were previously infected. Dr. Hooman Noorchasm in a letter to
Dr. Whelan, FDA’s Janet Woodcock warns that Pfizer and Moderna must consider the danger COVID
vaccines pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2 — especially the elderly,
frail or anyone with significant cardiovascular risk factors. Inoculating patients with occult SARS-CoV-2
infections or lingering viral antigens, is a clear and present potential danger to the health of these patients. In
the case of vaccines, previous infected persons with Covid may be more at higher risk for allergic reactions and
other adverse events. “Recently, or asymptomatically, infected persons are very highly likely to be at risk of an
exacerbated and dangerous hyper-inflammatory immune response when indiscriminately vaccinated — several
cases of this complication in the recently infected and vaccinated have emerged over the past few weeks across
the nation, including the deaths.”
###### https://noorchashm.medium.com/
http: / /fullmeasure.news/news/cover-story/cdc-investigation
https: / [/www.regulations.gov/document/FDA-2020-N-l](http://www.regulations.gov/document/FDA-2020-N-l) 898-0246
https: / /noorchashm.medium.com/uregnt-fda-communication-catastrophic-blood-clot-risk-absent-medical-
necessity-of-covid-19-a6bb35b806df
https: / /noorchashm.medium.com/a-letter-of-urgent-warning-to-the-university-of-notre-dame-president-rev-
831129535973

###### HEAVIER PERIODS IN WOMEN

**HEAVIER** **PERIOD** **POST** **VAX-** **WARNING:** **UNKNOWN** **IMPACT** **ON** **REPRODUCTIVE**
**SYSTEM**
**25,000+** **Women** **are** **now** **reporting** **to** **an** **Illinois** **research** **team,** **regarding** **abnormal** **changes** **and**
**unusual** **occurrences** **in** **periods,** **menstruation,** **unregulated** **periods,** **bruising,** **bleeding,** **blood** **clots,**
**400%** **increase** **in** **miscarriages,** **etc.** **for** **both** **women** **receiving** **the** **shot** **and** **also** **reactions** **in** **women**
###### being in close proximity to recently inoculated persons. Possible speculation includes the protein
**spike** **is** **shedding** **from** **those** **who** **have** **received** **it** **and** **the** **implications** **on** **fertility** **and** **reproductive**
**health** **are** **concerning,** **but** **unclear.**
https://www.dailymail.co.uk/femail/article-9446907/Some-women-report-heavier-painful-PERIODS-
getting-COVID-19-vaccine.html
###### https://madison.com/news/state-and-regional/abnormal-periods-after-covid-19-vaccine-university-of-
illinois-professor-researcl'iing-reports/article [2de33962-9f32-5814-b805-c953758b9d61](https://madison.com/news/state-and-regional/abnormal-periods-after-covid-19-vaccine-university-of-illinois-professor-researcl'iing-reports/article_2de33962-9f32-5814-b805-c953758b9d61_.htmlhttps://redcap.healtlainstitute.illinois.edu/surveys/index.php?s=LL8TKKC8DP) .html
https://redcap.healtlainstitute.illinois.edu/surveys/index.php?s=LL8TKKC8DP
###### https://twitter.com/KateClancy/status/1364671490772320259 https:/ /montanadailygazette.com/2021 /04/16/unvaccinated-women-report-miscarriages-after-interactions-
with-vaccinated-people/

###### ABNORMAL PHENOMENON ALARMING WOMEN

 PHENOMENON OF BLEEDING AND CLOTTING Phenomenon happening. Thousands of reports are coming in. Uncertain outcomes. It’s so new,
**there** **is** **no** **data** **in** **clinical** **trials,** **or** **peer** **reviewed** **literature** **to** **explain** **it.** **Except** **for** **SAE** **(Secondary**
**Adverse** **Events)** **reports.**
###### https:/ /envirowatchrangitikei.wordpress.com/2021 /04/25/six-doctors-discuss-the-phenomenon-of-
bleeding-and-clotting-in-women-who-have-received-the-cv-injection/

Copyright and intellectual property of Protection of the Educational Rights of Kids 18

[www.perk-group.com](http://www.perk-group.com)


-----

###### INVESTIGATION OF VACCINE (SAE) FROM SKIN OR INHALING BREATH

 Separate from the clinical trial participants, reports into investigations into (SAE) serious adverse events from exposure to a vaccinated person, are kept in a separate study. “An occupational exposure occurs when a person receives unplanned direct contact with a vaccine test subject, which may or may not lead to the occurrence of an adverse event. These people may include health care providers, family members, and other people who are around the trial participant.” “A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact.” “A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception.” (See 8.3.5.1, 83.5.3, p. 65-70) https://media.1ghn.org/medialibrary/2020/ll/C4591001 Clinical Protocol Nov2020 Pfizer Bio NTech.j it

 FERTILITY, BREAST FEEDING, PREGNANCY UK states shot should not be used by pregnant, breast-feeding mother, or children.

**Fertility-** Unknown “Animal studies do not indicate direct or indirect harmful effects with respect to
reproductive toxicity (see section 5.3)” But alarmingly the guide has only one tiling to say about the vaccine’s
impact on fertility: they don’t know if it does or doesn’t. “It is unknown whether COVID-19 mRNA Vaccine
BNT162b2 has an impact on fertility.”

**Pregnancy-** Unknown impact. “There is limited experience with use of the COVID-19 mRNA Vaccine
BNT162b2 in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect
to pregnancy, embryo/fetal development, parturition or post-natal development (see section 5.3).

**Breast-feeding-** Unknown impact. “It is unknown whether the COVID-19 mRNA Vaccine BNT162b2 is
excreted in human milk.” “There are currendy insufficient data to make conclusions about the safety of the
vaccine in subpopulations such as... pregnant and lactating individuals” (MODERNA/PFIZER)

**2** **Months-** Avoid pregnancy at least 2 months after shot. Unknown impacts. Tins means that it could take a
relatively long time before a noticeable number of cases of post vaccination infertility could be observed,
“women of child-bearing potential” can take part only if they are not pregnant or breastfeeding and are using
contraception, it could take “a relatively long time before a noticeable number of cases of post-vaccination
infertility could be observed.”
###### https://assets.publislung.service.gov.uk/government/uploads/system/uploads/attachment data/file/97388 4/Temporary Authorisation HCP Information BNT162 8 0 UK.pdf
http: //virological.org/1/response-to-ncov2019- against-backdrop-of-endogenous-
###### retroviruses/396https://2020news.de/wp- content/uploads/2020/12/Wodarg Yeadon EMA Petition Pfizer Trial FINAL 01DEC2020 EN unsign
ed with Exhibits.pdf

**Dr.** **Stephanie** **Seneff,** an expert in protein synthesis who is a Ph.D. senior research scientist at
MIT. “The potential for blood clotting disorders and the potential for sterilization are only part of
###### the story. There are other potential long-term effects of these vaccines as well, such as autoimmune
disease and immune escape, whereby the vaccines administered to immune-compromised people
###### accelerate the mutation rate of the virus so as to render both naturally acquired and vaccine-induced antibodies no longer effective.” “This massive clinical trial on the general population could have devastating and irreversible effects on a huge number of people.”

Copyright and intellectual property of Protection of the Educational Rights of Kids | 9

[www.perk-group.com](http://www.perk-group.com)


-----

[https://www.iennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/](https://www.iennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/)

###### CONCERNS REGARDING THE FORMATION OF THE PLACENTA
Former Vice President of Pfizer’s petition called for a halt to Phase 3 clinical trials of Pfizer's mRNA vaccine.
Yeadon and Wodart warn that some of the vaccines may prevent the safe development of placentas in
pregnant women, resulting in “vaccinated women essentially becoming infertile.” In part due to the concern
###### that if a woman's immune system starts reacting against syncytin-1, there is the possibility she could become
infertile. Because the spike protein is derived from human endogenous retroviruses (HERV) and is
responsible for the development of a placenta in mammals and humans. If the mRNA vaccine triggers your
body to produce “antibodies against the SARS-CoV-2 spike protein, and spike proteins in turn contain
syncytin-homologous proteins that are essential for various functions in your body, including theformation _of_
_theplacenta_ in pregnant women.” Previously infected covid-19 patients with the wild virus had placental
problems. Dr. Jennifer Margulis describes concerns around spike proteins and the fertility issue as well.
###### https://assets.publislaing.service.gov.uk/government/uploads/system/uploads/attaclament data/file/97388 4/Temporary Authorisation HCP Information BNT162 8 0 UK.pdf
http: //virological.org/1/response-to-ncov2019- [against-backdrop-of-endogenous-retroviruses/396](http:_//virological.org/1/response-to-ncov2019-_against-backdrop-of-endogenous-retroviruses/396)
###### https://web.archive.Org/web/20201209042033/https:/2020news.de/wpcontent/uploads/2020/12/Wodarg

Yeadon EMA Petition Pfizer Trial KNAL 01DEC2020 EN unsigned with Exhibits.pdf
https: / / j amanetwork. com/j ournals/jama/fullarticle/2765616
###### https://www.thelancet.com/iournals/lancet/article/PIIS0140-6736(20)30311-1/fulltext https: / /wttvw.iennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/

**XL** **Several** **vaccine** **candidates** **arc** **expected** **to** **induce** **the** **formation** **of** **humoral** **antibodies**
**against** **spike** **proteins** **of** **SARS-CoV-2.** **Syncytin-1** **(sec** **Gallaher.** **B..** **“Response** **to** **nCoV2019**
**Against** **Backdrop** **of** **Endogenous** **Retroviruses**** **■** **hi** **m>-ncov2019-**
**against-backdrop-of-endogenous-retrovii** **^ji^^hich** **is** **derived** **from** **humancfiBbg^**
**rctroxiruscs** **(HERV^** **and** **is** **rcsponsibk** **the** **development** **of** **a** **placenta** **m** **mammals**
**humans** **and** **is** **therefore** **an** **esscntia^ri** **xjuisitc** **for** **a** **s** **ul** **pregnancy,** **is** **md** **in**

**homologous** **form** **in** **the** **spike** **i** **leins** **of** **SAKS** **viruses.** **There** **is** **no** **indication** **whether**
**antibodies** **against** **spike** **protc*[s** **of** **SARS** **viruses** **would** **also** **act** **like** **anti-Syncytin-1**
**antibodies.** **However,** **if** **this** **wcrl** **1to** **be** **the** **case** **this** **would** **then** **also** **prevent** **the** **formation** **of** **a**
**placenta** **which** **would** **result** **Ak** **vaccinated** **women** **eaeentiaOy** **becoming** **infertile.** **To** **my**
**knowledge,** **Pfizer** **BioNTech** **has'^Kt** **to** **release** **any** **samples** **of** **written** **materials** **prodded** **to**

**patients,** **so** **it** **is** **unclear** **what,** **if** **a** **regarding** **(potential)** **fertility-specific** **risks**
**caused** **by** **antibodies** **is** **included.**

**According** **to** **section** **10.42** **of** **the** **Pfizer** **BioNTech** **of** **childbearing**

**potential** **(WOCBP)** **is** **eligible** **to** **participate** **if** **she** **is** **not** **pregnant** **or** **breastfeeding,** **and** **is** **using**
**an** **acceptable** **contraceptive** **method** **as** **described** **in** **the** **trial** **protocol** **during** **the** **intervention**
**period** **(for** **a** **minimum** **of28** **days** **after** **the** **last** **dose** **ofstudy** **intervention).**

**This** **means** **that** **it** **could** **take** **a** **relatively** **long** **time** **before** **a** **noticeable** **number** **of** **cases** **ofpost­**
**vaccination** **infertility** **could** **be** **observed.**

**Xll.** **It** **appears** **that** **Pfizer** **BioNTech** **have** **not** **yet** **released** **any** **samples** **of** **written** **materials**
**provided** **to** **patients,** **so** **it** **is** **unclear** **what** **if** **any.** **instructions** **informarinn** **patients,** **subjects** **were**
**given** **regarding** **ADE** **and** **PEG-rclated** **issues** **and** **(potential)** **fertility** **or** **pregnancy** **-specific**

###### LOWER SPERM COUNT FOR MEN DURING CLINICAL TRIALS:
Has not yet been studied but there are strong enough concerns that studies are being proposed. Sperm counts
are lowered post vaccination, https: / [/www.clinicaltrials.gov/ct2/show/study/NCT04665258](https:_/_/www.clinicaltrials.gov/ct2/show/study/NCT04665258)

###### PFIZER CLINICAL TRIAL- DEFECTIVE DESIGN CLAIM

Copyright and intellectual property of Protection of the Educational Rights of Kids 20

[www.perk-group.com](http://www.perk-group.com)


-----

**PFIZER** **APPROVAL** **BASED** **ON** **DEFICIENT,** **UNRELIABLE** **CLINICAL** **TRIAL** **DATA,**
**DEFECTIVELY** **DESIGNED**
Stating in a joint petition, accusations were made that the current study designs for the Phase II/III trials of
BNT162b (“the Pfizer/BioNTech trial”) are inadequate to accurately assess efficacy, the designs of the
clinical trials were faulty, flawed, and that the vaccines were NOT properly tested. Trials and widespread use
###### of the product were based on misleading evidence, and therefore should not be recommended for widespread
use. “Vaccine candidates were not designed to stop transmission of the virus, the public will suffer irreparable
harm, the cases and non-cases were not accurate in the trial (using the faulty PCR test rather than a Sanger
test and cross examining).” Dr. Yeadon claims the design trial and results are inaccurate and not appropriately
designed to reduce transmission and reduction of COVID disease and deaths. “First, none of the leading
vaccine candidate trials is designed to test if the vaccine can reduce severe COVID-19 symptoms, defined as:
hospital admissions, ICU or death. And, second, the trials are not designed to test if the vaccine can interrupt
transmission.”

“Design flaws include PCR tests that are identical to or modeled after what is sometimes called the “Drosten-
###### Test” this can lead to false-positive results in trials designed such that PCR results are the primary evidence of
infection.” The complaint asserts that without the assuring proper safety trials of the vaccines now, the
people will not have the opportunity to object to receiving the vaccine based on deficient clinical trials later.
###### https://2020news.de/wp- content/uploads/2020/12/Wodarg Yeadon EMA Petition Pfizer Trial I INAI. 01DEC2020 EN unsign
ed with Exhibits.pdf

###### ONE SYMPTOM AND PCR DESIGN FLAW IN CASE DEFINITION IN CLINICAL TRIALS
" Evaluable cases consisted of a positive virological test [PCR test] plus at least one COVID-19
symptom... Fever         - New or increased cough         - New or increased shortness of breath         - Chills         - New
or increased muscle pain         - New loss of taste or smell         - Sore throat         - Diarrhea         - Fatigue         - Headache

             - Nasal congestion or runny nose             - Nausea." “External peer review of the RTPCR test to detect
SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level:
consequences for false positive results.”
###### https://www.fda.gov/media/144246/download
https: / [/www.fda.gov/media/144413](http://www.fda.gov/media/144413) /download

###### NO DAT/ NICAL TRIALS
Clinical trials were done on the “healthiest” subjects. There is no data to suggest safety or efficacy regarding:
auto-immune conditions, cancer patients, immunocompromised individuals, 3 doses, repeated annual doses,
safety in children under 18 or persons older than 55, pregnant or lactating mothers, fertility, transmission of
covid, duration of protection or immunity from covid, mortality prevention from covid, long-term health
impacts, interaction of different brands, interaction between other traditional vaccines, variants, and more.
###### https://www.fda.gov/media/144245/download (Pfizer pg 46-48) https://www.fda.gov/media/144434/download (Moderna pg 46-48)

**95%** **EFFICACY** **REPORTS** **IN** **CLINICAL** **TRIALS** **QUESTIONED**
BMJ Questions 95% efficacy reports when reviewing the clinical trials. “3410 total cases of suspected, but
unconfirmed covid-19 in the overall study population, 1594 occurred in the vaccine group vs. 1816 in the
placebo group.” If these were accounted for, EUA qualifications would not have been met, causing the
clinical trials to fall below 50% efficacy.
###### https://www.fda.gov/media/144245/download#page=42 (pg 42 FDA report)
 https:/ /blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-
more-details-and-the-raw-
###### data/?utm source=feedburner&utm medium=feed&utm campaign=Feed%3A+bmj%2Fblogs+%28Latest
+BMT+blogs%29&g=w bmj-com

Copyright and intellectual property of Protection of the Educational Rights of Kids 21

[www.perk-group.com](http://www.perk-group.com)


-----

**PFIZER** **FORMERVICE** **PRESIDENT** **YEADON** **PETITION** **REQUEST**
His request was to pause all trials until vaccine efficacy is determined in the Phase 3 or 2/3 trials. One of the
biggest reasons they cited was based upon the deaths of the ferrets in the prior SARS vaccine trials They
requested to confirm infection status with Sanger sequencing, given the high cycle thresholds of the PCR test
used in some trials. If verified by Sanger sequencing, rather than PCR, that would confirm that the tested
samples in fact contain a unique SARS-CoV-2 genomic RNA. This would remain consistent with the FDA
requirements for a confirmed diagnosis of human papillomavirus (HPV) using PCR, the sequencing
electropherogram must show a minimum of 100 contiguous bases matching the reference sequence with an
Expected Value.
###### https://web.arclaive.org/web/20201209042033/https:/ /2020news.de/wp- content/uploads/2020/12/Wodarg Yeadon EMA Petition Pfizer Trial FINAL 01DEC2020 EN unsign
ed with Exhibits.pdf
###### https: / /www.bmj .com/content/bmj /3 71 /bmj.m4037.full.pd

 GENEVA ETHICISTS SOUND THE ALARM ABOUT THE MRNA For decades Geneva ethicists were concerned. It’s actually more accurate to describe the new injections as
gene therapy rather than a vaccine. Traditional vaccines stimulate the immune system through an antigen and
adjuvant. Moderna plugs a small piece of coronavirus genetic code into human ceUs, attempting to
“reprogram” the ceUs in the body. Previous to now, it has been caUed off by Ethicists. It was previously
referred to as “germ line gene editing.”

###### CONSIDERED GENE THERAPY FROM MODERNA & FDA
“Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that
irreversibly alter ceU DNA and could act as a source of side effects, mRNA-based medicines are designed to
not irreversibly change cell DNA; however, side effects observed in gene therapy could negatively impact the
perception of mRNA medicines despite the differences in mechanism. In addition, because no product in
which mRNA is the primary active ingredient has been approved, the regulatory pathway for approval is
uncertain. The number and design of the clinical and preclinical studies required for the approval of these
types of medicines have not been established, may be different from those required for gene therapy products
or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete
clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority
varies significantiy from one pharmaceutical product to the next and may be difficult to predict.
[https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

###### GENETICALLY ENGINEERED RNA OR DNA, SEQUENCING IDENTIFIED
The new mRNA products through Pfizer, J&J, and Moderna are viral vector vaccines. Viral Vector use 50
billion adenovirus particles virus that have been genetically engineered to generate an artificial immune
response. RNA and DNA vaccines use genetically engineered RNA or DNA to generate a protein that itself
prompts an artificial immune response. It is unknown if the spike protein can be turned off. See the
sequence discovered by Stanford University Scientists using left overs in shot vials.

Copyright and intellectual property of Protection of the Educational Rights of Kids 22

[www.perk-group.com](http://www.perk-group.com)


-----

**Figure** **2:** **Spike-encoding** **contig** **assembled** **from** **Moderna** **mKNA-1273** **vaccine.**

**.A.v** **.....CGGCTGGACCCTCCCGAGGCCGAGGTGCAGATCGACCGGCTGATCACTGGCCGGCTGCAGAGCCTGCAGACCTACGTGACCCAGCAGCTGArCCGGGGGGCCGAGATTGGGGCCAGCGCGAAGCTGGGCGCGAGGAAGATGACGGAGT'CCGTGCTGGGCCAGAGCAAGGGGGTGGACTTGTG**

**rcAccaACGCccTOGACTOCGCce^GGACCCTCTGACZ-aAGACCAACTGCACccTSAAGACCTTCACCGTQjiCAAGGOCATCTACCAGAC** **CGGCAAGGGCTACCACCTGATGAGCTTTCCCCAGAGCGCACCCCACGGAGTGGTGTTCCTGCACGTGACCTACGTGCCCGCCCAGGAGAAG**

**CAGCAACT!CCG<WTCCIMKCCAc:3*GM^?CCTGca^TCCCauu»TCACCAACCTCTXX^rcG3CCyuK7GTrcAACGCCACC** **AACTTCACCACCGCCCCAGCCATCTGCCACGACGGCAAGGCCCACTTTCCCCGGGAGGGCGTGTTCGTGAGCAACGGCACCCACTGGTTCG**
**CGCTrCGCCAGCGTGTACOCCTSSAACCGGAAGCGGArCAfiCAACTCCGTGGCCGACTACAGCGTGCTGTACAACAGCGCCAGCTTCAGCA** **TGACCCAGCGGAACTTCTACGAGCCCCAGATCATCACCACCGACAACACCTTCGTGAGCGGCAACTGCGACGTGGTGATCGGCATCGTGAA**

**lUkCACCAACAACCTXXACAGCAASCTGCGCGCCAACTACAACTACeTCTACCCCCTCTTCeGGASGAGCAACCTGAAGCCCTTCGAGCGCC** **GACCTGGGCGACATCAGCGGCATCAACGCCAGCGTGGTGAACATCCAGAAGGAGATCGATCGGCTGAACGAGGrGGCCAAGAACCTGAACG**

**C<X^GCAGCrrcGOXXXX;TGA3CGTCM-.-aM:CCCAaxyUXAACACCAGCJUlCXACJGTCGCCGTGCrGTACCAGCMkCGIGAACTGCACC** **CCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTrCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCAAAAAAAAA**

**Cyan:** **Putative** **5’** **UTR**
**Green:** **Start** **Codon**

**_CQCCtnaGtGCMGMMGMCACCCAGOMmnTn&XCMGTWMMAKTACMGMXXXTCCCATCMGG^^_** **Yellow:** **Signal** **Peptide**

"                               - a a . \ ; / a **i** **\** . a^ **■** **1** **Orange:** **Spike** **encoding** **region**

**Red:** **Stop** **codon(s)**

**A** **t** **Purple:** **3*** **UTR**

**:Wvr** : \\a **V** ***'** a **Blue:** **Start** **ofpolyA** **region** **(incomplete)**
###### V

 https://www.the-scientist.com/news-opinion/scientists-reverse-engineer-mrna-sequence-of-moderna-
vaccine-68640
###### https:/ /github.com/NAalytics/Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-
vaccines-BNT-162b2-and-mRNA-1273 /blob/main/Assemblies%20of0/o20putative0/o20SARS-CoV2-spike-
encoding%20mRNA%20sequences%20for%20vaccines%20BNT-162b2%2Qand%2QmRNA-l273.docx.pdf
###### https:/ /berthub.eu/articles/posts/reverseengineering-source-code-of-the-biontech-pfizer-vaccine/

**GENETICALLY** **ENGINEERED** **AND** **INTRODUCE** **FOREIGN** **DNA** **AND** **RNA** **INTO**
**CELLS** **OF** **THE** **BODY:**
Introducing a non-human substances and foreign synthetic material (mRNA vaccines) have created instability
in the body and ineffective delivery in the past. **Synthetic** **mRNA** **leads** **to** **instability** **in** **the** **body,** **possible**
**toxicity.** In studies of mRNA vaccines it is described along with a comparison to DNA vaccines, the greater
inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility
for vaccines and for the potential tonicity.
###### ProTherlmmune, 3656 Happy Valley Road, Lafayette, CA 94549, USA
Vaccines **2019,** 7(2), 37; **[https://doi.org/10.3390/vaccines7020037](https://doi.org/10.3390/vaccines7020037)**
###### https://www.mdpi.com/journal/vaccines/special issues/advances DNA vaccines

 ANEW FIELD CALLED EPITRANSCRIPTOMICS AND POSSIBLE ROLE IN CANCER
Epigenetic gene regulation is studied by examining dynamic modifications of DNA and proteins—so-
called epigenetic modifications. The modifications can turn genes on or off without changing the underlying
genetic code. Over the last five years, there has been an enormous increase in the amount of research into
RNA modifications—a field called epitranscriptomics. ("Deciphering the epitranscriptome in cancer."
Trends in cancer 4, no. 3 (2018): 207-221. "Epitranscriptomic signatures in IncRNAs and their possible roles
in cancer." Genes 10, no. 1 (2019): 52.)
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997933/ https://genomebiology,biomedcentral. com/articles/10.1186/sl 3059-017-1336-6?optIn=true

**POSSIBLE** **REVERSE** **TRANSCRIPTION** **PROBLEMS,** **RNA** **AND** **DNA-** **COMMON** **IN** **HIV**
SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. Detection of reverse
transcriptase activity in human cells. Here are samples of three nonmalignant and seven leukemic human cells
###### that were examined for DNA polymerase activity that could be identified as RNA tumor virus reverse
transcriptase. This is common in HIV retroviruses.
[https://doi.org/10.1101/2020.12.12.422516](https://doi.org/10.1101/2020.12.12.422516)
###### https://www.ncbi.nlm.nih.gov/books/NBK19424/ https://pubmed.ncbi.nlm.nih.gov/87260/ https://www.ibc.org/article/S0021-9258(20)78303-1/fulltext

Copyright and intellectual property of Protection of the Educational Rights of Kids 23

[www.perk-group.com](http://www.perk-group.com)


-----

###### GENE THERAPY RISKS WITH ALTERING CELL DNA IRREVERSIBLY
Directly from the Moderna 2018 report. “In the EU, mRNA has been characterized as a Gene Therapy
Medicinal Product... a clinical hold on gene therapy products across the field due to risks associated with
altering cell DNA irreversibly may apply to our mRNA investigational medicines irrespective of the
mechanistic differences between gene therapies and mRNA. Adverse events reported with respect to gene
therapies or genome editing therapies could adversely impact one or more of our programs. Although our
mRNA development candidates and investigational medicines _are_ _designed_ not to make any permanent changes
to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies products
caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our
mRNA investigational therapies, and as a result may delay one or more of our trials or impose additional
testing for long-term side effects.
**Pg.26-27**
[https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

1. Anti-PEG Antibodies

###### LIPID MODEL

 LIPID CARRYING VECTOR
The lipid carrier (vector) is problematic= aids in vulnerability
The spike in protein interaction with PEG in the body. Causing allergic reactions. (Anaphylactic)
Immunologist Says the foreign, synthetic mRNA, creates significant instability in the body: (see sources in
anti-PEG section.)
“Gene therapies and mRNA based medicines may activate one or more immune responses against any and all
components of the drug product (e.g., the mRNA or the delivery vehicle, such as a lipid nanoparticle) (LNP)
as well as against the encoded protein, giving rise to potential immune reaction related adverse events.
Eliciting an immune response against the encoded protein may impede our ability to achieve a pharmacologic
effect upon repeat administration or a side-effect.” Page 22
[https://www.sec.gOv/ArctHves/edgar/data/1682852/000119312518323562/d577473dsl.htm#toc577473](https://www.sec.gOv/ArctHves/edgar/data/1682852/000119312518323562/d577473dsl.htm%2523toc577473_6) 6

###### LIPID MODEL PREVIOUSLY PROBLEMATIC
Lipid nano particles can cross the blood brain barrier. It was never proved safe enough to test in humans,
according to several former Moderna employees and collaborators who worked closely on the project. Covid
19 clinical trials for both Pfizer and Moderna show increased reactions, with repeated injections, increased
inflammation due to Lipid Nano Particle model.
###### https:/ /www.statnews.com/2017/01 /I O/moderna-trouble-mrna/ https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain0/o20is0/o20a0/o20delicat
e,Blood%20Brain%20Barrier%20(BBB).&text=Nevertheless%2C0/o201ipid%20nanoparticles%20are0/o20take
mbecause%20of%20their%201ipophilic%2Onature.
###### https://pubmed.ncbi.nlm.nih.gov/30370619/

 LNP CROSSING BLOOD BRAIN BARRIER
**Impact** **on** **CNS,** **Brain,** **and** **entering** **cells,** **watch** **for** **danger** **signals**
###### https://pubmed.ncbi.nlm.nih.gov/30370619/ https://pubmed.ncbi.nlm.nih.gov/29886842/#:0/o7E:text=Background0/o3A0/o20Brain0/o20is0/o20a0/o20delicat
e,Blood%20BrainQ/o20Barrier0/o20(BBB).&text=Nevertheless0/o2C%201ipid0/o20nanoparticles%20are0/o20take
n.because%20of%20their%201ipophilic%20nature.
###### https://pubmed.ncbi.nlm.nih.gov/18313785/ https://pubmed.ncbi.nlm.nih.gov/32116044/

Copyright and intellectual property of Protection of the Educational Rights of Kids 24

[www.perk-group.com](http://www.perk-group.com)


-----

###### LIPID MODEL RISKS, mRNA TECHNOLOGY NEVER APPROVED, SAFETY ISSUES
Previous attempts at mRNA technology from Moderna resulted in troubling effects on the liver in animal
studies. Just a few years ago, Moderna could not demonstrates that its technology can safely treat a disease.
###### In their corporate prospectus9 released in 2018 at the time of their stock market launch, Moderna
acknowledged that their LNPs carried risks. "No mRNA drug has been approved in this new potential
category of medicines, and may never be approved as a result of efforts by others or us. mRNA drug
development has substantial clinical development and regulatory risks due to the novel and unprecedented
nature of this new category of medicines." Before COVID, the company was teetering on bankruptcy with
$1.5 billion debt.

"Gene therapies and mRNA based medicines may activate one or more immune responses against any and all
components of the drug product (e.g., the mRNA or the delivery vehicle, such as a lipid nanoparticle (LNP))
as well as against the encoded protein, giving rise to potential immune reaction related adverse events.
[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dsl.htm)
###### https:/ /www.statnews.com/2017/01 /1 O/moderna-trouble-mrna/ https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a0/o20delicat
e,Blood0/o20Brain0/o20Barrier0/o20(BBB).&text=Nevertheless0/o2C0/o201ipid0/o20nanoparticles0/o20are0/o20take
n,because0/o20of0/o20their0/o201ipopl'iilic0/o20nature.
###### https://pubmed,ncbi.nlm.nih.gov/30370619/

 PEG ANAPHYLACTIC REACTIONS

**PEG** **PROTIENS** **ARE** **A** **PROBLEM,** **SERIOUS** **ANAPHYLACTIC** **REACTIONS** **FOR** **SOME**
CDC, Pfizer, UK knew allergic reactions were coming. It is important to note that individuals with a “history
###### of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any
component of the study intervention(s)” were **excluded** from Pfizer’s clinical trials. Study to Describe the
Safety, Tolerability, Immunogenicity, and Efficacy of **RNA** Vaccine Candidates Against COVID-19 in
Healthy Adults. Exclusion Criteria.

‘Very inconsistent’: 2 allergic reactions in the UK to COVID-19 vaccine puzzle researchers.USA Today Dec.
9, 2020.
###### https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-
considerations.html?CDC AA refVal=https0/o3A0/o2FQ/o2Fwww.cdc.gov%2Fvaccines%2Fcovid-l90/o2Finfo-
by-product0/o2Fpfizer0/o2Fclinical-considerations.html
###### https:/ /healthimpactnews.com/wp-content/uploads/sites/2/2020/12/CDC-05-covid-clark.pdf
https: / [/www.fda.gov/media/144413](http://www.fda.gov/media/144413) /download
###### https:/ /jamanetwork,com/j ournals /jama/fullarticle/2777417?guestAccessKey=e4d454f9-7f06-42b5-81el -
0ea01dl43ed3&utm source=silverchair&utm medium=email&utm campaign=article alert-
jama&utm content=olf&utm term=030821

###### ANTI-PEG ANTIBODIES (Allergic Reactions)
These mRNA vaccines are coated with PEGylated lipid nanoparticles (polyethylene glycol). Unfortunately,
PEGylated lipid nanoparticles (which have been used for years in several drugs) have been shown to
imbalance certain immune responses and can induce allergies and even autoimmune diseases. A majority of
the population unknowingly have anti-PEG antibodies.

"While we have continued to optimize our LNPs, there can be no assurance that our LNPs will not have
undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: immune
reactions, infusion reactions, complement reactions, opsonation reactions, antibody reactions including IgA,
IgM, IgE or IgG or some combination thereof, or reactions to the PEG from some lipids or PEG otherwise
associated with the LNP."

Copyright and intellectual property of Protection of the Educational Rights of Kids 25

[www.perk-group.com](http://www.perk-group.com)


-----

###### PEG antibodies may also reduce vaccine effectiveness. Pfizer/BioNTech is also inserting an ingredient
derived from a marine invertebrate, mNeonGreen, into its vaccine. The ingredient has bioluminescent
qualities, making it attractive for medical imaging purposes, but it is unclear why an injected vaccine would
need to have that quality. mNeonGreen has unknown antigenicity.
https: / [/www.ncbi.nlm.nih.gov/pmc/articles/PMC4515207](https:_/_/_www.ncbi.nlm.nih.gov/pmc/articles/PMC4515207_/) /
###### https://www.tandfonline.com/doi/pdf/10.1517/17425247.2012.720969 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747248/
https: / [/www.iacionline.org/article/S0091](https:_/_/_www.iacionline.org/article/S0091_--6749_(15)01667-X/fulltext) --6749 (15)01667-X/fulltext
###### https://www.karger.com/Article/Abstract/233512 https://www.sciencedirect.com/science/article/abs/pii/SOl 68365907002428
https://www.sec.gov/ArclTives/edgar/data/1682852/000119312518323562/d577473dsl.htm
###### https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-
anaphylaxis.html?CDC AA refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-l 90/o2Finfo-by-
product%2Fpfizer0/o2Fanaphylaxis-management.html

###### IMMUNE ESCAPE, VIRAL VARIANTS

**VACCINE** **INTERFERENCE** **CATASTROPHIC**
While a virus is transmitting through the population, vaccination interference may cause catastrophic
problems. “As mass vaccination campaigns have started in the vulnerable population, not only vaccinated
subjects but also not yet vaccinated younger age groups will become a breeding ground for new infectious
variants. There can be no doubt that continued mass vaccination campaigns will enable new, more infectious
viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite
enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete
resistance of circulating variants to the current vaccines.”
**(33** **Studies/Links:** **Peer** **Reviewed,** **Resources,** **Science** **Journals** **supporting** **immune** **escapes,** **NK**
**cells,** **Innate** **Immune** **System,** **Vaccine** **Induced** **Immune** **Escape,** **Reduced** **Protection** **from** **Stronger**
**Variants)** [https://37b32f5a-6ed9-4d6d-b3el](https://37b32f5a-6ed9-4d6d-b3el)        -

5ec648ad9ed9.tilesusr.com/ugd/28d8fe lca60c7d40dl41b89dbf26c7afb9f50b.pdf

###### NATURAL AND VACCINE-INDUCED IMMUNE ESCAPE Due to the intervention of mass inoculation, Immune pressure (immune escape), redirects the virus into the
asymptomatic population, creating worse viral variants, and altering natural immunity. Interventions of
vaccines create “Immune pressure” which causes virus adaptation, with new worse viral variants. Immune
escape. Without vaccination interventions, the virus does not have this immune escape. Before vaccine
intervention, the natural immune system was equipped to limit variants. Mass inoculation of vulnerable
groups does not abrupt viral transmission chains but increasingly redirects transmission events to
asymptomatic carriers. Evident in the form of having transformed “a quite harmless virus into an
uncontrollable monster.”
###### https://www.biorxiv.org/content/10.1101 /2020.12.28.424451 vl https:/ / science.sciencemag.org/content/371 /6527/329 https:/ /journals.plos.org/plosbiology/article?id=l 0.1371/journal.pbio. 1002198
doi: https: / /doi.org/10.1016/82468-2667(21)00036-0
doi: [https://doi.org/lCf-1016/50140-6736(21)00183-5](https://doi.org/lCf-1016/50140-6736(21)00183-5)
###### https:/ /immunology, sciencemag.org/content/6/57/eabg6461
doi: [https://doi.org/10.1016/50140-6736(21)00468-2](https://doi.org/10.1016/50140-6736(21)00468-2)
[https://www.sciencedirect.com/science/article/pii/S0092867421003676?via%3Dihub](https://www.sciencedirect.com/science/article/pii/S0092867421003676?via%25253_Dihub)

https://www.the-scientist.com/news-opinion/will-delaying-vaccine-doses-cause-a-coronavirus-escape-
###### mutant—68424 https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00036-0/fulltext

Copyright and intellectual property of Protection of the Educational Rights of Kids 26

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://science.sciencemag.org/content/371 /6527/329 https://vancouversun.com/news/covid-19-cases-of-vaccine-resistant-variant-more-than-doubles-in-b-c https://www.tagesspiegel.de/wissen/die-angst-vor-der-supermutante-was-wenn-kein-impfstoff-mehr-
wirkt/27048992.html
###### https://www.nature.com/articles/s41591 -021 -01318-5

**VIRAL** **VARIANTS** **SIGNS** **OF** **IMMUNE** **ESCAPE,** **POTENTIAL** **FOR** **REINFECTION**
The multiple emerging, “much more infectious” viral variants, are already examples of “immune escape”
from our ‘innate immunity’, and were most-likely created by the government interventions. Variants emerging
in conjunction with mass inoculation.

            - Ongoing mass vaccination deployments are “highly-likely to further enhance ‘adaptive’ immune
escape as none of the current vaccines will prevent replication/transmission of viral variants”

            - As such, “The more we use these vaccines for immunizing people in the midst of a pandemic, the
more infectious the virus will become”.

            - “With increasing infectiousness comes an increased likelihood of viral resistance to the vaccines”.

            - “One shouldn’t use a prophylactic vaccine in populations exposed to lugli infectious pressure (which
is now certainly the case as multiple highly infectious variants are currently circulating”).

            - To “fully escape”, the highly mutable virus, “only needs to add another few mutations in its receptor­
binding domain”.

[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641391/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641391/)
###### doi: https://doi.Org/10.1099/jgv.0.001439 https:/ / science.sciencemag.org/content/371 /6527/329

(Brazil) [https://www.bmj.com/content/373/bmj.n879](https://www.bmj.com/content/373/bmj.n879)
(Indian)https: / /www.thehindu.com/sci-tech/science/what-is-driving-the-second-wave-in-
india/article34232390.ece

(Turkey)https: / [/www.aninews.in/news](http://www.aninews.in/news) /world/middle-east/turkeys-daily-covid-19-cases-hit-a-new-
record20210402074805

**MORE** **DANGEROUS** **STRAINS** **POST** **VACCINATION**
###### In 2001, research with poultry viruses led to the conclusion that low-efficacy vaccines could even promote
the development of more dangerous virus strains. _Deutsche_ _Welle,_ January 26,
2021, [https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759](https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759)
###### https:/ /www.biorxiv.org/content/10.1101 /2021.01.18.427166v2.full.pdf

**VARIANTS** **MORE** **LETHAL** **AND** **MORE** **INFECTIOUS**

             - "Covid-19 cases have soared throughout Brazil in the past month and have been attributed to the spread of
###### P.l, which is estimated to be 1.4-2.2 times more transmissible than previous variants. Growing evidence
shows that young people are not only more likely to get infected with P.l but also to die from it, some
experts have warned. (...) Yet the increase is higher in regions where P.l is more prevalent, suggesting that it is
not only more transmissible but also more lethal. (...) P.l appears to be more lethal among young men and
women than the original strain.” _British_ _MedicalJournal,_ April 1,
2021, [https://www.bmi.com/content/373/bmi.n879](https://www.bmi.com/content/373/bmi.n879) Unresolved Questions
https: / [/www.geertvandenbossche.org/unresolvedquestions](https:_/_/_www.geertvandenbossche.org/unresolvedquestions)

###### VACCINE RESISTANT VIRUS

**MASS** **INNOCOLATION** **CREATES** **VACCINE** **RESISTANT** **VIRUS**
Vaccinologist Geert Vanden Bossche calls for a halt to the mass vaccination program. He has written urgent
letters to the WHO and others across the world. Geert Vanden Bossche, PhD, DVM, is a vaccine research
expert. He has a long list of companies and organizations he’s worked with on vaccine discovery and
preclinical research, including GSK, Novartis, Solvay Biologicals, and Bill & Melinda Gates Foundation. Dr

Copyright and intellectual property of Protection of the Educational Rights of Kids 27

[www.perk-group.com](http://www.perk-group.com)


-----

Vanden Bossche also coordinated the Ebola vaccine program at GAVI (Global Alliance for Vaccines and
Immunization). He is board-certified in Virology and Microbiology, the author of over 30 publications, and
inventor of a patent application for universal vaccines.

“It is, indeed, my interpretation of the science that ongoing mass vaccination campaigns will only drive the
emergence of additional, more infectious variants as a result from selective immune escape and ultimately lead
to full ant-vaccine resistance.” In the middle of a pandemic alters the natural immune system AND makes the
virus mutate and eventually become vaccine resistant, more serious for children, and alters the body’s ability
to respond. The problem centers in interfering with the natural immune system’s NK Cells ability to respond
to other strains. He wrote his letter to the WHO about immune escape and enhancing the virus to dangerous
levels. Based upon the findings of Professor Bieniasz’s team and those made by several other scientists, it can
no longer be denied that selective immune pressure and will, therefore, selectively drive emergence of viral
variants.
https: //37b32f5a-6ed9-4d6d-b3el          -
5ec648ad9ed9.filesusr.com/ugd/28d8fe 9fe5ccall71c48b29c6a3c5af4840c90.pdf
###### https://www.pnas.Org/content/102/3/797
**(Gert** **Slide** **Show** **Presentation** **Ohio)** https://37b32f5a-6ed9-4d6d-b3el-
5ec648ad9ed9.filesusr.com/ugd/28d8fe lca60c7d40dl41b89dbf26c7afb9f50b.pdf
**(Gert** **response** **to** **criticism** **and** **questions)** https://37b32f5a-6ed9-4d6d-b3el-
5ec648ad9ed9.filesusr.com/ugd/28d8fe 46f8422498b94078987c32f36bc82ba2.pdf
**(Gert** **11** **page** **Summary)** [https://37b32f5a-6ed9-4d6d-b3el-](https://37b32f5a-6ed9-4d6d-b3el-)
5ec648ad9ed9.filesusr.com/ugd/28d8fe d4ac099217c547ba8213783697ad85c5.pdf
**(Gert** **Interview** **and** **Videos)** [https://www.geertvandenbossche.org/](https://www.geertvandenbossche.org/)

###### LOSS OF INNATE IMMUNE SYSTEM

**LOSS** **OF** **NATURAL** **‘INNATE’** **IMMUNITY’** **POSSIBLE** **CONSEQUENCE**
Experts are “beyond worried”, that the humankind may severely damage it’s own, natural immune system
because of the mass deployment of vaccination programs at this critical juncture. Our ‘innate’ immunity
would be lost (a rich, variant-nonspecific, form of natural immunity).
###### It would also mean that vaccine-induced protection would be lost. https://dryburgh.com/byram-bridle-coronavirus-vaccine-concerns/ https:/ /dryburgh.com/wp-content/uploads/2021 /02/Bryram-Bridle-PlanB-2021 -Slides.pdf
**(Gert** **Slide** **Show** **Presentation** **Ohio)** [https://37b32f5a-6ed9-4d6d-b3el-](https://37b32f5a-6ed9-4d6d-b3el-)
5ec648ad9ed9.filesusr.com/ugd/28d8fe lca60c7d40dl41b89dbf26c7afb9f50b.pdf
**(Gert** **response** **to** **criticism** **and** **questions)** https://37b32f5a-6ed9-4d6d-b3el-
5ec648ad9ed9.filesusr.com/ugd/28d8fe 46f8422498b94078987c32f36bc82ba2.pdf
**(Gert** **11** **page** **Summary)** https: //37b32f5a-6ed9-4d6d-b3e 1-
5ec648ad9ed9.filesusr.com/ugd/28d8fe d4ac099217c547ba8213783697ad85c5.pdf
**(Gert** **Interview** **and** **Videos)** [https://www.geertvandenbossche.org/](https://www.geertvandenbossche.org/)
**(Gert** **letter** **to** **the** **who)** [https://37b32f5a-6ed9-4d6d-b3el](https://37b32f5a-6ed9-4d6d-b3el_-)        -
5ec648ad9ed9.filesusr.com/ugd/28d8fe 266039aeb27a4465988c37adec9cdldc.pdf
###### https://youtu.be/l ksalhli5c
https: / [/www.washingtonexaminer.com/news/study-covid-variant-pfizer-vaccinated-unvaccinated](https:_/_/_www.washingtonexaminer.com/news_/_study-covid-variant-pfizer-vaccinated-unvaccinated)
###### https:/ / science.sciencemag.org/content/early/2021 /03/24/science.abg9175 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291398/
https: / [/www.medrxiv.org/content/10.1101/2020.12.18.20248447vl](http://www.medrxiv.org/content/10.1101/2020.12.18.20248447vl)
###### https://www.nature.com/articles/s41392-021-00525-3

Copyright and intellectual property of Protection of the Educational Rights of Kids 28

[www.perk-group.com](http://www.perk-group.com)


-----

:e l l s a b il it y t o a t t a c k c o ist a n t u **n**

Intervention with a mass inoculation program, WHILE the virus is circulating has potentially dangerous
problems. TK cells and NK cells are our bodies natural protectors. With the possibility of NK cells to acquire
immunological memory. The wild virus is constantly mutating. Our body is designed for a general immune
response to wild infection, where you will make antibodies that are not totally specific but can protect against
a wider range of changes that occur in nature. They are capable of recognizing and attacking a broad and
diversified spectrum of pathogenic agents, including mutations. If this natural innate immune system is
disrupted or programmed through slight alterations, it no longer may be able to recognize and attack variants
or mutated strains. The shot may program your body to create specific antibodies, but may not hit the
mutated strains, leaving you to think you are protected but you may not be. (mRNA programs the body for
only focused set, while the virus continues to mutate, and the body is now at a disadvantage.)
###### https:/ /journals.plos.org/plosbiology/article?id=l 0.1371/journal.pbio. 1002198

 WARNING FROM EXPERTS AROUND THE GLOBE

 ADDITIONAL EXPERT VOICE CONCERN OF IMMUNE ESCAPE, VACCINE RESISTANT
**VARIANTS,** **INNANTE** **IMMUNE** **SYSTEM,** **RETROVIRUSES,** **VACCINE** **INDUCED** **MORE**
###### INFECTIOUS VARIANTS, IMMUNE ESCAPE-REDUCED VACCINE EFFECTIVENESS, AND LACK OF PROTECTION

**Paul** **Bienasz** "Rolling out a partially effective vaccine regime in the peak of a highly prevalent viral epidemic
is just not a great idea if one of your goals is to avoid vaccine resistance (...) There’s a chance, (...) that people
waiting for their second dose may have a sub-optimal level of immunity that places selective pressure on the
virus. If someone were to become infected during the interval between jabs, that pressure could allow for the
emergence of a mutant version of SARS-CoV-2 able to shake off a person’s immune response — a so-called
escape variant. Any such variant that also proved capable of causing severe disease could potentially spark a
whole new, devastating wave of infections and deaths." PhD, Howard Hughes Medical Institute/Rockefeller
University, New York, February 10, 2021.

**Viola** **Priesemann** (PhD, Max Planck Institut, Gottingen) According to Viola Priesemann, (PhD, Max
Planck Institut, Gottingen) new Coronavirus variants capable of escaping vaccine-induced immune protection
could develop. Such immune escape variants can particularly develop in places where many people are
vaccinated on a background of a lugli incidence rate. In a worst case scenario, this would require to restart
vaccinations from scratch.         - March 25, 2021         - RND /ARD.

###### Theo Dingermann “Mutants also occur in the absence of selection pressure. However, selection pressure
substantially increases if the reservoir for the virus is drying up. In this regard, Mr. Vanden Bossche is
absolutely right.” PhD, Goethe Universitat Frankfurt, March, 2021 .

**Byran** **Bridle** “Although Geert gets there by a slightly different route, we both end up at the same
conclusion: that current design of the vaccines and the way they are being rolled out creates risk of the
emergence of immunoevasive variants. (...) I can guarantee that he knows what he is talking about."        - (PhD,
Ontario Veterinary College, University of Guelph, Canada) March 19, 2021. Career vaccine developer, Viral
Immuniolgist.
https: / [/dryburgh.com/byram-bridle-coronavirus-vaccine-concerns](https:_/_/_dryburgh.com/byram-bridle-coronavirus-vaccine-concerns_/) /
###### https:/ /dryburgh.com/wp-content/uploads/2021 /02/Bryram-Bridle-PlanB-2021 -Slides.pdf

**Andrew** **Read** "But new findings from the British government's "New and Emerging Virus Threats Advisory
Group" suggest that the variant first discovered in the UK might not just be up to 70 percent more
contagious, but perhaps deadlier as well. There's not enough data to prove this yet, though. (...) When weak

Copyright and intellectual property of Protection of the Educational Rights of Kids 29

[www.perk-group.com](http://www.perk-group.com)


-----

vaccines are used, however, or the second dose is delayed for too long, the vaccine has the exact opposite of
the desired effect. In 2001, his research with poultry viruses led him to the conclusion that low-efficacy
vaccines could even promote the development of more dangerous virus strains. -Pennsylvania State
University virologist, _Deutsche_ _Welle,_ January 26, 2021,
[https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759](https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759)

**Bjorn** **Meyer** “We can’t really put a number on it,” a virologist at the Pasteur Institute in Paris, referring to
the risk of delayed dosing leading to the evolution of an escape variant. Every time the virus replicates there is
a chance that it could mutate into a more transmissible or more deadly form. In a single individual, the odds
###### of this happening are vanishingly small but the picture changes somewhat when you consider that tens of
millions of people are currently waiting for their second dose." _The_ _Scientist,_ Feb. 4, 2021, https://www.the-
scientist.com/news-opinion/will-delaying-vaccine-doses-cause-a-coronavirus-escape-mutant—68424
###### https:/ /journals.plos.org/plosbiology/article?id=l 0.1371/journal.pbio. 1002198 https:/ /immunology, sciencemag.org/content/6/57/eabg6461 https://www.thehindu.com/sci-tech/science/what-is-driving-the-second-wave-in-india/article34232390.ece
https: / [/www.aninews.in/news/world/middle-east/turkeys-daily-covid-19-cases-hit-a-new-](http://www.aninews.in/news/world/middle-east/turkeys-daily-covid-19-cases-hit-a-new-)
record20210402074805

**Laetitia** **Atlani-Duault,** **Bruno** **Lina,** **Franck** **Chauvin,** **Jean-Franyois** **Delfraissy,** **Denis** **Malvy,**
###### "If substantial immune evasion occurs, current vaccines are likely to still offer some benefit to individuals. At
the population level, however, they could induce viral selection and escape. (...) This virological game changer
has numerous consequences, not only for vaccines and treatment, but also for prevention and control
strategies. The fervently awaited end of this global health crisis might be continually postponed, as new
variants emerge and immune evasion reduces vaccination effectiveness in the short and medium term. (...)
We scientists working against COVID-19 must have the courage to address those in power, who bear
ultimate responsibility for the policies chosen and their consequences. If this responsibility is shirked or
delayed, the inevitable day of reckoning might be terrible."
_-Members_ _ofthe_ _French_ _COVID-19 Scientific_ _Council,_ in _The_ _Faucet,_ Feb. 18, 2021,
###### https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00036-0/fulltext

**Salim** **S** **Abdool** **Karim** "Immune-escape variants have raised concerns about the effectiveness of vaccines as
the world scales up SARS-CoV-2 immunization. (...) New variants, especially 501Y.V2 (B.1.351), which
escape natural-induced and vaccine-induced immunity, have created uncertainty on whether the vaccines are
effective in preventing both mild and severe COVID-19.” _The_ _Faucet,_ _Vaccines_ _andSARS-CoV-2_ _variants:_ _the_
_urgent_ _needfor_ _a_ _correlate_ _ofprotection,_ March 22,
2021, [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00468-](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00468-)
###### 2/fulltext?fbclid=IwARlK_tzlvBP4_yJ95jnpsj0yBxqjClZrcEQDemR5xMA64HopMZMmSVlJkKw

**Kai** **Kupferschmidt** "But now, they're also focusing on a potential new threat: variants that could do an end
###### run around the human immune response. Such “immune escapes” could mean more people who have had
COVID-19 remain susceptible to reinfection...- _Science,_ Jan. 22, 2021,
###### https:/ / science.sciencemag.org/content/371 /6527/329

"The Pl variant is especially concerning because it contains a mutation that makes it both highly contagious
and more resistant to the antibodies produced from vaccines and previous coronavirus infections. It has the
potential to infect people who have been vaccinated and even reinfect people who have had COVID-19. (...)
###### It is concerning because this is a variant that we’ve seen be very destructive in Brazil and there is concern
about the effectiveness ofvaccines."        - _The_ _Vancouver_ _Sun,_ _'Cases_ _ofvaccine-resistant_ _variant_ _more_ _than_ _doubles_ _in_ _B.Cd_
             - March 28,2021, https://vancouversun.com/news/covid-19-cases-of-vaccine-resistant-variant-more-than-
doi I les- >-c

Copyright and intellectual property of Protection of the Educational Rights of Kids 30

[www.perk-group.com](http://www.perk-group.com)


-----

**Dr.** **Stephanie** **Seneff,** an expert in protein synthesis who is a Ph.D. senior research scientist at
MIT. “The potential for blood clotting disorders and the potential for sterilization are only part of
###### the story. There are other potential long-term effects of these vaccines as well, such as autoimmune
disease and immune escape, whereby the vaccines administered to immune-compromised people
###### accelerate the mutation rate of the virus so as to render both naturally acquired and vaccine-induced antibodies no longer effective.” “This massive clinical trial on the general population could have devastating and irreversible effects on a huge number of people.”
https: / [/www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/](https:_/_/_www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/)

**Chancellery** **Chief** **Helge** **Braun** “Will a tin rd pandemic wave enhance circulation of viral mutants? Tins is
what Chancellery Minister, Helga Braun (CDU), has been warning against. If infectivity rates show a steep
rise despite ongoing vaccination campaigns, there will be an increased risk that a new virus mutant resists the
vaccine, as Braun told “Bild am Sonntag”. In case of a such mutation, we would be standing here empty-
handed,” _Der_ _Tagesspiegel,_ March 29,2021, https: [//www.tagesspiegel.de/wissen/die-angst-vor-der-](http://www.tagesspiegel.de/wissen/die-angst-vor-der-supermutante-was-wenn-kein-impfstoff-mehr-wirkt/27048992.html)
supermutante-was-wenn-kein-impfstoff-mehr-wirkt/27048992.html

###### Delphine Planas, Timothee Bruel, Oliver Schwartz, “Thus, faster-spreading SARS-CoV-2 variants
acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which
was most frequently detected in individuals with low antibody levels. Our results indicate that SARS-CoV-2
variants may increase the risk of infection in immunized individuals”         - "In conclusion, our results
demonstrate that suboptimal or declining antibody responses are associated with a loss of cross-reactivity
against novel emerging viral strains." _Nature_ _Medicine,_ March 26,
2021, [https://www.nature.com/articles/s41591](https://www.nature.com/articles/s41591_-021_-01318-5) -021 -01318-5

“These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced
efficacy of spike-based vaccines”          - March 1,
2021, [https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2.full.pdf](https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2.full.pdf)

**Dr.** **Sucharit** **Bhakdi,** World-renown, award winning researcher, German-Thai-American microbiologist,
former head of the Institute of Medical Microbiology and Hygiene in Germany. A professor of virology and
microbiology for 30 years in Germany. Dr. Sucharit Bhakdi warns, “.. .that the COVID “vaccines” are set to
cause a global catastrophe and a decimation of the human population. He explains that the PCR test has been
abused to produce fear in a way that is unscientific. He explains what the mRNA vaccines are going to do to
the human body in terms and using analogies that anyone can understand.
He expects massive deadly clotting as well as immune system responses that will destroy the human body.
https: / /healthimpactnews.com/2021 /german-microbiologist-they-are-killing-people-with-these-covid-
[vaccines-to-reduce-the-worlds-population/?fbclid=IwARlSdA7nay-](https:_/_/healthimpactnews.com/2021_/_german-microbiologist-they-are-killing-people-with-these-covid-vaccines-to-reduce-the-worlds-population/?fbclid=IwARlSdA7nay-51zSodkaSLXooKaynZCZlTizEBJiJFrYlzlH81XnaXzKodO)
51zSodkaSLXooKaynZCZlTizEBJiJFrYlzlH81XnaXzKodO
###### https://rumble. com/vfx0h3-german-microbiologist-they-are-killing-people-with-covid-vaccines-to-
reduce.html

**Dr.** **Carrie** **Madej,** **Dr.** **Lee** **Merritt** **&** **Dr.** **Christiane** **Northrup** “Unique phenomena happening around
those who recently had the shot and those who have not. Thousands of stories coming in. Uncertainty
about what is happening, but this the beginning of a round table discussions below. Discussion includes
blood clotting in women. Christiane Northrup is an expert gynecologist who has written numerous books, 3
New York Best Sellers, Oprah Show, 8 Public TV specials, Readers Digest most trusted Doctors, and decades
###### of expertise in reproductive health.
[https://rumble.com/vfyvcn-critically-thinking-with-dr.-t-and-dr.-p-episode-44.html](https://rumble.com/vfyvcn-critically-thinking-with-dr.-t-and-dr.-p-episode-44.html)
###### https: / /mamm. org/could-their-shot-be-harming-you/?fbclid=IwARl 4kQB40WflOw4GS-
4b9CKy7pUzMuR-tXEXxGGavm9WBi-fdYyPwvXTRc

Copyright and intellectual property of Protection of the Educational Rights of Kids 31

[www.perk-group.com](http://www.perk-group.com)


-----

**Dr.** **Lawrence** **Palevsky** a renowned board certified pediatrician, published author, and sought-after lecture.
Hundreds of thousands of women are experiencing abnormalities. Warning that something is not right. Top
and Bottom video. (Youtube videos are being removed, people are taking to rumble, bitchute, etc.)
http: / /www.truthunmasked.org/p/stay-
away.html?fbclid=IwAR3kWEMEv6s7muV9oMArGKRKUq4y4inTNnN2dqdgE5UxykqEIXEeqiDL5O&
###### m=l https://www.bitchute.com/video/iN8JWKJfyP4e/

**Judy** **Mikovitz** A 20 year veteran of the National Cancer Institute. On July 22, 2009, a special meeting was
held with twenty-four leading scientists at the National Institutes of Health to discuss early findings that a
newly discovered retrovirus was linked to chronic fatigue syndrome (CFS), prostate cancer, lymphoma, and
eventually neurodevelopmental disorders in children. In recent interviews, she has been outspoken
surrounding warnings that the CV shot will negatively impact millions. Most of her interviews are censored
and removed. Here are few. Pastor Rob McCoy hosted Dr. Mikovitz for a Q&A at his church in California.
https://rumble.com/vbsulp-dr.-iudy-mlkovitz-and-rob-mccoy-deleted-by-youtube.html
https://rumble.com/vcri2t-dr.-iudy-mikovits-and-robert-f.-kennedy-ir.-q-a-godspeak-calvary-chapel.html
###### https://drcharlieward.com/dr-judy-mikovits/ (April 15)
https: / [/www.bitchute.com/video/RaLH5EWHhMUh/?fbclid=IwAR2ZUDVLKy56nTO5tLK9oHi6LebDg](https:_/_/_www.bitchute.com/video/RaLH5EWHhMUh/?fbclid=IwAR2ZUDVLKy56nTO5tLK9oHi6LebDg)
iIzOS7sf9aURALDdxdTr7WwN3H9rb4
https: / /z3news.eom/w/dr-judy-mikovits-50-million-people-die-america-vaccine/

**19** **DOCTORS** **AROUND** **THE** **WORLD** **WARNING**
https://rumble.com/veseil-world-doctors-warn-do-not-take-mrna-shot.html
https://principia-scientific.com/professor-dolores-cahill-people-will-start-dying-after-covid-vaccine/ Calaill
https://z3news.eom/w/dr-iudy-mikovits-50-million-people-die-america-vaccine/

**FULLY** **VACCINATED** **BREAK** **OUTS:** **WA,** **HI,** **SC,** **LONG** **ISLAND,** **MI,** **TX,** **MN,** **KY**
More examples of consequences from mass inoculation. Media calls it break through cases or blames those
who have NOT gotten the shot. Governments are preparing for additional lock downs. Instead, a careful
evaluation may give more credibility to the numerous experts warning of ADE, immune escape, ineffective
protection from the shot, short immune protection beyond 2 months was never achieved in clinical trials, red
flags inoculation previously infected with covid, including asymptomatic carriers, allergic reactions to PEG,
instability in the body, toxicity, new unforeseen results from a new, investigational product, stronger variants
consequentially from mass inoculation, enhanced disease as seen in failed animal trials, faulty designed clinical
trials based on ineffective case definition, trials deficient in safety and efficacy, transmission not stopped after
inoculation, no long term studies, no data on mass population responses to the shots, no data on mutations,
no data on co-infections, no data on immunocompromised taking shot, unknown reactions to mNeonGreen,
ignoring warnings of pathogenic priming, ignoring the censorship of: (scientists, doctors, researchers,
virologists, whistleblowers, across the globe), and game changing altering of our innate immune systems.
(5800) https: [//www.pbs.org/newshour/health/the-shock-and-reality-of-catching-covid-after-being-](https:_//www.pbs.org/newshour/health/the-shock-and-reality-of-catching-covid-after-being-vaccinatedPutm_source=facebook&utm_medium=news_tab&utm_content=algorithm)
vaccinatedPutm source=facebook&utm medium=news tab&utm content=algorithm
https: / /www.kiro7.com/news/local/doh-vaccine-breakthrough-cases-confirmed-
wasl-ungton/UXIAR3OU4JB63GOORHTSK45OAA/
###### https:/ /www.foxnews.com/health/ny-woman-contracts-coronavirus-month-after-covid-19-vaccination-
report-says
https: / [/www.theepochtimes.com/over-1](http://www.theepochtimes.com/over-1) OO-fully-vaccinated-people-in-washington-state-test-positive-for-
covid-19 3757218.html
###### https:/ /pixl 1 .com/news/coronavirus/faces-of-the-pandemic/long-island-woman-tests-positive-for-covid-
after-2-vaccine-shots/
###### https://www.deadlinedetroit.com/articles/27635/updated vaccinated Oakland county woman gets covid
michigan identifies 145 others

Copyright and intellectual property of Protection of the Educational Rights of Kids 32

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.doh.wa.gov/Newsroom/Articles/ID/2720/Cases-of-COVID-19-vaccine-breakthrough-
confirmed-in-Washington-state
###### https://www.wistv.com/2021/03/29/hospitals-see-rare-covid-cases-fully-vaccinated-patients/
https: / [/www.newschannel6now.com/2021](http://www.newschannel6now.com/2021) /03/30/ seven-covid-vaccine-breakthrough-cases-active-wichita-
county/
https: / [/www.startribune.com/minnesota-reports-89-covid-l](https:_/_/_www.startribune.com/minnesota-reports-89-covid-l_9-cases-in-vaccinated-individuals/600038033_/) 9-cases-in-vaccinated-individuals/600038033 /
https: / [/www.lifesitenews.com/news](http://www.lifesitenews.com/news) / several-nuns-die-after-taking-first-shot-of-covid-vaccine

###### RESURGENCE IN HOSPITALIZATIONS AND DEATHS DOMINATED BY 2 DOSES

 In this study found on the website of the British government, entided "SPI-M-O: Summary of further
modelling of easing restrictions        - Roadmap Step 2" dated March 31, 2021, states that:
“The resurgence in both hospitalizations and deaths is dominated by those that have received two doses of
the vaccine, comprising around 60% and 70% of the wave respectively. Tins can be attributed to the lugli
levels of uptake in the most at-risk age groups, such that immunization failures account for more serious
illness than unvaccinated individuals.” (in paragraphs 55 and 56)
###### https://assets.publislring.service.gov.uk/government/uploads/system/uploads/attaclrment data/tile/97590
9/S1182 SPI-M-O Summary of modelling of easing roadmap step 2 restrictions.pdf
###### https://blog.fdik.org/2021-04/S1182 SPI-M-
O Summary of modelling of easing roadmap step 2 restrictions.pdf

###### PREVIOUS CRIMINAL HISTORY AND BEHAVIOR

 PFIZER, T&T, AND ASTRAZENECA PREVIOUS CRIMINAL HISTORY
Tens of billion in damages from other drugs such as Bextra, Celebrex, Thalidomide, and Opioids.
Commonality in suits: **_bringingproducts_** **_to_** **_market_** **_even_** **_though_** **_they_** **_knewinjuries_** **_and_** **_deaths_** **_would_**
**_result._** Pfizer, Johnson and Johnson, and AstraZeneca are considered serial felons. J&J lost major suits 1995­
2019. Also convicted of fraud, knowingly bringing harmful products to market, destroying documents, federal
charges, billions in settiements, testing new drugs on children without parental consent, bribery settlements,
improper payments, deliberately misleading about hazards and harm, fatalities unwarned, knowing dangerous
side effects of (VIOXX, Bextra, Celebrex), product safety issues, environmental issues, dumping toxic waste
products, chemicals released, violations of international law, human rights violations for testing on children
without parental consent, labor issues with employees, worker safety problems, endless violations and
lawsuits.
###### https://www.mp-22.com/vax
https://www.iustice.gov/opa/pr/iohnson-iohnson-pay-more-22-billion-resolve-criminal-and-civil-
investigations
###### https://www. sec.gov/news/press-release/2012-2012-152htm https://www.washingtonpost.com/wp-dyn/content/article/2007/07/02/AR2007070201255.html
https: / [/www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing](https:_/_/_www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing)
https: / [/www.reuters.com/article/us-astrazeneca-texas-lawsuits-idUSKBNlKT0Q9](http://www.reuters.com/article/us-astrazeneca-texas-lawsuits-idUSKBNlKT0Q9)

**PFIZER** **PREVIOUS** **CRIMINAL** **HISTORY**
**Pfizer** has the distinction of the biggest criminal payout in history. Fraud, knowingly bringing harmful
products to market, federal charges, billions in settiements, testing new drugs on children without parental
consent, bribery settlements, improper payments, deliberately misleading about hazards and harm, fatalities
unwarned, knowing dangerous side effects of (same as VIOXX,:Bextra, Celebrex), product safety issues,
environmental issues, dumping toxic waste products, chemicals released, violations of international law,
human rights violations for testing on children without parental consent, labor issues with employees, worker
safety problems, endless violations and lawsuits. In the category of vaccine manufacturing, they have ZERO

Copyright and intellectual property of Protection of the Educational Rights of Kids 33

[www.perk-group.com](http://www.perk-group.com)


-----

liability. They are demanding that countries where they don’t have liability protection to put up collateral,
such as embassies, military bases, and bank reserves to cover vaccine-injury lawsuits.
###### https://www.mp-22.com/vax
https://www.wionews.com/world/how-pfizer-tried-to-bully-argentina-and-brazil-in-exchange-for-vaccines-
366037
###### https://www. sec.gov/news/press-release/2012-2012-152htm
https: / [/www.washingtonpost.com/wp-dyn/content/](http://www.washingtonpost.com/wp-dyn/content/) article/2007 /07/02/AR2007070201255.html

**J&J** **KITTLED** **WITH** **FRAUD,** **FALSE** **CLAIMS,** **HIDING** **PRODUCTS** **DEFECTS**
###### Johnson and Johnson have never brought a vaccine to market before covid. Pfizer, Johnson and Johnson,
and AstraZeneca are considered serial felons. J&J lost major suits 1995-2019. Johnson and Johnson does
have a track record with previous products including: False claims, destroying documents, bribery, fraud,
hiding defects from public, billions in settlements, prison, purposefully misleading products, misbranding,
carcinogenic ingredients (baby powder knowingly containing asbestos), 45 states filed civil suits, illegal heart
drug, 2.2 Billion more penalties (DOJ), no warning about internal bleeding, 25,000 plaintiffs, 14,000 lawsuits
about talcum cancer risk, opioid crises come from same manufacturers, the company had to partner with
Merck (who is no less trustworthy) to manufacture its COVID vaccine to meet demand.
[https://fcpablog.com/2020/07/27/johnson-johnson-discloses-new-fcpa-investigation/](https://fcpablog.com/2020/07/27/johnson-johnson-discloses-new-fcpa-investigation/)
https: / [/www.justice.gov/criminal-fraud/foreign-corrupt-practices-act](http://www.justice.gov/criminal-fraud/foreign-corrupt-practices-act)
[https://www.reuters.com/article/us-brazil-corruption-healthcare-exclusiv-idUSKCNISNOZZ](https://www.reuters.com/article/us-brazil-corruption-healthcare-exclusiv-idUSKCNISNOZZ)
###### https://www. sec.gov/news/press/2011/201 l-87.htm
https: / /wu^.nytimes.com/2013 /11/20/business/johnson-iohnson-to-offer-2-5-billion-hip-device-
seti ment
https: / /www.waslungronpost. com/wp-dyn/content/article/2010/05 /27/AR2010052705484.html
https://abcnews.go.com/Health/PainManagement/fda-official-testify-agency-knew-johnson-johnson-
recall/story?id=11765649
https: / [/www.nytimes.com/1995](http://www.nytimes.com/1995) /04/11 /business/ortho-tined-7.5-million-in-retin-a-case.html
###### https://www.ftc.gov/news-events/press-releases/1996/01 /ftc-gives-tlnal-approval-consent-agreement-
johnson-johnson

**T&T** **CORRUPTION,** **FALSE** **LABEL** **CLAIMS,** **ILLEGAL** **SALES,** **TOXIC** **INGREDIENTS**
The extensive track record continues. Corruption, bribery, false label claims, toxic ingredients for children,
and endless settiements. There is a difference between this list of products and manufacturing the CV shot.
There will be no settlements, lawsuits, or criminal proceedings. If there is foul play with yet another product
in mass production to the entire population, they have full indemnity and all liability has been removed.
###### https://www.nytimes.com/2001/04/18/business/johnson-johnson-settles-lawsuits-over-contact-lenses.html
[https://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-](https://www.nytimes.com/2001/04/18/business/johnson-johnson-settles-lawsuits-over-contact-lenses.htmlhttps://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-label-promotion)
label-promotion
[https://www.cbsnews.com/news/jj-settles-criminal-case-alleging-ceo-reviewed-illegal-heart-drug-sales-plan/](https://www.cbsnews.com/news/jj-settles-criminal-case-alleging-ceo-reviewed-illegal-heart-drug-sales-plan/)
https: / [/www.forbes.com/sites/amywestervelt/2011/11/01/as-report-reveals-toxic-ingredients-in-baby-](http://www.forbes.com/sites/amywestervelt/2011/11/01/)
shampoo-johnson-johnson-goes-public-with-plans-to-clean-up-products/?sh=a9b9ba94b5ad
https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-
investigations
https: / [/childrenshealthdefense.org/defender/russel-brand-opiod-crisis-pandemic/](https:_/_/_childrenshealthdefense.org/defender/russel-brand-opiod-crisis-pandemic/)
https: / [/www.nytimes.com/2019/11/15](http://www.nytimes.com/2019/11/15) /health/opioids-oklahoma-johnson-tine.html

**T&T** **BRIBERY,** **CORRUPT** **PRACTICES** **GLOBALLY**
“Brazil’s Public Prosecution Service started an investigation into J&J’s antitrust activities under the Foreign
Corrupt Practices Act (FCPA) for “possible improper payments in its medical device industry. The company
had to pay out a $70 million penalty for buying off officials in Greece, Poland and Romania. In 2010, an
executive for J&J’s subsidiary DePuy was sentenced to a year in prison for corrupt payments to physicians
within the Greek national healthcare system.”

Copyright and intellectual property of Protection of the Educational Rights of Kids 34

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.sec.gov/news/press/2011/2011-87.htm

**T&T** **FAILED** **QUALITY** **CONTROL** **AND** **HEALTH** **CITATIONS**
Fifteen million doses ofJohnson & Johnson (J&J’s) vaccine failed quality control after workers at a Baltimore
manufacturing plant negligentiy combined ingredients from AstraZeneca and J&J’s COVID vaccine. Plant
has a series of health citations already, https://www.chicagotribune.com/coronavirus/vaccine/ct-aud-nw-
johnson-and-j ohnson-coronavirus-vaccine-20210401 -btekuav34vfjtlbo4iuugjroy4-story.html
https: / [/www.nytimes.com/2021](http://www.nytimes.com/2021) /03 /31 /world/johnson-and-johnson-vaccine-mixup.html
https: / [/www.emergentbiosolutions.com/](https:_/_/_www.emergentbiosolutions.com/)

###### ASTRAZENECA SUSPENSION https://www.cnbc.com/2021/03/31/germany-suspends-use-of-astrazenecas-covid-shot-for-the-under-
60s
https: / /www.businessinsider.com/astrazeneca-covid-vaccine-countries-suspend-denmark-thailand-batch-
blood-clots-2021-3?op=l
###### https://www.rki.de/EN/Content/infections/Vaccination/Vaccination node.html https://gth-online.org/wp-content/uploads/2021/03/GTH Stellungnahme AstraZeneca 3 19032021-
3.pdf
###### https:/ /apnews.com/article/germany-cities-suspend-astrazeneca-vaccine-under-60-
c6da4f4ed846ebebbe24505bfbf9bfce
https: / [/thehighwire.com/videos/astrazeneca-vaccine-falls-from-grace/](https:_/_/_thehighwire.com/videos/astrazeneca-vaccine-falls-from-grace/)

###### NIH (NIAID IS PART OF) CLAIMS JOINT OWNERSHIP OF MODERNA’S VACCINE
Contracts reflect jointly owned-Contract between NIH and Moderna. NIH Director statement, NIH has
particular stake in IP behind Moderna’s Coronavirus vaccine.
[https://www.axios.com/moderna-nih-coronavirus-vaccine-ownership-agreements-22051c42-2dee-4bl9-](https://www.axios.com/moderna-nih-coronavirus-vaccine-ownership-agreements-22051c42-2dee-4bl9-)
938d i99afc lf6a0
###### https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential- Agreements.html#document/pl05 /a568569 (Contract) https:/ /www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html(NIH)
[https://www.economicclub.org/events/dr-francis-collins-chris-nassetta-and-mary-brady](https://www.economicclub.org/events/dr-francis-collins-chris-nassetta-and-mary-brady)
###### https://www.nature.com/articles/nbt.2785
https: / [/childrenshealthdefense.org/defender/truth-rfk-jr-naomi-wolf-constitutional-](https:_/_/_childrenshealthdefense.org/defender/truth-rfk-jr-naomi-wolf-constitutional-)
###### rights/?utm source=salsa&eType=EmailBlastContent&eId=26b5c090-223d-4d5d-9526-e0f692535e8c
(Patents and Fauci)

###### 40 BILLION IN PROFITS

**$40** **BILLION** **PROFITS** **AND** **PROFIT** **MARGINS:**
4000% Increase in profits for Moderna, who previously couldn’t get funds for CV vaccines. SI 8.4 billion in
revenue this year. Overall, the liability free manufacturers are expecting a S41 Billion dollar business profits
this year alone. mRNA vaccines are faster and cheaper to produce than traditional vaccines and for vaccine
manufacturers, more cost-effectiveness translates to greater profits. Bernstein market analyst Ronny Gal also
predicts COVID-19 vaccine sales will reach $40 billion this year.
https: / /www.fool.com/investing/2020/12/10 [/how-much-money-](https:_/_/_www.fool.com/investing/2020/12/10_/how-much-money-_will-moderna-make-from-its-covid-va/) will-moderna-make-from-its-covid-va/
###### https://investorplace.com/2021 /03/covid-19-vaccine-orders-are-piling-up-mrna-stock-has-room-to-grow/
[https://www.theguardian.com/business/2021](https://www.theguardian.com/business/2021) /feb/25/moderna-forecasts-18bn-in-sales-of-covid-vaccine-
thls-year

###### BILLIONS IN CONTRACTS AND MARKETING DOLLARS

Copyright and intellectual property of Protection of the Educational Rights of Kids 35

[www.perk-group.com](http://www.perk-group.com)


-----

**JS** **GNED** **C(** **NTRACTS** **AND** **MARKET:** **4G** **CAMP** **TC** **FHE**

Governments across the world are locked into contractual deals to push the acceptance, marketing, and
distribution of these new vaccines. **$4** **Billion** **Marketing** **Dollars,** **Marketing** **analysis** **on** **how** **to**
**persuade** **people** **to** **take** **the** **vaccine.** U.S, government’s SI billion deal with J&J to buy 100 million doses
###### of its experimental vaccine. https://www.hhs.gov/sites/default/files/ strategy-for-distributing-COVID-19-vaccine.pdf
https://www.theguardian.com/business/2021 /feb/25/m(Sdema-fdfecasts-18bfi-iri-saIes-of-covid-vaccin&-
this-year
https: / /w^^v.bloomberg.com/news /articles /2020 -03-3 0 / j-j -surges-after-1 -billion-vaccine-deal-with-u-s-
government

**IF** **TREATMENTS** **BELOW** **EXIST,** **VACCINE** **MANUFACTURES** **AND** **BILLION** **DOLLAR**

**>NTRACTS** **ARE** **NOT** **NEEDED**

###### https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-
information en.pdf
###### https://budesonideworks.com/validation-2/ https: / /covid 19criticalcare.com/wp-content/uploads /2020 /12/One-Page-Summary-of-the-Clinical-Trials-
Evidence-for-Ivermectin-in-COVID-19.pdf
https: / /cl [9early.com](https:_/_/cl_9early.com)
###### https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext

 BRAZIL AND ARGENTINA EMBASSIES, MILITARY BASES, BANK RESERVES

**BRAZIL** **AND** **ARGENTINA** **EMBASSIES,** **MILITARY** **BASES,** **BANK** **RESERVES**
Argentina and Brazil both rejected Pfizer contracts because of demands from Pfizer:
**Pfizer** **demands** **from** **Argentina:** compensations from the government from any future lawsuits, the
government should buy an international insurance for any future lawsuits, sovereign assets as collateral (bank
reserves, military bases, embassy buildings.
**Pfizer** **demands** **from** **Brazil:** the government should create a "guarantee fund" and deposit money in a
foreign bank account, waiving sovereignty of abroad assets, Brazilian laws should not be applied to Pfizer,
exempt Pfizer from all civil liability
https://www.wionews.com/world/how-pfizer-tried-to-bully-argentina-and-brazil-in-exchange-for-vaccines-
366037
https: / [/greatgameindia.com/pfizer-demanding-military-bases-vaccines](https:_/_/_greatgameindia.com/pfizer-demanding-military-bases-vaccines_/) /

**FINANCIAL** **DISCLOSURE** **FORM** **FOR** **COVID** **INJECTIONS**
###### https://pandemic, solari.com/family-financial-disclosure-form-for-covid-19-injections/

 b JTEWORTHY LEGAL CASES

 REINER IN GERMANY WON 4/22/2021A FAVORABLE RULING
Reiner in Germany filed a case for “crimes against humanity,” cases in Norway, Israel, against the WHO, and
won a favorable ruling for one of them from the German court this week.
[https://m.youtube.com/watch?v=7RG3k76zTRM](https://m.youtube.com/watch?v=7RG3k76zTRM)
###### https://www.israelnationalnews.com/News/News.aspx/297626
https: / /www.covidtruths.co.uk/2021 /03 [/dr-reiner-fuellmich-pcr-lawsuit-update-march-2021/](https:_/_/_www.covidtruths.co.uk/2021_/03_/_dr-reiner-fuellmich-pcr-lawsuit-update-march-2021_/)
###### https:/ /goldenageofgaia.com/2021 / 03/30/government-of-norway-indicted-for-crimes-against-humanity/

**ROCCO** **GALATI** **IN** **CANADA** **CONSTITUTIONAL** **LAWYER** **LITIGATE** **AGAINST** **CA**
https: / [/www.youtube.com/watch?v=OotKzj7yU9o](https:_/_/_www.youtube.com/watch?v=OotKzj7yU9o)
https: / [/www.youtube.com/channel/UCU](https:_/_/www.youtube.com/channel/UCU_5kkoB3taGIDfwbyWhlAw/videos) 5kkoB3taGIDfwbyWhlAw/videos

Copyright and intellectual property of Protection of the Educational Rights of Kids **36**

[www.perk-group.com](http://www.perk-group.com)


-----

**ISRAEL** **NUREMBERG** **CASE** **FILED**
Unvaccinated threatened to be expelled, Threatening to deny unemployment benefits, Unvaccinated law
proposed to prevent unvaccinated to enter work place, Preventing entry into schools, theatres, entertainment,
and other receipt of services and goods. Applying social pressure, economic pressure, aggression from
insurance, health authorities. Financial benefit cards and incentives promoting vaccination. Separating
unvaccinated from society through green card system and passport. Heavily redacted contract agreement
between Israel and Pfizer. The contract between Israel government and Pfizer is required Israel to transfer all
the personal and medical records of citizens to Pfizer, without consent of the people. Israeli’s were told and
marketed that the vaccine was fully approved rather than EUA status. No voluntary participation or
informed consent given. Nuremberg case is brought because the force upon the people is also without the
ability to opt out or refuse. Including false advertisement about FDA approval.
https://www.archyde.com/international-criminal-court-accepts-israeli-governments-nuremberg-code-
violation-complaint/

**ISRAEL** **INFORMATION** **RELENTLESSLY** **BEING** **SUPRESSED**
###### REPORT SUBMITTED TO ISRAEL ATTORNEY GENERAL AND THE HEALTH MINISTER In Israel yesterday, an independent legal body that calls itself the Civilian Probe (CP)* published its finding
regarding the catastrophic impact of the Pfizer vaccine on the nation. “Every world citizen who is concerned
about the future of humanity should be alarmed by the CP’s findings and particularly by the **desperate** **and**
**relentless** **attempts** **to** **suppress** **free** **academic,** **scientific** **and** **ethical** **discussion** about Covid, the so-
called vaccines’ or anything else.” The CP study also presents alarming medical findings regarding the **scale**
###### of lethal side effects and possible attempt to mislead not just Israelis but also the entire world.
http://www.nakim.org/israel-forums/viewtopic.php?t=270812
###### https://www.francesoir.fr/videos-debriefings/vaccination-en-israel-des -claiffres-de-mortalite-qui-
interpellent-video
###### https://archive.ph/o/iiIVR/https://www.israelnationalnews.com/News/News.aspx/297051

**ISRAEL** **PROMISED** **SAFETY** **MONITORING** **SYSTEM** **NOT** **IN** **PLACE**
“Monitoring systems that enable the detection of side effects are a basic and critical condition for granting
permission for mass use of any new medicine, certainly when a mass operation of treatment that is defined as
experimental is given to millions, and especially when this treatment is given to an entire country...”.
“In the absence of a transparent monitoring system that reports on side effects, not only have the Israeli
government and the Ministry of Health failed citizens by **providing** **them** **with** **misleading** **information,**
the Israeli government have failed both Pfizer and the rest of the world awaiting the results of the (so
called) **‘real** **world** **experiment’** (that is taking place in Israel).”

“On the one hand, the state did **not** **inform** **the** **citizens** **that** **Pfizer’s** **vaccine** **is** **in** **experimental**
###### stages that have not yet been completed, and that at this stage they are actually taking part in the experiment. On the other hand, the state did not maintain transparent and open control and monitoring systems for
**the** **public.** As a result, there is a serious concern that this critical and negligent omission stems from: (a) the
fear that such disclosure could interfere with the fulfilment of the objectives that may be implied by the
Israel-Pfizer agreement or (b) the fear of diminishing demand for the exceptional number of vaccines that
were purchased by Israel in advance, and / or (c) the fear of revealing unflattering results of the ‘experiment’
being carried out in Israel.”
[http://www.nakim.org/israel-forums/viewtopic.php?t=270812](http://www.nakim.org/israel-forums/viewtopic.php?t=270812)
###### https://www.francesoir.fr/videos-debrietings/vaccination-en-israel-des -chiffres-de-mortalite-qui-
interpellent-video
###### https://archive.ph/o/jiIVR/https://www.israelnationalnews.com/News/News.aspx/297051

 INTERNATIONAL COURT TAKES ON ISRAEL NUREMBERG VIOLATION CASE

Copyright and intellectual property of Protection of the Educational Rights of Kids 37

[www.perk-group.com](http://www.perk-group.com)


-----

The CP argues that “in order to generate demand (amongst the people) for the vaccine, the government and
the Ministry of Health have **launched** **an** **unprecedented** **aggressive** **campaign,** **aiming** **to** **make** **Israelis**
**rush** **to** **‘get** **vaccinated.’** During that campaign, all the basic rules of medical caution and ethics were
disregarded, and with them also key guidelines formed after WWII regarding participation in medical trials
(the Nuremberg Code). Instead of transparent and clear explanations, the public was **misled** **by** **repeated**
**official** **statements** that the (Pfizer vaccine) has been ‘approved by the FDA’ after passing ‘rigorous tests.’”

“the Pfizer-Israel agreement is suffocated with redacted segments, consequently, it is not possible to analyze
it legally and/or fully grasp Its implications as far as public health is concerned... **This** **concealment** **casts** **a**
**heavy** **shadow** **over** **anyone** **who** **took** **part** **in** **the** **(Israeli/Pfizer)** **negotiations..**
https: / /www.archyde.com/international-criminal-court-accepts-israeli-governments-nuremberg-code-
violation-complaint/

###### IVERMECTIN TREATMENT TESTIMONIES GIVEN TO HOMELAND SECURITY

Ivermectin, miracle drug for COVID. Dr. Pierre Kory, president of the FLCCC Alliance testifies before
Senate Committee on Homeland Security and Governmental Affairs looking into early outpatient COVID-19
treatment. FLCCC discovered ivermectin has a potent real-world properties in mild, moderate, and severe
disease states. Database below of all IVERMECTIN COVID-19 studies. (89 studies, 48 peer-reviewed, 52
with treatment and control groups.)
https: / [/www.c-span.org/video/?c4929855](http://www.c-span.org/video/?c4929855) /user-clip-dr-pierre-kory-president-flccc-alliance-testifies-senate-
committee-homeland-security
https: / /cl [9ivermectin.com](https:_/_/cl_9ivermectin.com) (Database of Ivermectin studies including 48 peer reviewed.)
https: / /covidl [9criticalcare.com/ivermectin-in-covid-19](https:_/_/_covidl_9criticalcare.com/ivermectin-in-covid-19_/) /
###### https://covidl9criticalcare.com/wp-content/uploads/2020/12/Qne-Page-Summary-of-the-Clinical-Trials-
Evidence-for-Ivermectin-in-COVID-19.pdf
###### https:/ /osfio/wx3zn/

 HDROX
Database of all HCQ Covid-19 studies. 285 studies, 213 peer-reviewed, 236 comparing to control groups.
###### https://cl9hcq.com https://pubmed.ncbi.nlm.nih.gov/33430933/ https://pubmed.ncbi.nlm.nih.gov/32616063/ https://budesonideworks.com/validation-2/

**VITAMIN** **D,** **QUERCITIN,** **SURAMIN**

74 Studies on Vitamin D. Database of all vitamin D Covid-19 studies. Analyzing outcomes and effect.
https: / /cl [9vitamind.com](https:_/_/cl_9vitamind.com)
###### https:/ /odysee.com/@SaveMedia:5/capitol-clarity-ryan-cole-on-covid-19-vitamin-d-vaccine-concerns:2 https://pubmed.ncbi.nlm.nih.gov/33278625/

 BUDESONIDE CASE STUDY AND MEDICAL JOURNALS
The most recent study by Oxford University (randomized control trial) showed a 90% reduction in
hospitalization for people with COVID. Below are links to a peer-reviewed studies, articles in medical
journals, or news articles regarding the **efficacy** **of** **budesonide.** Medical Journals Articles and Studies in
Additional Resource Section Addendum.
###### https:/ /www.medrxiv.org/content/10.1101 /2021.02.04.21251134vl
https://www.ox.ac.uk/news/2021-02-09-common-asthma-treatment-reduces-need-hospitalisation-covid-19-
patients-study
[https://budesonideworks.com](https://budesonideworks.com)

Copyright and intellectual property of Protection of the Educational Rights of Kids 38

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://covidsilverbullet.com/wp-content/uploads/2020/07/Bartlett COVID Case Study.pdf http://stateofthenation.co/?p=19630
_Common_ _asthma_ _treatment_ _reduces_ _needfor_ _hospitalisation_ _90%]_ _in_ _COVID-19_ _patients,_ _stud)!_ _suggests_ _(University_ _of_

_Oxford)_

_Pathophysiological_ _Basis_ _and_ _Bationalefor_ _Early_ _Outpatient_ _'Treatment_ _ofSARS-CoV-2_ _(COVID-19)_ _Infection_ _—_
_ScienceDirect_ _(from_ _the_ _AmericanJournal_ _ofMedicine)_

###### HOME-BASED TREATMENT RESOURCES From the association of American Physicians and Surgeons, a group representing over 500,000 medical
professionals across the United States.
###### https://aapsonline.org

 Additional topics covered below in Addendum 1

 Including ingredient sm-102, Moderna Patent, Spike protein injuries, Prion’s Disease and Covid Vaccine, and DARPA (A program operating under the DOD specialising in BioTech.)

Copyright and intellectual property of Protection of the Educational Rights of Kids 39

[www.perk-group.com](http://www.perk-group.com)


-----

###### ADDENDUM 1 ADDITIONAL SIGNIFICANT RESOURCES

 Table of Contents

**10** **BILLION** **IN** **ADDITIONAL** **MARKETING** **CAMPAIGNS...........................................................................41**

**DANGER** **INGREDIENT** **SM-102** **"THIS** **PRODUCT** **IS** **NOT** **FOR** **HUMAN** **OR** **VETERINARY** **USE."** **41**

**MODERNA** **PATENT** **16** **CITATIONS** **OF** **GENE** **THERAPY,** **GENE** **TRANSFER,** **GENE**
**THERAPEUTIC,** **GENE** **EDITING,** **GENE** **LINING** **REFERENCES...........................................................41**

**GENETICALLY** **ENGINEERED** **DNA** **VACCINES** **AND** **TUMORS...............................................................42**

**DOCTORS** **CENSORED** **FOR** **INTRODUCING** **EARLY** **PREVENTION** **TREATMENTS......................... 42**

**MOST** **COMPREHENSIVE** **LIST** **OF** **VAX** **SIDE** **EFFECTS** **DR.** **RAY** **SAHELIAN,** **MD............................. 43**

**INJURY** **RELATED** **TO** **SPIKE** **PROTEIN...........................................................................................................44**

**INJURY** **RELATED** **TO** **ANTI-S-ANTIBODY** **AND** **ILLNESS** **DUE** **TO** **IMMUNE** **SYSTEM**
**SUPPRESSION........................................................................................................................................................ 44**

**PRION** **DISEASE** **AND** **COVID** **VACCINE...........................................................................................................45**

**17** **YEARS** **OF** **IMMUNITY** **FROM** **PREVIOUS** **COVID** **INFECTION...........................................................45**

**COVID** **SURVISORS** **IMMUNITY** **COULD** **LAST** **FOR** **YEARS.......................................................................46**

**WOMEN’S** **PERIOD** **STORIES,** **PERIOD** **DISRUPTION,** **AND** **RESEARCH................................................ 46**

**POSSIBLE** **3RD** **WAVE** **DOMINATED** **IN** **THE** **UK** **BY** **60%** **VACCINATED** **IN** **HOSPITAL...................** **46**

**NEW** **STANDFORD** **STUDY,** **INFLATED** **DISEASE** **SEVERITY** **IN** **CHILDREN....................................... 47**

**FORMER** **HHS** **ADVISOR** **WARNS** **VAX** **WILL** **HARM** **CHILDREN...............................................................47**

**MAMMOGRAM** **RESULTS** **SIDE** **EFFECT...........................................................................................................47**

**75%** **OF** **VAERS** **INJURY** **REPORTS** **IN** **APRIL** **IS** **ABNORMALLY** **ONLY** **J&J** **REPORTS......................... 48**

**LINK** **FOR** **INJURY** **STORIES.................................................................................................................................48**

**ESTIMATED** **CLINICAL** **TRIALS** **STUDY** **COMPLETION** **DATE..................................................................48**

**DARPA** **FUNDED** **MODERNA.............................................................................................................................. 48**

**DARPA+MODERNA+PROFUSA+GOOGLE+NIH+CEPHEID..................................................................... 49**

**DARPA** **(DIGET).......................................................................................................................................................49**

**DARPA** **HYDROGEL................................................................................................................................................** **49**

Copyright and intellectual property of Protection of the Educational Rights of Kids 40

[www.perk-group.com](http://www.perk-group.com)


-----

**10** **BILLION** **IN** **ADDITIONAL** **MARKETING** **CAMPAIGNS**

Biden approved nearly $10,000,000,000.00 for marketing campaigns, anticipating an oversupply. The U.S.
government funded vaccine research to the tune of more than $9 billion, spent $22 billion to support vaccine
distribution, shelled out another $10 billion to expand access and currently announced $3 billion to spend on
an ad campaign to combat vaccine hesitancy.
###### https:/ /\v \v a v . mTimes.com/2021 704/01/us/politics/coronavirus-vaccine-hesitancy.html
https: / [/www.nytimes.com/2021](http://www.nytimes.com/2021) /04/01 /us/politics /coronavirus-vaccine-hesitancy.html
###### https://www.aanp.org/news-feed/nurse-practitioners-mobilize-to-increase-vaccinations-across-minority-
communities-and-combat-vaccine-hesitancy

###### DANGER INGREDIENT SM-102 "THIS PRODUCT IS NOT FOR HUMAN OR VETERINA
**USE."**

Connecticut Department of Public Health recently released Moderna Ingredient (sm-102). SM-102 is an
ingredient in Moderna’s lipid nanoparticle mixture. The SM-102 product likely comes from Cayman
Chemical, as their page lists it being used in lipid nanoparticle preparation and cites a publication by
Moderna-affiliated authors. It's 10% SM-102 (ionizable lipid) and 90% chloroform (solvent). The Safety Data
Sheet (SDS) for their product states it is an extremely toxic and hazardous substance, suspected of causing
cancer, developmental toxicity, suspected of damaging fertility or the unborn child, damage to the central
nervous system, the kidneys, the liver and the respiratory system through prolonged or repeated exposure.
The company states: "This product is not for human or veterinary use."
###### http://www.abovetopsecret.com/forum/threadl286756/pgl https://faqs.in.qov/hc/en-us/articles/360054156652-What-are-the-inqredients-in-the-Moderna-

iV 11

###### https://www.fda.gov/media/144637/download (See 13. Pg. 20 DESCRIPTION of the FDA vaccine sheet) https://www.caymanchem.com/product/33474/sm-102 https://www.caymanchem.com/msdss/33474m.pdf (pg. 1,2,10)

 MODERNA PATENT 16 CITATIONS OF GENE THERAPY, GENE TRANSFER, GENE THERAPEUTIC, GENE EDITING, GENE LINING REFERENCES

 16 Citations and references in Moderna’s official patent referencing mRNA therapy medicine as gene therapy, gene transfer, gene therapeutics, gene delivery, mRNA encoding humans. https://www.modernatx.com/sites/default/tiles/USl 0702600.pdf
Page 5-6

###### • Kuhn , A.N., et al. , mRNA as a versatile tool for exogenous protein expression . Current Gene Therapy. Oct. 2012 ; 12 (5 ) : 347-361 .

 • Lorenzi, J.C. , et al., Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis. BMC Biotechnol. Oct. 2010 ; 10 ( 77) : 1-11 .

 • Rabinovich , PM., et al., Synthetic messenger RNA as a tool for gene therapy. Hum . Gene Ther .
Oct. 2006; 17 : 1027-1035 .

###### • Schott, J.W. ,et al., Viral and non - viral approaches for transient delivery of mRNA and proteins .
Current **_Gene_** **_Ther._** 2011 ; 11 ( 5 ) : 382-398 .

Copyright and intellectual property of Protection of the Educational Rights of Kids 41

[www.perk-group.com](http://www.perk-group.com)


-----

###### • Segura , J. , et al. , Monitoring gene therapy by external imaging of mRNA : Pilot study on murine
erythropoietin . Ther Drug Monit. Oct. 2007 ; 29 (5 ) : 612-8 .

###### • Smits, E. , et al. , RNA - based gene transfer for adult stem cells and T cells. Leukemia . 2004 ; 18

: 1898-1902 .

###### • Strong , V.T. et al., Incorporation of beta - globin untranslated regions into a Sindbis virus vector
for augmentation of heterologous mRNA expression . Gene Ther . Jun . 1997 ; 4 (6) : 624-7 .

###### • Tavernier , G. , et al., mRNA as gene therapeutic: How to control protein expression . J. of
Controlled Release . Mar. 2011 ; 150 (3 ) : 238-247 .

###### • Wang et al., Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine
kinase for targeted cancer **_gene_** **_therapy._** Mol Ther . Feb. 2013 ; 21 (2) : 358-67 . doi: 10.1038 /
mt.2012.250 . Epub Dec. 11 , 2012 .

###### • Yamamoto et al. , Current prospects for mRNA gene delivery, European Journal of Pharmaceutics
and Biopharmaceutics 71 (2009 ) 484-489 .

###### • Sahin et al. , mRNA - based therapeutics developing a new class ofdrugs . Nat Rev Drug Discov .
Oct. 2014 ; 13 (10) : 759-80 . doi: 10.1038 / nrd4278 . Epub Sep. 19,2014 .

###### • Hecker , J.G. et al., Non - Viral DNA and mRNA Gene Delivery to the CNS Pre - Operatively for Neuroprotection and Following Neurotrauma . Molecular Therapy . 2004 ; 9 , S258 - S258 .

 • Hoerr , I. et al. , Stabilized Messenger RNA (RNActiveTM) as a Tool for Innovative Gene Delivery. Tissue Engineering . Apr. 2007 ; 13 (4) : 865-925 . Hoerr ,

 • More than a messenger : A new class of drugs - mRNA - based therapeutics. Genetic Engineering & Biotechnology News .Jun . 18,2013. http://www.genengnews.com/gen-

articles/more-than-a-messenger a             - new             - class             - of             - drugs             - mrna             - based             - therapeutics / 4916 / [

last accessed Mar. 25,2016 ] .

###### • Kisich et al. , Antimycobacterial agent based on mRNA encoding human beta - defensin 2 enables
primary macrophages to restrict growth of Mycobacterium tuberculosis . Infect Immun . Apr. 2001 ;
69 (4) : 2692-9 .

**GENETICALLY** **ENGINEERED** **DNA** **VACCINES** **AND** **TUMORS**

Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune
responds to foreign antigens, such as hMPV antigens and/or PIV antigens and/or RSV antigens. The direct
injection of genetically engineered DNA (e.g. naked plasmid DNA) into a living host results in a small
number of its cells directly producing an antigen, resulting in a protective immunological response, including
the possibility of insertional mutagenesis, wlaich could lead to the activation of oncogenes or the **_inhibition_**
###### oftumor suppressorgenes.
 https://www.modernatx.com/sites/default/tiles/USl 070260Q.pdf (Modern patent Pg. 31)

 DOCTORS CENSORED FOR INTRODUCING EARLY PREVENTION TREATMENTS

Copyright and intellectual property of Protection of the Educational Rights of Kids 42

[www.perk-group.com](http://www.perk-group.com)


-----

One of America's most-published physicians, **_Peter_** **_McCullough,_** MD, has been repeatedly censored. Peter
A. McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center. Doctors
discuss suppression of treatment. Coundess Doctors have stated their successful treatments have been
suppressed. Including renowned Dr. **His** **Testimony** **to** **US** **Senate** **Committee** **Hearing:**

**Hearing** **ent** **Outpatient**
**Treotme** **tial** **Part**
**at** **a** **Cv** **iution** **'**

Video on November 19th, 2020        - **Early** **Outpatient** **Treatment:** **An** **Essential** **Part** **of** **a** **COVID-19**
**Solution.** Dr. McCullough and other witnesses give testimony at a US Senate Committee Hearing
[https://www.hsgac.senate.gov/hearings/early-outpatient-treatment-an-essential-part-of-a-covid-19-solution](https://www.hsgac.senate.gov/hearings/early-outpatient-treatment-an-essential-part-of-a-covid-19-solution)

**Video** **on** **His** **Treatment** **Publication:** October 11, 2020, see video of Dr. McCullough providing a critical
update: **_Ambulatory_** **_Treatment_** **_ofCOVID-19._** (Association of American Physicians and Surgeons)
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410805/ http://pb-site.eom/l/bB-OGOZVx/rl kx WuVBjN

 UNPRECEDENTED ULL )F PEER REVIEWED MANU 2RIPT
Tills was the second time this happened. The prior issue of IVERMECTIN manuscript was pulled at the last
minute in February. Unprecedented in medicine, interference and suppression of completed and successfully
acceptance of peer-review work. It was then picked up by the American Journal of Therapeutics, 3 rounds
peer-review and was published on 4/29. See the full resignation LETTER and unprecedented interference
below. Dr. Marik is one of eleven doctors with the Frondine Covid-19 Critical Care Alliance, and the second
most published critical care doctor in the world. Dr. Pierre Kory, “I was trying to be fair and generous before
now. This is clear censorship. There is no other possible rational explanation. It’s indefensible in science to
reject a peer-reviewed accepted publication. It went through three rounds of peer review by experts in the
field. It’s well-defensed. Out conclusions in that paper match exactly the conclusions of the international
effort which is the British IVM Recommendation Development Guideline Committee meeting which is
experts, researchers, clinicians from all over the world. Those conclusions are the same. Yet this journal did
not want to publish our paper and they removed it. It is unconscionable.”
https: //www.hartgroup,org/.../05/ResignationsFrontiers.pdf
###### https:/ /tinTOfl.com/v6TOytp7

**MOST** **COMPREHENSIVE** **LIST** **OF** **VAX** **SIDE** **EFFECTS** **DR.** **RAY** **SAHELIAN,** **M.D,**

After reviewing thousands of VAERS reports, Dr. Sahelian describes side effect details more thoroughly than
most. His description and summary of the spike protein covid shot is also enlightening and informative.
Giving readers the most comprehensive informed consent on risks and adverse reactions.
###### https:/ /raysahelian.com/covidvaccinesideeffects.html https:/ /raysahelian.com/index.html

Copyright and intellectual property of Protection of the Educational Rights of Kids 43

[www.perk-group.com](http://www.perk-group.com)


-----

###### CHILDREN EUA APPROVAL OF COVID SHOT WITH NO SAFETY DATA ON CO­ ADMINISTRATION OF OTHER VACCINES
 On May 12, 2021, the ACIP committee approved the EUA authorization of the Pfizer shot for 12-15 year
old’s. They also are allowing CO-ADMINISTRATION with other shots on the same day. There aren’t any
studies or data on the interaction of a new mRNA shot with the existing other shots.
###### https://www.bmj.com/content/373/bmj.nl244/rr- l?fbclid=IwARlthWVZTPnHp TYU9TMmCqd6K9Oah8Wtn5gnhOoriNl-H986M5oNPRWTEI https://www.hhs.gov/live/live-l /index.html#13231

**INJURY** **RELATED** **TO** **SPIKE** **PROTEIN**

Spike protein         - immobilize M2 macrophages:, cardiac damage, ACE2 Receptors, spike proteins bind tightly to
ACE2, multi-organ system failure, pulmonary artery hypertension, spike proteins attach to sperm and eggs,
(Syncytin         - "Quite simply, syncytin is critical and without it, human life could never form.”), spike proteins:
loss of BBB integrity, Amyotrophic Lateral Sclerosis (ALS), prion disease, damage to FUS gene and TDP-43
protein: The RNA sequence in the vaccine [3] contains sequences believed to induce TDP-43 and FUS to
aggregate in their prion based conformation leading to the development of common neurodegenerative
diseases, 5 Types frontotemporal lobe degeneration, FUS gene and cancer, adenoviruses and cancer, 20
mechanisms of injury (MOI). Complied by Dr. Sherri Tenpenny. [www.DrTenpenny.com](http://www.DrTenpenny.com)
###### https://insight.ici.org/articles/view/123158 (cardiac damage)
[https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-keyrole-](https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-keyrole-) (in illness)
###### https://pubmed.ncbi.nlm.nih.gov/15141377/ (ACE2 Receptors)
https: / [/www.preprints.org/manuscript/202003.0422/vl](http://www.preprints.org/manuscript/202003.0422/vl) (Spike Proteins bind tightly to ACE2)
###### https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533045/ (Multiorgan system failure) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827936/ (pulmonary artery hypertension)
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941816](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941816_() (spike proteins: attach to sperm and eggs)
http: / [/isciencemag.co.uk/features/the-syncytin-gene-viruses-responsible-for-human-life/](http:_/_/isciencemag.co.uk/features/the-syncytin-gene-viruses-responsible-for-human-life/_) Syncytin- “without
it, human life could never form.”
###### https://www.sciencedirect.com/science/article/pii/S096999612030406X?via0/o3Dihub (loss BBB integrity) https://carterheavyindustries.files.wordpress.com/2021 /02/covidl9-rna-based-vaccines-and-therisk- (ALS) https://www.hopkinsmedicine.org/health/conditions-and-diseases/prion-diseases (prion disease)
[https://principia-scientitic.com/covid-19-rna-based-vaccines-and-the-risk-of-priondisease/](https://principia-scientitic.com/covid-19-rna-based-vaccines-and-the-risk-of-priondisease/) neurodegenerativ
###### https://pubmed.ncbi.nlm.nih.gov/23041957/ (frontotemporal lobe degeneration) https://medlineplus.gov/genetics/gene/fus/#conditions (FUS gene and cancer) https://www.ncbi.nlm.nih.gov/books/NBK8503/ (adenoviruses and cancer)

**INJURY** **RELATED** **TO** **ANTI-S-ANTIBODY** **AND** **ILLNESS** **DUE** **TO** **IMMUNE** **SYSTEM**
**SUPPRESSION**

Already cited are acute reactions (anaphylaxis, cardiac arrest) and illness or damage caused by spike proteins.
Cited below is injury caused by anti-S-antibody and illness/damage to immune system (macrophage damage,
###### ADE, original antigenic sin, etc)
[https://insight.jci.org/aiticles/view/123158](https://insight.jci.org/aiticles/view/123158) (anti-S-antibody damage, lung damage)
###### https://www.frontiersin.org/articles/10.3389/fimmu.2020.617089/full#fl (28 of 55 tissue types react- antibody)
https:/ [/www.frontiersin.org/articles/10.3389](http://www.frontiersin.org/articles/10.3389) /fimmu.2020.01120/full (original antigenic sin)
###### https://peerj.com/articles/10112/ (flu shots and COVID deaths)
[https://jamanetwork.com/journals/jama/aiticle-abstract/2777390](https://jamanetwork.com/journals/jama/aiticle-abstract/2777390) (severe and prolonged illness)
###### https://www.frontiersin.org/aiticles/10.3389/fimmu.2020.01120/full
https: / [/www.sbi-online.org/Portals](http://www.sbi-online.org/Portals) /0/Position%20Statements/2021 /SBI-recommendations-formanaging-
axillary-adenopathy-post-COVID-vaccination.pdf (Swollen lymph node)
[https://jamanetwork.com/journals/jama/aiticle-abstract/2777390](https://jamanetwork.com/journals/jama/aiticle-abstract/2777390) (mutant strains)

Copyright and intellectual property of Protection of the Educational Rights of Kids 44

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.sciencedirect.com/science/article/abs/pii/S1286457920300344?via%3Dihub (ADE on re-exposure) https://www.fda.gov/media/146219/download (Injected of transgenes and DNA can lead to anti-DNA
antibodies. Foreign DNA can integrate into human DNA. JJ Shot pg 12 — Transgene.
###### https://www.i-sis.org.uk/transgenicLinesUnstable2.php (Instability of transgene lines)
https://www.academia.edu/23304303/Medical [conditions](https://www.academia.edu/23304303/Medical_conditions_associated_with_a_positive_anti_dou) associated with a positive anti dou
ble_stranded_deoxyribonucleic_acid (dsDNA Antibodies associated with long list of illnesses)
###### https://covidl 9-sciencetable.ca/sciencebrief/vaccine-induced-prothrombotic-immunethrombocytopenia-vipit-
following-astrazeneca-covid-19-vaccination/ (deadly blood clots)
(MOI) Complied by Dr. Sherri Tenpenny. [www.DrTenpenny.com](http://www.DrTenpenny.com)

###### ACUTE REACTIONS MOI #1 anaphylaxis/PEG: https:/ /www.sciencedirect.com/science/article/pii/S2451945619300352

 PRION DISEASE AND COVID VACCINE

**"Covid-19** **RNA** **Based** **Vaccines** **and** **the** **Risk** **of** **Prion** **Diseases,”** just published in MICROBIOLOGY
AND INFECTIONS DISEASES, **addresses** **one** **of** **the** **many** **potential,** **unintended,** **adverse** **health**
**effects** **of** **the** **experimental** **mRNA** **Covid-19** **vaccines** **presently** **being** **deployed** **worldwide,** **namely,**
**their** **possible** **induction** **of** **prion** **diseases,** **a** **category** **of** **highly** **fatal** **brain** **disorders.** The concluding
paragraph in the 3-page journal article: "Many have raised the warning that the current epidemic of COVID-
19 is actually the result of an bioweapons attack released in part by individuals in the United States
government [10,11]. Such a theory is not far fetched given that the 2001 anthrax attack in the US originated at
Fort Detrick, a US army bioweapon facility. Because the FBI’s anthrax investigation was closed against the
advice of the lead FBI agent in the case, there are likely conspirators still working in the US government. In
such a scenario the primary focus of stopping a bioweapons attack must be to apprehend the conspirators or
the attacks will never cease. Approving a vaccine, utilizing novel RNA technology without extensive testing is
extremely dangerous. The vaccine could be a bioweapon and even more dangerous than the original
infection."
###### https://scivisionpub.com/pdfs/covidl9-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf https://www.greenmedinfo.com/blog/study-finds-plausible-lmk-between-deadly-prion-brain-diseases-
experimental-mrna-3

**17** **YEARS** **OF** **IMMUNITY** **FROM** **PREVIOUS** **COVID** **INFECTION**

Robust immune response from T-Cells with protective cross over immunity, protection, and qualities
protective of other COVID viruses and infections. Memory T-cells persist with cross over protection for
years. Studies include convalescent SARS-CoV-2 patients and found they had also produced similar T-cells.
While SARS-CoV-2 is a new virus and distinct from SARS-CoV-1, there is strong reason to believe that T-
Cell memory produced by the body to protect from future relapses of this virus would not be weaker or more
short-lived than T-cell memory from SARS-1.
###### https://www.nature.com/articles/s41586-020-2550-z
https: / /immunology, sciencemag.org/content/2/14/eaan5393
https: / [/www.nature.com/articles](https:_/_/_www.nature.com/articles_/_nri820) /nri820
###### https:/ /linkinghub.elsevier.com/retrieve/pii/SI 074761313000526 https:/ /linkinghub.elsevier.com/retrieve/pii/0140673693930637
https: / [/www.frontiersin.org/articles/10.3389](http://www.frontiersin.org/articles/10.3389) /fimmu.2018.02225 /full
###### https:/ /www.cell.com/cell-reports/fulltext/S2211 -1247 (20)30515­
5? returnURL=https%3A%2Fo/o2Flinkinghub.elsevier.com%2Fretrieve0/o2FpiiQ/o2FS2211124720305155%3F
showall%3Dtrue
###### https:/ /rupress.org/jem/article/201 /5/675/40209/Heterologous-T-cell-immunity-in-severe-hepatitis-C https://www.sciencedirect.com/science/article/pri/S0264410X16002589?via 0/o3Dihub

Copyright and intellectual property of Protection of the Educational Rights of Kids 45

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.cell.com/cell-host-microbe/fulltext/Sl 931-3128(20)30072-
X? returnURL=https%3A%2F%2Flinlanghub.elsevier.com%2Fretrieve%2Fpii7o2FS193131282030072X%3
Fshowall%3Dtrue
###### https: / /www.cell.com/immunity/fulltext/S1074-7613 (20)30181­
3? retumURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FSl074761320301813%3F
showall%3Dtrue

**UR** **ITY** **COULD** **LAST** **FOR** **YEARS**

The human immune system is more than just antibodies. T-cells, NK cells, antibodies, and more are critical
to a healthy immune system. Previous Sars Covid infections have the potential of 17 years of immunity.
###### https://www.technologyreview.com/2021/01 /06/1015822/covid-19-immunity-likely-lasts-for-
years/?fbclid=IwARlCcU339aOL8kxwtOY3WL5kSJb72ZPtYeiH6JbZcs3IOSve7CyLn3A2x-8
**https:** **/** **/www.cell.com/cell/fulltext/50092-8674(20)30610-3**
**https:** **/** **[/www.lji.org/news-events/news/post/exposure-to-common-cold-coronaviruses-can-teach-](https:_/_/_www.lji.org/news-events/news/post/exposure-to-common-cold-coronaviruses-can-teach-the)**
###### the-immune-system-to-recognize-sars-cov-2/
**https:** **/** **[/science.sciencemae.org/content/371/6529/eabf4063](https:_/_/_science.sciencemae.org/content/371/6529_/_eabf4063)**
###### https://www.psychologytoday.com/us/bloe/live-better-longer/202104/are-we-immune-covid-19-if- weve-been-exposed https://www.nature.com/articles/s41577-020-00436-4

 QUESTIONS SURROUNDING SPIKE PROTEIN SHEDDING
Can people shed the spike that the vaccine is asking their cells to make?
###### https:/ /academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075

 WOMEN’S PERIOD STORIES, PERIOD DISRUPTION, AND RESEARCH

Concerning stories coming from women.
[https://www.risemamarise.com/cycles?fbclid=IwAR016utHbFeW](https://www.risemamarise.com/cycles?fbclid=IwAR016utHbFeW_LD9PZFh6qqKucHHIHRQmgi3QOLu) LD9PZFh6qqKucHHIHRQmgi3QOLu
###### NdkjmOReCcurl 4TLaA
[https://www.risemamarise.com/cycles](https://www.risemamarise.com/cycles)
###### https://mycyclestory.com/

**POSSIBLE** **3RD** **WAVE** **DOMINATED** **IN** **THE** **UK** **BY** **60%** **VACCINATED** **IN** **HOSPITAL**
According to a UK government study on the government website, entitled "SPI-M-O: Summary of further
modelling of easing restrictions        - Roadmap Step 2" dated March 31, 2021, states that:
“The resurgence in both hospitalizations and deaths is dominated by those that have received two doses of
the vaccine, comprising around 60% and 70% of the wave respectively. Tins can be attributed to the high
levels of uptake in the most at-risk age groups, such that immunization failures account for more serious
illness than unvaccinated individuals. Tins is discussed further in paragraphs 55 and 56.“ The study states that
people with already two doses of vaccination now make up the rise in Corona deaths and hospitalizations.
They account for about two-tlairds of all cases. Link of the study & back up link below.
###### https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment data/file/97590
9/S1182 SPI-M-O Summary of modelling of easing roadmap step 2 restrictions.pdf
###### https://blog.fdik.org/2021-04/S1182 SPI-M-
O Summary of modelling of easing roadmap step 2 restrictions.pdf (page 10)

**ME** **IT** **F<**

###### “I understand that these may not be all the side effects of the COVID-19 vaccine as the vaccine is
**still** **being** **studied** **in** **clinical** **trials.** **I** **also** **understand** **that** **it** **is** **not** **possible** **to** **predict** **all** **possible** **side**
**effects** **or** **complications** **which** **could** **be** **associated** **with** **the** **vaccine.** **I** **understand** **that** **the** **long-term**

Copyright and intellectual property of Protection of the Educational Rights of Kids **46**

[www.perk-group.com](http://www.perk-group.com)


-----

**side** **effects** **or** **complications** **of** **this** **vaccine** **are** **not** **known** **at** **this** **time.”**
https://principia-scientific.com/have-you-actually-read-a-covidl9-vaccine-consent-form-
yet/?fbclid=IwAR31gpKl 52gzwIX9-IgeLYFlyOShPTagTL2a9q96OFDBerrA-nGfreL-128

###### NEW STANDFORD STUDY, INFLATED DISEASE SEVERITY IN CHILDREN

Dr. Schroeder and his team suggested that pediatric hospitalization rates are used as a marker of coronavirus
disease 2019 (COVID-19) disease severity in children but may be inflated by the detection of mild or
asymptomatic infection via universal screening.
https: / /hosppeds.aappublications.org/content/hosppeds/early/2021 /05 /21 /hpeds.2021 -006001 .fullpdf

**FORMER** **HHS** **ADVISOR** **WARNS** **VAX** **WILL** **HARM** **CHILDREN**
Former HHS COVID advisor, Dr. Paul Alexander warns against children getting the COVID19 vaccine.
Fox news is one of the few stations willing to carry this warning. “Kids have a 1 in 50,000 chance of dying if
they are covid infected. It’s a very, very small risk. Again the issue is why would they be placing parents in
this position to vaccinate these children with such low risk. When this is an experimental vaccine. It’s highly
untested as to safety and they will not have the requisite time duration and sample size to get the power to
detect any meaningful differences. So, I think they are absolutely wrong.. .The risk to children is so small.
There is no reason too put our children in harms way at this point. Not with these untested vaccines and with
a sample size of 3000.. .There is no way they can derive meaningful results and safety data for parents. This is
reckless.”
“Exposing children to an untested Emergency Use medication implies that there is a dire risk to the children
without it. There are no data to support such a potential risk.” “The key for parents to understand is this,
these will NOT provide you the type of safety data to give you the level of confidence to put these vaccines
in your children’s arms. Because we are talking about, children have 70-80 years more life to live. There
could be devastated by these vaccines if something goes wrong. And again the issue is the liability waiver.”
https: / [/www.aier.org/article/why-we-must-not-be-forced-into-vaccinating-our-children-from-covid-beware/](https:_/_/_www.aier.org/article/why-we-must-not-be-forced-into-vaccinating-our-children-from-covid-beware/)
###### https://video.foxnews.com/v/6252603254001
https://www.lifesitenews.com/news/its-reckless-to-vaccinate-children-for-covid-19-former-hhs-coronavirus-
advisor

**:STIMONY** **FROM** **DOCTOR** **SCIENTIST** **CALLS** **FOR** **A** **HALT**

A sobering testimony to the CDC from a research scientist who saw ovarian destruction in novel
contraceptive tests earlier. Menses disruptions, blood clotting, sperm issues, immunosuppressive issues,
fertility issues, now, highlighted. She calls for a halt.
https: / [/www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/](https:_/_/_www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/)

**VACCINE** **CHECKERS** **GOING** **DOOR** **TO** **DOOR** **IN** **CALIFORNIA**
Thousands laired to go door to door.
###### https:/ /californiaglobe.com/section-2/gov-newsom-sending-vax-checkers-door-to-door/ https://www.msn.com/en-us/news/us/knock-knock-have-you-had-your-vaccine-yet-california-sends-out-
thousands-to-check/ar-BBlgUqD0?fbclid=IwAR3aG3vgKnW-
Ympm4AlzR04WI2UAN UWvq3nxOs7wz54kIMhNtrpdGtRIiO

**MAMMOGRAM** **RESULTS** **SIDE** **EFFECT**

As women get their yearly mammograms, doctors have noticed something impacting results: the presence of
swollen lymph nodes, a common side effect of the COVID-19 vaccine.
###### https://www.thvll.com/article/news/health/covid-vaccine-side-effect-imammogram-results/91-lab98fb0-
eda0-4bc3-9aef-100c26a93667

Copyright and intellectual property of Protection of the Educational Rights of Kids 47

[www.perk-group.com](http://www.perk-group.com)


-----

**75%** **OF** **VAERS** **INJURY** **REPORTS** **IN** **APRIL** **IS** **ABNORMALLY** **ONLY** **T&T** **REPORTS**

Reporter Berenson shows evidence today that HHS is rushing to add J&J adverse event reports to VAERS
while slow walking reports for Pfizer & Moderna. But the harms from Pfizer & Moderna are greater than
from the J&J product. “So you've gotta ask WHY? Is this a story of financial conflicts of interest (shared
patents with NIH for the mRNA products). Or something else? Why kill the adenovirus vector products and
protect the mRNA product line when the mRNA safety profile is actually worse?”
###### https://twitter.com/AlexBerenson/status/1392499188794003460

**PRO** **VACCINE** **PEDIATRICIAN** **DOCTOR** **TESTIFIED** **BEFORE** **TEXAS** **SENATE** **TO**
**PROTECT** **CHILDREN** **FROM** **THIS** **SHOT**
###### In public testimony, Pediatrician Dr. Angelina Farella said, “Never in history before have we given
medications that were not FDA approved to people who were not initially studied in the trial. There were no
trial patients under the age 18. There were no trial patients previously had covid.. .1 have given tens of
thousands of vaccines in my office. At the recent ACIP meeting, one of the things that is extremely troubling,
and it’s on their ACIP guidelines for the Pfizer vaccine in particular, is that recommendations about safety
and efficacy and adverse events will come out AFTER authorization.”
“We are currently allowing children to get this vaccine, and they were never studied in the clinical trial. On
top of that.. .they are extrapolating the data from adults down to children and adolescents.. .Children are not
littie adults. Tins is unacceptable. Children have a 99.997% survivability.”
https: / [/youtu.be/mIPbOAtEvAE](https:_/_/_youtu.be/mIPbOAtEvAE)

###### THE CONTROL GROUP NO LONGER EXISTS If the unblinding and the offer to placebo recipients to get vaccinated in a randomized placebo-controlled
trial (RCT) began within weeks of EUA, then we had an RCT for only the duration of time till EUA (2-3
months). After that, the trial can no longer be deemed a randomized placebo-controlled trial, as the control
group, which is needed to know the baseline rates of COVID and adverse events against which to compare
the rates in the vaccinated group, no longer exists. They might as well terminate the trials altogether right
after EUA instead of continuing with this farse and pretending they are doing science.
Peter Doshi's article in the BMJ: [https://www.bmi.com/content/373/bmj.nl244/rr-l](https://www.bmi.com/content/373/bmj.nl244/rr-l)

###### LINK FOR INJURY STORIES

http: / [/covidvaccinevictims.com/](http:_/_/_covidvaccinevictims.com/)

###### ESTIMATED CLINICAL TRIALS STUDY COMPLETION DATE

**April** **6,** **2023**
###### https:/ /clinicaltrials.gov/ct2/show/NCT04368728

**DARPA** **FUNDED** **MODERNA**

Moderna, The first company in the United States to enter clinical trials with a vaccine for the virus was
###### funded by DARPA. Additionally, the second company, working was also funded by DARPA as well.
Receiving over $1.5 Billion dollars this year. Without disclosing DARPA and government invested funds.
The Defense Advanced Research Projects Agency (DARPA) is a research and development agency of the
United States Department of Defense responsible for the development of emerging technologies for use by
the military. The DARPA SIGMA+ program is developing networked sensors to detect a variety of chemical,
biological, and explosive threats..Key to this undertaking are technologies centered on DNA and RNA—
including some developed under DARPA’s, ADEPT program. Using these tools, through a biological version

Copyright and intellectual property of Protection of the Educational Rights of Kids 48

[www.perk-group.com](http://www.perk-group.com)


-----

###### of reverse engineering, manufacture genetic constructs that, when delivered, can instruct an individual’s
body to produce similar protective antibodies.
_https:/_ _/_ _wmv.statnen’s.com/pharmalot!2020)08/28/moderna-coiid'l9-vacclne-coronai'irus-patents-darpa!_
###### https://www.darpa.mil/work-with-us/covid-19
[https://www.darpa.mil/news-events/2017-02-06a](https://www.darpa.mil/news-events/2017-02-06a)
https: / [/www.darpa.mil/program/autonomous-diagnostics-to-enable-prevention-and-therapeutics](https:_/_/_www.darpa.mil/program/autonomous-diagnostics-to-enable-prevention-and-therapeutics)

###### DARPA+MODERNA+PROFUSA+GOOGLE+NIH+CEPHEID

DARPA funds Moderna (after years of DARPA iniatiaves and focused RNA and DNA vaccines
technologies. DARPA funds Profusa which created a wearable injected biosensor, which syncs up to a smart
phone app. Google backs Profusa, while Google also is intimately involved in surveillance programs,
censorship, and contact tracing initatives. Profusa is also partnered and funded by the NIH and DARPA.
DARPA’s years-old goal of creating a national, web-based database of preemptive diagnoses is noticed in the
current “push” for a national contact tracing system, vaccine passports, and health pass systems based on
citizens’ private health data and vaccine status. The additional overlap runs deep as the co-founder of Profusa
is also a co-founder in Cepheid the diagnostic company of a rapid coronavirus test, who won FDA approval.
https: / /www.theguardian.com/science/2017/dec/04/us-military-agency-invests-1 OOm-in-genetic-extinction­
technologies
###### https://profusa.com/our-team/
https: / /www.theverge.com/platform/amp/interface/2020/4/14/21219289 /apple-google-contact-tracing-
app-android-ios-pros-cons-quarantine-testing
###### https://profusa.com/partners-investors/
https: / /techstartups.com/2020 /03 /21 /fda-approves-rapid-coronavirus-test-results-45-minutes-test-
conducted-california-based-diagnostic-testing-company-cepheid/

**DARPA** **(DIGET)**

DARPA began the Detect It with Gene Editing Technologies (DIGET) and the Epigenetic Characterization
and Observation (ECHO) programs focused on rapid discovery, validation, and manufacture of diagnostics
detecting any threat, anytime, anywhere. DARPA provided near-real-time diagnostic results during a 2 month
###### study... The team is now focusing on expanding the cohort and tracking long-term host response. DARPA
Gel or hydrogel is part of the vaccines.
[https://www.darpa.mil/work-with-us/covid-19](https://www.darpa.mil/work-with-us/covid-19)

**DARPA** **MICROCHIP** **SENSOR**
Sensor under the skin.
https://www.dailymail.co.uk/news/article-9460389/Pentagon-scientists-invent-microchip-senses-COVID-
19-body-symptoms.html

**DARPA** **HYDROGEL**

DARPA’s ongoing web series highlighting the agency’s active programs focused on the diagnosis, detection,
treatment, prevention and manufacture of _medical_ _countermeasures._ Over the years, DARPA-funded projects
have created the building blocks of GPS, the first computer mouse, protocols that underpin the modern
Internet. The agency pioneered stealth technology that made American fighter jets all but invisible to enemy
radar. It advanced a bevy of new weaponry, including drones. As DARPA shifted to biotechnology, including
funding Profusa’s creation of a wearable sensor, it’s not so far-fetched that DARPA hydrogel contains
nanoparticles and nanotechnology.
https: / [/www.darpa.mil/work-with-us/covid-19](https:_/_/_www.darpa.mil/work-with-us_/_covid-19)
**https:/** **Zwww.darpa.mil/**

Copyright and intellectual property of Protection of the Educational Rights of Kids 49

[www.perk-group.com](http://www.perk-group.com)


-----

https://www.washingtonpost.com/national-security/how-a-secretive-pentagon-agency-seeded-the-ground-
for-a-rapid-coronavirus-cure/2020/07/30/adl 853c4-c778-11 ea-a9d3-74640f25b953 story.html

**CATEGORIES** **COVERED**

$10 Billion in Marketing Sm-102
Moderna Patent 16 Gene Therapy Citations Tumors
Early Treatment Suppression Most Cited Doctor Censored
Peer-Reviewed Journal Problems Most Comprehensive List of Vaccine Side Effects
###### No Safety Data on Co-Administration on Children Spike Protein (MOI)- 20 Mechanisms of Injury
Prion Disease 17 Years of Immunity, Covid Survivors
DARPA Funded Moderna Disrupted Menstruation Cycles
Projection of 3rd Wave in the UK Informed Consent Form
Stanford Study- Inflated Hospital Numbers in Children HHS Advisor Warning About Children
###### Doctor Warns to Halt Everything Door to Door Vaccine Checkers
Mammogram Disruption Abnormal J&J Reporting
The Control Group No Longer Exists

**_***Medical_** **_disclaimer:_** _This_ _pdf,_ _information,_ _resource_ _list,_ _and_ _website_ _information_ _was_ _createdfor_
_informational_ _purposes_ _only_ _and_ _has_ _no_ _ties_ _to_ _any_ _drug_ _company_ _or_ _physician._ _The_ _content_ _is_ _not_ _intended_
_to_ _be_ _a_ _substitutefor_ _professional_ _medical_ _advice,_ _diagnosis,_ _or_ _treatment._ _Always_ _seek_ _the_ _advice_ _ofyour_
_physician_ _or_ _other_ _qualified_ _health_ _provider_ _with_ _any_ _questionsyou_ _may_ _have_ _regarding_ _a_ _medical_
_condition._ _Never_ _disregard_ _professional_ _medical_ _advice_ _or_ _delay_ _in_ _seeking_ _it_ _because_ _ofsomethingyou_ _have_
_read_ _on_ _this_ _website._ _In_ _addition,_ _no_ _one_ _involved_ _in_ _this_ _website_ _hasfinancial_ _ties_ _to_ _any_ _ofthe_ _suggested_
_therapies._ _We_ _are_ _merely_ _advocates_ _ofinformed_ _consent,_ _open_ _dialogue_ _on_ _all_ _sides_ _ofan_ _issue,_ _andfight_
_medical_ _censorship._ _***_

Copyright and intellectual property of Protection of the Educational Rights of Kids 50

[www.perk-group.com](http://www.perk-group.com)


-----

###### CONCLUSION

 From the beginning, professionals have raised concerns and warnings of ADE, immune escape, ineffective protection from the shot, short immune protection beyond 2 months was never shown in clinical trials, red flags concerning inoculating previously infected with covid, including asymptomatic carriers, allergic reactions to PEG, and instability in the body, toxicity. Many voiced problems about new unforeseen results from a new, investigational product, never before approved, including problems with stronger variants consequentially from mass inoculation. Others alerted of a failed injury surveillance system and enhanced disease as seen in failed animal trials.

 Whistleblowers claimed faulty designed clinical trials were based on ineffective case definition with trials deficient in safety and efficacy. Still yet, clinical trials did not prove transmission would be stopped after inoculation. There are no long-term studies, no long-term data on mass population responses to the shots, no data on effectiveness on mutations, no data on co-infections, no data on immunocompromised taking the shot. Prevalent with numerous unknown reactions including to mNeonGreen. What happens if there continues to be an ignoring of warnings signs of pathogenic priming? The unexplained phenomenon is shaking women across the world to the core. A minimum of thousands of women are reporting having reproductive health issues including abnormal bleeding, bruising, clotting reactions, including women who were not injected with the new shot, but are simply around recently inoculated persons. If we ignore the censorship of: (scientists, doctors, researchers, virologists, whistleblowers, across the globe), and game changing altering of our innate immune systems, what happens to our children, this generation, and humanity?

 Previously convicted criminals leading the charge in manufacturing, brand new medicine that itself had been plagued with ethical concerns and high risks. Those convicted with fraud, bribery, corruption, false labeling, defective products, toxic products, knowingly letting them stay in public circulation with consumers, NOW, have no liability or way to be held accountable if past behavior patterns transfer into these golden “liability free” products.

 This list predominately comes from the original sources, credible scientific journals, peer reviewed studies, to allow people access to original source information. Information has been withheld from traditional searches or labeled with blanket misinformation stamps. Leaving truth seekers unsure what is true and reliable. Those warning from around the world are being canceled, attacked, dismissed, and their information is being deleted.

 A “SHOT” heard around the world is symbolic for a historic global moment. A careful evaluation may give credence to the thousands of experts who have been censored, removed from online, targeted with removal of their licenses, as they lay it all on the line to get this information to the public. May we hear the “SHOT heard around the word” before our children are unnecessarily harmed.

**_***Medical_** **_disclaimer:_** _Thispdf,_ _information,_ _and_ _website_ _information_ _was_ _createdfor_ _informationalpurposes_ _only_ _and_ _has_ _no_ _ties_ _to_
_any_ _drug_ _company_ _orphysician._ _The_ _content_ _is_ _not_ _intended_ _to_ _be_ _a_ _substituteforprofessional_ _medical_ _advice,_ _diagnosis,_ _or_ _treatment._ _Always_
_seek_ _the_ _advice_ _ofyourphysician_ _or_ _other_ _quaffed_ _healthprovider_ _with_ _any_ _questionsyou_ _may_ _have_ _regarding_ _a_ _medical_ _condition._ _Never_
_disregardprofessional_ _medical_ _advice_ _or_ _delay_ _in_ _seeking_ _it_ _because_ _ofsomethingyou_ _have_ _read_ _on_ _this_ _website._ _In_ _addition,_ _no_ _one_ _involved_ _in_
_this_ _website_ _hasfinancial_ _ties_ _to_ _any_ _ofthe_ _suggested_ _therapies._ _We_ _are_ _merely_ _advocates_ _ofinformed_ _consent,_ _tying_ _to_ _save_ _lives,_ _andfight_
_medical_ _censorship._ _***_

Copyright and intellectual property of Protection of the Educational Rights of Kids 51

[www.perk-group.com](http://www.perk-group.com)


-----

###### ADDITIONAL RESOURCE LINKS

**MORE** **RESOURCES** **IN** **JOURNALS** **ABOUT** **PREVIOUS** **ADE** **IN** **CV** **FAMILY** **OF** **VIRUSES:**
###### https://pubmed.ncbi.nlm.nih.gov/32428113/ https://pubmed.ncbi.nlm.nih.gov/32229574/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165470/
https: / [/pubmed.ncbi.nlm.nih.gov/32092539](https:_/_/_pubmed.ncbi.nlm.nih.gov/32092539_/) /
###### https://pubmed.ncbi.nlm.nih.gov/12725690/ https://pubmed.ncbi.nlm.nih.gov/29740424/ https://pubmed.ncbi.nlm.nih.gov/21200427/ https://pubmed.ncbi.nlm.nih.gov/21401915/ https:/ /pubmed.ncbi.nlm.nih.gov/30796434/ https://pubmed.ncbi.nlm.nih.gov/24182427/
[https://www.ncbi.nlm.nih.gov/pubmed/28360135](https://www.ncbi.nlm.nih.gov/pubmed/28360135)
###### https://pubmed.ncbi.nlm.nih.gov/12810865/ (ADE mice)
[https://www.ncbi.nlm.nih.gov/pubmed/28817732](https://www.ncbi.nlm.nih.gov/pubmed/28817732) (White rabbits)
###### https://pubmed.ncbi.nlm.nlh.gov/19122397/ (feline)
https: / [/pubmed.ncbi.nlm.nih.gov/2154621](https:_/_/pubmed.ncbi.nlm.nih.gov/2154621_/) / (feline)
https: / [/pubmed.ncbi.nlm.nih.gov/6754243](https:_/_/pubmed.ncbi.nlm.nih.gov/6754243_/) / (feline in Dengue)
###### https://pubmed.ncbi.nlm.nih.gov/17049691 / (hamsters) https://www.ncbi.nlm.nih.gov/pubmed/21937658 (Mice, increase lung inflammation on challenge) https://pubmed.ncbi.nlm.nih.gov/29029938/ (vaccine enhanced disease) https://www.nature.com/articles/d41586-020-00751-9 (don’t rush CV vaccine without guarantees) https://pubmed.ncbi.nlm.nih.gov/32179860/ https://pubmed.ncbi.nlm.nih.gov/32317716/ (danger antibody response in rushed CV-shots) https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm pubs (Ebola) https://pubmed.ncbi.nlm.nih.gov/27339099/ (zika)
https: / /technology.inquirer.net/69907 [/pharma-firm-issues-caution-anti-dengue-vaccine-sanofi-dengvaxia-](https:_/_/_technology.inquirer.net/69907_/_pharma-firm-issues-caution-anti-dengue-vaccine-sanofi-dengvaxia-)
vaccine-health-dengue (Pharma firm issues caution on use of anti-dengue)
###### https://pubmed.ncbi.nlm.nih.gov/3Q410732/
https: / [/www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018](https:_/_/www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018) (Dengue distrust
in free vaccines post scare of Dengue outcome.)
https: / /www.telegraph.co.uk/news /2018 /02/05 [/philippines-immunisation-rates-plummet-amid-dengue-](https:_/_/_www.telegraph.co.uk/news_/2018_/02/05_/_philippines-immunisation-rates-plummet-amid-dengue-)
vaccination/ (Philippines)

###### BUDESONIDE MEDICAL JOURNAL ARTICLES AND STUDIES
_Common_ _asthma_ _treatment_ _reduces_ _needfor_ _hospitalisation_ _90%]_ _in_ _C0l7ID-19patients,_ _study_ _suggests_ _(University_ _of_

_Oxford)_

_Pathophysiological_ _Basis_ _and_ _Rationaleforlgarly_ _Outpatient_ _Treatment_ _ofSARS-CoV-2_ _(C0V7D-19)_ _Infection_ _—_
_ScienceDirect_ _(from_ _the_ _AmericanJournal_ _ofMedicine)_
_Multifaceted_ _highly_ _targeted_ _sequential_ _multidrug_ _treatment_ _ofearly_ _ambulatory_ _high-risk_ _SARS-CoV-2_ _infection_ _(C0U1D-_

_19)_ _(Revieu’s_ _in_ _Cardiovascular_ _Medicine)_

_Inhaled_ _corticosteroids_ _and_ _C0VID-19:_ _a systematic_ _review_ _and_ _clinicalperspective_ _from_ _Uuropean_ _Respiratory_ _Journal)_
_Inhaled_ _corticosteroids_ _in_ _vimspandemics:_ _a_ _treatmentfor_ _C0VID-19?_ _(From_ _The_ _Uancet)_
_SARS-CoV-2_ _and The_ _Casefor_ _Empirical_ _Treatment_ _(The_ _Global_ _(ournal_ _ofScience_ _Frontier_ _Research_ _—_ _Volume 20,_ _Issue_

_Pathophysiological_ _Basis and_ _Rationalefor_ _Early_ _Outpatient_ _Treatment_ _ofSMRS-CoV-2_ _(C0VID-19)_ _Infection_ _(US_
_Mational_ _Eibrary_ _ofMedicine_ _National_ _Institutes_ _ofHealth)_
_Budesonidefacilitates_ _weaningfrom_ _mechanical_ _ventilation_ _in_ _difficult-to-ivean_ _very_ _severe_ _C0PDpatients_ _(US_ _National_
_Eibrary_ _ofMedicine_ _National_ _Institutes_ _ofHealth)_

Copyright and intellectual property of Protection of the Educational Rights of Kids 52

[www.perk-group.com](http://www.perk-group.com)


-----

_Effect_ _ofnebulised_ _budesonide_ _on_ _respiratory_ _mechanics_ _and_ _oxygenation_ _in_ _acute_ _lung_ _injury/_ _acute_ _respiratory_ _distress_
_syndrome_ _(US_ _National_ _Eibrary_ _ofMedicine_ _National_ _Institutes_ _ofHealth)_

###### IVERMECTIN ADDITIONAL LINKS https:/ /pubmed.ncbi.nlm.nih.gov/32251768/ https://pubmed.ncbi.nlm.iiih.gov/33234158/ https://pubmed.ncbi.nlm.nih.gov/33115543/
https: / [/pubmed.ncbi.nlm.nih.gov/32513289](https:_/_/_pubmed.ncbi.nlm.nih.gov/32513289_/) /
https: / [/pubmed.ncbi.nlm.nih.gov/33038449](https:_/_/_pubmed.ncbi.nlm.nih.gov/33038449_/) /
###### https://pubmed.ncbi.nlm.nih.gov/33341233/ https:/ /pubmed.ncbi.nlm.nih.gov/33397429/ https:/ /pubmed.ncbi.nlm.nih.gov/33430924/ https://pubmed.ncbi.nlm.nih.gov/33662102/ https:/ /pubmed.ncbi.nlm.nih.gov/32493494/ https://pubmed.ncbi.nlm.nih.gov/33407777/

V **NA** **JRCES**

###### https://pubmed.ncbi.nlm.nih.gov/32252338/ https://pubmed.ncbi.nlm.nih.gov/32755992/ https://pubmed.ncbi.nlm.nih.gov/32474141 / https://pubmed, ncbi.nlm.nih.gov/32946517/ https://pubmed,ncbi.nlm.nih.gov/32784601 / https://pubmed.ncbi.nlm.nih.gov/32605780/ https://budesonideworks.com/validation-2/

 JOHN HOPKINS SECOND DOSE WORSE SIDE EFFECTS
 https://www.ihsph.edu/covid-19/articles/side-effects-and-covid-19-vaccines-what-to-expect.html https://pubmed.ncbi.nlm.nih.gov/30370619/

 PFIZER, ASTRAZENECA, MODERNA HEALTH CARE INFORMATION UK https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment data/file/96786 0/Temporary Authorisation Patient Information BNT162 7 0 UK .pdf
https: / [/www.england.nlis.uk/coronavirus/wp-](https:_/_/_www.england.nlis.uk/coronavirus_/_wp-)
###### content/uploads/sites/52/2021/01/Information for UK recipients COVID-19 Vaccine AstraZeneca.pdf https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-
information en.pdf
https: //www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-
information en.pdf

**DATA** ON **DE** **ATHS** AND **RECLASSIFCATIONS**
###### https:/ /drive.google.com/file/d/1 -Xgb7aKGd5K-hOCiL4pA7440R-DeWlSDF/view

 RE-EXPOSURE TO S PROTEIN IN SUBJECTS PREVIOUSLY PRIMED BY NATURAL INFECTION ELICITS CROSS-VARIANT NEUTRALIZING ANTIBODIES
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection _(Science)_

###### INFLUENZA PANDEMIC 1918: AUTOPSY SAMPLES INDICATE NO NEW VARIANTS
**OCCURRED**
1918 Influenza Pandemic Caused by Highly Conserved Viruses with Two Receptor-Binding Variants
1918 Influenza: the Mother of All Pandemics

Copyright and intellectual property of Protection of the Educational Rights of Kids 53

[www.perk-group.com](http://www.perk-group.com)


-----

**ABORTED** **FETAL** **CELL** **LINES** **USED** **IN** **TESTING** **AND** **VACCINE**
###### https:/ / soundchoice.org/vaccines/covid-19-vaccine-chart/
https: / /cogforlife.org/wp-content/uploads/CovidCompareMoralImmoral.pdf

###### ADDITTIONAL REFERENCES ON IMMUNE ESCAPE, NK CELLS, INATE IMMUNINTY,
**VARIANTS,** **CURRENT** **CPC** **RATES,** **AND** **MORE**

###### NATURAL ANTIBODIES (B-1A CELLS, SIGM, NATURAL ABS & INNATE IMMUNITY TO
**COV** **AND** **COVID-19)**
###### https:/ /www.ncbi.nlm.nih.gov/pmc/articles/PMC7202830/
doi: [https://doi.org/10.1016/S2352-4642(20)30135-8](https://doi.org/10.1016/S2352-4642(20)30135-8)
###### https://www.frontiersin.org/articles/10.3389/timmu.2020.02139/full https://www.nature.com/articles/s41385-020-00359-2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526850/
https: / [/www.frontiersin.org/articles/10.3389](http://www.frontiersin.org/articles/10.3389) /timmu.2020.595535 /full
###### https://journals.lww.eom/shockjournal/fulltext/2020/11000/therapeutic potential of b la cells in covid

19.2.aspx

###### https:/ /wvttv.frontiersin.org/articles/10.3389/fphar.2020.01309/full https://pubmed.ncbi.nlm.nih.gov/23692567/ https://pubmed.ncbi.nlm.nih.gov/20948548/ https://www.sciencedirect.com/science/article/pii/Sl939455120303793 https://www.frontiersin.org/articles/10.3389/timmu.2019.00483/full

**ROLE** **OF** **NATURAL** **ABS** **AND** **NK** **CELLS** **IN** **ASYMPTOMATIC** **CARRIERS**
             - Substantial transmission by asymptomatically infected subjects; protection of asymptomatic
carriers not due to Abs
###### https://www.medrxiv.org/content/10.1101 /2020.12.18.20248447vl https://pubmed.ncbi.nlm.nih.gov/33391280/
https: / [/www.ncbi.nlm.nih.gov/pmc/articles/PMC7608887/](https:_/_/_www.ncbi.nlm.nih.gov/pmc/articles/PMC7608887_/)
###### https://wvttv.nature.com/articles/s41392-021-00525-3

 NATURAL 1 35 1ILITATE MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION
Conserved, CoV-associated cell surface-expressed MHC cl. I peptides
###### https://www.nature.com/articles/nm933 https://pubmed.ncbi.nlm.nih.gov/19439480/

**CD** **T** **>**

The CDC has quietly revised its infection fatality rates estimates on 03/19/2021:
New estimates for survival rates by age: 0-17 99.998% 18-49 99.95% 50-64 99.4% 65+ 91%
###### https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html

**ABS** **MAY** **BIND** **TO** **SARS-COV-2** **WITHOUT** **NEUTRALIZING** **THE** **VIRUS/** **PREVENTING**
###### INFECTION
https: / [/www.pennmedicine.org/news/news-releases/2021](https:_/_/_www.pennmedicine.org/news/news-releases/2021_/_february/antibodies-to-common-cold-) /february/antibodies-to-common-cold-
coronaviruses-do-not-protect-against-sars-cov2

**MECHANISM** **OF** **VIRAL** **SHEDDING**
###### https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30172-5/fulltext

**FDA** **MANDATED** **ADVERSE** **EVENTS** **REPORTING** **IN** **QUESTION**
###### https://www.fda.gov/media/144413/download
https: / /vaers.hhs.gov/reportevent.html

Copyright and intellectual property of Protection of the Educational Rights of Kids 54

[www.perk-group.com](http://www.perk-group.com)


-----

###### https://www.fda.gov/media/78526/download https:/ /journals, sagepub.com/doi/10.1177/0960327112440111 https: / /www.congress.gov/106/crpt/hrpt977/CRPT-106hrpt977.pdf https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-publlc-health-vaccine-adverse-event-
reporting-system
###### https://pubmed.ncbi.nlm.nih.gov/31580725/
https: / [/www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html](http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html)
https: / / j amanetwork. com /j ournals /jama/fullarticle/2772137

**MORE** **J&J** **CRIMINAL** **RECORD**
https://www.accessdata.fda.gov/drugsatfda [docs/label/2009/020272s056,020588s044,021346s033,021444s](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s)
031bl.pdf
###### https://www.theguardian.com/business/2019/oct/09/iohnson-johnson-risperdal-female-breast-tissue-boys
https: / /www.nytimes.com/2019/03/25/health/xarelto-blood-thinner-lawsuit-settlement.html
###### https://www.nytimes.com/2018/12/14/business/baby-powder-asbestos-iohnson-iohnson.html
[https://www.cnbc.com/2019/07/19/iudge-denies-iis-request-to-transfer-talc-lawsuits-to-federal-court.html](https://www.cnbc.com/2019/07/19/iudge-denies-iis-request-to-transfer-talc-lawsuits-to-federal-court.html)

###### JOHNSON & JOHNSON INFO:

Polysorbate 80, an ingredient in J&J’s vaccine, is a suspected underlying cause of anaphylactic COVID
vaccine adverse reactions. Studies show that polysorbate 80 disrupts the normally protective blood-brain
barrier. J&J 1 Billion contract with US government, promise of 100 Million doses. Is this why it has
resumed?
###### https://snacksafely.com/2021/03/iohnson-iohnson-covid-19-vaccine-list-of-ingredients/
https://www.bloomberg.com/news/articles/2020-03-30/i-i-surges-after-l-billion-vaccine-deal-with-u-s-
government

**SWITZERLAND** **REJECTS** **ASTRAZENECA,** **CANADA** **SUSPENDS** **EXPERIMENTAL** **COVID**
**BIOLOGIC,** **INDIA** **REJECTS** **PFIZER** https://www.express.co.uk/news/politics/1392962/eu-
vaccine-latest-astrazeneca-switzerland-ban-oxford-vaccine-uk-latest
###### https://www.cbc.ca/news/politics/astrazeneca-under-55-1.5968128
https: / /theprint.in/health/why-indias-expert-panel-rejected-emergency-use-nod-for-pfizer-vaccine/599529 /

**50** **TOPICS** **COVERED** **BELOW** **WITH** **RESOURCE** **LINKS**

1. Operating under Emergency Use Authorization

2. Biologies Application

3. Full Licensure

4. Previous Approval Problems

5. Capturing Adverse Reactions AFTER Licensure

6. Injuries, Injury Backlog, Underreporting

7. Liability Removed

8. PREP Act

9. Animal Studies Bypassed

10. Failure in Previous Animal Studies

11. ADE (antibody enhancement, cytokine storm, pathogenic priming)

12. Blood Clots

13. Increase in Autoimmune issues

14. Increase in Liver Toxicity Problems

15. HIV Vector Increase in Aids Susceptibility in Men

16. Safety and Effectiveness Questions and Problems

17. Safety Not Properly Done

18. Short-term Safety Data Without Robust Monitoring System

Copyright and intellectual property of Protection of the Educational Rights of Kids 55

[www.perk-group.com](http://www.perk-group.com)


-----

19. 2 Month Immunity

20. Unknowns (Mutations, Co-Infection, Transmission, Long-term Effect, Stopping Death)

21. Safety Data on Children under 16, elderly 85+, Immunocompromised

22. Red Flags in People Previously Infected with Covid

23. Heavier Periods in Women (25,000 reports)

24. Abnormal Phenomenon Alarming Women

25. Fertility, Breast Feeding, Pregnancy

26. Concerns Around Formation of Placenta

27. Lower Sperm Count

28. Pfizer Clinical Trial-Defective Design Claim

29. No Data

30. Gene Therapy

31. Genetically Engineered RNA, DNA Sequence

32. Epitranscriptomics

33. Reverse Transcription Concerns (mRNA and DNA)

34. Gene Therapy Risks

35. Lipid Carrying Vector

36. Lipid Model Previously Problematic

37. PEG Anaphylactic Reactions

38. Anti-PEG Antibodies

39. Immune Escape, Viral Variants

40. Vaccine Resistant Virus

41. Loss of Innate Immune System

42. Warning from Experts Around the Globe

43. Fully Vaccinated Outbreaks

44. Profits and Profit Margins

45. Billions in Marketing and Contracts

46. Brazil, Argentina, Switzerland, California, India, Israel

47. Closer Look at Israel

48. Note Worthy Lawsuits

49. Previous Track Record and Criminal Behavior

50. Successes with Ivermectin and More (Direct Links to hundreds of clinical trials & peer reviewed)

51. Additional References

Copyright and intellectual property of Protection of the Educational Rights of Kids 56

[www.perk-group.com](http://www.perk-group.com)


-----

-----

-----

-----

-----

-----

-----

-----

-----

-----

The Fauci/COVID-19 Dossier
###### This document is prepared for humanity by Dr. David E. Martin. Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
1

The Fauci/COVID-19 Dossier

###### This document is prepared for humanity by Dr. David E. Martin. This work was supported^ in part., by a fund-raising effort in which approximately 330 persons contributed funds in support of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CCBY-NC-SA.
 Any derivative use of this dossier must be made public for the benefit of others. All documents^ references and disclosures contained herein are subject to an AS-IS representation. The author does not bear responsibility for errors in the public record or references therein. Throughout this document, uses of terms commonly accepted in medical and scientific literature do not imply acceptance or rejection of the dogma that they represent.
 Background:
 Over the past two decades, my company - M-CAM - has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases,
and of Bacteriological Methods of Warfare
###### (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 Global Technology
 Assessment: Vector Weaponization M-CAM highlighted China-’s growing involvement in Polymerase Chain Reaction
(PCR) technology with respect to joining the world stage in chimeric
###### construction of viral vectors. Since that time, on a weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other research institutions, and their commercial affiliations.
The National Institute of Health-’s grant AI23946-08 issued to Dr. Ralph Baric at
###### the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci-’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.l In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on


-----

a composite of DNA segments.
###### "Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urban! strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones .■”2

On April 19, 2002      - the Spring before the first SARS outbreak in Asia      -
###### Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, "an infectious, replication defective, coronavirusThis work was supported by the NIH grant referenced above and
GM63228. In short, the U.S. Department
###### of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.
1 U.S. Provisional Application No. 60/206,537, filed May 21, 2000
2 [https://www.pnas.org/content/100/22/12995](https://www.pnas.org/content/100/22/12995)
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
2

###### Against this backdrop, we noted the unusual patent prosecution efforts of the
CDC, when on April 25, 2003 they sought
###### to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003
SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality
###### did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries. In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC-’s f852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the
###### recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization-’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining "novelty" of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including lohnson & Johnson;
###### Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock


-----

###### Biosciences; and, others), a powerful group of interests constituted what we would suggest are "interlocking directorates" under U.S. anti-trust laws. These entities also were affiliated with the WHO-’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic "desk­ top" exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an "epidemic" scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi
and Dr. Baric’s work on zoonotic transmission of coronavirus identified
###### overlapping mutations in coronavirus in bat populations located in these areas. This dossier is by no means exhaustive. It is, however, indicative the numerous criminal violations that may be associated with the COVID-19 terrorism. All source materials are referenced herein. An additional detailed breakdown of all the of individuals, research institutions, foundations, funding sources,
and commercial enterprises can be accessed
###### upon request. Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
3

###### Contents

35 U.S.C. § 101

###### .............. 5

18 U.S.C. §2339 C et seq.      - Funding and Conspiring to Commit Acts of Terror
###### ................................................................................................................................... 7

18 U.S.C. § 2331 §§ 802      - Acts of Domestic Terrorism resulting in death of

###### American Citizens ............................................................................... 10

18 U.S.C. § 1001      - Lying to Congress

###### .................................................................................................... 12

15 U.S.C. §1-3      - Conspiring to Criminal Commercial Activity

###### ............................ 16

15 U.S.C. §8      - Market Manipulation and Allocation

###### ....................................................... 20

15 U.S.C. § 19      - Interlocking Directorates

###### ..................................................................................... 21

35 U.S.C. §200      - 206      - Disclosure of Government Interest

###### .................................. 23

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial


-----

###### ............................................................................. 25

The Commercial Actors

###### ............................................................................................................................................. 27 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
4

35 U.S.C. § 101

From lustice Clarence Thomas-* opinion for the majority

###### Section 101 of the Patent Act provides: "Whoever invents or discovers any new
and useful ... composition of matter,
###### or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.
We have "long held that this provision contains an important implicit
###### exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at __ , 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "'they are the basic tools of scientific
and technological work'" that lie beyond
###### the domain of patent protection. Id., at __ , 132 S.Ct., at 1293. As the Court
 has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at __ , 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "'manifestations... of nature
 [are] free to all men and reserved exclusively to none'").3 In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held** that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the
CDC made false and misleading claims to the United States Patent & Trademark
###### Office by stating that, “A newly isolated
human coronavirus has been identified as the causative agent of SARS, and is
###### termed SARS-CoV.**4 No “causal** data was provided for this statement.

When they filed their patent application on April 25, 2003 their first claim
###### (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the
genome for SARS CoV.
###### While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal. In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that


-----

###### they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen. It is important to note that the CDC-’s patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their
own filing. In the first non-final rejection, the
USPTO stated that the CDC-’s genome was published in four Genbank accession
###### entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences.5 Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the
SARS outbreak.
###### After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent-’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be "publicly available”.6 Tragically, this public statement is falsified by the simple fact that their own publication in
3 Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576
###### (2013)
 4 U.S. Patent 7,220,852

5 USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.
6 [https://apnews.com/article/145b4e8dl56cddc93e996ae52dc24ec0](https://apnews.com/article/145b4e8dl56cddc93e996ae52dc24ec0)
###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
5

###### Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law. While not covered under 35 U.S.C. §101, Dr. Fauci-’s abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term "vaccine” in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.
 In the 1905 lacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In lacobson v. Massachusetts, 197 U.S.
11 (1905), the court held that the context for their opinion rested on the
###### following principle: "This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health,
and prosperity of the state...”
The Moderna and Pfizer "alleged vaccine” trials have explicitly acknowledged
###### that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an Si spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and the Supreme Court-’s determination is moot in this case. Further, the USPTO, in its RE3ECTION of Anthony Fauci's HIV vaccine made the


-----

###### following statement supporting their rejection of his bogus "invention" Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
6

18 U.S.C. §2339 C et seq.       - Funding and Conspiring to Commit Acts of Terror
###### Indirectly., unlawfully and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out-
 (A) an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as implemented by the United States, or
 (B) any other act intended to cause death or serious bodily injury to a civilian, or to any other person not
 taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its
 nature or context, is to intimidate a population, or to compel a government or
an international
###### organization to do or to abstain from doing any act....
By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging
###### the association of SARS with bioterror
 potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a “SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current "pandemic”) and two candidate vaccines focused on the SARS CoV spike protein.7
Led by three Chinese researchers
###### under his employment - Zhi-yong Yang, Wing-pui Kong, and Yue Huang - Fauci had at least one DNA vaccine in animal trials by 2004.8 This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps Institute, Harvard, MIT and NIH, Dr. Fauci-’s decision to unilaterally promote vaccines as a primary intervention for several designated "infectious diseases” precluded proven therapies from being applied to the sick and dying.9
The CDC and NIAID led by Anthony Fauci entered into trade among States
###### (including, but not limited to working with
 EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in
 working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.
By October 2013, the Wuhan Institute of Virology 1 coronavirus SI spike protein
was described in NlAlD-’s funded work


-----

###### in China. This work involved NIAID^ USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response.10
By March 2015, both the virulence of the SI spike protein and the ACE II
###### receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.il Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:
7 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/)
8 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/)
9 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)
###### 10 Ge, XY., Li, 3L., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535-538 (2013).

11 Forum on Medical and Public Health Preparedness for Catastrophic Events;
Forum on Drug Discovery, Development, and Translation; Forum on

###### Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering,
and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases:
###### Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/
 Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
7

###### "Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the
 need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow
 the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at
 the end of process, Daszak stated.■’■’12 Economics will follow the hype.
The CDC and NIAID entered into trade among States (including, but not limited to
###### working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during
a time when the work being performed was prohibited by the United States
###### National Institutes of Health.
The public was clearly advised of the dangers being presented by NlAlD-funded
###### research by 2015 and 2016 when the

Wuhan Institute of Virology material was being manipulated at UNC in Ralph
###### Baric’s lab.


-----

###### "The only impact of this work is the creation, in a lab, of a new, non-natural risk/' agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research. In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved”. But Baric and others say the research did have benefits. The study findings "move this virus from a candidate emerging pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe. Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention.”13 Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population - including the citizens of the United States - when, in September 2019, they published the following mandate: "Countries, donors and multilateral institutions must be prepared for the worst.
A rapidly spreading pandemic due to a
###### lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate nonpharmaceutical interventions. All countries must develop a system for immediately sharing
genome sequences of any
12 Ibid.
13
###### https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-researc h-%201.18787 Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
8

new pathogen for public health purposes along with the means to share limited
###### medical countermeasures across countries. Progress indicator(s) by September 2020


-----

         - Donors and countries commit and identify timelines for: financing and
###### development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its
Member States develop options for
###### standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.

         - Donors, countries and multilateral institutions develop a multi-year plan and
###### approach for strengthening R&D research capacity, in advance of and during an epidemic.

         - WHO, the United Nations Children-’s Fund, the International Federation of Red
###### Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum.■’■’14
As if to confirm the utility of the September 2019 demand for "financing and
###### development of" vaccine and the fortuitous
SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that
###### his fortunes for additional funding were likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows: ""The emergence of the new virus is going to change that figure, likely considerably, Fauci said. "I don-’t know how much it-’s going to be. But I think it-’s going to generate more sustained interest in coronaviruses because it-’s very clear that coronaviruses can do really interesting things.""15 14 https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8)

15
###### https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hu rt-coronavirus-research/
CC-BY-NC-SA Dr. David E. Martin
###### Fauci/COVID-19 Dossier
9

18 U.S.C. § 2331 §§ 802       - Acts of Domestic Terrorism resulting in death of
###### American Citizens Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic,” as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion; Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.
 With no corroboration, Dr. Anthony Fauci promotedl6 Professor Neil Ferguson-’s computer simulation derived claims that, "The world is facing the most serious public health crisis in generations. Here
we provide concrete estimates of the
###### scale of the threat countries now face.
"We use the latest estimates of severity to show that policy strategies which


-----

###### aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to
 suppress transmission to low levels. It is likely such measures - most notably, large scale social distancing - will need
 to be in place for many months, perhaps until a vaccine becomes available.-” 17 Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated
and could not be measured with any accuracy, Dr. Fauci intimidated and coerced
###### the population and the government
 into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods.18 Neither the Imperial College nor the "independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda
 Gates Foundation)19 had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.
0 The imposition of social distancing was based on computer simulation and
###### environmental models with NO disease transmission evidence whatsoever.
0 The imposition of face mask wearing was directly against controlled clinical
###### trial evidence and against the written policy in the Journal of the American Medical Association. "Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”20
0 In both the Imperial College and the IHME simulations, quarantines were
###### modeled for the sick, not the healthy. 16 https://www.cato.org/blog/did-mitigation-save-two-million-lives
17
###### https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likel y-impact/
18
###### https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-th e-data-that-led-to-extension-of-guideline
19
###### https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/lHME-Announc ement
20
###### https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhu odui03QRbiHRcgE3uDKG_21N4oL5zAfciQfWCyHAsetlmo
10
###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

###### Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.21 Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively


-----

###### suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.
21
###### https://www.neuters.com/investigates/special-report/health-coronavirus-usa-cost/ Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
11

18 U.S.C. § 1001       - Lying to Congress

###### (a)Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully-
 (1) falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
 (2) makes any materially false, fictitious, or fraudulent statement or representation; or
 (3) makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry; shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

On October 22, 2020, the United States Government Accountability Office (GAO)
###### published a report entitled:
BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the
###### Licensing of Its Intellectual Property. In this document, the authors reported that the National Institutes of Health (NIH) received, "up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019.-”22
A casual review of the NIH Office of Technology Transfer report of active
###### licenses23 appears to conflict with the GAO report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active compounds generating billions of dollars in revenue. Why would it be that the
GAO and the NIH couldn-’t agree on
###### something as simple as drugs generating income for NIH? Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following
Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade
###### later, it doubled again to $15.6 billion. In the
wake of September 2001, the National Institute for Allergy and Infectious
###### Diseases (NIAID) saw its direct budget increase over 300% without accounting for DARPA funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH-’s


-----

###### budget was over $41 billion.

What has become of the $763 billion of taxpayer funds allocated to making
###### America healthier since inventors have been commercially incentivized? Who has been enriched?
The answer, regrettably, is that no accountability exists to answer these
###### questions.
The NIH is the named owner of at least 138 patents since 1980.
The United States Department of Health and Human Services is the named owner of
###### at least 2,600 patents. NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO report. SIGA-’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its programs.
22 [https://www.gao.gov/products/GAO-21-52](https://www.gao.gov/products/GAO-21-52)
23 [https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics](https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics)
###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
12

###### NlAlD-’s Director, Dr. Anthony Fauci is listed as an inventor on 8 granted U.S. patents. None of them are reported in NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his interleukin-2 "invention-” - payments he reportedly donated to an unnamed charity.24
 Of the 21 patents listed in the U.S. Food and Drug Administration-*s (FDA) Orange book itemized in the GAO report, none of Dr. Anthony Fauci-’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that
 Gilead Sciences and lanssen Pharmaceuticals (a division of lohnson & lohnson) have generated over $2 billion annually from sales that were the direct result of NIAID funded science. Missing from the
GAO report are 2 patents for Velclade®
###### which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta® are listed in the GAO report. None of the Lumoxiti® patents are listed in the
GAO report. None of the Kepivance®

###### patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the
GAO report fail to disclose government interest despite being the direct result
###### of NIH funding. Dr. Anthony Fauci-’s Own Patent Track Record:
US Patent 6,190,656 and 6,548,055 Immunologic enhancement with intermittent
###### interleukin-2 therapy


-----

A method for activating a mammalian immune system entails a series of IL-2
###### administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an antiretroviral
 therapy comprising, for example, the administration of AZT, ddl or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient. This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat.
No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26,
###### 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.
 Filed May 19, 1993 Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced
and modified claims granted May 8, 2000.
###### This family of patents was the basis of Fauci-’s lie to the British Medical Journal in which he falsely stated: "Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for
 the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropiate (sic) to receive payment and donated the entire amount to charity.-”25
He was not "required by lawJJ to commit fraud on the patent office and then get
###### paid for it! 24 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/
25 Ibid.
###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
13

US Patent 6,911,527 HIV related peptides

###### This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.


-----

###### Filed May 6, 1999 Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.
US Patent 7,368,114 Fusion protein including of CD4
###### Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of
a mammalian immunoglobulin heavy
###### chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an igM antibody. Also disclosed herein are methods for using these CD4 fusion proteins. Filed October 24, 2002 Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner-’s findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent
and the USPTO granted less than half the claims that had been sought in the
###### original filing.
US Patent 9,896,509, 9,193,790 and 9,441,041 Use of antagonists of the
###### interaction between HIV GP120 and .alpha.4.beta.7 integrin
 Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gpl20 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.l or .beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of
CWLDVC. Methods are also provided to
###### reduce HIV replication or infection. The methods include contacting a cell with
an effective amount of an agent that
###### interferes with the interaction of gpl20 and .alpha.4 integrin, such as a .alpha.4.beta.l or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
 Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

A sample of the convoluted flow of funds that evades public disclosure.
###### U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.26


-----

26
###### https://www.technologynetworks.com/genomics/news/alnylam-awarded-23-million-us-g overnment-contract-to-develop-rnai-therapeuticsl86097 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 14
 In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for "relentless and egregious" misappropriation of Tekmira-’s trade secrets. From the patent filing-’s earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology
now used in the Moderna COVID-19
###### intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus - formerly Tekmira - which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer-’s collaboration with BioNTech. Additional references can be found at:
 https://www.ott.nih.gov/nih-and-its-role-technology-transfer https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Origls000TAl tr.pdf
 https://www.gao.gov/assets/720/710287.pdf https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Inf ectious%20Diseases%22 Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
15

15 U.S.C. §1-3       - Conspiring to Criminal Commercial Activity

###### Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be
deemed guilty of a felony, and, on
###### conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.
The National Institute of Health-’s grant AI23946-08 issued to Dr. Ralph Baric at
###### the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci-’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.27 In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full


-----

###### length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on
a composite of DNA segments.
###### "Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urban! strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.■”28

On April 19, 2002      - the Spring before the first SARS outbreak in Asia      -
###### Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, "an infectious, replication defective, coronavirusThis work was supported by the NIH grant referenced above and
GM63228. In short, the U.S. Department
###### of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.
 Against this backdrop, we noted the unusual patent prosecution efforts of the
CDC, when on April 25, 2003 they sought
###### to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003
SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality
###### did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries. In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC-’s f852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the
###### recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization-*s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining "novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including lohnson & lohnson;
###### Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are "interlocking directorates” under U.S. anti-trust laws.
27 U.S. Provisional Application No. 60/206,537, filed May 21, 2000


-----

28 [https://www.pnas.org/content/100/22/12995](https://www.pnas.org/content/100/22/12995)
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
16

###### 1986-1990 NIAID Grant Al 23946 leading to patent U.S. 7^279^327 "Methods for Producing Recombinant Coronavirus'” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
The paper first published from the NIAID grant is
###### https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6^372^224 on a vaccine for the S-protein on coronavirus November 14^ 2000 which was abandoned April 2010 making it public domain. 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the "emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-l-4615-1899-0_91.pdf 2000
2001
2002
2003
###### Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant
CoV
###### National Institute of Health, Allergy and Infectious diseases. "Reverse Genetics with a Coronavirus
 Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI Asia CoV SARS outbreak April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent
on the RNA
###### sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation-’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 Duly 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued
on November 17, 2009. [https://patents.google.com/patent/US7618802B2](https://patents.google.com/patent/US7618802B2)
Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal
###### antibody to neutralize SARS
CoV. This research is supported by several NIH grants including National
###### Institutes of Health Grants
 A128785, A148436, and A1053822. 2004 January 6, 2004 - SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators.


-----

###### https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706 At this conference, the term "The New Normal” was introduced by Merck

FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and
###### Infectious Diseases.
SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10%
###### effort. 4/1/04- 3/31/09.
The project develops a SARS-CoV full length infectious cDNA, the development of
SARS-CoV replicon
###### particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic
mouse model for SARS-CoV infection.

###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
17

###### National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus
Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million
###### November 22, 2004 University of Hong Kong patents SARS associated spike protein
on CoV and
###### pursues patent US 7,491,489
2005
DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological
###### Warfare Enabling Technologies, lune 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
2008
2009
###### 2010 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54Al057157&arg_ProgOffice Code=104 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID) Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID) Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.
 August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and "inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. lason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn-’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding


-----

###### in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al
 _3ACS_2009.pdf

2011
###### Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7^344^820 to UNC Chapel Hill (non-competitive grant from NIAID)
2012
MERS isolated in Egypt

###### Biodefense Grant U54 AI057157 continues with $7^627^657 to UNC Chapel Hill (non-competitive grant from NIAID)
2013
###### 2014 Biodefense Grant U54 AI057157 continues with $7^226^237 to UNC Chapel Hill (non-competitive grant from NIAID) April 23^ 2014^ Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
18

###### 2015
 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the
mRNA-1273 lead developer and inventor Guiseppe Ciaramella.
###### https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreeme nts.html 2016
NIH through Scripps Institute and Dartmouth College file patent application WO
###### 2018081318A1 "Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna-’s technology. https://patents.google.com/patent/WO2018081318Al/en Lead Inventor Barney Scott
Graham was well

known to Moderna as he's the person at NIH that Moderna "e-mailed” to get the
###### sequence for SARS CoV-2 according to Moderna's report here ("In January 2020, once it was discovered that the infection in
Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney
###### Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357Al/en ?inventor=Jason+MCLELLAN.
2017


-----

2018
2019
###### August - Sanofi buys Protein Science Corp with considerable SARS patent holdings lune - Sanofi buys Ablynx with considerable SARS patent holdings Marche
 https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-c reateaffordable-molecular-diagnostics/ funded by Open Philanthropy - the same organization that would be the financial sponsor of the Event 201 "table-top" exercise that laid out the entire "pandemic" plan in October 2019.
 Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
19

15 U.S.C. §8       - Market Manipulation and Allocation

###### Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

 Around March 12, 2020, in an effort to enrich their own economic interests by
way of securing additional funding from
###### both Federal and Foundation actors, the CDC and NlAlD-’s Dr Fauci elected to suspend testing and classify COVID-19 by capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project - funded by the Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) - not a public health agency - Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate


-----

"COVID cases" with positive PCR tests in the
###### living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly^ this was necessitated by the apparent fall in cases that constituted Dr. Fauci-’s and others-* criteria for depriving citizens of their 1st Amendment rights.
 Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
20

15 U.S.C. § 19       - Interlocking Directorates

###### (1) No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are-
 (A) engaged in whole or in part in commerce; and (B) by virtue of their business and location of operation, competitors, so that the elimination of competition
 by agreement between them would constitute a violation of any of the antitrust laws; if each of the corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted pursuant to paragraph (5) of this subsection. Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to be, on the World Health Organization-*s Global Preparedness Monitoring Board. He is joined on this board by the conflicted donor from the Bill and Melinda Gates Foundation-*s Dr. Chris Elias
and the State Council of China-’s Dr. George
###### F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the release of a respiratory pathogen. Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the pathogen for which he is directly compensated.

As referenced in the section covering violations of 18 U.S.C. § 1001 above,
###### numerous undisclosed commercial relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below entitled "The Commercial Actors". It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter "NIAID" and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese


-----

Academy of Sciences) through the 2014 et seq National Institutes of Health Grant
###### R01AI110964 to exploit their patent rights. It further appears that, during the period of patent enforcement and after the
Supreme Court ruling confirming that
###### patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter "NIAID") entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. It further appears that, during the period of patent enforcement and after the
Supreme Court ruling confirming that
###### patents on generic material was illegal, the CDC and NIAID entered into trade
among States (including, but not limited to
###### working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during,
and following the determination made by
###### the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity
and safety standards.
###### In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
21

when the U.S. Supreme Court confirmed that such patents were illegal and when
###### the National Institutes of Health issued
a moratorium on such research.
###### Reportedly, in lanuary 2018, the U.S. Embassy in China sent investigators to
Wuhan Institute of Virology and found that,
###### "During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory." The Washington Post reported that this information was contained in a cable dated 19 lanuary 2018. Over a year later, in lune 2019, the CDC conducted an inspection of Fort Detrick-’s U.S. Army Medical Research Institute of Infectious Diseases (hereinafter "USAMRIID") and ordered it closed after alleging that their inspection found biosafety hazards. A report in the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and
USAMRIID on coronavirus research
###### followed by considerable subsequent collaboration. The CDC, for what appear to
be the same type of concern identified
###### in Wuhan, elected to continue work with the Chinese government while closing the


-----

###### U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in
###### January 2020 with the CDC-’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a "novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the
CDC could manufacture and distribute tests
###### for a "novel” pathogen when their own subsequent record on development and deployment of tests has been shown to
be without reliability
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
22

35 U.S.C. §200       - 206       - Disclosure of Government Interest

35 U.S.C. §202 (C)(6)

An obligation on the part of the contractor, in the event a United States patent
###### application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.
 Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below, file issue priority total 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
0
0
0
0
10
10
12
12
0
0
29
29
0
0
0
0
###### 120 338 290 328 297 256 188 198 207 244 371 407 466 451 416 326 199 9
63 135 179 224 275 334 391 61
1


-----

8
38 129 506 487 408 335 370 279 256 303 279 322 330 348 342 208 95
0
0
###### file 314 431 420 504 513 449 578 231 issue
25
38 129 627 888 833 842 891 810 778 892 547 574 1015 1186 1228 1163 1024 800 777
###### 240 total priority total
 5111 5111 5111 15333
On Duly 23, 2020, the Patent Trial and Appeal Board of the United States Patent
and Trademark Office rejected
###### Moderna-’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally
owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to
###### deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.
mRNA-1273      - the experimental vaccine developed by Moderna for COVID-19      - uses
###### the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus-* prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.
M-CAM and Knowledge Ecology International have independently confirmed that
###### Moderna has violated U.S. law in failing to disclose the U.S. government-*s funding interest in their patents and patent applications. While this negligence impacts all of Moderna-’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (f600)
 which is the patent relating to, "a messenger ribonucleic acid (mRNA) comprising
an open reading frame encoding a
###### betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.-’* The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 - 9 months before the SARS CoV-2 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
23

###### outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent.
 In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics
(ADEPT) program awarded grant funding to

###### Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant
was W911NF-13-1-0417. The company used that technology to develop its COVID-19
###### vaccine, currently undergoing


-----

Phase I clinical trials in conjunction with NIH.29
###### Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-l(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the "Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent...-”. In addition to the patents cited by the USPTO in their examination of *'600, M-CAM has identified fourteen other issued patents preceding the f600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac. In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci
and his NIAID, since its inception, it has been engaged in illegal patent
###### activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.
29 [https://crsreports.congress.gov/product/pdf/IN/IN11446](https://crsreports.congress.gov/product/pdf/IN/IN11446)
###### Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin
###### 24

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

###### It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to: a. Establish the research with a duly authorized and independent institutional review board; b. Secure informed consent of all participants including a statement of risks
and benefits; and,
###### c. Engage in consultation with the community in which the study is to be conducted. Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S. Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought or secured for any of the "medical countermeasures” forced upon the population
and no independent review board      - as
###### defined by the statute - has been empaneled. Through April 2020, the official recommendation by the Journal of the American Medical Association was unambiguous. "Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”30 Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness.31


-----

###### In contravention to established science. States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a "belief" that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.
 All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.32 Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.33 That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:
 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43 In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a "belief" that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.
30 [https://jamanetwork.com/journals/jama/fullarticle/2762694](https://jamanetwork.com/journals/jama/fullarticle/2762694)
31 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)
32
###### https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover­ guidance.html
33 Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to
###### Influenza Virus Aerosols During Routine Patient Care, The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037-1046, https://doi.org/10.1093/infdis/jis773
CC-BY-NC-SA Dr. David E. Martin
###### Fauci/COVID-19 Dossier
25

###### It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure
human disease unless you possess competent and reliable scientific evidence,
###### including, when appropriate, wellcontrolled
human clinical studies, substantiating that the claims are true at the time they
###### are made. As a result, every party promoting the use of face masks is violating the FTC Act.
 All of these laws have been broken. All relevant authorities in the United States must cease and desist the use of face


-----

masks until the matters above are rectified.
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
26

The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999^ the ability to
###### manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals^ institutions and commercial organizations in public, private,
and not-for-profit sectors. The following is the list of over 5,100 patents and
###### patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.
PATENT Title
###### US9995706 Amperometric gas sensor
US9995705 Amperometric gas sensor
US9994558 Multicyclic compounds and methods of using same
US9994550
US9993543
###### Heterocyclic modulators of lipid synthesis for use against cancer and viral infections Immunogenic compositions comprising silicified virus and methods of use
US9982257 Chiral control
US9982241 Recombinant HCMV and RHCMV vectors and uses thereof
US9982025 Monomeric griffithsin tandemers
US9981036
###### Compositions, comprising improved 11-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
US9975885 Broad-spectrum non-covalent coronavirus protease inhibitors
###### US9974850 Immunogenic compositions and uses thereof
US9974848 Tetanus toxoid and CCL3 improve DC vaccines
US9974845 Combination of vaccination and inhibition of the PD-1 pathway
US9970061 Bioagent detection oligonucleotides
Owner
###### Steris Corporation Steris Corporation Karyopharm Therapeutics Inc. 3-V Biosciences, Inc. Portland State University
WAVE LIFE SCIENCES LTD.
###### Oregon Health & Science University
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
PURDUE RESEARCH FOUNDATION
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Duke University
###### CureVac AG IBIS BIOSCIENCES, INC.
US9969793 Compositions and methods for the treatment of immunodeficiency ADMA
###### Biologies, Inc.
US9963718
US9963611

###### LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virusproducing


-----

###### cells for the therapy of tumors Composition for use in decreasing the transmission of human pathogens
US9963427 Dithiol mucolytic agents
US9962439 Injectable vaccine composition
US9957302 Treating cancer with viral nucleic acid
US9957300
US9957238
###### Virus-like particles, methods of preparation, and immunogenic compositions
 Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9951317 Highly efficient influenza matrix (Ml) proteins
VIRATHERAPEUTICS GMBH
###### Innonix Technologies, Incorporated
PARION SCIENCES, INC.
NITTO DENKO CORPORATION
Mayo Foundation for Medical Education and Research
Emory University
###### Parion Sciences, Inc.
NOVAVAX, INC.
###### Priori ty 253unl2 253unl2 20Sepl3 73anl4 313anl3 133U1-12 14Mayl0 53unl3 12Decll 28Aprl6 25Marl5
14NOV13
###### 22Febl3 27Decll 280ctl4 8Oct08
29May09
###### 23Augl3 30ctl3 20Feb07
17May02
###### 13Decl3 llJul-03 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### File
d
###### Dat
e
30Sep


-----

###### -14
30Sep
###### -14
19Sep
###### -14 7Jan -15
313an
###### -14 12JU113 lOct -15
53un
###### -14 26Feb -16 28Apr -17 25Mar -16
14N0V
###### -14 21Feb -14
27Dec
###### -12
13NOV
###### -17
7Apr
###### -17
21May
###### -10 HMar -16 2Oct -14 63ull5
4May
###### -15 IMar -17 6Oct -16
27
###### Issu
e
###### Dat
e
###### 123unl8 123unl8 123unl8 123unl8 123unl8
29May


-----

###### -18

29May

###### -18

29May

###### -18

29May

###### -18

22May

###### -18

22May

###### -18

22May

###### -18

22May

###### -18

15May

###### -18

15May

###### -18

8May

###### -18

8May

###### -18

8May

###### -18

8May

###### -18
 iMay
 -18
 iMay
 -18
 iMay
 -18
 24Aprl8
 27US9951124
 Antibody producing non-human mammals
US9951122 Antibodies against influenza virus and methods of use thereof
US9950062 Compounds and compositions as TLR activity modulators
US9945856
US9945780
US9944928
###### Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
Use of a fluorescent material to detect failure or deteriorated
###### performance of a fluorometer Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions
US9944695 Antibody producing non-human mammals
###### US9944686 Treatment of tumors with recombinant interferon alpha
US9944649 Compounds and compositions as toll-like receptor 7 agonists
###### US9943614
US9938300
US9938275
###### Cationic steroid antimicrobial diagnostic, detection, screening and


-----

###### imaging methods IsothiazolopyrimidinoneSj pyrazolopyrimidinoneSj and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
MERUS N.V.
BURNHAM INSTITUTE FOR MEDICAL RESEARCH

GLAXOSMITHKLINE BIOLOGICALS SA
AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.
GEN-PROBE INCORPORATED
###### York Yuan Yuan Zhu
Menus N.V.
SUPERLAB FAR EAST LIMITED
###### Novartis Ag
BRIGHAM YOUNG UNIVERSITY
Forma Therapeutics^ Inc.
3M Innovative Properties Company
US9938258 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
###### Karyopharm Therapeutics Inc.
US9932351 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9932323
US9931316
US9926340
###### Therapeutic hydroxypyridinones., hydroxypyrimidinones and hydroxypyridazinones
 Antiviral activity from medicinal mushrooms and their active constituents
NAD analogs and methods of using said NAD analogs in determining
###### ribosylation of proteins with PARP mutants
US9925215
###### Anionically modified polyallylamine derivative., use of anionically modified polyallylamine derivative as medicine., particularly for propylaxis and treatment of infections of respiratory tract caused by
human metapneumovirus (hMPV)., human rhinoviruses (HRV)., and
###### infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative

Forma Therapeutics, Inc.
###### Rutgers, The State University of New Jersey Not Available Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH Jun08 6Dec07 2Sep09
18Aug03
###### 14Junl2 23JU1-07 27Jun08 28Feb01 lMayl4 17Jun08 SFeblS 18Jun04


-----

29NOV12
###### SFeblS llSepl2 31Marl5 8Aprl5 253an -13
12Aug
###### -13 iSep -10
13Aug
###### -14 73un -13 23ull5 30Apr -14
5Sep
###### -13 29Apr -15 163un -09 4Feb -16 233an -17
27NOV
###### -13 4Feb -16 133an -17
14Sep
###### -15 lApr -16
 24Aprl8 24Aprl8 24Aprl8 17Aprl8 17Aprl8 17Aprl8 17Aprl8 17Aprl8 17Aprl8 17Aprl8 10Aprl8 10Aprl8 10Aprl8 3Aprl8 3Aprl8 3Aprl8


-----

###### 27Mar
 -18

UNIWERSYTET
DAGIELLONSKI
###### 29JU1-14 250ct
 -17
 27Mar
 -18
 21US9920314 Compositions for and methods of identifying antigens
US9920128 Synthetic antiserum for rapid-turnaround therapies
###### US9919034
US9915613
###### Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector US9914976 Methods and compositions for prostate cancer metastasis
US9913801
US9909176
###### Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq) US9908946 Generation of binding molecules
US9908675 Powdered pouch and method of making same

###### Fauci/COVID-19 Dossier President and Fellows of Harvard College
The lohns Hopkins University
TAMIR BIOTECHNOLOGY, INC.
GEN-PROBE INCORPORATED

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
(FA

YOUR ENERGY SYSTEMS, LLC
The lohns Hopkins University
###### Merus N.V.
MONOSOL, LLC
CC-BY-NC-SA Dr. David E. Martin

Feb06
###### 283anl5 28Marl4 24Febll 25Marll 15Febl3 8Sepl4 26Sepll 16Aprl2
6May

###### -15
 203an
 -16
 103un
 -15


-----

###### 21Mar -14
27May
###### -16 15Mar -13 ISep -15
16Sep
###### -15 19JU116
28
###### 20Mar -18 20Mar -18 20Mar -18 13Mar -18 13Mar -18 13Mar -18
6Mar
###### -18
6Mar
###### -18
6Mar
###### -18
 4US9907796
 Methods of treating tumoral diseases^ or bacterial or viral infections INHIBIKASE THERAPEUTICSj INC.
US9895692 Sample-to-answer microfluidic cartridge
US9895411 Analogs of C5a and methods of using same
US9895341 Inflammation and immunity treatments
US9894888 Transgenic immunodeficient mouse expressing human SIRP-alpha
US9890419 Nanoreporters and methods of manufacturing and use thereof
US9890408 Multiple displacement amplification
US9890362 Compositions, methods and uses for inducing viral growth
US9890361
###### Methods for increasing the infectivity of viruses utilizing alkynemodified fatty acids US9890206 MINI flu virus neutralizing antibodies
US9890169 Triazolinone compounds as HNE inhibitors
###### US9890124 Benzazepine sulfonamide compounds US9889194 Immunogenic composition for MERS coronavirus infection
US9885092 Materials and methods for detection of HPV nucleic acids
US9885082 Embodiments of a probe and method for targeting nucleic acids
US9885037 Chiral control
US9884895 Methods and compositions for chimeric coronavirus spike proteins
US9884876
###### Anti-viral compounds^ pharmaceutical compositions, and methods of use thereof


-----

US9884129 Release of agents from cells
US9884032
###### Esters of short chains fatty acids for use in the treatment of immunogenic disorders US9884026 Modular particles for immunotherapy
US9880151
###### Method of determining, identifying or isolating cell-penetrating peptides US9879026 Substituted spirocycles
US9879003 Host targeted inhibitors of dengue virus and other viruses
US9878988
###### Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
US9873678 Chemical compounds
###### US9873674 C-Rel inhibitors and uses thereof US9872900 Nucleic acid vaccines
US9872898
US9872895
###### Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
TLR5 ligands, therapeutic methods, and compositions related
###### thereto Fauci/COVID-19 Dossier Micronics, Inc.

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Ocean Spray Cranberries, Inc.
###### INSTITUT PASTEUR NanoString Technologies, Inc. IBIS BIOSCIENCES, INC. Takeda Vaccines, Inc. LIFE TECHNOLOGIES CORPORATION Medigen Biotechnology Corporation CHIESI FARMACEUTICI S.P.A. Hoffmann-La Roche Inc.
New York Blood Center, Inc.
QIAGEN GAITHERSBURG INC.
###### University of Idaho
WAVE LIFE SCIENCES LTD.
The University of North Carolina at Chapel Hill
###### Kineta, Inc.
The Brigham and Women's Hospital, Inc.
PROPONENT BIOTECH GMBH
YALE UNIVERSITY
###### Phylogica Limited Boehringer Ingelheim International GmbH Dana-Farber Cancer Institute, Inc.
PARION SCIENCES, INC.

###### AstraZeneca AB
CORNELL UNIVERSITY
###### ModernaTX, Inc. Ohio State Innovation Founation
Emory University
CC-BY-NC-SA Dr. David E. Martin
###### Octl2


-----

###### 29:ani0 29Dunl0 lAprll 26Marl2
23Dec05
###### 15Oct09
5Dec08
###### 26Janl2 20Augl5 14Decl5 15Decl5 lMarl3 24Febll 19JU1-11 13JU1-12 20Marl4 9Mayl4 15Oct09 30ctl2
1N0V13
###### 23Mayll 12Sepl4 HAprl2 29Mayl2 18Marl4 21Sepl2 23Aprl4 24Aprl2 24Sepl0
15Sep
###### -16
5Aug
###### -15 293un -11
30Mar
###### -12 26Mar -13
20May
###### -16 150ct -10
19Sep
###### -14 253an -13
20Aug
###### -15
12Dec
###### -16

143 un
###### -17 28Feb


-----

###### -14 23Feb -12 19JU112 12JU113 20Mar -15
8May
###### -15
53an
###### -15
3Mar
###### -16 310ct -14
23May
###### -12
29NOV
###### -16 15Mar -13
53an
###### -16 17Mar -15
19Sep
###### -13
5Apr
###### -16 30ct -16
20Sep
###### -11
29
6Mar
###### -18 20Feb -18 20Feb -18 20Feb -18 20Feb -18 13Feb -18 13Feb -18 13Feb -18 13Feb -18 13Feb -18


-----

###### 13Feb
 -18
 13Feb
 -18
 13Feb
 -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18

6Feb

###### -18 303anl8 303anl8 303anl8 303anl8 233anl8 233anl8 233anl8 233anl8 233anl8

US9868952

###### Compositions and methods for a€ceresistance-proofa€ SiRNA therapeutics for influenza US9868740 Pyrimidinone compounds which are HNE inhibitors US9868736 Deubiquitinase inhibitors and methods for use of the same
US9867882 Carbohydrate conjugates as delivery agents for oligonucleotides
US9867877 Methods for preparing squalene
###### US9862706 Compounds US9861614 Nuclear transport modulators and uses thereof US9856254 Alkoxy substituted imidazoquinolines
US9856241
###### Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US9856228 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
###### US9856224 Stable sodium channel blockers
US9855287 Anti-viral azide containing compounds
###### US9855284 Pharmaceutical compositions and methods
US9849143 Broad spectrum antiviral and methods of use
US9845342

###### Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
US9840731 Preservation of biological materials in non-aqueous fluid media
US9840719


-----

US9840491
US9839687
###### Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors

###### Acetylenedicarboxyl linkers and their uses in specific conjugation of
a cell-binding molecule
US9834812 Probe kit for detecting a single strand target nucleotide sequence
###### Sirnaomics, Inc. 8-3U112 12CHIESI
FARMACEUTICI S.p.A.

THE REGENTS OF THE UNIVERSITY OF MICHIGAN
###### Alnylam Pharmaceuticals, Inc.

NOVARTIS AG
###### CHIESI FARMACEUTICI S.p.A. Karyopharm Therapeutics Inc.
3M Innovative Properties Company
###### Karyopharm Therapeutics Inc.
PROZYMEX A/S
PARION SCIENCES, INC.
###### LIFE TECHNOLOGIES CORPORATION
Pop Test Oncology LLC
The Burlington HC Research Group, Inc.
Spogen Biotech Inc.
###### Gentegra, LLC
The Children's Hospital of Philadelphia

FORMA Therapeutics, Inc.

SUZHOU M-CON3 BIOTECH CO., LTD.

###### Fondazione Istituto Italiano Di Tecnologia

US9834791 CRISPR-related methods and compositions with governing gRNAS Editas
###### Medicine, Inc.
US9834757
US9834595
###### Hand, foot, and mouth vaccines and methods of manufacture and use thereof
 Amino acid sequences directed against envelope proteins of a virus
and polypeptides comprising the same for the treatment of viral
###### diseases US9833504 Virus-like particles and process for preparing same
US9833492 Combinations of a caspase inhibitor and an antiviral agent
US9832998 Antiviral compositions
US9828382 Pyrimidinone compounds as human neutrophil elastase inhibitors
US9828379
###### Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof US9828370 Compositions and methods for inhibiting kinases US9828346 N-myristoyl transferase inhibitors
 Fauci/COVID-19 Dossier
 Takeda Vaccines, Inc. Ablynx N.V.
 Folia Biotech Inc.
 Centre National de la Recherche Scientifique


-----

Long Island University
###### Chiesi Farmaceutici S.p.A.
ABIDE THERAPEUTICSj INC.
###### INHIBIKASE THERAPEUTICSj INC. University of Dundee
CC-BY-NC-SA Dr. David E. Martin
###### Junl4 10Octl3 4Dec07 12Mayl0 31Mayl6 9Mayl2 3Oct03 3-3U113 9Sepl3 303unl4 283U1-10 3Augl5 17Apr06 17Sepl4 14Marl3 223U1-13 SFeblS 15JU1-15 27Decl2
7NOV13
7NOV14
###### 53un08 13Mayll
2NOV07
30May07
###### 18Decl2 3-3U113 23Aprl5 2Sep08 3ull3 123un -14 10Oct -14
25Aug
###### -15
22NOV
###### -16
26May
###### -17 233un -15 133un -16
33U114
8Sep
###### -14
303an


-----

###### -17
20Aug
###### -15
6Dec
###### -16
 16Feb -17

17Sep
###### -15
 14Mar -14
 22JU114 4Feb
 -16
 15JU115
27Dec
###### -13

7Nov
###### -14

6Nov
###### -15 290ct -15 iMay -12

15May
###### -15
 19Mar -15

10May
###### -16
 1JU114 22Apr -16
31Aug
###### -15
30
###### 3anl8 163anl8 163anl8 163anl8 163anl8 93anl8 93anl8 23anl8 23anl8 23anl8 23anl8 23anl8 23anl8
26Dec
###### -17
19Dec
###### -17


-----

12Dec

###### -17

12Dec

###### -17

12Dec

###### -17

12Dec

###### -17
5Dec
###### -17
5Dec
###### -17
5Dec
###### -17
5Dec
###### -17
5Dec
###### -17
5Dec
###### -17
5Dec
###### -17

28NOV

###### -17

28NOV

###### -17

28NOV

###### -17

28NOV

###### -17
 716

US9828342

US9827190
US9822339
###### Isatin derivatives^ pharmaceutical compositions thereof, and methods of use thereof 24CITY
OF HOPE

###### Intradermal delivery of immunological compositions comprising tolllike receptor 7 agonists

Means and methods for influencing the stability of antibody
###### producing cells
US9822173 Heterodimeric immunoglobulins
US9822165
US9822155
###### Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41
membrane proximal external region
###### Method of preventively treating a subject at the risk of developing infections of a respiratory virus
US9822127 GAK modulators as antivirals
US9822065 Benzazepine dicarboxamide compounds
US9821052 Reverse genetics systems
US9821051 Reducing hospitalization in elderly influenza vaccine recipients
US9816078


-----

###### Compositions for increasing polypeptide stability and activity, and related methods
GLAXOSMITHKLINE BIOLOGICALS SA
ACADEMISCH MEDISCH CENTRUM BID DE UNIVERSITEIT
VAN AMSTERDAM
AMGEN INC.
DANA-FARBER CANCER INSTITUTE, INC.
###### Xiangxue Group (Hong Kong) Company Limited
The Board of Trustees of the Leland Stanford Junior
###### University Hoffmann-La Roche Inc. Seqirus UK Limited Seqirus UK Limited
SOLIS BIODYNE OAce
###### US9815886 Compositions and methods for the treatment of immunodeficiency ADMA
BIOLOGICS, INC.
US9815805
###### Certain (2S)-N-[(IS)-l-cyano-2-phenylethyl]-l,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors
US9814777 Targeting lipids
US9810683
Use of live cell inteferometry with reflective floor of observation
###### chamber to determine changes in mass of mammalian cells
US9809845 Methods and reagents for amplifying nucleic acids
###### US9809796 Animal protein-free media for cultivation of cells
US9809632 Universal protein tag for double stranded nucleic acid delivery
US9809591 Heterocyclic modulators of lipid synthesis
###### US9808490 Induced hepatocytes and uses thereof
US9803236
###### Microarray-based assay integrated with particles for analyzing molecular interactions
ASTRAZENECA AB
###### Arbutus Biopharma Corporation
The Regents of the University of California
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Baxalta GmbH University of Washington Through its Center for Commercialization 3-V Biosciences, Inc.
ACCELERATED BIOSCIENCES CORP.
###### CapitalBio Corporation
US9803197 Particle-nucleic acid conjugates and therapeutic uses related thereto
Emory University
US9802937 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors
US9802919 Compounds
US9801948 Antimicrobial compositions and methods of use thereof
US9801947 Methods and compositions for enhancing immune response
US9801935 Soluble needle arrays for delivery of influenza vaccines
US9801897 Delivery of RNA to trigger multiple immune pathways
US9797000
###### Non-target amplification method for detection of RNA splice-forms in
a sample
US9796979 Oligonucleotide modulators of the toll-like receptor pathway


-----

###### Fauci/COVID-19 Dossier
ORIGENIS GMBH
###### CHIESI FARMACEUTICI S.p.A. Yale University
3M INNOVATIVE PROPERTIES COMPANY
SEQIRUS UK LIMITED
GLAXOSMITHKLINE BIOLOGICALS SA
QIAGEN GAITHERSBURG INC.
###### Quark Pharmaceuticals Inc.
CC-BY-NC-SA Dr. David E. Martin
###### Febl2 lFebl3
9Dec05
21NOV12
###### 183un09 9Mayl3 233U1-14 GMarlS 313U1-09 28Octl0
19NOV09
###### 280ctl4 243anl4 4Dec07
6May09
###### 6Augl2 29Oct04 230ctl3 SMarll
26NOV14
###### 6Augl0 253unl2 21Aprll 31Mayl6 21Sepll 10Apr03 20Augl0 6-3U110 lMay09 3Marll 25Feb -13
303an
###### -14
26Aug
###### -15
21NOV
###### -13 183un -10
23Aug
###### -16
233U115
###### 14Feb


-----

###### -17
30DU110
###### 210ct -11 llMar -16
SDan
###### -15
8Nov
###### -16 220ct -13
25NOV
###### -13

6Aug
###### -12
18May
###### -17 220ct -14 50ct -15
25NOV
###### -15

6Aug
###### -10 27Feb -13 23Apr -12
26May
###### -17
21Sep
###### -12 60ct -14 HOct -16
6JU111
###### 30Apr -10 283U116
31
28NOV
###### -17
28NOV
###### -17
21NOV
###### -17
21NOV
###### -17
21NOV
###### -17
21NOV


-----

###### -17

21N0V

###### -17

21N0V

###### -17

21N0V

###### -17

21N0V

###### -17

14N0V

###### -17

14N0V

###### -17

14N0V

###### -17

14N0V

###### -17

7Nov

###### -17

7Nov

###### -17

7Nov

###### -17

7Nov

###### -17

7Nov

###### -17

7Nov

###### -17 310ctl7 310ctl7 310ctl7 310ctl7 310ctl7 310ctl7 310ctl7 310ctl7 240ctl7 240ctl7
 20US9796735
 Boron-containing small molecules
US9795669
US9795668
US9795666

###### Lipidated immune response modifier compound compositions, formulations, and methods Delivery of self-replicating RNA using biodegradable polymer particles High-yield transgenic mammalian expression system for generating virus-like particles
US9791437 Multianalyte assay
US9789180
###### D-amino acid derivative-modified peptidoglycan and methods of use thereof


-----

###### US9786050 Stain-free histopathology by chemical imaging
US9783595 Neutralizing GP41 antibodies and their use
###### US9782470 Method of obtaining thermostable dried vaccine formulations US9782434 Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution US9770504 Generating peptoid vaccines
US9770463 Delivery of RNA to different cell types
US9765395
###### System and method for DNA sequencing and blood chemistry analysis
US9765133 Antibody producing non-human mammals
US9765071 Substituted imidazo ring systems and methods
US9764027 Outer membrane vesicles
US9759723 B-cell antigen presenting cell assay
###### US9758840 Parasite detection via endosymbiont detection US9758820 Organism identification panel
US9758775 TAL effector-mediated DNA modification
US9758568 Oligopeptide-free cell culture media
US9758553
###### Yeast strain for the production of proteins with terminal alpha-1.,31inked galactose Anacor Pharmaceuticals, Inc.

3M INNOVATIVE PROPERTIES COMPANY

###### GlaxoSmithKline Biologicals S.A. Academia Sinica

Nexus Dx, Inc.
The Regents of the University of California
The Board of Trustees of the University of Illinois
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Merck Sharp & Dohme Corp.
Sonoma Pharmaceuticals, Inc.
The Board of Regents of the University of Texas System
GLAXOSMITHKLINE BIOLOGICALS SA
###### Nanomedical Diagnostics, Inc. Merus N.V.

3M INNOVATIVE PROPERTIES COMPANY

GLAXOSMITHKLINE BIOLOGICALS SA
###### University of Pittsburgha€JJOf the Commonwealth System of Higher Education IBIS BIOSCIENCES, INC. BioFire Diagnostics, LLC Iowa State University Research Foundation, Inc. Baxalta GmbH

MERCK SHARP & DOHME CORP.
US9757478 Mutant protease biosensors with enhanced detection characteristics
Promega Corporation
###### US9757470 Peptides for assisting delivery across the blood brain barrier US9757446 Influenza virus vectors and uses therefor
US9757407
###### Treatment of viral infections by modulation of host cell metabolic pathways
US9751945 Sortase-modified VHH domains and uses thereof


-----

US9750798
###### Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses
US9750797 Sustained release vaccine composition
US9750690
###### Circulation of components during microfluidization and/or homogenization of emulsions Fauci/COVID-19 Dossier
 Children's Medical Center Corporation
FLUGEN, INC.

The Trustees of Princeton University
###### Whitehead Institute for Biomedical Research
STICHTING WAGENINGEN RESEARCH
VIRBAC CORPORATION
NOVARTIS AG
Dun07
###### 17Augl0 6-JU110 5Sep06 30Apr07
30NOV12
###### 15Marl3
7NOV11
###### 16Octl3 203an06 3Mayl3 6-3U110 28Aprl4 273un08
25NOV03
###### 18Sepl2 8Aprl0 14Marl0 2Apr07
10D6C09
###### 43an06
30May08
###### HMayl0
22May06
###### 17Marl4 13un07 13Aprl2 21Mayl3 163un04
3Dec09
CC-BY-NC-SA
###### Dr. David E. Martin
7Nov
###### -14 iSDec -15
23NOV
###### -15 HFeb


-----

###### -15
15Dun
###### -15
31Mar
###### -16 14Mar -14
2Aug
###### -16 130ct -14 73ull5
2May
###### -14 73un -11 10Apr -15 29Apr -14 14Mar -16
18Sep
###### -13 21Mar -16 llMar -11 lApr -08 14Apr -14
16N0V
###### -15 23ull4 73an -16 30Apr -14 13Mar -15
21Dec
###### -15 15Apr -13
21May
###### -14 163un -05
5Sep
###### -14
32
###### 240ctl7 240ctl7


-----

###### 240ctl7 240ctl7 170ctl7 170ctl7 10Octl7 10Octl7 10Octl7 10Octl7
26Sep

###### -17

26Sep

###### -17

19Sep

###### -17

19Sep

###### -17

19Sep

###### -17

19Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17

12Sep

###### -17
5Sep
###### -17
5Sep
###### -17
5Sep
###### -17
5Sep
###### -17

US9746985

###### System and method for detecting, collecting, analyzing, and communicating event-related information 25Georgetown University
US9746459 Antigen presenting cell assay


-----

US9745306
###### 2-( (4-amino-3- (3-fluoro-5-hydroxyphenyl) - 1H-pyrazolo [ 3., 4D]pyrimidin-l-yl) methyl) -3-(2-(trifluoromethyl)benzyl) quinazolin4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
US9744231
US9744229
###### Quality control methods for oil-in-water emulsions containing squalene
 Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
US9744183 Nucleic acid prodrugs and methods of use thereof
###### US9738894 Short interfering RNA (siRNA) analogues US9738624 Nuclear transport modulators and uses thereof
US9737618
###### Adeno-associated virus (AAV) glades, sequences, vectors containing
same, and uses therefor
US9737593 Carbon nanotube compositions and methods of use thereof
US9730997 Alphavirus vectors for respiratory pathogen vaccines
US9730912 Pharmaceutical compounds
###### US9727810 Spatially addressable molecular barcoding
US9726607 Systems and methods for detecting multiple optical signals
US9725770
###### Methods and compositions for identification of source of microbial contamination in a sample
US9725487 Compositions and methods for measles virus inhibition
US9719106
###### Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US9719083 Bioagent detection methods
###### US9718774 Indole carboxamide derivatives as P2X7 receptor antagonist
US9717755 Method of treating inflammation
US9717749 Production of stable non-polyadenylated RNAs
US9717732 Drug combination
US9714411 Animal protein-free media for cultivation of cells
###### University of Pittsburgha€JJOf the Commonwealth System of Higher Education Respivert Limited
Feb08
###### 8Aprl0 15Marl3 8NOVARTIS

AG
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
WAVE LIFE SCIENCES LTD.

Roche Innovation Center Copenhagen A/S
###### Karyopharm Therapeutics Inc.
The Trustees of the University of Pennsylvania
###### Yale University
 Novartis Vaccines and Diagnostics, Inc.

ASTEX THERAPEUTICS LIMITED
###### Cellular Research, Inc.
GEN-PROBE INCORPORATED


-----

The Regents of the University of California
###### Autoimmune Technologies., LLC
The Trustees of the University of Pennsylvania
###### IBIS BIOSCIENCES, INC. IDORSIA PHARMACEUTICALS LTD Cytosorbents Corporation Massachusetts Institute of Technology
VERONA PHARMA PLC

###### Baxalta GmbH
US9714283 Compositions and methods for the treatment of immunodeficiency ADMA
BIOLOGICS, INC.
###### US9714226 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc.
US9713641 Anti-TIGIT antigen-binding proteins and methods of use thereof
US9713606
###### Methods for treating pulmonary emphysema using substituted 2Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)amides inhibitors of cathepsin C
US9708375 Inhibitory polypeptides specific to WNT inhibitors
US9707278
###### Methods of modulating immune responses by modifying Akt3 bioactivity Fauci/COVID-19 Dossier Potenza Therapeutics, Inc.
NOV06
###### 4Apr08 6-3U109 21Mar03 213unl3
30Sep03
###### 19Mar08 21May04 12Oct06 27Febl5 10Mar05 6Marl2
4NOV03
###### 29Aprl3 8Mar09 12Decl2 lAprl0 16Octl2 15Marl3 29Oct04 280ctl4 293U1-11 13Febl7 14Boehringer Ingelheim International GmbH
 Marl3
ISAmgen
###### Inc.
 Augusta University Research Institute, Inc.


-----

CC-BY-NC-SA Dr. David E. Martin
###### Marl3 17Aprl4 20Apr
 -11
 noct
 - 13 14Mar
 - 14

27Aug

###### - 13
 28Apr
 - 14
 63ull0 28Mar
 - 16
 203un
 - 14
 203U115 15Mar
 - 13

20Aug

###### - 14 12Oct
 - 07
 26Feb
 - 16
3Mar
###### - 14
 6Mar
 - 13
13May

###### - 15
 29Apr
 - 14

8Mar

###### - 10
 llDec
 - 13
 lApr
 - 11
 16Oct
 - 13
 17Mar
 - 14
30Nov
###### - 15
23U115
13NOV

###### - 15
 13Feb
 - 17
 iDec
 - 15


-----

###### 14Mar -14 17Apr -15
33
29Aug
###### -17
29Aug
###### -17
29Aug
###### -17
29Aug
###### -17
29Aug
###### -17
29Aug
###### -17
22Aug
###### -17
22Aug
###### -17
22Aug
###### -17
22Aug
###### -17
15Aug
###### -17
15Aug
###### -17
8Aug
###### -17
8Aug
###### -17
8Aug
###### -17
8Aug
###### -17 lAug -17 lAug -17 lAug -17 lAug -17 lAug -17 lAug -17
253U117
253U117
253U117
253U117
253U117


-----

###### 18JU117 18JU117
 US9701736
 Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
20New

###### York Blood Centerj Inc.
US9701638 Therapeutic hydroxyquinolones
US9700616
###### Arranging interaction and back pressure chambers for microfluidization US9700614 Intranasal vaccination dosage regimen
US9700558
###### Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
US9696247 Sample fixation and stabilisation
US9695445
###### Method for production of reprogrammed cell using chromosomally unintegrated virus vector
US9695135 Therapeutic catechols
###### US9695134
US9689018
US9688982
3., 5-diamino-6-chloro-N- (n          - (4-phenylbutyl )carbamimidoyl)pyrazine2-carboxamide
compounds

###### Mixed cell diagnostic systems for detection of respiratory, herpes
and enteric viruses
###### Methods and compositions for the treatment of cancer or other diseases US9687536 Methods and compositions for intranasal delivery US9683256 Biological specimen collection and transport system
US9683017 Inhibitory peptides of viral infection
US9682133 Disrupted adenovirus-based vaccine against drugs of abuse
US9677089
US9676867
###### Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody
US9676857 Soluble engineered monomeric Fc
US9676727 Myxovirus therapeutics, compounds, and uses related thereto
US9675550
###### Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9670507 Directed evolution and in vivo panning of virus vectors
US9670166
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9669092 Antagonism of the VIP signaling pathway
US9669089
###### Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US9669088 Vaccination with multiple clades of H5 influenza A virus


-----

###### US9661856 Synergy of plant antimicrobials with silver
US9657278 Methods to produce bunyavirus replicon particles
US9657076
GM-CSF and IL-4 conjugates, compositions, and methods related
###### thereto
US9657048 Enantiomers of the la€2,6a€2-isomer of neplanocin A
###### Rutgers, The State University of New Jersey
NOVARTIS AG
###### Eurocine Vaccines AB
VERONA PHARMA PLC
RNASSIST LTD.
###### ID Pharma Co., Ltd. Rutgers, The State University of New lersey Parion Sciences, Inc. Diagnostic Hybrids, Inc. CITY OF HOPE
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

###### Longhorn Vaccines and Diagnostics, LLC UNIVERSITY TENNESSEE RESEARCH FOUNDATION
CORNELL UNIVERSITY
The Trustees of the University of Pennsylvania
###### Dana-Farber Cancer Institute Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Children's Healthcare of Atlanta, Inc.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
The University of North Carolina at Chapel Hill
###### Boehringer Ingelheim International GmbH
Emory University
###### Octl0
9NOV12
3Dec09
###### 17Decl2 15Marl3 lMarl3 163U1-08 12Mayl4 17Decl2 24Apr98 263an07 15Aprl0 lOct07 173U1-14 17Marl0
17Dec01
###### 2Dec05 16Marl2 240ctll 263U1-10 30Apr08 6Febl3 2Febll iSCureVac
AG


-----

###### Febl2 26Seqirus
UK Limited
The Arizona Board of Regents on Behalf of The University
###### of Arizona Stichting Dienst Landbouwkundig Onderzoek Children's Healthcare of Atlanta., Inc. Auburn University

Nov07
###### 24Augl2 20Sepl0 230ctl2 4Augl4
 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 9Oct
 -14

8Nov

###### -13
 22Mar
 -16

17Dec

###### -13
 17Mar
 -14
 28Feb
 -14

293U115
###### llMay
 -15
 83an
 -15

4Aug

###### -14
 HOct
 -13
 15Apr
 -11

15Dec

###### -15

163U115
###### 17Mar
 -11
30Mar
###### -16

8May

###### -13
 14Mar
 -13

73U116
###### 253an
 -13
 283un


-----

###### -16

5Aug
###### -16 31Jan -12
15Feb
###### -13
25NOV
###### -08
26Aug
###### -13 103ull5 230ct -13
4Aug
###### -15
34
###### 113U117
113U117
###### 11JU117 11JU117 11JU117 43ull7 43ull7 43U117 43U117 273unl7 273unl7 273unl7 20Junl7 203unl7 203unl7 133unl7 133unl7 133unl7 133unl7 133unl7 63unl7 63unl7 63unl7 63unl7 63unl7
30May
###### -17
23May
###### -17
23May
###### -17
23May
###### -17

US9657015
US9655896
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity


-----

###### Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
US9655845 Oil-in-water emulsions that contain nucleic acids
US9655367 Disinfecting composition and wipes with reduced contact time
US9651543 Malaria antigen screening method
US9650685 Selective detection of human rhinovirus
US9650649

###### LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virusproducing cells for the therapy of tumors US9649324 Use of tylvalosin as antiviral agent
US9649309
###### Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity US9644180 Synthetic membrane-receiver complexes
US9642876
US9642873
###### US9637524 Method of preventing or treating sinusitis with oxidative reductive potential water solution Combinations of TGFI2 and COX-2 inhibitors and methods for their therapeutic application
 Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
US9637491 Pyrazolo[4j3-D]pyrimidines as kinase inhibitors
###### US9636410 Cationic oil-in-water emulsions
US9636397 Adjuvant compositions and related methods
###### US9636370 AAV vectors targeted to oligodendrocytes
US9629907
###### Compositions for and methods of inducing mucosal immune responses
US9624173 Heterocyclic modulators of lipid synthesis
US9623040
###### Immunomodulation by controlling expression levels of microRNAs in dendritic cells
US9618508 Flow cytometry analysis of materials adsorbed to metal salts
###### US9618476 System and method for electronic biological sample analysis
US9618429 Polymer stabilization of chromogen solutions
US9611481
###### US9611474 Chimeric polynucleotides and polypeptides enabling the secretion of
a polypeptide of interest in combination with exosomes and uses
###### thereof Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof US9605276 Replication defective adenovirus vector in vaccination US9603864 Substituted nucleosides, nucleotides and analogs thereof US9603850 MerTK-specific pyrazolopyrimidine compounds US9599606 ADP-ribose detection reagents
US9598459 Pharmaceutical compositions and methods

###### Fauci/COVID-19 Dossier Boehringer Ingelheim International GmbH 313U1-14
27PARION
SCIENCES, INC.


-----

###### GlaxoSmithKline Biologicals., S.A.
LONZAj INC.

The United States of America as Represented by the
###### Secretary of the Navy
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
VIRATHERAPEUTICS GMBH
CAMBRIDGE UNIVERSITY TECHNICAL SERVICES
The University of North Carolina at Chapel Hill
RUBIUS THERAPEUTICS, INC.
SONOMA PHARMACEUTICALS, INC.
###### Sirnaomics, Inc.
The Regents of the University of California
ORIGENIS GMBH
GLAXOSMITHKLINE BIOLOGICALS SA
###### Vaxliant, LLC
The University of North Carolina at Chapel Hill
The Trustees of the University of Pennsylvania
###### 3-V Biosciences, Inc.

The Board of Trustees of the Leland Stanford lunior
###### University GlaxoSmithKline Biologicals SA
NANOMEDICAL DIAGNOSTICS, INC.

###### Ventana Medical Systems, Inc.
UNIVERSITE DE MONTPELLIER
QUARK PHARMACEUTICALS, INC.
###### Etubics Corporation Alios BioPharma, Inc.
The University of North Carolina at Chapel Hill
The Board of Regents of the University of Texas System
Pop Test Oncology LLC
CC-BY-NC-SA Dr. David E. Martin
###### Junll 6-Julll
6NOV13
31Aug05
5Dec08
###### 8Oct08 133U1-06 HAprl4
18NOV13
30D6C03
###### 4Mayl0 27Feb09 19Octl2 6-3U111 24Marl5 28Sepl2
19NOV04
###### SMarll 143U1-14 14Decl0 28Aprl4 233anl2


-----

###### 24Sep09 12Sepl2 24Augl2 243unl4 HAprl4 10:unl4 3Augl5 273U115 123an -15
63U112
4Nov
###### -14 19Apr -13
15Dec
###### -14 80ct -09 83un -15
3Apr
###### -15 123un -15 270ct -15
4May
###### -11
5Nov
###### -14 180ct -13 63ull2 24Mar -16
27Sep
###### -13 280ct -11 19Mar -15 10JU115
14Dec
###### -11 28Apr -14 183an -13
23Sep
###### -10
12Sep
###### -13 15Mar


-----

###### -13 223un -15
3Apr
###### -15
93un
###### -15 283U116
35
May
###### -17
23May
###### -17
23May
###### -17
23May
###### -17
16May
###### -17
16May
###### -17
16May
###### -17
16May
###### -17
16May
###### -17
9May
###### -17
9May
###### -17
9May
###### -17
2May
###### -17
2May
###### -17
2May
###### -17
2May
###### -17
2May
###### -17 25Aprl7 18Aprl7 18Aprl7 HAprl7 HAprl7 HAprl7 4Aprl7 4Aprl7 28Mar -17 28Mar


-----

###### -17
 28Mar
 -17
 21Mar
 -17
 21Mar
 -17

23

###### 6US9597333
 Benzazepine dicarboxamide compounds US9593334
Use of the chromosome 19 microRNA cluster (C19MC) for treating
###### viral disease and promoting authophagy Hoffmann-La Roche Inc. University of Pittsburgha€JJOf the Commonwealth System of Higher Education
US9593331 Double-stranded nucleic acid molecule for gene expression control
Osaka City University
###### US9593084 US9592284
US9592277
###### Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity Immunization regimen with E4-deleted adenovirus prime and Eldeleted adenovirus boost Compositions with modified nucleases targeted to viral nucleic acids
and methods of use for prevention and treatment of viral diseases
US9588069 Methods for performing thermal melt analysis
US9587250
###### Adeno-associated virus (AAV) serotype 8 sequences^ vectors containing same, and uses therefor
US9586998 Methods of propagating monkey adenoviral vectors
US9586911
###### Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds
US9586910
###### 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6pentahydroxyhexyl)amino)ethox y)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide
US9585968
US9585953
###### Hydrazino lH-imidazoquinolin-4-amines and conjugates made therefrom
 Immunogenic compositions in particulate form and methods for producing the same US9585874 Nuclear transport modulators and uses thereof
US9585849 Broad spectrum antiviral and methods of use
###### US9580474 Polyionic papilloma virus-like particle (VLP) vaccines
US9580468
###### Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells Parion Sciences, Inc.
The Trustees of the University of Pennsylvania


-----

###### Aviridj Inc.
GEN-PROBE INCORPORATED
###### Trustees of the University of Pennsylvania GenVec, Inc.
 Parion Sciences^ Inc.
 MarlS 7Marl2 2Novll
17D6C12
###### 28Apr04 14Apr04 31JU1-12
17D6C01
9NOV09
13D6C13
###### 27Parion Sciences, Inc. Junll
33M
###### Innovative Properties Company

MUCOSIS B.V.
###### Karyopharm Therapeutics Inc.
The Burlington HC Research Group, Inc.
THE 3OHNS HOPKINS UNIVERSITY
CENTRE DE INVESTIGACION BIOMEDICA EN RED
BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER
BBN)
US9580429 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
###### AstraZeneca AB
US9574189 Enzymatic encoding methods for efficient synthesis of large libraries
###### Nuevolution A/S
US9574181 Influenza virus reassortment method
US9573955 Compounds
US9573938
###### Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
US9572899 Compositions for enhancing transport of molecules into cells
###### US9572864 Compositions and uses of lectins
US9572823 Boron-containing small molecules
###### US9567336 Conjugated TLR7 and/or TLR8 and TLR2 agonists US9566326 Adjuvanted influenza vaccines for pediatric use
US9566291 Nutritional composition comprising indigestible oligosaccharides
###### US9566290 Boron-containing small molecules
 Fauci/COVID-19 Dossier
 Seqirus UK Limited Chiese Farmaceutici S.p.A. Rutgers, The State University of New lersey AVI BIOPHARMA, INC.

Emory University

###### Anacor Pharmaceuticals, Inc.

INVIVOGEN
###### Seqirus UK Limited N.V. Nutricia Anacor Pharmaceuticals, Inc.


-----

CC-BY-NC-SA Dr. David E. Martin
###### Junll 22Marll 9Mayl2 17Apr06 8Sepl0 IBJanll 6Dec04 lDec05 21Mayl0 16Decl3 HSepl2 29Apr03 12Febl0 16Feb05
19NOV12
###### 22Feb08 24Aug04 16Feb05
28Sep

###### - 16

6Mar

###### - 13
 INov
 - 12

13Dec

###### - 13
 27Apr
 - 05
 14Apr
 - 05 31JU113 163an
 - 15

4Aug

###### - 15

19Dec

###### - 14

18Dec

###### - 13

14Aug

###### - 15
 22Mar
 - 12
 63an
 - 16
 17Apr
 - 07

8Sep

###### - 11
 133an
 - 12

15Sep

###### -14


-----

###### IDec -06 240ct -14
16Dec
###### -14 llSep -13
5Nov
###### -08 llDec -15
5Apr
###### -16 15Mar -13 213un -13
24Aug
###### -05 20Apr -16
36
###### 21Mar -17 14Mar -17 14Mar -17 14Mar -17 14Mar -17 14Mar -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17
7Mar
###### -17 28Feb


-----

###### -17
 28Feb
 -17
 28Feb
 -17
 21Feb
 -17
 21Feb
 -17
 21Feb
 -17
 21Feb
 -17
 21Feb
 -17
 21Feb
 -17
 21Feb
 -17
 14Feb
 -17
 14Feb
 -17
 14Feb
 -17
 14Feb
 -17
 16US9566289
 Boron-containing small molecules
US9565857 Antimicrobial solutions
###### US9562110 Bispecific antibody
US9561263 Treatment of inflammatory illnesses with ACE2
US9556237 Antiviral rift valley fever virus peptides and methods of use
US9556229 Modification of peptides using a bis(thioether)arylbridge approach
###### US9556184 Phosphoinositide 3-kinase inhibitors
US9556117 Indole carboxamide derivatives as P2X7 receptor antagonists
US9555031
US9555030
US9550773
###### Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US9550757 Nuclear transport modulators and uses thereof
US9549949 Antiviral agent
US9549938 Boron-containing small molecules
US9546371
###### Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions Anacor Pharmaceuticals, Inc.
 Board of Regents, The University of Texas System


-----

Wuhan YZY Biopharma Co.., Ltd.
###### Apeiron Biologies AG
The United States of America, as represented by the
###### Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases
The Regents of the University of California
###### Respivert, Ltd.

ACTELION PHARMACEUTICALS LTD.
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill
3M Innovative Properties Company
###### Karyopharm Therapeutics Inc.
NBC MESHTEC, INC.

###### Anacor Pharmaceuticals, Inc.

FebOS
###### 10Sepl0 21Novl2
18Dec07
###### 6Decl2 18Mayl2 15Marl3 18Decl2 HAprl4 HAprl4 183un04 5Marl0
3Sep08
###### 16Feb05
18CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE
###### Mar08 13US9546184
 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines 3M INNOVATIVE
PROPERTIES COMPANY
US9546150
###### Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 US9545440 Methods for preparing squalene
US9540373 Substituted spirocycles
US9539321 HMGBl-derived peptides enhance immune response to antigens
US9539217 Nanoparticle compositions
US9533978
US9533037
###### US9529974 Pyrimidine derivatives and their use in the treatment of cancer and further diseases Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes System and method for detecting, collecting, analyzing, and communicating event-related information
US9527903 Engineered antibody constant domain molecules
US9526803 Diagnostic chewing gum for pathogens
###### US9526700 Composition for inactivating an enveloped virus


-----

US9522962
###### US9522894 Peptides, conjugates and method for increasing immunogenicity of a vaccine Certain (2S)-N-[(IS)-l-cyano-2-phenylethyl]-l,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors Fauci/COVID-19 Dossier
HYBRIGENICS SA
NOVARTIS AG
###### Boehringer Ingelheim International GmbH
The Regents of the University of California
###### Allertein Therapeutics, LLC Sumitomo Dainippon Pharma Co., Ltd Declion Holdings LLC Georgetown University
The United States of America, as represent by the
###### Secretary, Department of Health and Human Services Julius-Maximilians-Universitaet Wuerzburg
VIROBLOCK SA
###### Academisch Ziekenhuis Leiden h.o.d.n. LUMC AstraZeneca AB
CC-BY-NC-SA Dr. David E. Martin
###### Aug08 2Sepll 12Mayl0 12Sepl4 27JU1-10 3Aprl3
21May09
###### 16Oct07 25Feb08 31Jan08 8Marl2
19May06
###### 15Marl0 24Janl4 17Feb -16
9Sep
###### -11
21NOV
###### -12
18Dec
###### -08 4Jun -15
17May
###### -13
4Dec
###### -15
17Dec
###### -13
3Apr
###### -15


-----

3Apr
###### -15 13Apr -15 283un -13
3 lAug
###### -09 HMar -16 18Mar -09 83un -15
29Aug
###### -12 230ct -15
10Sep
###### -15
9Mar
###### -15
3Apr
###### -14
26Aug
###### -14 160ct -08 27JU111 lOct -13
8Mar
###### -13
17NOV
###### -14 15Mar -11 213an -15
37
###### 14Feb -17 14Feb -17
7Feb
###### -17
7Feb
###### -17 313anl7 313anl7 313anl7 313anl7 313anl7 313anl7


-----

###### 24:anl7 24:anl7 24:anl7 24:anl7 17:anl7 17:anl7 17:anl7 17:anl7 10:anl7 10:anl7 10:anl7 3:anl7 33anl7
27Dec
###### -16
27Dec
###### -16
27Dec
###### -16
27Dec
###### -16
20Dec
###### -16
20Dec
###### -16
US9522171

EV576 for use in the treatment of viral infections of the respiratory
###### tract
US9518093 Topical formulation of arginine-rich cyclic antimicrobial peptides
US9518083 Gadd45beta targeting agents
US9517263 Benzonaphthyridine-containing vaccines
US9517205 Soluble needle arrays for delivery of influenza vaccines
US9512471 Methods and kits for detecting human papillomavirus
###### SVolution
Immuno Pharmaceuticals SA
NOVABIOTICS LIMITED
###### Imperial Innovations Limited GlaxoSmithKline Biologicals SA Seqirus UK Limited
DIACARTA me
US9512443 Recombinant expression of multiprotein complexes using polygenes ETH
ZURICH
US9512181

###### Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor US9511070 Heterocyclyl carboxamides for treating viral diseases
US9506063
SiRNA compositions and methods for treatment of HPV and other
###### infections
US9504747 Lipids and lipid compositions for the delivery of active agents
US9504673
###### Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
US9504255 Physical antimicrobial method


-----

US9499799
###### Cells and methodology to generate non-segmented negative-strand
RNA viruses
US9499535 Kinase inhibitors
US9499489 Myxovirus therapeutics, compounds, and uses related thereto
US9498548
###### US9498544 Method of using oxidative reductive potential water solution in dental applications Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US9498527 Vaccine composition
US9494571 Methods of testing for intracellular pathogens
US9493788
US9493572
US9493518
###### Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
GITR antibodies and methods of inducing or enhancing an immune
###### response Compositions and methods for treating Clostridium difficileassociated diseases
US9492528 Influenza virus-like particles (VLPS) comprising hemagglutinin
US9492413
US9489495
Use of salt of an acetylsalicylic acid for the treatment of viral
###### infections System and method for detecting, collecting, analyzing, and communicating event-related information
US9487838 Oligonucleotide probe for the detection of adenovirus
US9487837
###### Exosome-mediated diagnosis of hepatitis virus infections and diseases
US9487778 Oligonucleotide modulators of the toll-like receptor pathway
###### Tetragenetics, Inc. NovaDrug, LLC Sirnaomics, Inc. Novartis AG
LTD a€ceValenta-lntellekta€
NMS TECHNOLOGIES CO., LTD.
###### Centre National De La Recherche Scientifique
ORIGENIS GMBH
###### Children's Healthcare of Atlanta, Inc. Oculus Innovative Sciences, Inc. Tissue Regeneration Therapeutics Inc.
NITTO DENKO CORPORATION
###### Novartis AG
The Trustees of the University of Pennsylvania
###### GITR, Inc. National Health Research Institutes
MEDICAGO INC.
###### Ventaleon GMBH
GEORGETOWN UNIVERSITY
QIAGEN HAMBURG GMBH


-----

MOREHOUSE SCHOOL OF MEDICINE
QUARK PHARMACEUTICALS, INC.
US9487749 Use of methylsulfonylmethane (MSM) to modulate microbial activity
###### Biogenic Innovations, LLC DanlO 24Feb06 22Oct09 101un09 20Augl0 301unl0
8NOV05
###### 27Mayll 31Augl2 293U1-10 8Marl3
21May09
###### lAugl2 22Dec06 21Aprll 240ctll
2May05
###### 21Apr08 4Aprl2 8Marl0
17Dec01
###### 25Mar05 14Marl3 133U1-07 143an08 25Feb08 28Decl0 6Oct08 3Marll 30Oct09 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 23an -15
9Nov
###### -15 10Feb -15 103un -10
19Aug
###### -11
303un
###### -10
6Nov
###### -06
29May
###### -12
30Aug


-----

###### -13 293an -13
7Mar
###### -14
10May
###### -10 16JU113 150ct -13 23Apr -12 240ct -12
2May
###### -06 13Mar -15
3Apr
###### -13
7Mar
###### -11 163an -15 23Mar -15 13Mar -14 23ul09
143 an
###### -09
28Aug
###### -08
28Dec
###### -10 213an -14 iMar -12
12Aug
###### -14
38
20Dec
###### -16
13Dec
###### -16
13Dec
###### -16
13Dec
###### -16
13Dec
###### -16
6Dec
###### -16


-----

6Dec

###### -16

6Dec

###### -16

6Dec

###### -16

29NOV

###### -16

29NOV

###### -16

29NOV

###### -16

29NOV

###### -16

22NOV

###### -16

22NOV

###### -16

22NOV

###### -16

22NOV

###### -16

22NOV

###### -16

22NOV

###### -16

15N0V

###### -16

15N0V

###### -16

15N0V

###### -16

15N0V

###### -16

15N0V

###### -16

15N0V

###### -16

8Nov

###### -16

8Nov

###### -16

8Nov

###### -16

8Nov

###### -16

8Nov

###### -16

9US9487528

Compounds
US9486479
US9481912
###### Antimicrobial solutions containing dichloride monoxide and methods of making and using the same


-----

###### Compositions and methods for detecting and identifying nucleic acid sequences in biological samples US9481724 hDC-sign binding peptides
US9481630
###### Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same US9476090 Signal propagation biomolecules, devices and methods
US9476032 Attenuated viruses useful for vaccines
US9475872
###### Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US9475862 Neutralizing GP41 antibodies and their use
###### Chiesi Farmaceutici S.p.A. Oculus Innovative Sciences, Inc.
 Longhorn Vaccines and Diagnostics, LLC
 Sloan-Kettering Institute for Cancer Research
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
BIOTECHNOLOGY
STC.UNM
The Research Foundation for The State University of New
###### York

ImmunoQure AG
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
US9475832 Phosphonates with reduced toxicity for treatment of viral infections
The Regents of the University of California
###### US9475804
US9475779
###### Heterobifunctional linkers with polyethylene glycol segments and
immune response modifier conjugates made therefrom
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475775 Benzazepine dicarboxamide compounds
###### US9474844
US9474759
###### Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto
 Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses US9469876 Circulating biomarkers for metastatic prostate cancer US9464276 Highly efficient influenza matrix (Ml) proteins
US9464123
US9463240
US9459247
###### Peptides having activity of inhibiting infections of respiratory viruses
and use of the same

###### Arranging interaction and back pressure chambers for microfluidization Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry
US9459233 Amperometric gas sensor
US9458492 Methods and cells for identifying RIG-I pathway regulators


-----

US9458470
###### Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin US9458184 Compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9458113
###### US9457074 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
US9453043 Nucleic acid chemical modifications
US9452973 Modulators of the relaxin receptor 1
US9452210
###### Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant Fauci/COVID-19 Dossier
3M Innovative Properties Company
###### Boehringer Ingelheim International GmbH Hoffmann-La Roche Inc. Hemalux LLC Kansas State University Research Foundation Caris Life Sciences Switzerland Holdings GmbH Novavax, Inc.
XIANGXUE GROUP (HONG KONG) COMPANY LIMITED
NOVARTIS AG
###### Academia Sinica Steris Corporation Kineta, Inc.
MEDICAGO INC.
INVIVOGEN
###### Boehringer Ingelheim International GmbH Ohio State Innovation Foundation
ALNYLAM PHARMACEUTICALS, INC.
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF
TRUSTEES
MEDICAGO INC.
CC-BY-NC-SA Dr. David E. Martin
###### 3unl4 13Mar07 12Sep06 19Decll 19Octll 21Mayl3 30Mar07 28Decll
7NOV11
###### 14Aprl0 33unll 313U1-14 GMarlS 220ctl4 27Sepll 6Aprl0 11JU1-03


-----

###### 9Mayl3
3Dec09
###### 29Marl0 253unl2 25Febll 213an08 153unl2 31JU1-14 24Aprl2 2Mar09 4Mayl2 133ul-07
53un
###### -15 21JU114 80ct -13
10Dec
###### -12
28Sep
###### -12
21May
###### -14
31Mar
###### -08 23an -13
7Nov
###### -12
29Sep
###### -14 13un -12 273ull5 4Mar -16
29Dec
###### -15
27Sep
###### -12
6Apr
###### -11 23Feb -15 21Feb -14 11JU114 29Mar -11 26Feb -13 23Feb -12 233an


-----

###### -13 15Mar -13
273U115
###### 23Feb -15 223an -15 15Mar -13 43an -13
39
8Nov
###### -16
8Nov
###### -16 INov -16 INov -16 INov -16 25Octl6 25Octl6 25Octl6 25Octl6 25Octl6 250ctl6 25Octl6 25Octl6 25Octl6 25Octl6 18Octl6 110ctl6 noctie noctie 40ctl6 40ctl6 40ctl6 40ctl6 40ctl6 40ctl6 40ctl6
27Sep
###### -16
27Sep
###### -16
27Sep
###### -16

US9447462

###### unknown ^antifieation of an

 18IBIS


-----

BIOSCIENCES, INC.
US9447132 Highly active nucleoside derivative for the treatment of HCV
US9447097 4-amino-imidazoquinoline compounds
US9446062 Methods of treating ischemia-reperfusion injury with siRNAs
US9442107
###### Antibody-nanoparticle conjugates and methods for making and using such conjugates
US9441247 TC-83-derived alphavirus vectors, particles and methods
###### US9440960 Substituted oxetanes and their use as inhibitors of cathepsin C
US9440930
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9435795 Enhanced deposition of chromogens utilizing pyrimidine analogs
###### US9435000 Primate T-lymphotropic viruses
US9434997
US9434769
US9433672
###### Methods, compounds and systems for detecting a microorganism in
a sample
###### Peptide compositions and methods for inhibiting herpesvirus infection Compositions and methods for activating innate and allergic immunity US9430610 Re-sequencing pathogen microarray
US9428739 Norovirus and Sapovirus antigens
###### US9428574 Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US9428571 Antibodies and processes for preparing the same
###### US9428490 Nuclear transport modulators and uses thereof
US9428439 Hydrobenzamide derivatives as inhibitors of Hsp90
US9426989 Organic peroxide compounds for microorganism inactivation
US9422367 Antigenic GM-CSF peptides and antibodies to GM-CSF
###### US9421254 Immunostimulatory combinations of TLR ligands and methods of use
 Achillion Pharmaceuticals, Inc. Hoffmann-La Roche Inc. Quark Pharmaceuticals, Inc. Ventana Medical Systems, Inc.
ALPHAVAX, INC.

###### Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH
 Ventana Medical Systems, Inc.
 lohns Hopkins University Lawrence Livermore National Security, LLC

The Administrators of the Tulane Educational Fund
###### ID Biomedical Corporation of Quebec
The United States of America, as represented by the
###### Secretary of the Navy
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
COMPUGEN LTD.
TAIGA BIOTECHNOLOGIES, INC.
###### Karyopharm Therapeutics Inc.


-----

ASTEX THERAPEUTICS LTD.
NOVARTIS AG
###### Morphotekj Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services US9416416 Biological specimen collection/transport compositions and methods Longhorn Vaccines and Diagnostics, LLC
US9416409
US9416396
###### Capture primers and capture sequence linked solid supports for molecular diagnostic tests Covalently linked thermostable kinase for decontamination process validation
US9415392 Slip chip device and methods
US9415087 Compositions and methods for treating coronavirus infection
US9415033
US9409987
###### Esters of short chains fatty acids for use in the treatment of immunogenic disorders Polypeptides and polynucleotides, and uses thereof for treatment of
immune related disorders and cancer
US9409917 Heterocyclic amide derivatives as P2X7 receptor antagonists
###### IBIS BIOSCIENCES, INC.
The Secretary of State for Health
The University of Chicago
###### Ludwig-Maximilians-Universitaet Muenchen
PROPONENT BIOTECH GMBH
COMPUGEN LTD
ACTELION PHARMACEUTICALS LTD.

Feb04
###### 12Aprl3 22Aprl4 25Oct06 27Aprl0 18May04 lAugl4 313U1-14 30Decl0 21Feb05
24Aug07
###### 30Oct09 26Aprl2 2-3U104 24Mar01 303unll
16May08
###### 293U1-11 12Oct06 6Mayl0 7Feb06
24Sep07
###### ioct07 313U1-09 20Feb08


-----

###### 24Mar09 llMarl4 30ctl2 ISAprll 203anl2 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 273an -14 14Apr -14
7Apr
###### -16 Sian -15 21Apr -15
6JU115
###### 31JU115
273U115
###### 6Oct -14
20Sep
###### -13
21Aug
###### -08 93ull4 28Apr -14 10Apr -08
27NOV
###### -12
1JU112
###### 18Mar -15
263U112
###### 73an -14
6May
###### -11
26NOV
###### -13
24Sep
###### -08
16Dec
###### -11 303U110 18Feb -09 23Mar -10
8May


-----

###### -15 30ct -13 16Apr -12 183an -13 40
20Sep
###### -16
20Sep
###### -16
20Sep
###### -16
20Sep
###### -16

13Sep
###### -16
13Sep
###### -16
13Sep
###### -16
13Sep
###### -16
6Sep
###### -16
6Sep
###### -16

6Sep
###### -16
6Sep
###### -16
6Sep
###### -16
30Aug
###### -16
30Aug
###### -16
30Aug
###### -16
30Aug
###### -16
30Aug
###### -16
30Aug
###### -16
30Aug
###### -16
23Aug
###### -16

23Aug
###### -16
16Aug
###### -16


-----

16Aug

###### -16

16Aug

###### -16

16Aug

###### -16

16Aug

###### -16

16Aug

###### -16

9Aug

###### -16

9Aug

###### -16
 15US9409870

Compounds
US9408908 Combination adjuvant formulation
US9408907
Homogenous suspension of immunopotentiating compounds and
###### uses thereof US9404160 Methods for the detection of microorganisms
US9403868 Crystalline tripeptide epoxy ketone protease inhibitors
US9402921 Directed evolution and in vitro panning of virus vectors
US9402878 Depsipeptide and uses thereof
US9402812 Methods for the preparation of liposomes
US9394092 Powdered pouch and method of making same
###### US9393564 Bioagent detection systems^ devices^ and methods
US9393295 Nanoparticles for use in pharmaceutical compositions
US9393215 Nanoparticles for use in immunogenic compositions
US9388429
###### US9388234 Method for propagating adenoviral vectors encoding inhibitory gene products Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US9388198 Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388197 Heterocyclic amide derivatives as P2X7 receptor antagonists
US9387242
###### Chimeric viruses presenting non-native surface proteins and uses thereof US9382590 Methods and compositions for prostate cancer metastasis
US9382545
US9382288
CpG oligonucleotide analogs containing hydrophobic T analogs with
###### enhanced immunostimulatory activity Derivatives of steroid benzylamines., having an antiparasitic antibacterial, antimycotic and/or antiviral action US9381244 VISTA modulators for diagnosis and treatment of cancer
US9381239
VLPS derived from cells that do not express a viral matrix or core
###### protein US9381226 Methods and compositions related to inhibition of viral entry US9381220 Sceletium extract and uses thereof
US9380785 Antiviral resin member


-----

US9376486
Human monoclonal antibody with specificity for Dengue virus
###### serotype 1 E protein and uses thereof
US9376398 Carboxylic acid compounds
US9375465
US9372156
###### Conjugates of GM-CSF and IL-7, compositions and methods related thereto System for processing contents of a receptacle to detect an optical signal emitted by the contents
US9371563 Nanoreporters and methods of manufacturing and use thereof
###### CHIESI FARMACEUTICI S.p.A. Not Available GlaxoSmithKline Biologicals SA Becton^ Dickinson and Company
Onyx Therapeutics, Inc.
The University of North Carolina at Chapel Hill
###### NovoBiotic Pharmaceuticals, LLC Indu laveri
MONOSOL, LLC
###### IBIS BIOSCIENCES, INC. Novartis AG Novartis AG GenVec, Inc. Not Available
ACTELION PHARMACEUTICALS LTD.
ACTELION PHARMACEUTICALS LTD.
###### Icahn School of Medicine at Mount Sinai
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
(FAMU)
COLEY PHARMACEUTICAL GMBH
###### lustus-Liebig-Universitat Giessen KING'S COLLEGE LONDON Novavax, Inc. UNIVERSITY OF UTAH RESEARCH FOUNDATION
H. L. Hall & Sons Limited
NBC MESHTEC, INC.
DSO National Laboratories
###### Astrazeneca Aktiebolag Children's Healthcare of Atlanta, Inc.
GEN-PROBE INCORPORATED
###### NanoString Technologies, Inc. Decl4 16Oct08
15Dec09
22D6C09
###### 20Mar09 30Apr08 3Decl2
23Sep09
###### 16Aprl2 30Mar09 28Apr08 2Dec05


-----

10NOV05
6Dun03
###### 213anl4 223anl3 2Dec05 25Marll 27Sep06 6Octl0 7Sepl2
25May07
###### 8Feb07 20Mar09 6-Julll 14Decl0 18Mayl2
14N0V11
###### 10Mar05
23Dec05
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
27NOV
###### -15 15Feb -13
15Dec
###### -10
21Dec
###### -10
5Mar
###### -15 22Oct -14
13U115
23Sep
###### -10 14Mar -13
30Mar
###### -10 28Apr -09 iDec -06
28May
###### -14 193un -13 213an -14 213an -14 IDec -06


-----

20May
###### -15 Oct -13 60ct -11
9Sep
###### -13
 14Apr -14
8Feb
###### -08
 15JU114 63ull2
14Dec
###### -11

17May
###### -13

13N0V
###### -12
 22Feb -11
 HMar -13
41
9Aug
###### -16
9Aug
###### -16
9Aug
###### -16
2Aug
###### -16
2Aug
###### -16

2Aug
###### -16

2Aug
###### -16

2Aug
###### -16 19JU116 19JU116 19JU116 19JU116 12JU116 12JU116 12JU116 12JU116 12JU116 53ull6 53ull6 53ull6 53ull6


-----

5JU116
5JU116
5JU116
5JU116
###### 283unl6 283unl6 283unl6 21Junl6 21Junl6
 4US9370582
 Carbohydrate conjugates as delivery agents for oligonucleotides
US9370581 Carbohydrate conjugates as delivery agents for oligonucleotides
###### US9370570 Polychlorinated biphenyls and squalene-containing adjuvants
US9370531
###### Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US9365577 Pyrimidinone compounds as human neutrophil elastase inhibitors
US9365567 Alkoxy substituted imidazoquinolines
US9365523 Imidazolyl amide compounds and uses related thereto
###### US9365506 Compounds and compositions as TLR2 agonists
US9364511 Antiviral preparations obtained from a natural cinnamon extract
###### US9359360 TLR agonists
US9358280
###### Decreasing potential iatrogenic risks associated with influenza vaccines
US9353133 Boron-containing small molecules
US9352048 Carbohydrate conjugates as delivery agents for oligonucleotides
US9347055
###### Method and kit for preparation of sample for use in nucleic acid amplification US9346866 Inhibition of tace activity with cyclic peptides US9346794 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9346769 Tetrazolones as inhibitors of fatty acid synthase
US9346753 Dithiol mucolytic agents
US9345760
US9340507
###### IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
ALNYLAM PHARMACEUTICALS, INC.
ALNYLAM PHARMACEUTICALS, INC.
###### Novartis AG
New York University
###### Chiesi Farmaceutici S.p.A.
3M Innovative Properties Company
###### Children's Healthcare of Atlanta., Inc.
NOVARTIS AG
RAMOT AT TEL-AVIV UNIVERSITY LTD.
The Regents of The University of California
###### Novartis AG Anacor Pharmaceuticals, Inc.


-----

ALNYLAM PHARMACEUTICALS, INC.
EIKEN KAGAKU KABUSHIKI KAISHA
The Regents of the University of California
###### Boehringer Ingelheim International GmbH Infinity Pharmaceuticals., Inc.
PARION SCIENCES, INC.

###### Advanced Bionutrition Corporation Boehringer Ingelheim International GmbH
US9339561 Mutant protease biosensors with enhanced detection characteristics
PROMEGA CORPORATION
US9339525 Inhibition of biofilm organisms
US9334268 4-amino-imidazoquinoline compounds
###### US9328110 Substituted imidazo ring systems and methods
US9328093
###### Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications
US9326972
Use of phenylmethimazoles, methimazole derivatives, and
###### tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US9322827 B-cell antigen presenting cell assay
US9321999
US9321847
###### Compositions for increasing polypeptide stability and activity, and related methods Activatable toxin complexes comprising a cleavable inhibitory peptide Fauci/COVID-19 Dossier Novabiotics Limited
HOFEMAN-LA ROCHE INC.
3M INNOVATIVE PROPERTIES COMPANY
HYBRIGENICS SA
D6C07
4D6C07
28D6C07
31Aug07
###### 18Decl2 3Oct03 31Marll 23Marl0
24D6C03
22Aug05
###### 9Sep04 16Feb05 4Dec07
5NOV07
###### 23unll 23Augl2 5Mayl0 23Augl3 9Sepll 23Augl2


-----

###### llMayie 31Mar09 22Aprl4
25NOV03
###### 153anl0 16Ohio University Mar04 University of Pittsburgh - Of the Commonwealth System of Higher Education
SOLIS BIODYNE OAce

RAMOT at Tel Aviv University Ltd.
###### CC-BY-NC-SA Dr. David E. Martin 8Aprl0 19Nov09 20Sepl0
113U114
113U114
10Dec

###### -13
 iSep
 -08

17Dec

###### -13
30Sep
###### -14 28Mar
 -12
 93U114 223un
 -06

20NOV

###### -12
 Ilian
 -13

7Mar

###### -14
 223ull4
SNov
###### -08

19Sep

###### -14

29Dec

###### -15

23Aug

###### -13

13Aug

###### -14

7Sep

###### -12

2Sep

###### -15
5May


-----

Aews
###### 9T-
XewoT
###### 9T-
Xewz.T
###### 9T-
Xewz.T
###### 9T-
Xewz.T
###### 9T-

 9T-

 9T-

 9T-

 9T-

 9T-

 9T- Aewis
 9T- Aewis 9xunc£ 9Tunc£ 9TuncvT 9TuncvT 9TuncvT 9TuncvT 9TuncvT 9Tuncx2 9Tuncx2 9Tuncx2 9Tuncx2

_ZV_
TT-
###### §nvzz 0T-
A0N6T
TT-
###### Jdvg
ZT-
###### q9d6 VT-
d9S£T
###### VT-
JBWTT
ST-
###### vidvzz 0T- jewT£ VT-


-----

###### -16
3May
###### -16
3May
###### -16 26Aprl6 26Aprl6 26Aprl6 1US9321831
 RSV-specific binding molecules and means for producing them US9320784 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
US9320748 Immunologically useful arginine salts
###### US9315530 Adsorption of immunopotentiators to insoluble metal salts
US9310375

###### Luminophore-labeled molecules coupled with particles for microarray-based assays
US9310088
###### Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter
US9309325 Antibodies and methods of use thereof
US9303068
###### D-amino acid derivative-modified peptidoglycan and methods of use thereof US9303000 Olefin containing nuclear transport modulators and uses thereof US9297010 Short interfering RNA (siRNA) analogues
US9295732 Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9295708 Modified release formulations for oprozomib
###### US9295646 Cationic oil-in-water emulsions
US9291628 Direct clone analysis and selection technology
US9291597 Detecting targets using mass tags and mass spectrometry
Medlmmune Limited
###### Not Available Novartis AG Novartis AG CapitalBio Corporation 3un07 7Aug09 7Marl2 lSepl0 27Octl0 Technical University of Denmark 173ul-09
7The
###### Regents of the University of California
The Regents of the University of California
KARYOPHARM THERAPEUTICS INC.
Roche Innovation Center Copenhagen A/S
INVIVOGEN
Onyx Therapeutics, Inc.
###### Novartis AG


-----

###### Dublin City University
VENTANA MEDICAL SYSTEMS, INC.
###### US9290794 Mutant protease biosensors with enhanced detection characteristics
PROMEGA CORPORATION
###### US9290786 Monoclonal antibody production by EBV transformation of B cells US9290760 Modified iRNA agents
US9290745 Luciferase biosensor
US9290545 Compositions and methods for the treatment of viral infections
US9290459
US9290457
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9289487 II-key/antigenic epitope hybrid peptide vaccines
US9284560
US9278128
###### Application of highly conserved domain sequences from viral
genome as template to design therapeutic sliRNAs
###### Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same US9278126 Influenza vaccines with reduced amounts of squalene US9272024 US9271494 Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions US9266844 Suppression of SARS replication by SARS helicase inhibitors Fauci/COVID-19 Dossier Institute for Research in Biomedicine
ALNYLAM PHARMACEUTICALS, INC.
PROMEGA CORPORATION
###### Dana-Farber Cancer Institute, Inc. Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH Antigen Express, Inc.
 Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.
The Trustees of the University of Pennsylvania
###### Seqirus UK Limited
The Trustees of the University of Pennsylvania
###### Ecolab USA, Inc.
The Curators of the University of Missouri
CC-BY-NC-SA Dr. David E. Martin
May09
30NOV12
###### 17Janll 21Mar03 22Febl3 240ctl2 6-3U110 133U1-10 2-3U110


-----

###### llMayie 26Feb03 15Sepl0 10Oct03 233an08 6Febl3 31JU1-14
14Sep99
###### 19Sepll
14Sep09
###### 10Feb09 12Decll
30Aug07
###### 153unl2
13Sep
###### -13 19JU112
7Mar
###### -13 ISep -11 270ct -10 14JU110
4May
###### -10
27NOV
###### -13 163an -12 llFeb -14 22Feb -13 240ct -13
18Sep
###### -11 13JU111 Uulll
12N0V
###### -12 25Apr -13
14Sep
###### -11 14Feb -14 233U110
9Nov
###### -15 273ull5 lllan -05


-----

###### 9T-

JBW8

###### 9T-
```
                                                jbwst

 9T-
```
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewzz

###### 9T-
viewez

###### 9T-
viewez

###### 9T-
viewez

###### 9T-
viewez
9TvidvS
9TvidvS
9TvidV3T
9TvldV2T
9TvldV2T
###### 9TJdV6T
9Tvidv9Z
9Tvidv9Z
9Tvidv9Z

£17

###### £T-
uncz.T

###### £0- §nv0£

ZT-

39QTT

###### 0T- q9d0T
 VT- uec9

TT-
d9S6T


-----

8Mar

###### -16 iMar -16 iMar -16 23Feb -16

9US9266843

###### Nuclear transport modulators and uses thereof
US9265876
US9260398
###### Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases US9255144 Anti-IL-18 antibodies and their uses
US9255140
US9254315
###### Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9254265 Small liposomes for delivery of immunogen encoding RNA
US9249427 Recombinant HCMV and RHCMV vectors and uses thereof
US9249195 Reovirus vaccines and methods of use therefor
###### Karyopharm Therapeutics Inc. Hemalux Technologies LLC
PARION SCIENCES, INC.

Medlmmune Limited
NEW YORK BLOOD CENTER, INC.
###### Not Available
NOVARTIS AG
###### Oregon Health & Science University Vanderbilt University
US9248201 Mutant protease biosensors with enhanced detection characteristics
PROMEGA CORPORATION
US9248178
US9242980
US9238809
###### Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
 Lipidated immune response modifier compound compositions, formulations, and methods Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material
US9234175 Creating bioengineered lymph nodes
US9233148
###### Replikin-based compounds for prevention and treatment of influenza
and methods of differentiating infectivity and lethality in influenza
US9227977 Phosphoinositide 3-kinase inhibitors
US9222075 Animal protein-free media for cultivation of cells
US9221832 Heterocyclic amide derivatives as P2X7 receptor antagonists
US9221807


-----

US9220768
US9217745
###### Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity Decreasing potential iatrogenic risks associated with influenza vaccines Arrayed detector system for measurement of influenza immune response
US9217157 Recombinant influenza viruses and uses thereof
US9216192 Toll-like receptor agonist formulations and their use
US9213027
US9212399

###### Lipoparticles comprising proteins, methods of making, and using the
same
###### Biological specimen collection and transport system and method of use
US9212205 Nucleic acid binding compounds and methods of use
###### US9206396 Methods and devices for quantitative viral assays Not Available
3M Innovative Properties Company
QIAGEN GAITHERSBURG, INC.
H. Lee Moffitt Cancer Center and Research Institute, Inc.
###### Not Available Respivert Ltd. Baxalta GmbH

ACTELION PHARMACEUTICALS LTD.

###### Boehringer Ingelheim International GmbH Novartis AG University of Rochester Icahn School of Medicine at Mount Sinai
 VentiRx Pharmaceuticals, Inc.
 Integral Molecular, Inc. Longhorn Vaccines and Diagnostics, LLC
 University of Rochester Wisconsin Alumni Research Foundation
US9206158 Hydrazide containing nuclear transport modulators and uses thereof
###### Karyopharm Therapeutics Inc.
US9200329 Rapid epidemiologic typing of bacteria
###### BioFire Diagnostics, LLC
 Mayl2 220ctl4 29Mayl2 20Decl0 153un04 28Apr04 31Augl0 14Mayl0 7Aprl0 HMayl0 83un09 17Augl0
24Sep09
17NOV09
###### 93an09


-----

###### 15Marl3 29Oct04 223U1-11 21Febl4 9Sep04
2May08
###### 273U1-09 lAug08 303U1-03 lOct07 263ul-07
16NOV05
###### 29JU1-11
19May08
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
9May
###### -13 22Oct -14
9Dec
###### -14
20Dec
###### -11 23Mar -09
3Feb
###### -10
31Aug
###### -11
14N0V
###### -12 4Apr -11
SMay
###### -14 83un -10
16Aug
###### -11
5Aug
###### -10
16NOV
###### -10 16Oct -09 14Mar -14
2May
###### -14
203U112
###### 12Feb -15


-----

###### 140ct -11 11JU113 27JU110 16JU112 INov -13 71an -14
283U108
16NOV
###### -06 103un -15
18May
###### -09 44 23Feb -16 23Feb -16 16Feb -16
9Feb
###### -16
9Feb
###### -16
9Feb
###### -16
9Feb
###### -16
2Feb
###### -16
2Feb
###### -16
2Feb
###### -16
2Feb
###### -16 263anl6 193anl6 123anl6 123anl6 53anl6
29Dec
###### -15
29Dec
###### -15
29Dec
###### -15
29Dec
###### -15
22Dec
###### -15


-----

22Dec
###### -15
22Dec
###### -15
15Dec
###### -15
15Dec
###### -15
15Dec
###### -15
8Dec
###### -15
8Dec
###### -15 IDec -15
US9200287

US9200280
US9200279
###### Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity 18AdiuTide Pharmaceuticals GmbH
 Methods and compositions for the treatment of cancer or other diseases Methods and compositions for the treatment of cancer or other diseases US9200074 Antibodies to IL-1 RI and methods of making them
US9199981 Compounds and compositions as C-kit kinase inhibitors
US9199897 Methods for preparing squalene
US9198927
US9193780
US9192661
###### Targeting opposite strand replication intermediates of singlestranded viruses by RNAI Amino acid sequences directed against envelope proteins of a virus
and polypeptides comprising the same for the treatment of viral
###### diseases Delivery of self-replicating RNA using biodegradable polymer particles CITY OF HOPE CITY OF HOPE
MEDIMMUNE LIMITED
NOVARTIS AG
NOVARTIS AG
ALNYLAM PHARMACEUTICALS, INC.
###### Ablynx N.V. Novartis AG
US9187748 Compositions and methods for silencing ebola virus gene expression Not
###### Available US9187426 Organic compounds
US9186419 Directed evolution and in vitro panning of virus vectors
US9186399
Immune stimulatory oligonucleotide analogs containing modified


-----

###### sugar moieties Novartis AG
The University of North Carolina at Chapel Hill
###### AdiutTide Pharmaceuticals GmbH
US9181303 Treatment of bacterial infections with cyclic antimicrobial peptides
###### NovaBiotics Limited
US9181290
###### Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-Dglucopyranose
US9175047
###### Peptidomimetic macrocycles
US9174925
###### Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
US9169318 Neutralizing molecules to viral antigens
US9168318
US9168299
US9168269
###### Oxidative reductive potential water solution and methods of using the same Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
US9163222 Mutations in 0AS1 genes
US9163065 Depsipeptide and uses thereof
###### US9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand
US9156811 N-myristoyl transferase inhibitors
US9155309 Virus inactivating sheet
US9149473
US9149445
###### Targeted whole genome amplification method for identification of pathogens Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
US9145588 Generation of binding molecules
CHANG GUNG UNIVERSITY
###### Aileron Therapeutics, Inc.
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
BIOTECHNOLOGY
Sea Lane Biotechnologies, Inc.
###### Oculus Innovative Sciences, Inc.
LIPUM AB
THE TRUSTEES OF PRINCETON UNIVERSITY
###### Kineta Two, LLC NovoBiotic Pharmaceuticals, LLC Trustees of Dartmouth College Univeristy of Dundee
NBC MESHTEC, INC.
###### IBIS BIOSCIENCES, INC.
THE TRUSTEES OF PRINCETON UNIVERSITY
MERUS BIOPHARMACEUTICALS B.V.
May07
###### 263an07 263an07


-----

7NOV08
###### iSepll 12Mayl0 24Sep04
5Dun08
###### 6-JU110 20:111-09 271un08 30Apr08 9Oct07 22Dec05 17Junll 141an09 260ctll 28Mar08
30Dec03
###### 8Apr09 18Febl0
4May05
###### 3Decl2
30Dec02
2Sep08
###### 2Oct09 14Sep06 273U1-09 26Sepll
15May
###### -08
93un
###### -14
143 an
###### -14 16Apr -14
27Aug
###### -12
12May
###### -11 iMar -10
51un
###### -09 71un -11 28Mar -14 253un -09 173an -14
29Sep
###### -08 201un -14


-----

19Sep
###### -11 MJan -10
28Sep
###### -12 183ulll HAug -04 30Oct -13 18Feb -11
14N0V
###### -12
3Dec
###### -13 220ct -12
29Aug
###### -09 40ct -10
14Sep
###### -07 273ull0
26Sep
###### -12 iDec -15 IDec -15 IDec -15 IDec -15 IDec -15 IDec -15 IDec -15
24N0V
###### -15
24N0V
###### -15
17N0V
###### -15
17N0V
###### -15
17N0V
###### -15
17N0V
###### -15


-----

10NOV

###### -15

10NOV

###### -15
3Nov
###### -15
3Nov
###### -15
 270ctl5 270ctl5 270ctl5 270ctl5 20Octl5 20Octl5 20Octl5 130ctl5 130ctl5 60ctl5 60ctl5
29Sep

###### -15 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
45

###### 1US9145585
 Method for using permuted nucleic acid probes US9145410 Pyrazolopyridines and analogs thereof
US9144575 Anti-viral azide containing compounds
US9139833 Modified small interfering RNA molecules and methods of use
US9139647 Diagnosis and treatment of cancer using anti-TM4SF20 antibody
###### US9139620 Feline morbillivirus and uses thereof
US9138472 CD40L vaccines, compositions, and methods related thereto
US9134247
###### Method and apparatus for two-step surface-enhanced raman spectroscopy
US9133248 Methods of propagating monkey adenoviral vectors
US9132423 Sample-to-answer microfluidic cartridge
US9132175 Bacillus based delivery system and methods of use
US9128101 Biomarkers for theranostics
US9127256
US9127251
US9127028
US9125952
US9115093
###### Method for production of reprogrammed cell using chromosomally unintegrated virus vector

Means and methods for influencing the stability of antibody
###### producing cells Substrates for chromogenic detection and methods of use in detection assays and kits Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes Substituted bicyclic dihydropyrimidinones and their use as inhibitors


-----

###### of neutrophil elastase activity
US9115065
###### Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses
US9109199 Methods to produce bunyavirus replicon particles
###### US9107970 Method and a filter for capturing airborne agents
US9107958
###### Hydrazino lH-imidazoquinolin-4-amines and conjugates made therefrom Ventana Medical Systems, Inc.

3M Innovative Properties Company
###### LIFE TECHNOLOGIES CORPORATION Arrowhead Research Corporation
FORERUNNER PHARMA RESEARCH CO., LTD.
THE GOVERNMENT OF THE HONG KONG SPECIAL
ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF
CHINA
EMORY UNIVERSITY
REAL-TIME ANALYZERS, INC.
###### GenVec, Inc. Micronics, Inc.
The Curators of the University of Missouri
###### Caris Life Sciences Switzerland Holdings GmbH
DNAVEC CORPORATION
ACADEMISCH MEDISCH CENTRUM BID DE UNIVERSITEIT
VAN AMSTERDAM
###### Ventana Medical Systems, Inc.
 Industry Academic Cooperation Foundation, Hallym University Boehringer Ingelheim International GmbH
Sep06
###### 3Oct03 283U1-10 263U1-02
25D6C08
###### 203anl2 28Sepl0 16Decll
9NOV09
###### 293anl0 ISAprll IMarlO 163U1-08
9Dec05
###### 16Augl0 173U1-09 4Marl3 GKineta, Inc. Dec04
20STICHTING
DIENST LANDBOUWKUNDIG ONDERZOEK
###### Not Available


-----

3M Innovative Properties Company
###### US9107906 Compositions and methods for the treatment of immunodeficiency ADMA
BIOLOGICSj INC.
###### US9107904 Immunostimulatory compositions and methods of use thereof
US9102938 2a€2 and 5a€2 modified monomers and oligonucleotides
US9102911 High density self-contained biological analysis
US9102741 GAS57 mutant antigens and GAS57 antibodies
###### Massachusetts Institute of Technology
ALNYLAM PHARMACEUTICALS, INC.

###### BioFire Diagnostics, LLC Novartis AG US9102740 Cna-B domain antigens in vaccines against gram positive bacteria
NOVARTIS AG
US9102633
###### US9102624 Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity Parion Sciences, Inc. Boehringer Ingelheim International GmbH Sepl0 153U1-08 33unll 280ctl4 5Aprl2 31Marll
15May09
12Sep07
###### 123an09 13Decl3 23Augl2
5Aug
###### -14 263an -12
283U111
###### 12Mar -13
25Dec
###### -09 223an -13
28Sep
###### -11

16Dec

###### -11

9Nov

###### -10 283an
 -11 18Apr -11 IMar


-----

###### -11
16DU109
8Dec
###### -06
12Aug
###### -11
13Aug
###### -14 20Feb -14 26Feb -13
20Sep
###### -11
133U109
###### 13un -12 83an -15 15Mar -13
3 IMar
###### -11 283an -13 130ct -14 73un -13
13Dec
###### -13
20Aug
###### -13
29Sep
###### -15
29Sep
###### -15
29Sep
###### -15
22Sep
###### -15
22Sep
###### -15
22Sep
###### -15
22Sep
###### -15
15Sep
###### -15
15Sep
###### -15
15Sep
###### -15
15Sep


-----

###### -15
8Sep
###### -15
8Sep
###### -15
8Sep
###### -15
8Sep
###### -15
8Sep
###### -15
25Aug
###### -15
25Aug
###### -15
18Aug
###### -15
18Aug
###### -15
18Aug
###### -15
18Aug
###### -15
18Aug
###### -15 HAug -15 HAug -15 HAug -15 HAug -15 HAug -15 HAug -15 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 46
 14US9101597
 Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC
US9101582
Use of a pneumococcal P4 peptide for enhancing
###### opsonophagocytosis in response to a pathogen
US9096585 Antiviral compounds and uses thereof
US9096543 Nuclear transport modulators and uses thereof
US9090897 Production of IFN-Iambda by conventional dendritic cells
US9085641 Peptides regulating the surface expression of the T cell receptor
US9084808 Modified small interfering RNA molecules and methods of use
US9084758
###### Antiviral compositions comprising ethanol extract of Tetracera


-----

###### scandens and use thereof
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services^ Centers for Disease Control and Prevention Icahn School of Medicine at Mount Sinai Karyopharm Therapeutics Inc. Bavarian Nordic A/S
 Max-Delbruck-Centrum Fur Molekulare Medizin Arrowhead Research Corporation
The Catholic University of Korea Industry-Academic
###### Cooperation Foundation
US9080209 Non-mass determined base compositions for nucleic acid detection IBIS
BIOSCIENCES, INC.
###### US9080204 Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009
US9079965 Bispecific antibody
US9079943 TC-83-derived alphavirus vectors, particles and methods

###### Longhorn Vaccines and Diagnostics, LLC

Wuhan YZY Biopharma Co., LTD.
ALPHAVAX, INC.
US9079865 Hydrazide containing nuclear transport modulators and uses thereof
###### Karyopharm Therapeutics Inc.
US9078885 Respiratory disease treatment
US9078868
US9073869
US9072738
US9072726
###### Therapeutic agent for accelerating recovery of animal under medical treatment Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
 Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
US9072702 Reverse genetics using non-endogenous pol I promoters
US9067873
###### Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses US9066964 Use of tylvalosin as antiviral agent
US9063150
###### Method for detection of antigen-specific antibodies in biological samples
US9061001 Combination adjuvant formulation
###### US9056900 Compositions and methods for coronavirus inhibition
US9056898 Attenuated RNA virus and applications thereof
US9056071 Compounds and methods for preventing or treating a viral infection
US9051619 Methods and compositions for prostate cancer metastasis
###### US9051564 Compositions for and methods of identifying antigens
US9051353 Crystalline tripeptide epoxy ketone protease inhibitors
###### Fauci/COVID-19 Dossier Pulmagen Therapeutics (Inflammation) Limited


-----

###### DAIICHI SANKYO COMPANY, LIMITED Boehringer Ingelheim International GmbH
PARION SCIENCES, INC.

###### Oculus Innovative Sciences, Inc. Novartis AG Marl3
 31JU1-08 28Mayl0 9Mayl2
18Dec09
###### 233un06 lOct04 243U1-12 6Aug09 12Sep06
21NOV12
###### 18May04 293U1-11 7Aug08 153anl0 14Marl3 273unll 203an06
21May09
###### GKineta Four, LLC Dec04 Cambridge University Technical Services
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention Dalhousie University Autoimmune Technologies, LLC. Washington University
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
###### (C.N.R.S.)
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
(FAMU)
###### President and Fellows of Harvard College
Onyx Therapeutics, Inc.
CC-BY-NC-SA Dr. David E. Martin
###### 133U1-06 2Sep08 16Oct08
4NOV03
20Sep07
2NOV07
###### 25Marll 21Feb06 20Mar09 14Mar -13 27Mar


-----

###### -13
31May
###### -11
9May
###### -13
17Dec
###### -10 233un -07
9May
###### -14
25Aug
###### -14
6Aug
###### -10
30Dec
###### -11 13Mar -14 28Mar -14 293ull2
7Apr
###### -14
143 an
###### -11 llSep -14 273un -12
21Dec
###### -09
21May
###### -10
19Dec
###### -13
133U107
25Aug
###### -09 150ct -09
8Aug
###### -13
22Sep
###### -08 193un -13 23Mar -12 21Feb -07
24Sep
###### -13
47


-----

###### HAug -15 HAug -15
4Aug
###### -15
4Aug
###### -15 28JU115 21JU115 21JU115 21JU115 14JU115 14JU115 14JU115 14JU115 14JU115 14JU115 14JU115
7JU115
7JU115
7JU115
7JU115
###### 301unl5 303unl5 233unl5 233unl5 163unl5 163unl5 163unl5 93unl5 93unl5 93unl5

7US9050376

###### Conjugates of synthetic TLR agonists and uses therefor
US9046523 Rapid bioluminescence detection system
US9045855 Anti-viral member
US9045727
###### Virus-like particles, methods of preparation, and immunogenic compositions
US9045472 Imidazoquinoline compounds
###### US9045470 Compounds and compositions as TLR activity modulators
US9044420
US9040310
US9034646
US9034313
US9029413
US9029382
###### Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses Antibody-nanoparticle conjugates and methods for making and using such conjugates
 Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof


-----

###### Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same Treatment of viral infections by modulation of host cell metabolic pathways
3., 5-diamino-6-chloro-N- (N          - (4-phenylbutyl) carbamimidoyl)
###### pyrazine-2-carboxamide compounds
US9029315 Soluble PD-1 variants, fusion constructs, and uses thereof
US9028841
###### Synergistic bacterial compositions and methods of production and use thereof
US9028837 Methods and compositions for poxvirus A35R protein
US9028823
###### Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies
US9024001 Alphavirus replicon packaging constructs
US9023855 Compounds
US9023839 Compounds and compositions as c-kit kinase inhibitors
US9017699
###### Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus US9017696 Adenovirus vectors
US9012622
US9011767
###### US9006264 US9006194 Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer Transportable vacuum assisted decontamination unit and decontamination process Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines Compositions and methods for diminishing viral infection and inflammation associated with viral infection US9005974 Means and methods for influencing the stability of cells
US9005665
US9005599
###### Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
The Regents of the University of California
THE SECRETARY OF STATE FOR HEALTH
NBC Meshtec, Inc.
EMORY UNIVERSITY
ASTRAZENECA AB
IRM LLC
IMMUNE DESIGN CORP.

###### Ventana Medical Systems, Inc.
ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.
###### Inovio Pharmaceuticals, Inc.
The Trustees of Princeton University
###### Parion Sciences, Inc.
The University of Hong Kong
###### Seres Health, Inc.


-----

###### East Carolina University GITR, Inc. Novartis Vaccines and Diagnostics, Inc. Chiesi Farmaceutici S.p.A.
IRM LLC
New York Blood Center, Inc.
###### Isis Innovation Limited Not Available
STERIS Inc.
3M Innovative Properties Company
###### Drexel University Academish Medisch Centrum Bij de Universiteit van Amsterdam Ohio State Innovation Foundation Tissue Regeneration Therapeutics Inc. US8999996 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc.
Feb07
###### 71an09
26Dec08
17May02
###### 16Decl0 2Sep09 SAprll 27Aprl0 25Mayl0 8Febl0 13un07 17Decl2
11NOV10
23NOV12
###### 73unl2 25Mar05 25May04 14Sepll ISepll 153un04 10Apr07
31Dec08
###### lAprl3 183un04
19Dec08
9Dec05
###### 24Aprl2 21Apr08 293U1-11 193un -14
2Aug
###### -13
28Dec
###### -09 4Apr -06


-----

16Dec

###### -11 iSep -10

6Apr

###### - 12
 27Apr
 - 11

26NOV

###### - 12

8Feb

###### - 11
3Apr
###### - 12

13Dec

###### - 13

11N0V

###### - 11
 20Mar
 - 14

20Dec

###### - 12 IMar
 - 13

20May

###### - 05
 HFeb
 - 14
 22Apr
 - 14
 18Feb
 - 10
 10Apr
 - 08
31Dec
###### - 09
3 IMar
###### -14

9Sep

###### -13

17Dec

###### -09

9Dec

###### -05 24Apr
 -13
 20Apr
 -09
 19Mar
 -14 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
48


-----

###### 93unl5 23unl5 23unl5 23unl5 23unl5 23unl5 23unl5
26May

###### -15

19May

###### -15

19May

###### -15

12May

###### -15

12May

###### -15

12May

###### -15

12May

###### -15

12May

###### -15

12May

###### -15
5May
###### -15
5May
###### -15
5May
###### -15
 28Aprl5 28Aprl5 21Aprl5 21Aprl5 14Aprl5 14Aprl5 14Aprl5 14Aprl5 14Aprl5 7Aprl5

US8999975

###### Substituted N- [l-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
US8999678 Method of increasing the function of an AAV vector
US8999349 HMGBl-derived peptides enhance immune response to antigens
###### US8999316 Antiviral compounds
US8993717 Gadd45beta targeting agents
US8993581 Methods for treating viral disorders
US8993295
###### Methods^ compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8992939 Highly efficient influenza matrix (Ml) proteins
US8987249


-----

###### Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzylcyano-methyl)-amides inhibitors of Cathepsin C
US8987191 Bioactive peptides and methods of using same
US8986933 Selective detection of human rhinovirus
US8986926
###### Compositions comprising oriented., immobilized macromolecules and methods for their preparation
US8986702 Antibodies and processes for preparing the same
US8980898
###### Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
US8980338 Sceletium extract and uses thereof
US8980281
###### High-yield transgenic mammalian expression system for generating virus-like particles
US8975389 Nucleic acid chemical modifications
US8969362 9-substituted 8-oxoadenine compound
US8969350
US8962580
US8962332
US8962330
###### Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient Chemical modifications of monomers and oligonucleotides with cycloaddition
 Adeno-associated virus (AAV) serotype 8 sequences^ vectors containing same, and uses therefor
 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US8961983 Mucosal vaccine using cationic nanogel
US8961477 Delivery of immune response modifier compounds
US8956863 Agents from cells
US8956616
###### Constructs binding to phosphatidylserine and their use in disease treatment
US8951768 Mutations in 0AS1 genes
US8951528 Immune response modifier conjugates
US8945943
###### Personal glucose meters for detection and quantification of a broad range of analytes US8945904 Influenza virus reassortment
 Fauci/COVID-19 Dossier 19Boehringer Ingelheim International GmbH
The Trustees of the University of Pennsylvania
The Regents of the University of California

Long Island University
###### Imperial Innovations Limited Trustees of Boston University
The General Hospital Corporation
###### Novavax, Inc. Boehringer Ingelheim International GmbH
Compugen Ltd.


-----

The United States of America as represented by the
###### Secretary of the Department of Health and Human Services^ Centers for Disease Control NanoString Technologies, Inc. Taiga Biotechnologies, Inc. Parion Sciences, Inc. H.L. Hall & Sons Limited Academia Sinica Alnylam Pharmaceuticals, Inc. AstraZeneca Aktiebolag Astrazeneca AB Alnylam Pharmaceuticals, Inc.
The Trustees of the University of Pennsylvania
The Trustees of the University of Pennsylvania
###### National University Corporation Tokyo Medical and Dental University
3M Innovative Properties Company
The Brigham and Women's Hospital, Inc.
###### Board of Regents, The University of Texas System Kineta Two, LLC
3M Innovative Properties Company
The Board of Trustees of the University of Illinois
###### Novartis AG
CC-BY-NC-SA Dr. David E. Martin
###### Sepll 7Apr05 273U1-10
30May07
###### 22Oct09
24Sep09
###### 203U1-06 113U1-03 14Marl3 123U1-07
5Dec08
23Dec05
16May08
###### 29Mayl2 20Mar09 5Sep06 2Mar09 26Mar04
18Dec08
23Sep08
17Dec01
17Dec01
###### 31Oct08
25Aug03
###### 15Oct09 243an05
4May05
###### 22Feb06 26Mayl0 21Mayl0


-----

14Sep
###### -12
7Apr
###### -06 27JU111
30May
###### -08 220ct -10 lUun -13
203U107
###### 240ct -11 12Mar -14 213un -13
5Dec
###### -08
22Dec
###### -06
18May
###### -09
29May
###### -13 16Mar -10 12Feb -10
2Mar
###### -10 210ct -13
17Dec
###### -09
23Sep
###### -09
13Sep
###### -13 310ct -07
5Sep
###### -14
25Aug
###### -04 150ct -10
243 an
###### -06
113U111
###### 21Feb -07
26May


-----

###### -11
20May
###### -11 49 7Aprl5 7Aprl5 7Aprl5 7Aprl5
3 IMar
###### -15
3 IMar
###### -15
3 IMar
###### -15
31Mar
###### -15 24Mar -15 24Mar -15 24Mar -15 24Mar -15 24Mar -15 17Mar -15 17Mar -15 17Mar -15 10Mar -15
3Mar
###### -15
3Mar
###### -15 24Feb -15 24Feb -15 24Feb -15 24Feb -15 24Feb -15 17Feb -15 17Feb -15 10Feb -15


-----

###### 10Feb
 -15
3Feb
###### -15
3Feb
###### -15
 US8945610
 Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics US8940864 Stabilized therapeutic small helical antiviral peptides
US8940501 Methods for ligation and uses thereof
###### US8937154 Stabilized therapeutic small helical antiviral peptides
14BASF
SE
New York Blood Center, Inc.
###### Whitehead Institute for Biomedical Research
New York Blood Center, Inc.
###### US8933210 Label-free functional nucleic acid sensors for detecting target agents
The Board of Trustees of the University of Illinois
US8933019 Antiviral cell-penetrating peptides
US8916552 Pharmaceutical combinations
US8916340
US8906872
US8906863
###### Method for identifying and validating dominant T helper cell epitopes
 using an HLA-DM-assisted class II binding assay
 Antisense antiviral compound and method for treating ssRNA viral infection Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
New York Blood Center, Inc.

###### Astex Therapeutics Limited
The 3ohn Hopkins University
###### Sarepta Therapeutics, Inc.
The Regents of the University of California
US8906862 Multiple antigen delivery system using hepatitis E virus-like particle
###### National Institute of Infectious Disease
US8901071 Compounds and their use
US8900585
###### Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
US8895629 Circulation of components during homogenization of emulsions
US8895577 Compounds and compositions as TLR activity modulators
###### US8895570 Purine derivatives US8895534 Boron containing small molecules
US8895295 High density self-contained biological analysis
US8889708
US8889692
###### Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C Pyrazinone derivatives, pharmaceutically acceptance salts thereof
and their uses
###### US8889656 Boron-containing small molecules
US8889398 Composition for inactivating an enveloped virus


-----

US8889181
US8889118
###### Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes Anticancer agent containing dendritic cell having RNA virus transferred thereinto
US8889117 Modular nanoparticles for adaptable vaccines
###### US8884020 Indole compounds US8883790 Pharmaceutical combinations
US8883500
###### Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
US8883481 Reverse genetics methods for virus rescue
US8883477 Oligoadenylate synthetase (OAS)
###### Novabiotics Limited
New York Blood Center^ Inc.
###### Novartis AG Not Available AstraZeneca AB Anacor Pharmaceuticals, Inc. Biofire Diagnostics, LLC Boehringer Ingelheim International GmbH AstraZeneca AB Anacor Pharmaceuticals, Inc. Viroblock SA
 Industry Academic Cooperation Foundation, Hallym University
DNA VEC Research Inc.
###### Yale University Ironwood Pharmaceuticals, Inc. Astex Therapeutics Limited Northeastern University Novartis AG Kineta Two, LLC
Nov07
###### 5Oct06 303an09 5Oct06 6Octl0
6May08
###### 12Oct06 63an06 16Sep04 27Feb09 27Feb09 3IMarlO 20Octl0
3Dec09
3Mar08
17D6C10
###### 203un07
15NOV06
###### 14Marl3 273un07


-----

###### 16Feb05
19May06
###### 17JU1-09
24Dun04
###### 15Feb07
7Aug06
###### 12Oct06
5Dec08
###### 20Oct09
23NOV05
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### UNov -08 2Oct -07 iFeb -10
2Feb
###### -12 6Oct -11 31Oct -12 12Oct -07 83an -07
22Dec
###### -11 ISep -11
29Aug
###### -11
30Mar
###### -11 20Oct -11
3Dec
###### -10 22Apr -13
14Dec
###### -11 303U110
14N0V
###### -07 12Mar -14
14Sep
###### -12 30Apr -13


-----

18May
###### -07
16Dun
###### -10 28Apr -05 15Feb -08
7Aug
###### -07 120ct -07
7Dec
###### -09 20Oct -10
141 un
###### -13
50
3Feb
###### -15 271anl5 271anl5 201anl5 131anl5 131anl5
23Dec
###### -14
23Dec
###### -14
9Dec
###### -14
9Dec
###### -14
9Dec
###### -14
2Dec
###### -14
2Dec
###### -14
25NOV
###### -14
25NOV
###### -14
25NOV
###### -14
25NOV
###### -14
25NOV
###### -14
18N0V
###### -14
18N0V
###### -14


-----

18N0V

###### -14

18N0V

###### -14

18N0V

###### -14

18N0V

###### -14

18N0V

###### -14

11N0V

###### -14

11NOV

###### -14

11NOV

###### -14

11NOV

###### -14

11NOV

###### -14
 US8882484

US8881040
US8877775
US8877187
###### Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells System and method for detecting, collecting, analyzing, and communicating event-related information Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzylcyano-methyl)-amides inhibitors of cathepsin C Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases US8877060 Methods for removing pathogens from a platelet preparation US8871816 Methods for producing vaccine adjuvants US8871790 Heterocyclic modulators of lipid synthesis
US8871783
###### Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyanomethyl)-amides inhibitors of cathepsin C
US8871782 Alkoxy substituted imidazoquinolines
US8871503 Construct
US8871487 Compositions, methods and uses for inducing viral growth
US8871442 Enhanced deposition of chromogens
US8865865
###### N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic US8865166 Antibodies to IL-17A and uses thereof 28Bayer Healthcare LLC Georgetown University
 Boehringer Ingelheim International GmbH
 Avianax, LLC
 Biovec Transfusion, LLC Novartis AG


-----

###### 3-V Biosciences, Inc. Boehringer Ingelheim International GmBh
3M Innovative Properties Company
###### Isis Innovation Limited Takeda Vaccines, Inc. Ventana Medical Systems, Inc.
 Philipps-Universitat Marburg

Medlmmune Limited
US8859568 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
###### Astrazeneca AB
US8859251 Oligoadenylate synthetase (OAS)
US8858958 Adjuvant comprising aluminum, oligonucleotide and polycation
US8858957 GAS57 mutant antigens and GAS57 antibodies
US8854617 Compounds and markers for surface-enhanced Raman scattering
US8853382 Expression of antibody or a fragment thereof in lactobacillus
###### US8846710 Method of preferentially inducing the biosynthesis of interferon
US8846697 Purine analogs
###### Kineta Two, LLC Novartis AG Novartis AG 3ulius-Maximilians-Universitat Wurzburg Hera Pharmaceuticals, Inc.
3M Innovative Properties Company
The Regents of the University of California
US8846643 Phosphonates with reduced toxicity for treatment of viral infections
The Regents of the University of California
US8846051
###### Modulation of replicative fitness by deoptimization of synonymous codons
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention US8841100 Use of methylsulfonylmethane (MSM) to modulate microbial activity Biogenic Innovations, LLC
US8840899 Use of mTOR inhibitors to enhance T cell immune responses
US8840890
US8840873
###### US8840774
US8835107
###### Rapid expression cloning of human monoclonal antibodies from
memory B cells
###### Method of treating second and third degree burns using oxidative reductive potential water solution Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics Fauci/COVID-19 Dossier
Emory University
###### University of Maryland, Baltimore Oculus Innovative Sciences, Inc.
 Board of Regents of the University of Texas System
 Amsterdam Institute of Viral Genomics B.V.
May08


-----

###### 28Aug08 14Marl3 253U1-05
23NOV10
3Dec09
###### SMarll 14Marl3 3Oct03 28Mar06
5Dec08
###### 30Decl0 29Oct08 233un06 6Dec04
23NOV05
###### 27Aug09 12Sep07 24Sep07 5Augl0 23Feb05
31May06
###### 14Aprl0 8Oct04 30Oct09
5Aug08
12NOV08
###### 23Mar05 33un05
18Aug03
###### CC-BY-NC-SA Dr. David E. Martin
27May
###### -09
2Dec
###### -09 12Mar -14
23NOV
###### -10 310ct -11
3Dec
###### -10
8Mar
###### -12 12Mar -14 lOct -04 28Mar -07
4Dec
###### -09
28Dec


-----

###### -11 290ct -09 221un -07
3Nov
###### -10
1JU113
27Aug
###### -10 14Mar -13
24Sep
###### -08
4Aug
###### -11 22Feb -06 23Apr -07 HOct -12 7Oct -05 16Feb -11
5Aug
###### -09
12NOV
###### -09 23Mar -06 28Oct -13 263U110
51
11NOV
###### -14
4Nov
###### -14
4Nov
###### -14
4Nov
###### -14
4Nov
###### -14 280ctl4 280ctl4 280ctl4 280ctl4 280ctl4 280ctl4 280ctl4 210ctl4


-----

###### 210ctl4 140ctl4 140ctl4 140ctl4 140ctl4 70ctl4 70ctl4
30Sep
###### -14
30Sep
###### -14
30Sep
###### -14
30Sep
###### -14
23Sep
###### -14
23Sep
###### -14
23Sep
###### -14
23Sep
###### -14
23Sep
###### -14

16Sep
###### -14

US8834445

US8828962
###### Methods of treating or preventing peritonitis with oxidative reductive potential water solution 20Oculus Innovative Sciences, Inc.
SiRNA compositions and methods for potently inhibiting viral
###### infection US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides
US8828940
US8828929
US8828673
###### Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof Mixed cell diagnostic systems for detection of respiratory, herpes
and enteric viruses
US8828659 Method for producing nucleic acid probes
US8828407 Chimaeric protein
###### US8828406 Influenza viruses and uses thereof
US8822512 Crystalline tripeptide epoxy ketone protease inhibitors
US8822409
###### Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
US8821897 Viral adjuvants


-----

US8816089
US8816053
###### Methods for controlling SR protein phosphorylation., and antiviral agents whose active ingredients comprise agents that control SR protein activity
 Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
US8815837 Respiratory disease treatment
###### Xiangxue Group (Hong Kong) Company Limited Alnylam Pharmaceuticals., Inc.
Compugen Ltd.
###### Japan as Represented by Director-General of National Institute of Infectious Diseases Diagnostic Hybrids Inc Ventana Medical Systems^ Inc.
The Pirbright Institute
###### Icahn School of Medicine at Mount Sinai

Onyx Therapeutics, Inc.

###### Phylogica Limited
The University of North Carolina at Chapel Hill
###### Masatoshi Hagiwara ZymoGenetics, Inc. Pulmagen Therapeutics (Inflammation) Limited
US8815831 Treatment of Acinetobacter with alginate oligomers and antibiotics
###### Algipharma AS
US8815611 Surface for label independent detection and method thereof
US8815249 li-key/antigenic epitope hybrid peptide vaccines
###### US8815244 Method for production of antibody using ostrich
US8809377 Deubiquitinase inhibitors and methods for use of the same
US8808703
Compounds (cystein based lipopeptides) and compositions as TLR2
###### agonists used for treating infections, inflammations, respiratory diseases etc US8808686 Adjuvant-sparing multi-dose influenza vaccination regimen
US8802853 Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8802647
US8802106
US8796423
###### Materials and methods for prevention and treatment of RNA viral diseases Peptide compositions and methods for inhibiting herpesvirus infection
 Anti-TSG101 antibodies and their uses for treatment of viral infections
US8790655 Conjugates of synthetic TLR agonists and uses therefor
US8785408
###### Compositions and methods for reducing or protecting against delayed graft function (DGF)
US8785375 Cyclic antimicrobial peptides for treating bacterial infections
###### Corning Incorporated Antigen Express, Inc.
 Japan Science and Technology Agency
The Regents of the University of Michigan
###### Not Available


-----

###### Novartis AG
3M Innovative Properties Company
###### University of South Florida
The Administrators of the Tulane Educational Fund
###### Eli Lilly and Company
The Regents of The University of California
###### Quark Pharmaceuticals, Inc. Novabiotics Ltd. 3an06 HDec08 4Dec07 18Sep06
28NOV08
###### 24Apr98 !Sep06 7-JU109 301U1-09 20Mar09 203un07 9-3U104 26Dec03
2Apr04
###### 7Aug08 33un09 10Apr08 4Sep99 29Aug05 24Sepl0 23Marl0 153un06
29D6C03
###### 30Apr02 30Oct09
15NOV06
###### 7Feb07 273un07
22Dec05
###### Fauci/COVID-19
 Dossier CC-BY-NC-SA Dr. David E. Martin
30Mar
###### -12

12Dec

###### -11

4Dec

###### -12

14Dec

###### -10

27NOV

###### -09
 iMar
 -12
 llMar
 -13


-----

5JU110
29DU110
20Sep
###### -11 201un -08
24N0V
###### -10
19N0V
###### -12
7Sep
###### -12 291un -12
3Dun
###### -10
3Apr
###### -09 263ull0
16Aug
###### -11
23Sep
###### -11 23Mar -11
19Sep
###### -11
17Dec
###### -04
17Sep
###### -12 290ct -10 18Apr -08 83an -13 263un -08
22Aug
###### -12
52
16Sep
###### -14
9Sep
###### -14
9Sep
###### -14
9Sep
###### -14
9Sep
###### -14
9Sep
###### -14


-----

9Sep

###### -14

9Sep

###### -14

9Sep

###### -14

2Sep

###### -14

2Sep

###### -14

2Sep

###### -14

26Aug

###### -14

26Aug

###### -14

26Aug

###### -14

26Aug

###### -14

26Aug

###### -14

26Aug

###### -14

26Aug

###### -14

19Aug

###### -14

19Aug

###### -14

19Aug

###### -14

12Aug

###### -14

12Aug

###### -14

12Aug

###### -14
5Aug
###### -14
 29JU114 22JU114 22JU114
 US8784900
 Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same
US8779132 Pharmaceutical compounds
US8778963
###### Hydroxylamine and oxime substituted imidazoquinolines., imidazopyridineSj and imidazonaphthyridines US8778846 Composition, device and associated method
US8778845 Composition, device and associated method
US8778358
###### Immunogenic compositions for gram positive bacteria such as


-----

###### Streptococcus agalactiae
US8778275 Methods for producing vaccine adjuvants
US8772471 Targeted delivery of siRNA
US8765939
###### Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers US8765704 Modified small interfering RNA molecules and methods of use
US8765643 Composition, device and associated method
###### US8765146 Adenoviral vector-based malaria vaccines
US8765138 Antiviral and antibacterial activity from medicinal mushrooms
US8765133 Method of producing anti-CD166 antibody in ostrich
US8759307
###### Oligonucleotide compound and method for treating nidovirus infections
US8758763 Archaeal polar lipid aggregates for administration to animals
###### US8758680 Method and device for cleaning air
US8754071 Compounds and compositions as c-kit kinase inhibitors
US8754015
###### Modified phage for displaying post-translationally modified proteins
and uses thereof
US8748567 Method for delivery across the blood brain barrier
###### US8748464
US8748405
Use of SIRTl activators or inhibitors to modulate an immune
###### response
 Methods and compositions for the treatment of cancer or other diseases US8748156 Animal protein-free media for cultivation of cells
US8741813 Composition, device and associated method
US8741653 Single recombination system and methods of use
###### US8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody US8741564 Quantitative nuclease protection assay (QNPA) and sequencing
(QNPS) improvements

US8741311 Methods and compositions for immunization against virus
###### 13Oculus Innovative Sciences, Inc.
 Astex Therapeutics Limited
3M Innovative Properties Company
###### General Electric Company Genral Electric Company Novartis Vaccines and Diagnostics, Inc. Novartis AG
Immune Disease Institute
###### AstraZeneca AB Novartis AG General Electric Company GenVec, Inc. Not Available Japan Science and Technology Agency Sarepta Therapeutics, Inc. National Research Council of Canada Not Available


-----

###### Not Available University of Rochester Children's Medical Center Corporation
The J. David Gladstone Institutes
###### City of Hope Baxter Healthcare SA General Electric Company Emergent Product Development GmbH
Medimmune Limited
HTG Molecular Diagnostics, Inc.
###### Academia Sinica
US8735567 Multi-targeted RNAi therapeutics for scarless wound healing of skin
###### Not Available
US8735559 Mutant protease biosensors with enhanced detection characteristics
Promega Corporation
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### Mar07 12Oct06
25NOV03
4D6C06
15Dec05
###### 293U1-04
3Dec09
###### 263an07
22NOV07
###### 28Feb08
4D6C06
31Aug05
###### 63an04
29Aug05
24D6C03
###### 15Dec06 29Sepl0 iSepll
21NOV06
22May06
###### 7Feb08 263an07 29Oct04
15Dec05
22Dec08
7NOV08
###### 4Mayll 27Mar09
6NOV07
###### HMayl0 13Mar -08 12Oct -07
24NOV
###### -04 IMar


-----

###### -07 IMar -07 180ct -10
3Dec
###### -10
25Han
###### -08
16Aug
###### -12
14Dec
###### -11 IMar -07
31Aug
###### -06
24Sep
###### -08
16Aug
###### -11 25Apr -08 233an -13
27Sep
###### -11
19Sep
###### -13
20NOV
###### -07
22May
###### -07 16JU110
9Sep
###### -11 16Apr -13 28Feb -07
16Dec
###### -09
14Sep
###### -12 26Apr -12 26Mar -10
6Nov
###### -08 HMay -11
53
###### 223ull4


-----

###### 15JU114 15JU114 15JU114 15JU114 15JU114 15JU114 8JU114 1JU114 1JU114 1JU114 1JU114 1JU114 1JU114 243unl4 243unl4 243unl4 17:unl4 17:unl4 10:unl4 10:unl4 10:unl4 10:unl4 33unl4 33unl4 33unl4 33unl4 33unl4
27May
###### -14
27May
###### -14

30US8735421

###### Imidazoquinolinyl sulfonamides US8735410 Quinazoline derivatives as tyrosine kinase inhibitors
US8735348 Casein derived peptides and uses thereof
US8734823
###### Device including altered microorganisms, and methods and systems of use
US8728793 Amphipathic alpha-helical peptide compositions as antiviral agents
US8722917 Boron-containing small molecules
US8722741
US8722725
US8718948
###### Biphenyloxyacetic acid derivatives for the treatment of respiratory disease Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector
3M Innovative Properties Company
###### AstraZeneca AB Peptera Ltd.
The Invention Science Fund I, LLC
The Board of Trustees of the Leland Stanford lunior


-----

###### University Anacor Pharmaceuticals, Inc. AstraZeneca AB Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Gen-Probe Incorporated US8716464 Compositions and methods for silencing Ebola virus gene expression Not Available
US8716461 Human parvovirus
###### US8710224 Heterocyclic compounds as CCR2B antagonists
US8709730
US8709496
US8709447
###### Methods of preventing and treating viral infections by inhibiting the delSGylation activity of OTU domain-containing viral proteins
Use of deuterium oxide for the treatment of virus-based diseases of
###### the respiratory tract Compositions and methods for activating innate and allergic immunity
US8709441 TC-83-derived alphavirus vectors, particles and methods
US8704169 Direct impact ionization (DII) mass spectrometry
US8703748
US8703467
US8702958
US8697873
###### Cleaning composition for treating tissue for transplantation derived from human/animal Inactivation of a pathogen in a sample by a treatment with formalin
and UV light
###### Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode
 Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8697853 TAL effector-mediated DNA modification
US8697659 Analogues of glycolipids useful as immunoadjuvants
###### US8697140 Virucidal disinfectant
US8697088
US8697087
VLPs derived from cells that do not express a viral matrix or core
###### protein Influenza vaccines including combinations of particulate adjuvants
and immunopotentiators
US8691837 Substituted imidazo ring systems and methods
###### US8691826 Compounds Blood Systems, Inc. AstraZeneca AB Icahn School of Medicine at Mount Sinai
D2 Bioscience Group Ltd.
###### ID Biomedical Corporation of Quebec Alphavax, Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
CG BIO Co., Ltd.
###### Baxter Healthcare SA


-----

###### Board of Regents of the University of Texas System
3M Innovative Properties Company
###### Iowa State University Research Foundation, Inc. Luigi Panza
B. Braun Medical AG
###### Novavax, Inc. Novartis AG
3M Innovative Properties Company
###### Chiesi Farmaceutici S.p.A.
US8691781 Compositions for treating respiratory viral infections and their use
###### Sirnaomics, Inc.
Dec03
###### 26Feb05 lMar00
14Dec05
###### 193U1-07 16Feb05 24Aug04 23Mar07 24Febll 203U1-09 24May04
24D6C04
###### 5Apr07 63anl0 22Oct03 18May04 HOctll HFeb09 27May04 33un05 24Mar04
10D6C09
###### 12Oct07 283an05
25May07
4NOV05
25NOV03
###### 14Sepll
5NOV04
23Dec

###### -04
 24Feb
 -06
SSep
###### -12

28May

###### -10

143U108
###### 233an
 -12

6Dec

###### -11

2 IMar


-----

**l-l** **I** **l-l** **I** **hJ** **I** **hJ** **I** **hJ** **I** **hJ** **i** **hJ** **i** **i** **pi** **i** **hJ** **i** **CT\** **i** **hJ** **ihJlp'lp'lhJlUJlhJ** **i** **pl** **i** **piCTli** **hJi** **hJi** **'Ji**
**WPWP©PMPMP\I** **P'^IS^P'UJS^S^S^I** **SOOSSP'SS^P'P'SCTi** **P'SP'P'<-IP'CT1P'<j JS>P'**

**S** **tn** **O** **M** **W** **Ji** **Z** **(?** **O** **00** **3** **o£>** **2** **oo** **O** u j **i_i** **tn** **2** **M** **2** **tn** **2** **S** **Tl** **pi** **O** **C** **N** **>** **M** **3** **00** **<JJ**

**Qj** **Qj** **Qj** **Qj** **Qj** **Qj** **o>** **<** **rD** **o** **<** **a>** **QJ** **r>** **QJ** **QJ** **QJ** **QJ** **fD** **r>** **I—'** **"O** **QJ** **”5**

**"O** **<** **r+** **Z5** **-5** **CT** **r+** **P»** **-5**


-----

###### -14
13May
###### -14
6May
###### -14
6May
###### -14
6May
###### -14 29Aprl4 29Aprl4 29Aprl4 29Aprl4 29Aprl4 22Aprl4 22Aprl4 22Aprl4 22Aprl4 15Aprl4 15Aprl4 15Aprl4 15Aprl4 15Aprl4 15Aprl4 8Aprl4 8Aprl4 8Aprl4 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
54

###### 27US8691777
 Combination therapy
US8686152
US8682619
###### 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1) Device including altered microorganisms, and methods and systems of use
US8679839 Cell line from rousettus as host cell for pathogen amplification
###### US8678184 Methods for producing vaccine adjuvants
Emory University
###### lanssen Pharmaceutica NV
The Invention Science Fund I, LLC
###### Probiogen AG Novartis AG
US8678002 Devices and methods for decreasing human pathogen transmission
###### Filligent Limited

US8673983 Melanins synthesized chemically or via enzyme catalysis
US8673932 Oxime substituted imidazo-containing compounds
US8673907
###### Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4ylpropyl)


-----

###### amino] methyl }phenyl) acetate and their use in therapy US8673904 Epoxide inhibitors of cysteine proteases
US8673558 Luciferase biosensor
US8673331
###### Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof
US8669263 Use of TAM receptor inhibitors as antimicrobials
US8669262
###### 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6pentahydroxyhexyl)amino)ethox y)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide
US8669240
###### Biological specimen collection and transport system and method of use US8664274 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses
US8664218 Pharmaceutical compounds
US8664188
###### siRNA compositions and methods for potently inhibiting viral infection
US8663922 Systems and methods for detecting multiple optical signals
US8658767 Lipidated polyepitope vaccines
US8658697
###### Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses US8658666 Substituted imidazoquinolines and imidazonaphthyridines
US8658178 Carbon nanotube compositions and methods of use thereof
US8653252 Short interfering RNA (siRNA) analogues
###### US8653084 Hydrobenzamide derivatives as inhibitors of Hsp90 US8653034
US8652836
###### Compositions and methods comprising phosphatidylethanolaminebinding peptide derivatives Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response Fauci/COVID-19 Dossier Loyola University Chicago
3M Innovative Properties Company
###### lanll 10Marl0
14Dec05
###### 4Mar08
3Dec09
###### 263un07
21D6C07
12Aug03
###### 17AstraZeneca

AB
The Board of Trustees of the Leland Stanford lunior
###### University


-----

Promega Corporation
GP&E
###### Salk Institute for Biological Studies
Dec07
###### 131un06 10Oct03 ISNovll
9NOV07
###### 27Parion Sciences, Inc. lunll ILonghorn Vaccines & Diagnostics, LLC Oct07 6Siga Technologies, Inc. Dec04 llAstex Therapeutics Ltd. Xiangxue Group (Hong Kong) Company Limited Gen-Probe Incorporated National Health Research Institutes Apr08 HDec08 10Mar05
15NOV10
###### 6Siga Technologies, Inc. Dec04
113M
###### Innovative Properties Company Yale University Santaris Pharma A/S Astex Therapeutics Ltd.
 Board of Regents, The University of Texas System Providence Health System
Feb05
###### 19Mar08 21Mar03 12Oct06 153U1-02 293U1-05 253an -12
9Mar
###### -11
28May
###### -10 4Mar -09
3Dec
###### -10 253un -08


-----

22Dec

###### -08

12Aug

###### -04

16Dec

###### -08
 133un
 -07 24Apr
 -12

18N0V

###### -11

8Mar

###### -13
 263un
 -12
 19Mar
 -13
6JU111
303an
###### -13
 llDec
 -09
 13un
 -10

15N0V

###### -11 260ct
 -10
 10Feb
 -06
 19Mar
 -09
 22Mar
 -04
 120ct
 -07
8May

###### -08
 273ul06
CC-BY-NC-SA
###### Dr. David E. Martin
55
###### 8Aprl4 lAprl4 25Mar
 -14
 25Mar
 -14
 25Mar
 -14
 25Mar
 -14
 18Mar


-----

###### -14
 18Mar
 -14
 18Mar
 -14
 18Mar
 -14
 18Mar
 -14
 18Mar
 -14
 llMar
 -14
 llMar
 -14
 llMar
 -14
 4Mar
 -14
 4Mar
 -14
 4Mar
 -14
 4Mar
 -14
 25Feb
 -14
 25Feb
 -14
 25Feb
 -14
 25Feb
 -14
 18Feb
 -14
 18Feb
 -14
 18Feb
 -14
 18Feb
 -14

US8652782

###### Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids 12Longhorn
 Vaccines & Diagnostics, LLC
US8652533 Durable biocides and disinfectants
###### US8648076 Cysteine protease inhibitors and their therapeutic applications US8647676 Antimicrobial composition from copepods
US8642596
###### Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses US8642260 Single quantum-dot based aptameric nanosensors


-----

US8633322 Alkynyl derivatives useful as DPP-1 inhibitors
US8633308
Compounds for preventing or treating viral infections and methods
###### of use thereof US8632764 Directed evolution and in vivo panning of virus vectors
US8629283
Compounds that modulate negative-sense, single-stranded RNA
###### virus replication and uses thereof
US8629271 Compounds
###### Mitsui Norin Co., Ltd. Hybrigenics SA Nofima Ingrediens
Sep06
###### 7-3ul04
5Aug05
###### 28Oct08 6Siga Technologies, Inc. Dec04
21The
###### Research Foundation of the City University of New York lanssen Pharmaceutica NV
The Governors of The University of Alberta
###### University of North Carolina at Chapel Hill Icahn School of Medicine at Mount Sinai
 AstraZeneca AB
US8629098 Compositions and methods for adoptive and active immunotherapy Yale
###### University US8628786 Polychlorinated biphenyls and squalene-containing adjuvants
US8624011
###### Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
US8623419 Technology for preparation of macromolecular microspheres
###### Novartis AG
The Trustees of the University of Pennsylvania
###### Ansun Biopharma, Inc.
US8623382 Immunogenic compositions for inducing an immune response to HIV Wyeth
LLC

###### US8623364 Antigenic GM-CSF peptides and antibodies to GM-CSF
US8617838 Fluorescent proteins and related methods and compounds
US8615368 Method for determining the amount of an analyte in a sample
US8609370
US8609101
###### Highly active glycoproteins-process conditions and an efficient method for their production Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
US8604215 Crystalline tripeptide epoxy ketone protease inhibitors
US8603469
###### Methods of treating cancer with human monoclonal antibodies against interleukin 8
US8599383 Optical cytometry
US8598192 Hydroxylamine substituted imidazoquinolines


-----

###### US8598134
RNAi modulation of RSV, PIV and other respiratory viruses and uses
###### thereof US8598116 Treatment of influenza virus infection
US8598106
US8597650
###### Anti-microbial composition exhibiting residual anti-microbial properties on a surface
 Methods for treating rheumatoid arthritis with anti-bile saltstimulated lipase (BSSL) antibodies Fauci/COVID-19 Dossier Morphotek, Inc. University of Massachusetts Gen-Probe Incorporated Glycotope GmbH Theraclone Sciences, Inc.
Onyx Therapeutics, Inc.
Genmab A/S
The Regents of the University of California
3M Innovative Properties Company
###### South Alabama Medical Science Foundation Educational Fund and Autoimmune Technologies, LLC Byotrol PLC
HERNELL OLLE
CC-BY-NC-SA Dr. David E. Martin
###### Oct08 29Oct09 28Feb07 30Apr08 6Mar08 6Feb08 153an08
28D6C07
14Sep09
###### 243an06 173un04 8Feb06 20Sep04 10Mar05 13Feb04 23Apr09 20Mar09
16D6C02
6May09
14NOV03
###### 22Oct04
4NOV03
17Sep07
###### 8Apr09 26Apr
 -11
53U105
###### 263U106 28Oct


-----

###### -09
6Dec
###### -05 210ct -09 280ct -10 27Feb -08 29Apr -09
6Mar
###### -09
2Apr
###### -12
141 an
###### -09
2Dec
###### -11
14Sep
###### -10
4N0V
###### -11 181an -11 240ct -12
20Sep
###### -05 10Mar -06 14Feb -05 23Apr -10 22Mar -10
27Dec
###### -11
6May
###### -09
12N0V
###### -04 23JU110
29May
###### -12
53U111
6Apr
###### -10
56
###### 18Feb -14 18Feb -14


-----

###### llFeb
 -14
 llFeb
 -14
 4Feb
 -14
 4Feb
 -14
 21Janl4 21Janl4 21Janl4 14Janl4 14Janl4 14Janl4 14Janl4 71anl4 71anl4 71anl4 71anl4
31Dec
###### -13

24Dec

###### -13

17Dec

###### -13

17Dec

###### -13

10Dec

###### -13

10Dec

###### -13
3Dec
###### -13
3Dec
###### -13
3Dec
###### -13
3Dec
###### -13
3Dec
###### -13
3Dec
###### -13

US8592567

###### Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same
US8592391 Method for therapeutic^ clinical and veterinary use poly-ICLC
###### US8586770 Unsaturated steroid compounds US8586364 Cells and methodology to generate non-segmented negative-strand
RNA viruses
US8586363 TAL effector-mediated DNA modification
###### US8581584 Membrane proteins, mechanisms of action and uses thereof
US8580927 Engineered antibody constant domain molecules


-----

US8580268
CpG oligonucleotide analogs containing hydrophobic T analogs with
###### enhanced immunostimulatory activity
US8569283 Compounds and compositions as c-Kit kinase inhibitors
###### US8562996 RSV-specific binding molecules and means for producing them
US8562943
US8560339
US8557767
###### Quality control methods for oil-in-water emulsions containing squalene System and method to predict the global spread of infectious agents via commercial air travel Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557248 Methods and compositions for treating malaria
US8552051 Use of pharmaceutical compositions containing mesembrenone
US8552032 Bicyclic derivatives useful as inhibitors of DPP-1
US8551968 Methods for generation of antibodies
###### US8551756 Avian influenza chimeric VLPS
US8551750
US8551749
###### Device including bone cage and method for treatment of disease in
a subject
###### Device including bone cage and method for treatment of disease in
a subject
13The
###### Trustees of the University of Pennsylvania
SALAZAR ANDRES
###### Harbor Therapeutics, Inc. Institut Pasteur Iowa State University Research Foundation, Inc. Florida State University Research Foundation
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Coley Pharmaceutical GmbH LIU XIAODONG
Medlmmune Limited
###### Novartis AG
Kamran Khan
UAB Research Foundation
###### Cyvax, Inc.
H. L. Hall & Sons Limited
###### lanssen Pharmaceutica NV National Jewish Health Novavax, Inc.
The Invention Science Fund I, LLC
The Invention Science Fund I, LLC
US8551738 Systems and methods for rapid identification of nucleic acid variants
###### Ibis Biosciences, Inc.
US8551469
###### Treatment of tumors and viral diseases with recombinant interferon alpha
US8546432 Tetrazolones as inhibitors of fatty acid synthase
US8546383 Chiral fused [1,2]imidazo[4,5-c] ring compounds


-----

US8546082 Methods for identification of sepsis-causing bacteria
US8541568
US8541457
US8541438
###### Compositions and methods using siRNA molecules for treatment of gliomas Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541221 Primate T-lymphotropic viruses
US8541003
###### Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using Fauci/COVID-19 Dossier
 Superlab Far East Limited Infinity Pharmaceuticals, Inc.
3M Innovative Properties Company
###### Ibis Biosciences, Inc.
BIGNER DARELL D

Xenon Pharmaceuticals Inc.

3M Innovative Properties Company
###### lohns Hopkins University Protein Sciences Corporation
CC-BY-NC-SA Dr. David E. Martin
###### 3an06 1-3U103 29Sep04 22Dec06
10D6C09
###### 26Mayl0 313an08 27Sep06 iSepll 13un07
8NOV06
###### 2Apr07
28Aug07
###### 9Augl0 20Mar09
18D6C09
###### 13Mar07 113U1-03 23Apr09 23Apr09 213U1-05 28Feb01 5Mayl0
30D6C04
###### HSep03
24May08
###### 33un05 183un04


-----

###### 21Feb05
20Dun03
3May
###### -12 170ct -08 18Feb -11
21Dec
###### -07
10Dec
###### -10
26May
###### -11
303an
###### -09
27Sep
###### -07
29Aug
###### -12
30May
###### -08
6Nov
###### -07

2Apr
###### -08
27Aug
###### -08

9Aug
###### -11 16Mar -10
16Dec
###### -10 13Mar -08 193an -10
283U109
###### 23Apr -09 UNov -09 6Oct -08
5May
###### -11
25May
###### -12
25May
###### -07
26May
###### -09
53un


-----

###### -06
 2iDec
 -10
 1JU110 213un
 -04
 57 26Nov
 -13
 26Nov
 -13

19Nov

###### -13

19N0V

###### -13
 19Nov
 -13
 12Nov
 -13

12Nov

###### -13

12Nov

###### -13
 290ctl3 220ctl3 220ctl3 150ctl3 150ctl3 150ctl3 80ctl3 80ctl3 80ctl3 80ctl3 80ctl3 80ctl3 80ctl3 80ctl3 10ctl3 10ctl3 10ctl3 24Sep
 -13
 245ep
 -13
 245ep
 -13
 24Sep
 -13
 245ep
 -13
 US8529968

US8524715
US8524488
###### Decontaminating composition having simultaneously bactericidal


-----

###### fungicidal and virocidal properties, methods for obtaining and using said composition Phenoxyacetic acid derivatives useful for treating respiratory diseases Methods and devices for determining a cell characteristic, and applications employing the same 29Hightech Bio-Activities Holding GmbH
 Astrazeneca AB
The Regents of the University of California
US8524241 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
The General Hospital Corporation
###### US8519106 Monoclonal human tumor-specific antibody
US8507545 Cytotoxic T cell activator comprising EP4 agonist
###### US8507544 Bi-aryl amide compounds as CRTh2 receptor modulators
US8507455 Folate conjugates
###### University of Zurich National University Corporation, Hamamatsu University School of Medicine Astrazeneca AB Alnylam Pharmaceuticals, Inc.
US8506968 SARS vaccine compositions and methods of making and using them Eli

###### Lilly and Company
 US8506966 Adjuvanted influenza vaccines for pediatric use US8501746 Organic compounds
US8501699 Bicyclic nucleosides and nucleotides as therapeutic agents
US8501461 System for performing multi-formatted assays
US8497405 Process for dispersing vaporous hydrogen peroxide
US8497112 Method for producing viral vaccines
US8494781
###### Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US8492329 Bioactive peptides and methods of using same
US8486959 Dibenzo[f,h]isoquinoline derivatives
US8486678 Pharmaceutical compositions for the treatment of virus infection
US8486619
###### Arrayed imaging reflectometry (air) sensor chip comprising
 influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses US8486420 Live virus vaccines
US8481547
US8481270
###### Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
 Method for chromogenic detection of two or more target molecules
 in a single sample
US8481255 Scytovirin domain 1 related polypeptides
US8476292
###### Amide and carbamate derivatives of
 N-{2-[4-amino-2(ethoxymethyl)-IH-imidazo[4,5-c] quinolin-1-Yl]-l,ldimethylethyl}methanesulfonamide
and methods
US8476288 Salts 756
US8476265 Compounds-801


-----

US8470771
US8470769
###### Method and medicament for inhibiting the infection of influenza virus Method of treatment of bacterial infection by administration of polylysine Fauci/COVID-19 Dossier Novartis AG Novartis AG Biota Scientific Management Pty Ltd Gen-Probe Incorporated
STERIS Inc.
###### Baxter Healthcare SA
BOGOCH ELENORE S
Compugen Ltd.
###### National Health Research Institutes Kineta Two., LLC University of Rochester Children's Hospital, Inc. Janssen Pharmaceutica NV Ventana Medical Systems, Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
3M Innovative Properties Company
###### Mar04
23NOV04
10Sep02
###### 20JU1-07 13Mar07
8May07
###### 5-JU107 4Dec07 29Jun00 22Feb08 5Jun06 3-JU108 10Mar05 6Mar07
28Aug07
###### 6Jun03 12JU1-07 14Janl0
23NOV05
2May08
###### 15Feb05
18D6C09
22Aug08
25May05
9Sep05
###### 21AstraZeneca

AB
###### AstraZeneca AB
 Institute of Microbiology, Chinese Academy of Sciences Novabiotics, Ltd.


-----

CC-BY-NC-SA Dr. David E. Martin
May09

###### 30JU1-10
14NOV07
###### 18Aug04 29Mar
 -05

22NOV

###### -05
 9Mar
 -05
 183U108 13Mar
 -08

7May

###### -08 33ul08

4Dec

###### -08

28Dec

###### -09
 20Feb
 -09
 43un
 -07

7Sep

###### -12
3Dec

###### -09
 28Feb
 -13

28Aug

###### -08

10Dec

###### -10
 113U108
143 an

###### -11
 iFeb
 -12
 iMay
 -09
 15Feb
 -06

16Dec

###### -10

21Aug

###### -09
30Sep
###### -11

8Sep

###### -06

20May

###### -10


-----

14Sep

###### -12

18Dec

###### -07
30NOV
###### -11
58
10Sep

###### -13
3Sep
###### -13
3Sep
###### -13
3Sep
###### -13

27Aug

###### -13

13Aug

###### -13

13Aug

###### -13

13Aug

###### -13

13Aug

###### -13

13Aug

###### -13

6Aug

###### -13

6Aug

###### -13

6Aug

###### -13
303U113
303U113
233U113
233U113
###### 16JU113 16JU113 16JU113 16JU113 93ull3 93ull3 93ull3 23ull3 23ull3 23ull3 253unl3 253unl3
 10US8470346
 Anti-viral pharmaceutical compositions
US8470335
###### US8466284 Recombinant SARS-CoV nspl2 and the use of thereof and the


-----

###### method for producing it
Some 2-pyrazinone derivatives and their use as inhibitors of
###### neutrophile elastase
US8466167 Compounds and compositions as TLR activity modulators
###### US8466124
RNA sequence motifs in the context of defined internucleotide
###### linkages inducing specific immune modulatory profiles Mast Therapeutics, Inc.
 Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation Astra Zeneca AB

IRM LLC
###### Coley Pharmaceutical GmbH
US8465751 Cnaa€”B domain antigens in vaccines against gram positive bacteria
###### Novartis AG
US8461125 Compositions and methods to treat asthma
###### US8460914 Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens
US8460605 Decontaminant dispenser suitable for use as a projectile
US8455483 Compoundsa€”801
US8450471 TAL effector-mediated DNA modification
US8450467 Carbohydrate conjugates as delivery agents for oligonucleotides
###### US8450350 Triazoles as inhibitors of fatty acid synthase US8450284 Coiled-coil lipopeptide helical bundles and synthetic virus-like particles
US8450055 Malaria antigen screening method
US8445650
US8445447
US8444961
###### Mutant botulinum neurotoxin serotype A polypeptide and uses thereof

B7-DC variants immunogenic compositions and methods of use
###### thereof

RNA virus infection inhibitor, method for inhibition of infection by
RNA virus, RNA virus infection-inhibiting product, and use as RNA
###### virus infection inhibitor US8440704 Quercetin-containing compositions
US8440649 Phenanthroindolizidine analogues
US8440642 Boron-containing small molecules
US8440432 Tai effector-mediated DNA modification
US8440431 TAL effector-mediated DNA modification
US8440408 Animal protein-free media for cultivation of cells
US8436178 Imidazoquinolines with immuno-modulating properties
###### US8436024 2-pyridone compounds
US8431160
###### US8431134 Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
Use of a pneumococcal P4 peptide for enhancing
###### opsonophagocytosis in response to a pathogen
US8426565 Dendritic cell marker and uses thereof


-----

US8420798 Method for producing nucleic acid probes
###### Fauci/COVID-19 Dossier

The Children's Hospital of Philadelphia
###### Novartis AG
STERIS Inc.
###### AstraZeneca AB
 Iowa State University Research Foundation, Inc.
 Alnylam Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Universitaet Zuerich
The United States of America as Represented by the
###### Secretary of the Navy
Thomas Jefferson University
The Johns Hopkins University
###### Sekisui Chemical Co., Ltd. Quercegen Pharmaceuticals LLC National Health Research Institutes
 Anacor Pharmaceuticals, Inc.
 Iowa State University Research Foundation, Inc. Iowa State University Research Foundation, Inc. Baxter Healthcare S.A.
 AstraZeneca AB Astrazeneca AB
 Novartis AG
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Walter and Eliza Hall Institute of Medical Research Ventana Medical Systems, Inc.
CC-BY-NC-SA Dr. David E. Martin
Dec03
###### 13Jun08
6NOV07
3Mar08
13Aug07
###### 12Jan09 14Feb08 9Sep04 6Mar07 31JU1-09
10D6C09
###### 4Dec07
 5Mayl0 9Dec06
31Aug05
25Sep07
###### 13JU1-07 16Jun09 17JU1-06 24Feb09 16Feb05
10D6C09
10D6C09
###### 29Oct04


-----

8May07
###### 2Oct09 24Feb06 31JU1-08
30Aug07
###### lSep06
19May
###### -11 133un -08
5Nov
###### -08 27Feb -09 123un -12 123an -10
13Aug
###### -10 103an -13 20Feb -08 303U110 22Mar -12
14Dec
###### -11
5May
###### -11
6Dec
###### -07
25Aug
###### -06
25Sep
###### -08
7Mar
###### -12 163un -10
16Dec
###### -09 llFeb -10 iSep -11 22Mar -12 22Mar -12
10Dec
###### -10
6May


-----

###### -08 lOct -10 24Feb -07 31JU109
29Aug
###### -08
31Aug
###### -07
59
###### 253unl3 253unl3 183unl3 183unl3 183unl3 183unl3 113unl3 113unl3 113unl3 43unl3
28May
###### -13
28May
###### -13
28May
###### -13
28May
###### -13
28May
###### -13
21May
###### -13
21May
###### -13
21May
###### -13
14May
###### -13
14May
###### -13
14May
###### -13
14May
###### -13
14May
###### -13
14May
###### -13
7May
###### -13
7May
###### -13 30Aprl3


-----

###### 30Aprl3 23Aprl3 16Aprl3
 27US8420784
 Interleukin 10 receptor, (IL-10R) antibodies
US8420096
###### Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
Kyowa Hakko Kirin Co., Ltd.

###### Vanderbilt University US8420094 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
The General Hospital Corporation
###### US8415394 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
US8415361 Use of TAM receptor inhibitors as antimicrobials
US8415330
###### Biological specimen collection and transport system and method of use
US8415309 Bicyclic nucleosides and nucleotides as therapeutic agents
US8415118 Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof
US8415102
###### Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8410149
###### Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses US8410114 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8409589 Mutant forms of streptolysin 0
US8399651 Nucleic acids encoding GAS57 mutant antigens
US8398992 Methods and compositions for polytopic vaccination
###### US8394986 Phenoxiacetic acid derivatives
US8394945 Compositions for use in identification of bacteria
US8394386
###### Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
 Astrazeneca AB
The Salk Institute for Biological Studies

###### Longhorn Vaccines & Diagnostics, LLC Biota Scientific Managment Pty Ltd
 Virginia Tech Intellectual Properties, Inc.
 NanoString Technologies, Inc.
May08
###### 4Mar04 203U1-07 6Oct05
9NOV07
###### lOct07 1-3U109 29Oct07 10Apr07


-----

###### 6Siga Technologies Inc. Dec04 SAstraZeneca

AB
###### Novartis AG Novartis AG Polytopos LLC AstraZeneca AB Ibis Biosciences, Inc.
The Trustees of the University of Pennsylvania
US7829712 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
Xenon Pharmaceuticals Inc.
US7829707 Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy
###### AstraZeneca AB
US7829302 Method for detecting the specificity of activated lymphocyte
US7820210
###### Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers
US7812135 GITR-binding antibodies
US7803918
US7803796
US7803765
###### Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom US7799800 Lipid-modified immune response modifiers
US7794998 Primate T-lymphotropic viruses
HU DUN
###### Inhalation, Inc.
TOLERRX, me.
###### Amsterdam Institute of Viral Genomics B.V. Sungkyunkwan University Foundation For Corporate Collaboration Phylogica Limited
3M Innovative Properties Company
###### lohns Hopkins University
US7794659 Signal measuring system having a movable signal measuring device
###### Gen-Probe Incorporated
US7790878
RNAi modulation of RSV, PIV and other respiratory viruses and uses
###### thereof Fauci/COVID-19 Dossier Alnylam Pharmaceuticals, Inc.
CC-BY-NC-SA Dr. David E. Martin
May06
21D6C07
12Sep07
###### 29Apr05
21Aug03
###### HSep03


-----

###### 28Apr04 20Sep04 6Dec04
8D6C03
###### 3Apr00 25Mar05
18Aug03
###### 22Dec06 20Feb04 30Oct03 21Feb05 10Mar05 22Oct04
27May
###### -09 4Mar -05
183U108
21Dec
###### -11
7Nov
###### -08 lOct -12 Ilian -12 29Oct -08 10Apr -08 28Oct -10 63an -12
14Sep
###### -11
10Sep
###### -12
22Dec
###### -11
263U111
###### 7Mar -07

2 7Apr
###### -05
20Sep
###### -05
5Dec
###### -05
7Dec
###### -04
 18Mar -08 27Mar


-----

###### -06
18Aug
###### -04
20Dec
###### -07 20Feb -04
12Aug
###### -04 24Feb -07 10Mar -06 253un -09
60
###### 16Aprl3 16Aprl3 16Aprl3 9Aprl3 9Aprl3 9Aprl3 9Aprl3 9Aprl3 9Aprl3 2Aprl3 2Aprl3 2Aprl3 19Mar -13 19Mar -13 12Mar -13 12Mar -13 12Mar -13
9Nov
###### -10
9Nov
###### -10
9Nov
###### -10 26Octl0 12Octl0
28Sep
###### -10
28Sep
###### -10
28Sep
###### -10
21Sep
###### -10


-----

14Sep

###### -10

14Sep

###### -10

7Sep

###### -10

US7790449

US7790159
US7786290
US7785775
###### Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor
17The
###### Trustees of the University of Pennsylvania Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids Double-stranded ribonucleic acid with increased effectiveness in an organism
Human virus causing severe acute respiratory syndrome (SARS)
and uses thereof
US7785612 Polyamino acid for use as adjuvant
###### US7781226 Particle on membrane assay system
US7781203
###### Supports for assaying analytes and methods of making and using thereof US7777036 Heterocyclic derivatives and their use as therapeutic agents
US7777022
###### Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
US7776521 Coronavirus isolated from humans
US7767817
US7767677
###### Water soluble boronic acid fluorescent reporter compounds and methods of use thereof Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7767658 Vaccine composition
US7767657 Boron-containing small molecules
###### US7767210 RNA virus vaccines and methods
US7763618 Pyridyl derivatives and their use as therapeutic agents
US7758868
###### Modified polymerases and attenuated viruses and methods of use thereof
US7754711 Pyridazine derivatives and their use as therapeutic agents
US7750123 Antibodies against SARS-CoV and methods of use thereof
US7749445 Method and apparatus for analyzing bioprocess fluids
###### US7745486 Quercetin-containing compositions
US7745442 Methods of reducing risk of infection from pathogens
US7745147 Methods and uses of antibodies in the purification of interferon
US7745119 System for detecting polynucleotides
US7745118 Comparative genomic resequencing
###### US7741450 Antibodies to GM-CSF US7741360 Bi-aryl or aryl-heteroaryl substituted indoles
US7740858 SARS-CoV-specific B-cell epitope and applications thereof


-----

US7737135
###### Biphenyloxyacetic acid derivatives for the treatment of respiratory disease US7736850 Strain of SARS-associated coronavirus and applications thereof Board of Regents, The University of Texas System Alnylam Pharmaceuticals, Inc. Versitech Limited Masanori Baba
The Board of Regents of the University of Texas System
###### Corning Incorporated
Xenon Pharmaceuticals Inc.
###### Rosetta Genomics, Ltd.
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
FANG HAO
Xenon Pharmaceuticals Inc.
###### Aventis Pasteur SA Anacor Pharmaceuticals, Inc.
The Board of Regents of the University of Oklahoma
Xenon Pharmaceuticals Inc.
The Penn State Research Foundation
Xenon Pharmaceuticals Inc.
Dana Farber Cancer Institute, Inc.
###### BioScale, Inc.
 Quercegen Pharma LLC Parion Sciences, Inc.
 ViraNative AB Investigen, Inc.
Roche Nimblegen, Inc.
###### Morphotek Inc. AstraZeneca AB National Taiwan University AstraZeneca AB Centre National de la Recherche Scientifique DecOl 153ul-02 133un03 24Mar03 20Apr05 27Feb04
29Dec05
###### 20Sep04
26NOV02
###### 25Apr03
5Sep03
###### 20Sep04
17NOV03
###### 16Feb05
14Dec05
###### 293U1-03 22Dec06 303U1-03
25NOV03


-----

2May05
###### 17JU1-06
20Aug03
###### 12Feb05
20May03
###### 8Apr04 8Feb06
26May06
###### 21Sep04 24Aug04 2Dec03 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
6Sep
###### -07 ISAug -03
143 un
###### -04 83un -07 19Apr -06
22Dec
###### -04 73un -06
20Sep
###### -05
26May
###### -04
14May
###### -07
7Sep
###### -04
20Sep
###### -05
93an
###### -08
16Aug
###### -06
14Dec
###### -06
293U104
24Dec
###### -07
9Feb
###### -05
24NOV
###### -04
19Dec
###### -06
163U107


-----

18Aug
###### -04 13Feb -06
21N0V
###### -05
8Apr
###### -05
8Feb
###### -07
25May
###### -07
21Sep
###### -04
22Aug
###### -05
2Dec
###### -04
61
7Sep
###### -10
7Sep
###### -10
31Aug
###### -10
31Aug
###### -10
31Aug
###### -10
24Aug
###### -10
24Aug
###### -10
17Aug
###### -10
17Aug
###### -10
17Aug
###### -10
3Aug
###### -10
3Aug
###### -10
3Aug
###### -10
3Aug
###### -10
3Aug
###### -10 273ull0 203U110 13JU110 63ull0 63ull0


-----

###### 293unl0 293unl0 29:unl0 29:unl0 29:unl0 22:unl0 22:unl0 22:unl0 153unl0 153unl0
 23US7732177
 Oligoadenylate Synthetase (OAS)
US7731978 Mutant forms of streptolysin 0
###### US7728110 Antibodies to SARS coronavirus
US7725565
###### System and method for detecting, collecting, analyzing, and communicating event related information US7723570 Edible vaccines expressed in soybeans
US7723041
US7722886
US7714109
US7713515
US7709521
###### Assay for SARS coronavirus by amplification and detection of the replicase sequence Compositions and methods for treatment of severe acute respiratory syndrome (SARS) Combinations and kits for cancer treatment using selected antibodies to aminophospholipids Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
US7709511 Benzothiazolone derivatives
US7709188 Multi-allelic detection of SARS-associated coronavirus
US7700782 Compounds 569
US7700728
Use of chimeric receptors in a screening assay for identifying
###### agonists and antagonists of cell receptors
US7700727 Compositions and kits for detecting pathogen infection
US7700273
US7700120
###### Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV)
CCR5 coreceptor
###### Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus US7696406 Expression of a recombinant transgene US7696330 Binding molecules against SARS-coronavirus and uses thereof
US7691877 Pharmaceuticals
US7691646
###### Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet,
and the like, and storage method thereof


-----

###### Illumigen Biosciences., Inc. Novartis AG
Amgen, Inc.
###### Georgetown University SoyMeds, Inc. Becton, Dickinson and Company
Wyeth

###### Board of Regents, The University of Texas System R.E.D. Laboratories N.V.
 AstraZeneca AB AstraZeneca AB Birch Biomedical Research LLC AstraZeneca AB Schering Corporation Biokit, S.A.
The United States of America as represented by the
###### Department of Health and Human Services
New York Blood Center
###### Board of Trustees Operating Michigan State University Crucell Holland B.V. Pfizer Inc.
Nov05
21D6C07
19May06
###### 25Feb08 12Oct04
12Sep03
###### 20May04 15JU1-02
27May03
18Aug03
9Aug05
22Aug03
19D6C07
###### 24Mar05
23D6C03
###### 9Apr04 153un04 3-3U103 223U1-03 17Feb06 28Daikin Industries, Ltd. Mar03
2US7691599
###### Mammalian genes involved in viral infection and tumor suppression Zirus, Inc. US7691390 Viral protein
US7687535 Substituted 3-sulfur indoles
US7687475 RNA interference in respiratory epithelial cells
US7682688
###### Microporous materials, methods, and articles for localizing and quantifying analytes US7678774 Treating severe acute respiratory syndrome
US7678386


-----

US7674795

###### Liposomes coated with selected antibodies that bind to aminophospholipids Fluorene derivatives, composition containing said derivatives and the use thereof Fauci/COVID-19 Dossier
CHANG MING-FU
###### AstraZeneca AB University of Iowa Research Foundation University of Utah Research Foundation Hemispherx Biopharma Board of Regents the University of Texas Aventis Pharma SA
CC-BY-NC-SA Dr. David E. Martin
May02
###### 2Mar04
27May03
###### 9-JU104
26NOV02
16May03
###### 153U1-02
19May05
17NOV
###### -06
19Dec
###### -08
21May
###### -07
19NOV
###### -08 12Oct -05
3Feb
###### -09
20May
###### -04
15Aug
###### -03
26May
###### -04
16Aug
###### -04
3Aug
###### -06
13Aug
###### -04
19Dec
###### -07 24Mar -06 27Apr -05 llApr -05


-----

###### 153un -05 2:Jul04 201an -06 16Feb -07
21N0V
###### -08
2May
###### -03
19Sep
###### -07
25May
###### -04 160ct -07
20NOV
###### -03 263an -07
15Aug
###### -03
14N0V
###### -07
62
###### 83unl0 83unl0 13unl0
25May
###### -10
25May
###### -10
25May
###### -10
25May
###### -10
 HMay -10 HMay -10
4May
###### -10
4May
###### -10
4May
###### -10 20Aprl0 20Aprl0 20Aprl0 20Aprl0 20Aprl0 13Aprl0 13Aprl0


-----

###### 6Aprl0 6Aprl0 6Aprl0 6Aprl0
30Mar
###### -10
30Mar
###### -10
 23Mar
 -10
 16Mar
 -10
 16Mar
 -10

9Mar

###### -10

US7670807

###### RNA-dependent DNA polymerase from Geobacillus stearothermophilus 10East Tennessee State Univ. Research Foundation
US7670565 Building decontamination with vaporous hydrogen peroxide
###### US7666996 Casein derived peptides and uses thereof
US7666592
US7662860
###### Methods for concurrent identification and quantification of an
unknown bioagent
###### 3D-structure model of SARS coronavirus 3CL protease and antiSARS drugs
US7648997 Hydroxylamine substituted imidazoquinolines
###### US7648844 Method and apparatus for detection of analyte using an acoustic device
US7645881 Methods for treating hepatitis C
###### US7642350 Purine derivatives
US7636637 Variable length probe selection
US7635557 Enzymatic diagnostic test for SARS and other viral diseases
US7635485 Method of accelerated vaccination against Ebola viruses
US7632638
US7629443
###### Methods and apparatus for detecting viruses using an acoustic device Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
US7629385 Sphingolipid-derived pharmaceutical compositions
US7629137
###### US7629114
US7625563
###### Methods and apparatus for detecting bacteria using an acoustic device Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer Cancer treatment methods using selected immunoconjugates for


-----

###### binding to aminophospholipids
US7625492 Charge-based water filtration systems
US7625428 Bioagent air filtration systems
US7623997
###### Computer-implemented biological sequence identifier system and method
US7622559 Human monoclonal antibodies against interleukin 8 (IL-8)
US7622125 Polycistronic HIV vector constructs
US7622118
###### Cancer treatment methods using selected antibodies to aminophospholipids
US7622112 Anti-SARS monoclonal antibodies
US7619067 Evolved interferon-alpha polypeptides
US7618802
US7618788
###### Compositions of coronaviruses with a recombination-resistant
genome
###### Proteome epitope tags and methods of use thereof in protein modification analysis
US7618635 Super-antigen fusion proteins and the use thereof
US7615381
###### Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device Fauci/COVID-19 Dossier Steris Inc Peptera Pharmaceuticals Ltd Ibis Biosciences, Inc. Shanghai Institute of Materia Medica, Chinese Academy of Sciences Coley Pharmaceutical Group, Inc. BioScale, Inc.
PTC Therapeutics, Inc.
###### Pfizer Limited
Roche NimbleGen, Inc.

MND Diagnostic Ltd.
The United States of America as represented by the
###### Department of Health and Human Services BioScale, Inc.
New York Blood Center, Inc.
Dado Technologies GmbH
###### BioScale, Inc.
 World Sense Technology Limited
 Board of Regents, The University of Texas System
The University of Wyoming Research Corporation
The University of Wyoming Research Corporation
The United States of America as represented by the
###### Secretary of the Navy
Genmab A/S
###### Novartis Vaccines and Diagnostics, Inc. Board of Regents, The University of Texas System Not Available Maxygen, Inc.
The University of North Carolina at Chapel Hill
###### Millipore Corporation


-----

###### Healthbanks Biotech Co.^ Ltd.
 BioScale., Inc.
CC-BY-NC-SA Dr. David E. Martin
###### Mar04
 311an03 lMar00 18Feb04 43un03 12Aug03
2May05
###### 223U1-04
4May05
###### 183un04 233un03 lAug03
2May05
###### 23un04 293un04
2May05
###### 26Aug03 153U1-02 283an03 283an03 2-3U104 16Dec02
5May04
###### 153U1-02
5Dec03
18May05
###### 213U1-03
10May02
###### 213U1-04
2May05
###### 10Mar
 -04
3Mar
###### -08
 IMar
 -04
 17Feb
 -05

2Dec

###### -05
 12Aug
 -04

2May

###### -06

143U105
3May
###### -06
 203un
 -05
 233un
 -04


-----

###### 17:an -06
2May
###### -06
8Feb
###### -06 293un -05
2May
###### -06
20Aug
###### -04
15Aug
###### -03 283an -04 283an -04 63un -06 273un -07
5May
###### -05
15Aug
###### -03
6Dec
###### -04
17May
###### -06 193an
 -06
5Feb
###### -04
193U105
2May
###### -06
63
2Mar

###### -10
2Mar
###### -10 23Feb -10 23Feb -10 16Feb -10 193anl0 193anl0 123anl0 53anl0
22Dec
###### -09


-----

22Dec

###### -09

22Dec

###### -09

15Dec

###### -09

8Dec

###### -09

8Dec

###### -09

8Dec

###### -09

8Dec

###### -09
 iDec
 -09
 IDec
 -09
 IDec
 -09

24N0V

###### -09

24N0V

###### -09

24N0V

###### -09

24N0V

###### -09

24N0V

###### -09

17N0V

###### -09

17N0V

###### -09

17N0V

###### -09

17N0V

###### -09

10NOV

###### -09
 US7615223 Selected immunoconjugates for binding to aminophospholipids

US7611908
###### US7611704 Method and apparatus for therapeutic drug monitoring using an acoustic device Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7605161 Pyridyl derivatives and their use as therapeutic agents
US7605135 Baicalin as a treatment for SARS infection
###### US7604960 Transient protein expression methods
US7604801 Methods for detecting parvovirus infections
US7598382 Aryl substituted imidazoquinolines
###### US7598094 Methods and apparatus for detecting cardiac injury markers using


-----

an acoustic device
US7598072 Assay to detect viral uncoating
###### Board of Regents, The University of Texas System 15JU1-02 2BioScale, Inc. Board of Regents, The University of Texas System
Xenon Pharmaceuticals Inc.
The University of Hong Kong
###### Crucell Holland B.V.
The Research Foundation of State University of New York
###### Coley Pharmaceutical Group, Inc. BioScale, Inc.
 Wisconsin Alumni Research Foundation US7597936 Method of producing a pigmented composite microporous material University of Utah Research Foundation
US7595381 Method for detecting SARS coronavirus
US7595163 Method for detecting SARS coronavirus
US7592343
US7592322
###### Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
RNAi modulation of RSV, PIV and other respiratory viruses and uses
###### thereof
US7592008 Membrane scaffold proteins
US7589092 Prodrugs of heteroaryl compounds
US7585647 Nucleic acid encoding recombinant interferon
###### US7582740 Methods and kits for detecting SARS-associated coronavirus
US7582621 Boron-containing small molecules
###### US7579396 Polymer composite
US7579359 1-alkoxy IH-imidazo ring systems and methods
US7572621
US7572448
###### Detection, characterization and treatment of viral infection and methods thereof Combined cancer treatment methods using selected antibodies to aminophospholipids Eiken Kagaku Kabushiki Kaisha Eiken Kagaku Kabushiki Kaisha
Xenon Pharmaceuticals Inc.
###### Alnylam Pharmaceuticals, Inc.
The Board of Trustees of the University of Illinois, a body
###### corporate and politic of the State of Illinois Koronis Pharmaceuticals, Incorporated
WEI GUANGWEN
The Trustees of Columbia University In the City of New
###### York Anacor Pharmaceuticals, Inc. Eastman Kodak Company
3M Innovative Properties Company
###### Canadian Blood Services Board of Regents, The University of Texas System
US7572442 Selected antibody compositions for binding to aminophospholipids Board
###### of Regents, The University of Texas System


-----

US7569536
###### Method for controlling SR protein phosphorylation., and antiviral agents whose active ingredients comprise agents that control SR protein activity US7569384 Albumin fusion proteins US7550140 Antibody to the human 0X40 receptor
US7547698
US7547516
###### Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCO)
 Method for reducing the presence of amplification inhibitors in a reaction receptacle Fauci/COVID-19 Dossier
 Masatoshi Hagiwara
Human Genome Sciences, Inc.
###### Crucell Holland B.V.
Xenon Pharmaceuticals Inc.
###### Gen-Probe Incorporated
CC-BY-NC-SA Dr. David E. Martin
May05
###### 153U1-02 303U1-03
10NOV03
###### 15Apr99
5May03
20D6C02
2May05
9Dec03
26NOV02
###### 273un03 273un03 20Sep04 22Oct04
20NOV00
###### 203un03
28Aug03
###### 17Apr03 16Feb05 313an07 2Sep04 9Apr03 153U1-02 153U1-02
26Dec03
###### 9Feb04 133un02 20Sep04 10Mar05

Aug

###### -03

2May

###### -06
 ISAug
 -03


-----

29:11104
8Nov
###### -04 Uun -07 160ct -08 131an -06
2May
###### -06
8Dec
###### -04
26May
###### -04 101un -08 101un -08
20Sep
###### -05
141 un
###### -05 Ilian -05
27Dec
###### -06
26Aug
###### -04 231an -04 16Feb -06
311an
###### -07 iSep -05 HOct -05
15Aug
###### -03 151U103
24Dec
###### -04
8Aug
###### -06 131un -03
20Sep
###### -05 10Mar -06 64
Nov


-----

###### -09
3Nov
###### -09
3Nov
###### -09
 20Oct09 20Oct09 20Oct09 20Oct09 6Oct09 6Oct09 6Oct09 6Oct09
29Sep

###### -09

29Sep

###### -09

22Sep

###### -09

22Sep

###### -09

22Sep

###### -09

15Sep

###### -09

8Sep

###### -09
 ISep
 -09
 ISep
 -09

25Aug

###### -09

25Aug

###### -09
 HAug
 -09
 HAug
 -09
 HAug
 -09

4Aug

###### -09

4Aug

###### -09
 233un09 163un09 163un09 1510

US7547512

###### High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)
24The
###### University of Hong Kong


-----

US7544697 Pyrazolopyridines and analogs thereof
###### US7541436 Interferon-alpha polypeptides and conjugates
US7541163 Interferon-alpha polypeptides and conjugates
###### US7531630 Interferon-alpha polypeptides and conjugates US7531324 Interferon-alpha polypeptides and conjugates US7521424 Albumin fusion proteins
US7521185
###### Assay for SARS coronavirus by amplification and detection of the replicase sequence US7514436 Pyridazine derivatives and their use as therapeutic agents US7511124 Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents US7504384 Use of lipid conjugates in the treatment of infection
US7504382
US7504205
###### Protease inhibitors for coronaviruses and SARS-CoV and the use thereof Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMPdependent kinase and a target for SARS therapy
US7504097 Interferon-alpha polypeptides and conjugates
###### Coley Pharmaceutical Group, Inc. Maxygen, Inc. Maxygen, Inc. Maxygen, Inc. Maxygen, Inc.
Human Genome Sciences, Inc.
###### Becton, Dickinson and Company

Xenon Pharmaceuticals Inc.

###### Board of Regents, The University of Texas System
 Yissum Research Development Company of the Hebrew University of Jerusalem Cytovia, Inc.
The Burnham Institute
###### Maxygen, Inc.
US7498409 Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
###### Schering Corporation
US7498152 Interferon-alpha polypeptides and conjugates
US7495011 Anti-coronavirus drug
US7491793 Influenza virus inhibiting peptides
US7491706
US7491508
US7491489
###### Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
US7491397 Receptor binding polypeptides
US7488801 Interferon-alpha polypeptides and conjugates
US7488589 Interferon-alpha polypeptides and conjugates
US7488473 Interferon-alpha polypeptides and conjugates


-----

US7485432 Selective modulation of TLR-mediated biological activity
###### US7482334 Therapeutic treatment methods
US7482149
###### US7479484
US7470666
###### Inhibition of SARS coronavirus infection with clinically approved antiviral drugs Peptides and peptidomimetics having immune-modulating., antiinflammatory
and anti-viral activity
Use of Ulinastatin and its pharmaceutical composition for treating
###### severe acute respiratory syndrome Fauci/COVID-19 Dossier
 Maxygen, Inc. aRigen Pharmaceuticals, Inc.
The Administrators of the Tulane Educational Fund
###### Changchun Huapu Biotechnology Co., Ltd.
The Trustees of the University of Pennsylvania
The University of Hong Knog
###### National Health Research Institutes Maxygen, Inc. Maxygen, Inc. Maxygen, Inc.

3M Innovative Properties Company
###### Hollis-Eden Pharmaceuticals, Inc.
Genome Institute of Singapore
###### Takeda Pharmaceutical Company Limited Guangdong Techpool Biochem. Pharma. Co., Ltd.
CC-BY-NC-SA Dr. David E. Martin
###### Mar03
 3Oct03 19May04 19May04 19May04 19May04 223an03
12Sep03
###### 303U1-03 153U1-02 103an00
6May03
###### 17May04
18NOV02
###### 24Mar05
18NOV02
###### 153U1-03
4NOV03
###### 253U1-03 203un03
22NOV04
###### 93an04
18NOV02
18NOV02
18NOV02
###### 27Feb03


-----

###### 28Aug02 9Jun03 25Jun03
26May03
###### 24Mar -04 lApr -05
4May
###### -07 14Aug -07 13Sep -06
13Sep
###### -06
7JU105
13Sep
###### -04 293U104 ISAug -03
8Sep
###### -05
6May
###### -04
17May
###### -05 30Oct -06 23Mar -06 30Oct -06
```
     143u104

```
3Nov
###### -04
```
     26Ju104

 153un -04 280ct -05 10Jan -05 30Oct -06 30Oct -06 30Oct -06 27Feb -04 12Feb -07

```

-----

93un
###### -04 25Jun -04
25May
###### -04
65
###### 16Jun09 93un09 2Jun09 2Jun09
12May
###### -09
12May
###### -09 21Apr09 21Apr09 7Apr09
31Mar
###### -09 17Mar -09 17Mar -09
17Mar
###### -09 17Mar -09
3Mar
###### -09 3Mar -09 24Feb -09 17Feb -09 17Feb -09
17Feb
###### -09 17Feb -09 17Feb -09 10Feb -09 10Feb -09 10Feb -09
3Feb
###### -09 27Jan09 27Jan09


-----

20Dan09
30Dec
###### -08

US7470548

###### Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet,
and the like, and storage method thereof
US7468418 Compositions for enhancing transport of molecules into cells
US7465836
US7462615
US7460960
###### Hydrolytically-resistant boron-containing therapeutics and methods of use Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
 Proteome epitope tags and methods of use thereof in protein modification analysis US7456180 Piperazine derivatives and their use as therapeutic agents
US7455833
###### Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7452542 Live attenuated coronavirus vaccines
US7445889 Methods for detecting parvovirus infections
US7442761 Replikin peptides and uses thereof
US7442508 Methods for detection and production of influenza viruses
US7439349
###### Method for preparation of large volume batches of poly-lCLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
US7439052 Method of making modified immunodeficiency virus particles
US7435588
US7435538
###### Systems for detection and production of respiratory, herpes and enteric viruses High throughput screening method of drug for physiologically active protein
US7432045 Method of inhibiting influenza infection with antiviral peptides
US7429656
US7427479
US7424370
###### Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
 Methods and kits for identifying target nucleotides in mixed populations Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US7407663 Modified immunodeficiency virus particles
US7407662
###### Modified viral particles with immunogenic properties and reduced lipid content
US7405207
###### Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof


-----

###### US7405046 Compositions and methods for treatment of rhinovirus
US7399588 Method for detecting SARS coronavirus
###### US7396914 SARS nucleic acids, proteins, antibodies, and uses thereof US7393856 Anti-viral uses of borinic acid complexes
US7393638 Assay system and methods for detecting SARS-CV
US7387271 Immunostimulatory combinations
###### 28Daikin Industries, Ltd. Mar03 29AVI BioPharma., Inc. Anacor Pharmaceuticals, Inc. Hybrigenics SA Epitome Biosystems, Inc.
Xenon Pharmaceuticals Inc.
###### Board of Regents, The University of Texas System Vanderbilt University
The Research Foundation of State University of New York
BOGOCH ELENORE S
###### Diagnostic Hybrids, Inc. Not Available Lipid Sciences Diagnostic Hybrids, Inc. CellFree Sciences Co., Ltd. Wisconsin Alumni Research Foundation
The University of Hong Kong
###### Applera Corporation Council of Scientific and Industrial Research Lipid Sciences, Inc. Lipid Sciences, Inc.
 Apr03 163un03 8Dec05
10May02
###### 303U1-03 153U1-02 21May04
5May03
###### 63un03 24Apr98 3-3U102 293un00
20Sep05
###### 8Sep03
1D6C03
19May03
###### 30Apr04 203U1-04 293un00 293un00 17Epigenesis Pharmaceuticals, Inc. 3un02
6The


-----

###### Quigley Corporation Eiken Kagaku Kabushiki Kaisha University of Massachusetts Anacor Pharmaceuticals, Inc.
AsiaGEN Corporation
3M Innovative Properties Company
###### Aug01 27Iun03 4Aug03 143un04 1-3U103
30D6C02
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 26Mar -04 29Apr -04 153un -04
8Dec
###### -05
13NOV
###### -03
293U104
15Aug
###### -03
23May
###### -05
5May
###### -04 43un -04 28Apr -06 13ul03 10Apr -06 28Apr -06
8Sep
###### -04 IDec -04
143 un
###### -06 29Apr -05
7Feb
###### -05 203un -03 213un


-----

###### -04 17:un
 -03 270ct
 -06 153un
 -04
4Aug
###### -04
143 un

###### -05 13ul03
30Dec
###### -03
66
30Dec
###### -08

23Dec
###### -08

16Dec
###### -08
9Dec
###### -08

2Dec
###### -08

25NOV
###### -08

25NOV
###### -08

18N0V
###### -08
4Nov
###### -08 28Oct08 28Oct08 21Oct08 21Oct08 14Oct08 14Oct08 7Oct08
30Sep
###### -08
23Sep
###### -08
9Sep
###### -08
5Aug
###### -08
5Aug
###### -08
293U108
293U108
153U108
###### 83ul08


-----

1JU108
1JU108
###### 173un08

US7384909

US7378386
US7375210
US7375202
US7375180
US7374883
###### Anti-viral treatment methods using phosphatidylethanolaminebinding peptides linked to anti-viral agents
 Anti-viral treatment methods using phosphatidylethanolaminebinding peptide derivatives
PCR primer set for detecting severe acute respiratory syndrome
###### (SARS)-Coronavirus., method and kit for detecting SARSCoronavirus using the same
Human virus causing severe acute respiratory syndrome (SARS)
and uses thereof
###### Methods and compositions related to IRM compounds and Toll-like receptor 8
 Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS) US7371850 Method and composition for reducing expression of ROCK-II
US7371837 Human virus causing respiratory tract infection and uses thereof
US7371525
US7361747
###### Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS) Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus US7361304 Building decontamination with vaporous hydrogen peroxide
US7358068 Antiviral oligonucleotides
US7354908
###### Materials and methods for prevention and treatment of RNA viral diseases
US7354551 Room decontamination with hydrogen peroxide vapor
US7344740
###### Methods and apparatus to prevent^ treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers US7344720 Vaccine composition
US7339051
###### Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
US7335658 Pyridazine derivatives and their use as therapeutic agents
US7332475 Preventive or therapeutic composition for viral infectious disease
###### US7332294 CXCL10-based diagnosis and treatment of respiratory illnesses
US7320857
###### Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
US7318918 Interferon-alpha polypeptides and conjugates
US7314613 Interferon-alpha polypeptides and conjugates
US7312036
###### Compositions for use in identification of viral hemorrhagic fever viruses


-----

###### US7297786 RNA interference in respiratory epitheial cells
US7291498
###### Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7282568 Human monoclonal antibodies against interleukin 8 (IL-8)
US7282199
US7267942
###### Adeno-associated virus (AAV) serotype 8 sequences^ vectors containing same, and uses therefor Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) Fauci/COVID-19 Dossier Board of Regents, The University of Texas System 15JU1-02 Board of Regents, The University of Texas System
Samsung Electronics Co., Ltd.
The University of Hong Kong
3M Innovative Properties Company

QIAGEN Diagnostics GmbH
###### Myriad Genetics, Inc.
The University of Hong Kong
The Chinese University of Hong Kong
The University of Hong Kong
###### Steris Inc. Replicor, Inc. University of South Florida Steris Inc Inhalation, Inc. Sanofi Pasteur SA Isis Pharmaceuticals, Inc.

Xenon Pharmaceuticals Inc.
Kyowa Hakko Kogyo Co., Ltd.
###### University Health Network Chinese National Human Genome Center at Shanghai Maxygen, Inc. Maxygen, Inc.
 ISIS Pharmaceuticals, Inc. University of Iowa Research Foundation
The Trustees of the University of Pennsylvania
Genmab A/S
The Trustees of the University of Pennsylvania
The University of Hong Kong
CC-BY-NC-SA Dr. David E. Martin
###### 15JU1-02
12D6C03
###### 24Mar03 13Feb03 30Apr03
20Aug03
###### 213ul-04 293ul-03
22May03
###### 313an03


-----

13Sep02
###### 30Apr02 8-3U104 3Apr00
17NOV03
###### 28Apr03 303U1-03 223ul-03 17Aug04 9-3U104 19May04
18NOV02
###### 22Mar04 9-3U104 203un03
16Dec02
17Dec01
###### 24Mar03
Aug
###### -03 ISAug -03
24N0V
###### -04 24Mar -04 12Feb -04 30Apr -04
20Aug
###### -04
16May
###### -05
283U104
24May
###### -04 293an -04
12Sep
###### -03 30Apr -03
83U104
27NOV
###### -04
15N0V
###### -04 26Apr -04
293U104
223U104
17Aug
###### -04


-----

9DU104
18May
###### -05
19May
###### -04

2 IMar
###### -05 11JU105 20:un -03
16Dec
###### -03 25Apr -03 24Mar -04

67
###### 3un08
27May
###### -08
20May
###### -08
20May
###### -08
20May
###### -08
20May
###### -08
13May
###### -08
13May
###### -08
13May
###### -08 22Apr08 22Apr08 15Apr08 8Apr08 8Apr08 18Mar -08 18Mar -08 4Mar -08 26Feb -08 19Feb -08 19Feb -08 223an08 153an08 13an08


-----

25Dec

###### -07

20NOV

###### -07

6Nov

###### -07
 16Oct07 16Oct07 USep
 -07
 1510

US7261867

###### Production of silver sulfate grains using organo-sulfate or organosulfonate additives
US7247303 Selected antibody CDRs for binding to aminophospholipids
US7244732 Prodrugs of heteroaryl compounds
US7223787
###### Prenylation inhibitors reduce host cell permissiveness to viral replication
US7220852 Coronavirus isolated from humans
US7183300
US7166435
###### Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl
 thiazole ureas and analogues thereof Compositions and methods for reducing the transmissivity of illnesses
US7163947 1-Amino IH-imidazoquinolines
US7151163
###### Antiviral agents for the treatment^ control and prevention of
 infections by coronaviruses
US7151091 Compositions and methods for preventing infection
US7148248
US7129223
US7129042
###### Method of treating or inhibiting the development of brain inflammation and sepsis Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference Compositions and methods for detecting severe acute respiratory syndrome coronavirus
US7115563 Composition and its therapeutic use
###### US7091214 Aryl substituted Imidazoquinolines
US7048953
###### Methods and apparatus to prevent^ treat and cure infections of the

human respiratory system by pathogens causing severe acute
###### respiratory syndrome (SARS)
US7023593 Apparatus for forming nano-grating device
US6946291 Mixed cell diagnostic systems
US20200176
079
US20200173
925
US20200172
883


-----

US20200172
879
US20200172
###### 600
US20200172
513
US20200172
###### 480
US20200171
085
US20200171
###### 060
US20200166
505
US20200165
632
METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME
DETERMINATION OF DISEASE STATES
MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY
DETECTION METHOD, AND MICROSCOPIC BODY DETECTION
DEVICE
COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
###### ACTIVITY, AND RELATED METHODS
DHFR TUNABLE PROTEIN REGULATION
###### 7Eastman Kodak Company Board of Regents, The University of Texas System Koronis Pharmaceuticals, Incorporated Board of Regents, The University of Texas System
The United States of America as represented by the
###### Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
AGARWAL ATUL
The Quigley Corporation
3M Innovative Properties Company
###### Sequoia Pharmaceuticals, Inc.
La lolla Biosciences LLC
NOZAKI MASAKO
The University of HongKong
###### Diagnostic Hybrids, Inc. Insignion Holding Limited
3M Innovative Properties Co.
###### Inhalation, Inc. Industrial Technology Research Institute Diagnostic Hybrids, Inc. Not Available
3APAN SCIENCE AND TECHNOLOGY AGENCY
###### Not Available Not Available
RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME GLAXOSMITHKLINE
BIOLOGICALS, SA
DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc.
CON3UGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC
AGENTS


-----

###### Method of Treating Respiratory Tract Infection
FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST
FILOVIRUSES AND FLAVIVIRUSES

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC
ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING
NEODYMIUM MAGNETS
ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR
rAAV VECTOR PRODUCTION
###### Fauci/COVID-19 Dossier

HANGZHOU DAC BIOTECH CO., LTD.
###### Not Available Not Available
The U.S.A., as represented by the Secretary, Department
###### of Health and Human Services Spark Therapeutics, Inc.
CC-BY-NC-SA Dr. David E. Martin
###### Apr06
 15JU1-02 201un03 21Oct03 25Apr03
11NOV04
###### 6Aug01 7Mar03 28Apr03
20Sep02
29NOV02
19May03
3NOV03
29May02
20D6C02
###### 3Apr00
28NOV03
###### 24Apr98 193U1-17 29Marl7
19NOV09
###### 3Marl7 153U1-09 123unl6 123U1-12 19Mayl7 313U1-17 ISeplS 73unl7
7Apr

###### -06
 ISAug
 -03
3 IMar
###### -04
 21Oct
 -03
 12Apr


-----

###### -04
10NOV
###### -05
14Dec
###### -04
3Sep
###### -04 28Apr -04
22Sep
###### -03
26NOV
###### -03
19May
###### -04
3N0V
###### -03
29May
###### -03
18Dec
###### -03
2May
###### -03 17Mar -04
30Mar
###### -04 18JU118 28Mar -18
13Sep
###### -19
2Sep
###### -19
16Aug
###### -17
5Feb
###### -20
5Feb
###### -20
18May
###### -18 263an -18
303an
###### -20 63un -18
68
28Aug
###### -07 243ul07
173U107
29May


-----

###### -07
22May
###### -07 27Feb -07 233an07 163an07
19Dec
###### -06
19Dec
###### -06
12Dec
###### -06 31Oct06 31Oct06 3Oct06 ISAug -06
23May
###### -06 4Apr06
20Sep
###### -05 43un20 43un20 43un20 43un20 43un20 43un20 43un20 43un20 43un20
28May
###### -20
28May
###### -20
 US20200165 630 US20200165 613 US20200165 594 US20200165
585
US20200165
357
###### US20200164
334
###### US20200164 067 US20200164 058 US20200164 020


-----

US20200163
878
US20200157
###### 600
US20200157
222
US20200157
221
US20200155
###### 704
US20200155
699
US20200155
667
US20200155
###### 664
US20200155
662
US20200155
###### 660
US20200155
###### 646
US20200149
062
US20200149
048
US20200148
749
US20200147
203
US20200147
193
US20200147
171
US20200140
547
US20200140
###### 493
US20200140
398
###### 29C0MP0SITI0NS
FOR THE TREATMENT OF DISEASE
VIRUS LIKE PARTICLE
CRISPR SYSTEM BASED ANTIVIRAL THERAPY
NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS
CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF
USE THEREOF
MICROSPOTTING DEVICE
###### Methods and Compositions for Inhibiting Akt3
TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE
EAST RESPIRATORY SYNDROME-CORONAVIRUS
PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION
###### LIPID NANOPARTICLE MRNA VACCINES

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME


-----

AMPLIFICATION
###### ANTI-PD-L1 ANTIBODIES AND USES THEREOF
ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
MODIFIED VIRUS-LIKE PARTICLES OF CMV
VACCINE COMPOSITIONS
###### Not Available
The University of Leeds
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
###### Not Available Not Available Not Available Not Available King Abdulaziz University Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Not Available
COMBINATION IMMUNOTHERAPIES COMPRISING IL-15
SUPERAGONISTS
COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER
NANOPARTICLE DELIVERY
EV576 For Use in the Treatment of Viral Infections of the
###### Respiratory Tract
ENGINEERED TSC2
###### Transbiotic Regulation of Bacterial Gene Expression
ANTIBODIES AND PROCESSES FOR PREPARING THE SAME
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND
IMMUNOTHERAPY INVOLVING HER ANTIGENS
COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR
MODULATING AN IMMUNE RESPONSE AGAINST CANCERS,
INFECTIONS DISEASES AND DISORDERS
MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE
IMMUNE TOLERANCE
###### Engineering Virus-like Nanocarriers for Biomolecule Delivery
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS
###### Fauci/COVID-19 Dossier Not Available Not Available Volution Immuno Pharmaceuticals SA Not Available Not Available Not Available Not Available Not Available Aprl6 Uunl7


-----

###### 7-JU117 27JU1-17 2Dec05 18Aprl2 15Danl6
27NOV18
###### 12Aprl7 260ctl6
19NOV18
###### 29Marl8 303unl6
30Sep03
###### 220ctl4 273ul-17 10Feb09 26Mayl7 23Sepl5 83anl0 14JU1-17 22Mayl7
16May08
###### 26Sepl4 23unl7 18Not
 Available
 Not Available Not Available

AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
CC-BY-NC-SA Dr. David E. Martin
###### Sepl8 26Mayl7 26Octl8 13Febl5 28Apr
 -17
31May
###### -18

63U118
273U118
###### 21Oct
 -19
 HOct
 -19
SFeb
###### -20

27NOV

###### -18
 12Apr
 -17
 26Oct
 -17

19NOV

###### -18
 29Mar


-----

**N>iN>iN>iN>iN>iN>iN>iN>iN>iN>CTiiCriiN>iN>ih^iN>ih^ih^iN>h^i^liN>iN>iN>iN>iN>iUJiN>i**
###### SOSOSOSOSOSOSOSOSOS OOJ ©U^OXS^'XJC ^ZX3'X)^IQ‘-I^ZO^Q‘-I^
**QJQJQJQJQJQJQJQJQJQJ** **^OCDCD^CDnCDC^OCUCCDOCUCU**

**r+** **"O** **ZSr+^l—1** **<** **=5** **=5** **<** **Z5** **Z5**

**00**


-----

###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
21May
###### -20
14May
###### -20
14May
###### -20
14May
###### -20
14May
###### -20
14May
###### -20
14May
###### -20
7May
###### -20
7May
###### -20
7May
###### -20

US20200138
937
US20200138
###### 936
US20200138
###### 818 US20200138 780 US20200131
518
###### US20200129 487
US20200127
###### 954 US20200124


-----

599
US20200123
233
US20200123
205
US20200123
203
US20200115
###### 448
US20200115
###### 434
US20200113
###### 996
US20200113
967
US20200113
831
US20200113
###### 830
US20200109
###### 403
US20200108
###### 136
US20200102
558
US20200102
550
US20200102
###### 544
US20200102
362
US20200102
292
US20200101
158
US20200101
153
US20200101
142
###### 2Genetically Attenuated Nucleic Acid Vaccine Phenotypically Wild-Type and Genetically Attenuated Viruses
METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS
USING LAPATINIB
METHODS FOR TREATING PULMONARY EMPHYSEMA USING
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES
PRODUCED IN CELL CULTURE
CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND
RNA TARGETING METHODS AND COMPOSITIONS
ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE
DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF


-----

DETECTION SIGNAL
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME
FOR THE TREATMENT OF VIRAL DISEASES
###### Inhibition Of TCR Signaling With Peptide Variants
COMPOSITIONS COMPRISING CURONS AND USES THEREOF
CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND
CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
###### ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES
THEREOF
CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS
###### ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES
PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS
LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA
MOLECULES
PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING
RNA
###### IN VIVO DELIVERY OF OLIGONUCLEOTIDES Not Available Not Available Not Available Junl7 21unl7 7Novl8 14N0t Available Marl3 14N0t Available
TAIHO PHARMACEUTICAL CO., LTD.
###### Salk Institute for Biological Studies
CELLEMEDY CO., LTD
###### Marl7 30Iunl7 22Augl7 13Aprl7 SAblynx N.V. 3un08 22Not Available
FLAGSHIP PIONEERING INNOVATIONS V, INC.
###### Not Available Not Available Not Available Not Available
GLAXOSMITHKLINE BIOLOGICALS SA
GLAXOSMITHKLINE BIOLOGICALS S.A.
###### Not Available
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available
TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID
DELIVERY
TAL EFFECTOR-MEDIATED DNA MODIFICATION
POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS


-----

CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND
METHODS OF MAKING AND USING THE SAME
TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN
COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
AND USES THEREOF
###### ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE
THEREOF
###### Not Available Not Available OctlS 13Junl7 26Aprl7 230ctl5 233unl7 26Mayl7 6-Julll 31Augll 12Decll 6Apr07 3Aprl7
10Dec09
###### 30Not Available Decl3 6Not Available Not Available Not Available
MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN Not Available
PDFS COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
###### Not Available Aprl7 3-JU113 lOctlS 6Aprl7 123unl7 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### llun -18 llun -18
6Nov
###### -19
19Dec
###### -19 14Mar -18 293un -18
31Dec
###### -18


-----

###### 13Apr -18 lAug -19
18Dec
###### -19 133un -18 220ct -19 290ct -19 213un -18
26May
###### -17
16Dec
###### -19
16Dec
###### -19
18Dec
###### -19
22NOV
###### -19 30ct -19
28Aug
###### -19 llSep -19
5Apr
###### -18 10JU119 220ct -19
6Apr
###### -18 123un -18
70
7May
###### -20
7May
###### -20
7May
###### -20
7May
###### -20 30Apr20 30Apr20 23Apr20 23Apr20 23Apr20 23Apr20


-----

###### 23Apr20 16Apr20 16Apr20 16Apr20 16Apr20 16Apr20 16Apr20 9Apr20 9Apr20 2Apr20 2Apr20 2Apr20 2Apr20 2Apr20 2Apr20 2Apr20 2Apr20

US20200101
119
###### US20200101
087
US20200100
###### 480
US20200095
###### 324
US20200093
919
###### US20200093 909 US20200093
855
###### US20200093
841
###### US20200087
655
###### US20200087 646 US20200087 630 US20200087
359
###### US20200087
313
###### US20200087
298
###### US20200087 280
US20200086
###### 324 US20200085 984 US20200085 947 US20200085


-----

943
US20200085
872
US20200085
852
US20200085
###### 756
US20200080
141
US20200080
111
US20200079
###### 820
US20200079
781
US20200078
335
US20200072
###### 836
US20200071
723
27METH0DS
OF TREATMENT OF INFECTIONS USING BACTERIA
PHARMACEUTICAL COMPOSITIONS AND METHODS
TRAIT SELECTION IN AVIANS
###### ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE
THEREOF
MODIFIED PEDV SPIKE PROTEIN
PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND
TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO
ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC
OXIDE

###### Broad Spectrum Antiviral and Methods of Use
PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM
OXIDES
OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION
CASSETTES AND THEIR USE
INFLUENZA VIRUS AND TYPE 1 DIABETES
###### GRIFFITHSIN MUTANTS
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
###### ImidazoEA,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION
APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING
AND/OR KILLING A VIRUS
###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available


-----

###### Not Available Not Available Not Available Istituto Zooprofilattico Sperimentale delle Venezie
The United States of America,as represented by the
###### Secretary,Department of Health and Human Services Not Available Not Available Not Available Not Available
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
NEW YORK

###### VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available
PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC
CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR
PEPTIDE ANTIGEN
###### CureVac AG
IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS Not Available
EPIDERMAL MRNA VACCINE
NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE
THEREOF
METHODS AND COMPOSITIONS FOR ENRICHMENT OF
###### AMPLIFICATION PRODUCTS Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof
DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A
CELL BINDING MOLECULE
###### Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases
COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS
MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES
(MENSA) AND USES THEREOF
RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL
###### Fauci/COVID-19 Dossier Not Available Not Available Not Available Not Available Hangzhou DAC Biotech Co., Ltd. Not Available Not Available Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### SeplS BAuglS 31Mayl7 30Marl7 20Sepl8 19Aprl7 HSepl7 17Apr06 14JU1-15


-----

###### 31Mayl7 10Octl2 10Febl5 29JU1-11 iMarl? 5Febl5 303unl6 7Marll 7Sepl2 313anl2 19Aprl7 5Augl5 14Sepl8 llDecl3 18Sepl5 20Aprl6 5Sepl8 lMayl7 5Mayl4 30Augl8
26Sep
###### -19
21N0V
###### -19
31May
###### -18
30Mar
###### -18
18Sep
###### -19 19Apr -18
33un
###### -19 30Apr -19
22NOV
###### -19
31May
###### -18
253U119
27NOV
###### -19 25Apr -19 27Feb -18
25NOV
###### -19
27Dec
###### -18
25NOV
###### -19
14May


-----

###### -19
29Aug
###### -19 19Apr -18
5Aug
###### -16 12JU119
19N0V
###### -19
19Sep
###### -16 20Apr -16 lAug -19 IMay -18
2Apr
###### -19
29Aug
###### -19
71
###### 2Apr20 2Apr20 2Apr20 26Mar -20 26Mar -20 26Mar -20 26Mar -20 26Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20 19Mar -20


-----

###### 19Mar
 -20
 19Mar
 -20
 19Mar
 -20
 19Mar
 -20
 19Mar
 -20
 12Mar
 -20
 12Mar
 -20
 12Mar
 -20
 12Mar
 -20
 12Mar
 -20

5Mar

###### -20
5Mar
###### -20

US20200071

###### 421
US20200069
###### 814
US20200062
###### 764
US20200061
187
US20200061
###### 185 US20200060 981 US20200056 221 US20200056 159 US20200055 927
US20200055
###### 926 US20200054
731
###### US20200054 660 US20200054
259
US20200048
722
US20200048
649


-----

US20200048
###### 636
US20200046
865
US20200046
###### 826
US20200046
692
US20200040
###### 408
US20200040
042
###### 20BISPECIFIC
ANTIBODY
CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE
ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING
AND USING SAME
METHODS FOR PREPARING SQUALENE
PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE
CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS
CAPACITY OF LIVE VIRUSES
METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING
ADSORPTION MEDIA
NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND
USES THEREFOR
MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
AND VIRAL INFECTION
MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
AND VIRAL INFECTION
IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE
THEREOF
DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY
HIGH DENSITY ANALOG MULTIPEXING
METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION
AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN
NUCLEIC ACIDS
###### VIRUS-LIKE PARTICLES AND USES THEREOF Not Available Hangzhou DAC Biotech Co., Ltd. Not Available Not Available
The Scripps Research Institute
###### Not Available Not Available Not Available Not Available Not Available Not Available St. Jude Children's Research Hospital EnLiSense, LLC Not Available Not Available
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GLAXOSMITHKLINE BIOLOGICALS
SA


-----

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
CAVITATION
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
VIRUS
###### SPECIFIC AKT3 INHIBITOR AND USES THEREOF
HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID
###### IDENTIFICATION
CHIMERIC MOLECULES AND USES THEREOF
US20200038
871
DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF
NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR
METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE,
POLYMERASE, AND SEQUENCING REACTIONS
US20200038
373
US20200033
343
US20200032
255
US20200031
871
US20200031
819
US20200030
###### 441
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
OR OTHER DISEASES
NOVEL DEPSIPEPTIDES AND USES THEREOF
COMPOSITIONS AND METHODS FOR INHIBITING KINASES
###### Lipidated Immune Response Modifier Compound Compositions Formulations, and Methods Fauci/COVID-19 Dossier Not Available Academia Sinica Not Available Not Available Not Available Novl3 6Aprl7
17NOV16
###### 12Mayl0 25Octl6 9Decl6
8NOV13
###### 28Febl7 8Sepl6 8Sepl6 73anl4 9Decl6 17Augl8


-----

###### 8Mayl5 13Marl7 6-3U110
29DeC17
###### 27Mar09 153anl6 8Febl6 30Marl7 29Not Available Marl7 9Not Available Not Available Not Available Not Available Not Available Not Available Mayl2 6Oct08 263an07 4Aprl7 23Aprl5 17Augl0
CC-BY-NC-SA
###### Dr. David E. Martin
8Apr
###### -19
6Apr
###### -17
17NOV
###### -17
4N0V
###### -19 250ct -17 UDec -17 250ct -19 27Feb -18 250ct -19 250ct -19 153U119
7Dec
###### -17 16Allg -19
24Aug
###### -19 13Mar


-----

**i-'ihJihJihJihJihJihJihJihJihJihJihJiLniLn** **'jooiixjiujicnii—‘ii—‘i**

**N><_i|-‘CTil-‘SI-‘Sl-1-^l-1CT'l-1** **U)|_iU)|_i2l-1Ol-1<-il-1bJI-100l-'**

**TiOmOmOmOmOmOmOmOmOmOmOmOQj** **®** **Qj** **c** **IO** **u** **00** **3** **O)** **U3** **O** **3** **M** **3** **oo** **3** **ai** **iO** **n** **tfoc** **uo** **>** **U)** **O** **M**
###### (DrDrDrDrDrDrDrDrDrDrorD"}-} 1—1 c QJ ”5 n QJ QJ GJ r+ Z5 c r> crcrcrcrcrcrcrcrcrcrcrcr -5-5 CTO r+

**1X0**


-----

###### -20 13Feb -20 13Feb -20 13Feb -20 13Feb -20 13Feb -20
6Feb
###### -20
6Feb
###### -20
6Feb
###### -20
6Feb
###### -20 303an20 303an20 303an20 303an20 303an20
 US20200030 432
US20200030
###### 422 US20200024 616 US20200024
310
US20200020
###### 420
US20200017
###### 926
US20200017
832
US20200017
588
US20200017
###### 554
US20200017
###### 514
US20200017
###### 455
US20200016
589
US20200016
###### 286
US20200016
###### 280
US20200016
161


-----

US20200010
883
US20200010
519
US20200009
###### 244
US20200002
###### 674
US20200000
931
US20190391
###### 150
US20190390
249
US20190390
229
US20190390
179
US20190390
###### 176
US20190389
###### 816
US20190388
###### 473
US20190382
799
###### 17Z00N0TIC
DISEASE RNA VACCINES
COMBINATION OF VACCINATION AND 0X40 AGONISTS
NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH
ENHANCED HUMAN PANCREATIC TROPISM
NOVEL DEPSIPEPTIDE AND USES THEREOF
###### Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof
CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN
MICROBIOME AND COMPONENTS THEREOF
COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC
CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES
THEREOF
MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM
SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIXHELIX
BUNDLE PROTEINS
ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS
INFECTION
CERTAIN (2S)-N-[(lS)-l-CYAN0-2-PHENYLETHYL]-l,40XAZEPANE-2-CARB0XAMIDES
AS DIPEPTIDYL PEPTIDASE 1
###### INHIBITORS
LOADING VIALS
###### Production of Immune-Response-Stimulating Aerosols By NonThermal Plasma Treatment Of Airborne Pathogens Compositions For Enhancing Transport Of Molecules Into Cells
METHODS FOR TREATING VIRAL DISORDERS
METHODS AND COMPOSITIONS FOR ENRICHMENT OF
###### AMPLIFICATION PRODUCTS


-----

NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY
HOMOLOGY-DIRECTED TRANSGENE INTEGRATION
NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL
COMPONENTS
###### ModernaTXj Inc. CureVac AG Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
TRUSTEES OF BOSTON UNIVERSITY
###### Not Available Not Available Not Available
ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE Not Available
SYNTHETIC NANOPARTICLES FOR DELIVERY OF
IMMUNOMODULATORY COMPOUNDS
COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES
###### Not Available Not Available
BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM Longhorn Vaccines and
###### Diagnostics, LLC
GENE EDITING REAGENTS WITH REDUCED TOXICITY
SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF
NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH
ENHANCED HUMAN SKELETAL MUSCLE TROPISM
###### ANTIVIRAL COMPOUNDS AND METHODS
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
###### VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS Not Available Not Available Not Available Biotron Limited Not Available Not Available Marl? 9Sepl6 30Marl8 3Decl2 8Decl6
7NOV13
###### SAprl? 140ctl6 23Marl? 123U1-18 243anl4


-----

10NOV11
###### 13JU1-18 29Apr03
24Sep09
###### 90ctl5 10Marl7 133unl8
18NOV13
###### 15JU1-16 iMaylS lOct07 21Aprl6 12Aprl6 2Decl5 263un03 lAprl4 270ctl6 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 16Mar -18 ISApr -19 29Mar -19 lAug -19
7Dec
###### -17
28Aug
###### -19
5Apr
###### -18 16Oct -17 22Mar -18 123ull8 19Mar -19
24Sep
###### -19 12JU119
9Apr
###### -19
223U119
###### 73un -19
9Mar
###### -18 133un -19
16Sep


-----

###### -19 10Apr -19
10Sep
###### -19
 19Jun
 -17 20Apr -17 12Apr -17 3JU119
29Aug
###### -19
30Aug
###### -19
 19Apr -19
73
###### 303an20 303an20 233an20 233an20 163an20 163an20 163an20 163an20 163an20 163an20 163an20 163an20 163an20 163an20 163an20 93an20 93an20 93an20 23an20 23an20
26Dec
###### -19

26Dec
###### -19

26Dec
###### -19

26Dec
###### -19

26Dec
###### -19

26Dec
###### -19

26Dec
###### -19

19Dec


-----

###### -19

US20190382

###### 433
US20190381
###### 180
US20190381
162
US20190381
155
US20190380
995
US20190380
891
US20190376
151
US20190376
###### 034
US20190375
801
###### US20190374 650 US20190374 610 US20190374
576
US20190370
###### 834
US20190367
553
US20190367
525
US20190367
###### 453
US20190365
925
US20190365
###### 756
US20190359
###### 990
US20190359
635
US20190359
629
US20190358
335
US20190358
312

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
FOR USE IN THERAPY
HYBRID CARRIERS FOR NUCLEIC ACID CARGO
PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF
MAKING
COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1
PATHWAY


-----

PREVENTION AND TREATMENT OF VIRAL INFECTIONS
MOBILE CLINICS
MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES
THEREOF
HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR
TREATMENT OF INFECTIOUS DISEASE
COMPOSITIONS AND METHODS FOR DELIVERY OF
POLYMER/BIOMACROMOLECULE CONIUGATES
MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF
FIBROSIS
###### VIRAL METHODS OF T CELL THERAPY
SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS
PATHOGENS
COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE
RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS
CONIUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC
AGENTS
AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS
4THE
###### UNIVERSITY OF NOTTINGHAM Not Available Not Available CureVac AG Not Available Baylor College of Medicine Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
HANGZHOU DAC BIOTECH CO., LTD.
###### Not Available Not Available
 VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF Not Available
ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS
THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS
STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER
CONJUGATES
###### Not Available Not Available Not Available
ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE Not Available


-----

US20190358
###### 304

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)
OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS
ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC
DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND
EXPOERIMENTALLY INDUCED OCULAR DISORDERS
US20190358
###### 170
US20190352
639
US20190352
615
###### Lipids and Lipid Compositions for the Delivery of Active Agents
GENOME EDITING REAGENTS AND THEIR USE
METHOD FOR PURIFYING VIRUS
###### Aprl4 93unl6 28Marl6 22Febl3 23unl6
12NOV14
###### 4Aprl2
18NOV13
###### 9Sepl6 22Febl7 20Decl6 27Octl6 13unl8 27Octl7 30Decl4 123U1-12
21NOV14
###### 43unl8 253anl7 5Febl5 5Febl5 123anl7 19Decl7 18Not Available Octl3 19N0t Available Not Available Not Available Decl3 10Febl7 22Decl6 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
253U119
93un


-----

###### -17 27Mar -17
29Aug
###### -19 3JU119
28Aug
###### -19
8Feb
###### -19
23Aug
###### -19
8Sep
###### -17 21Feb -18
20Dec
###### -17 19Apr -19 13un -18 26Apr -19 19JU119
13Aug
###### -19 133un -19
33un
###### -19 253an -18 18JU119 18JU119 123an -18
19Dec
###### -18
29May
###### -19
12Aug
###### -19 12Feb -18
21Dec
###### -17 74
19Dec
###### -19
19Dec
###### -19
19Dec
###### -19


-----

19Dec

###### -19
19Dec
###### -19
19Dec
###### -19
12Dec
###### -19

12Dec
###### -19
12Dec
###### -19
12Dec
###### -19
12Dec
###### -19
12Dec
###### -19
SDec
###### -19
5Dec
###### -19
5Dec
###### -19
SDec
###### -19
SDec
###### -19
SDec
###### -19
28NOV
###### -19
28Nov
###### -19
28Nov
###### -19
28Nov
###### -19
28Nov
###### -19
28Nov
###### -19
28l\lov
###### -19
21Nov
###### -19
21Nov
###### -19

US20190352
608
###### US20190352
357
US20190346
###### 443


-----

US20190345
###### 504
US20190345
503
US20190345
###### 481
US20190345
221
US20190345
###### 166
US20190343
862
US20190337
###### 990
US20190336
969
US20190336
611
US20190336
608
US20190336
597
US20190336
###### 456
US20190330
618
US20190330
572
US20190330
245
US20190330
187
US20190330
###### 164
US20190330
149
US20190328
869
US20190328
865
US20190328
###### 804
US20190323
068
US20190322
989
US20190322
725
US20190321
###### 481
US20190321
###### 403
CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING
LYMPHOCYTE SELECTION


-----

###### 16N0t
 Available
HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT
PROTEIN-PROTEIN INTERACTIONS
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES
###### ARTIFICIAL NUCLEIC ACID MOLECULES
CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION
PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM
OXIDES
BROAD SPECTRUM VACCINE, PREPARING METHOD AND
APPLICATION THEREOF
COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
AGONISTS
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS
POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC
PROTEINS AND THEIR USE IN GENE THERAPY
PARALLELIZED SAMPLE HANDLING
HYBRID CARRIERS FOR NUCLEIC ACID CARGO
CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY
METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE
RESPONSES
USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL
INFECTIONS
ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF
LARGE LIBRARIES
###### Colorado State University Research Foundation Not Available CureVac AG Not Available Not Available Tianjin Dongya Biological Technology Co., Ltd. Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available Not Available CureVac AG CureVac AG Not Available
ABIOGEN PHARMA S.P.A.
###### Not Available
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available
###### Boron-Containing Small Molecules Chemical Compounds
HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND
USES THEREOF
CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC
AGENTS
IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR
COMBINATION THERAPY
IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS
INFECTION
AAV Vectors Targeted to Oligodendrocytes
PCR Ready Compositions and Methods for Screening Biological


-----

###### Samples
PRODUCTION OF VIRUSES IN CELL CULTURE
COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY
CONSTRUCTS AND USES THEREOF
IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING
THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS
ENGINEERED B CELLS AND RELATED COMPOSITIONS AND
METHODS
###### Anacor Pharmaceuticals, Inc. Not Available Not Available
HANGZHOU DAC BIOTECH CO., LTD.
###### Transgene SA Not Available Not Available Longhorn Vaccines and Diagnostics, LLC Not Available Not Available NantBio, Inc. luno Therapeutics, Inc. Sepl3
7NOV14
###### 6Oct08 30Decl4 203unl6 143U1-15 9Mayl8 lMayl4 6-3U110 13Febl5 19Aprl3 93unl6 93unl6 83anl3 153U1-16
IDecOS
###### 8Sepl6 16Feb05 18Marl4 293U1-11 123U1-12 10Octl6 283U1-14 28Sepl2 12Sep06
24NOV15
###### 13Mayl4
11NOV16
###### 2Decl6
303an
###### -19
7Aug
###### -19 283un


-----

###### -19
26:11119
###### 15Jun -17 5JU119
9May
###### -18 24JU119 16JU119
51un
###### -19 27Mar -19
91un
###### -17
91un
###### -17
17May
###### -19 13JU117 221an -19 21Jun -19 12JU119
10May
###### -19
28NOV
###### -18
9May
###### -19 10Oct -17
17N0V
###### -17 15JU119 281un -19 251an -19
2JU119
9Nov
###### -17
30NOV
###### -17
21N0V
###### -19
21N0V
###### -19
14N0V
###### -19
14N0V
###### -19
14N0V


-----

###### - 19

14N0V

###### - 19

14N0V

###### - 19

14N0V

###### - 19

14N0V

###### - 19

7Nov

###### - 19

7Nov

###### - 19

7Nov

###### - 19

7Nov

###### - 19

7Nov

###### - 19

7Nov

###### - 19 310ctl9 310ctl9 310ctl9 310ctl9 310ctl9 310ctl9 310ctl9 310ctl9 310ctl9 240ctl9 240ctl9 240ctl9 240ctl9 240ctl9 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
75

###### US20190316

109
US20190316
091
US20190316
###### 090
US20190316
089
US20190315
###### 840
US20190315
807
###### US20190314 496 US20190314


-----

###### 483 US20190314 482 US20190314 480 US20190314 471 US20190314 455 US20190314
372
US20190310
168
US20190309
357
US20190309
262
US20190309
261
US20190309
048
US20190309
039
US20190308
###### 980
US20190308
969
US20190308
943
US20190307
878
US20190307
722
US20190298
###### 824
US20190298
752
US20190298
###### 750
US20190293
###### 656
US20190292
580
COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY
DEPLETES P16 POSITIVE SENESCENT CELLS
ERYTHROID CELLS COMPRISING ARGINASE
ERYTHROID CELLS COMPRISING ARGININE DEIMINASE
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING
VARIANT FC REGIONS, AND METHODS OF USE
###### VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR
INDUCING THE EXPRESSION OF ANTIBODIES
POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN
IMMUNOSTIMULATING AGENT OR AS AN AD3UVANT


-----

###### Vaccines Including Antigen From Four Strains of Influenza Virus
VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE
STRANDED RNA VIRUSES
IMMUNOGENIC COMPOSITIONS AND USES THEREOF
MOLECULAR VACCINES FOR INFECTIOUS DISEASE
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE
AND INFECTIOUS DISEASES
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS
AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND
DEVICES FOR MONITORING AIRBORNE AGENTS
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE
ERYTHROID CELLS COMPRISING LYSINE OXIDASE
###### Optimized Human Clotting Factor VIII Gene Expression Cassettes
and Their Use
CRYPTIC POLYPEPTIDES AND USES THEREOF
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
###### 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2- CARBOXAMIDE COMPOUNDS
IMMUNE COMPLEX
###### ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
LINKED TO CORONAVIRUSES
###### ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND
METHODS OF USE THEREOF
METHODS FOR THE USE OF S'-ADENOSINE DIPHOSPHATE RIBOSE
(ADPR)
###### Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto
NON-RADIOACTIVE CYTOTOXICITY ASSAYS
DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR
BIOCHEMICAL SENSING
###### 17N0t Available Not Available
RUBIUS THERAPEUTICS, INC.
###### Not Available Not Available Not Available CureVac AG Not Available Medigen, Inc. Not Available Not Available Not Available Not Available Not Available
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
###### Not Available Not Available Not Available Not Available Not Available


-----

###### Not Available Parion Sciences, Inc.
The Rockefeller University
###### Not Available
THE UNITED STATES OF AMERICA, as represented by the
###### Secretary, Department of Health and Human Serv Invirsa, Inc. Not Available Not Available Rutgers, The State University of New lersey
 Aprl2

18NOV13
18NOV13
18NOV13
###### 16Sepl6 273U1-16 lAprl4
6Dec06
28NOV16
###### 25Marl5 2Oct08 3Augl7 5Decl6 223U1-14 9Decl6
18NOV13
18NOV13
###### 6Febl5 293anl5 30Decl4
11NOV16
###### 17Decl2 20Marl5 21Octl6 4Mayl6 27Marl8 HSepl3 19Sepl6 23Marl8 Fauci/COVID-19
 Dossier 103un
 -19
30May
###### -19
30May
###### -19

10May

###### -19
 103un
 -19

263U117
###### 183un
 -19


-----

30NOV
###### -18
21N0V
###### -17 23Apr -19 273un -19 73un -19 25Mar -19
 4Mar
 -19
 25Feb
 -19 43un -19 43un -19
20May
###### -19 22Apr -19
243 un
###### -19
13N0V
###### -17 13Mar -19

10May
###### -19 20Oct -17
4May
###### -17
 26Mar
 -19

21N0V

###### -18
19Sep
###### -17 22Mar -19
CC-BY-NC-SA
###### Dr. David E. Martin
76
###### 170ctl9 170ctl9 170ctl9 170ctl9 170ctl9 170ctl9 170ctl9


-----

###### 170ctl9 170ctl9 170ctl9 170ctl9 170ctl9 170ctl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 10Octl9 30ctl9 30ctl9 30ctl9
26Sep
###### -19
26Sep
###### -19

US20190292
563
US20190292
561
US20190292
###### 236
US20190292
###### 216
US20190292
178
US20190290
###### 674
US20190285
632
###### US20190284
575
###### US20190284
531
###### US20190284 230
US20190282
###### 694
US20190282
608
US20190276
523
US20190275
519
US20190275
101


-----

US20190269
###### 694
US20190269
672
###### US20190264
267
###### US20190264
177
US20190263
###### 934
US20190262
###### 448
US20190262
371
US20190256
585
US20190256
579
US20190255
085
###### US20190254
968
US20190250
153
US20190248
883
US20190248
###### 866

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
17The
###### Trustees of the University of Pennsylvania
SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENOASSOCIATED
###### VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION
CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE
MODULATION OF IFI16 AND STING ACTIVITY
###### Cyclic Di-Nucleotide Induction of Type I Interferon
HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
VIRUSES
Dec01
1SPARK
THERAPEUTICS, INC.
###### Decl5 9N0t Available
 Not Available Dana-Farber Cancer Institute, Inc. Composition for Promoting Production of Immunostimulatory Factor Kyoto University
METABALOMICS AND VIRAL DIAGNOSTICS SUITE
###### Excision Biotherapeutics, Inc.
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS Not Available
DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL
COSTIMULATION AND USES THEREOF


-----

ASSEMBLED GLYCOPROTEINS
IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
METHODS
###### Method Of Treating Inflammation Not Available Not Available
AUTOIMMUNE TECHNOLOGIES, LLC
###### Not Available
COMPOSITION AND METHODS OF TREATING B CELL DISORDERS Not Available
SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS Not Available
STRUCTURE OF GII.4 NOROVIRUS PROTEASE      - DESIGN OF BROADSPECTRUM
PROTEASE INHIBITORS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
###### Specific Akt3 Inhibitor and Uses Thereof
PHASING
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
FC VARIANTS WITH ENHANCED BINDING TO FCRN AND
PROLONGED HALF-LIFE
###### Cationic Oil-In-Water Emulsions
METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL
INFECTIONS
ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE
DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE
PEPTIDE
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
IMMUNOGENS, ANTIBODIES, AND THEIR USE
METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
VIRUS INFECTIONS
###### OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS
MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING
SAME
###### Not Available Not Available Not Available
Wave Life Sciences Ltd.
###### Not Available Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available Not Available
The U.S.A., as represented by the Secretary, Department
###### of Health and Human Services Not Available
GLAXOSMITHKLINE BIOLOGICALS S.A.

###### Board of Regents, The University of Texas System
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available
POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF
AUTOIMMUNE DISORDERS AND INFECTION
###### Fauci/COVID-19 Dossier Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Augl6 3Mayl3 HAprl2


-----

###### 2Augl6 24Mayl6
21May09
###### ISMaylS 29Sepl6 14Marl3 lAprl0 2Sepl6
8NOV16
###### 50ctl6 SMarll 153anl6 253U1-16
18NOV13
###### 263anl8 ISSepll 20Octl6 103unl5 24Febl5 16Sepl5 6-Julll 20Octl6
16Dec02
###### 303unll
8 Apr
###### -19 iDec -16

9 Aug
###### -17 19Feb -19 263an -18 31JU117
24May
###### -17
303an
###### -19

24May
###### -19

22Sep
###### -17
30May
###### -19

29May
###### -19
5Sep
###### -17

8Nov

###### -17 50ct -17
 HOct


-----

###### -18
20May
###### -19 24JU117
10May
###### -19 251an -19
7Mar
###### -19 20Oct -17 101un -16
3May
###### -19 iFeb -19
2May
###### -19 190ct -17 20Feb -19 30Apr -18
77
26Sep
###### -19
26Sep
###### -19
26Sep
###### -19
26Sep
###### -19
26Sep
###### -19
26Sep
###### -19
19Sep
###### -19
19Sep
###### -19
19Sep
###### -19
19Sep
###### -19
19Sep
###### -19
19Sep
###### -19
12Sep
###### -19
12Sep


-----

###### -19
12Sep
###### -19
SSep
###### -19
5Sep
###### -19
29Aug
###### -19
29Aug
###### -19
29Aug
###### -19
29Aug
###### -19
29Aug
###### -19 22Aug -19
22Aug
###### -19
22Aug
###### -19
22Aug
###### -19
15Aug
###### -19 15Aug -19
15Aug
###### -19

US20190248
865
US20190247
529
US20190247
###### 489
US20190247
###### 485
US20190247
###### 440
US20190247
367
###### US20190241 646
US20190241
618
###### US20190240
317
US20190233
###### 447
US20190232
282
###### US20190231


-----

###### 004
US20190225
###### 986
US20190225
971
###### US20190224
339
US20190223
###### 445
US20190220
###### 524
US20190219
563
US20190218
###### 574
US20190218
277
US20190218
207
US20190216
951
US20190216
917
US20190216
915
US20190216
841
US20190211
361
US20190211
355
US20190211
###### 024 ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES
THEREOF
METHOD AND SYSTEM FOR DECONTAMINATING SMALL
ENCLOSURES
AD3UVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC
PRIMING
###### Dimethyl Fumarate and Vaccination Regimens
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
TREATMENT OF INFECTIOUS DISEASES
ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE
TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION
###### INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS
HPIV3 RNA VACCINES
PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN
EMBEDDED TISSUE USING CAGED HAPTENS
METHODS AND COMPOSITIONS FOR DETECTING ANALYTES
MASK
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING
###### LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA
VIRUS SPIKE PROTEIN
METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA


-----

MOLECULE
COMPOSITIONS FOR THE TREATMENT OF DISEASE
ANTIMICROBIAL GEOPOLYMER COMPOSITIONS
DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN
KNOWLEDGE GRAPHS
###### Assay for Detecting TH1 and TH2 Cell Populations
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR
ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING
VARIANT FC REGIONS, AND METHODS OF USE
###### 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators
METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
PROTEINS
HMPV RNA VACCINES
TRANSGENIC VER0-CD4/CCR5 CELL LINE
###### Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
COMPOSITIONS COMPRISING CURONS AND USES THEREOF
DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING
AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND
USES THERE OF
SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES
###### 23Not Available Not Available Not Available Biogen MA Inc. Not Available
CHILDREN'S MEDICAL CENTER CORPORATION
###### Not Available Not Available ModernaTX, Inc. Not Available Not Available
NBC MESHTEC INC.
###### OctlS 29Ded7 20Octll 14Marl4 lAprl4 263anl5 ISMarl?
30Sep09
###### 22Octl5 28Augl5 23Sepl6 17Octl6 28Not Available Oct05 10Not Available Not Available Not Available


-----

###### Not Available Not Available
The Trustees of the University of Pennsylvania
###### Not Available Not Available CureVac AG ModernaTXj Inc. Not Available Not Available Not Available Not Available General Research Laboratory AuglS 29Aprl6 14JU1-16 16Janl8 16Mayl4 2Oct07 16Sepl6 17Augl5 21Augl3 22Octl5 20ctl5 20Aprll 13Junl7 53anl5 19Augl6 21Oct -16 23Apr -19
16NOV
###### -18 23Apr -19 12Apr -19 23Apr -19 15Apr -19 22Oct -18 28Mar -19 25Feb -19
20Sep
###### -17 13Oct -17
30Nov
###### -18
4Aug


-----

###### -16 28Apr -17 13JU117 29Mar -18
17Dec
###### -18 28Mar -19
15Sep
###### -17
17Aug
###### -16 lApr -19 28Mar -19 15Feb -19 20Mar -19 27Mar -19 Alan -16
19Aug
###### -17
15Aug
###### -19
15Aug
###### -19
15Aug
###### -19
15Aug
###### -19
15Aug
###### -19
15Aug
###### -19
8Aug
###### -19
8Aug
###### -19
8Aug
###### -19 lAug -19 lAug -19 lAug -19 25JU119 25JU119


-----

25:11119
###### 25JU119 18JU119 18JU119 18JU119 18JU119 18JU119 18JU119 18JU119 18JU119 18JU119 11JU119 11JU119 11JU119 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
78

US20190209

678
US20190209
###### 604
US20190207
###### 890 US20190204
330
US20190203
268
US20190203
###### 186
US20190203
###### 170
US20190202
929
US20190202
868
US20190202
###### 854
US20190201
565
US20190201
###### 564
US20190201
552
US20190201
###### 433
US20190201
352
US20190201
337
###### US20190194
728
###### US20190194
717


-----

###### US20190194
628
###### US20190194
322
###### US20190194
299
###### US20190194 226 US20190194 150
US20190192
691
US20190192
581
US20190187
151
US20190187
###### 130
US20190185
922
MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS
WITH ENHANCED STABILITY
###### 2Not Available
OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD.
RNA TARGETING METHODS AND COMPOSITIONS
APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION
###### IN IHC AND ISH ASSAYS
LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED
ASSAY FOR DETECTING MICROBES
PRODUCTION OF VIRUSES IN AVIAN EGGS
###### Avian Cells for Improved Virus Production
COMPOSITIONS AND METHODS FOR IDENTIFICATION,
ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING
USP10 BIOMARKERS AND MODULATORS
CORONAVIRUS PROTEINS AND ANTIGENS
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A
DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
CAVITATION
DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
CAVITATION
###### Aptamer Compositions and Methods of Use Thereof 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR
RNA VIRUS TREATMENT
DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
AD3UVANTS
###### Salk Institute for Biological Studies Not Available Not Available Not Available Not Available Decl4


-----

###### 33unl6 22Augl7 283unl6 23anl8
24NOV15
###### 53unl3 20Not Available Sepl6 7Phibro Animal Health Corporation Not Available Not Available Not Available Not Available Atea Pharmaceuticals, Inc. Not Available Not Available Systemic inflammatory and pathogen biomarkers and uses therefor Not Available
METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM 3APAN SCIENCE AND
TECHNOLOGY AGENCY
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION
###### IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE
CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
FUSED [l,2]IMIDAZ0[4,5-C] RING COMPOUNDS SUBSTITUTED
WITH GUANIDINO GROUPS
COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION
REGULATED BIOCIRCUIT SYSTEMS
###### Methods of Populating a Gastrointestinal Tract
ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING
STABLE ISOTOPE STANDARDS
COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTIDYE
QUINONE METHIDE AND TYRAMIDE CON3UGATES
LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
FOR MICROARRAY-BASED ASSAYS
###### Takeda Pharmaceutical Company Limited
BIO-TECHNE CORPORATION
###### Not Available Not Available Arrakis Therapeutics, Inc. Not Available Not Available UVic Industry Partnerships Inc. Not Available CapitalBio Corporation Febl4 4Augl4 29Decl7 29Decl7 28Decl7 7Sepl6 303anl5


-----

3Dec09
###### 24Augl6 5Sepl6 lSepl6 3Augl6 25Aprl4 26Augl6 1-JU116 llAprie 4Febl3 63unl6 283unl6 5Decl3 12Mar -19 23un -17
31Dec
###### -18
19Dec
###### -18
31Dec
###### -18 253an -19
21Dec
###### -18
20Sep
###### -17 15Mar -19
8Mar
###### -19 llSep -18
29Dec
###### -17
28Dec
###### -18
5Mar
###### -19 12Mar -19
33an
###### -19
24Aug
###### -17
4Sep
###### -17 iSep -17
3Aug
###### -17
19N0V


-----

###### -18 lAug -17
301un
###### -17 llApr -17 lAug -18

7Apr

###### -17

19Dec

###### -18

20NOV

###### -18 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
79
###### 11JU119 11JU119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
43U119
###### 273unl9 273unl9 273unl9 273unl9 273unl9 273unl9 273unl9 273unl9 273unl9 203unl9 203unl9 203unl9

US20190185

832
###### US20190184
067
###### US20190184
018
US20190183


-----

968
US20190183
918
US20190177
739
US20190175
###### 716
US20190175
528
US20190169
677
US20190169
639
US20190169
595
US20190167
787
US20190167
###### 786
US20190167
###### 636
US20190166
###### 866
US20190160
129
US20190160
063
###### US20190154
687
###### US20190154
550
US20190153
###### 471
US20190153
###### 086
US20190151
###### 844
US20190151
###### 474 US20190144 930 US20190144
929
###### US20190144
827
###### US20190144
556
###### US20190144 484 DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING
CAS9 NUCLEASE AND USES THEREOF
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND
APPLICATIONS
CARBOHYDRATE CON3UGATES AS DELIVERY AGENTS FOR


-----

OLIGONUCLEOTIDES
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED
DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS
SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES
RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
PRODUCED IN TRANSGENIC PLANTS
###### Adenoviral Vector INHIBITION OF BIOFILM ORGANISMS
PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR
THE DETECTION OF TARGET VIRUSES
CRISPR-RELATED METHODS AND COMPOSITIONS WITH
GOVERNING gRNAS
RNA TARGETING METHODS AND COMPOSITIONS
###### Methods and Compositions for Inhibiting Akt3
EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR
AD3UVANTING SPLIT INFLUENZA VACCINES
METHODS FOR TREATING PULMONARY EMPHYSEMA USING
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX
FROM A CRUSTACEAN CATCH
###### Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
DETECTION DEVICE AND DETECTION METHOD
BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE
COMPOSITIONS FOR THE TREATMENT OF DISEASE
###### Heterodimeric Immunoglobulins
DEVICES AND METHODS FOR THE DETECTION OF MOLECULES
USING A FLOW CELL
RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS,
APTAMERS AND SMALL MOLECULES
ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION
DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR
SUPERFAMILY ANTIBODIES
ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE
THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO
###### 3N0t Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Click Diagnostics, Inc.
EDITAS MEDICINE, INC.
###### Salk Institute for Biological Studies Not Available Not Available


-----

###### Dunl6
1N0V15
###### 4Dec07 13Janll 123unl3 213an08 233unl6 31Mar09
9NOV17
7NOV13
###### 22Augl7 153anl6
4NOV05
###### 14N0t Available Marl3 4Not Available Not Available Not Available Kabushiki Kaisha Toshiba Not Available Not Available Not Available Click Diagnostics, Inc. Kyoto University Not Available Not Available
RUBIUS THERAPEUTICS, INC
###### Not Available Not Available Decl7 lOctlS 31Decl5
17NOV17
###### 6Aprl6 29Aprl6
21NOV12
###### 293unl6 8Sepl4 6Decl3 15Marl7
18NOV13
###### 13Mayl6 28Aprl6 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 23un -17 28Feb -19
20NOV
###### -18


-----

###### 27Feb -19 290ct -18
13Dec
###### -18 233un -17 13Feb -19
9Nov
###### -18
243 an
###### -19 253an -19
6Feb
###### -19 93ull8
8Feb
###### -19
30Nov
###### -18 iFeb -19
30Dec
###### -16
7Mar
###### -18
6Apr
###### -17 28Apr -17
5Feb
###### -19
21Dec
###### -18
8Sep
###### -15
93an
###### -19 15Mar -18
19N0V
###### -18
12May
###### -17 28Apr -17
80
###### 203unl9 203unl9 203unl9 203unl9


-----

###### 203unl9 133unl9 133unl9 133unl9 63unl9 6Junl9 63unl9 63unl9 63unl9 63unl9 63unl9
30May
###### -19
30May
###### -19

23May
###### -19

23May
###### -19

23May
###### -19
23May
###### -19
23May
###### -19
23May
###### -19
16May
###### -19
16May
###### -19
16May
###### -19
16May
###### -19
16May
###### -19

US20190142
###### 929 US20190142 927
US20190136
###### 226
US20190136
215
###### US20190135
875
###### US20190135
873
US20190135
788
###### US20190134 214 US20190134


-----

193
###### US20190134 186 US20190134
062
US20190128
893
US20190128
###### 810
US20190127
###### 441
US20190127
###### 405
US20190127
###### 401
US20190127
###### 400
US20190127
399
US20190125
858
US20190125
###### 806
US20190125
###### 724
US20190119
###### 744
US20190119
743
US20190119
701
US20190119
###### 266
US20190119
###### 220
US20190117
793
US20190117
702
US20190112
596
US20190112
###### 394
INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED
STRAINS
LOW-ADDITIVE INFLUENZA VACCINES
DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION
###### 10Not Available Not Available Not Available Replication Conditional Virus that Specifically Kills Senescent Cells Not Available
TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS


-----

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY
###### INHIBITING EXOSOME RELEASE Not Available Not Available
DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc.
###### GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND
TAM ACTIVATORS AS IMMUNOSUPPRESSORS
INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION
ADJUVANT
PHARMACEUTICAL COMPOSITIONS AND METHODS
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION
SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR
PERFORMANCE
###### Not Available
SALK INSTITUTE FOR BIOLOGICAL STUDIES
###### Not Available Not Available Not Available Not Available
METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY University of Vermont
and State Agricultural College
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION
CHARGED LINKERS ANDTHEIR USES FOR CONJUGATION

CHARGED LINKERS ANDTHEIR USES FOR CONJUGATION

CHARGED LINKERS ANDTHEIR USES FOR CONJUGATION

COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE
ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY
###### Antimicrobial and Antiviral Agents Antimicrobial and Antiviral
Member., and Method for Producing Antimicrobial and Antiviral Agent
PREVENTION AND TREATMENT OF VIRAL INFECTIONS
CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID
SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS
COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
VARIANTS
METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND
COMPOSITIONS THEREOF
COMPOSITIONS AND METHODS FOR INHIBITING KINASES
CARBOXYLIC ACID COMPOUNDS
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,
###### KITS AND ASSAYS
USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR
PROTEIN LIGATION
###### Fauci/COVID-19 Dossier Not Available
HANGZHOU DAC BIOTECH CO., LTD.
HANGZHOU DAC BIOTECH CO., LTD.
HANGZHOU DAC BIOTECH CO., LTD.
###### Not Available Murata Manufacturing Co., Ltd. Not Available


-----

###### Not Available Not Available Not Available Not Available Sumitomo Dainippon Pharma Co.., Ltd. Not Available Indiana University Research and Technology Corporation Not Available Whitehead Institute for Biomedical Research
CC-BY-NC-SA Dr. David E. Martin

Feb09
###### 271un07 HMayl6 17Aprl2 18Mayl6 19Decl6 12Junl6 6Mayl6
9NOV07
4NOV05

###### BAuglS 24Febl4 BlDeclS 13Aprl6 24Febl4 12Augl6 12Augl6 12Augl6 18Aprl6 13Junl6 23unl6 313U1-09 15Augl6 8Sepl7 23Aprl5 18Mayl2 15Feb07 6Mayl4 4Aprl2 283unll ISOct
 -18
 263un
 -18

9Nov

###### -18

63U118
17May

###### -17

19Dec

###### -18

7Dec

###### -18

4May


-----

###### -17
9Aug
###### -18 10JU118
8Dan
###### -19
7Nov
###### -18
13Dec
###### -18 13Apr -17
7Nov
###### -18
20Dec
###### -18
20Dec
###### -18
20Dec
###### -18 18Apr -17
13Dec
###### -18
27NOV
###### -18
5Nov
###### -18 260ct -18
7Sep
###### -18 240ct -18 230ct -18 lOct -18 31Oct -18 12Apr -18
24Sep
###### -18
81
16May
###### -19
16May
###### -19
9May
###### -19
9May
###### -19
9May


-----

###### -19

9May
###### -19

9May
###### -19
9May
###### -19
9May
###### -19
9May
###### -19
9May
###### -19
2May
###### -19
2May
###### -19
2May
###### -19
2May
###### -19

2May
###### -19
2May
###### -19
2May
###### -19
2May
###### -19
2May
###### -19
2May
###### -19 25Aprl9 25Aprl9 25Aprl9 25Aprl9 25Aprl9 25Aprl9 25Aprl9 18Aprl9 18Aprl9

US20190111
141
###### US20190105
653
US20190105
381
###### US20190105 334
US20190100
586
###### US20190099 493


-----

US20190099
###### 479 US20190094 224
US20190091
329
US20190091
221
US20190085
057
US20190085
###### 024
US20190085
013
###### US20190084
943
US20190083
602
US20190083
592
US20190083
569
US20190083
525
US20190083
520
US20190083
###### 408
US20190083
397
US20190078
###### 060
US20190078
051
US20190077
847
US20190077
###### 764
US20190077
763
US20190076
520
US20190076
###### 468
6A
PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE
PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING
WATERBORNE PATHOGENS
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING
CANCER
###### Anti-Viral Azide Containing Compounds Humanized Anti-Claudin-1 Antibodies and Uses Thereof Targeting Lipids


-----

Ewha University      - Industry Collaboration Foundation
###### Not Available Not Available Not Available
Chu Strasbourg^ Les HA'pitaux Universitaires de
###### Strasbourg Arbutus Biopharma Corporation
RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available
METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL
RECEPTOR AFFINITY AND SEQUENCE
CATIONIC OIL-IN-WATER EMULSIONS
METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLYINDUCED
CONDITIONS
MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
AND VIRAL INFECTION
###### Alpha-Ketoamide Inhibitors Of Cysteine Proteases
NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
USES RELATED THERETO
CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
SODIUM CHANNEL BLOCKING ACTIVITY
METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS
IMMUNOSTIMULATORY COMBINATIONS
MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
###### VIRAL INFECTIONS
COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR
AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS
###### N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES
THEREOF
###### OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES
###### Animal Protein-Free Media for Cultivation of Cells
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME
FOR THE TREATMENT OF VIRAL DISEASES
BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY
AMIDE FUNCTION
BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY
AMIDE FUNCTION
VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND
COMPOSITIONS AND METHODS OF USING
ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC
OXIDE
###### Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
TRUSTEES OF BOSTON UNIVERSITY
###### Not Available Not Available Not Available Parion Sciences, Inc. Not Available Not Available


-----

###### Not Available Not Available Not Available Not Available
NOVARTIS AG
###### Novartis AG Baxalta GmbH Aprl6 SOctl? 16Marl6 28JU1-10 22Marl6 4Dec07 14Mayl0 HAprlG 6-Julll HMarl0 8Sepl6 15Sepl7 7Marl6 17Decl2 22Decl5
30Dec02
###### munis 111U1-17 10Marl6 2Decll
23D6C15
###### 9Sep04 29Oct04 SAblynx N.V. 3un08 23Hoffmann-La
Roche Inc.
###### Hoffmann-La Roche Inc. Not Available Not Available Mayl6 23Mayl6 4Apr08 HSepl7 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
6Apr
###### -17 SOct -18 16Mar -16
3Dec
###### -18 21Mar


-----

###### -17 10Oct
 -17 27Apr -18
6Apr
###### -17
6Dec
###### -18 23Apr -18
15N0V
###### -18
17Sep
###### -18
7Mar
###### -17
23Aug
###### -18
22Dec
###### -16 220ct -18 243ull8 10JU118 10Mar -17
4Dec
###### -18
21Dec
###### -16
8Nov
###### -18 290ct -18 170ct -17
13N0V
###### -18
13N0V
###### -18 llSep -18 llSep -17
82
###### 18Aprl9 HAprl9 HAprl9 HAprl9 4Aprl9 4Aprl9 4Aprl9 28Mar


-----

###### -19 28Mar -19 28Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 21Mar -19 14Mar -19
14Mar
###### -19 14Mar -19 14Mar -19 14Mar -19 14Mar -19 14Mar -19

US20190071
###### 423 US20190071 422 US20190071 421 US20190071 420 US20190071 419 US20190071 418 US20190062


-----

785
US20190062
###### 724
US20190062
713
US20190062
###### 408
US20190062
380

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
MULTIVALENT VACCINES FOR RABIES VIRUS AND
CORONOVIRUSES
RNA TARGETING METHODS AND COMPOSITIONS
HIGHLY EFFICIENT INFLUENZA MATRIX (Ml) PROTEINS
CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE
EPITOPE, AND METHODS OF USE
FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE,
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND
USE THEREOF
US20190062
326
US20190062
323
US20190060
###### 435
US20190060
###### 364
US20190060
363
US20190060
262
US20190060
239
US20190056
122
US20190055
###### 256
US20190055
241
US20190055
###### 234 US20190054
188


-----

###### US20190054
127
###### US20190054
122
US20190049
378
US20190048
###### 344
US20190048
082
###### 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1j2-A]PYRIDINE
DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS,
FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS
###### PI-Kinase Inhibitors with Anti-Infective Activity
PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR
INDUCING AN IMMUNE RESPONSE
INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF
THERAPY
INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF
THERAPY
ENHANCED EXPRESSION OF RNA VECTORS
###### Technology for the Preparation of Microparticles Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use Thereof ANTI-VIRAL DRUG
GUANIDINE SUBSTITUTED IMIDAZ0[4,5-c] RING COMPOUNDS
COMPOSITIONS AND METHODS FOR INHIBITING KINASES
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
###### ANTIVIRAL AGENT AND ANTIVIRAL FOOD
INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF
THERAPY
CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC
ACID AMPLIFICATION ASSAYS
CHEMICAL MODIFICATIONS OF MONOMERS AND
OLIGONUCLEOTIDES WITH CYCLOADDITION
PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
POLYPEPTIDES
###### Fauci/COVID-19 Dossier SNot Available Not Available Not Available Not Available Not Available Not Available Not Available Salk Institute for Biological Studies Not Available Not Available Not Available FeblS SFeblS SFeblS


-----

###### SFeblS SFeblS SFeblS 4Aprl6 22Augl7 11JU1-03
25Aug08
###### 7Sepl2
10BAYER
PHARMA AKTIENGESELLSCHAFT
###### DeclS 26N0t Available
The United States of America, as represented by the
###### Secretary, Dept of Health and Human Service Not Available Not Available UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH Not Available Synexis LLC
DORING INTERNATIONAL GMBH
###### Not Available Not Available Not Available
EDUCATIONAL CORPORATION MUKOGAWA GAKUIN
###### Not Available Not Available Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Febl6 27Febl6 31JU1-15 31JU1-15 25Marl3 243U1-07 20Aprl5 24Febl6 31Augl5 23Aprl5
30Sep03
###### 4Marl6 31JU1-15 10Mar05
23Sep08
###### 303unl6
2Nov
###### -18
2Nov
###### -18
2Nov
###### -18
2Nov
###### -18


-----

2Nov
###### -18
2Nov
###### -18
31Mar
###### -17 27Mar -18 22Mar -18 201un -18
28Aug
###### -18
7Dec
###### -16 24Feb -17 27Feb -17
6N0V
###### -18
6Nov
###### -18
5Sep
###### -18 170ct -18 20Apr -16 24Feb -17 220ct -18 240ct -18 20ct -18
22NOV
###### -16
5Nov
###### -18 213un -18
16Aug
###### -18 250ct -18
83
7Mar
###### -19
7Mar
###### -19
7Mar


-----

###### -19

7Mar

###### -19

7Mar

###### -19

7Mar

###### -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 28Feb
 -19
 21Feb
 -19
 21Feb
 -19
 21Feb
 -19
 21Feb
 -19
 21Feb
 -19
 21Feb
 -19
 21Feb
 -19
 14Feb
 -19
 14Feb
 -19
 14Feb
 -19

US20190048

049
US20190048


-----

###### 026
US20190046
###### 690
US20190046
###### 654
US20190046
635
US20190040
###### 451
US20190040
378
US20190040
370
US20190040
105
US20190038
742
US20190032
077
US20190032
041
US20190031
###### 740
US20190031
679
US20190031
605
US20190030
187
US20190030
###### 094
US20190025
292
###### US20190024 096
US20190023
799
US20190023
779
US20190023
769
US20190022
249
US20190022
###### 216
US20190022
###### 214
US20190022
213
US20190022
###### 116
US20190017
112
US20190017


-----

068
10CARGOMERS
###### Boron-Containing Small Molecules
MATERIALS WITH IMPROVED PROPERTIES
CERENIS THERAPEUTICS HOLDING SA
###### Anacor Pharmaceuticals, Inc. Not Available
ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF Not Available
COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND
VACCINE PHARMACEUTICAL COMPOSITION
FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC
NUCLEIC ACID SEQUENCES
NOVEL NUCLEIC ACID MOLECULES
TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR
DELIVERY OF CRISPR/CAS9
###### Method for Preventing and Treating Hyperpermeability
MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND
METHODS FOR USING THE SAME
###### ARTIFICIAL NUCLEIC ACID MOLECULES
NITTO DENKO CORPORATION
###### Not Available Not Available Not Available Not Available Longeveron LLC CureVac AG
COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available
COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY
CONSTRUCTS AND USES THEREOF
NOVEL MONOTHIOL MUCOLYTIC AGENTS
TETRAHYDRONAPHTHALENE DERIVATIVE
###### sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection
BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR
TREATING RESPIRATORY DISORDERS
ANTIGEN PRESENTING CELL ASSAY
###### Not Available Not Available
ONO PHARMACEUTICAL CO., LTD.
###### Sirnaomics, Inc. Not Available University of Pittsburgh - Of the Commonwealth System of Higher Education
PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL Not Available
GITR Antibodies And Methods Of Inducing Or Enhancing An Immune
###### Response
METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH
DESIRED SPECIFICITY
COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN
INFECTION
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
###### ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES


-----

THEREOF
###### Attenuated Infectious Bronchitis Virus
MERS-CoV Vaccine
###### N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE
PROTECTION

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
HTG Molecular Diagnostics, Inc.
###### Not Available Augl? 16Feb05 iNovlS 9Augl7 2Febl6 81anl6 4-JU117
23NOV15
5Mar09
###### 4Febl6 30Decl3 21Feb06 13Mayl4 303anl5 293anl6 SSeplS 273anl6 8Aprl0 7Augl5 25Mar05 28Decll 29Octl2
30Sep03
###### 230ctl5 273anl6
29NOV13
###### 26Decl4 HFeblG
17Dec01
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
10Aug
###### -18 18Oct


-----

###### -18
2Nov
###### -16
9Aug
###### -18 iFeb -17
91an
###### -17 3JU118
3Aug
###### -18 190ct -18
2Feb
###### -17 9JU118 12Feb -18 150ct -18
5Sep
###### -18 271an -17
7Sep
###### -16 271an -17
25Sep
###### -18
7Aug
###### -15 281un -18 5Oct -18
21Sep
###### -18 2Oct -18
4Sep
###### -18 261an -17 291un -18
16Dec
###### -15 10Feb -17
26Sep
###### -18 84


-----

###### 14Feb -19 14Feb -19 14Feb -19 14Feb -19 14Feb -19
7Feb
###### -19
7Feb
###### -19
7Feb
###### -19
7Feb
###### -19
7Feb
###### -19 31Janl9 31Janl9 313anl9 313anl9 313anl9 313anl9 313anl9 243anl9 243anl9 243anl9 243anl9 243anl9 243anl9 243anl9 243anl9 243anl9 243anl9 173anl9 173anl9

US20190017
###### 000
US20190016
785
US20190016
772
US20190016
###### 710
US20190016
###### 690
US20190015
527
US20190015
522
US20190015


-----

501
US20190015
###### 432
US20190010
###### 469
US20190010
###### 240
US20190010
132
US20190008
###### 954
US20190008
948
US20190008
833
###### US20190004
061
US20190002
###### 477
US20190002
###### 448
US20190002
393
US20190001
###### 010
US20190000
959
US20190000
745
US20180372
747
US20180372
733
US20180371
536
US20180371
###### 461
US20180371
###### 410
US20180369
386
US20180369
###### 364
8CLEANING
COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available
ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS
AND USES THEREOF
GM-CSF and IL-4 Conjugates, Compositions, and Methods Related
###### Thereto
MULTICYCLIC COMPOUNDS AND USES THEREOF
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE


-----

THEREOF
NUCLEIC ACID VACCINES
###### Lipid Disulfide Prodrugs and Uses Related Thereto
ATTENUATED VIRUSES USEFUL FOR VACCINES
COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF
SUPERFAMILY LIGAND
ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
SODIUM CHANNEL BLOCKING COMPOUNDS
NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES
FOR IMMUNOSTIMULATION
NUCLEIC ACID VACCINES
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
DETECTING TARGETS USING MASS TAGS AND MASS
SPECTROMETRY
###### ANTI-VIRAL COMPOUNDSj PHARMACEUTICAL COMPOSITIONS, AND
METHODS OF USE THEREOF
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
AND USES THEREOF
###### Lipids and Lipid Compositions for the Delivery of Active Agents ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND
METHODS THEREOF
NUCLEIC ACID VACCINES
POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS
OF USE THEREOF
METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE
TUMOR TISSUE
ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR
MAKING AND USING SUCH CONJUGATES
METHODS FOR RNA QUANTIFICATION
APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES,
SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS
VIRUSES AND TREATING PRRS VIRUS INFECTION
###### Not Available Not Available Not Available Not Available Not Available Not Available ModernaTX, Inc. Not Available Not Available Not Available Parion Sciences, Inc. CureVac AG ModernaTX, Inc. Not Available Not Available Kineta, Inc. Not Available Not Available Not Available ModernaTX, Inc. exion labs Inc. Not Available


-----

###### Not Available Not Available Sepl6 7Octl5 230ctl2 31Decl5 31Decl5
30Sep03
###### 5Aprl2 23Aprl4 13JU1-17 30Mar07 15Marl3 13Decl3 313anl2 23Aprl4 9Mayl2 2-JU110 9Mayl4 31Decl5 5Sepl4 8Decl4 23Aprl4 283ul-16
22NOV15
###### 27Aprl0 13unl5 10Not Available DeclS
4MEANS
AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available
###### LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
AGENTS
RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE
IMMUNODEFICIENCY VIRUS GAG PROTEIN
###### Fauci/COVID-19 Dossier Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
Dec09
###### 8Marl3 2-3U115
19Sep
###### -18 7Oct -16 2Oct -18
29Dec
###### -16
30Dec
###### -16
253U118


-----

###### 19JU118
27Sep
###### -18

131U118
163U118
2Aug
###### -18 4Apr -18 lUun -18
 16JU118 17JU118
4Aug
###### -18
311an
###### -18
29Dec
###### -16
19Sep
###### -18
 13JU118 273ull8
4Sep
###### -18
21May
###### -18 213un -18
26May
###### -16 iDec -16
28Aug
###### -18
29Aug
###### -18
 1JU116
85
###### 173anl9 173anl9 173anl9 173anl9 173anl9 173anl9 173anl9 173anl9 173anl9 103anl9 103anl9 103anl9 103anl9 103anl9 103anl9


-----

###### 3:anl9 33anl9 33anl9 33anl9 33anl9 33anl9 33anl9
27Dec
###### -18
27Dec
###### -18
27Dec
###### -18
27Dec
###### -18
27Dec
###### -18
27Dec
###### -18
27Dec
###### -18

US20180368
###### 417
US20180365
375
US20180363
027
US20180362
625
US20180360
877
US20180360
###### 736
US20180355
017
US20180353
###### 594
US20180346
###### 574
US20180346
573
US20180346
522
US20180346
516
US20180346
###### 485
US20180346
###### 480 US20180344
877
###### US20180344
832
###### US20180344


-----

751
US20180340
219
US20180340
218
US20180340
215
US20180340
###### 154
US20180340
153
US20180339
991
US20180339
988
US20180339
###### 014 US20180334 480
US20180333
###### 485
US20180327
###### 800
23ANTIMICROBIAL
COMPOSITIONS AND METHODS
METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC
CLASSIFICATION
###### STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
RIBONUCLEIC ACID
REGULATION OF CYTOKINE PRODUCTION
METHODS FOR EXPANDING A POPULATION OF ALVEOLAR
MACROPHAGES IN A LONG TERM CULTURE
###### FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE
PARTICLES
COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
###### Not Available Not Available Not Available Not Available Not Available Intelgenx Corp. Not Available
METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available
###### ANTI-PD-L1 ANTIBODIES AND USES THEREOF ANTI-PD-L1 ANTIBODIES AND USES THEREOF
HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS,
NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM,
AND METHODS OF USING THE SAME
PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS
ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS
THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS


-----

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
EXPRESSION IN LIVER AND USE THEREOF
METHODS AND COMPOSITIONS FOR COMBINATION
IMMUNOTHERAPY
###### Broad Spectrum Antiviral and Methods of Use
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET
SEQUENCE
PRODUCTION OF VIRUSES IN AVIAN EGGS
PRODUCTION OF VIRUSES IN CELL CULTURE
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS
PEPTIDOMIMETIC MACROCYCLES
CORONAVIRUSES EPITOPE-BASED VACCINES
###### Compositions, Comprising Improved 11-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
OF B CELLS
###### Fauci/COVID-19 Dossier Not Available Not Available Sepl4 24Aprl5 6Oct06 4Decl5 SDeclS 2Decl3 7Iunl7 26JU1-13 133unl6 133unl6 10Not Available Aprl2 27Not Available Not Available Not Available Children's Healthcare of Atlanta, Inc. Not Available Not Available
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
###### Not Available Not Available Not Available Not Available Not Available Not Available
RAMOT AT TEL-AVIV UNIVERSITY LTD.
###### Not Available


-----

###### Not Available Novl5 5Febl5 5Febl5 16Aprl5 20Aprl5 17Apr06 9Decl6
9D6C16
###### 28Augl5
24NOV15
24NOV15
30D6C14
###### 30Decl4 143an09 17Sepl5 12Decll 26Feb03 CC-BY-NC-SA Dr. David E. Martin 193un
 -18
 40ct
 -17

15May

###### -18

2Dec

###### -16

8Dec

###### -16

23Aug

###### -18
 63un
 -18
 21Aug
 -18

9Aug

###### -18

9Aug

###### -18

6Aug

###### -18

28NOV

###### -16
 27Feb
 -18
 IMar
 -18
8Aug

###### -18
 20Apr
 -16

26Dec

###### -17


-----

9Mar
###### -18
9Mar
###### -18
26Aug
###### -16
23NOV
###### -16
23NOV
###### -16
24May
###### -18 183an -18 73un -18
15Sep
###### -16
9May
###### -18
21May
###### -18
86
27Dec
###### -18
20Dec
###### -18
20Dec
###### -18
20Dec
###### -18
20Dec
###### -18
20Dec
###### -18
13Dec
###### -18
13Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec
###### -18
6Dec


-----

###### -18
6Dec
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
29NOV
###### -18
22NOV
###### -18
22NOV
###### -18
15N0V
###### -18
 US20180327 738
US20180327
697
US20180327
###### 484 US20180326 070 US20180326 051 US20180326 045 US20180326 044
US20180326
039
US20180325
###### 076
US20180321
242
US20180319
811
US20180319
779
US20180318
###### 447
US20180318
366
US20180318


-----

350
US20180312
575
US20180312
545
US20180312
###### 544
US20180311
338
US20180311
273
US20180305
773
US20180305
###### 760
US20180305
###### 451
US20180305
###### 412
US20180305
357
US20180305
356
US20180303
###### 874
US20180303
768
US20180303
###### 090 20STABILIZED
REAGENTS FOR GENOME MODIFICATION
###### Not Available
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available
###### RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING
THEM
CARBOHYDRATE CON3UGATES AS DELIVERY AGENTS FOR
OLIGONUCLEOTIDES
###### LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONS, FORMULATIONS, AND METHODS
COMBINATION PIV3/HMPV RNA VACCINES
NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES,
THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL
APPLICATIONS
VACCINE COMPOSITIONS
ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL
POLYMERIC BINDING SYSTEM
###### VIRAL BIOMARKERS AND USES THEREFOR
DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION
AND THEIR USE FOR TREATING VIRAL INFECTIONS
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
AND USES THEREOF
COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR
EFFICIENCY
METHOD OF TREATMENT USING ONCOLYTIC VIRUSES


-----

Immune Cells with DNMT3A Gene Modifications and Methods
###### Related Thereto
ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE
THEREOF
OPTIMIZED NUCLEIC ACID MOLECULES
RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3
###### (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND
USES THEREOF
MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME
###### Method of Treating Inflammation
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA
DETECTION
###### Pathogen biomarkers and uses therefor HIDEl COMPOSITIONS AND METHODS
COMPOSITIONS AND METHODS FOR TREATING DISEASES BY
###### INHIBITING EXOSOME RELEASE
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS
NOVEL KINASE INHIBITORS
###### Not Available Not Available Not Available
ModernaTX., Inc.
###### Not Available Not Available
OXISCIENCE, LLC
###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
The United States of America, as represented by the
###### Secretary, Dept, of Health and Human Services Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Compositions and Methods for the Prevention of Microbial Infections Not Available
DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL
BENEFIT
###### Fauci/COVID-19 Dossier Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### NovlS


-----

###### 8Sepl6 Uun07 4Dec07 17Augl0 220ctl5 130ctl5 16Sepl5 28Augl4
6NOV15
###### 30Octl5 3-JU113 3Decl5 153unl5
4NOV15
###### 6Dec07
9NOV15
###### 203anl5 lUanie lAprl0 12Aprl7 30Sepl5 13JU1-15 19Decl6 22Dec06 190ctl2
10NOV11
###### 303anl5 30Octl5
18Nov
###### -16 123un -18
233U118
20Nov
###### -17 243ull8 203ull8 130ct -16
16Sep
###### -16 243ull8
4Nov
###### -16 280ct -16
4Dec
###### -17
30NOV
###### -16 153un -16
4Nov
###### -16


-----

###### 20Mar -18
9Nov
###### -16 201an -16
111U118
###### 261un -18 12Apr -18
30Sep
###### -16 13JU116 93ull8 253un -18
18May
###### -18
30Nov
###### -17 23ull8 170ct -16
87
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
15N0V
###### -18
8Nov
###### -18
8Nov
###### -18
8Nov
###### -18
8Nov
###### -18
8Nov
###### -18
8Nov


-----

###### -18 INov -18 INov -18 INov -18 INov -18 INov -18 250ctl8 250ctl8 250ctl8 25Octl8 250ctl8 250ctl8 250ctl8 250ctl8 250ctl8

US20180267
###### 031 US20180265
847
###### US20180265
822
###### US20180265 574 US20180265
507
###### US20180264 098 US20180258
162
###### US20180258 160 US20180258
159
###### US20180258
151
###### US20180251
737
###### US20180251
540
###### US20180251 436
US20180250
602
US20180250
381
###### US20180245 056
US20180245
053


-----

###### US20180244
759
###### US20180244 756 US20180244
669
###### US20180244 660
US20180243
347
US20180237
835
US20180237
788
US20180237
###### 786
US20180237
502
US20180237
###### 435
US20180236
058
US20180236
###### 054
METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC
ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING
NEODYMIUM MAGNETS
The U.S.A.j as represented by the Secretary^ Department
###### of Health and Human Services
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
###### LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE
THEREOF
###### Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
VIRUSES
MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF
SYNONYMOUS CODONS
###### Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections Optimized Crosslinkers for Trapping a Target on a Substrate
COMPOSITIONS AND METHODS FOR THE TREATMENT OF
IMMUNODEFICIENCY
RECOMBINANT SUPER-COMPOUND INTERFERON AND USES
THEREOF
COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL
GROWTH
###### Not Available Not Available Not Available Dana-Farber Cancer Institute, Inc.
The Government of the USA as represented by the
###### Secretary of the Dept, of Health and Human Service Not Available


-----

###### Not Available Not Available Not Available Not Available
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available
CERTAIN (2S)-N-[(IS)-1-CYANO-2-PHENYLETHYL]-lj40XAZEPANE-2-CARB0XAMIDES
AS DIPEPTIDYL PEPTIDASE 1
###### INHIBITORS
PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
STIMULATION OF THE INNATE IMMUNE RESPONSE
###### Not Available Not Available
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available
COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
###### ACTIVITYj AND RELATED METHODS VIRAL VACCINES AND METHODS OF FORMING THE SAME
NOVEL METHODS OF GENERATING ANTIBODIES
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
IMMUNOGENS, ANTIBODIES, AND THEIR USE
###### IMIDAZO[4,5-C] RING COMPOUNDS CONTAINING SUBSTITUTED
GUANIDINE GROUPS
CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE
###### INHIBITORS
IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE
THEREOF
METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS
IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION
###### ARTIFICIAL NUCLEIC ACID MOLECULES
PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES,
###### ANTIBODIES, AND ANTIBODY COCKTAILS
GUANIDINE SUBSTITUTED IMIDAZ0[4,5-c] RING COMPOUNDS
REVERSE GENETICS SYSTEMS
###### Tetanus Toxoid and CCL3 Improve DC Vaccines Not Available Not Available Rutgers, The State University of New lersey
The United States of America, as Represented by the
###### Secretary, Dept, of Health and Human Services Not Available Not Available Not Available American International Biotechnology, LLC
The Regents of the University of California
CUREVAC AG
###### Integrated BioTherapeutics, Inc. Not Available Not Available
Duke University
###### iSeplS 18Novl3 8Sepl6 iSMarl? HAprl2 8Oct04


-----

###### 2:anl5
13NOV15
###### 280ctl4 28Feb01
5Dec08
16Dec02
###### 243anl4 llFebl4 20Augl0
19NOV09
###### 27Febl7 19Augl5 24Febl5 31Augl5 17Augl5 25Augl5 31JU1-15 8Augl5 28Augl5 HMarlS 31Augl5 313ul-09
14NOV13
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
8Aug
###### -16 29Mar -18
21May
###### -18 iSMar -17 263an -18
31May
###### -18
22May
###### -18 llMay -18
14May
###### -18
2Mar
###### -18
28Dec
###### -17 30Apr -18
19Sep
###### -17 iMay -18


-----

###### 120ct -17 90ct -17 27Feb -18
18Aug
###### -16 24Feb -16
26Aug
###### -16
17Aug
###### -16
22Aug
###### -16 29JU116
5Aug
###### -16
22Aug
###### -16 llMar -16
26Aug
###### -16 160ct -17 19Apr -18
88
20Sep
###### -18
20Sep
###### -18
20Sep
###### -18
20Sep
###### -18
20Sep
###### -18
20Sep
###### -18
13Sep
###### -18
13Sep
###### -18
13Sep
###### -18
13Sep
###### -18
6Sep
###### -18
6Sep
###### -18


-----

6Sep
###### -18
6Sep
###### -18
6Sep
###### -18
30Aug
###### -18
30Aug
###### -18
30Aug
###### -18
30Aug
###### -18
30Aug
###### -18
30Aug
###### -18
30Aug
###### -18 23Aug -18 23Aug -18 23Aug -18 23Aug -18 23Aug -18

23Aug
###### -18
23Aug
###### -18
 US20180235 948
US20180230
521
US20180230
###### 447 US20180228
695
###### US20180223 290 US20180222 906 US20180221 464
US20180216
###### 164
US20180216
###### 067 US20180215
831


-----

US20180215
801
US20180215
###### 794 US20180214 430
US20180209
###### 960
US20180208
897
US20180208
659
US20180208
653
US20180207
258
US20180207
145
US20180201
998
US20180201
907
US20180201
687
US20180200
365
US20180200
###### 364
US20180200
###### 224
US20180200
###### 196
US20180196
061
US20180195
048

###### (S,E)-3-(6-AMIN0PYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3METHYLPYRROLIDINE-1-CARBONYL)P
HENYL)-7-(4FLU0R0PHENYL)BENZ0FURAN-2-YL)METHYL)ACRYLAMIDE
FOR THE
TREATMENT OF CANCER
BIOAGENT DETECTION OLIGONUCLEOTIDES
ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN
CONVERTING ENZYME 2 (ACE2)
DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF
ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN
AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS
METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING
###### INHIBITORY GENE PRODUCTS
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
IMIDAZONAPHTHYRIDINES
IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS,
AND METHODS OF GENERATING IMMUNE RESPONSES
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES


-----

###### 18Not
 Available AuglS 27Not Available Northwestern University Decll 241anl7 UNot Available AuglS lOGenVeCj Inc.
3M Innovative Properties Company
###### Not Available Not Available Not Available
 Antibody Derivatives with Conditionally Enabled Effector Function Not Available
CRYPTIC POLYPEPTIDES AND USES THEREOF
TREATING CANCER WITH VIRAL NUCLEIC ACID
###### Selective Inhibitors Of i-NOS For Use Against Viral Infection Method of Determining., Identifying or Isolating Cell-Penetrating Peptides
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
###### ANTI-PD-L1 ANTIBODIES AND USES THEREOF
METHODS FOR ENHANCING AN IMMUNE RESPONSE
AD3UVANTED INFLUENZA VACCINES FOR PEDIATRIC USE
PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR
TREATING INFECTIOUS DISEASES
COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC
DEAFNESS GENE MUTATION
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES
ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES
THEREOF
###### Methods and Compositions for Inhibiting Akt3 LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONSj FORMULATIONSj AND METHODS
###### Antiviral Activity from Medicinal Mushrooms and Their Active Constituents Modular Particulars for Immunotherapy
INFLUENZA POTENCY ASSAYS
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION
###### Not Available
Mayo Foundation for Medical Education and Research
UCL Business PLC
###### Not Available Not Available Not Available Not Available Not Available GlaxoSmithKline Intellectual Property (No. 2) Limited CapitalBio Corporation Not Available Not Available


-----

###### Not Available
3M Innovative Properties Company
###### Not Available Not Available Not Available Takeda Vaccines, Inc.
NOV05
###### 18Iun04 3Augl5
15NOV06
18NOV13
###### 273U1-15 293anl5 20Feb07 173U1-15 23Mayll
18NOV13
###### 133unl6 203anl7 22Feb08 12Mayl4 143U1-15 263anl2 7-3U115 173anl7 17Augl0 31Marl5
1NOV13
###### 7-3U115 13Febl5 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
18Aug
###### -16 13Apr -18
243 an
###### -18 HAug -16
7Sep
###### -17
9Apr
###### -18
3Aug
###### -16 19Mar -18 29Mar -18 273U116 293an -16


-----

###### 27Mar -18 15JU116 llDec -17 19Mar -18 13Jun -17 19Jan -18
5Mar
###### -18 19Mar -18
 14JU115 13Mar -18
7311116
###### 20Feb -18
27NOV
###### -17 12Mar -18
31an
###### -18
7311116
###### 12Feb -16
89
23Aug
###### -18
16Aug
###### -18
16Aug
###### -18
16Aug
###### -18
9Aug
###### -18

9Aug
###### -18

9Aug
###### -18

2Aug
###### -18

2Aug
###### -18

2Aug
###### -18

2Aug
###### -18

2Aug


-----

###### -18
2Aug
###### -18 26JU118 26JU118 26JU118 26JU118 26JU118 26JU118 19JU118 19JU118 19JU118 19JU118 19JU118 19JU118 19JU118
121U118
121U118

###### US20180194 850 US20180194
829
###### US20180194
735
US20180193
###### 477
US20180187
213
US20180187
211
US20180187
165
US20180187
###### 154
US20180187
153
US20180187
131
US20180186
897
US20180186
821
US20180186
802
US20180186
792
US20180186
###### 534
US20180185
###### 469
US20180185
392
US20180185
345


-----

US20180180
###### 544
US20180179
300
US20180179
###### 274
US20180177
863
US20180177
862
US20180177
###### 860
US20180163
182
US20180162
838
US20180162
835
US20180161
###### 425
ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR
SUPERFAMILY ANTIBODIES
###### 15Not Available
POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
###### Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines Not Available Hoffmann La-Roche Inc.
DRUG-CON3UGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS Not Available
###### Variant AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues
METHODS AND COMPOSITIONS FOR COMBINATION
IMMUNOTHERAPY
HAND, FOOT, AND MOUTH VACCINES AND METHODS OF
MANUFACTURE AND USE THEREOF
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
###### DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME
AND USE THEREOF
The Children's Hospital of Philadelphia
###### Not Available Takeda Vaccines, Inc. Not Available Not Available
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX
ENERGIES ALTERNATIVES
NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA Not Available
PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN
EMBEDDED TISSUE USING CAGED HAPTENS
COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
AGONISTS
HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL
SEGMENTS AND IMMUNE RESPONSE MODIFIER CON3UGATES MADE


-----

THEREFROM
###### Powdered Pouch And Method Of Making Same
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
###### Pharmaceutical Compositions and Methods
METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS
INDUCED CONDITIONS
USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
DETERIORATED PERFORMANCE OF A FLUOROMETER
GENERATION OF BINDING MOLECULES
PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES
THEREOF
METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES
###### ANTIGENICALLY MATCHED INFLUENZA VACCINES
VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA
EXTRACT, AND PREPARATION METHOD THEREFOR
PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC
###### ACID-CONTAINING COMPOSITIONS Chemical Compounds
QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY
PRODUCTION IN IMMUNIZATION
###### Not Available Not Available
3M Innovative Properties Company
MONOSOL, LLC
###### Not Available Not Available Not Available Not Available
Menus N.V.
###### Not Available Not Available Not Available Not Available
Human Services
###### Not Available Not Available Not Available MaylS ISAprll 17Sepl5 15JU1-15 22JU1-13 93anl5
7NOV14
18NOV13
18NOV13
###### 163unl5 263unl5 28Augl5 IMaylA 33unll


-----

###### 16Aprl2 24Aprl2 3Augl5 193unl5 143unl2 26Sepll 263unl5 23Sepl5 263unl5 lUunlS 103unl5 18Marl4 5Febl5 10Decl4
13May
###### -16
13N0V
###### -17
8Mar
###### -18
 15JU116
6Dec
###### -17 73an -16 270ct -17 20Feb -18 20Feb -18 153un -16

243 un
###### -16 28Feb -18 27Feb -18 26Feb -18
29Dec
###### -17

14Dec
###### -17
29NOV
###### -17 173un -16 22Feb -18
22NOV
###### -17

243 un


-----

###### -16 310ct -17

241 un

###### -16
 71un
 -16
 101un
 -16

13Dec

###### -17 llDec -17

10Dec

###### -15

121U118
121U118
121U118
121U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
53U118
###### 281unl8 281unl8 281unl8 281unl8 281unl8 281unl8 141unl8 141unl8 141unl8 141unl8 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 90

US20180161

###### 422
US20180161
279
US20180160
662
US20180149


-----

659
US20180148
727
US20180142
239
US20180142
198
US20180142
###### 006
US20180142
005
US20180142
###### 004
US20180142
003
US20180142
002
US20180140
659
US20180140
625
US20180140
580
US20180135
099
US20180135
012
###### US20180134
783
###### US20180134 770
US20180133
###### 246
US20180127
###### 836
US20180127
783
US20180127
###### 384
US20180125
965
US20180125
952
US20180125
883
US20180112
###### 270
US20180111
991
NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEMLOOP
AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL
FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC
ANTIGEN
GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR


-----

OPROZOMIB AND PROCESS TO MAKE THEREOF
###### iSCureVac
AG
###### Febl2 14N0t Available Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Institut Pasteur
DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE Not Available
###### ARTIFICIAL NUCLEIC ACID MOLECULES
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
OR OTHER DISEASES
DELIVERY OF BIOMOLECULES TO IMMUNE CELLS
ANTIBODY PRODUCING NON-HUMAN ANIMALS
ANTIBODY PRODUCING NON-HUMAN ANIMALS
ANTIBODY PRODUCING NON-HUMAN ANIMALS
ANTIBODY PRODUCING NON-HUMAN ANIMALS
ANTIBODY PRODUCING NON-HUMAN ANIMALS
ANALOGS OF CSa AND METHODS OF USING SAME
PRODUCTION OF STABLE NON-POLYADENYLATED RNAS
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE
THEREOF
MEMBRANE-RECEIVER COMPLEX THERAPEUTICS
###### Not Available Not Available Not Available Merus N.V. Merus N.V. Merus N.V. Merus N.V. Merus N.V. Not Available Massachusetts Institute of Technology Not Available Not Available Not Available
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available
ANTIBODY PRODUCING NON-HUMAN ANIMALS
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF
VIRUSES
CRISPR-RELATED METHODS AND COMPOSITIONS WITH
GOVERNING gRNAS
HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND
USES THEREOF
HAND, FOOT, AND MOUTH VACCINES AND METHODS OF
MANUFACTURE AND USE THEREOF
PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT
LEAST ONE mRNA CONSTRUCT
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
C-CBL MUTATIONS AND USES THEREOF


-----

MODULATORS OF ACTIVIN AND METHODS FOR MODULATING
IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS
Menus N.V.
###### Not Available Not Available
EDITAS MEDICINEj INC.
###### Not Available Takeda Vaccines, Inc. Not Available Not Available Not Available Not Available Decl6 26Marl2 Alums

30D6C14
###### 2613007 310ctl4 271un08 271un08 271un08 271un08 271un08 291unl0 160ctl2
29NOV02
23D6C05
###### 13Mayl5
16D6C02
###### 271un08 7Marl2 7Mayl5
7NOV13
###### 291U1-11
7NOV14
###### ISMaylS 7Marl2 41unl0 2Decl4
8Feb

###### -18

13Dec

###### -17
 251an
 -18
31un
###### -16

29Dec

###### -15

141 un

###### -17 30Oct -15
 121an


-----

Xewizz
###### 8T-

 8T-

 8T-

 8T-
 Aewis 8T-
 Aewis STuncvx STuncvx STuncvx
 L1- uncz 9T-
viewzz

###### L1-
d9S0Z
###### 9T- Aewsi
ST-

A0N9

###### L1- uridz
 L1-

AON62
###### 9T-
Xewg
###### L1-
AONT
###### 8T- ueczx 9T-
vidv93
###### 9T-

Aew£T
###### 8T- uecz
 L1-

IDOEZ

ZTinCTS
###### 8T- ueczx 8T- uecs 8T- uec6 8T-
UBCTT
###### 8T- ueczx 8T-


-----

###### -18
24May
###### -18
24May
###### -18
24May
###### -18
24May
###### -18
24May
###### -18
24May
###### -18
17May
###### -18
17May
###### -18
17May
###### -18
17May
###### -18
17May
###### -18
10May
###### -18
10May
###### -18
10May
###### -18
10May
###### -18
10May
###### -18
10May
###### -18 26Aprl8 26Aprl8 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
91

US20180111

907
US20180110
845
US20180105
815
US20180105
596
US20180105
###### 514 US20180104
241
US20180100


-----

181
US20180099
999
US20180098
972
US20180092
932
US20180087
049
US20180086
818
US20180085
###### 457
US20180085
###### 432
US20180085
388
US20180079
###### 746
US20180078
625
US20180078
532
US20180078
507
US20180073
073
US20180072
813
US20180072
###### 796
US20180072
752
US20180071
219
US20180067
299
US20180066
228
US20180066
###### 216
US20180065
981
DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER
MUCOSAL DISEASES
METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN
AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
###### Bivalent siRNA Chimeras and Methods of Use Thereof ANTI-TYRO3 ANTIBODIES AND USES THEREOF
HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS
CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE
POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS


-----

FOR USE IN PRACTICING THE SAME
FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR
USING RECOMBINANT BACTERIA
TREATMENT OF INFECTIOUS DISEASES
###### Anti-Viral Azide Containing Compounds MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN
RAPID CLOT TUBES
COMPOSITIONS AND METHODS FOR THE TREATMENT OF
IMMUNODEFICIENCY
###### ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES
THEREOF
STING (Stimulator of Interferon Genes), A Regulator of Innate
Immune Responses
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
COMPOSITIONS AND METHODS FOR DELIVERY OF
BIOMACROMOLECULE AGENTS
IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB
BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN
ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES
THEREOF
METHODS AND COMPOSITIONS FOR LABELING TARGETS AND
HAPLOTYPE PHASING
CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF
USE THEREOF
MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
AND VIRAL INFECTION
COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL
COMPOSITION THEREOF, ITS PREPARATION AND USE
###### Technology for Preparation of Macromolecular Microspheres
ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION
MONITORING
###### Detection of T Cell Exhaustion or Lack of T Cell Costimulation and Uses Thereof 29Not Available Mayl2 31Not Available Not Available Not Available Not Available
PARION SCIENCES, INC.
###### Not Available Not Available
CHILDREN'S MEDICAL CENTER CORPORATION
###### Not Available Not Available Not Available Not Available Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available Not Available


-----

AMGEN INC.

###### Not Available Not Available Not Available Not Available Not Available Not Available
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
###### INSTITUTE Not Available
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available
HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE
ADENOSINE-A2B-RECEPTOR
###### Fauci/COVID-19 Dossier Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Aug07 18Octl6 17Aprl5 7Aprl6 27Junll 17Aprl5 17Sepl4 2613015 281U1-10 27Sepl6 280ctl4 230ctl5 4Aug08 6-1U110 19Marl5 25Marl5 21Sepl6 16Sepl6 18Marl5
2D6C05
###### 8Sepl6 30Marl5 243an06 7Sepl6 15Mayl5 8Sepl6 26Marl5
20Dec
###### -17
18Dec
###### -17 60ct -17 15Apr -16
33an
###### -18
15Dec


-----

###### -17 15Apr -16
14Dec
###### -17 263an -16
7Dec
###### -17
7Sep
###### -17
13Nov
###### -17 iDec -17
15Sep
###### -17 50ct -17 15Mar -16 25Mar -16
18Sep
###### -17
15Sep
###### -17 16Mar -16
9May
###### -17
17Nov
###### -17
2Feb
###### -16
25Sep
###### -17
31May
###### -17
15Nov
###### -17
6Sep
###### -17 21Mar -16
92
###### 26Aprl8 26Aprl8 19Aprl8 19Aprl8 19Aprl8 19Aprl8 12Aprl8 12Aprl8


-----

###### 12Aprl8 5Aprl8 29Mar -18
 29Mar
 -18
 29Mar
 -18
 29Mar
 -18
 29Mar
 -18
 22Mar
 -18
 22Mar
 -18
 22Mar
 -18
 22Mar
 -18
 15Mar
 -18
 15Mar
 -18
 15Mar
 -18
 15Mar
 -18
 15Mar
 -18

8Mar

###### -18

8Mar

###### -18

8Mar

###### -18

8Mar

###### -18
 US20180064 790 Composition for Treatment or Prevention of Infectious Inflammatory Diseases., or Composition for Immune Enhancement., Comprising Tryptophanyl-tRNA Synthetase as an Active Ingredient 26Not Available FeblS
25Aug
###### -17
8Mar
###### -18
 US20180064
752

###### ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF


-----

###### ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF
INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN
METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE
###### Not Available 29JU1-14 250ct -17
Mar
###### -18 8US20180058
988
US20180057
871
US20180057
841
US20180057
817
US20180057
###### 594
US20180057
509
US20180057
###### 488
US20180055
925
US20180055
769
US20180051
267
US20180051
###### 266
US20180050
059
###### US20180044
687
###### US20180044
328
US20180043
007
US20180037
952
US20180037
942
US20180037
871
US20180037
###### 636
US20180037
###### 634
US20180037


-----

617
US20180036
398
1SAMPLE
FIXATION AND STABILISATION
COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
VARIANTS
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR
###### Particle-Nucleic Acid Conjugates and Therapeutic Uses Related Thereto
PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
POLYPEPTIDES
ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
THIAZOLONAPHTHYRIDINES
COMPOSITIONS AND METHODS FOR INHIBITING KINASES
DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS
CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION
AND/OR HOMOGENIZATION OF EMULSIONS
TAL EFFECTOR-MEDIATED DNA MODIFICATION
TAL EFFECTOR-MEDIATED DNA MODIFICATION
DELIVERY OF RNA TO DIFFERENT CELL TYPES
###### ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN
EXPRESSION
PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I
###### INHIBITORS
INFLUENZA VIRUS VECTORS AND USES THEREFOR
SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD
CHEMISTRY ANALYSIS
ENZYME-INDEPENDENT MOLECULAR INDEXING
CANCER INITIATING CELL AND USE THEREOF
STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF
USE
ENGINEERED POLYPEPTIDES AND USES THEREOF
METHODS AND COMPOSITIONS FOR TREATING AND/OR
PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH
ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF
PROTEINS
FLAVIVIRUS REPLICONS
###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Not Available Not Available Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available Prozymex A/S Not Available


-----

###### Nanomedical Diagnostics, Inc. Not Available Not Available
DANA-FARBER CANCER INSTITUTE, INC.
###### Not Available Marl3 15Augl6 7Apr05 25Iunl2 30Iunl6 9Feb05 23Aprl5 3Marl5
3Dec09
10D6C09
10D6C09
###### 6-3U110 12Decl4 SMarlS 17Marl4 28Aprl4 3Augl6 8Augl6 183un09 2Augl6 22Institute of Biophysics, Chinese Academy of Sciences Augl4
 27Not
 Available
 FeblS
14Aug

###### -17

1NOV

###### -17
 27Oct
 -17
 9Oct
 -17

29Sep

###### -17

2Nov

###### -17

7Nov

###### -17

7Aug

###### -15
 263un
 -17 5Oct -17

21Aug

###### -17
30Aug


-----

###### -17 llDec -15 4Mar -16
21Aug
###### -17
21Aug
###### -17 lAug -17
8Aug
###### -16
21Sep
###### -17
2Aug
###### -17
21Aug
###### -15 25Feb -16 iMar -18 iMar -18 iMar -18 iMar -18 iMar -18 iMar -18 iMar -18 iMar -18 iMar -18 22Feb -18 22Feb -18 22Feb -18 15Feb -18 15Feb -18 15Feb -18
8Feb
###### -18
8Feb


-----

###### -18

8Feb

###### -18

8Feb

###### -18

8Feb

###### -18

8Feb

###### -18

8Feb

###### -18 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
93

###### US20180036

237
US20180031
555
US20180030
###### 429
US20180030
###### 411
US20180028
677
US20180028
###### 626
US20180028
562
US20180028
###### 449
US20180028
###### 431
US20180023
048
US20180022
781
US20180021
###### 448
US20180016
307
US20180016
285
US20180016
243
US20180015
###### 174
US20180015
052
US20180010
167
US20180010
125
US20180009


-----

787
US20180008
689
US20180002
743
US20180002
###### 406
US20180000
929
US20180000
###### 926
US20180000
868
US20180000
###### 724
US20170369
843
US20170369
###### 470
23OIL/SURFACTANT
MIXTURES FOR SELF-EMULSIFICATION
METHOD FOR SELECTING A SINGLE CELL EXPRESSING A
HETEROGENEOUS COMBINATION OF ANTIBODIES
###### Polypeptide Assemblies and Methods for the Production Thereof
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
###### Peptides for Assisting Delivery Across the Blood Brain Barrier
IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION
THERAPY
METHODS OF TREATING OR PREVENTING INFLAMMATION AND
###### HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL
WATER SOLUTION
###### Technology for the Preparation of Microparticles
POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS
OF USE THEREOF
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC
PROTEINS AND THEIR USE IN GENE THERAPY
###### Conjugates of Cell Binding Molecules with Cytotoxic Agents GRIFFITHSIN MUTANTS Boron-Containing Small Molecules
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS
SYNTHETIC NANOPARTICLES FOR DELIVERY OF
IMMUNOMODULATORY COMPOUNDS
DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
ORGANISM IDENTIFICATION PANEL
DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
AND METHODS OF USE THEREOF
NOVEL COMPOUNDS
RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL
ROBUSTNESS AND SEQUENCE SPACE
FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE
DETECTION OF TARGET RNA SEQUENCES
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE


-----

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND
METHODS OF USE THEREOF
METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C
VIRUS

###### Induced Hepatocytes and Uses Thereof

METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL
AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
###### Cyclic Compounds and Uses Thereof Fauci/COVID-19 Dossier

GLAXOSMITHKLINE BIOLOGICALS, SA
###### Merus N.V. Not Available Not Available Children's Medical Center Corporation Transgene SA
SONOMA PHARMACEUTICALS, INC.
###### Not Available exion labs Inc. Not Available
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
(CNRS)
###### Hangzhou DAC Biotech Co., Ltd.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Not Available Not Available Not Available Not Available Not Available Quark Pharmaceuticals Inc. CHIESI FARMACEUTICI S.P.A. Not Available Not Available
The United States of America, as represented by the
###### Secretary, Department of Health and Human Not Available Not Available Not Available Not Available Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### FeblS 271un08 27Febl5
18NOV13
22May06
###### 13Febl5 203an06 243U1-07 283U1-16 29Oct04 13Febl5


-----

###### 12DU1-12 10Febl5
20Dun07
###### 13Febl5 15JU1-16 303anl5 2Apr07 12Sepl2 31Mayl6 283anl5 183unl6 7Novll
30NOV12
###### 153anl5
26NOV14
###### 263ul-10
18NOV13
###### 16Decl4 23Feb -16
 18JU117 29Feb -16 130ct -17
303un
###### -17 12Feb -16
 10Oct
 -17
 273un -17
273U117
22Sep
###### -17 12Feb -16 16Apr -14 10Feb -16
28Sep
###### -17 12Feb -16 14JU117 283an -16
263U117
###### 15Feb
 -17

22Sep
###### -17


-----

STueciz
8TUBCV
8TUBCV
8TUBCV
8TUBCV

8TUBCTT
8TUBCTT
8TUBCTT
8TUBCTT
8TUBC8T
8TUBC8T
8TUBC8T
8TUBC8T
8TUBC8T
8TUBCSZ
8TUBCSZ
8TUBCSZ

###### 8T-
q9dT

###### 8T-
q9dT

###### 8T- qsdT
 8T- qsdT 8T-
 qsdT 8T-
 qsdT 8T-
 qsdT 8T-
 qsdT 8T-
 q9d8

V6
ST-
###### 39091
 L1-
viewez

###### L1-

ABW0T

###### L1-
d9SST
###### 9T-

UBCST

###### L1-
d9SVT

###### L1-
d9S8

###### L1- uncgx 9T-

UBC8Z


-----

###### 4:anl8
28Dec
###### -17
28Dec
###### -17

US20170368
203
US20170368
201
US20170368
167
US20170362
300
US20170362
297
US20170362
187
US20170362
###### 170
US20170360
962
US20170360
###### 960
US20170360
908
US20170360
881
US20170360
875
US20170358
082
###### US20170354
727
US20170348
###### 433
US20170348
###### 402
US20170348
369
US20170342
###### 442
US20170342
###### 405
US20170342
###### 056
US20170340
735
US20170340
725
US20170340
721
US20170340
611
US20170337


-----

###### 459
US20170336
###### 412
US20170336
###### 411
US20170335
###### 408 29Compositions For Enhancing Transport Of Molecules Into Cells
SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT
###### LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE
SYSTEM
COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL
DISORDERS
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA
###### Not Available
The Children's Hospital of Philadelphia
###### Not Available Not Available
CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Not Available
###### 3j5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2- CARBOXAMIDE COMPOUNDS
###### HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS
NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS
RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES
AAV Vectors Targeted to the Central Nervous System
VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED
IMMUNITY CONTAINING BISPHOSPHONATES
PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
###### Parion Sciences^ Inc. Not Available Not Available Not Available
NITTO DENKO CORPORATION
###### Not Available
METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS MIDDLE TENNESSEE STATE
###### UNIVERSITY
STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING
MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF
SYNONYMOUS CODONS
NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS
RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES
SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR
PROTEIN TO CELLS
###### Plant Extract and Its Therapeutic Use
RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA
MOLECULES
MOLECULAR INDEXING OF INTERNAL SEQUENCES
NOVEL COMPOUNDS
###### Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof
COMBINATION PIV3/HMPV RNA VACCINES
METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
RESPONSES
NOVEL COMPOUNDS


-----

SPATIALLY ADDRESSABLE MOLECULAR BARCODING
###### Multiplex Immuno Screening Assay
B-CELL ANTIGEN PRESENTING CELL ASSAY
###### Methods and Systems of Multi-Assay Processing and Analysis Not Available Not Available
The Board of Trustees of the Leland Stanford Junior
###### University Not Available Not Available
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available CHIESI FARMACEUTICI S.P.A. Not Available ModernaTXj Inc. Not Available CHIESI FARMACEUTICI S.P.A. Not Available Institut Pasteur
The University of Pittsburgh      - Of the Commonwealth
###### System of Higher Education Not Available
 Apr03
 15Marl3 21Augl2 4Jan06 19Decl4 17Decl2
3Aug07
###### 16Febl6
21NOV14
###### 3Sepl4 17Junl6 22Decl4 15Marl3 8Oct04 16Febl6 30JU1-14
16May08
###### HOctll 31Mayl6 31Mayl6 lOctlS 22Octl5 3Sepl4 31Mayl6 27Febl5 4Mayl2 8Aprl0 15Marl6 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 10Jan


-----

###### -17
8Sep
###### -17
6Dun
###### -16
7Aug
###### -17
21Dec
###### -15 291un -17 291un -17
18Aug
###### -17
20NOV
###### -15
2Sep
###### -15
16Dun
###### -17
22Dec
###### -15
2Aug
###### -17
23Aug
###### -17 16Feb -17
303U115
###### 18JU117
15Aug
###### -17
16May
###### -17
26May
###### -17 193un -17 HAug -17
3Sep
###### -15
26May
###### -17
2Aug
###### -17
 19JU117
9Aug
###### -17 15Mar -17
95
28Dec


-----

###### -17
28Dec
###### -17
28Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
21Dec
###### -17
14Dec
###### -17
14Dec
###### -17
7Dec
###### -17
7Dec
###### -17
7Dec
###### -17
30NOV
###### -17
30NOV
###### -17
30NOV
###### -17
30NOV
###### -17
30NOV
###### -17
30NOV
###### -17
30NOV
###### -17
23NOV
###### -17
23NOV
###### -17
23NOV
###### -17
23NOV


-----

###### -17
US20170335

###### 374 US20170334 984 US20170334
973
###### US20170334
941
METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE
OF MICROBIAL CONTAMINATION IN A SAMPLE
###### 6N0t Available
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available
NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS
MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE
GLYCOPROTEINS
###### 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER Not Available Not Available Marl2
16Dec02
###### 280ctl4 310ctl4 US20170334
919
###### 2-((4-AMIN0-3-(3-FLUORO-5-HYDROXYPHENYL)-1HPYRAZOLO[3J4-D]PYRIMIDIN-1
 -YL)METHYL)-3-(2-(TRIFLUORO-MET
 HYL)BENZYL)QUINAZ0LIN-4(3H)-ONE DERIVATIVES AND THEIR
USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
63U117
###### 26Apr
 -16
 27Oct
 -15 30Oct -15

23NOV

###### -17

23NOV

###### -17

23NOV

###### -17

23NOV

###### -17

15RESPIVERT
LTD.

###### Marl3
273U117
23NOV

###### -17
 US20170334 864


-----

US20170333
586
US20170333
553
US20170333
###### 494
US20170333
###### 457
US20170333
267
US20170328
819
US20170327
543
US20170327
###### 472
US20170327
###### 439
US20170326
###### 256
US20170326
123
US20170322
682
US20170322
201
US20170321
192
US20170319
712
US20170319
673
US20170319
551
US20170313
765
US20170313
685
US20170312
371
###### 3j 5-DIAMIN0-6-CHL0R0-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDR0XYHEXYL)AMINO)ETHOX Y) PHENYL)BUTYL)
CARBAMIMIDOYL)PYRAZINE -2-CARBOXAMIDE
###### 27Parion Sciences, Inc. Junll ADDITIVE
COMPOSITIONS FOR PIGMENTED DISINFECTION AND
METHODS THEREOF
###### LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONS, FORMULATIONS, AND METHODS
PROBIOTIC THERAPEUTIC APPLICATIONS
###### Anti-Viral Azide Containing Compounds
MOBILE CLINICS


-----

SAMPLE FIXATION AND STABILISATION
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES
CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
SODIUM CHANNEL BLOCKING ACTIVITY
DIHYDRONAPHTHALENE DERIVATIVE
RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
EXPRESSION IN LIVER AND USE THEREOF
###### Throat solution for treatment of cold, flu and sore throat
SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
AND COMMUNICATING EVENT-RELATED INFORMATION
ANTIGEN PRESENTING CELL ASSAY
###### Recombinant RNA Viruses and Uses Thereof
METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
RESPONSE
TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
DIRECT EXPRESSION OF ANTIBODIES
BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE
###### INHIBITORS
MODIFIED VIRUS-LIKE PARTICLES OF CMV
###### Fauci/COVID-19 Dossier 8Not Available Not Available Not Available Not Available Baylor College of Medicine Not Available Not Available Parion Sciences, Inc.

ONO PHARMACEUTICAL CO., LTD.
###### Children's Healthcare of Atlanta, Inc. Not Available Georgetown University University of Pittsburgh - Of the Commonwealth System of Higher Education Icahn School of Medicine at Mount Sinai
3M INNOVATIVE PROPERTIES COMPANY
###### Not Available Not Available Not Available Purdue Research Foundation SAIBA GMBH Decl4 21Mayl3
10NOV14
###### 283U1-10
12NOV14
###### lMarl3 8Sepl0 17Decl2 3Decl4 IGAprlS 12Mayl6


-----

###### 25Feb08 8Aprl0 6Dunl0 10Apr03
13NOV14
###### 9Mayl2 290ctl4 28Aprl6 220ctl4
CC-BY-NC-SA
###### Dr. David E. Martin IMar -17

23May
###### -15 lAug -17

9Nov

###### -15

8Aug
###### -17

11N0V

###### -15
30May
###### -17
313an
###### -17
7Mar
###### -17
3Dec
###### -14
 15Apr -16

12May
###### -16 273ull7 203ull7
6Apr
###### -17
273U117
12NOV
###### -15

243 an

###### -17
 28Oct
 -15
28Apr
###### -17 20Oct -15 96
23NOV
###### -17

23NOV


-----

###### -17
23NOV
###### -17
23NOV
###### -17
23NOV
###### -17
23NOV
###### -17
16N0V
###### -17
16N0V
###### -17
16N0V
###### -17
16N0V
###### -17
16N0V
###### -17
16N0V
###### -17
9Nov
###### -17
9Nov
###### -17
9Nov
###### -17
9Nov
###### -17
9Nov
###### -17
9Nov
###### -17
2Nov
###### -17
2Nov
###### -17
2Nov
###### -17

US20170312
357
###### US20170308
679
###### US20170307
562
US20170306
354
US20170306
293
US20170306
###### 001 US20170305
868
###### US20170304


-----

829
###### US20170304 466 US20170304 459 US20170304 429 US20170304 420 US20170304 354
US20170299
591
US20170298
###### 100
US20170296
663
US20170296
###### 574
US20170292
132
US20170290
909
US20170281
###### 966
US20170281
759
US20170275
621
US20170275
592
US20170275
323
US20170275
253
US20170275
243
###### US20170274 064 US20170274 024
2MANUFACTURE
OF SURFACTANT-CONTAINING COMPOSITIONS
BIOSECURITY SCREENING SYSTEM AND METHOD
CHEMICALLY DIFFERENTIATED SENSOR ARRAY
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
ANTIBODY PRODUCING CELLS
CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL
ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS
MULTIPLE INFLUENZA A H5N1 CLADES
ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
SODIUM CHANNEL BLOCKING COMPOUNDS


-----

PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION
MODULE
###### AAV-Based Gene Therapy
METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF
CONIUGATED OLIGONUCLEOTIDE
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
POLYMER ADJUVANT
TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE
NANOFIBERS
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES
###### ANTI-VIRAL PEPTIDES Conjugates of Cell Binding Molecules with Cytotoxic Agents Method of Treating Inflammation
TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF
METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION
WITH RECOMBINANT MVA ENCODING FLAGELLIN
###### Device to Kill Micro-Organisms Inside the Respiratory Tract
BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL
COMPOSITION FOR HUMORAL IMMUNITY
CHIRAL CONTROL
CULTURE MEDIUM
GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
FOR USE IN THERAPY
BENZAZEPINE SULFONAMIDE COMPOUNDS
###### Lipids and Lipid Compositions for the Delivery of Active Agents
MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES
AAV Vectors Targeted to Oligodendrocytes
###### Not Available Not Available Nanomedical Diagnostics, Inc. Not Available Not Available Decl4 160ctl4 28Aprl4
17Dec01
9Dec05
27NATIONAL
###### UNIVERSITY OF SINGAPORE Marl4 IBParion Sciences, Inc. Click Diagnostics, Inc. Not Available Not Available Not Available Oxford University Innovation Limited Marine Polymer Technologies, Inc. Not Available Not Available Hangzhou DAC Biotech Co., Ltd. Not Available


-----

###### Not Available Bavarian Nordic A/S Not Available
NITTO DENKO CORPORATION
###### Not Available Koninklijke Nederlandse Akademie Van Wetenschappen
THE UNIVERSITY OF NOTTINGHAM
###### Hoffmann-La Roche Inc. Novartis AG Not Available Not Available Decl3 22Aprl6 60ctl4 10Octl4 26Sepl4 10Octl4 ISAprll 6Oct08 10ctl4 16Aprl4 lAprl0 29Aprl3 26Sepl4 lAprlG 3Sepl4 133U1-12
27NOV14
###### 4Aprl4 18Decl4 5Sepl4 5Sepl4 28Sepl2
2Dec

###### -15
 12Oct
 -15

8May

###### -17
 iMay
 -17
 23un
 -17
 27Mar
 -15
 iMar
 -17
 21Apr
 -17
 6Oct
 -15
 7Oct
 -15

25Sep


-----

###### -15 90ct
 -15 13Mar -17
13Dec
###### -16
30Sep
###### -15 16Apr -14 283un -17 203un -17
25Sep
###### -15 28Mar -17
2Sep
###### -15 17Mar -17
27NOV
###### -15

7Apr
###### -15

143 un
###### -17
4Sep
###### -15
4Sep
###### -15 17Apr -17

2Nov
###### -17 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 260ctl7 190ctl7 190ctl7 190ctl7 190ctl7 120ctl7


-----

###### 120ctl7 50ctl7 50ctl7
28Sep

###### -17

28Sep

###### -17

28Sep

###### -17

28Sep

###### -17

28Sep

###### -17

28Sep

###### -17

28Sep

###### -17 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
97

US20170267

969
US20170267
722
US20170267
649
US20170266
272
US20170266
###### 190
US20170266
###### 160
US20170261
###### 431
US20170260
223
US20170260
147
US20170259
###### 976
US20170258
###### 904
US20170258
893
US20170253
861
US20170252
###### 430
US20170252
###### 417
US20170247
688
US20170247


-----

###### 453
US20170247
###### 423
US20170246
347
US20170241
998
US20170240
639
US20170239
397
US20170239
###### 364
US20170239
349
US20170239
291
###### US20170234
781
US20170226
593
US20170226
511
US20170226
232
###### 29Animal Protein-Free Media for Cultivation of Cells INHIBITORY PEPTIDES OF VIRAL INFECTION
STABLE SODIUM CHANNEL BLOCKERS
TRANSGENIC VER0-CD4/CCR5 CELL LINE
DRUG COMBINATION
METHODS FOR TREATING PULMONARY EMPHYSEMA USING
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC
ACID AMPLIFICATION ASSAYS
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A
###### ANTIVIRAL COMPOUNDS AND METHODS
DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME
###### Antagonism of the VIP Signaling Pathway
MERS-CoV Vaccine
HIGHLY EFFICIENT INFLUENZA MATRIX (Ml) PROTEINS
POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN
IMMUNOSTIMULATING AGENT OR AS AN AD3UVANT
PROTEIN-CHAPERONED T-CELL VACCINES
ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF
LARGE LIBRARIES
SOLUBLE ENGINEERED MONOMERIC FC
STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES
TO TREAT INFECTION
MATERIALS WITH IMPROVED PROPERTIES
METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES
###### Baxalta GmbH


-----

###### Not Available
PARION SCIENCES, INC.
###### Not Available Not Available Oct04 17JU1-14 301unl4 20ctl5 15Marl3 14N0t Available Marl3 10Not Available Not Available Biotron Limited
MONOSOL, LLC
###### Not Available Not Available Not Available Not Available Not Available
NUEVOLUTION A/S
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Not Available Not Available Not Available ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY Not Available
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND
APPLICATIONS
METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL
ENTRY
COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL
DISORDERS
METHOD OF PREVENTING OR TREATING SINUSITIS WITH
###### OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION
MEMBRANE-ASSISTED PURIFICATION
HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID
###### IDENTIFICATION
APTAMERS FOR BINDING FLAVIVIRUS PROTEINS
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND
APPLICATIONS
###### Not Available Not Available Not Available
SONOMA PHARMACEUTICALS, INC.
###### Accelerate Diagnostics, Inc. Not Available National University of Singapore Not Available Mar05 4Augl4 263un03


-----

###### 30ctl4 2Febll
29NOV13
###### HJul-03 lAprl4 7Marl6 lDec05 16Marl2 29Febl6
1N0V15
###### 22Febl6 22Febl6
1N0V15
###### 28Marll 20Febl5
30Dec03
###### 7Marll 8Febl6
13NOV13
1N0V15
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
18May
###### -17
25May
###### -17
303an
###### -17
6Apr
###### -17
53un
###### -17 63un -17
19May
###### -17
17May
###### -17
23May
###### -17 2Oct -15
22May
###### -17
26NOV
###### -14 6Oct -16 lApr -15
7Mar
###### -17
12Dec


-----

###### -16
9May
###### -17 28Feb -17
5May
###### -17 17Feb -17 22Feb -17
5May
###### -17
2Mar
###### -17 61un -16
9May
###### -17
3May
###### -17
8Feb
###### -16
13N0V
###### -14
2Nov
###### -16
98
21Sep
###### -17
21Sep
###### -17
21Sep
###### -17
21Sep
###### -17
21Sep
###### -17
21Sep
###### -17
14Sep
###### -17
14Sep
###### -17
14Sep
###### -17
14Sep
###### -17
14Sep
###### -17
14Sep
###### -17
7Sep
###### -17


-----

7Sep
###### -17
7Sep
###### -17
3 lAug
###### -17
3 lAug
###### -17
31Aug
###### -17
31Aug
###### -17
24Aug
###### -17
24Aug
###### -17
24Aug
###### -17
24Aug
###### -17
24Aug
###### -17
24Aug
###### -17
17Aug
###### -17
10Aug
###### -17
10Aug
###### -17
10Aug
###### -17
 US20170226
222
US20170226
173
###### US20170224
813
###### US20170224
812
###### US20170224 616
US20170219
560
US20170216
###### 431
US20170216
###### 430
US20170216
###### 429
US20170216
###### 427
US20170216
348


-----

###### 20BISPECIFIC
ANTIBODY
GM-CSF and IL-4 Conjugates, Compositions, and Methods Related
###### Thereto
VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING
APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION
OF CTL
###### LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND
VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE
THROMBOSIS TREATMENT DRUG
###### OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS
MALARIA ANTIGEN SCREENING METHOD
VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL
ADMINISTRATION
IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING
NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL
COMPOSITION
COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL
IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION
###### Coronavirus
METAL NANOCLUSTERS AND USES THEREOF
###### Not Available Not Available
NITTO DENKO CORPORATION
NOV13
###### 230ctl2 4Augl4 4NITT0
DENKO CORPORATION
###### Augl4
GLAXOSMITHKLINE
BIOLOGICALS SA
###### United States of America as Represented by the Secretary of the Navy
NITTO DENKO CORPORATION
NITTO DENKO CORPORATION
###### 6-3U111
31Aug05
###### 20ctl4 4Augl4 4NITT0
DENKO CORPORATION
###### Not Available Not Available Augl4 233U1-14 7Augl4 183an -17 19Apr -17
4Aug
###### -15
4Aug


-----

###### -15 24Apr -17 10Apr -17 lOct -15
4Aug
###### -15
4Aug
###### -15 23JU115
7Aug
###### -15
10Aug
###### -17
10Aug
###### -17
10Aug
###### -17
10Aug
###### -17
10Aug
###### -17
3Aug
###### -17
3Aug
###### -17
3Aug
###### -17
3Aug
###### -17
3Aug
###### -17
3Aug
###### -17
US20170216
347
###### ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF
###### ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF
INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN
METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE
UNIWERSYTET 3AGIELLONSKI
###### 293ul-14 293ull5
Aug
###### -17 3US20170212 116


-----

US20170212
019
US20170211
###### 096
US20170211
069
US20170211
058
US20170209
###### 844
US20170209
595
US20170209
590
US20170209
570
US20170209
376
US20170205
399
BIOSENSORS
FOR THE DETECTION OF INFECTION AND
ASSOCIATED MALADIES
31ULISSE
BIOMED SRL
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS
###### LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating VirusProducing Cells for the Therapy of Tumors
USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR
TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY
METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF
POOLED SAMPLES
MICROSPOTTING DEVICE
DISULFUR BRIDGE LINKERS FOR CON3UGATION OF A CELLBINDING
MOLECULE
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED
DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS
###### Carbon Nanotube Compositions and Methods of Use Thereof
COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL
NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND
TREATMENT OF VIRAL DISEASES
POLYMERS AND CON3UGATES COMPRISING THE SAME
###### Fauci/COVID-19 Dossier Not Available Not Available University of Pittsburgh - Of the Commonwealth System of Higher Education Not Available Not Available Suzhou M-Conj Biotech Co.., Ltd. Not Available Not Available 3anl4 233anl2


-----

###### 293unll 7Marl2 6Augl4 18Aprl2 15JU1-15 13Janll 19Mar08 14N0t Available Apr04
 2Not
 Available
CC-BY-NC-SA Dr. David E. Martin
###### 0ctl4 261an
 -15 10Apr
 -17

7Apr

###### -17
 271an
 -17
5Aug
###### -15
5Dan

###### -17
5Apr

###### - 17
 101an
 - 17 17Mar
 - 17
 10Mar
 - 17
3 IMar

###### -17

99
273U117
###### 273U117 273U117 273U117 273U117 273U117 273U117 273U117 273U117
273U117
203U117

###### US20170204

143
###### US20170204
083
###### US20170202 975


-----

US20170202
###### 960
US20170202
959
US20170202
###### 956
US20170202
955
US20170202
949
US20170202
829
US20170196
979
US20170196
###### 954
US20170191
933
US20170191
079
US20170190
###### 770
US20170189
521
US20170175
###### 140
US20170173
585
US20170173
###### 176
US20170173
168
US20170173
###### 164
US20170168
052
US20170168
###### 044
US20170166
###### 574
US20170165
366
US20170165
359
US20170165
341
US20170165
###### 230
US20170160
218
###### Constrained proteins and uses therefor Not Available
THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES
AND HYDROXYPYRIDAZINONES


-----

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING
MOLECULE
CATIONIC OIL-IN-WATER EMULSIONS
ADJUVANT COMPOSITIONS AND RELATED METHODS
###### Methods and Compositions for Inhibiting Akt3 Adjuvanted Influenza Vaccines for Pediatric Use
DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND
METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE
###### Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
AGENTS
PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A
###### LENTIVIRAL VECTOR
 Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal Detector
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
###### Suzhou M-Conj Biotech Co., Ltd.
GLAXOSMITHKLINE BIOLOGICALS, SA
###### Not Available Not Available Not Available Providence Health & Services - Oregon Not Available Novartis AG Not Available Not Available Not Available
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) CORMORANT
PHARMACEUTICALS AB
###### LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONS, FORMULATIONS, AND METHODS
METHODS FOR USING A 5'-EXONUCLEASE TO INCREASE
HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS
POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR
DISEASE DETECTION
ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC
CONJUGATION OF A CELL-BINDING MOLECULE
ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC
CONJUGATION OF A CELL-BINDING MOLECULE
HYDRAZINO 1H-IMIDAZ0QUIN0LIN-4-AMINES AND CONJUGATES
MADE THEREFROM
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES
QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE
MEASURING
NOVEL COMPOUNDS
###### Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof
IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
METHODS OF USE
3M Innovative Properties Company
###### Not Available Not Available


-----

SUZHOU `m-con:` BIOTECH CO., LTD.
SUZHOU M-CONI BIOTECH CO., LTD.
###### Not Available Not Available
XIAMEN UNIVERSITY
###### CHIESI FARMACEUTICI S.P.A. Not Available Not Available
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available
USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE
###### PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY
APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT
ANALYSES AND AMPLIFICATIONS
###### Not Available Not Available 21JU1-14 USeplZ 15JU1-15 6-Julll 24Marl5 15Janl6 22Feb08
291111-05
###### 151anl6 8Marl3 151U1-14 31Decl5 7Apr05
16D6C02
###### 17Augl0 16Decl5
111111-14
###### 151U1-15 151U1-15 31unll 6Oct08 91unl4 14Decl5 10ctl5 HAugl0 24Augl2 9Aprl4 311U1-12
211U115
###### 131an -17
5Apr
###### -17 23Mar -17 23Mar -17 171an -17


-----

30Dec
###### -16
29Dec
###### -16 171an -17
27Sep
###### -16
 14JU115
23Dec
###### -16 183an -17 26Apr -16
19Aug
###### -16
14Dec
###### -16
 10JU115
3Mar
###### -17
3Mar
###### -17
6Mar
###### -17
13Dec
###### -16
24Sep
###### -14
12Dec
###### -16 13Feb -17
23Aug
###### -16 15Feb -17

9Apr
###### -15 23Feb -17 203ull7 203ull7 203ull7 203ull7 203ull7 203ull7 203ull7 203ull7 203ull7 13JU117 13JU117 63ull7


-----

6JU117
6JU117
6JU117
###### 223unl7 22:unl7 22:unl7 22:unl7 22:unl7 153unl7 153unl7 153unl7 153unl7 153unl7 153unl7 153unl7 83unl7 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E . Martin
###### 100

US20170159

027
US20170159
###### 026
US20170158
752
US20170157
262
US20170157
151
US20170152
###### 274
US20170152
271
US20170151
346
US20170151
291
US20170145
###### 394 US20170144 984
US20170143
845
US20170143
###### 820
US20170143
758
US20170143
749
US20170137
527
US20170137
###### 430


-----

US20170136
118
US20170136
043
US20170131
271
US20170130
###### 200
US20170129
947
US20170129
891
US20170128
###### 465
US20170122
853
US20170121
372
US20170119
872
US20170119
871
US20170119
###### 820
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
###### Novel Recombinant Adeno-Associated Virus Capsids with Enhanced
Human Skeletal Muscle Tropism
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
CON3UGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC
AGENTS
###### Broad Spectrum Antiviral and Methods of Use
CHARGED LINKERS AND THEIR USES FOR CON3UGATION
GAK MODULATORS AS ANTIVIRALS
DISULFUR BRIDGE LINKERS FOR CON3UGATION OF A CELLBINDING
MOLECULE
SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF
PRODUCTION AND USE THEREOF
TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR
DELIVERY OF CRISPR/CAS9
MODULATORS OF THE RELAXIN RECEPTOR 1
ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC
CON3UGATION OF A CELL-BINDING MOLECULE
IMMUNOGENIC COMBINATIONS
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS
THEREOF
GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING
AN IMMUNE RESPONSE
###### Nuclear Transport Modulators And Uses Thereof
NEUTRALIZING MOLECULES TO VIRAL ANTIGENS
THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE


-----

COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
ANTIBODY-NANOPARTICLE CONIUGATES AND METHODS FOR
MAKING AND USING SUCH CONIUGATES
INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF
THERAPY
REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND
###### LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
IMIDAZONAPHTHYRIDINES
###### Pharmaceutical Compositions and Methods
PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN
VIVO
NOVEL DEPSIPEPTIDE AND USES THEREOF
###### 30Not Available Not Available Not Available Not Available Not Available Hangzhou DAC Biotech Co.^ Ltd. Katholieke Universiteit Leuven
SUZHOU M-CONI BIOTECH CO., LTD.
###### Not Available Not Available Not Available
SUZHOU M-CONI BIOTECH CO., LTD
GLAXOSMITHKLINE SA
###### Advanced Inhalation Therapies (AIT) Ltd. Not Available Not Available Not Available Not Available
The University of North Carolina at Chapel Hill
###### Not Available Not Available Kolltan Pharmaceuticals, Inc. Not Available Not Available
THE UNITED STATES OF AMERICA, AS REPRESENTED BY
THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN
SERV
###### Not Available
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available
LOW-ADDITIVE INFLUENZA VACCINES
MODIFIED CELLS AND METHODS OF THERAPY
###### Fauci/COVID-19 Dossier Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
Sep03
###### ZDeclS 25Aprl4 12IU1-12 17Apr06


-----

###### 28Febl4 23JU1-14 15JU1-15
25NOV13
23NOV15
###### 4Mayl2 15JU1-15 133unl4 llSepl3 243unl4 25Mar05 29JU1-11 28Mar08 HAprl4 27Aprl0 31JU1-15 253U1-12 183un04 3Augl5 8Augl4 3Decl2 20Augl0 273un07 31JU1-15 15Feb -17
2Dec
###### -16 27Apr -15 123U112 16Feb -17 28Feb -14 233U115 13Feb -17
25NOV
###### -14
22NOV
###### -16
25Aug
###### -16
3Feb
###### -17 123un -15 41an -17
2Feb
###### -17
7N0V
###### -16


-----

22DU116
8Dun
###### -16
SODan
###### -17
12Sep
###### -16

293U116
20Sep
###### -16 231an -17
6Dec
###### -16

7Aug
###### -15 151un -16 llOct -16

241 un
###### -16

291U116
###### 81unl7 81unl7 81unl7 81unl7 81unl7 llunl7 llunl7 llunl7 llunl7
25May
###### -17
25May
###### -17
25May
###### -17
25May
###### -17
25May
###### -17
25May
###### -17 i8May -17
18May
###### -17
18May
###### -17
18May
###### -17 HMay -17


-----

###### llMay -17 llMay -17 llMay -17 llMay -17
4May
###### -17
4May
###### -17
4May
###### -17
4May
###### -17
4May
###### -17
101

US20170119
###### 786
US20170119
###### 734
US20170118
995
###### US20170114
053
US20170112
929
US20170107
###### 254
US20170107
195
US20170106
077
US20170101
###### 459
US20170101
###### 413
US20170100
###### 474
US20170100
385
US20170096
###### 646
US20170096
###### 455
US20170096
###### 441
US20170096
###### 417
US20170095
818
US20170095


-----

521
US20170089
911
US20170088
858
US20170088
848
US20170088
559
US20170086
###### 463
US20170082
608
US20170082
607
US20170081
655
US20170081
393
US20170081
392
8HETER0CYCLIC
MODULATORS OF LIPID SYNTHESIS
TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE
SAME, AND METHOD FOR CONTROLLING UNICELLULAR
ORGANISMS AND/OR VIRUSES
HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
###### Not Available Not Available Marll 5Mayl0 17Riken Techno System Co., Ltd.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available Modified Antimicrobial Peptides Chemical Compounds
INFLUENZA VIRUS VECTORS AND USES THEREFOR
CLEAVAGE AND EXCHANGE OF MA30R HISTOCOMPATIBILITY
COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING
PEPTIDES
NOVEL COMPOUNDS
###### Not Available AstraZeneca AB Not Available Not Available CHIESI FARMACEUTICI S.p.A.
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available
PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR
TREATING INFECTIOUS DISEASES
###### Modified Adenovirus Hexon Protein and Uses Thereof
METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS


-----

SPIKE PROTEINS
PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF

###### VIRAL INFECTIONS Multicyclic Compounds And Methods Of Using Same

INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION
AND MICROARRAY DETECTION

###### Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR

###### Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing Hemagglutinin
ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
THIAZOLONAPHTHYRIDINES
###### ANTIVIRAL AGENT Assay for Detecting TH1 and TH2 Cell Populations
MALARIA ANTIGEN SCREENING METHOD
PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM
OXIDES
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES
COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY
CONSTRUCTS AND USES THEREOF
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2)
###### LIMITED Not Available
The University of North Carolina at Chapel Hill
###### Not Available Karyopharm Therapeutics Inc. CapitalBio Corporation Not Available Not Available Not Available Medicago Inc. Not Available Not Available Not Available Not Available Not Available
The U.S.A., as represented by the Secretary, Department
###### of Health and Human Services Not Available Sepl4 12Junl4 7Sepl2 2Aprl4 18Marl4 17Marl4 61unl4 12Junl4 6Apr07 12Mayl4 28Apr06 20Marl4


-----

###### 14Aprl0 20Sepl3 31Marl4 10ctl5 24Febl4
17Dec01
###### 213an08 9Feb05
3Sep08
###### 16Mayl4
31Aug05
###### 14JU1-15 313an08 13Mayl4
11NOV
###### -16 22Apr -16
6Dec
###### -16 123un -15 63un -16
2Apr
###### -15 17Mar -15 13Mar -15
53un
###### -15 123un -14 223U116
8May
###### -15
20Dec
###### -16 20Mar -15
9Sep
###### -16
19Sep
###### -14
31Mar
###### -15
30Sep
###### -16
24Aug
###### -16 20Oct -16
2Sep


-----

###### -16
12Dec
###### -16
12Dec
###### -16
15May
###### -15 19Apr -13 13JU116
2Dec
###### -16
13May
###### -15
4May
###### -17
4May
###### -17
4May
###### -17 27Aprl7 27Aprl7 20Aprl7 20Aprl7 20Aprl7 13Aprl7 13Aprl7 13Aprl7 13Aprl7 6Aprl7 6Aprl7 6Aprl7 6Aprl7 6Aprl7 6Aprl7
30Mar
###### -17
30Mar
###### -17
30Mar
###### -17
30Mar
###### -17
30Mar
###### -17 23Mar -17 23Mar -17 23Mar -17 23Mar -17 23Mar


-----

###### -17 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
102

###### US20170080
 084
US20170080
079
US20170080
078
US20170079
###### 920
US20170079
###### 916
US20170079
253
US20170073
738
US20170073
###### 730
US20170073
727
US20170073
390
US20170073
352
US20170072
053
US20170071
###### 980
US20170071
###### 964
US20170071
867
US20170067
###### 030
US20170067
021
US20170066
788
US20170066
787
US20170066
731
US20170065
###### 706
US20170065
693
US20170065
677
US20170065
###### 636
US20170058


-----

###### 430
US20170058
365
US20170057
978
US20170057
968
US20170057
938
###### 170IL/SURFACTANT
MIXTURES FOR SELF-EMULSIFICATION
METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
###### Technology for the Preparation of Microparticles
COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER
NANOPARTICLE DELIVERY
TRANSGENIC MICE HAVING A HUMAN MA30R HISTOCOMPATIBILITY
COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND
APPLICATIONS
###### Compositions and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood Samples
METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION
METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING
ADSORPTION MEDIA
###### Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay
NOVEL SUBSTITUTED SPIROCYCLES
METHODS FOR PREPARING SQUALENE
METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER
SOLUTION IN DENTAL APPLICATIONS
METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
VIRUS INFECTIONS
NOVEL NANOPARTICLE COMPOSITIONS
ATTENUATED VIRUSES USEFUL FOR VACCINES
MODIFIED CELLS AND METHODS OF THERAPY
BORON-CONTAINING SMALL MOLECULES
BORON-CONTAINING SMALL MOLECULES
SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS
METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS
VECTOR FOR USE WITH MULTIPLE VACCINATIONS
###### Sequential administration of a replication defective adenovirus vector in vaccination protocols
EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE
RESPIRATORY TRACT
MODIFIED CELLS AND METHODS OF THERAPY
BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS
###### Not Available Not Available Not Available Not Available Not Available INSTITUT PASTEUR Longhorn Vaccines and Diagnostics, LLC


-----

###### Not Available Not Available Not Available Not Available Not Available
OCULUS INNOVATIVE SCIENCES, INC.
###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Volution Immuno Pharmaceuticals SA Not Available Not Available
SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS Not Available
###### ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
METHODS OF USE THEREOF
COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
AGONISTS
CERTAIN (2S)-N-[(lS)-l-CYAN0-2-PHENYLETHYL]-l,40XAZEPANE-2-CARB0XAMIDES
AS DIPEPTIDYL PEPTIDASE 1
###### INHIBITORS Fauci/COVID-19 Dossier Kineta, Inc.
NOVARTIS AG
###### Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Marl4 23Sepl5 24Aprl2 24Iul-07 23Sepl5 303U1-03 lOct07 USeplS
8NOV13
###### 63an06 12Sepl4 12Mayl0
2May05
###### 16Sepl5 3Aprl3 30Mar07 313U1-15 16Feb05 16Feb05 7Marl4 2-3U107 2-3U107 83anl0


-----

###### 31JU1-15 18Febl4 iSeplS 9Mayl4 lMayl4 24:anl4 17Mar -15
23Sep
###### -16 30ct -16
5Dec
###### -16
23Sep
###### -16 17JU112
25NOV
###### -16
8Sep
###### -16
2Nov
###### -16
5Dec
###### -14
29NOV
###### -16
22NOV
###### -16
22NOV
###### -16
16Sep
###### -16
28NOV
###### -16
7Sep
###### -16
2Sep
###### -16
18N0V
###### -16
18N0V
###### -16
5Mar
###### -15
14Sep
###### -16
14Sep
###### -16
22311116
29Aug
###### -16 18Feb -15


-----

3Feb
###### -16
8May
###### -15 29Apr -15
8Nov
###### -16
103
###### 23Mar -17 23Mar -17 23Mar -17 23Mar -17 23Mar -17 23Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17 16Mar -17
9Mar
###### -17
9Mar
###### -17
9Mar
###### -17
9Mar
###### -17
9Mar
###### -17
9Mar
###### -17
9Mar
###### -17
9Mar


-----

###### -17 9Mar -17
2Mar
###### -17
2Mar
###### -17
2Mar
###### -17
2Mar
###### -17
2Mar
###### -17

US20170052
###### 190
US20170051
###### 053 US20170051 046 US20170051
022
US20170051
007
US20170049
813
###### US20170044 603 US20170044
595
###### US20170044
237
###### US20170044
168
US20170042
###### 994 US20170042 898
US20170039
###### 316
US20170039
###### 314
US20170038
085
###### US20170037 457
US20170037
379
US20170037
376
US20170037
###### 090
US20170037
###### 045 US20170035


-----

878
US20170035
845
US20170029
877
US20170029
847
US20170029
###### 489
US20170028
082
US20170028
###### 054
US20170027
975
###### Covalently Linked Thermostable Kinase for Decontamination Process Validation
METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH
DESIRED SPECIFICITY
H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES
ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
PHARMACEUTICAL COMPOSITIONS AND METHODS
ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE
AND METHODS OF MAKING AND USING THE SAME
CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID
SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS
PCR Ready Compositions and Methods for Detecting and Identifying
###### Nucleic Acid Sequences
ANTIBODIES AND PROCESSES FOR PREPARING THE SAME
COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
AGONISTS
COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE
ANTIGEN TO DENDRITIC CELLS
METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLYINDUCED
CONDITIONS
###### Compositions, processes and algorithms for microbial detection
BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE
BINDING
###### AIR CURTAIN DEVICE
NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING
MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME
CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS
AND USES THEREOF
METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL,
COMPOSITION USED IN METHOD, AND USES THEREOF
RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING
POLYGENES
HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE
THEREFROM
###### Multi-Functional Mucosal Vaccine Platform Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine
Gene Expression
POLYTAG PROBES


-----

###### ARTIFICIAL NUCLEIC ACID MOLECULES
HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE
VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
VACCINE COMPOSITION
###### Methods of Treating Coronavirus Infection 20Not Available Not Available
MEDIGEN BIOTECHNOLOGY CORPORATION
###### Not Available Not Available
OCULUS INNOVATIVE SCIENCES, INC.
###### Not Available Longhorn Vaccines and Diagnostics, LLC Not Available
NOVARTIS AG
ASSISTANCE PUBLIQUE      - HOPITAUX DE PARIS
HEMAQUEST PHARMACEUTICALS, INC.
###### Not Available
IOGENETICS, LLC
###### Not Available Not Available Icahn School of Medicine at Mount Sinai
GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH,
CHINESE ACADEMY OF SCIENCES
###### Not Available
3M Innovative Properties Company
###### Not Available Not Available Not Available CureVac AG Not Available
Feb08
###### 28Decll 20Augl5 30Aprl4 3Augl5 13Mar07 313U1-09
24Aug07
16May08
###### lMayl4 223U1-11 HMarlO
12NOV03
###### 23Marl0 7Augl5 5Febl4 2Dec05
15NOV13
8NOV05
###### 33unll


-----

###### llFebl4 7Augl5 26Febl0 30Decl3 14Decl0 30Not Available
NITTO DENKO CORPORATION
###### United States Government as represented by the Secretary^ Department of Health and Human Services
Sep03
###### 4Aprl2 7Aprl4 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
83U116
7Sep
###### -16
20Aug
###### -15 30Apr -15 283U116
8Nov
###### -16
15Aug
###### -16 26Oct -16
23Aug
###### -16 29Apr -15 293U116 27Oct -16 250ct -04
13Sep
###### -12
19NOV
###### -15 293an -15
3Mar
###### -16
12NOV
###### -14 26Oct -16 240ct -16 llFeb


-----

###### -15
5Aug
###### -16
31Mar
###### -16 281un -16 llun -16
3Aug
###### -16 llOct -16
7Apr
###### -15 104 23Feb -17 23Feb -17 23Feb -17 23Feb -17 23Feb -17 23Feb -17 16Feb -17 16Feb -17 16Feb -17 16Feb -17 16Feb -17 16Feb -17
9Feb
###### -17
9Feb
###### -17
9Feb
###### -17
9Feb
###### -17
9Feb
###### -17
9Feb
###### -17
9Feb
###### -17


-----

9Feb
###### -17
9Feb
###### -17
9Feb
###### -17
2Feb
###### -17
2Feb
###### -17
2Feb
###### -17
2Feb
###### -17
2Feb
###### -17
2Feb
###### -17

US20170027
###### 944
US20170022
577
US20170022
242
US20170021
013
US20170020
###### 926
US20170016
048
US20170015
###### 716 US20170014 496 US20170014 423
US20170011
131
US20170010
###### 264
US20170009
237
US20170007
577
US20170002
042
US20170000
878
US20170000
873
US20160376
596
US20160376
321


-----

US20160375
137
US20160375
132
US20160369
268
US20160368
###### 956
US20160368
###### 904
US20160367
587
US20160367
188
US20160363
557
US20160362
###### 730
US20160362
###### 454
US20160361
382
24METH0DS
FOR TREATING VIRAL DISORDERS
METHODS OF TESTING FOR INTRACELLULAR PATHOGENS
NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS
D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND
METHODS OF USE THEREOF
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF
NUCLEIC ACIDS
###### STABILIZED ANTI-MICROBIAL PEPTIDES
COMBINATION OF VACCINATION AND 0X40 AGONISTS
###### Benzazepine Dicarboxamide Compounds
SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
AND COMMUNICATING EVENT RELATED INFORMATION
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES
###### Short Interfering RNA (siRNA) Analogues
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
PEPTIDOMIMETIC MACROCYCLES
CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
THEREFOR
###### Dimethyl Fumarate and Vaccination Regimens
COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED
IMMUNE RESPONSE USING POXVIRUS VECTORS
A NOVEL SARS IMMUNOGENIC COMPOSITION
TARGETING LIPIDS
HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING
COMPOUNDS AND USES THEREOF
TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES
AND METHODS OF SYNTHESIS AND USE
METHOD OF PREVENTIVELY TREATING A SUB3ECT AT THE RISK OF


-----

DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
AND USES THEREOF
###### Systemic In Vivo Delivery of Oligonucleotides
ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND
DEVELOPERS' TOOL KIT
AMPEROMETRIC GAS SENSOR
###### Not Available Novartis AG
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D
###### Not Available Not Available Not Available Not Available Not Available Hoffmann-La Roche Inc. Georgetown University Not Available Not Available Not Available Not Available Not Available Not Available Bavarian Nordic A/S
BAYLOR COLLEGE OF MEDICINE
###### Tekmira Pharmaceuticals Corporation Not Available
The Board of Regents of the University of Texas System
###### Not Available Not Available Oncolmmunin, Inc. Not Available Not Available
PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS Not Available
###### Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
###### VIRAL INFECTIONS Not Available Not Available
Sep09
###### 8Marl0 17Aprl4
30NOV12
###### lAprl4 ISMaylS 2-JU115 12Marl4 GMarlS 25Feb08 6Oct08 21Mar03
29NOV02
###### 1-3U115


-----

###### 233unl0 14Marl4
28NOV13
26NOV13
###### 4Dec07 15Dec09 1-JU113 9Mayl3 3-JU113 123unl3 173unl5 253unl2
26Fet>14
###### 70ctll lUunlS Fauci/COVID-19 Dossier 18Feb -15
23Sep
###### -16
 17Apr -15
31Mar
###### -16 13Mar -15
17May
###### -16 1JU116 12Mar -14
28Sep
###### -16
23Sep
###### -16
20Sep
###### -16 28Mar -16
19Sep
###### -16 1JU116
9Aug
###### -16 13Mar -15
25NOV
###### -14
21NOV
###### -14 220ct -13 53ull6


-----

###### 253un
 -14

23Aug

###### -16
33U114
###### 123un
 -14

10Sep

###### -15

25Aug

###### -16

26Aug

###### -16
 103un
 -16
 133un
 -16

CC-BY-NC-SA
###### Dr. David E. Martin
105
2Feb

###### -17
 263anl7 263anl7 263anl7 263anl7 193anl7 193anl7 193anl7 193anl7 123anl7 123anl7 123anl7 123anl7 53anl7 53anl7 53anl7
29Dec

###### -16

29Dec

###### -16

29Dec

###### -16

29Dec

###### -16

22Dec

###### -16

22Dec

###### -16

22Dec

###### -16

22Dec

###### -16

22Dec


-----

###### -16

15Dec

###### -16

15Dec

###### -16

15Dec

###### -16

15Dec

###### -16

US20160361

259
###### US20160354 451 US20160354 428 US20160354
347
US20160348
153
US20160348
132
US20160348
115
US20160348
###### 110
US20160347
###### 816
US20160347
###### 814
US20160347
###### 784
US20160346
309
US20160340
713
US20160340
319
US20160339
097
US20160338
998
US20160333
356
US20160333
089
US20160333
###### 076
US20160331
828
###### 23Methods for the Preparation of Liposomes
METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN
AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL


-----

ENTRY
###### Nuclear Transport Modulators and Uses Thereof
EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES
FROM PATHOGENS
###### Not Available Not Available Not Available Not Available
THE UNITED STATES OF AMERICA, as represented by the
###### Secretary, Department of Health and Human Serv TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
###### Enhanced Immunostimulatory Activity
NUCLEIC ACID CHEMICAL MODIFICATIONS
POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR
TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE
RELATED DISEASES
###### Not Available Not Available Not Available
Sep09
31Aug07
###### 8Feb07 9Mayl2 29Mayl5 18May04 27Sep06 2Mar09 ISAprll UNot Available
NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Not Available
TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL
METABOLIC PATHWAYS
###### STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
RIBONUCLEIC ACID
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
CORONAVIRUS PROTEINS AND ANTIGENS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND
COMBINATIONS THEREOF
OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
PATHWAY
###### Antigenic GM-CSF Peptides and Antibodies to GM-CSF
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE
NUCLEIC ACID VACCINES
US20160331
###### 816
ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)
OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS
ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION
AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY


-----

INDUCED OCULAR DISORDERS
US20160331
758
US20160327
506
US20160327
###### 484
US20160326
598
US20160326
325
###### Not Available Not Available Not Available
M3 Biologies, Inc.
###### 3-V Biosciences, Inc. Not Available Not Available
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Moderna Therapeutics, Inc. Sepl3 6-3U109 13un07 6Oct06 6Febl3 7Febl4 20Decl3 3Marll 8Feb06
7NOV11
###### 23Aprl4 18N0t Available Octl3 1TOLL-LIKE
RECEPTOR AGONIST FORMULATIONS AND THEIR USE Not Available
CAPACITIVE LIQUID CRYSTAL BIOSENSORS
A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF
A PLANT OR YEAST HYDROLYSATE AND ITS USE
METHODS AND COMPOSITIONS FOR PROSTATE CANCER
METASTASIS
POWDERED POUCH AND METHOD OF MAKING SAME
###### Not Available Not Available Not Available Not Available Aug08 6Mayl5 30Decl3 25Marll 16Aprl2 Fauci/COVID-19 Dossier


-----

CC-BY-NC-SA Dr. David E. Martin
2Aug

###### - 16

93un

###### - 16
 20un
 - 16

61an

###### - 16
31May
###### - 16
 HAug
 - 16

26May

###### - 16
 HAug
 - 16
 29Feb
 - 16
 10Mar
 - 16

27May

###### - 16

21Dec

###### - 15

20May

###### - 16
5Aug
###### - 16

4Aug

###### - 16

19Dec

###### - 14
 283U116 18JU116
2Aug

###### -16
5Apr
###### - 16
 18Apr
 - 16

21Dec

###### - 15
5May
###### - 16

18Dec
###### - 14
27May

###### - 16
 19JU116
15Dec

###### - 16

8Dec

###### - 16


-----

8Dec
###### -16

8Dec

###### -16 iDec -16 IDec -16 IDec -16 IDec -16 IDec -16 IDec -16 IDec -16 IDec -16
24N0V
###### -16
24N0V
###### -16
24N0V
###### -16
24N0V
###### -16
17N0V
###### -16
17N0V
###### -16
17N0V
###### -16
17N0V
###### -16
17N0V
###### -16
17N0V
###### -16
10Nov
###### -16
10NOV
###### -16
10NOV
###### -16
10NOV
###### -16 106
 US20160326
233
US20160326
141
###### US20160325


-----

283
###### US20160324 834
US20160320
390
US20160318
985
US20160318
861
US20160317
647
US20160317
637
US20160317
###### 496
US20160317
###### 458
US20160312
###### 276
US20160311
###### 886
US20160311
835
US20160311
###### 816
US20160311
759
US20160310
511
US20160305
###### 936 US20160304 954 US20160304
942
###### US20160304 904 US20160304
883
###### US20160304
882
###### US20160304
586
###### US20160304
579
###### US20160304 472
US20160303
###### 194
US20160303
052
US20160299
141
US20160298


-----

179
NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST
###### HEPATITIS B VIRUS SURFACE ANTIGEN 16N0t Available
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE
AGAINST CANCER AND VIRAL INFECTIONS
BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS
Use of mTOR Inhibitors to Enhance T Cell Immune Responses
COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES
###### Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored
GM-CSF and IL-4 Conjugates
NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS
NUCLEIC ACID VACCINES
IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE
THEREOF
METHODS OF TREATING CANCER AND OTHER DISORDERS
###### Lipids and Lipid Compositions for the Delivery of Active Agents
METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME
AMPLIFICATION
###### Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging
NOVEL ANTIBIOTICS
COMPOSITIONS AND METHODS FOR INHIBITING KINASES
###### Lipids and Lipid Compositions for the Delivery of Active Agents Myxovirus Therapeutics, Compounds, and Uses Related Thereto
DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY
COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
VARIANTS
###### Enhanced Methods of Ribonucleic Acid Hybridization Directed Evolution and In Vivo Panning of Virus Vectors ARTIFICIAL NUCLEIC ACID MOLECULES
METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING
###### INHIBITORY GENE PRODUCTS
PROCESS FOR PREPARING INFLUENZA VACCINES
POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF
AUTOIMMUNE DISORDERS AND INFECTION
###### Hydrazide Containing Nuclear Transport Modulators and Uses Thereof Compositions And Method For Treatment Of Inflammatory Bowel Disease
MODULAR PARTICLES FOR IMMUNOTHERAPY
NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN
DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS
LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
FOR MICROARRAY-BASED ASSAYS
###### Fauci/COVID-19 Dossier Not Available Not Available Not Available Not Available Not Available
PARION SCIENCES, INC.
###### Moderna Therapeutics, Inc.


-----

###### Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available CureVac AG GenVec, Inc. Crucell Holland B.V. Not Available Not Available Not Available Not Available Biolog Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH CapitalBio Corporation
CC-BY-NC-SA Dr. David E. Martin
###### Janl4 71anl4 30Mar09
5Aug08
###### IMaylS 29Aprl5 30Aprl5 23Aprl4 73anl4
12NOV10
###### 19Decl3 23Aprl5 243an05 26Mayll 23Aprl5 19Decl3 240ctll 133U1-10 HDecl3 6Decl3 30Apr08 30Decl3
10NOV05
###### 5Decl3 303unll 293U1-11 23unll
1NOV13
###### SAprlS 5Decl3


-----

15Dan
###### -15 71an -15 18JU116
16May
###### -16 IMay -15 29Apr -16
2May
###### -16 lApr -16 71an -15 271un -16
17Dec
###### -14 21Apr -16 12JU116
30Nov
###### -15 22Apr -16
17Dec
###### -14
7311116
###### 18Feb -16 llDec -14
5Dec
###### -14 281un -16 281un -16 271un -16
4Dec
###### -14 29Feb -16
13N0V
###### -15 21Apr -16 310ct -14 lApr


-----

###### -16
2Dec
###### -14
107
10NOV
###### -16
10NOV
###### -16
10NOV
###### -16
10NOV
###### -16
3Nov
###### -16
3Nov
###### -16
3Nov
###### -16
3Nov
###### -16
3Nov
###### -16
3Nov
###### -16
3Nov
###### -16 270ctl6 270ctl6 270ctl6 270ctl6 270ctl6 270ctl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 20Octl6 130ctl6 130ctl6
 US20160296
617
US20160296
###### 616 US20160295 844 US20160292
393
###### US20160289


-----

###### 740
US20160289
191
US20160288
121
US20160287
697
US20160287
622
US20160281
109
US20160280
707
US20160279
237
US20160279
193
US20160279
165
US20160279
163
US20160278
349
US20160272
707
US20160271
241
US20160271
###### 240
US20160271
137
US20160267
###### 244
US20160265
025
###### US20160264
971
###### US20160264
962
US20160263
###### 156
US20160258
949
US20160257
932
US20160257
653
###### llmmunogenic Composition for MERS Coronavirus Infection
IMMUNOGENIC COMPOSITIONS AND USES THEREOF
GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF
USE THEREOF
SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND
PROVIDING RESULTS THEREOF


-----

###### Not Available Not Available Not Available Not Available
METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING Not Available
ORGANIC COMPOUNDS
###### Slip Chip Device and Methods
IN1ECTABLE VACCINE COMPOSITION
COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL
DISORDERS AND MODULATING PROTEIN-RNA INTERACTION
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING
###### LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA
VIRUS SPIKE PROTEIN
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES
ADJUVANT COMPOSITIONS AND RELATED METHODS
IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY
PULSE INHALATION OF NITRIC OXIDE FOR TREATING
RESPIRATORY DISEASES
###### Method of Treating Inflammation Immunocompromised Ungulates
VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF
CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES
BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR
GENES AND METHODS FOR GENERATING THESE VIRUSES
###### Tetanus Toxoid and CCL3 Improve DC Vaccines INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID
METABOLISM AS BROAD SPECTRUM ANTI-VIRALS
METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN
COUNTS
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE
THEREOF
COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS
GENE EXPRESSION
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,
###### KITS AND ASSAYS
RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND
THEIR USE FOR THE TREATMENT OF LUNG DISEASE
###### CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX
PNEUMOCOCCUS SEROLOGY
GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS
COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER
POLYPEPTIDE
###### Benzazepine Dicarboxamide Compounds Fauci/COVID-19 Dossier
NOVARTIS AG
###### Not Available
NITTO DENKO CORPORATION
###### Massachusetts Institute of Technology Marl3 ZSMarlS 13Aprl5 24Octl3 30Marl5 273un08


-----

###### 24Mar09 30ctl3
18NOV13
###### 28Not
 Available Oct05
 3Not
 Available
 Not Available Not Available Not Available Not Available Not Available Not Available Oct03 24Marl5
6NOV13
###### 24Marl5 lAprl0 27Oct08 HSepl3 21Stichting Dienst Landbouwkundig Onderzoek
Duke University
###### Not Available Not Available Not Available Not Available Not Available University of Pittsburgh - Of the Commonwealth System of Higher Education Not Available Not Available Hoffmann-La Roche Inc.
CC-BY-NC-SA Dr. David E. Martin
###### Mayl3
14NOV13
###### 18Febl0 8Aug08
23Dec05
###### 203U1-09 4Aprl2
7NOV13
###### 9Octl3
18NOV13
###### 6Marl5 28Feb
 -14
 25Mar
 -16
 12Apr
 -16
 13Apr
 -16


-----

###### 29Mar -16 90ct -15
25May
###### -16 20ct -14
7Nov
###### -14 101un -16 13Jun -16 24Mar -16
6Nov
###### -14 24Mar -16
31un
###### -16 23Mar -15 llSep -14
21May
###### -14
14N0V
###### -15 270ct -15
19May
###### -16
20May
###### -16 90ct -15
283U115
6Nov
###### -14 90ct -14
17May
###### -16 4Mar -16
108
###### 130ctl6 130ctl6 130ctl6 60ctl6 60ctl6 60ctl6


-----

###### 60ctl6 60ctl6 60ctl6
29Sep
###### -16

29Sep
###### -16
29Sep
###### -16

29Sep
###### -16

29Sep
###### -16

29Sep
###### -16
29Sep
###### -16
22Sep
###### -16

22Sep
###### -16

22Sep
###### -16
22Sep
###### -16

15Sep
###### -16

15Sep
###### -16

15Sep
###### -16
15Sep
###### -16
15Sep
###### -16
8Sep
###### -16
8Sep
###### -16
8Sep
###### -16
 US20160256 870
US20160256
541
###### US20160253 584 US20160251
637
###### US20160251
631
###### US20160251
399
###### US20160251


-----

362
US20160251
319
US20160250
326
US20160250
278
US20160250
168
US20160238
601
US20160238
###### 600
US20160237
###### 455
US20160237
123
US20160237
082
US20160235
###### 840
US20160235
837
US20160235
835
US20160235
675
US20160230
###### 190
US20160229
###### 904
US20160229
872
US20160229
###### 864
US20160229
833
US20160228
540
US20160228
533
US20160228
532
US20160228
###### 463 24Slip Chip Device and Methods Cationic Oil-In-Water Emulsions
SPATIALLY ADDRESSABLE MOLECULAR BARCODING
COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
###### ACTIVITYj AND RELATED METHODS
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES
PEPTIDOMIMETIC MACROCYCLES


-----

NOVEL COMPOUNDS
CARBOXYLIC ACID COMPOUNDS
###### Conjugates of GM-CSF and IL-7, and Compositions Thereof
PEPTIDOMIMETIC MACROCYCLES
ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE
TREATMENT OF IMMUNOGENIC DISORDERS
METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS
AND THERAPEUTICS
METHOD FOR SELECTING A SINGLE CELL EXPRESSING A
HETEROGENEOUS COMBINATION OF ANTIBODIES
CRISPR-RELATED METHODS AND COMPOSITIONS
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL
INFECTIONS
DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE
SAME
###### Compositions, Comprising Improved 11-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same
THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE
EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE
###### Technology for the Preparation of Microparticles
 Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof Optimized Human Clotting Factor VIII Gene Expression Cassettes
and Their Use
ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS
THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
###### INHIBITORS
QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
NASAL MUCOSAL VACCINE COMPOSITION
Use of EGFR Pathway Inhibitors to Increase Immune Responses to
###### Antigens
METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE
FORMULATIONS
BORON-CONTAINING SMALL MOLECULES
###### Fauci/COVID-19 Dossier Not Available Not Available Not Available Not Available Novartis AG Not Available CHIESI FARMACEUTICI S.P.A. Astrazeneca Aktiebolag Not Available Not Available Not Available Not Available Merus B.V. Editas Medicine, Inc. Not Available


-----

###### Not Available Not Available Mar09 6-JU110 27Febl5
19NOV09
###### 9Sep04 141an09
18D6C12
###### 18Mayl2
14N0V11
###### 141an09 30ctl2 140ctl3
30May03
###### 27Sepl3 233an08 10Octl3 12Decll 16N0t
 Available Seqirus UK Limited Not Available Not Available Not Available Not Available Not Available Not Available
NITTO DENKO CORPORATION
Emory University

###### Merck Sharp & Dohme Corp. Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Octl3 10Feb09 243U1-07 17Sepl3 6Febl5 SFeblS SFeblS SFeblS 30ctl3 23Sepl3 16Octl3 16Feb05
25May

###### - 16
 HMar
 - 16
 26Feb
 - 16
 HMar
 - 16

9May


-----

###### -16
7Apr
###### -16
10May
###### -16
 HMay
 -16
18May
###### -16
7Apr
###### -16
3Mar
###### -16 140ct -14 27Apr -16
26Sep
###### -14
4May
###### -16
 10Oct
 -14 26Feb -16 160ct -14 271an -16 24Mar -16
17Sep
###### -14
5Feb
###### -16 4Feb -16 4Feb
 -16 4Feb -16 20ct -14
23Sep
###### -14 130ct -14 20Apr -16
8Sep
###### -16
8Sep
###### -16 iSep


-----

###### -16 ISep -16 ISep -16 ISep -16 ISep -16 ISep -16 ISep -16 ISep -16 ISep -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16
18Aug
###### -16 HAug -16 HAug -16 HAug -16 HAug -16 HAug -16 HAug -16 HAug -16 HAug -16 HAug -16
109


-----

US20160222
###### 414
US20160222
072
US20160222
023
US20160222
###### 010
US20160221
###### 994
US20160220
###### 664
US20160220
595
CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA
###### VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES Universal Protein Tag for Double Stranded Nucleic Acid Delivery
NOVEL MONOTHIOL MUCOLYTIC AGENTS
###### 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS 14N0t Available Not Available
PARION SCIENCES, INC.
###### Hoffmann-La Roche Inc. Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Not Available
ANTIGEN AND METHOD FOR PRODUCTION THEREOF
NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
USES RELATED THERETO
US20160220
536
USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND
TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF
AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLLLIKE
RECEPTOR OVEREXPRESSION
US20160215
282
US20160215
262
US20160213
###### 776
US20160213
773
US20160213
761
US20160213
647
US20160213
###### 610
US20160207
###### 980
US20160207
949
US20160207
###### 900


-----

US20160206
729
US20160206
719
US20160206
638
US20160206
575
US20160202
258
US20160201
###### 110
US20160201
088
US20160199
###### 486
US20160199
###### 449
SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES
CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING
LYMPHOCYTE SELECTION
ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL
SALTS
MUCOSAL VACCINE COMPOSITION
CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE
THEREOF
###### Not Available Not Available Marl3 230ctl3 303anl5 22Aprl4
29NOV12
###### 13Sepl3 HSepl3 16N0t Available Mar04 28Not Available Not Available GlaxoSmithKline Biologicals SA
NITTO DENKO CORPORATION
###### Not Available
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION Not Available
MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE,
CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES
NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL
BINDING MOLECULE
PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I
###### INHIBITORS
IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME
CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS


-----

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1
PATHWAY
BORON-CONTAINING SMALL MOLECULES
###### Inhibition of Biofilm Organisms
B-CELL ANTIGEN PRESENTING CELL ASSAY
DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
MICROFLUIDIZATION
METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF
VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON
###### Not Available
AMGEN INC.
###### Hangzhou DAC Biotech Co., Ltd
PROZYMEX A/S
###### Not Available CureVac AG Not Available
NOVABIOTICS LIMITED
###### University of Pittsburgh - Of the Commonwealth System of Higher Education Not Available Not Available Not Available Hemispherx Biopharma, Inc. Janis 16Sepl3 iSeplO 30ctl3 19Mar08 28Janl5 240ctl2 5Sepl3 2Sepl3 9Sepl3 19Sepl3 22Febl3 16Feb05 31Mar09 8Aprl0 9Janl5
17Dec01
3Dec09
###### 21Augl3 ISApr -16 22Oct -14 29Jan -16
7Apr
###### -16
27NOV


-----

###### -13
12Sep
###### -14
10Sep
###### -14 19Feb -16 203an -16
16Sep
###### -14
7Apr
###### -16 20ct -14
5Apr
###### -16 273an -16 283an -16
5Sep
###### -14
2Sep
###### -13
8Sep
###### -14
19Sep
###### -14
5Apr
###### -16
5Apr
###### -16 28Mar -16 21Mar -16
17N0V
###### -15
30Mar
###### -16 22Mar -16
21Aug
###### -14 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 110
4Aug
###### -16
4Aug
###### -16
4Aug


-----

###### -16
4Aug
###### -16
4Aug
###### -16
4Aug
###### -16
4Aug
###### -16
4Aug
###### -16 28JU116 28JU116 28JU116 28JU116 28JU116 28JU116 28JU116 21JU116 21JU116 21JU116 21JU116 21JU116 21JU116 21JU116 14JU116 14JU116 14JU116 14JU116 14JU116

US20160199
###### 416
US20160199
###### 407 US20160194
387
###### US20160194
322
###### US20160194
278
US20160193
603
US20160193
327
US20160193
321
US20160193
315
US20160192
658
US20160185
###### 786
US20160185
785


-----

###### US20160184 424 US20160184 334
US20160177
337
US20160177
336
US20160175
###### 433
US20160175
###### 394
US20160175
387
###### US20160174
631
US20160168
203
US20160168
101
US20160166
###### 710
US20160166
###### 676
US20160160
258
US20160160
178
US20160159
927
US20160158
341
###### 26lnduced Hepatocytes and Uses Thereof
HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION
###### Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections
SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS
###### DITHIOL MUCOLYTIC AGENTS
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE
MUCOSAL VACCINE COMPOSITION
MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS
PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
COMPOSITIONS COMPRISING SAID PEPTIDES
HYDROGEN-CONTAINING ANTIMICROBIAL AGENT
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC
PROTEASE 7 INHIBITORS
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS
INTRANASAL VACCINATION DOSAGE REGIMEN
BORON-CONTAINING SMALL MOLECULES
METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING
CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR
###### Expression Tools for Multiprotein Applications


-----

###### LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONSj FORMULATIONSj AND METHODS
###### Compositions and Uses of Lectins
Use of Immune Suppressive Domains as Medicaments
PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT
ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER,
FORMULATIONS FORMING THE SAME, AND METHOD OF
PRODUCING THEREOF
###### Cyclic Antimicrobial Peptides
NOVEL COMPOUNDS
METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
PROTEINS
Use of Immune Suppressive Peptides as Adjuvants
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
OF B CELLS
IMMUNOTHERAPY USING STEM CELLS
###### IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (VR)
AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND
ANTAGONISTS
PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS
###### Fauci/COVID-19 Dossier Not Available
THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
###### Not Available Not Available
PARION SCIENCES, INC.
###### Not Available
NITTO DENKO CORPORATION
###### Novartis AG Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
Emory University
###### Not Available Novl4 251an08 21anl5
25NOV03
###### 23Augl3 293anl0 30ctl3 HSep06 7Aug09 13Augl3 30Decl4 30Decl4 17Decl2 16Feb05


-----

###### 16JU1-08 9Mar04 17Augl0 12Febl0 10Aprl3 23Not
 Available Decl4 24N0VABI0TICS LIMITED
 CHIESI FARMACEUTICI S.p.A. CureVac AG Not Available Not Available Not Available Not Available Novartis AG CC-BY-NC-SA Dr. David E. Martin

Feb06
###### 15Decl4 21Augl3 10Aprl3 26Feb03 9Decl4 5Decl4 18Mar08
25NOV

###### - 15

17Dec

###### - 15
31Dec
###### - 15
 14Mar
 - 16
 llMar
 - 16
5Aug

###### - 15
 2Oct
 - 14
5Nov
###### - 15
 17Mar
 - 16
5Aug
###### - 14
29Dec

###### - 15

29Dec

###### - 15

17Dec

###### - 13
 llMar
 - 16


-----

8Mar
###### -16 llDec -15
15Dec
###### -15 llDec -15 10Apr -14
10Dec
###### -15
9Nov
###### -15
27NOV
###### -15 19Feb -16 10Apr -14
8Feb
###### -16
2Dec
###### -15
7Dec
###### -15
7Dec
###### -15 14JU116 14JU116 7JU116 7JU116 7JU116 7JU116 7JU116 7JU116 7JU116 7JU116 301unl6 303unl6 303unl6 303unl6 233unl6 233unl6 233unl6 233unl6 233unl6 233unl6 163unl6 163unl6 163unl6 163unl6 93unl6 93unl6


-----

###### 93unl6 93unl6
111

US20160158
340
US20160158
339
US20160158
308
US20160158
###### 294
US20160158
###### 154
US20160153
###### 034
US20160152
693
US20160152
###### 676
US20160152
667
US20160152
596
US20160151
399
US20160146
###### 806
US20160146
###### 786
US20160145
###### 246 US20160144
061
US20160139
143
US20160137
702
US20160137
649
US20160135
###### 453
US20160130
367
US20160130
345
US20160130
265
US20160129
###### 110
US20160129
###### 104
US20160129
095
US20160128


-----

937
US20160122
###### 412
INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX
PROTEINS
###### 27Not Available
METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available
TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE
DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
###### Methods of Populating a Gastrointestinal Tract
PROTEIN VESICLES AND METHODS OF MAKING AND USING
THEREOF
###### Rapid Epidemiologic Typing of Bacteria
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME
FOR THE TREATMENT OF VIRAL DISEASES
HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT
PROTEIN-PROTEIN INTERACTIONS
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL
INFECTIONS
###### Nuclear Transport Modulators and Uses Thereof
BORON-CONTAINING SMALL MOLECULES
RECEPTORS FOR B7-H4
###### Method of monitoring cellular trafficking of peptides
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
###### Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides
DETECTING TARGETS USING MASS TAGS AND MASS
SPECTROMETRY
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES
PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL
USES THEREOF
SHELF STABLE, REDUCED CORROSION, READY TO USE
PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS
GENERATION OF BINDING MOLECULES
COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1
PATHWAY
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
NEUTROPHIL ELASTASE ACTIVITY
IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
METHODS
HAND, FOOT, AND MOUTH VACCINES AND METHODS OF
MANUFACTURE AND USE THEREOF
###### Immunostimulatory Combinations
CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION
AND/OR HOMOGENIZATION OF EMULSIONS
COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF
SUPERFAMILY LIGAND
CHILDREN'S HEALTHCARE OF ATLANTA, INC.
###### Not Available Not Available Not Available


-----

Dan06
###### 26JU1-13
12NOV13
###### 4Febl3
 5Decl4
19May08
###### SAblynx N.V. 3un08
7C0L0RAD0
STATE UNIVERSITY RESEARCH FOUNDATION
###### Not Available Karyopharm Therapeutics Inc. Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available
Menus B.V.
###### Not Available Not Available

AUTOIMMUNE TECHNOLOGIES, LLC

###### Not Available Not Available Novartis AG Not Available Novl4 233an08 213unl3 16Feb05 17Mayl3 263unl3 9Mayl2 153U1-02 2-JU110
12Sep07
###### 3-JU113
30Aug07
###### 26Sepll 22Febl3 23Augl2 14Marl3
7NOV14
30D6C02
3Dec09
###### 15Marl3
4Dec

###### -15
 243ull4
14Aug


-----

###### -14 4Feb -14
7Dec
###### -15
11N0V
###### -15 29Oct -15
9Nov
###### -15
9Feb
###### -16 201un -14 17Feb -16
19May
###### -14
26Dun
###### -14 233un -15 4Feb -16
28Dec
###### -15
7Aug
###### -15 1JU114 201an -16
16Sep
###### -15 21Feb -14
29Dec
###### -15 17JU115
6Nov
###### -15
10Sep
###### -15
5Sep
###### -14 16Mar -14 93unl6 93unl6 93unl6 93unl6 93unl6 23unl6 23unl6


-----

###### 23unl6 23unl6 23unl6 23unl6
26May

###### - 16

26May

###### - 16

26May

###### - 16

26May

###### - 16

19May

###### - 16

19May

###### - 16

19May

###### - 16

19May

###### - 16

12May

###### - 16

12May

###### - 16

12May

###### - 16

12May

###### - 16

12May

###### - 16

12May

###### - 16

12May

###### - 16
5May
###### -16 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
112

US20160122

397
US20160122
312
US20160122
306
US20160116
###### 462
US20160115
522
US20160115
221
###### US20160114
322


-----

###### US20160114
037
###### US20160114
027
###### US20160114
022
US20160113
929
US20160113
###### 920
US20160113
881
US20160113
###### 870
US20160108
###### 463
US20160108
###### 461
US20160108
359
US20160108
097
US20160108
###### 096
US20160108
063
US20160106
842
US20160102
295
US20160102
091
US20160101
145
US20160096
899
US20160096
895
US20160095
###### 936
US20160090
589
REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY
AND LETHALITY IN INFLUENZA
###### ANTI-VIRAL COMPOUNDSj PHARMACEUTICAL COMPOSITIONS AND
METHODS OF USE THEREOF
DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER
MUCOSAL DISEASES
ANTIBODY-NANOPARTICLE CON3UGATES AND METHODS FOR
MAKING AND USING SUCH CON3UGATES
MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
CHARACTERISTICS


-----

COMPOSITIONS AND METHODS FOR THE TREATMENT OF
IMMUNODEFICIENCY
PARALLELIZED SAMPLE HANDLING
COMPOSITIONS AND METHODS FOR THE TREATMENT OF
IMMUNODEFICIENCY
###### 23Not Available Apr09 Not Available 16JU1-13
29PARION
SCIENCES, INC.
###### Mayl2 27Not Available Not Available Not Available Not Available Not Available
RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available
THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR
FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS
METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLYINDUCED
CONDITIONS
COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND
###### VIRAL PATHOGENS
NOVEL NANOPARTICLE COMPOSITIONS
CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION
AND/OR HOMOGENIZATION OF EMULSIONS
###### Biological Specimen Collection and Transport System
TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR
###### IDENTIFICATION OF PATHOGENS
AVIAN CELLS FOR IMPROVED VIRUS PRODUCTION
MONOMERIC GRIFFITHSIN TANDEMERS
FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR
USING RECOMBINANT BACTERIA
BORON-CONTAINING SMALL MOLECULES
###### LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
AGENTS
MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
###### Not Available Not Available Not Available Not Available Novartis AG Longhorn Vaccines and Diagnostics, LLC Not Available Not Available
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Not Available Not Available


-----

###### Not Available Not Available 3-V BIOSCIENCES, INC.
PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF Not Available
METHODS FOR TREATING 3UVENILE ARTHRITIS WITH ANTI-BILE
SALT-STIMULATED LIPASE (BSSL) ANTIBODIES
BINDING MEMBERS-513
IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE
THEREOF
###### Not Available Not Available Not Available
COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available
###### AprlO
 HMaylO 280ctl4 19Aprl3 280ctl4 14Mayl0 110ctl4 HMarlO 240ctl4 3Aprl3
3Dec09
###### lOct07 14Sep06 53unl3 53unl3 17Sepl4 16Feb05 8Marl3 28Apr06 SMarll 24Sepl4 8Apr09
7NOV08
###### 5Aprl2 21Feb06 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
2Dec
###### -15
163U114
53an
###### -16 21Apr -15 73an -16
23U115
###### 18Apr -14 83an


-----

**kO** **kO** **kO** **kO** **kO** **kO** **kO**

**in**

c l **o**

**C** **O** **C** **CL** o j **-p** **c** **cz** **OJ** **OJ** **C_** **03** **I—I** **CL** **CL** **CL** **Q_** **Q_** **Q_** **O_**

**LH** **Z5** **LH** **O** **Ln** **CL** **CD** **^■Qinomzs^-zs** **tn** **in** **Q** **m** **ro** **s** **in** **uLnLninLninoin** **^rummruLDrukO** **a5kD<<<<<<<**

**।** **cxi** **।** **cxi** **।** **m** **।** **in** **H।** **inrd** **H।** **Oin** **H।** **rm)** **H।** **rin)** **HrxHHH^HfXlHi** **rd** **i** **CXI** **ik0** **i** **CXI** **i** **O^H^rHOOrHCHrHin** **i** **CXI** **i** **CXI** **i** **CXI** **i** **CXI** **kD** **i** **rd** **in** **i** **m** **i** **inSr-100।** **cxi** **cxi00** **cxi00** **cxi00** **cxi00** **cxi00** **cxi00**


-----

###### 28Aprl6 28Aprl6 28Aprl6 28Aprl6 21Aprl6 21Aprl6 21Aprl6 21Aprl6 21Aprl6 21Aprl6 21Aprl6 14Aprl6 14Aprl6 14Aprl6 7Aprl6 7Aprl6 7Aprl6
31Mar
###### -16
 US20160090
389
###### US20160084
835
US20160083
748
US20160083
689
US20160082
###### 074
US20160081
982
US20160081
346
US20160077
###### 094
US20160076
###### 094
US20160076
053
US20160075
###### 704 US20160074
507
###### US20160074
506
###### US20160074 481
US20160068
843
US20160068
587
US20160068
573
US20160067


-----

333
US20160060
598
US20160060
231
US20160060
###### 230
US20160060
###### 224
US20160058
###### 814
US20160058
012
US20160058
008
###### US20160054
312
US20160053
308
US20160053
222
###### IBPhosphoinositide 3-Kinase Inhibitors
METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING
ADSORPTION MEDIA
TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
INFECTION
METHODS FOR TREATING PULMONARY EMPHYSEMA USING
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
ANTIMICROBIAL COMPOSITIONS AND METHODS
###### Media Elaborated with Newly Synthesized Antibodies (MENSA) and Uses Thereof Efficient Deep Sequencing and Rapid Genomic Speciation of RNA Viruses (vRNAseq) Respivert Ltd.
EXTHERA MEDICAL CORPORATION
###### Not Available Not Available LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Marl3
8NOV13
###### 29Aprl3 29Oct04 HMarl4 14N0t Available Marl3 23Not Available


-----

###### Not Available Not Available
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available
NOVEL SUBSTITUTED SPIROCYCLES
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING
IMMUNE RESPONSE
DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE
POLYMER PARTICLES
###### Clottable Concentrate Of Platelet Growth Factors And Preparation Method Thereof Compositions and Methods for "Resistance-Proof" SiRNA Therapeutics for Influenza
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA
PEPTIDOMIMETIC MACROCYCLES
GENERATING PEPTOID VACCINES
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
ANTIBODY PRODUCING CELLS
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
N-MYRISTOYL TRANSFERASE INHIBITORS
PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND
SYSTEMS
WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS
OF USE
ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL
POLYMERIC BINDING SYSTEM
CHEMICALLY DIFFERENTIATED SENSOR ARRAY
PROBE KIT FOR DETECTING A SINGLE STRAND TARGET
NUCLEOTIDE SEQUENCE
BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE
###### Not Available Not Available Not Available Zheng Yang Biomedical Technology Co.^ LTD. SirnaomicSj Inc. Not Available Not Available
The Board of Regents of the University of Texas System
###### Not Available Not Available Sepl4 5Mayl4 8Sepl4 24Augl2 12Sepl4 16Sepl4 6-JU110 71an08 8-JU112 31an07 141an09


-----

###### 3Mayl3
9Dec05
###### 6Febl3 6Not Available UNIVERSITY OF DUNDEE Not Available Not Available Not Available Nanomedical Diagnostics, Inc. Fondzione Istituto Italiano Di Tecnolgia Not Available Febl3 2Sep08 26Augl4 14Decl0 28Augl4 28Aprl4 27Ded2 ISAprll Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
4Dec
###### -15 16Oct -15 29Apr -14
30Nov
###### -15
8May
###### -15 iDec -15
22Sep
###### -15
5May
###### -15 iSep -15 15Mar -13
10Sep
###### -15
16Sep
###### -15
23NOV
###### -15
30Nov
###### -15
73U113
16NOV
###### -15


-----

14Sep
###### -15
2May
###### -14
26Aug
###### -15
9Nov
###### -15
9Nov
###### -15
31Aug
###### -15
26Aug
###### -14
24Sep
###### -15
28Aug
###### -15 150ct -15
27Dec
###### -13
9Sep
###### -15 114
31Mar
###### -16 24Mar -16 24Mar -16 24Mar -16 24Mar -16 24Mar -16 24Mar -16 17Mar -16 17Mar -16 17Mar -16 17Mar -16 17Mar -16 17Mar -16 17Mar -16 10Mar


-----

###### -16
 10Mar
 -16
 10Mar
 -16
 10Mar
 -16
3Mar
###### -16
3Mar
###### -16
3Mar
###### -16
3Mar
###### -16
3Mar
###### -16
3Mar
###### -16
3Mar
###### -16
 25Feb
 -16
 25Feb
 -16
 25Feb
 -16

US20160052

959
US20160051
691
US20160051
###### 670
US20160051
669
US20160046
705
US20160046
687
US20160045
547
US20160041
168
US20160040
161
US20160039
867
US20160039
###### 860
RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND
DIAGNOSTIC METHODS
22BRIGHAM

YOUNG UNIVERSITY
CARBOHYDRATE CON3UGATES AS DELIVERY AGENTS FOR


-----

OLIGONUCLEOTIDES
METHODS FOR PREPARING SQUALENE
COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING
TREGS
HETERODIMERIC IMMUNOGLOBULINS
GM-CSF AND IL-4 CONIUGATES, COMPOSITIONS, AND METHODS
RELATED THERETO
METHOD OF PREVENTING OR TREATING SINUSITIS WITH
###### OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION
ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
IMMUNE RESPONSE
###### In Vivo Delivery of Oligonucleotides
SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A
US20160039
###### 826 2-((4-AMIN0-3-(3-FLUORO-5-HYDROXYPHENYL)-1HPYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2(TRIFLUOROMETHYL)BENZYL)
 QUINAZ0LIN-4(3H)-ONE
DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE
###### INHIBITORS
US20160039
812
US20160032
319
US20160031
861
US20160031
831
US20160031
###### 830
US20160031
829
US20160031
825
US20160030
###### 443
US20160025
675
US20160025
603
###### US20160024
525
###### US20160024
158
US20160022
801
US20160016
999
US20160016
###### 986
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE


-----

SEQUENCES AND METHODS OF USE
SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF
CATHEPSIN C
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS
###### INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T
CELL FUNCTION
METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS
AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND
DEVICES FOR MONITORING AIRBORNE AGENTS
###### Not Available Not Available Not Available Not Available Not Available
OCULUS INNOVATIVE SCIENCES, INC.
###### Not Available Oncolmmunin Inc. Complix NV Not Available Augl4 4Dec07 12Mayl0 21Augl4
21NOV12
###### 230ctl2
30Dec03
2May08
###### 12Decll 8Dec08 4Augl4 ISNot Available Marl3
19Aug
###### -15
25Aug
###### -15 230ct -15
21Aug
###### -15
21NOV
###### -13 230ct -13 27Oct -15


-----

###### 230ct -15
12Dec
###### -12
21Aug
###### -15
4Aug
###### -15 14Mar -14 25Feb -16 25Feb -16 25Feb -16 25Feb -16 18Feb -16 18Feb -16 18Feb -16 llFeb -16 llFeb -16 llFeb -16 llFeb -16 llFeb -16 Not Available 31JU1-14
15THE
CHILDREN'S HOSPITAL OF PHILADELPHIA
###### Not Available Not Available Marl3 lAugl4 313U1-14 Not Available 313U1-14 Not Available Not Available Not Available Nanomedical Diagnostics, Inc. Not Available
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS NOVARTIS AG


-----

###### Inhibitory Polypeptides Specific to WNT Inhibitors
RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIERSPECIFIC
###### ANTIGENICITY INHIBITORY PEPTIDES OF VIRAL INFECTION STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT Fauci/COVID-19 Dossier Not Available Not Available Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### 31JU1-14 31JU1-14 14Marl3 28Aprl4
223111-14
21May09
###### 15Marl3 15Marl3 17JU1-14 21JU1-14 273ull5 14Mar -14 31JU115
27311115
273U115
273U115
273U115
###### 14Mar -14 lOct -15 213U115
7May
###### -15 14Mar -14 14Mar -14 163U115 213U115 llFeb -16 4Feb -16 4Feb -16 4Feb -16 4Feb -16 4Feb -16


-----

###### 4Feb -16 4Feb -16 28Hanl6 28Hanl6 28Hanl6 28Hanl6 28Hanl6 21Janl6 21Janl6
115

###### US20160016
 916
US20160015
###### 826
US20160015
803
US20160011
183
US20160008
809
US20160008
###### 461
US20160008
###### 451
US20160008
397
US20160008
363
US20160003
747
US20160002
608
US20160000
905
US20160000
###### 790
US20160000
###### 754
US20150377
887
US20150376
621
Exo Olefin-Containing Nuclear Transport Modulators and Uses
###### Thereof 15Not
 Available Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging
IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF
MULTIANALYTE ASSAY
METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID
MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID


-----

###### AMPLIFICATION FOR DISEASE DIAGNOSIS
METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE
RESPONSES
NANOPARTICLE-BASED COMPOSITIONS
IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF
MICRORNAS IN DENDRITIC CELLS
DRUG COMBINATION
###### Apparatus for two-step surface-enhanced raman spectroscopy
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES
###### Nanoparticle Delivery of TLR Agonists and Antigens
DRUG COMBINATION
###### Antiviral Activity from Medicinal Mushrooms and their Active Constituents IN SITU AFFINITY MATURATION OF ANTIBODIES
MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
OF USE
US20150376
###### 584
METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY
###### RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA,
VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS,
ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND
POXVIRUS IN MAMMALIAN PATIENTS
US20150376
145
US20150376
131
###### US20150374
723
###### US20150374 626
US20150369
###### 806
US20150368
661
US20150368
###### 294
US20150366
888
US20150366
###### 796
STABLE SODIUM CHANNEL BLOCKERS
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
NEUTROPHIL ELASTASE ACTIVITY
###### Anti-Viral Azide Containing Compounds
TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES
INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY
FORMULATED GLUTATHIONE
DETECTION OF VIRAL DISEASES USING A BIOCHIP THAT
CONTAINS GOLD NANOPARTICLES
METHODS FOR PRODUCING ANTIBODIES
GADD45BETA TARGETING AGENTS
SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS
THEREOF


-----

INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS
COMPRISING TOLL-LIKE RECEPTOR AGONISTS
###### Not Available Not Available Not Available Marl3 241an05 18JU1-14 30Apr07 University of Texas at El Paso 103U1-14 8Not Available Not Available Not Available
VERONA PHARMA PLC
REAL-TIME ANALYZERS, INC
###### Not Available Not Available
VERONA PHARMA PLC
###### Not Available Not Available
ARROWHEAD RESEARCH CORPORATION
###### 3anl3 14Marl3 143U1-14 15Marl3 16Decll 20Sepl0 25Febl3 15Marl3 63an04 27Febl3 28Feb08
28TAMIR
BIOTECHNOLOGY, INC.
###### Marl4
30PARION
SCIENCES, INC.
###### Not Available Not Available 3unl4 23Augl2 283U1-10 15YOUR
ENERGY SYSTEMS, LLC
###### Febl3 19N0t Available Not Available Not Available Not Available Not Available


-----

###### DunM llFebl3 22Oct09 243unl4 lFebl3 14Mar -14
2Feb
###### -15 17JU115 153un -15 10JU115
2Aug
###### -14 14Mar -14 10JU115 17Mar -14 llSep -15 10JU115 24Feb -14 17Mar -14
14Sep
###### -15 27Feb -14
14May
###### -15 103un -15
303un
###### -15
2Sep
###### -15
20Aug
###### -15 15Mar -13 173un -15 llFeb -14 10Feb -15 223un -15
303an
###### -14 213anl6


-----

###### 21Janl6 21Janl6 14:anl6 14:anl6 14:anl6 14:anl6 14:anl6 14:anl6 7:anl6 7:anl6 7:anl6 7:anl6 7:anl6
31Dec
###### -15
31Dec
###### -15
31Dec
###### -15
31Dec
###### -15
31Dec
###### -15
31Dec
###### -15
31Dec
###### -15
24Dec
###### -15
24Dec
###### -15
24Dec
###### -15
24Dec
###### -15
24Dec
###### -15 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 116

US20150361

###### 432
US20150361
097
US20150361
###### 096
US20150359
871
US20150359
###### 746
US20150355
172
US20150353


-----

905
US20150353
596
US20150353
561
US20150352
218
###### US20150344 425
US20150343
028
US20150337
369
US20150337
###### 334
US20150337
015
US20150335
733
US20150335
728
US20150335
657
US20150329
###### 866
US20150329
###### 834
US20150328
282
US20150322
###### 491
US20150322
155
US20150322
137
US20150322
022
US20150322
008
US20150320
842
US20150320
801
US20150315
612
MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
OF USE
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONISTS
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONISTS
IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS
AND METHODS OF USE
###### Technology for the Preparation of Microparticles


-----

ADP-RIBOSE DETECTION REAGENTS
###### Not Available 261U1-02 22Not Available Not Available
PORTLAND STATE UNIVERSITY
###### Not Available
The Board of Regents of the University of Texas System
CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO Not Available
###### 17-Substituted Steroid Compounds
NOVEL COMPOUNDS
HYDRAZINO 1H-IMIDAZ0QUIN0LIN-4-AMINES AND CONJUGATES
MADE THEREFROM
INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONISTS
METHODS OF MODULATING IMMUNE RESPONSES BY MODIFYING
AKT3 BIOACTIVITY
SINGLE CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT
MULTIPLEX AMPLIFICATION AND DEEP SEQUENCING
METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING
CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR
###### ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF
USE
###### Immunogenic Composition and Methods of Using the Compositions for Inducing Humoral and Cellular Immune Responses
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
VIRUS
###### Methods for Modulating Sirtuin Enzymes
NOVEL siRNAS AND METHODS OF USE THEREOF
METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS
METHODS FOR TREATING VIRAL DISORDERS
###### High density self-contained biological analysis
ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC
CONJUGATION OF A CELL-BINDING MOLECULE
HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR
###### ANTIGEN-BINDING FRAGMENT THEREOF
THERAPEUTIC CATECHOLS
INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONIST
A COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL
INFECTION COMPRISING SAMHD1 OR A NUCLEIC ACID MOLECULE
ENCODING THE SAMHD1
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
CONTAINING SAME, AND USES THEREFOR
###### Fauci/COVID-19 Dossier Not Available CHIESI FARMACEUTICI S.P.A.
3M INNOVATIVE PROPERTIES COMPANY
ACTELION PHARMACEUTICALS LTD
###### Not Available Not Available Not Available


-----

The United States of America, as represented by the
###### Secretary of the Army, on behalf of the United Not Available
 Academia Sinica
 Not Available Not Available GenVec, Inc. Not Available Not Available Robert Yongxin Zhao Not Available
RUTGERS, THE STATE UNIVERSITY OF NEW 1ERSEY

ACTELION PHARMACEUTICALS LTD
SNU R&DB FOUNDATION
###### Not Available Not Available Danis 22lanl3 31Danl3 243U1-07 103unl4 163anl3
28Aug02
###### 93unl4 33unll 18Decl2 17Aprl4 7Mayl4 163U1-08 6Decl2 SAprll 27Mar09 5Mayl4 25Oct06
9NOV09
24Sep09
15NOV06
###### ISDul-lS 283anl3 12Mayl4 12Decl2 73anl3 6Mayl4
30Sep03
CC-BY-NC-SA
###### Dr. David E. Martin
Aug

###### -15
 213an
 -14
 213an
 -14
313an
###### -14


-----

###### 17:un -15
91un
###### -15 15Jan -14
24Aug
###### -15
51un
###### -15
14Aug
###### -15
17Dec
###### -13 17Apr -15 30Apr -15 293ull5 Alun -15 27Apr -15 18Feb -14
4May
###### -15 Sian -15
4Aug
###### -15
5Aug
###### -15
161U115
151U115
###### 281an -14 HMay -15 llDec -13 71an -13
6May
###### -15
201U115
17Dec
###### -15
17Dec
###### -15
17Dec
###### -15
17Dec
###### -15


-----

17Dec

###### -15

10Dec

###### -15

10Dec

###### -15

10Dec

###### -15

10Dec

###### -15

10Dec

###### -15
3Dec
###### -15
3Dec
###### -15

26NOV

###### -15

26NOV

###### -15

26NOV

###### -15

26NOV

###### -15

26NOV

###### -15

26NOV

###### -15

19N0V

###### -15

19N0V

###### -15

19N0V

###### -15

12N0V

###### -15

12N0V

###### -15

12N0V

###### -15

12N0V

###### -15

12N0V

###### -15

12N0V

###### -15

12N0V

###### -15
5Nov
###### -15

117
6
US20150315

###### 574


-----

###### US20150314
017
US20150313
###### 960
US20150313
929
US20150313
909
US20150309
018
US20150307
###### 936
US20150307
935
US20150307
849
US20150307
572
US20150307
530
US20150306
213
US20150306
212
US20150306
205
US20150306
137
US20150301
055
US20150299
728
US20150299
707
US20150299
667
US20150299
271
US20150299
###### 194
US20150299
142
US20150297
###### 700
US20150297
677
US20150297
668
US20150291
609
US20150291
###### 606
US20150291
605


-----

US20150291
531
16PR0DUCTI0N
OF STABLE NON-POLYADENYLATED RNAS
DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING
MOLECULE
NOVEL DEPSIPEPTIDE AND USES THEREOF
USE OF TYLVALOSIN AS ANTIVIRAL AGENT
###### ANTIVIRAL COMPOUNDS AND METHODS
SYSTEM AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE
ANALYSIS
SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD
CHEMISTRY ANALYSIS
NON-MASS DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID
DETECTION
HIGHLY EFFICIENT INFLUENZA MATRIX (Ml) PROTEINS
BIOACTIVE PEPTIDES AND METHODS OF USING SAME
NOVEL MUCOLYTIC AGENTS
HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO
ANTIGENS
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
VACCINE COMPOSITION FOR NAIVE SUBJECTS
METHODS OF TREATING OR PREVENTING INFLAMMATION AND
###### HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL
WATER SOLUTION
CIRCULATING BIOMARKERS FOR DISEASE
###### Massachusetts Institute of Technology Dr. Robert Yongxin Zhao Not Available
CAMBRIDGE UNIVERSITY TECHNICAL SERVICES
###### Biotron Limited
NANOMEDICAL DIAGNOSTICS, INC.
###### Nanomedical Diagnostics, Inc. Not Available Not Available Not Available
PARION SCIENCES, INC.
The Regents of the University of California
###### Not Available Not Available
OCULUS INNOVATIVE SCIENCES, INC.
###### Not Available TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available
CONSTRUCTION OF POOL OF INTERFERING NUCLEIC ACIDS
COVERING ENTIRE RNA TARGET SEQUENCE AND RELATED
COMPOSITIONS
INFLUENZA VIRUS AND TYPE 1 DIABETES
TREATING CANCER WITH VIRAL NUCLEIC ACID
###### 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS 3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2-CARBOXAMIDE COMPOUNDS
###### Novel Adenovirus Vectors
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY
ANALOGS OF C5a AND METHODS OF USING SAME


-----

MERTK-SPECIFIC PYRIMIDINE COMPOUNDS
MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS
MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS
THERAPEUTIC HYDROXYQUINOLONES
BIOMICS BIOTECHNOLOGIES CO., LTD.
###### ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE
VENEZIE
###### Not Available
HOFFMANN-LA ROCHE INC.
PARION SCIENCES, INC.
###### Not Available Children Medical Center Corporation
BOARD PF REGENTS OF THE UNIVERSITY OF NEBRASKA
###### Not Available Not Available Not Available
RUTGERS, THE STATE UNIVERSITY OF NEW 1ERSEY
###### Octl2 15JU1-15 3Decl2 13JU1-06 263un03 28Aprl4 28Aprl4 6Aug09 113U1-03 123U1-07 31Augl2 273U1-10
18NOV13
###### 17Decl2 203an06 6Aprl0 18May04 7-3U108 10Octl2 20Feb07 22Aprl4 17Decl2 10Apr07 13Decl2 293unl0 HAprl4 HAprl4 HAprl4
9NOV12
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 16Oct -13
153U115
###### Hulls 83un


-----

###### -15
6Feb
###### -15 28Apr -14 10Apr -15 13JU115 23Feb -15 23Feb -15
30Aug
###### -13
9Mar
###### -15 123un -15
17Dec
###### -13
73U115
1JU115
6311115
2311115
###### 10Oct -13
63U115
###### 22Apr -15 83an -15 27Apr -15

12Dec
###### -13 293un -11
3Apr
###### -15
3Apr
###### -15
3Apr
###### -15
8Nov
###### -13
5Nov
###### -15
5Nov
###### -15
5Nov
###### -15
5Nov
###### -15
5Nov


-----

###### -15
 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 290ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 220ctl5 150ctl5 IBOctlB IBOctlB IBOctlB
118

###### US20150290

235
USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN
COMBINATION WITH (DEOXY)NUCLEOSIDE OR

(DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND
HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS
US20150290
###### 234
US20150290
212
US20150290
197
US20150290
###### 194
US20150290
189
US20150290
###### 134
US20150289
573
###### US20150284 475 US20150284 451 US20150284 416
US20150283
531


-----

US20150283
233
US20150283
221
US20150275
183
###### US20150274
698
US20150272
988
US20150267
245
US20150267
202
US20150267
###### 194
US20150266
929
US20150266
901
US20150266
882
US20150265
721
US20150265
697
US20150265
###### 696
US20150259
###### 427 23Not Available Novl2
23TARGETED
INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS
THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE
COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE
COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH
ANTI-MER TYROSINE KINASE ACTIVITY
CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE
POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR
MICROSPHERES
###### Not Available Not Available Not Available Not Available
PARION SCIENCES, INC.
###### Not Available
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE Not Available
###### BISPECIFIC ANTIBODY
COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN


-----

INFECTION
###### Not Available Not Available
NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES SUZHOU M-CONJ BIOTECH
###### CO.j LTD Microspotting Device Compositions and Methods for Enhancing Immune Responses
ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE
VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS
Human Betacoronavirus Lineage C and Identification of N-Terminal
###### Dipeptidyl Peptidase As Its Virus Receptor Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS
FLUID MEDIA
ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING
SS/RNA VIRAL INFECTION
DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
AND METHODS OF USE THEREOF
###### VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND
IMMUNOGENIC COMPOSITIONS
ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
THIAZOLONAPHTHYRIDINES
###### PYRAZ0L0[4,3-D]PYRIMIDINES AS KINASE INHIBITORS
Compounds and Methods for Modulating an Immune Response
###### HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR
GENERATING VIRUS-LIKE PARTICLES
###### Compositions And Methods For Treating And Preventing Porcine Reproductive And Respiratory Syndrome
GITR BINDING MOLECULES AND USES THEREFOR
###### Fauci/COVID-19 Dossier Not Available Not Available
The Board of Trustees of the University of Illinois
###### Not Available Not Available Advanced Inhalation Therapies (AIT) Ltd. GenTegra, LLC Not Available Quark Pharmaceutical, Inc. Not Available Not Available Not Available Not Available Academia Sinica Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Mar07 HAprl4 HAprl4 HAprl4


-----

**rd** **kD** **(N** **(N** **in** **(N** **(N** **CXI** **rd** **CO** **CXI** **CXI** **CXI** **CXI** **LH**
**rlOrxHrlrlrlrl^H** **i** **CXI** **r-1** **CD** **r-1** **©** **LH** **H** **O** **O** **H** **O**
**C** **CO** **>** **-P** **C** **C** **CH** **Q.H** **H** **£_** **Q.** **Q** **>** **O** **■P** **C** **CD** **C** **C** **C** **C** **C** **C** **>** **-p** **C** **C** **C** **CL**
**^rucoo^Q-^Cdi^cruaiairu-Q** **U** **05** **CL** **CL** **05** **>** **CL** **C.** **C.** **£_** **05** **CL** **=5** **O** **U** **Z5** **CL** **Z5** **C_** **OJ**
**i—>** **i—>** **ci** **o** **m** **<** **i—)** **n_** **un** **n** **os** **s** **tn** **tn** **s** o j **OS** **0J<S** **O** **m** **<** **LH** **CL** **LH** **CL** **LH** **Q.LnnL^<LnnLnZ(NO** **m** **n** **in** **<** **m** **n** **m** c l l h l o **m**
**rx^nHooo3Ln<moz^O(NrxLL** **O^rCItZl^Lfl^rHrHrH'^vH'^rH'^rHCXIrHrHrHCOrHrHrHO^**
**CXI** **CXI** **r-1** **CXI** **CXI** **r-1** **r-1** **r-1** **CXI** **CXI** **r-1** **r-1** **r-1** **r-IO** **rH** c xi **in** **cxi** **cxi** **co** **।** **cxi** **।** **m** **im** **।** **rn** **।** t h । c xi i c xi i c xi i c xi **i** **rd** **i** **rd** **i** **rd** **i** **i** **CXI** **i**


-----

7Mar
###### -13 14Mar -14
6Nov
###### -14
12Sep
###### -13
4May
###### -15 83un -15 180ct -13
23Dec
###### -14 llFeb -15 23Feb -15 23Mar -15
119
###### 150ctl5 150ctl5 150ctl5 150ctl5 150ctl5 150ctl5 150ctl5 150ctl5 80ctl5 80ctl5 80ctl5 80ctl5 80ctl5 80ctl5 10ctl5 10ctl5 10ctl5
24Sep
###### -15
24Sep
###### -15
24Sep
###### -15
24Sep
###### -15
24Sep
###### -15
24Sep
###### -15
24Sep
###### -15


-----

24Sep
###### -15
24Sep
###### -15
17Sep
###### -15

US20150259
399
US20150259
340
US20150259
292
US20150258
191
US20150252
###### 439
US20150252
###### 080
US20150250
###### 896
US20150247
###### 190
US20150246
###### 110
US20150246
091
US20150246
015
US20150239
###### 940
US20150239
875
US20150238
550
US20150238
###### 489
US20150232
957
US20150232
881
US20150232
878
US20150232
###### 454
US20150231
232
US20150225
###### 432
US20150218
162
US20150218
109
US20150216
973


-----

US20150211
###### 006
US20150210
733
US20150210
655
US20150203
847
###### 16ANTIB0DIES
AND PROCESSES FOR PREPARING THE SAME
NOVEL KINASE INHIBITORS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
MICROFLUIDIZATION
###### Methods and Compositions for Prostate Cancer Metastasis
FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE,
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND
USE THEREOF
HYDROPHILIC LINKERS AND THEIR USES FOR CON3UGATION OF
DRUGS TO A CELL BINDING MOLECULES
METHODS AND SYSTEMS FOR MICROFLUIDICS IMAGING AND
ANALYSIS
AD3UVANTED INFLUENZA VACCINES INCLUDING CYTOKINEINDUCING
AGENTS
COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A
###### VIRAL INFECTION Esters of Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders
COMPOSITIONS AND METHODS FOR VIRUS INHIBITION
SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS
###### INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
AAV Vectors Targeted to Oligodendrocytes
###### Not Available Not Available Not Available Novartis AG Not Available Not Available Hangzhou DAC Biotech Co., Ltd. Not Available Novartis AG Not Available Not Available
AUTOIMMUNE TECHNOLOGIES, LLC
###### Not Available Not Available
HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES Not Available
MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
CRISPR-RELATED METHODS AND COMPOSITIONS WITH
GOVERNING gRNAS
###### Construct
THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES
AND HYDROXYPYRIDAZINONES


-----

OUTER MEMBRANE VESICLES
###### Not Available
EDITAS MEDICINEj INC.
###### Not Available
RUTGERS, THE STATE UNIVERSITY OF NEW 1ERSEY
###### Not Available
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS Novartis AG
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
IMIDAZONAPHTHYRIDINES
C-REL INHIBITORS AND USES THEREOF
METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE
CHIRAL CONTROL
NUCLEIC ACID CHEMICAL MODIFICATIONS
CERTAIN (2S)-N-[(lS)-l-CYAN0-2-PHENYLETHYL]-l,40XAZEPANE-2-CARB0XAMIDES
AS DIPEPTIDYL PEPTIDASE 1
###### INHIBITORS
CHEMICAL MODIFICATIONS OF MONOMERS AND
OLIGONUCLEOTIDES WITH CYCLOADDITION
###### Not Available Not Available Not Available Not Available Not Available
ASTRAZENECA AB
###### Not Available
May08
###### 19Octl2 SMarll
3Dec09
###### 25Marll 7Sepl2
24NOV12
###### 50ctl2
4NOV05
2NOV07
###### 30ctl2
4NOV03
###### 21Febl4 28Sepl2 31Augl2 4Aprl2
7NOV13
###### 28Mar06 HSepl2 18Sepl2 2Sep09 183un04 21Sepl2 8Augl2 133U1-12 2Mar09 243anl4
23Sep08
###### 18Mar


-----

###### -15 180ct
 -13 19Mar -15 13Mar -15
20May
###### -15
9Sep
###### -13
24N0V
###### -12 40ct -13
14May
###### -15
15May
###### -15 30ct -13
13May
###### -15 12Feb -15
27Sep
###### -13
30Aug
###### -13 4Apr -13
7Nov
###### -14 20Oct -14 llSep -13
18Sep
###### -13 24Apr -15 13Apr -15
19Sep
###### -13
8Aug
###### -13 12JU113 223an -15 213an -15
31Dec
###### -14


-----

17Sep

###### -15

17Sep

###### -15

17Sep

###### -15

17Sep

###### -15

10Sep

###### -15

10Sep

###### -15
10Sep

###### -15
3Sep
###### -15
3Sep
###### -15
3Sep
###### -15
3Sep
###### -15

27Aug

###### -15

27Aug

###### -15

27Aug

###### -15

27Aug

###### -15

20Aug

###### -15

20Aug

###### -15

20Aug

###### -15

20Aug

###### -15

20Aug

###### -15

13Aug

###### -15
6Aug

###### -15

6Aug

###### -15

6Aug

###### -15
303U115
303U115
303U115
###### 233U115 Fauci/COVID-19
 Dossier


-----

CC-BY-NC-SA Dr. David E. Martin
###### 120

US20150203

###### 816
US20150202
###### 284
US20150196
619
US20150196
578
US20150196
032
US20150191
###### 704
US20150191
607
###### US20150184
231
US20150183
837
US20150182
###### 636
US20150182
588
US20150176
027
US20150175
###### 656 US20150174
257
###### US20150174 206 US20150174
198
###### US20150174
158
US20150173
366
US20150168
###### 405
US20150166
989
US20150166
###### 966
US20150166
548
US20150166
532
US20150166
###### 488
US20150166
###### 487
US20150165
019


-----

US20150165
009
4MEANS
AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available
METHOD OF MAKING A VACCINE
EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE
RESPIRATORY TRACT
COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS
###### ANTIVIRAL COMPOSITIONS
POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS
CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND
METHODS OF MAKING AND USING SAME
###### Anti-fouling Paints and Coatings
BIOAGENT DETECTION OLIGONUCLEOTIDES
The United States of America, as represented by the
###### Secretary, Dept, of Health & Human Services Not Available Not Available
Long Island University
Dec09
###### HOct08 81anl0 14Oct09
30May07
###### 30Not Available Decl3
REACTIVE
SURFACES, LTD
###### Not Available
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF Not Available
GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR
CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL
OR CHEMICAL AGENTS
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
###### 3-3U103 27Decll
17D6C07
###### 21N0t Available Apr08 18Not Available Not Available
CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Not Available
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE
TRANSFER TO MONOCYTES AND MACROPHAGES
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING
###### LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA
VIRUS SPIKE PROTEIN
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY


-----

DISEASES
PHYSICAL ANTIMICROBIAL METHOD
OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD
PARTICLE-NUCLEIC ACID CONIUGATES AND THERAPEUTIC USES
RELATED THERETO
REVERSE GENETICS METHODS FOR VIRUS RESCUE
NOVEL COMPOUNDS
HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
VIRUSES
ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL
SODIUM CHANNEL BLOCKING COMPOUNDS
ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
SODIUM CHANNEL BLOCKING COMPOUNDS
###### Saccharide Conjugate Vaccines
TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS
RELATED THERETO
###### Fauci/COVID-19 Dossier Not Available Not Available Novl3
17Dec01
###### 20Mar09 29Apr09
28Aug03
###### 28Not Available Oct05 7Not Available
NMS TECHNOLOGIES CO., LTD.
###### Not Available Not Available Not Available CHIESI FARMACEUTICI S.p.A. Not Available
PARION SCIENCES, INC.
###### Parion Sciences, Inc. Not Available
Emory University
###### Marl2 lAugl2 16Febl0 253unl2 20Oct09 16Decl3 HAprl2 13Decl3 13Decl3
24D6C04
###### 24Sepl0
CC-BY-NC-SA
###### Dr. David E. Martin 26Mar -15


-----

###### 20:an -15 21an -15
10Dec
###### -14 19Mar -15
19Dec
###### -14
4Dec
###### -13
27Dec
###### -12 13Feb -15 13Mar -15
23Dec
###### -14 163an -15
5Mar
###### -15
3Mar
###### -15 283an -15
17N0V
###### -14
7Mar
###### -13 16JU113 24Feb -15 27Feb -13 lOCt -14
16Dec
###### -14 15Mar -13
19Dec
###### -14
13Dec
###### -13
5Aug
###### -14
20Sep
###### -11
233U115
233U115
###### 16JU115


-----

###### 16JU115 16JU115 9JU115 9JU115
2JU115
2JU115
2JU115
2JU115
###### 253unl5 253unl5 253unl5 253unl5 253unl5 253unl5 253unl5 183unl5 183unl5 183unl5 183unl5 183unl5 183unl5 183unl5 183unl5 183unl5
121

###### US20150164 800
US20150159
205
US20150159
173
US20150157
###### 636
US20150152
149
US20150150
963
US20150150
893
US20150150
878
US20150148
###### 402
US20150147
346
US20150141
625
US20150141
387
US20150140
121
US20150139
949
US20150133


-----

633
US20150133
###### 402
US20150133
391
US20150132
339
US20150132
337
US20150132
###### 220
US20150126
722
US20150125
540
US20150125
502
US20150125
###### 483
US20150125
###### 475
US20150125
###### 384
US20150119
###### 445
US20150119
###### 444
REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND
###### LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE
METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR
METHODS FOR TREATING VIRAL DISORDERS

###### Peptides Having Activity of Inhibiting Infections of Respiratory Viruses and Use of the Same
VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS
###### Salk Institute For Biological Studies 253U1-12
The
###### United States of America, as represented by the Secretary, Department of Health and Human
The Trustees of the University of Pennsylvania
###### Not Available Not Available
THE AUSTRALIAN NATIONAL UNIVERSITY
ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION Not Available
###### Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins
MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
OF USE
###### REPLIKIN SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS,
THERAPEUTICS, AND VACCINES AGAINST PRION AND
NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S
DISEASE
IMMUNE RESPONSE MODIFIER CON3UGATES


-----

PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE
###### INHIBITOR AND A SECOND ACTIVE INGREDIENT Compositions and Methods for Tight Junction Modulation ANTI-VIRAL COMBINATION THERAPY
MODIFICATION OF PEPTIDES USING A
BIS(THIOETHER)ARYLBRIDGE APPROACH
BORON-CONTAINING SMALL MOLECULES
CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN
MICROBIOME AND COMPONENTS THEREOF
ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE
ANTIGENS
COMBINATION GAS VACCINES AND THERAPEUTICS
###### Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides
OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING
NIDOVIRUS INFECTIONS
RELEASE OF AGENTS FROM CELLS
###### DISINFECTING COMPOSITION AND WIPES WITH REDUCED
CONTACT TIME
FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS,
GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR
IMMUNOLOGICALLY USEFUL ARGININE SALTS
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
###### Not Available
NOVARTIS AG
###### 6Augl2 7Apr05
24Sep09
###### 9Mayl3 5Junl2 18Junl2 4Aprl2 lOct04 2Not Available Mayl2 22Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Not Available Tetragenetics, Inc. Not Available Not Available Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available


-----

###### Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available
 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin

Feb06
###### 18Dec08 81unl2 6Aprll 18Mayl2 201un07
7NOV13
###### 7Marl2 17Sep08 15JU1-02 24Dec03 15Oct09
6NOV13
###### 27Mayll 7Marl2 15Feb07 4Dec07 4Dec07 233U113
6Aug

###### -12
 18Feb
 -15
 18Feb
 -15
 21Feb
 -14
53un
###### -13
31May

###### -13
 4Apr
 -13

9May

###### -14
 IMay
 -13
 203an
 -15
143 an

###### -15
 103un
 -13

19May

###### -14

17May

###### -13

7Nov

###### -14

7Nov

###### -14


-----

**LH** **LH** **LH**

**LH** **LH** **LH** **LH**

**>** **I—I** **r—|** **in** **c** **c** **c** **H** **H** **H** **H** **>** **>*,** **>*,**

**C** **C** **>** **05** **C** **O** **Z5** **Z5** **rd** **Z5** **Z5** **Z5** **C** **C** **C** **C** **05** **05** **05** **ro** **ro** **ro** **ro** **ro**
**Ln^^-nsino^-ScN** j i—j c i —)i—)i—) **Z5** **3** **3** **Z5** **S** **LH** **S** **LH** **S** **LH**
**Hr)rHOrH2rHO>rHi** **।** **LH** **i** **i** **CXI** **i** **S** **i** **rd** **।** **CXICx|** **rdH** **D□** **HH** **HH** **HH** **I—)** **I—)** **I—)** **I—)** **COCXI** **T—II** **COCXI** **T—II** **T—CXII** **T—II** **CXIHHHHHH^fH^fHi** **CXI** **i** **CXI** **i** **fl** **i** **rd** **I**


-----

7May
###### -15
7May
###### -15
7May
###### -15
7May
###### -15
7May
###### -15 30Aprl5 30Aprl5
122
18
###### US20150119
 426
US20150119
###### 364
US20150119
318
US20150118
###### 746
US20150118
319
US20150118
265
US20150118
###### 264 US20150118
222
US20150118
201
US20150118
183
US20150111
###### 955
US20150111
945
US20150111
893
US20150110
807
US20150105
375
###### US20150104 867 US20150104
500
US20150099
###### 770
US20150099
769
US20150099
###### 764


-----

US20150099
###### 656
US20150099
263
US20150099
261
US20150093
###### 413
US20150086
576
US20150080
###### 447
US20150080
396
4M0DULAT0RS
OF THE RELAXIN RECEPTOR 1
BORON-CONTAINING SMALL MOLECULES
PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING
HERPESVIRUS INFECTION
INFLUENZA VIRUS REASSORTMENT METHOD
PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E
VIRUS AS AN ORAL DELIVERY VECTOR
###### Not Available Not Available
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL
FUND
###### Not Available Not Available
MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF Anthrogenesis Corporation
PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC
CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR
PEPTIDE ANTIGEN
TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND
IMMUNOTHERAPY
###### Directed Evolution and In Vitro Panning of Virus Vectors
NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES
FOR IMMUNOSTIMULATION
AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER
TO CELLS, ORGANS AND TISSUES
COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS
GENE EXPRESSION
###### Nuclear Transport Modulators and Uses Thereof
HDC-SIGN BINDING PEPTIDES
METHODS FOR TREATING PULMONARY EMPHYSEMA USING
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
###### Methods and Compositions for Preventing a Condition
CARBOXYLIC ACID COMPOUNDS
###### PYRROLO[3,2-D]PYRIMIDIN-4-0NE DERIVATIVES AND THEIR USE IN THERAPY
DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER


-----

MUCOSAL DISEASES
###### Multiplex Immuno Screening Assay
SELECTIVE DETECTION OF HUMAN RHINOVIRUS
RESPIRATORY INFECTION ASSAY
NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEMLOOP
AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL
FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC
ANTIGEN
SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF
###### Sceletium Extract and Uses Thereof Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases Fauci/COVID-19 Dossier CureVac GMBH Not Available Not Available
CUREVAC GMBH
###### Not Available Not Available Not Available Sloan-Kettering Institute for Cancer Research Mayl2 16Feb05 30Oct09 21Mayl0 27Feb09 13Marl2 313anl2 250ctl3 30Apr08 313anl2 17Febl2 203U1-09 9Mayl2 19Decll 14N0t Available Marl3 29Baxter Healthcare SA Not Available Not Available Not Available Oct04 9Augl0 18Mayl2 6Dec04
29PARION
SCIENCES, INC.
###### Mayl2 4N0t Available Not Available Not Available


-----

###### Mayl2

5Dec08
###### 9Decll 15CureVac
GmbH

###### Febl2 13Not
 Available
H. L. Hall & Sons Limited
ASTRAZENECA AB
###### Aprl2
 20Mar09
21May09
CC-BY-NC-SA
###### Dr. David E. Martin ISMar
 -13

10Nov

###### -14

9311114
###### 240ct
 -14
SNov
###### -14
 12Mar
 -13
311an
###### -13
 240ct
 -14
 22Oct
 -14
311an
###### -13
 19Feb
 -13
 28Mar
 -14

9May

###### -13

10Dec

###### -12

18Dec

###### -14

2May

###### -14

28Aug

###### -14

17May

###### -13
 issep
 -14

9Dec

###### -14


-----

3May
###### -13
15Dec
###### -14
10Dec
###### -12 15Feb -13 15Apr -13 153U114
26Aug
###### -14
123
###### 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 30Aprl5 23Aprl5 23Aprl5 23Aprl5 23Aprl5 16Aprl5 16Aprl5 16Aprl5 9Aprl5 9Aprl5 9Aprl5 9Aprl5 9Aprl5 9Aprl5 2Aprl5 26Mar -15 19Mar -15 19Mar -15
 US20150080
344
###### US20150080
319
###### US20150079
155
###### US20150079 121 US20150073 136


-----

US20150072
973
US20150072
023
US20150065
###### 459
US20150065
###### 458 US20150064
137
US20150056
###### 636
US20150056
305
US20150051
###### 206
US20150050
713
US20150050
308
US20150050
278
US20150045
###### 412 US20150044
768
###### US20150044
305
###### US20150044
279
US20150037
288
US20150037
281
###### US20150034 084
US20150031
038
US20150031
###### 016
US20150031
###### 014
US20150030
627
US20150030
###### 626
PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF

###### VIRAL INFECTIONS
 Inhibition Of Tace Activity With Cyclic Peptides Cationic Liposomal Drug Delivery System for Specific Targeting of
Human CD14+ Monocytes in Whole Blood
Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid
###### Constructs And Vaccines Made Therefrom, And Methods Of Using
Same


-----

PYRAZINONE DERIVATIVES
NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE
###### 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR
THERAPEUTIC APPLICATIONS
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
BORON-CONTAINING SMALL MOLECULES
###### Composition for Inactivating an Enveloped Virus
USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT
CELLS
###### 14N0t Available Not Available Not Available Not Available Not Available AprlO ZJunll 14Marl2 10Aprl2 271un07 13Not Available Augl0 UNot Available Not Available Not Available Kythera Biopharmaceuticals, Inc. Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Not Available DITHIOL MUCOLYTIC AGENTS
PARION SCIENCES, INC.
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
###### Technology for the Preparation of Microparticles
CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE
GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS
SOLUBLE ENGINEERED MONOMERIC FC
USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR
TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY
METHODS AND COMPOSITIONS FOR PRODUCTION OF
RECOMBINANT PROTEIN IN HBX-EXPRESSING MAMMALIAN CELLS
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
RESPONSE
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES
VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING
SAME
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
DISEASES
SAMPLE PREPARATION METHODS
###### Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
and Enteric Viruses
DETECTING ANALYTES WITH A PH METER


-----

###### Trans-complementingj replication deficient lentiviral vectors and methods for making and using them
IMMUNOMODULATORY CONJUGATES
###### Fauci/COVID-19 Dossier Not Available Not Available Not Available Not Available Sepl3 16Feb05
19May06
###### 17Aprl2 26Marl2 23Augl3 ISepll 24JU1-07
18Aug03
###### 16Marl2 7Marl2 28Not Available Not Available Not Available Not Available Icahn School of Medicine at Mount Sinai Advanced Inhalation Therapies (AIT) Ltd. Not Available Diagnostic Hybrids Inc.
The Board of Trustees of the University of Illinois
###### VIRxSYS.CON390 Ascend Biopharamaceuticals Ltd
CC-BY-NC-SA Dr. David E. Martin
May08
###### 7Marl2 10Apr03 26Janl2 2Marl2 7Marl2 6Sepll 24Apr98 25JU1-13 17Aug06
9NOV11
29Sep
###### -14
19Sep
###### -14 14Mar -13 10Apr -13
17NOV
###### -14
17Sep


-----

###### -14 llSep -14
10NOV
###### -14
17N0V
###### -14 16Apr -13 26Mar -13
13Aug
###### -14
29Aug
###### -12
253U114
13Aug
###### -14 14Mar -13
6Mar
###### -13 240ct -14
7Mar
###### -13 60ct -14 253an -13 iMar -13
7Mar
###### -13
6Sep
###### -12
4Aug
###### -14
253U114
###### 80ct -14
9Nov
###### -12 19Mar -15 19Mar -15 19Mar -15 19Mar -15 12Mar -15 12Mar


-----

###### -15 12Mar -15
5Mar
###### -15
5Mar
###### -15
5Mar
###### -15 26Feb -15 26Feb -15 19Feb -15 19Feb -15 19Feb -15 19Feb -15 12Feb -15 12Feb -15 12Feb -15 12Feb -15
5Feb
###### -15
5Feb
###### -15
5Feb
###### -15 291anl5 291anl5 291anl5 291anl5 291anl5 124
 US20150030
625
US20150030
607
###### US20150025 075 US20150024 415 US20150024 405 US20150024 002 US20150023


-----

###### 990
US20150023
###### 924
US20150023
921
US20150023
879
US20150021
###### 204
US20150021
203
US20150018
396
US20150018
332
US20150017
251
US20150011
615
US20150011
508
US20150010
983
US20150005
227
###### US20150004
188
###### US20140364 492 US20140364 408 US20140364
358
US20140363
###### 465
US20140363
###### 422
US20140357
673
US20140356
390
US20140349
375
12GAS57
MUTANT ANTIGENS AND GAS57 ANTIBODIES

INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES
FOR PREVENTING AND TREATING INFLUENZA VIRUS INFECTION
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONISTS
DETECTION AND QUANTIFICATION OF ANALYTES BASED ON
SIGNAL INDUCED BY ALKALINE PHOSPHATE
ENHANCED DEPOSITION OF CHROMOGENS UTILIZING PYRIMIDINE
ANALOGS
###### Not Available


-----

###### Not Available
ACTELION PHARMACEUTICALS LTD.
The Board of Trustees of the University of Illinois
###### Ventana Medical Systems, Inc.
ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES Not Available
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES
VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR
GENE TRANSFER TO CELLS, ORGANS AND TISSUES
###### HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS
DIAGNOSTIC CHEWING GUM FOR PATHOGENS
AMPEROMETRIC GAS SENSOR
AMPEROMETRIC GAS SENSOR
PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH
PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA
AGONIST
###### Nuclear Transport Modulators and Uses Thereof
MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS
3M INNOVATIVE PROPERTIES COMPANY
###### Not Available
BIOTRON LIMITED
###### 3ulius-Maximilians-Universitaet Wuerzburg Not Available Not Available Not Available
KARYOPHARM THERAPEUTICS INC.
NOVARTIS AG
###### Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL
GROWTH
METHOD OF TREATING AN ISCHEMIA-REPERFUSION IN3URYRELATED
DISORDER BY ADMINISTERING GPCR LIGANDS
COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC
CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND
METHODS OF USING THE SAME
PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL
COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL
INFECTIOUS DISEASES INCLUDING SAME
###### Hydrazide Containing Nuclear Transport Modulators And Uses Thereof Method for Preventing and Treating Hyperpermeability
MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE
SAME
METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH
DESIRED SPECIFICITY
###### Deubiquitinase Inhibitors and Methods for Use of the Same
MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF
SYNONYMOUS CODONS
METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL
###### ACTIVITY Fauci/COVID-19 Dossier Not Available Not Available
Sep07


-----

###### 20Octl0 20:anl2 16Febl2 30Decl0 21May04 3Oct03 223ul-13
3Aug07
###### 8Marl2 253unl2 253unl2 8Marl2 29JU1-11 6Aug08 4Dec07 ISepll
5Dec08
###### 18Sep06 12N0t Available
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
BIOTECHNOLOGY
KARYOPHARM THERAPEUTICS INC.

###### Apeptico Forschung UND Entwicklung GMBH Beth Israel Deaconess Medical Center, Inc. Not Available Not Available
The Government of the United States of America as
###### represented by the Secretary of the Department of Biogentic Innovations, LLC
CC-BY-NC-SA Dr. David E. Martin
###### Decll 26Octll 293U1-11
5Mar09
###### 4Aprll 28Decll 24Sepl0 8Oct04 30Oct09 13Oct -14 9Oct -14 183an -13 19Feb -13 6Oct -14
20Aug
###### -14
30Sep
###### -14


-----

22DU114
3Apr
###### -14
8Mar
###### -13
30Sep
###### -14
30Sep
###### -14
3Mar
###### -13
263U112
###### 18JU114 11JU114
28Aug
###### -12

19Sep
###### -14

7Sep
###### -14 llDec -12

28Sep
###### -12 293ull2
7Mar
###### -14
 4Apr -12 23an -13 31JU114
20Aug
###### -14

12Aug
###### -14 293anl5 293anl5 223anl5 223anl5 223anl5 223anl5 223anl5 223anl5 223anl5 223anl5 223anl5 223anl5 153anl5 153anl5 153anl5 83anl5 83anl5 83anl5


-----

###### Uanis Uanis llDec -14 llDec -14 llDec -14 llDec -14 llDec -14
4Dec
###### -14
4Dec
###### -14
27NOV
###### -14
125

US20140349
295
US20140349
###### 276
US20140348
###### 906
US20140348
791
US20140348
785
US20140348
781
US20140342
941
US20140342
###### 407
US20140336
245
US20140335
618
US20140335
592
US20140335
117
US20140335
111
US20140335
###### 104
US20140329
889
US20140329
878
US20140329
817
US20140328


-----

###### 946
US20140328
###### 874
US20140323
556
US20140323
392
US20140323
390
US20140322
355
US20140317
###### 766
US20140315
982
US20140315
215
###### US20140314
858
###### US20140314
839
###### US20140314
809
31METH0D
FOR DETECTING TARGET NUCLEIC ACID
###### Not Available
SIGNAL PROPAGATION BIOMOLECULES, DEVICES AND METHODS STC.UNM
IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOMEENCAPSULATED
OLIGONUCLEOTIDES AND EPITOPES
MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT
USING SAME
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE
CON3UGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS
RELATED THERETO
METHOD FOR USING PERMUTED NUCLEIC ACID PROBES
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE
VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY
TAL EFFECTOR-MEDIATED DNA MODIFICATION
TAL EFFECTOR-MEDIATED DNA MODIFICATION
###### Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND
COMPOSITIONS AND METHODS OF USING THE SAME
###### Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON
OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
PATHWAY
MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED
THERETO
ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE
AND METHODS OF MAKING AND USING THE SAME
SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION
SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT


-----

###### LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE
SYSTEM
METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL
ENTRY
COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS
ANTIBODY PRODUCING NON-HUMAN MAMMALS
DOUBLE-STRANDED NUCLEIC ACID MOLECULE FOR GENE
EXPRESSION CONTROL
THERMOSTABLE ASSAY REAGENTS
###### IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLEBASED
PLATFORM AND METHODS OF USING THE SAME
CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES
THEREOF
MALARIA ANTIGEN SCREENING METHOD
###### Fauci/COVID-19 Dossier Not Available Beth Israel Deaconess Medical Center, Inc. Not Available
CHILDREN'S HEALTHCARE OF ATLANTA, INC
###### Ventana Medical Systems, Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serv Not Available Iowa State University Research Foundation, Inc. Iowa State University Research Foundation, Inc. Not Available
The Trustees of the University of Pennsylvania
###### Not Available Not Available Not Available
CHILDREN'S HEATLHCARE OF ATLANTA, INC.
###### Not Available Not Available Not Available UNIVERSITY OF UTAH RESEARCH FOUNDATION
IRM LLC
###### 3-V BIOSCIENCES, INC. Not Available
Osaka City University
The Secretary of State for Health
###### Advanced BioNutrition Corporation Not Available Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Octll 21Mayl3 173U1-09 9Sepll
7NOV11
###### 22Mayl3 lSep06
7NOV11
22NOV11


-----

10Dec09
10Dec09
###### 70ctll 4Apr08
13May08
###### 3Mayl3 3Marll 240ctll 13Mar07 190ctll 15Marl3 28Marll 23Marl0 SMarli 273un08 2Novll 14Sepll 9Sepll 2Decll 19Aprl3 250ct -12
21May
###### -14
13Aug
###### -14
7Sep
###### -12
7Nov
###### -12
20May
###### -14
5Aug
###### -14
4Aug
###### -14
21Nov
###### -12 14Apr -14 24Feb -14 50ct -12 28Apr -14 14Apr -14
2May
###### -14 IMar -12 240ct -12


-----

###### 21JU114 190ct -12 17Mar -14 28Mar -12 9JU114 253un -14 29Apr -14 INov -12
14Sep
###### -12
7Sep
###### -12
30Nov
###### -12 19Apr -13
27NOV
###### -14
27NOV
###### -14
27NOV
###### -14
27NOV
###### -14
27NOV
###### -14
27NOV
###### -14
20Nov
###### -14
20Nov
###### -14
13NOV
###### -14
13NOV
###### -14
13NOV
###### -14
13NOV
###### -14
13NOV
###### -14
13NOV
###### -14
6Nov
###### -14
6Nov
###### -14


-----

6Nov
###### -14
6Nov
###### -14
6Nov
###### -14 30Octl4 30Octl4 30Octl4 30Octl4 230ctl4 230ctl4 230ctl4 230ctl4 230ctl4 230ctl4 126
 US20140314
797
###### US20140314
755
###### US20140314
739
US20140309
189
US20140309
###### 164
US20140308
379
US20140308
313
US20140308
211
US20140303
232
US20140303
071
US20140302
###### 124
US20140302
###### 120
US20140302
091
US20140302
077
###### US20140298
500
US20140296
179
US20140295
###### 404 US20140294
828
###### US20140294


-----

765
###### US20140294
727
###### US20140294 670
US20140287
987
US20140286
988
US20140283
945
US20140275
237
US20140275
159
US20140275
155
US20140275
###### 114
YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH
TERMINAL ALPHA-1,3-LINKED GALACTOSE
###### 30Not Available
ANTIBODY PRODUCING NON-HUMAN MAMMALS
###### Vaccine adjuvant composition comprising inulin particles
HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF
HCV
###### Not Available Vaxine Pty Ltd. Achillion Pharmaceuticals, Inc.
DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV Achillion
###### Pharmaceuticals, Inc.
USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT
OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES
COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D
LIGANDS
MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
CHARACTERISTICS
###### LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
AGENTS
CYCLIC ANTIMICROBIAL PEPTIDES
###### Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
The Trustees of the University of Pennsylvania
###### Not Available Not Available
NOVARTIS AG
###### Not Available Immunotape, Inc.
CON3UGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR Not Available
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available
###### LIVE ATTENUATED INFLUENZA VIRUS
MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
CHARACTERISTICS


-----

NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS
AND OLIGOSACCHARIDES
SAMPLE FIXATION AND STABILISATION
ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND
METHODS FOR PRODUCING THE SAME
LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF
CANCER
PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN
BARRIER
TRANSPORTABLE VACUUM ASSISTED DECONTAMINATION UNIT
AND DECONTAMINATION PROCESS
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
OR OTHER DISEASES
HYDRAZINO 1H-IMIDAZ0QUIN0LIN-4-AMINES AND CONIUGATES
MADE THEREFROM
LOADING VIALS
BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL
INFECTION
SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID
(BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANOMETHYL)-AMIDES
###### INHIBITORS OF CATHEPSIN C
SUBSTITUTED 2-AZA-BICYCLO[2.2.1JHEPTANE-3-CARBOXYLIC
ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
###### Westfaelische Wilhelms-Universitaet Munester Not Available N.V. NUTRICIA Not Available
COMPLIX SA
COMPUGEN LTD.
###### Children's Medical Center Corporation
STERIS Inc.
###### CITY OF HOPE
3M Innovative Properties Company
###### BioFire Diagnostics, LLC
Gemmus Pharma Inc.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
May08
###### 273un08 183unll 12Aprl3 12Aprl3
20NOV12
###### 15Mar06 HMayl0 8Marl3
22Dec05
###### 19Octll 7Feb07 6Apr07 2Sepll HMayl0


-----

###### 24Aug04 lMarl3 63anll 213unl2
22May06
###### lAprl3 263an07 33unll
10NOV11
###### 15Marl3 14Marl3 14Marl3 14Marl3 23ull4 30Apr -14 193un -12 14Apr -14 14Apr -14
19N0V
###### -13 263un -14
5May
###### -14
7Mar
###### -14 203un -14 180ct -12 193un -14
18N0V
###### -11
28Aug
###### -12
5May
###### -14
5Mar
###### -14 28Feb -14 63an -11 193un -13 30Apr -14
31Mar
###### -14


-----

**i** **h^i** **h^i** **h^i** **NJ** **।** **NJ** **।** **i**

`cz` **00** i-^ooi-^ooi-^ooi-^mi-^mi-^mooooooooooooocncncncncnuJUJUJi-^NJi-^
`in` **in** **in** ^cn^in^in^in^in^innnnnnnnnnnnnnOOOOOOOO-^S-^
`N>` **CD** **in** **CD** **CD** **CD** **CD** **CD** **CD** **CDr+r+r+r+r+r+r+r+r+r+r+r+r+nnnnnnnn** **CD**

**"O** **"O** **"O** **"O** **"O** **"O** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **I-*** **r+** **r+** **r+** **r+** **r+** **r+** **r+** **r+** **“5**

**CD** **1|-1|-1|-1|-1|-1|-1|-1**

O
```
          N>

```
**in**
```
          in

```
**ID**


-----

037
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR
TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING
INFECTIONS ASSOCIATED WITH ARENAVIRUSES
US20140275
025
###### US20140274 980
US20140273
228
US20140273
###### 156
US20140271
829
US20140271
###### 700
US20140271
580
US20140271
550
US20140270
###### 457
US20140255
###### 472
US20140255
###### 439
US20140255
###### 426
US20140255
349
US20140249
###### 296
US20140249
129
US20140248
###### 620
US20140248
357
US20140248
320
US20140248
313
US20140248
312
US20140243
505
US20140243
341
US20140242
692
US20140242
152
US20140242


-----

108
US20140235
###### 844
SUBSTITUTED 2-AZA-BICYCL0[2.2.1JHEPTANE-3-CARB0XYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
CATHEPSIN C
COMPOUND
METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING
###### INHIBITORY GENE PRODUCTS
LUCIFERASE BIOSENSOR
RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA
MOLECULES
COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM
###### DIFFICILE-ASSOCIATED DISEASES
IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
METHODS
###### Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING
PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING
RNA
###### VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME
WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS
PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND
THEIR USE
USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR
PROTEIN LIGATION
###### Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity Methods and Compositions for Prostate Cancer Metastasis Respiratory Disease Treatment
AD3UVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC
PRIMING
COMBINATION AD3UVANT FORMULATION
INFLUENZA VACCINES INCLUDING COMBINATIONS OF
PARTICULATE AD3UVANTS AND IMMUNOPOTENTIATORS
###### BISPECIFIC ANTIBODY
BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE
PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER:
PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES
MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION
IMMUNOGENIC COMPOSITIONS AND USES THEREOF
###### Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists Short Interfering RNA (siRNA) Analogues Fauci/COVID-19 Dossier 6Siga Technologies, Inc. Dec04
19Dec
###### -13
18Sep
###### -14
14B0EHRINGER
INGELHEIM INTERNATIONAL GMBH


-----

RESPIVERT LTD.

###### GenVec, Inc.

PROMEGA CORPORATION
###### Not Available National Health Research Institutes
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL
FUND

The Trustees of the University of Pennsylvania
The Board of Trustees of the University of Illinois
###### Not Available
FOLIA BIOTECH INC.

###### Children's Healthcare of Atlanta., Inc. Centre National de la Recherche Scientique Whitehead Institute for Biomedical Research Boehringer Ingelheim International GmbH Florida Agricultural and Mechanical University (FAMU)
PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED
###### Not Available Dalhousie University
NOVARTIS VACCINES AND DIAGNOSTICS SRL
WUHAN YZY BIOPHARMA CO., LTD.
###### Marl3 15Marl3
10NOV05
###### 10Oct03 HOctll 14Marl3 14Marl3 14Marl3 15Marl3 31Augll 13Mayll HMarl3 303unll 283unll 4Marl3 2SMarli 7Aug08 20Octll 16Oct08
4NOV05
21NOV12
###### 27Not
 Available Sepll 10Not
 Available
 Not Available
CAYLA
###### Santaris Pharma A/S Decl0 6-3ulll 22Febl3 21Mar03


-----

CC-BY-NC-SA
###### Dr. David E. Martin 12Mar -14 14Mar
 -14
28May
###### -14 14Feb -14 HOct -12 13Mar -14 14Mar -13 14Mar -14 14Mar -14
31Aug
###### -12 iMay -12 10Mar -14 283un -12 283un -12 20Feb -14 23Mar -12
7Apr
###### -14 19Oct -12 iSFeb -13 28Feb -14 13Mar -14
27Sep
###### -12 UDec -11
63U112
###### 22Feb -13 HFeb -14
18Sep


-----

###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14
18Sep
###### -14 llSep -14 llSep -14 llSep -14 llSep -14
4Sep
###### -14
4Sep
###### -14
4Sep
###### -14
4Sep
###### -14
4Sep
###### -14
4Sep
###### -14
4Sep
###### -14
28Aug
###### -14
28Aug
###### -14
28Aug
###### -14
28Aug
###### -14
28Aug
###### -14
21Aug
###### -14
128

US20140235
653


-----

US20140235
###### 460 US20140234
845
###### US20140234 374 US20140234
372
###### US20140234 274
US20140228
347
US20140227
###### 704
US20140227
346
US20140227
317
US20140227
262
US20140221
631
US20140221
###### 394
US20140221
335
US20140220
###### 690
US20140220
573
US20140220
###### 086
US20140220
083
US20140220
063
US20140212
###### 498
US20140212
###### 429
US20140206
682
US20140206
556
US20140205
629
US20140203
192
US20140203
189
US20140200
149
US20140199
379


-----

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND
USES THEREOF
QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND
SEQUENCING (QNPS) IMPROVEMENTS
ORGANISM IDENTIFICATION PANEL
COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND
ALLERGIC IMMUNITY
NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A
###### VIRAL MATRIX OR CORE PROTEIN Directed Evolution and In Vitro Panning of Virus Vectors Karyopharm Therapeutics, Inc. 29JU1-11
4HTG
###### Molecular Diagnostics, Inc. Not Available ID BIOMEDICAL CORPORATION OF QUEBEC Not Available University of North Carolina at Chapel Hill
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF
NUCLEIC ACID VARIANTS
###### IBIS BIOSCIENCES, INC.
IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF Not Available
HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE
THEREFROM
PD-1 Antagonists and Methods for Treating Infectious Disease
BORON-CONTAINING SMALL MOLECULES
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
MAMMALIAN GENES INVOLVED IN INFECTION
EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING
NUCLEIC ACIDS
###### Antimicrobial Compositions and Methods of Use Thereof
CATIONIC OIL-IN-WATER EMULSIONS
VACCINE COMPOSITION
###### OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS
BINDING MEMBERS-513
3M INNOVATIVE PROPERTIES COMPANY
AMPLIMMUNE, INC.
###### Anacor Pharmaceuticals, Inc. Astex Therapeutic Ltd.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
VANDERBILT UNIVERSITY
###### University Of Idaho Not Available Not Available Not Available Not Available
MEDIMMUNE LIMITED
COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS IRM LLC
###### Systems and Methods for Identifying Replikin Scaffolds and Uses of Said Replikin Scaffolds


-----

###### Not Available TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS AlphaVax, Inc.
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL
DETECTOR
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL
DETECTOR
###### Methods and compositions for identification of source of microbial contamination in a sample
COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE
ANTIGEN TO DENDRITIC CELLS
###### Gen-Probe Incorporated Mayll 2Apr07 26Aprl2
25May07
###### 30Apr08 ISepll
11NOV09
###### 6-Julll 33unll
25Aug08
###### 16Feb06 12Oct06 6Febl3
11NOV09
###### 193U1-11 21Sepll 6-Julll 5Febl3 6-Julll
7NOV08
###### ISepll 63un03 18May04 24Febll
24GEN-PR0BE
INCORPORATED
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
ASSISTANCE PUBLIQUE      - HOPITAUX DE PARIS
###### Febll 6Marl2 223U1-11 19Mar -14 IMay -14 lApr -08 28Apr -14 14Apr -14


-----

###### 17:an
 - 14
 22Apr
 - 14
 70ct
 - 13
 63ull2 13un
 - 12
 INov
 - 13

7Mar

###### - 14
 73an
 -14 283an -14
 28Oct
 - 10
 19JU112
21Sep

###### - 12
 63ull2 293an
 - 14
 63ull2 16Apr
 - 14
31Aug
###### - 12
 193un
 - 13
 28Mar
 - 14
 21Mar
 - 14
 21Mar
 - 14

6Mar

###### - 13

233U112
###### Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
129

Aug

###### - 14

21Aug

###### - 14

21Aug

###### - 14

21Aug

###### - 14

21Aug


-----

###### -14
21Aug
###### -14
14Aug
###### -14
14Aug
###### -14
14Aug
###### -14
14Aug
###### -14
14Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14
7Aug
###### -14 31JU114 31JU114
243U114
243U114
243U114
243U114
243U114
###### 17JU114 17JU114
21

US20140199
347
US20140199
281
###### US20140194
628
###### US20140194
500
###### US20140194
345
US20140193
###### 804
US20140193
###### 439
US20140186


-----

396
US20140186
292
US20140179
761
US20140179
###### 714
US20140178
977
US20140178
###### 429
US20140178
###### 428
US20140178
###### 422
US20140171
###### 447
US20140171
###### 414
US20140170
709
US20140170
###### 244
US20140170
183
US20140170
###### 174
US20140170
###### 156
US20140170
141
US20140163
213
US20140163
035
US20140162
941
US20140162
888
US20140162
357

ADJUVANT COMPOSITIONS WITH 4-1BBL
###### UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF
PRODUCTION AND USE THEREOF
SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS
###### Methods For Treating of SARS
NOVEL DEPSIPEPTIDE AND USES THEREOF
###### Biological Specimen Collection and Transport System and Method of
Use
VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15
RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING
THE SAME, AND METHODS FOR USING THE SAME


-----

METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED
VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS
DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND
METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE
TARGETING LIPIDS
NOVEL COMPOUNDS
SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL
SIGNALS
###### Vaccines Including Antigen From Four Strains of Influenza Virus
QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS
CONTAINING SQUALENE
###### Seres Health, Inc.
3M INNOVATIVE PROPERTIES COMPANY
###### Not Available Not Available Longhorn Vaccines and Diagnostics, LLC
7Feb
###### -12
NOV12
25NOV03
###### 83anl3 3Decl2 ioct07 14N0t Available
Sep09
###### 2STAKEDA
VACCINES, INC.

###### Providence Health & Services - Oregon Tekmira Pharmaceuticals Corporation Chiesi Farmaceutici S.p.A. Gen-Probe Incorporated
NOVARTIS AG
###### Novartis AG
PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM The Administrators of the
###### Tulane Educational Fund
CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
SODIUM CHANNEL BLOCKING ACTIVITY
NOVEL COMPOUNDS
VECTOR FOR GENE THERAPY

###### 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2- CARBOXAMIDE COMPOUNDS
###### D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use Thereof
POLYCHLORINATED BIPHENYLS AND SQUALENE-CONTAINING
AD3UVANTS
###### Parion Sciences, Inc. CHIESI FARMACEUTICI S.p.A.
TAKARA BIO INC.
###### Parion Sciences, Inc.
The Regents of the University of California
###### Novartis AG
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S
POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF


-----

AUTOIMMUNE DISORDERS AND INFECTION
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
###### Enhanced Immunostimulatory Activity
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR
ANTAGONISTS
PROCESS FOR PREPARING BIOLOGICAL SAMPLES
CIRCULATING BIOMARKERS FOR DISEASE
METHODS FOR GENERATION OF ANTIBODIES
COMPUGEN LTD.
COLEY PHARMACEUTICAL GMBH
ACTELION PHARMACEUTICALS LTD.
BAYLOR COLLEGE OF MEDICINE
###### Not Available
NATIONAL 1 EWISH HEALTH
Dec09
###### 291U1-05 4Dec08 14Sepll 10Mar05
6Dec06
8NOV06
###### 21Decl2 17Decl2 18Decl2 20Apr07 17Decl2
30NOV12
28D6C07
16D6C02
###### 30Junll 27Sep06 223U1-11 273U1-11 6Aprl0 13Mar07 20Mar -14 HMar -14 83an -13
3Dec
###### -13 73an -14 63an -14
6Mar
###### -14 10Feb -14 22Oct -13 llFeb


-----

###### -14
3Mar
###### -14
24Sep
###### -13
27Aug
###### -13

15N0V
###### -13

13Dec
###### -13

17Dec
###### -13
313an
###### -14

13Dec
###### -13

27NOV
###### -13

10Dec
###### -13

7Nov
###### -13

1JU112
###### 40ct -13
203U112
263U112
6Apr
###### -11
4Sep
###### -13 Febll 23173ull4 17JU114 10JU114 10JU114 10JU114 10JU114 10JU114 33ull4 33ull4 263unl4 263unl4 263unl4 263unl4 263unl4 263unl4 193unl4 193unl4 193unl4 193unl4 193unl4 193unl4


-----

###### 19:unl4 19:unl4 123unl4 123unl4 123unl4 123unl4 123unl4 10Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 130

US20140162

285
US20140161
###### 906
US20140161
###### 724
US20140155
370
###### US20140154
288
###### US20140154
282
###### US20140154 254
US20140148
350
US20140142
118
US20140142
###### 064
US20140141
###### 986
US20140141
502
US20140141
###### 452
US20140141
###### 070
US20140141
033
US20140135
###### 230 US20140134
699
###### US20140134 606 US20140134 206 US20140134 150
US20140128
###### 324
US20140127


-----

321
US20140127
310
US20140127
###### 216
US20140120
139
US20140116
887
US20140113
855
US20140107
133
###### 21Methods of Modulating Vesicular Trafficking
USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF
ABNORMAL VENOUS PROLIFERATION
###### Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
STIMULATION OF THE INNATE IMMUNE RESPONSE
CON3UGATES UTILIZING PLATFORM TECHNOLOGY FOR
STIMULATING IMMUNE RESPONSE
HETERODIMERIC IMMUNOGLOBULINS
CIRCULATING BIOMARKERS FOR DISEASE
CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE
POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
BORON-CONTAINING SMALL MOLECULES
CIRCULATING BIOMARKERS
###### Methods For Concurrent Identification And Quantification Of An
Unknown Bioagent
###### Method of Determining., Identifying or Isolating Cell-Penetrating Peptides
LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA
MOLECULES
CON3UGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS
###### Lipoparticles Comprising Proteins, Methods Of Making, And Using
The Same
NOVEL STABILISATION METHOD FOR VIRUSES OR BACTERIA
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
INFECTIONS AND DISEASES
INFLAMMATION AND IMMUNITY TREATMENTS
TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR
MICROSPHERES
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
OR OTHER DISEASES
###### ANTIVIRAL RESIN MEMBER
TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE
NANOFIBERS
NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY
OF ANTIGENIC PROTEINS
METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL
AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE


-----

ELECTROCHEMISTRY AND ELECTROGENERATED
CHEMILUMINESCENCE WITH A SINGLE FARADAIC ELECTRODE
###### Modified Release Formulations for Oprozomib 3j 5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDROXYHEXYL)AMINO)ETHOX Y) PHENYL)BUTYL)CARBAMIMI
DOYL)PYRAZINE-2-CARBOXAMIDE
###### Fauci/COVID-19 Dossier
The General Hospital Corporation
###### UNIVERSITY OF UTAH RESEARCH FOUNDATION Board of Regents, The University of Texas System Not Available
FOLIA BIOTECH INC.
###### Not Available
AMGEN INC.
###### Not Available
PARION SCIENCES, INC.
ANACOR PHARMACEUTICALS, INC.
###### Not Available IBIS BIOSCIENCES, INC. Phylogica Limited Not Available
CAYLA
###### Integral Molecular, Inc. Leukocare AG
MOREHOUSE SCHOOL OF MEDICINE
OCEAN SPRAY CRANBERRIES, INC.
###### Ansun Biopharma, Inc. CITY OF HOPE
NBC MESHTEC, INC.
###### Marine Polymer Technologies, Inc. Temasek Life Sciences Laboratory Limited Board of Regents, The University of Texas System
May09
8NOV07
###### 153U1-02 5Marl0 13Mayll 263anll
21NOV12
###### 18Augl0 273unll 16Feb05 22Febll 18Feb04 23Mayll 6-3U111
19NOV12
###### 303U1-03 283unll 6Oct08 lAprll 243an06 263an07


-----

###### 6-Julll ISAprll SFebll 26JU1-10 3Board of Regents of the University of Texas System Not Available lunes 240ctl2 27Parion Sciences, Inc. Junll
CC-BY-NC-SA
###### Dr. David E. Martin
2Dec
###### -13 123un -13
16Dec
###### -13 283un -13 IMay -12 263an -12
21NOV
###### -13
18Aug
###### -11 273un -12 273an -14 17Feb -12 271an -14
23May
###### -12
63U112
###### ISMar -13 INov -13 283un -12 213an -14
30Mar
###### -12 63an -14
141 an


-----

###### -14
6JU112
###### 16Apr -12
8Feb
###### -12
25Dan
###### -13 280ct -13 240ct -13
18Dec
###### -13 123unl4 123unl4 123unl4 53unl4 53unl4 53unl4 53unl4
29May
###### -14
22May
###### -14
22May
###### -14
22May
###### -14
22May
###### -14
22May
###### -14
22May
###### -14

22May
###### -14
15May
###### -14
15May
###### -14
15May
###### -14
15May
###### -14
15May
###### -14
8May
###### -14
8May
###### -14
8May
###### -14
8May


-----

###### -14 IMay -14 IMay -14 24Aprl4 17Aprl4
131

###### US20140106
335
US20140105
928
US20140105
912
US20140099
###### 696
US20140099
323
###### US20140094 404
US20140093
532
US20140087
###### 954
US20140087
363
US20140086
928
US20140082
769
US20140080
828
US20140080
171
US20140080
121
US20140079
667
US20140073
683
US20140073
651
US20140072
###### 956
US20140072
575
US20140066
592
US20140057
###### 926
US20140057
###### 920
US20140057
###### 916


-----

US20140057
315
US20140056
929
US20140051
148
US20140050
778
US20140050
763
###### 280LIG0NUCLE0TIDE
PROBE FOR THE DETECTION OF ADENOVIRUS Qiagen Hamburg GMBH
###### Antiviral and antibacterial activity from medicinal mushrooms Not Available
 VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER THE TRUSTEES OF DARTMOUTH
COLLEGE
###### Technology for the Preparation of Microparticles
METHODS FOR TREATMENT OF INFLAMMATORY DISEASES
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED
DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS
###### Immunogenic Compositions In Particulate Form And Methods For Producing The Same
QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND
SEQUENCING (QNPS) IMPROVEMENTS
METHOD FOR GENERATING, STORING, TRANSPORTING, ELUTING
AND DETECTING CLINICAL RELEVANT INFORMATION IN PLASMA
USING FILTER PAPER
###### Antigenic GM-CSF Peptides and Antibodies to GM-CSF
MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF
PROTEINS
###### Ansun Biopharma, Inc. Not Available Not Available
MUCOSIS B.V.
HTG Molecular Diagnostics, Inc.
###### Decl0 63an04 7Sepl2 243U1-07 8Apr09 133anll 22Marll 4Mayll
9HVIDOVRE
HOSPITAL
###### Decl0
8MORPHOTEK,
###### INC. Not Available
IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO CHILDREN'S HEATLHCARE OF
ATLANTA, INC.
OPTICAL CYTOMETRY
PRIMATE T-LYMPHOTROPIC VIRUSES
TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE


-----

MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
OF USE
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
COMPOSITION, DEVICE AND ASSOCIATED METHOD
###### RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING
THEM
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
OR OTHER DISEASES
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
NEUTROPHIL ELASTASE ACTIVITY
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
NEUTROPHIL ELASTASE ACTIVITY
ANTIGEN PRESENTING CELL ASSAY
IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA
LEVELS WITH THE LONG NON-CODING RNA NeST
###### Cells and Methodology to Generate Non-Segmented Negativestrand
RNA Viruses
NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND
USE THEREOF
MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES
AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND
PREVENTING INFECTIOUS DISEASES
The Regents of the University of California
###### Johns Hopkins University Infinity Pharmaceuticals, Inc. Not Available Actelion Pharmaceuticals Ltd. General Electric Company
Medlmmune Limited
###### City of Hope
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
###### University of Pittsburgh - Of the Commonwealth System of Higher Education
The Board of Trustees of the Leland Stanford Junior
###### University Centre National De La Recherche Scientifique UNIVERSITY OF ROCHESTER
Feb06
###### llMarll BIMarll
6May09
###### 21Feb05 5Mayl0 26JU1-02 22Febll
ISDecOS
###### Uun07 26Jan07 23Augl2 23Augl2


-----

###### 23Augl2 8Aprl0 23Augl2 22Dec06 28Decl0 29ELI LILLY & COMPANY 3un00
28Dec
###### -10
20Dec
###### -13
9Sep
###### -13 30Apr -13 30Oct
 -13 133an -12
 22Mar -12 26Apr -12
9Dec
###### -11
26NOV
###### -13
 12Mar -12 28Mar -12
25NOV
###### -13
20Sep
###### -13
23Aug
###### -13 12Mar -13 21Feb -12 28Feb -07
13Sep
###### -13 noct -13
20Aug
###### -13
20Aug
###### -13

20Aug
###### -13


-----

###### q9d0Z vx-
 q9d£Z vx- qsdzz vx- qsdzz vx- qsdzz vx- qsdzz vx-

JBW9
###### vx- jew£T vx- jew£T vx- jew£T vx- jew£T vx-
viewez
###### vx-
viewez
###### vx-
viewoz
###### vx-
viewoz
###### vx-
viewoz
###### vx-
viewz.^
###### vx-
viewz.^
###### vx-
viewz.^
VTJdVE
VTJdVE
VTJdV0T
VTJdV0T
VTJdvZ.T
VTJdvZ.T
VTJdvZ.T
```
                                               £T-
                                                 q-^oes

```
TT-
###### 39082
 £T-

IDOST

###### £T- §nv£2
 £T-
q-30TT


-----

###### -14 20Feb -14 20Feb -14 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
132

###### US20140050

753
US20140050
698
US20140045
919
US20140045
837
US20140045
###### 774
US20140045
743
###### US20140044
641
US20140038
978
US20140038
###### 174
US20140038
###### 170
US20140037
###### 700
US20140031
###### 418
US20140031
371
US20140031
333
US20140031
###### 276
US20140030
###### 740
US20140030
725
US20140030
703
US20140030
###### 364
US20140030
295
###### US20140024 804 US20140024
583
US20140023


-----

645
US20140023
592
US20140017
727
US20140017
285
US20140017
279
US20140011
982
US20140011
812
US20140011
777
###### 8POLYIONIC
PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES
RECOMBINANT SUPER-COMPOUND INTERFERON AND USES
THEREOF

###### Folate Conjugates
 9-Substituted 8-Oxoadenine Compound
METHODS FOR TREATING VIRAL DISORDERS
THE 3OHNS HOPKINS UNIVERSITY
###### Superlab Far East Limited Alnylam Pharmaceuticals., Inc. AstraZeneca Aktiebolag
TRUSTEES OF BOSTON UNIVERSITY
COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION Autoimmune Technologies, LLC
POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS
###### Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences in Biological Samples
APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL
MELT ANALYSES AND AMPLIFICATIONS
###### Composition and Method for Enhancing an Immune Response Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
POLY AROMATIC SODIUM CHANNEL BLOCKERS
COMPUGEN LTD.
###### AstraZeneca AB

LONGHORN VACCINES AND DIAGNOSTICS, LLC
###### Not Available
MICO BIO, INC.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
PARION SCIENCES, Inc.
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A
###### VIRAL INFECTION
 Rapid Bioluminescence Detection System

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
CHARACTERISTICS
###### Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences in Biological Samples


-----

###### ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF
TETRACERA SCANDENS AND USE THEREOF
Use of Sirtl Activators or Inhibitors to Modulate an Immune
###### Response Crystalline Tripeptide Epoxy Ketone Protease Inhibitors
ORGANIC COMPOUNDS
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
###### Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE
BACTERIA
ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
###### (C.N.R.S.)
The Secretary of State for Health
PROMEGA CORPORATION
LONGHORN VACCINES AND DIAGNOSTICS, LLC
###### Not Available
THE J. DAVID GLADSTONE INSTITUTES
Onyx Therapeutics, Inc.
###### Not Available
The United States of America, as represented by the
###### Secretary, Dept, of Health & Human Services Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung e.V. Not Available
NOVARTIS AG
ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS Novartis AG
###### Antibodies Against Influenza Virus and Methods of Use Thereof Methods of Treating Inflammation
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
IMIDAZONAPHTHYRIDINES
###### Fauci/COVID-19 Dossier
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
###### Massachusetts Institute of Technology
3M INNOVATIVE PROPERTIES COMPANY
CC-BY-NC-SA Dr. David E. Martin
###### SeplO 28Feb01 4Dec07 26Mar04
24Sep09
4NOV03
###### ISAprll
24D6C04
###### 26Aprll 313U1-12 20Aprll 20Aprll 26Feb08 iSepll
2NOV07
###### 73an09 HMayl0 12Sep06


-----

###### 24JU1-12 7Feb08 20Mar09
5Dun06
###### 31Jan08 25:111-07 121an09 24Marll 27Janll 6Dec07 8Octl0 181un04
8Sep
###### -11
5Sep
###### -13
8311113
###### 210ct -13
 lUun -13

8Aug
###### -13 16Apr -12
13Sep
###### -13 80ct -13 31JU113 19Apr -12 20Apr -12 lOct -13
19Sep
###### -13 19Jun -13

2Aug
###### -13
12NOV
###### -12 8Oct -13 28Mar -13
17Dec
###### -12
24Sep
###### -13
 15JU113 lOct


-----

###### -13
30Sep
###### -13 73un -13 23Mar -12 273an -12
12Aug
###### -13 70ct -11
9Sep
###### -13
133
###### 20Feb -14 20Feb -14 13Feb -14 13Feb -14 13Feb -14 13Feb -14 13Feb -14
6Feb
###### -14
6Feb
###### -14
6Feb
###### -14
6Feb
###### -14 303anl4 303anl4 303anl4 303anl4 303anl4 303anl4 303anl4 303anl4 303anl4 233anl4 233anl4 233anl4 233anl4 163anl4 163anl4 163anl4


-----

###### 9:anl4 9:anl4 9:anl4

US20140011
187
US20140010
837
US20140005
241
US20140005
102
US20140005
101
US20140005
097
###### US20140004
193
###### US20140004 146 US20140004
143
###### US20140004
128
###### US20140004
123
US20130345
###### 414
US20130345
###### 284
US20130345
###### 270 US20130344
613
###### US20130344 100
US20130341
###### 206
US20130338
###### 224
US20130338
###### 174
US20130338
###### 130
US20130336
###### 996
US20130336
929
US20130336
923
US20130331
313
US20130330
###### 840
US20130330


-----

335
###### US20130324
559
###### Biological Specimen Collection and Transport System and Method of
Use
###### Methods and Compositions for Preventing a Condition Suppression of Sars Replication by Sars Helicase Inhibitors Oligoadenylate Synthetase (OAS) Oligoadenylate Synthetase (OAS)
BIOACTIVE PEPTIDES AND METHODS OF USING SAME
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING
DROSOPHILA CELL AND APPLICATIONS THEREOF
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
VECTORS CONTAINING SAME, AND USES THEREFOR
###### ANTI-IL-18 ANTIBODIES AND THEIR USES
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
OF B CELLS
TREATING CANCER WITH VIRAL NUCLEIC ACID
###### siRNA Compositions and Methods for Treatment of HPV and Other Infections
METHODS OF TREATING CANCER AND OTHER DISORDERS
USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
DETERIORATED PERFORMANCE OF A FLUOROMETER
VIRUS LIKE PARTICLE PRODUCTION IN PLANTS
AMPEROMETRIC GAS SENSOR
DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY
BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES,
METHODS FOR OBTAINING AND USING SAID COMPOSITION
PURINE DERIVATIVES
METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG
RESISTANT MICROORGANISMS
NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS
CON3UGATED TO LIPIDS
METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY
REGULATORS
###### Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof
METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLYINDUCED
CONDITIONS
FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL
SALTS
BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE
BINDING
DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER
MUCOSAL DISEASES
###### ILonghorn Vaccines and Diagnostics, LLC Cyvax, Inc.
The Curators of the University of Missouri
###### Kineta Two LLC Kineta Two LLC


-----

Compugen Ltd.
###### Not Available INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF
SCIENCES
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Medlmmune Limited
###### Institute For Research in Biomedicine Not Available Not Available
Waake Forest University Health Sciences
GEN-PROBE INCORPORATED
MEDICAGO INC.
STERIS CORPORATION
###### Oct07 9Augl0 15Junl2
23NOV05
23NOV05
###### 123U1-07 24Aprl2 17Marll
17D6C01
20D6C10
###### 26Feb03 20Feb07 293U1-10
12NOV10
###### 143unl2
22D6C10
###### 253unl2
29HIGHTECH
###### BIO-ACTIVITIES HOLDING GMBH Mar04
17ABBOTT
###### PHILLIP Biogenic Innovations, LLC
CAYLA
###### KINETA, INC.
DANA-FARBER CANCER INSTITUTE, INC.
HEMAQUEST PHARMACEUTICALS INC
NOVARTIS AG
IOGENETICS, LLC
###### Decl0 30Oct09 153unl2 25Febll
2D6C05
###### HMarlO
14D6C10
###### 23Marl0
29PARION
SCIENCES, INC.
###### Mayl2 19Mar


-----

###### -13 llSep -13 173un -13
1JU113
143 un
###### -13 213un -13 24Apr -13 19Mar -12
13Sep
###### -13
20Dec
###### -11 25Apr -13
263U113
###### 293an -13
7Nov
###### -11 73un -13
22Dec
###### -11 26Feb -13
7Aug
###### -13
14Dec
###### -11
19Aug
###### -13 ISMar -13 23Feb -12
8May
###### -13 73un -13
14Dec
###### -11 21Mar -11
29May
###### -13 93anl4 93anl4 23anl4


-----

###### 2:anl4 2:anl4 2:anl4 2:anl4 2:anl4 2:anl4 2:anl4 2:anl4
26Dec

###### - 13

26Dec

###### - 13

26Dec

###### - 13

26Dec

###### - 13

26Dec

###### - 13

26Dec

###### - 13

19Dec

###### - 13

19Dec

###### - 13

19Dec

###### - 13

19Dec

###### - 13

19Dec

###### - 13

19Dec

###### - 13

12Dec

###### - 13

12Dec

###### - 13

12Dec

###### - 13
5Dec
###### - 13 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 134

US20130323

835
US20130323
819
US20130317
###### 080
US20130317
031
US20130315
952


-----

US20130302
351
US20130302
278
US20130295
129
US20130291
###### 134
US20130289
043
US20130288
922
US20130288
917
US20130287
832
US20130287
811
US20130287
772
US20130281
###### 324
US20130280
###### 806
US20130280
298
###### US20130274 465 US20130274
129
US20130273
540
US20130273
277
US20130273
###### 150
US20130273
###### 120
US20130273
113
US20130273
###### 104
US20130273
###### 080
US20130267
578
US20130267
532

###### Mammalian Genes Involved in Infection Zirus, Inc.
EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN
LACTOBACILLUS
MODIFIED iRNA AGENTS
###### Nuclear Transport Modulators And Uses Thereof


-----

ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR
TREATMENT OF PATHOGENIC INFECTION
ANTAGONISM OF THE VIP SIGNALING PATHWAY
USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO
ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE
THEREOF
HUMANIZED TRANSGENIC MOUSE MODEL
###### (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-l-YL)METHANONE-NCARBOXAMIDE
DERIVATIVES
ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
IMMUNE RESPONSE
###### Rapid High Resolution., High Throughput RNA Structure., RNAMacromolecular Interaction., and RNA-Small Molecule Interaction Mapping
ALVAREZ MIGUEL ANGEL
ALNYLAM PHARMACEUTICALS, INC.
###### Karyopharm Therapeutics Inc. Defyrus, Inc.
EMORY UNIVERSITY
IMMURX INC
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
BRUMEANU TEPDPR D
###### AstraZeneca AB
UNIV ROCHESTER
The Board of Trustees of the Leland Stanford Junior
###### University
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Novartis AG
###### Method for Producing Viral Vaccines
BIOMARKERS FOR THERANOSTICS
###### BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND
USING SUCH COMPLEXES
MAMMALIAN GENES INVOLVED IN INFECTION
###### Immunogenic Affinity-Conjugated Antigen Systems Based on
Papaya Mosaic Virus and Uses Thereof
ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL
SALTS
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,
###### KITS AND ASSAYS
METHOD FOR CHROMOGENIC DETECTION OF TWO OR MORE
TARGET MOLECULES IN A SINGLE SAMPLE
POWDERED POUCH AND METHOD OF MAKING SAME
###### Dendritic Cell Marker and Uses Thereof
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY
IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND
METHODS OF USE THEREOF
###### Adjuvanted Influenza Vaccines for Pediatric Use
SIALOADHESIN-RELATED COMPOSITIONS AND METHODS
COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE
EXPRESSION
CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT
OF DISEASE
###### Fauci/COVID-19 Dossier
BAXTER HEALTHCARE SA


-----

###### Caris Life Sciences Luxembourg Holdings Nuevolution A/S
HODGE THOMAS
LECLERC DENIS
IRM LLC
ARNOLD MATTHIAS
###### BIENIARZ CHRISTOPHER A Monosol, LLC.
CAMINSCHI IRINA
HARUTA SHUN1I
The Regents of the University of Michigan
GROTH NICOLA
DELPUTTE PETER
QUARK PHARMACEUTICALS, INC.
HORI SEIJI
###### lSJul-09
SAuglO
###### ISSeplO 9Mayl2 9Jun09 2Febll 15Jun07 5Aprl2 24Sepl0
15Dec08
2May08
###### 21Octl0 20Augl0
28Aug07
###### lMarl0 16Aprl0 17Mayl0
15NOV06
###### lSepl0 4Aprl2
22Aug08
###### 16Aprl2
30Aug07
###### 15Aprl0 12Aprl2 22Feb08 HMay06 15Jun07
19NOV10
CC-BY-NC-SA
###### Dr. David E. Martin 15JU110
4Aug

###### -11

14Sep

###### -11

9May

###### -13

13NOV


-----

###### -12
31Dan
###### -12 16Apr -13 ISMar -13
22Aug
###### -12 273un -13 11JU113 210ct -11
19Aug
###### -11 263un -13 IMar -11 16Apr -11
17May
###### -11 ISMar -13 iSep -11 4Apr -13 73un -13 14Mar -13
2 IMar
###### -13 14Mar -13 ISMar -13 213un -13 ISMar -13 63un -13
18N0V
###### -11
Dec
###### -13
SDec
###### -13
28NOV
###### -13


-----

28NOV

###### -13

28NOV

###### -13

14N0V

###### -13

14N0V

###### -13

7Nov

###### -13 310ctl3 310ctl3 310ctl3 310ctl3 310ctl3 310ctl3 310ctl3 240ctl3 240ctl3 240ctl3 170ctl3 170ctl3 170ctl3 170ctl3 170ctl3 170ctl3 170ctl3 170ctl3 170ctl3 10Octl3 10Octl3
135
5
US20130267

###### 436
US20130267
###### 429
US20130266
645
US20130266
612
US20130261
###### 196
LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
FOR MICROARRAY-BASED ASSAYS
BIOLOGICAL SAMPLE TARGET CLASSIFICATION, DETECTION AND
SELECTION METHODS, AND RELATED ARRAYS AND
OLIGONUCLEOTIDE PROBES
DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN
###### ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL
ACTION
VACCINE COMPOSITION

###### Nucleic Acids For Multiplex Organism Detection and Methods Of Use
And Making The Same


-----

US20130261
087
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR
TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING
INFECTIONS ASSOCIATED WITH ARENA VIRUSES
###### 27CapitaBio Corporation Octl0
21GARDNER
SHEA
Dec09
###### GIustus-Liebig-Universitat Giessen
NITTO DENKO CORPORATION
DIAMOND LISA
###### Octl0 4Aprl2 113unl0
6SIGA
TECHNOLOGIES INC.
###### Dec04 27Oct
 -10

2May

###### -13
 6Oct
 -11
3Apr
###### -13
 103un
 -11

63U111
###### 10Octl3 10Octl3 10Octl3 10Octl3 30ctl3 30ctl3
US20130261
049
US20130259
887
US20130259
871
US20130259
829
US20130253
002
US20130251
###### 746
US20130251
###### 734
US20130251


-----

590
###### US20130244 980 US20130244 920
US20130243
841
US20130243
###### 756
US20130243
727
US20130237
507
US20130236
###### 884
US20130236
###### 493
US20130236
396
US20130231
302
US20130230
919
US20130230
###### 856
ALPHABODIES
###### SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION
PROTEINS AND METHODS FOR PRODUCING THE SAME
REOVIRUS VACCINES AND METHODS OF USE THEREFOR
Human Monoclonal Antibody with Specificity for Dengue Virus
###### Serotype 1 E Protein and Uses Thereof CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE
FUNCTION
6COMPLIX
SA
BOEHME KARL W
DSO NATIONAL LABORATORIES
###### Viral Genetics, Inc.
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS CORTEZ ALEX
###### Methods and Compositions for Poxvirus A35R Protein
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS
###### Peracid/Peroxide Composition, Process for Accurately Making the
Same, and Method for Use as an Evaporating Film Anti-Microbial
###### Solution and as a Photosensitizer
BORON-CONTAINING SMALL MOLECULES
WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND
METHOD OF MAKING SAME
###### East Carolina University
The Salk Institute for Biological Studies
###### BioMed Protect ,LLC
ANACOR PHARMACEUTICALS, INC.
LEE DAVID M
CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION Novartis AG
###### Methods for Treating Diseases and HSV Using Antibodies to


-----

###### Aminophospholipids
TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE
###### Novel Amide Compounds
COMPOSITIONS FOR USE IN IDENTIFICATION OF
ORTHOPOXVIRUSES
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES
NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND
METHODS OF MAKING AND USING THE SAME
ANTIMICROBIAL SOLUTIONS
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING
INTERCALATOR MOLECULES
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
###### INFINITY PHARMACEUTICALS, INC.
BURKAMP FRANK
###### IBIS BIOSCIENCES, INC.
STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
###### UNIVERSITY OF UTAH RESEARCH FOUNDATION
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
###### Baxter Healthcare S.A.

QUANTIBACT A/S

###### Janll 7Aprl0 14Decl0 251U1-08
3Mar08
###### lDec08
9NOV07
###### HJan05 16Feb05 16Marl2 llunlO 15JU1-02 5Mayl0 3Apr09
5Dec03
###### 20Sepl0 3Mayl0 10Sepl0 29Oct04 27Octl0 Fauci/COVID-19 Dossier
2Dec
###### -11
 4Apr
 -11

14Dec

###### -11
 63un
 -13
 22Apr
 -13

20Dec


-----

###### -12
8Mar
###### -13
21Sep
###### -09 30Apr -13 16Mar -12 13un -11 19Feb -13 29Apr -13 17Apr -13
7May
###### -13
20Sep
###### -11
3May
###### -11
9Sep
###### -11 16Apr -13 270ct -11 CC-BY-NC-SA Dr. David E. Martin 136 30ctl3 30ctl3 30ctl3 30ctl3
26Sep
###### -13
26Sep
###### -13
26Sep
###### -13
26Sep
###### -13
19Sep
###### -13
19Sep
###### -13
19Sep
###### -13
19Sep
###### -13
19Sep
###### -13


-----

12Sep
###### -13
12Sep
###### -13
12Sep
###### -13
12Sep
###### -13
5Sep
###### -13
5Sep
###### -13
5Sep
###### -13
 US20130230
851
US20130230
578
US20130230
529
US20130225
655
US20130225
651
US20130225
637
US20130225
555
###### US20130224
245
###### US20130224 144
US20130217
###### 584
US20130217
071
US20130217
012
US20130216
612
US20130216
581
US20130216
573
US20130216
566
US20130210
###### 894
US20130210
###### 820
US20130210
###### 770
US20130209
550


-----

US20130209
510
US20130209
502
US20130209
###### 406
US20130209
###### 364
US20130203
###### 836
US20130203
655
US20130203
151
US20130202
###### 684
US20130202
609
###### 23Nanoreporters
And Methods Of Manufacturing And Use Thereof
###### LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
COMPOSITIONSj FORMULATIONSj AND METHODS
NOVEL PARAMYXOVIRUS AND USES THEREOF
###### Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application siRNA Compositions and Methods for Potently Inhibiting Viral Infection ISATIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS
THEREOF, AND METHODS OF USE THEREOF
###### Imidazoquinolines with Immuno-Modulating Properties
CONCENTRATION OF VACCINE ANTIGENS WITHOUT
###### LYOPHILIZATION
SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE
ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS
MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR
ANALYZING MOLECULAR INTERACTIONS
METHODS AND COMPOSITIONS FOR PERFORMING NUCLEIC ACID
###### AMPLIFICATION REACTIONS
C-CBL MUTATIONS AND USES THEREOF
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS
###### Carbon Nanotube Compositions and Methods of Use Thereof
INFLUENZA VIRUS REASSORTMENT

###### Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM
###### VIRAL GENOME AS TEMPLATE TO DESIGN THERAPEUTIC SLIRNAS Pharmaceutical Compounds
PHARMACEUTICAL FORMULATIONS
###### Anti-Viral Azide Containing Compounds
METHODS FOR PREPARING SQUALENE
ALUMINA NANOPARTICLE BIOCON3UGATES AND METHODS OF
STIMULATING AN IMMUNE RESPONSE USING SAID
BIOCON3UGATES


-----

RECOMBINANT RNA VIRUSES AND USES THEREOF
###### Anti-Viral Azide Containing Compounds 2' AND S' MODIFIED MONOMERS AND OLIGONUCLEOTIDES
METHODS FOR PREVENTING OR TREATING VIRAL INFECTION
PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN
PACKAGING CELLS
PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING
RNA
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES
###### Fauci/COVID-19 Dossier
NANOSTRING TECHNOLOGIES, INC.
3M INNOVATIVE PROPERTIES COMPANY
The University of Hong Kong
EVANS DAVID
The University of Hong Kong
HORNE DAVID A
###### AstraZeneca AB Novartis AG Etubics Corporation CapitalBio Corporation
MONTESCLAROS LUZ
The University of Chicago
BBB HOLDING B V
UNIV YALE
NOVARTIS AG
ADAMS DANIEL
DecOS
###### 17Augl0 2013012 4Mayl0
11D6C08
###### 24Febl2
8May07
###### llunlO 2-1U107 6Augl0 30Decll 43unl0 23Mar07 19Mar08 21Mayl0 203un03
20CHEN
###### LI
ASTEX THERAPEUTICS LIMITED
###### Anacor Pharmaceuticals, Inc. LIFE TECHNOLOGIES CORPORATION Novartis AG
HU HONG-MING
TENOEVER BENIAMIN R
###### LIFE TECHNOLOGIES CORPORATION
ALNYLAM PHARMACEUTICALS, INC.
###### KIELIAN MARGARET BALSITIS SCOTT


-----

###### Lichtstrasse
GRANDI GUIDO
###### CC-BY-NC-SA Dr. David E. Martin SeplO HApr08 16Feb05 283U1-10 12Mayl0 27Augl0 6Iunl0 28JU1-10 !Aprl0 12Febl0 26Aprl0 31Augl0
12Sep07
###### llMar -13
16Aug
###### -11 223an -13
4May
###### -11
12Dec
###### -11 25Feb -13 14Mar -13 13un -11
18Sep
###### -12
6Aug
###### -10
21Dec
###### -12
33un
###### -11
2May
###### -13 iSMar -13
20May
###### -11 213un -04
19Sep
###### -11
303an
###### -13 12Apr -13


-----

###### 28:ulll
12May
###### -11
26Aug
###### -11
6Dun
###### -11
28:11111
31Mar
###### -11
9Feb
###### -11 26Apr -11
31Aug
###### -11 14Mar -13
5Sep
###### -13
5Sep
###### -13
5Sep
###### -13
29Aug
###### -13
29Aug
###### -13
29Aug
###### -13
29Aug
###### -13
29Aug
###### -13
29Aug
###### -13
22Aug
###### -13
22Aug
###### -13
22Aug
###### -13
22Aug
###### -13
22Aug
###### -13
22Aug
###### -13
22Aug
###### -13
15Aug
###### -13
15Aug
###### -13


-----

15Aug
###### -13
15Aug
###### -13
15Aug
###### -13
15Aug
###### -13
15Aug
###### -13
15Aug
###### -13
8Aug
###### -13
8Aug
###### -13
8Aug
###### -13
8Aug
###### -13
8Aug
###### -13
137

US20130202
598
US20130202
593
US20130197
###### 296
US20130196
903
US20130196
380
US20130195
969
US20130195
968
US20130195
932
US20130195
###### 930
US20130195
###### 914
US20130195
893
US20130195
792
US20130190
###### 494
US20130190
381
US20130190
###### 206
US20130189


-----

###### 680
US20130189
351
US20130189
311
US20130189
247
###### US20130184 170
US20130183
###### 670
US20130183
355
US20130183
341
US20130183
321
US20130178
512
US20130178
###### 482
US20130178
###### 466
US20130178
###### 448
ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE
###### INHIBITORY PEPTIDE
20RAMOT
AT TEL-AVIV UNIVERSITY LTD.
INTRACELLULAR IMMUNITY
###### Removing Cells from an Organism Multimeric Inhibitors of Viral Fusion and Uses Thereof IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF
THE IGG TYPE
MEDICAL RESEARCH COUNCIL
DAPPRICH 3OHANNES
3V BIO SRL
3ANSEN GABRIELE
SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA NOVARTIS AG
###### VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA
MOLECULES
ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO
ANIMALS
###### Inulin and Inulin Acetate Formulations Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof
USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING
OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN
METHOD OF TREATING INFLAMMATION
PURINE ANALOGS
###### INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID
METABOLISM AS BROAD SPECTRUM ANTI-VIRALS
###### Direct Clone Analysis and Selection Technology
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS


-----

###### LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING
RNA
ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
MICROFLUIDIZATION
###### Novartis AG
NATIONAL RESEARCH COUNCIL OF CANADA
SOUTH DAKOTA SATE UNIVERSITY
###### Viracine Therapeutics Corporation
The Government of the United States of America as
###### represented by the Secretary of the department of
CYTOSORBENTS CORPORATION
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
THE TRUSTEES OF PRINCETON UNIVERSITY
###### Dublin City University
VENTANA MEDICAL SYSTEMS, INC.
NOVARTIS AG
###### Novartis AG Multimeric Proteins Comprising Immunoglobulin Constant Domains RESEARCH
CORPORATION TECHNOLOGIES, INC.
OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING
ONCOGENIC HPV
METHOD FOR PRODUCING NUCLEIC ACID PROBES
DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE
POLYMER PARTICLES
INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING
HEMAGGLUTININ PRODUCED WITHIN A PLANT
GITR BINDING MOLECULES AND USES THEREFOR
CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR
OLIGONUCLEOTIDES

###### 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDROXYHEXYL)AMINO)ETHOX Y) PHENYL)BUTYL)
CARBAMIMIDOYL)PYRAZINE -2-CARBOXAMIDE
###### Treatment of Microbial Infections Treatment of Respiratory Disorders
GENERA BIOSYSTEMS LIMITED
###### Ventana Medical Systems, Inc.
NOVARTIS AG
MEDICAGO INC.
###### GITR, INC.
ALNYLAM PHARMACEUTICALS, INC
###### SeplO 23JU1-10 13Janl2 HAuglO SFeblO 31Augl0 6-JU110 15Dec06 20Janl2 12Aprl0 31JU1-08 lAprlO
31May06


-----

###### 18Febl0 13JU1-10 233anl2 31Augl0
3Dec09
###### 12Febl0 5Apr07 lSep06 6-JU110 133U1-07 25Mar05 4Dec07 27Parion Sciences, Inc. Junll
11BI0C0PEA
###### LIMITED
BANNISTER ROBIN MARK
NOV09
###### SFeblO
22Aug
###### -11 233an -13
141 an
###### -13 HAug -11 4Feb -11
31Aug
###### -11
6JU111
###### 233an -13 223an -13
8Apr
###### -11 27Mar -13 lApr -11
8Mar
###### -13 18Feb -11 13JU111 ISIan -13
31Aug
###### -11
3Dec
###### -10


-----

###### llFeb -11 41un -12 llMar -13 73un -11 43an -13 IMar -13
4Dec
###### -12 263un -12
9Nov
###### -10 4Feb -11

8Aug
###### -13

8Aug
###### -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13 lAug -13
253U113
253U113
253U113
253U113
253U113
253U113
253U113
###### 18JU113 18JU113 18JU113


-----

###### 18JU113 18JU113 11JU113 11JU113 11JU113 11JU113 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
138

US20130178

383
US20130178
372
US20130177
###### 640
US20130177
639
US20130177
###### 477
US20130172
327
US20130171
241
US20130171
129
US20130165
###### 455
US20130165
###### 417
US20130157
###### 964
US20130157
###### 876
US20130157
283
US20130157
###### 254
US20130156
807
US20130149
375
US20130149
###### 194
US20130145
###### 484
US20130143
###### 810
US20130143
203
US20130142
833
US20130142
###### 826


-----

US20130142
773
US20130137
678
US20130137
172
US20130137
###### 140
US20130136
768
US20130130
262
12VESICLE
ISOLATION METHODS

###### Methods And Computer Systems For Identifying Target-Specific Sequences For Use In Nanoreporters
DELIVERY OF RNA TO DIFFERENT CELL TYPES
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS
KLASS MICHAEL
NANOSTRING TECHNOLOGIES, INC.
NOVARTIS AG
NOVARTIS AG
DECONTAMINANT DISPENSER SUITABLE FOR USE AS A PRO3ECTILE STERIS INC.
SUBSTITUTED N- [1-CYAN0-2- (PHENYL) ETHYL] -2-AZABICYCLO

###### [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C
LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE
FOR RNA DELIVERY
CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
THEREFOR
TLR AGONISTS
METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED
DISORDERS
###### Blockade Of Inflammatory Proteases With Cyclic Peptides Systems and Methods for Detecting Antibiotic Resistance
RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD

###### Method and apparatus for two-step surface-enhanced raman spectroscopy
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
NOVARTIS AG
COULIBALY FASSELI 3OSEPH
The Regents of The University of California
###### UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
TESSARAE, LLC
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
###### Real-Time Analyzers, Inc.
CON3UGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR The Regents of The
###### University of California
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GEALL ANDREW
ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM
###### INACTIVATION
ANTIBODY PRODUCING NON-HUMAN MAMMALS
###### Virally-Inactivated Growth Factors-Containing Platelet Lysate Depleted of PDGF and VEGF and Preparation Method Thereof


-----

COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
VIRUSES
CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF
EMULSIONS
RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
###### Mutations in OAS1 Genes Antiviral Compounds and Uses Thereof
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS
INCREASED PROTEIN EXPRESSION THROUGH INCREASED
MEMBRANE FORMATION
###### Recombinant HCMV and RHCMV vectors and uses thereof
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE
GREGERSEN DENS PETER
MERUS B.V.
BURNOUF THIERRY
###### IBIS BIOSCIENCES, INC. Novartis AG
MEDICAGO, INC.
KINETA TWO, LLC
MOUNT SINAI SCHOOL OF MEDICINE
###### BioFire Diagnostics, Inc. f/k/a Idaho Technology, Inc. UNIVERSITEIT GENT Oregon Health & Science University
BATTRELL C FREDERICK
NOV08
###### 10Apr07 6-JU110 6-JU110 6Mar07 19Sepll 6-JU110 231unl0
22Aug05
###### 23Aprl0 23unll 21Augl0 193anl0 16Decll 7Feb07 6-3U110 6Mayl0 273un08 25Mayl0
3Mar05
3Dec09
###### 213an08
4May05
###### 28Mayl0
15May09
###### 173unl0 14Mayl0 293anl0
29Aug


-----

###### -12
7Mar
###### -13 73un -11
6JU111
###### 28Feb -13
14Sep
###### -12
6JU111
###### 233un -11
20NOV
###### -12 23Apr -11 13un -12 21Feb -13 193an -11
16Dec
###### -11 83an -13
6JU111
6May
###### -11 253an -13
26NOV
###### -12
21May
###### -12
3Dec
###### -10 233an -13
14N0V
###### -12
31May
###### -11 283an -13 153un -11
14N0V
###### -12 283an -11 11JU113 11JU113


-----

###### 11JU113 11JU113 11JU113
43U113
###### 43U113 4JU113 273unl3 273unl3 20Junl3 203unl3 203unl3 203unl3 203unl3 133unl3 133unl3 63unl3 63unl3 63unl3 63unl3 63unl3 63unl3
30May

###### -13

30May
###### -13
30May
###### -13

30May
###### -13

23May
###### -13 Fauci/COVID-19
 Dossier CC-BY-NC-SA Dr. David E. Martin
139

###### US20130129

805
###### US20130129 786 US20130129
782
###### US20130129 781
US20130129
###### 702
US20130122
581
###### US20130122
516

###### US20130122 487 US20130122
043
US20130122


-----

038
US20130122
031
US20130115
593
US20130115
###### 244
US20130115
228
US20130115
215
US20130102
652
US20130102
560
US20130102
###### 524
US20130101
629
US20130101
622
US20130101
609
US20130096
103
US20130096
073
US20130096
###### 056
US20130096
###### 020
US20130095
552
US20130095
135
US20130091
611
COMPOSITION WITH STERILIZING ACTIVITY AGAINST BACTERIA
FUNGUS AND VIRUSES, APPLICATION THEREOF AND METHOD FOR
PREPARATION THEREOF
HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
AD3UVANTS
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY
MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
RNA VIRAL DISEASES
TAL EFFECTOR-MEDIATED DNA MODIFICATION
DETECTING TARGETS USING MASS TAGS AND MASS
SPECTROMETRY
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES
18GP&E
NOV11


-----

###### 3Novartis
AG
NOVARTIS AG
HARUTA SHUN!I
###### UNIVERSITY OF SOUTH FLORIDA
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
###### BIENIARZ CHRISTOPHER Novartis AG
MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF WHITEHEAD INSTITUTE FOR
BIOMEDICAL RESEARCH
HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES
VIRUS-BASED VACCINES
HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO
ANTIGENS
SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF
USE IN DETECTION ASSAYS AND KITS
###### Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant
IMMUNOSTIMULATORY COMBINATIONS
DOMAIN INSERTION IMMUNOGLOBULIN
METHODS AND COMPOSITIONS RELATED TO MODIFIED
ADENOSINES FOR CONTROLLING OFF-TARGET EFFECTS IN RNA
INTERFERENCE
NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS
AND OLIGOSACCHARIDES
Compounds And Their Use
HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING
COMPOUNDS AND USES THEREOF
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS
IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES
IMIDAZOQUINOLINE COMPOUNDS
###### Casein Derived Peptides And Uses Thereof
AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA
DESATURASE INHIBITORS
GENERATION OF BINDING MOLECULES
NOROVIRUS AND SAPOVIRUS ANTIGENS
PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE
PRODUCTION OF A VIRUS IN CELL CULTURE
###### Anti-viral Formulations Nanomaterials and Nanoparticles Crucell Holland B.V.
MESSMER DAVORKA
###### Ventana Medical Systems^ Inc. Yisheng Biopharma (Singapore) PTE. LTD.
TRUSTEES OF DARTMOUTH COLLEGE
ZHOU HONGXING
###### UNIVERSITY OF UTAH RESEARCH FOUNDATION N.V. NUTRICIA Novabiotics Limited
NOVARTIS AG
###### Novartis AG
NOVARTIS AG
NOVARTIS VACCINES & DIAGNOSTICS, INC.
SIDELMAN ZVI
XENON PHARMACEUTICALS INC.


-----

MERUS BIOPHARMACEUTICALS B.V.
###### Novartis Vaccines and Diagnostics, Inc. GlaxoSmithKline Biologicals S.A.
 LAMBKIN-WILLIAMS ROBERT

Dec09
###### 9Sep04 15Aprl0 30Apr02
10D6C09
###### 2-JU110 9Sep04 20Aprl0
14N0V11
###### 27JU1-10 16Augl0 13Ian06
30D6C02
###### 143U1-10 23Marl0 24Aug04 31Marl0
15Dec09
###### 23Mar06 243anl0 14Sep04 lMar00 33un05 26Sepll
22NOV05
###### 8-JU110 16Feb06 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
18NOV

###### -11
3Dec
###### -10
 Ilian
 -13
 ISApr
 -11

17Sep

###### -12
 103an
 -13
 llulll 103an
 -13
 20Apr
 -11

13NOV

###### -12
 27IU111


-----

12Aug
###### -11 lOct -12 22Oct -12 14JU111 23Mar -11
14Sep
###### -12
30Mar
###### -11
15Dec
###### -10
7May
###### -12
243 an
###### -11 193un -12
5Sep
###### -12
14Sep
###### -12
26Sep
###### -12
27NOV
###### -12
63U111
30Nov
###### -12
23May
###### -13
23May
###### -13
23May
###### -13
23May
###### -13
23May
###### -13
16May
###### -13
16May
###### -13
16May
###### -13
16May
###### -13
16May
###### -13
16May
###### -13


-----

9May
###### -13
9May
###### -13
9May
###### -13
9May
###### -13 25Aprl3 25Aprl3 25Aprl3 25Aprl3 25Aprl3 25Aprl3 18Aprl3 18Aprl3 18Aprl3 18Aprl3 18Aprl3 18Aprl3 18Aprl3 140

US20130087
###### 700
US20130085
095
###### US20130084
303
US20130071
###### 428
US20130059
###### 846
US20130059
832
US20130059
803
US20130059
802
US20130059
###### 776
US20130058
###### 945 US20110070
575
US20110067
###### 121
US20110065
###### 111
US20110065
###### 091 US20110065 089 US20110064 772


-----

US20110053
###### 986
US20110053
909
US20110053
###### 894
US20110053
893
US20110053
831
US20110053
169
US20110052
###### 716
US20110052
558
US20110046
155
US20110046
###### 134
US20110046
001
US20110045
###### 456
11DIRECT
IMPACT IONIZATION (DII) MASS SPECTROMETRY
PROTEIN COMPLEMENTATION REGULATORS
PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
COMPOSITIONS COMPRISING SAID PEPTIDES
PEPTIDES, CON3UGATES AND METHOD FOR INCREASING
IMMUNOGENICITY OF A VACCINE
###### Services, National Institutes of Health Trustees of Boston University
BOGOCH ELENORE S
ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC
BORON-CONTAINING SMALL MOLECULES
BORON-CONTAINING SMALL MOLECULES
###### Antiviral Cell-Penetrating Peptides Antigenic GM-CSF Peptides and Antibodies to GM-CSF Immunomodulatory Compositions, Combinations and Methods Transgenic mice having a human major histocompatibility complex
(MHC) phenotype, experimental uses and applications
###### Compositions For Use In Genotyping Of Klebsiella Pneumoniae Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and Diagnostics
NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND
APPLICATIONS THEREOF
###### VIRAL AD3UVANTS
RESPIRATORY DISEASE TREATMENT
Compounds      - 801
###### Broad Spectrum Antiviral and Methods of Use Anacor Pharmaceuticals, Inc.


-----

###### Anacor Pharmaceuticals, Inc.
CURRELI FRANCESCA
CHAO QIMIN
###### Coley Pharmaceutical Group, Inc. INSTITUT PASTEUR Ibis Biosciences, Inc.
VAN DER HOEK CORNELIA MARIA
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
###### University of North Carolina at Chapel Hill
FINCH HARRY
ALCARAZ LILIAN
LOVELACE RESPIRATORY RESEARCH INSTITUTE
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC
COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL
DISORDERS ASSOCIATED WITH THEREWITH
METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS
OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME
###### AMPLIFICATION ASSAY Adjuvant Comprising Aluminum, Oligonucleotide and Polycation
MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
RNA VIRAL DISEASES
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA
DESATURASE
###### Multiplex Assay for Respiratory Viruses
COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
CONTAMINANT VIRUSES
###### Fauci/COVID-19 Dossier Octll 29Sepll 7Aug09 15Marl0 iSepll iSepll 16Feb05 16Feb05
6May08
###### 8Feb06 8Dec04 301U1-03
31Aug09
18Aug03
2D6C03
###### 9-3U104 7Aug08 313U1-09 17Apr06 2Sep09 20Phylogica Limited 3un07
10GEN-PROBE
INCORPORATED


-----

O'HAGAN DEREK
###### UNIVERSITY OF SOUTH FLORIDA
FREDERICKSON MARTYN
BISCHOFF ALEXANDER
AUTOGENOMICSj INC.

###### IBIS BIOSCIENCES, INC.

MarOS
27Aug09
###### 30Apr02 12Oct06 213un07
20NOV07
###### 143un07
CC-BY-NC-SA
###### Dr. David E. Martin HOct -11
28Sep
###### -12
 19JU112 ISMar
 -11
27Aug
###### -12
29Aug
###### -12
7Sep
###### -12
7Sep
###### -12 31Oct -12 240ct -12
8Dec
###### -05
22Dec
###### -09
27Aug
###### -10 263U110
6Apr
###### -10
24NOV
###### -10
4Aug
###### -10 303U110 17Apr -07 iSep -10 203un -08


-----

4Nov
###### -10
27Aug
###### -10
15Dec
###### -09 120ct -07 290ct -10
20NOV
###### -08 12Jun -08
141
###### HAprl3 4Aprl3 4Aprl3 21Mar -13
7Mar
###### -13
7Mar
###### -13
7Mar
###### -13
7Mar
###### -13
7Mar
###### -13
7Mar
###### -13 24Mar -11 17Mar -11 17Mar -11 17Mar -11 17Mar -11 17Mar -11
3Mar
###### -11
3Mar
###### -11
3Mar
###### -11
3Mar
###### -11
3Mar
###### -11


-----

3Mar
###### -11
3Mar
###### -11
3Mar
###### -11 24Feb -11 24Feb -11 24Feb -11 24Feb -11

US20110045
###### 024
US20110045
022
US20110039
###### 884
US20110038
935
###### US20110038 900
US20110038
###### 884
US20110038
879
###### US20110038
852
US20110038
###### 849 US20110034 438 US20110033 498
US20110033
###### 485
US20110033
###### 454 US20110028
945
US20110028
715
US20110028
531
US20110028
###### 334
US20110027
315
US20110027
###### 314
US20110027
306


-----

US20110027
267
US20110027
257
US20110027
228
US20110027
181
US20110021
861
US20110021
###### 606
US20110021
###### 554
US20110021
###### 415
US20110020
897
14RNA
VIRUS VACCINES AND METHODS
VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF
INFLUENZA VIRUS
###### Imidazopyridinones
ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE
THEREOF
DITTMER DIRK P
###### TSAI THEODORE Pfizer Limited
LIDDINGTON ROBERT C
NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS NOVARTIS AG
IMMUNOPOTENTIATING AGENT COMPRISING EPl AGONIST
IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR
STREPTOCOCCUS PYOGENES
###### ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION
CHANNELS
###### INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR
TREATING CANCER
STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE
PHARMACEUTICAL USE THEREOF
METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY
###### INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAINCONTAINING VIRAL PROTEINS
ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOAD1UVANTS
###### Methods For Treating Diseases Using Antibodies to Aminophospolipids Device including altered microorganisms, and methods and systems of use
NOVEL ADENINE COMPOUND
NOVEL SIRNA COMPOUNDS FOR INHIBITING RTP801
CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID
SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS
PROTEIN CAGES AND THEIR USES
NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER.
SCHOOL OF MEDICINE


-----

NOVARTIS AG
###### 3-V BIOSCIENCES, INC. Intradigm Corporation
FORSCHUNGSVERBUND BERLIN E.V.
DecOS
6Dec06
3Aug07
###### 6Dec07 28Apr08 28Apr08 30Oct06 103un09 21Dec06 25Sep06 5FRIAS-STAHELI
NATALIA
###### Apr07
12PANZA
###### LUIGI Board of Regents, The University of Texas System Searete LLC, AstraZeneca Aktiebolag
FEINSTEIN ELENA
###### IBIS BIOSCIENCES, INC.
DOUGLAS TREVOR
###### Influenza Vaccines Containing Hemagglutinin and Matrix Proteins NOVARTIS
VACCINES AND DIAGNOSTICS GMBH & CO. KG
###### TC-83-Derived Alphavirus Vectors, Particles and Methods AlphaVax, Inc.
 Fusion Proteins of Mannose Binding Lectins for Treatment of Disease ANAPHORE INC.
CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND
PREPARATION METHOD THEREOF
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE
###### Device including altered microorganisms, and methods and systems of use
HAZARDOUS SUBSTANCE-REMOVING MATERIAL
RNAi Modulation of RSV, PIV and Other Respiratory Viruses and
###### Uses Thereof
IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS
ANTIMICROBIAL PEPTIDES
RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS
STEAROTHERMOPHILUS
GWO REI BIOMEDICAL TECHNOLOGY CORPORATION
WEI GUANGWEN
###### Searete LLC
KOSUGI TAKU3I
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
GUY CYNTHIA A
NOVABIOTICS LIMITED
LAMPSON BERT C
###### Oct07 153U1-02
14Dec05


-----

###### 20Mar07 20Mar08 31JU1-09 7Sep07 273an06 18May04
9NOV07
###### 73an08
28Aug03
14Dec05
###### 25Mar08 22Oct04 30Dec04 18Aug04 10Mar04 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
2Aug
###### -10
5Dec
###### -07 28Oct -10
8Dec
###### -08 28Apr -09 27Apr -09 30Oct -07
93un
###### -10
21Dec
###### -06
25Sep
###### -07
7Apr
###### -08 10Oct -08
26Aug
###### -10
28May
###### -10 140ct -10 17Mar -09 303U110
5Sep
###### -08 261an


-----

###### -07 6JU110
10NOV
###### -08 7:an -09 150ct -10
28May
###### -10 23Mar -09
23311110
29Sep
###### -10
29Sep
###### -10 iMar -10 24Feb -11 24Feb -11 17Feb -11 17Feb -11 17Feb -11 17Feb -11 17Feb -11 17Feb -11 17Feb -11 10Feb -11 10Feb -11 10Feb -11 10Feb -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
3Feb


-----

###### -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
3Feb
###### -11
 273anll 273anll 273anll 273anll 273anll
142

###### US20110020
315
US20110009
###### 414
US20110008
905
US20110008
838
US20110008
395
US20110008
###### 384
US20110008
283
US20110008
###### 280
US20110003
###### 890
US20110003
315
US20110002
958
US20110002
###### 946
US20110002
888
US20110000
###### 480
US20100330
592
US20100330
###### 190
US20100330
141
US20100330


-----

###### 140
US20100330
122
US20100330
###### 114
US20100330
075
US20100329
971
US20100319
###### 074
US20100317
###### 684
US20100317
601
US20100317
###### 054
US20100317
###### 034
US20100316
695
US20100316
641
18TREATMENT
OF INFLAMMATORY ILLNESSES WITH ACE2
HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC
AGENTS
SYSTEM FOR DETECTING POLYNUCLEOTIDES
CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES
MIXED MICELLES INCLUDING AMPHIPATHIC CON3UGATES OF RNA
AGENTS, AND USES THEREOF
###### Antiviral activity from medicinal mushrooms
INTERFERON FUSION PROTEINS

METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29
CYSTEINE MUTANTS
USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF
ABNORMAL VENOUS PROLIFERATION
CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND
ASSAYS USING SAME
###### Alphavirus Vectors for Respiratory Pathogen Vaccines Immunostimulatory Combinations Albumin Fusion Proteins
ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR
TREATMENT OF PATHOGENIC INFECTION
METHOD FOR DETECTING TRUNCATED MOLECULES
LOIBNER HANS
Xenon Pharmaceuticals Inc.
INVESTIGEN
PUSHKO PETER
LEVCHENKO TATYANA S
STAMETS PAUL EDWARD
ARTYMIUK PETER
###### ZymoGenetics, Inc.
KENNEDY THOMAS P


-----

###### INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
AHONEN CORY L
Human Gemone Sciences, Inc.
ENNIS DANE E
KEY MARC E
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF BOZIA IADRANKA
PRODUCT FOR ABSORPTION PURPOSES
DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN
TRANSMISSION
VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND
ANTIGENS
Use of SIRT1 Activators or Inhibitors to Modulate an Immune
###### Response
MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY
NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL
MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE
METHOD
MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND
HEALING OF SKIN
###### Amide and Carbamate Derivatives of N-{2-[4-Amino-2(Ethoxymethyl)-IH-Imidazo[4,5-c] Quinolin-1-Yl]-l,lDimethylethyl} Methanesulfonamide and Methods Casein Derived Peptides And Uses Thereof
PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
PRIMATE T-LYMPHOTROPIC VIRUSES
CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC
AROMATICS OR HETEROAROMATICS
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES
###### Fauci/COVID-19 Dossier
HIERTEN MARIE-CHRISTINE
###### FILLIGENT LIMITED
PUSHKO PETER
KWON HYE-SOOK
ABELA IRENE
MOCHIGASE CO., LTD.
###### SIR NAOMICS, INC.
Dec07
###### 20Sep04
20May03
###### 193U1-07 6-3U107 63an04 8Aug07 2Apr04
8NOV07
8May06
###### 21May04
30D6C02
21Dec01
###### 93un09 293an08
17D6C07


-----

###### 133un03 263un07 193ul-07 7Feb08 13Mar07 8Feb08
6NOV07
###### 9Coley Pharmaceutical Group, Inc.
Sep05
1SIDELMAN
###### ZVI VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
and lohns Hopkins University
BASF SE
DIMITROV DIMITER S
CC-BY-NC-SA Dr. David E. Martin
###### Mar00 29Oct07 21Feb05
14NOV07
###### 313an08
18Dec

###### -08

6May

###### -09

93un

###### -10

213U108
73U108
###### 27Mar
 -07
5Aug
###### -08

20May

###### -10

10NOV

###### -08

8May

###### -07
 13un
 -10
 293U110
33un
###### -10

93un

###### -10
 293an
 -09

17Dec

###### -08

13Sep

###### -10
 253un


-----

###### -08 21JU108 16JU110 13Mar -08
9Feb
###### -09
6Nov
###### -08
8Sep
###### -06 283U110 290ct -08
 1JU110
11N0V

###### -08
303an
###### -09
143
###### 273anll 13Janll 13Janll 13Janll 13Janll 13Janll 13Janll 13Janll 63anll 63anll 63anll 63anll 63anll 63anll
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10
30Dec
###### -10

16Dec
###### -10

16Dec
###### -10


-----

16Dec
###### -10
16Dec
###### -10
16Dec
###### -10
16Dec
###### -10
16Dec
###### -10
 US20100316 624
US20100311
797
US20100311
###### 656
US20100311
039
US20100310
638
US20100310
###### 604
US20100310
562
US20100305
138
###### US20100304
363
###### US20100304
361
US20100303
823
US20100298
547
US20100298
###### 364
US20100298
209
US20100297
651
US20100297
165
US20100297
108
US20100292
###### 504
US20100292
307
US20100291
###### 544
US20100291
145
US20100291
129


-----

US20100291
###### 120
US20100291
075
US20100291
033
US20100286
251
US20100286
238
US20100286
118
US20100286
025
21TREATMENT
OF FIBROSES AND LIVER DISORDERS
###### Novel Compounds
TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS
WITH ALPHA THYMOSIN PEPTIDES
NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA
SPLICE-FORMS IN A SAMPLE
LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS
RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES
THEREOF
LOIBNER HANS
BONNERT ROGER VICTOR
###### SciClone Pharmaceuticals, Inc.
QIAGEN GAITHERSBURG INC.
###### Board of Regents, The University of Texas System
MEDICAGO INC.
###### Bundesrepublik Deutschland letztvertreten durch das Robert Koch-Institut vertreten durch seinen
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS
###### INC.
PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS
CORONAVIRUS AND APPLICATION THEREOF
METHOD AND DEVICE FOR MONITORING A THERAPEUTIC
TREATMENT REGIME
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
###### INSTITUTE
DAS DEVELOPMENT PARTNERS
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S
METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE
AS ANTIBODY LIGANDS
SALTS 756
BONNIN DUSTAN
###### AstraZeneca AB
COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION ESTAQUIER 3EROME
###### Methods of Modulating Vesicular Trafficking
IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
METHODS OF USE
METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN


-----

AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
BORON-CONTAINING SMALL MOLECULES
###### Construct
COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF
###### HEPATITIS C VIRUS Il-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES Norovirus and sapovirus antigens
PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL
RECEPTOR

###### Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies Albumin Fusion Proteins Mammalian Genes Involved In Viral Infection And Tumor Suppression
SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY INFECTION
OR DISEASE
SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE
COMPOUNDS 750
SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND
METHODS OF USE
THE GENERAL HOSPITAL CORPORATION
###### Office of Technology Transfer
GRIMM DAN
###### Anacor Pharmaceuticals, Inc. ISIS INNOVATION LIMITED IBIS BIOSCIENCES, INC.

ANTIGEN EXPRESS, INC.
COIT DORIS
MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN
###### Theraclone Sciences, Inc.
Human Genome Sciences, Inc.
RUBIN DONALD H
ARNDT GREGORY MARTIN
FORD RHONAN
ANANTHARAMAIAH GATTADAHALLI M
Dec07
26May06
###### 23Apr03 lMay09 153U1-02 213an08
20NOV07
###### 293U1-03
27May09
###### 263U1-07
16D6C02
7May07
21May09
2NOV07
21May09
24Sep07
31Aug07
###### 203un07 28Mar06


-----

25May07
14Sep99
22NOV05
###### 233un06 23Apr09
21Dec01
###### HOct06
15May07
7May09
28Aug07
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
22Dec
###### -08 23un -10 163un -10 30Apr -10 4Mar -10 123an -09
19Nov
###### -08 153un -10
26May
###### -10
283U108
###### UNov -09
7May
###### -08
20May
###### -10 31Oct -08
21May
###### -10
24Sep
###### -08 iSep -08 303U110 28Mar -07
27May
###### -08 263U110 24Mar -09


-----

###### 233un -07 23Apr -10
33un
###### -10
5Mar
###### -10
14May
###### -08
6May
###### -10
27Aug
###### -08
16Dec
###### -10
9Dec
###### -10
9Dec
###### -10
9Dec
###### -10
9Dec
###### -10
9Dec
###### -10
9Dec
###### -10
2Dec
###### -10
2Dec
###### -10
2Dec
###### -10
2Dec
###### -10
25NOV
###### -10
25NOV
###### -10

25NOV
###### -10
25NOV
###### -10
25NOV
###### -10
25NOV
###### -10
18N0V
###### -10
18N0V
###### -10
18N0V
###### -10


-----

18N0V
###### -10
18Nov
###### -10
18Nov
###### -10
18N0V
###### -10
18N0V
###### -10
11N0V
###### -10
11NOV
###### -10
11NOV
###### -10
11NOV
###### -10 144

US20100285
###### 457
US20100285
###### 135 US20100284 968 US20100284
967
###### US20100284
965
###### US20100284 917 US20100284 016
US20100280
102
###### US20100280 067 US20100280
048
US20100280
001
###### US20100279 906
US20100279
888
US20100279
351
US20100279
###### 279
US20100279
###### 276
US20100279
273
US20100278


-----

861
US20100278
###### 846
US20100278
829
US20100273
997
US20100273
###### 854
US20100273
###### 740
US20100273
###### 670
US20100272
785
US20100272
###### 776
US20100272
771
US20100272
###### 730 High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS) Nanoparticles For Use In Immunogenic Compositions
Use of PS20/WFDC1 and Interferons to Diagnose., Monitor and Treat
###### Viral Diseases
MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY
MODIFIED PROTEINS AND USES THEREOF
COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE
IMMUNOTHERAPY
COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN
SCATTERING
OPTICAL CYTOMETRY
DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED
EFFECTIVENESS IN AN ORGANISM
###### INHIBITORS OF ACETYL-COA CARBOXYLASE
Some 2-pyrazinone derivatives and their use as inhibitors of
###### neutrophile elastase
24CHAN
KWOK HUNG
NOVARTIS AG
BAIG EHTESHAM
###### National Institutes of Health (NIH), U.S. Dept, of Health
and Human Services (DHHS) U.S. Govt.
###### Yale University 3ULIUS-MAXIMILIANS- UNIVERSITAT
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
###### Alnylam Pharmaceuticals
ACHARYA VINOD PARAMESHWARAN
ASTRAZENECA R&D
IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES BONNERT ROGER VICTOR
FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION BYOTROL PLC
COMPOSITIONS AND METHODS OF DETECTION
###### Method for Generation of Antibodies


-----

###### Compositions and methods for analysis of target analytes
METHODS FOR DETERMINING THE PRESENCE OF SARS
CORONAVIRUS IN A SAMPLE
NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND
DETECTION OF RESPIRATORY VIRUSES
METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND
EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS
NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALTTARGETING
AND PHAGOCYTIC POLYPEPTIDE TRANSPORT
SEQUENCES
DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY
MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR
SUPERFAMILY MEMBERS
###### Ribozyme to cleave coronavirus gene
COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE
EXPRESSION
###### Phospholipids for the Treatment of Infection by Togaviruses, Herpes
 Viruses and Coronaviruses
DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING
DNA MICROARRAY
RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED
INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE
MODULATORY PROFILES
###### Device including bone cage and method for treatment of disease in
a subject
###### Device including bone cage and method for treatment of disease in
a subject

###### Antigenic GM-CSF Peptides And Antibodies To GM-CSF Fauci/COVID-19 Dossier
GENERA BIOSYSTEMS LIMITED
NATIONAL 1EWISH MEDICAL AND RESEARCH CENTER
DANIELZADEH ROBERT
GEN-PROBE INCORPORATED
UNIVERSITE LAVAL
NIMAN HENRY L
###### Mar03 2Dec05 15Oct07
21NOV06
###### 153an08
24Sep07
6May09
###### 13Iun03 30Apr09
6NOV07
8May07
17Sep07
###### 5Apr07 13Mar07
17Sep03
###### 17Apr03 173U1-07 293an09
23FERGUSON


-----

IAN A
###### Iun04
6EDWARDS
###### III CARL KEITH
Feb09
###### 9FUKUDA
NOBORU
FEINSTEIN ELENA
FLEMING RONALD A
DAWSON ERICA
COLEY PHARMACEUTICAL GMBH
###### Searete LLC, a limited liability corporation of the State of Delaware
HARLOW ED
MORPHOTEK, INC.
CC-BY-NC-SA Dr. David E. Martin
###### Aug05 151un07 20Feb04 21Aug06
13Aug07
###### 23Apr09 23Apr09 8Feb06 123un -09 iDec -06 ISOct -08
20NOV
###### -07
143 an
###### -09
24Sep
###### -08
6May
###### -09 163un -10 30Apr -10
SNov
###### -08
6May
###### -08
17Sep
###### -08 4Apr -08 13Mar -08
30NOV
###### -07


-----

###### 6JU110
17DU108
###### 29:an -10 llDec -09
6Feb
###### -10
9Aug
###### -06 12Jun -08
23NOV
###### -09
21Aug
###### -07
8Aug
###### -08
281U109
###### 23Apr -09 16Apr -10
11N0V
###### -10
11NOV
###### -10
11NOV
###### -10
11NOV
###### -10
11NOV
###### -10
11NOV
###### -10
11NOV
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov
###### -10
4Nov


-----

###### -10
4N0V
###### -10
4N0V
###### -10
4N0V
###### -10
4N0V
###### -10 28Octl0 28Octl0 28Octl0 28Octl0 28Octl0 28Octl0 28Octl0 28Octl0 145
 US20100272 706 US20100272
668
US20100267
981
US20100267
805
US20100266
677
US20100266
###### 634
US20100266
###### 620 US20100266 604 US20100266 598 US20100262 374 US20100261
779
###### US20100261 690
US20100261
###### 026
US20100256
348
US20100256
105
US20100256
###### 104
US20100256
103
###### US20100256 096


-----

US20100256
###### 070 US20100254
985
###### US20100254 944 US20100254
942
US20100249
###### 200
US20100249
021
US20100248
219
US20100247
###### 574
US20100247
571
US20100247
560
US20100247
###### 554 22ANTIVIRALS ANTIVIRAL
SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER
STRUCTURE
BORON-CONTAINING SMALL MOLECULES
TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF
SINGLE-STRANDED VIRUSES BY RNAI
NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE
AD1UVANCY AND IMMUNE POTENTIATING PROPERTIES OF
NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS
###### Immunoconjugates for treatment of infectious diseases
USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND
TAM ACTIVATORS AS IMMUNOSUPPRESSORS
PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING
THE HIV CO-RECEPTOR, CCR5
###### Systems and methods for analyzing nanoreporters Phosphate-Modified Oligonucleotide Analogs with Enhanced Immunostimulatory Activity
NOVEL COMBINATIONS
###### Compositions comprising oriented, immobilized macromolecules and methods for their preparation Oligoadenylate Synthetase (OAS)
NOVEL COMPOUNDS
NOVEL AMIDE COMPOUNDS
NOVEL COMPOUNDS
###### Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides
and ureas, pharmaceutical compositions thereof, and methods for
###### treating hemorrhagic fever viruses, including infections associated with arenaviruses
RECOMBINANT VIBRIO CHOLERAE EXOTOXINS
###### Protein Formulations Albumin Fusion Proteins


-----

###### HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Novel Compounds 569
METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF
INFLUENZA VIRUS
###### Compositions for use in identification of influenza viruses
CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
VIRUS
MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND
USES THEREOF
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS
###### Fauci/COVID-19 Dossier
GREBER URS
###### Daiwabo Holdings Co.^ Ltd. Anacor Pharmaceuticals, Inc.
ALNYLAM PHARMACEUTICALS, INC.
###### UNIVERSITY OF ROCHESTER
NEW YORK BLOOD CENTER, INC.
SUN LE
The Salk Institute for Biological Studies
###### Government of the US, as Represented by the Secretary, Department of Health and Human Services
HWANG 1ENQ-NENG
1URK MARION
ASTRAZENECA R&D
###### NanoString Technologies, Inc.
ILLUMIGEN BIOSCIENCES, INC.
###### AstraZeneca R&D
ASTRAZENECA R&D
ASTRAZENECA R&D
Dun07
###### 20Feb08 16Feb05 24Sep04 261U1-07 151un04 201an06
9NOV07
###### 9Apr04
22May06
15May08
###### 3Apr09
23Dec05
23NOV05
###### 3Apr09 3Apr09 3Apr09 6BAILEY
THOMAS R
D6C04
SEED
BRIAN
MEDIMMUNE, LLC
STUMP DAVID CARTER


-----

BIOTRON LIMITED
CONNOLLY STEPHEN
###### INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF
SCIENCES
ESHOO MARK W
MAHMOOD KUTUB
ACADEMIA SINICA
THOMAS IEFFERSON UNIVERSITY
BHATTACHARYYA SUCHITA
CC-BY-NC-SA Dr. David E. Martin
201111-07
###### 3Feb06 14Sep06
3Aug07
20DGC06
14NOV07
###### 17Oct05 21Feb07 27Mar09
25Sep07
9NOV07
###### 203un -08 20Feb -09
2Dec
###### -09 iMar -10
283U108
###### 18Feb -10 193an -07
7Nov
###### -08
28Dec
###### -09
21May
###### -07 iSMay -08
30Mar
###### -10
22Dec
###### -06
30Mar
###### -10
30Mar
###### -10
30Mar
###### -10
30Mar
###### -10


-----

00
```
                         ooooooooooooo

```
**HHHHHHHHHHHHHOOOOOO** CD CD CD

C I—I CL **-Q** **£-** **O-** **+J+J+J+J+J+J+J+J+J+J+Jq_>q_>rHrHrHrHrHrH** H H H Q. CL CL CL

05 Z5 0J Dj O **05** **CD** **O** **CD** **05** **CD** **>** **O** **O** **O** **O** **O** **O** **O** **O** **O** **O** **O** **O** **O** **+-»** **+-»** **+-»** **+-»** **+-»** **+-»** +J qj qj QJ a; a; Qj

**i—)** **i—)** **os** c d **tn** **hs** **□** **XSOQ^O^** **l l** 00 £ © x 00 OCOkDOOOOOOOOOOOOO ’-J ’-J ’-J ’-J ’-J ’-J O O UXCDXOXQXCD
**rd** **o।** **xH** **kO** hi **mrd** **oi** **<OOHXO^Oi** **m** **i** **rd** **I** **rd** **I** cxir—lOkDr। cxi —। **Icxil HO^O^OOOOi** hs i **t** **—i** cxi cxi cxit —Icxit —Icxit —Icxit —Icxit —Icxit —Icxit —l^■^■^■^■OOOOOOt **—i** **t** **—i** **t** **—i** **t** **—i** hs hs m । m । m । l®rHm ।


-----

30Sep
###### -10
30Sep
###### -10
30Sep
###### -10

US20100247
550
US20100240
903
US20100240
###### 746
US20100240
693
US20100240
623
US20100240
063
US20100239
611
US20100239
###### 610
US20100239
593
US20100239
520
###### US20100234
355
US20100233
###### 250
US20100233
###### 146
US20100233
###### 116
US20100233
###### 084
US20100233
031
US20100227
767
US20100226
931
US20100222
###### 409
US20100222
###### 234
US20100221
755
US20100221
349
US20100221
307
US20100221
257


-----

US20100221
242
US20100216
843
US20100216
773
US20100216
689
US20100215
683
SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS
AND USES OF SAID REPLIKIN SCAFFOLDS
28BOGOCH
ELENORE S
CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Onyx Therapeutics, Inc.
STEREOISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE
###### Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring
Compounds and Methods
LUMAVITA AG
###### Coley Pharmaceutical Group, Inc
8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 COOK ANTHONY
SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL
SIGNALS
###### Combination adjuvant formulation
INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING
HEMAGGLUTININ PRODUCED WITHIN A PLANT
###### RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING
THEM
ORGANIC COMPOUNDS
ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF
CYTOKINE MEDIATED DISEASES
VACCINE
###### Coatings and Surface Treatments Having Active Enzymes and Peptides
ORGANIC COMPOUNDS
###### Method for Delivery Across the Blood Brain Barrier Method and Apparatus for Analyzing Bioprocess Fluids
STOCHASTIC CONFINEMENT TO DETECT, MANIPULATE, AND
###### UTILIZE MOLECULES AND ORGANISMS
Compounds for immunopotentiation
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF
PRO-APOPTOTIC GENES
###### Malaria antigen screening method
USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS
ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE
NUCLEIC ACID CONSTRUCTS
###### ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER
STRUCTURES
BINDING MEMBERS-513
###### ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND
METHODS OF USE
NOVEL SALT 628
PHENANTHROINDOLIZIDINE ANALOGUES
CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST


-----

PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS
HYPERVIRULENT STRAINS
GEN-PROBE INCORPORATED
BABIUK LORNE
MEDICAGO INC.
Medlmmune Limited
DALES NATALIE
MARTIN BARRIE
BARAS BENOIT
REACTIVE SURFACESj LTD.
DALES NATALIE
IMMUNE DISEASE INSTITUTE, INC.
###### BioScale, Inc.
BOEDICKER DAMES Q
SILVER DOEL B
FEINSTEIN ELENA
AGUAIR DOAO CARLOS
###### University of Rochester Powderject Vaccines, Inc.
DAIWABO HOLDINGS CO., LTD.
MEDIMMUNE LIMITED
MCMAHON DAMES B
ASTRAZENECA R&D
###### National Health Research Institutes National University Corporation, Hamamatsu University School of Medicine
NOVARTIS AG
###### Apr04 20Mar09 3-DU107 9Feb05
5-DU106
###### 10Mar05 16Oct08 13DU1-07 13un07 24Aug06 19Dun06
19Dun07
9Sep02
###### 15Aug06
22May06
2May05
###### 26DU1-07
24Dun04
27Dun07
31Aug05
15Dun07
###### lFeb05 20Feb08
7NOV08
IDecOS
###### 20Feb09 24Feb09


-----

8May07
###### 20Feb09
3Feb
###### -10 22Mar -10
3311108
8Feb
###### -06
31U107
###### Uun -10 150ct -09 11JU108
30May
###### -08
22Aug
###### -07 183un -07 201un -08
29May
###### -09
13Aug
###### -07
22May
###### -07
25May
###### -10
281U108
243 un
###### -05 263un -08
25Aug
###### -06 163un -08 iFeb -06 20Feb -09
5Nov
###### -09 iDec -06 16Feb -10 llFeb -10
7May
###### -08


-----

###### 16Feb -10
30Sep
###### -10

23Sep
###### -10
23Sep
###### -10

23Sep
###### -10
23Sep
###### -10

23Sep
###### -10
23Sep
###### -10

23Sep
###### -10
23Sep
###### -10

23Sep
###### -10
16Sep
###### -10

16Sep
###### -10
16Sep
###### -10
16Sep
###### -10
16Sep
###### -10
16Sep
###### -10
9Sep
###### -10
9Sep
###### -10
2Sep
###### -10
2Sep
###### -10
2Sep
###### -10
2Sep
###### -10
2Sep
###### -10
2Sep
###### -10
2Sep
###### -10

26Aug
###### -10


-----

26Aug

###### -10

26Aug

###### -10

26Aug

###### -10 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
147

US20100215

675
US20100210
745
US20100210
688
US20100209
###### 454
US20100209
###### 451
US20100209
###### 440 US20100204 286 US20100204 266 US20100204
203
US20100203
582
US20100197
748
US20100197
708
US20100196
285
US20100196
222
US20100190
748
US20100189
772
US20100186
###### 680 US20100184
663
###### US20100184
613
###### US20100184
192
###### US20100184 190 US20100184
019


-----

US20100183
673
US20100183
671
US20100183
###### 634
US20100183
516
US20100179
145
US20100178
299
REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY
AND LETHALITY IN INFLUENZA
###### Molecular Healing of Polymeric Materials^ Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes Novel Benzothiazolone Derivatives

ATTENUATED VIRUSES USEFUL FOR VACCINES
###### Compositions and Methods Related to Adenovirus Based Delivery of Antigens Targeted Delivery of siRNA
METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS
OF CYTOTOXIC AGENTS
COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED
POPULATIONS OF BIOAGENTS
###### Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors Protein Expression System Involving Mutated Severe Respiratory Syndrome-Associated Coronavirus 3C-Like Protease ANTI-MICROBIAL COMPOSITION
INDOLE COMPOUNDS
Use of Deuterium Oxide to Treat Virus-Based Diseases of the
###### Respiratory Tract AIR CLEANING APPARATUS
BORON-CONTAINING SMALL MOLECULES
###### Compositions of TLR ligands and antivirals
LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING
APPARATUS, AND LIVESTOCK OR LIVESTOCK MEAT
###### Methods and Compositions Related to Inhibition of Viral Entry Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis
AVIAN INFLUENZA CHIMERIC VLPS
###### Influencing viral lipid constituents Novel Human Virus Causing Severe Acute Respiratory Syndrome
(SARS) and Uses Thereof
METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS
VECTOR FOR USE WITH MULTIPLE VACCINATIONS
LOW-ADDITIVE INFLUENZA VACCINES
MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
PHARMACEUTICAL COMBINATIONS

METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE


-----

RESPONSES
9BOGOCH
ELENORE S
Dan09
9REACTIVE
SURFACESj LTD.
BONNERT ROGER
CELLO JERONIMO
INTROGEN THERAPEUTICSj INC.
Immune Disease Institute^ Inc.
BYRNES JOHN J
###### Ibis Biosciences, INC
BONNERT ROGER VICTOR
###### Academia Sinica
BYOTROL PLC
BARDEN TIMOTHY
BAYERL THOMAS
###### FUJIFILM CORPORATION Anacor Pharmaceuticals, Inc.
COLEY PHARMACEUTICAL GMBH
HAGIWARA NOBUKO
###### University of Utah Research Foundation Millipore Corporation
PUSHKO PETER
###### Medlmmune, LLC
CHAN KWOK HUNG
ETUBICS CORPORATION
###### Novartis Vaccines & Diagnostics GmbH & Co., KG Cornell University, a New York Corporation
BARTH STEFAN
GALLAGHER NEIL JAMES
###### Northeastern University
Sep02
9Aug05
###### 30Mar07 16Jun06 26Jan07 12Feb09 23Mar07 HJan07 12Feb09 17JU1-07
7Aug06
###### 7Jan09
20Sep07
###### 16Feb05 27Sep06 21Feb05 8Feb07
10May02
###### llJul-03 17Oct06 24Mar03 2-JU107


-----

###### 273un07 Uan09 25:111-07 12Oct06 13Feb07 160ct -09 291an -10 27Apr -10
31Mar
###### -08 183un -07 253an -08 llFeb -10 21Mar -08 103an -08 12Feb -09
173U108
7Aug
###### -07 63an -10
19Sep
###### -08
211U109
27Sep
###### -07 21Feb -06
8Feb
###### -08 90ct -09 193an -10 90ct -07 10Feb -10 43an -10 273un -08
31Dec
###### -09
253U108


-----

###### 120ct
 - 07
 13Feb
 - 08

26Aug

###### - 10

19Aug

###### - 10

19Aug

###### - 10

19Aug

###### - 10

19Aug

###### - 10

19Aug

###### - 10

12Aug

###### - 10

12Aug

###### - 10

12Aug

###### - 10

12Aug

###### - 10
5Aug
###### -10
5Aug
###### -10
5Aug
###### -10
5Aug
###### -10 293U110 293U110 293U110 223U110 223U110 223U110 223U110 223U110 223U110 223U110 223U110 223U110 15JU110 15JU110 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
148

US20100175

###### 006
US20100173
###### 980


-----

US20100173
###### 906
US20100173
325
US20100173
###### 280
US20100172
965
US20100172
917
US20100166
###### 874
US20100166
782
US20100166
###### 780
US20100166
769
US20100166
661
US20100160
###### 486
US20100160
323
US20100160
285
US20100160
245
US20100158
943
US20100158
935
US20100158
928
US20100152
###### 230
US20100152
197
US20100152
187
US20100152
###### 184
US20100151
###### 490
US20100150
###### 960
US20100150
943
US20100150
923
US20100146
647
###### US20100144 846


-----

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
AND COMMUNICATING EVENT-RELATED INFORMATION
###### ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV Substituted 3,4,6,7-Tetrahydro-5H-l,2a,4a,8Tetraazacyclopenta[cd]Phenalenes
and Methods
###### Composition and Method for Analysis of Target Analytes Systems for Detection and Production of Respiratory, Herpes and Enteric Viruses ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES Binding molecules against SARS-coronavirus and uses thereof Technology for Preparation of Macromolecular Microspheres CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE
FUNCTION
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
###### Enhanced Immunostimulatory Activity High-yield Transgenic Mammalian Expression System for Generating Virus-like Particles
SiRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING
###### VIRAL INFECTION
POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELTPROCESSING
METHODS
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA
DESATURASE
###### Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease Quercetin-Containing Compositions
ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH
INFLUENZA VACCINES
MUTANT FORMS OF STREPTOLYSIN 0
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS
HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS
###### (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-l-YL)METHANONE-NCARBOXAMIDE
DERIVATIVES
AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA
DESATURASE INHIBITORS
PHARMACEUTICAL COMPOUNDS
###### Antigenic Protein Conjugates and Process for Preparing Same
COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED
IMMUNE RESPONSE
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA
FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS
STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES
###### Antibody producing non-human mammals Oligoribonucleotides and uses thereof Fauci/COVID-19 Dossier 28Georgetown University
DUTEAU 3EAN-MARC
GRIESGRABER GEORGE W
###### Millipore Corporation Diagnostic Hybrids, Inc
DUTEAU 3EAN-MARC
###### Crucell Holland B.V.
FANG FANG


-----

AGADDANYAN MICHAEL
###### Pfizer Inc Academia Sinica LIN YONGPING
BISHOP KEVIN L
BISCHOFF ALEXANDER
BIRKINSHAW TIMOTHY NICHOLAS
###### Quercegen Pharma LLC
NOVARTIS VACCINES AND DIAGNOSTICS SRL
NOVARTIS AG
GRIESGRABER GEORGE W
###### Pfizer Inc.
ASTRAZENECA AB
XENON PHARMACEUTICALS INC.
ASTEX THERAPEUTICS LIMITED
ABBOTT LABORATORIES
The United States of America, as represented by the
###### Secretary,Department of Health and Human Servi
NOVARTIS AG
###### Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences
Menus B. V.
COLEY PHARMACEUTICAL GMBH
CC-BY-NC-SA Dr. David E. Martin
###### Aug08
13Sep02
6Sep06
17Sep03
20Sep05
13Sep02
###### 223U1-03 243an06 253U1-08 27Sep06 5Sep06 HDec08
19Dec08
23Dec08
###### 24Aug04 173U1-06
4NOV05
21D6C07
###### 25Dec06 2Sep05
15Dec08
###### 33un05
16NOV06
###### lSep06 22Sep06 263U1-06 203un05 273un08 26Oct06
2Dec


-----

###### -09
21Dec
###### -09
6Sep
###### -07
4DU109
19Sep
###### -06
21Dec
###### -09
16N0V
###### -09
8Dec
###### -09
23:11109
27Sep
###### -07 12Feb -10 llDec -09
19Dec
###### -08
22Dec
###### -09
18Dec
###### -09
16Dec
###### -09
6Nov
###### -06 24Feb -10
20Dec
###### -07 iSep -06
10Dec
###### -09
53un
###### -06 120ct -07 25Feb -10
21Sep
###### -07
26311107
###### 133un -06 190ct -09 260ct -07


-----

###### 8JU110 8JU110 8JU110 8JU110 8JU110 8JU110 8JU110 1JU110 1JU110 1JU110 1JU110 1JU110 243unl0 243unl0 243unl0 243unl0 243unl0 243unl0 243unl0 17:unl0 17:unl0 17:unl0 17:unl0 17:unl0 17:unl0 17:unl0 17:unl0 10Dunl0 10Dunl0
149

###### US20100144
833
###### US20100144
828
###### US20100144
759
###### US20100144 606 US20100144
589
###### US20100144 040 US20100144
015
US20100143
888
US20100143
881
US20100143
###### 411
US20100143
###### 406
US20100143
302


-----

US20100130
503
US20100130
###### 491
US20100130
###### 430
US20100129
811
US20100129
###### 437
US20100129
###### 400
US20100129
386
US20100129
321
US20100119
550
US20100113
745
US20100113
565
US20100113
510
US20100112
###### 710
US20100112
643
US20100112
092
US20100111
873
RNAi Modulation Of RSV^ PIV And Other Respiratory Viruses And
###### Uses Thereof
CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN,
AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION
AND USAGE THEREOF
NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS
MODULATORS OF CHEMOKINE RECEPTOR CCR4
COMBINATION 408
METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN
COUNTS
CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED
NEGATIVE-STRAND RNA VIRUSES
COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL
GROWTH
ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL
DISEASES
###### Selective detection of human rhinovirus
METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS
METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS
###### LIKE PARTICLES Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof


-----

NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE
SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN
CHAPERONE HSP 90
###### 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE
RECEPTOR (TLR7 ) MODULATORS
22BARIK
SAILEN
ZHEIIANG MEDICINE CO., LTD. XINCHANG
PHARMACEUTICA
###### Oct04 23Mar07 12AstraZeneca
AB
###### AstraZeneca AB
BOGOCH ELENORE S
CHARNEAU PIERRE
KINNEY RICHARD
MND Diagnostic Ltd.
and Human Services
The Government of the U.S.A, as represented by the
###### Secretary, Dept, of Health and Human Service
PUSHKO PETER
###### Beth Israel Deaconess Medical Center, Inc
SANOFI-AVENTIS
BONNERT ROGER VICTOR
###### STABILIZED THERAPEUTIC SMALL HELICAL ANTIVIRAL PEPTIDES New York Blood Center Inc
COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS
AERUGINOSA
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS
ATTENUATED VIRUSES, VACCINES AND METHODS OF USE
THEREOF
###### Composotions And Methods For The Identification And Treatment Of Immune-Mediated Inflammatory Diseases
DIARYL UREA FOR TREATING VIRUS INFECTIONS
RECOMBINANT MULTIVALENT VACCINE
Means and Methods for Influencing the Stability of Antibody
###### Producing Cells
IMMUNOSTIMULATORY COMBINATIONS AND METHODS
QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR
ANTAGONISTS
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGETSPECIFIC
SEQUENCES FOR USE IN NANOREPORTERS
METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID
ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE
AND METHODS OF MAKING AND USING THE SAME
TREATING CANCER WITH VIRAL NUCLEIC ACID
###### Ibis Biosciences, Inc.
BBB Holding B.V.
THE PENN STATE RESEARCH FOUNDATION
CONG YINGZI
BAYER HEALTHCARE LLC
GOMI YASUYUKI
###### Meibergdreef 9


-----

###### Not Available
FORD RHONAN
NANOSTRING TECHNOLOGIES, INC.
The Government of the United States of America, as
###### represented by the Secretary of the Navy Oculus Innovative Sciences, Inc.
HADAC ELIZABETH M
DecOS
###### 201un08 23Apr08
22D6C06
5Dec08
###### 23Iun03
5Dec08
27May08
###### 303un06 16Mar06 24Oct06 19Mar07 5Oct06 HSep03 23Mar07 22Dec06 243an06
ISDecOS
24NOV05
9Dec05
###### 8Dec04
19D6C06
###### 10Apr07
4NOV08
###### 13Mar07 20Feb07 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 253un -09 21Mar -08
8Dec
###### -09 193un -09
7Aug
###### -09
21Dec
###### -07
4Dec
###### -09
25NOV
###### -09
SDec
###### -08


-----

27May
###### -09 273un -07 15Mar -07
24N0V
###### -09 19Mar -08 20ct -07 20ct -09 21Mar -08 12:an -10
241 an
###### -07
6Dec
###### -06
24N0V
###### -05
8Dec
###### -06
8Dec
###### -05
17Dec
###### -07 10Apr -08
4Nov
###### -08 13Mar -08 20Feb -08 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0 101unl0
27May
###### -10
27May
###### -10


-----

27May
###### -10
27May
###### -10
27May
###### -10
27May
###### -10
27May
###### -10
27May
###### -10
13May
###### -10
6May
###### -10
6May
###### -10
6May
###### -10
6May
###### -10
6May
###### -10
6May
###### -10
6May
###### -10 150

US20100105
873
###### US20100105
642
###### US20100105 025
US20100105
###### 024 US20100104
503
US20100099
870
US20100099
745
US20100099
672
###### US20100099
665
###### US20100099
149
###### US20100099 079 US20100093 998 US20100093


-----

862
US20100093
851
US20100093
###### 816
US20100093
813
US20100093
627
US20100093
038
US20100092
###### 474
US20100092
###### 470
US20100092
###### 401
US20100092
399
US20100087
###### 443
US20100087
388
US20100086
###### 950
US20100086
942
US20100086
571
US20100075
298
US20100070
195
INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN
THERAPEUTICS
NOVEL COMPOUNDS 409
DEVICES FOR GENERATING DETECTABLE POLYMERS
RAPID TEST INCLUDING GENETIC SEQUENCE PROBE
MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES
NOVEL ADENINE COMPOUND
ENHANCING DISEASE RESISTANCE AGAINST RNA VIRAL
INFECTIONS WITH INTRACYTOPLASMIC PATHOGEN SENSORS
METHODS FOR TREATING HEPATITIS C
ISOQUINOLINONE DERIVATIVES
###### STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
RIBONUCLEIC ACID
###### Non-dividing cell-based assay for high throughput antiviral
compound screening
NOVEL ADENINE COMPOUND
POTENTIATION OF CELLULAR IMMUNITY USING HISTONE
DEACETYLASE (HDAC) INHIBITORS.
SILVER POLYAMIDE COMPOSITE
SALT
###### Salts 668


-----

ALBUMIN FUSION PROTEINS
Means and Methods for Influencing the Stability of Cells
PHARMACEUTICAL COMBINATIONS
###### ANTIBODIES, ANALOGS AND USES THEREOF
IMMUNE RESPONSE MODIFIER FORMULATIONS
METHODS OF TREATING OR PREVENTING INFLAMMATION AND
###### HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL
WATER SOLUTION
###### 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE
RECEPTOR (TLR7) MODULATORS
ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS
###### IP-10 BASED IMMUNOLOGICAL MONITORING
COMPOUNDS
METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME
POST IMMUNIZATION
MEDIMMUNE, INC.
###### 1-JU105
18ASTRAZENECA
AB
###### Not Available Transgenex Nanobiotech, Inc.
CAPLAN MICHAEL 1
###### AstraZeneca Aktiebolag
GUO ZHA
PTC THERAPEUTICS, INC.
###### AstraZeneca AB
DNA GENOTEK INC.
SAINZ DR BRUNO
###### AstraZeneca Aktiebolag Sapporo Medical Univeristy and Japan Science and Technology Agency
BISHOP KEVIN L
ARGENTA DISCOVERY LTD.
ASTRAZENECA AB
Human Genome Sciences. Inc.
###### Academisch Medisch Centrum bij de Universiteit van Amsterdam
GALLAGHER NEIL JAMES
###### ICB International, Inc. Graceway Pharmaceuticals, LLC Oculus Innovative Sciences, Inc. Not Available Not Available Hvidovre Hospital AstraZeneca AB
CLASSEN JOHN BARTHELOW
###### Method for rapid identification and quantification of microorganisms The Regents of the University of California
COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER
SYSTEM AND METHOD
The Government of the United States of America, as
###### represented by the Secretary of the Navy Jun08 12Oct06


-----

###### 14Dan08 15Feb07 20Mar07 18Oct06 22DU1-04 lOct08 6Oct06
26Sep08
###### 20Mar07
6Dec06
###### 14Oct08 7Feb07 8Feb07 9Feb04
9Dec05
###### 12Oct06 22Sep08 lSJul-06 209an06 19Mar07 3Oct05
5Sep06
###### 2iFeb07 5Oct06
23Sep08
###### 2-3U104
303un
###### -06 183un -09
 120ct -07 16Apr -09 15Feb -08 19Mar -08
 160ct -07
23Dec
###### -09 lOct -09 5Oct -07

24Sep
###### -09 19Mar -08

6Dec
###### -07 140ct -08


-----

6Feb

###### -08

6Feb

###### -08
3Aug
###### -09

9Dec

###### -05
 120ct
 -07

21Sep

###### -09

12DU107
21Dec

###### -09
 19Mar
 -08 30ct -06
5Sep
###### -07

4Dec

###### -09 50ct -07

23Sep

###### -08

12N0V

###### -09 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
151

###### Aprl0
 29Aprl0 29Aprl0 29Aprl0 29Aprl0 22Aprl0 22Aprl0 22Aprl0 22Aprl0 22Aprl0 22Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0 15Aprl0


-----

###### 15Aprl0 8Aprl0 8Aprl0 8Aprl0 8Aprl0 8Aprl0 25Mar -10 18Mar -10
29

###### US20100070 194 US20100069 614
US20100069
###### 427
US20100068
###### 223 US20100063 126
US20100062
###### 441
US20100061
###### 995
US20100061
961
US20100056
508
###### US20100056
383
US20100055
761
US20100055
###### 116
US20100048
###### 584
US20100048
575
###### US20100048 472
US20100047
282
US20100047
###### 277
US20100047
###### 264
US20100047
179
###### US20100042 394
US20100041
638
US20100041


-----

617
US20100041
013
US20100040
703
US20100040
###### 676
US20100040
655
US20100040
635
US20100035
973
METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF
NUCLEIC ACID VARIANTS
###### Antibody producing non-human mammals Oxime and Hydroxylamine Substituted Imidazo[4.,5-c] Ring
Compounds and Methods
###### Storage of Influenza Vaccines Without Refrigeration Carbazole-Derived Pharmaceutical Compositions
C-MET MUTATIONS AND USES THEREOF
###### Immunotherapy To Treat Or Prevent Viral Infection
RECOMBINANT SUPER-COMPOUND INTERFERON
AMINE DERIVATIVES AND THEIR USE IN BETA-2ADRENORECEPTOR
MEDIATED DISEASES
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS
METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE
ACTIVATION OF PROTOXINS THROUGH COMBINATORAL
TARGETING
###### Methods and Compositions for Targeting c-Rel
ECKER DAVID 3
###### 213ul-05 27Merus B.V.
COLEY PHARMACEUTICAL GROUP, INC.
SCHEFFCZIK HANNO
###### ladoLabs GmbH
SALGIA RAVI
CARRAGHER DAMIAN MICHAEL
WEI GUANGWEN
ASTRAZENECA AB
IONES DAVID E
THE GENERAL HOSPITAL CORPORATION
CHENG SHUHUA
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS
###### INC.
NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR
THERAPEUTIC APPLICATIONS
###### Albumin Fusion Proteins
METHOD OF ACCELERATED VACCINATION AGAINST EBOLA
VIRUSES
VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC
COMPOSITIONS


-----

###### Immunogenic Affinity-Conjugated Antigen Systems Based on
Papaya Mosaic Virus and Uses Thereof
TARGETED SPLIT BIOMOLECULAR CONIUGATES FOR THE
TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND
METHODS OF THEIR PRODUCTION
###### System and Method to Predict the Global Spread of Infectious Agents Via Commercial Air Travel Chemical Compounds 293 Modulating mxa expression
ASSAY FOR A HEALTH STATE
USE OF NITRIC OXIDE
POLYCISTRONIC HIV VECTOR CONSTRUCTS
###### Anti-viral Formulations Nanomaterials And Nanoparticles
NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES
DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO
ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES
###### Fauci/COVID-19 Dossier 3un08 HFebOS 24Mar06 293un04 15Mar07 8Sep08
28Aug03
20D6C06
15NOV06
###### 201U1-06 13Apr06 301U1-03
30COLLAND
FREDERIC
###### Oct06
22Human
Genome Sciences, Inc.
The Government of the USA as represented by the
###### Secretary of Health and Human Services, NIH
COMPANS RICHARD W
FOLIA BIOTECH INC.
###### 3an03 2Aug04 133U1-06
15NOV06
###### 27ST.
DUDE CHILDREN'S RESEARCH HOSPITAL
###### Oct06
2 KHAN
KAMRAN
ANDREWS GLEN
CHUNG EUN 3
HUMAN GENETIC SIGNATURES PTY LTD.
MILLER CHRIS
###### Novartis Vaccines and Diagnostics, Inc. INTRINSIC MATERIALS LIMITED
Sea Lane Biotechnologies


-----

###### Nationwide Children's Hospital., Inc.
 Apr07

27May08
###### 27Sep04
14Sep05
13Aug08
5May04
###### 16Feb06 28Mar08 17JU1-06
CC-BY-NC-SA
###### Dr. David E. Martin UNov
 - 09
 293un
 - 09
 10Feb
 - 06
 23Mar
 - 07
 293un
 - 05
 14Mar
 - 08

8Sep

###### - 08

4Sep

###### - 09

19Dec

###### - 07

14N0V

###### - 07

203U107
###### 13Apr
 - 07

2Sep

###### - 09
 250ct
 - 07
 20Apr
 - 09
5Nov
###### - 09

123U107
###### 250ct
 - 07
 26Oct
 - 07

2Apr

###### - 08

26May

###### - 09

27Sep

###### - 05


-----

14Sep
###### -06
12Aug
###### -09 220ct -09
 16Feb -07
 27Mar -09
13DU107
152
###### 18Mar -10
 18Mar -10
 18Mar -10
 18Mar -10
 HMar -10
 HMar -10
 HMar -10
 HMar -10 4Mar -10 4Mar -10 4Mar -10 4Mar -10 25Feb -10 25Feb -10 25Feb -10 25Feb -10 25Feb -10
 25Feb -10
 25Feb -10
 18Feb -10
 18Feb -10


-----

###### 18Feb -10 18Feb -10 18Feb -10 18Feb -10 18Feb -10 18Feb -10 HFeb -10

US20100035
848
US20100035
###### 836
US20100035
761
US20100035
239
US20100035
###### 234
US20100035
232
US20100035
227
###### US20100034
852
US20100029
732
US20100029
722
US20100029
718
US20100029
713
US20100029
585
US20100029
557
US20100029
552
US20100028
853
US20100028
381
US20100028
369
US20100022
###### 491
US20100021
987


-----

US20100021
907
US20100021
895
US20100021
###### 470
US20100016
388
US20100016
359
US20100015
633
US20100015
607
US20100015
###### 594
10THERAPY
FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT
BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC
AGENTS
###### High-throughput rna structure analysis Compositions for use in identification of bacteria
VACCINE ASSAYS
TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR
###### IDENTIFICATION OF PATHOGENS Compositions for use in identification of alphaviruses
METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING
DRUG RESISTANT STRAINS OF INFLUENZA VIRUS
###### Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone
ORGANIC COMPOUNDS
ORGANIC COMPOUNDS
###### QUINICLIDINE DERIVATIVES OF (HETERO)
ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR
ANTAGONISTS
BARNES THOMAS MICHAEL
BETHELL RICHARD
GIDDINGS MORGAN C
###### ISIS Pharmaceuticals, Inc. Novartis AG
ECKER DAVID 3
###### ISIS Pharmaceuticals, Inc.
NIMAN HENRY L
ASTRAZENECA AB
DALES NATALIE
###### Novartis AG
ASTRAZENECA AB
###### TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE DIETSCH GREGORY
ALPHA-LACTALBUMIN COMPOSITION
###### Peptide inhibitors of c-jun dimerization and uses thereof
OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS
GULDMANN MARIANNE
###### Phylogica Limited Not Available
FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES


-----

COMPANY
###### Hazardous substance removing material and method for removing hazardous substance
 A-HYDROXY^-OXO^^-DIHYDRO-l^-BENZOTHIAZOL-yYL
COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR
###### ACTIVITY FUJIFILM Corporation
ASTRAZENECA AB
###### Compositions., Methods^ and Kits for Enhancing Protein Expression LIFESENSORS INC.
METHOD OF DETECTING A PLURALITY OF NUCLEIC ACIDS
###### Vectors for Inducing Homozygous Mutations and Methods of Using
Same
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
OF B CELLS
###### Salts of a Selective Beta-2 Andrenoceptor Agonist
METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION,
AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE
AGENTS THAT CONTROL SR PROTEIN ACTIVITY
METHODS AND KIT FOR ANALYTE DETECTION
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE
THEREOF
HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID
PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL
SORTER (FACS)
###### Fauci/COVID-19 Dossier
KABUSHIKI KAISHA TOSHIBA
RULEY H EARL
###### INSTITUTE FOR RESEARCH IN BIOMEDICINE Not Available Mar08 3-JU108 5Jun06 HSep03
19May08
###### 14Sep06 3Mar04 25Jan07 8Feb07
20D6C06
###### 22Sep06
14NOV06
###### lAug08
17NOV06
###### 20Aug04 25Oct05 19Jun06 29JU1-08
20D6C06
30D6C04
###### 3-JU108 12JU1-06 26Feb03 lMar07


-----

###### 26Masatoshi Hagiwara
Dec03
GENERAL

ELECTRIC COMPANY
###### INSTITUTE FOR SYSTEMS BIOLOGY 18IU1-08
23Dec05
10GOULD
TOBY
CC-BY-NC-SA Dr. David E. Martin
###### Dec04 10Mar
 -09

13U109
53un
###### -07
 17Feb
 -05

19May

###### -09

14Sep

###### -07

2Mar

###### -05

243 an

###### -08

6Feb

###### -08

19Dec

###### -07

19Sep

###### -07

13NOV

###### -07
313U109
15NOV

###### -07

22Aug

###### -05

2Nov

###### -06
 183un
 -07

283U109
19Dec

###### -07
30Dec
###### -05
 123un
 -09

123U107
###### 26Feb
 -04


-----

###### 29Feb -08 293un -09
18DU108
22Dec
###### -06
9Dec
###### -05
 llFeb -10 llFeb -10 llFeb -10 llFeb -10 llFeb -10 llFeb -10 llFeb -10 llFeb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 4Feb -10 281anl0 281anl0 281anl0 281anl0 281anl0 21Janl0 21Janl0 21Janl0 21Janl0


-----

###### 21Janl0
153

US20100015
283
US20100015
211
US20100015
173
US20100010
217
US20100010
199
US20100010
###### 080
US20100009
343
###### US20100004 304
US20100003
723
US20100003
277
US20100003
269
US20090318
###### 435
US20090318
337
US20090317
###### 421
US20090317
###### 417
US20090312
285
US20090311
683
US20090311
###### 334
US20090311
288
US20090306
347
US20090306
###### 090
US20090306
042
US20090305
282
###### US20090304
743
###### US20090304
742
###### US20090304
739


-----

###### US20090304
729
###### US20090304
683
###### US20090304
681
###### Method of Preparing Powder Kimchi and Kimchi Composition Using the Same Combination Approaches For Generating Immune Responses COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES
METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING
COMPOUNDS
MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS
USE OF TYLVALOSIN AS ANTIVIRAL AGENT
COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION
OF INFLUENZA A VIRUS (H1N1) SWINE 2009
METHODS AND COMPOSITIONS FOR THE TREATMENT OF
MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY
THYROID AND PANCREATIC CANCER
RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS
STEAROTHERMOPHILUS
VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED
###### IL-15 AND METHODS FOR USING THE SAME
METHODS AND USES OF CAULIFLOWER AND COLLARD FOR
RECOMBINANT PROTEIN PRODUCTION
PYRAZOLOPYRIDINES AND ANALOGS THEREOF
###### Compositions and methods for activating innate and allergic immunity
COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL
BACTERIUM PROTEINS
###### Modified AAV Vectors Having Reduced Capsid Immunogenicity and
Use Thereof
BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM
AND METHODS OF USE
COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI
MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A
POLYINOSINIC ACID      - POLYCYTIDILIC ACID BASED AD3UVANT
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS
ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR
PRODUCTION THEREOF
HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA
DESATURASE INHIBITORS
###### Novel Compounds 010
NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION
AND USES THEREOF
###### Composition and Methods for Immunisation Using CD1D Ligands
INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION
AD3UVANT
INFLUENZA VACCINES INCLUDING COMBINATIONS OF
PARTICULATE AD3UVANTS AND IMMUNOPOTENTIATORS
CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL
CELL DNA
###### Soluble Fragments of The Sars-Cov Spike Glycoprotein


-----

###### Methods for the treatment and prevention of infection using antiselectin agents Fauci/COVID-19 Dossier 26Not Available
BARNETT SUSAN W
###### UNIVERSITAfA„T ZAfAffRICH PROREKTORAT FORSCHUNG
LAN JIONG
NOVARTIS AG
CAMBRIDGE UNIVERSITY TECHNICAL SERVICES
###### Longhorn Vaccines & Diagnostics, LLC
Dun06
1NOV04
###### 9Dec06 23Mar06 HSep06 13JU1-06 12Sep06
16GIULLANT
###### CESIDIO Mar04
10LAMPSON
BERT C
KUTZLER MICHELE
THOMAS 3EFFERSON UNIVERSITY
BONK 3ASON D
###### ID Biomedical Corporation of Quebec
BURTS MONICA
The Trustees of the University of Pennsylvania
###### Longhorn Vaccines & Diagnostics, LLC IBIS BIOSCIENCES, INC. LI LIE TAO VICTOR Novartis AG
3APAN SCIENCE AND TECHNOLOGY AGENCY
Xenon Pharmaceuticals Inc.
CAGE PETER ALAN
CHAN KWOK HUNG
###### GALLI GRAZIA Novartis Vaccines and Diagnostics SRL
NOVARTIS VACCINES AND DIAGNOSTICS SRL
NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG
DIMITROV DIMITER S
###### Not Available
CC-BY-NC-SA Dr. David E. Martin
###### Mar04 133an06 113U1-06 3Oct03 22Oct03 183an06 28Apr06 lOct07 6Apr06 133an06


-----

###### 23Mar06
29Aug05
###### 20Sep04
12Dec07
###### 213U1-04 15Mar06
4NOV05
4NOV05
1NOV05
###### 193an07 293U1-04 263un -07
 INov -05
6Dec
###### -07 23Mar -07 llSep -07
133U107
283U109
###### lOct -08 10Mar -04 123an -07
 283un -07 83un -09
 22Oct -04 183an -07 27Apr -07
 lOct -08

6Apr
###### -07 273un -06 23Mar -07

29Aug
###### -06
13Aug
###### -09

10Dec
###### -08 13un


-----

###### -09 15Mar -07
6Nov
###### -06
6Nov
###### -06 INov -06 19:an -07
27:11105
###### 154 21Janl0 21Janl0 21Janl0 14Janl0 14Janl0 14Janl0 14Janl0 71anl0 71anl0 71anl0 71anl0
24Dec
###### -09
24Dec
###### -09
24Dec
###### -09
24Dec
###### -09
17Dec
###### -09
17Dec
###### -09
17Dec
###### -09
17Dec
###### -09
10Dec
###### -09
10Dec
###### -09
10Dec
###### -09
10Dec
###### -09
10Dec
###### -09
10Dec
###### -09
10Dec
###### -09


-----

10Dec

###### -09

10Dec

###### -09

10Dec

###### -09 US20090304 630
US20090300
778
US20090299
###### 250
US20090298
###### 914
US20090298
821
US20090298
807
US20090297
555
US20090286
835
US20090286
813
US20090286
###### 726
US20090286
222
US20090285
921
US20090285
901
US20090285
###### 854
US20090281
042
US20090281
041
###### 16Treating severe and acute viral infections Neutral Sphingomyelinase-E and Its Use
 ANTIVIRAL FILTER AND ITS USE IN AN AIR PURIFIER, AIR
CONDITIONER OR AIR HUMIDIFIER
RNA Interference Mediated Inhibition of Severe Acute Respiratory
###### Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)
HYDROXY AND ALKOXY SUBSTITUTED IHIMIDAZONAPHTHYRIDINES
AND METHODS
Compounds
RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES
COMPRISING HETEROLOGOUS ANTIGENS
NOVEL COMPOUNDS
###### Thioxanthine Derivatives and Their Use as Inhibitors of MPO
USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR


-----

TREATMENT OF VIRAL DISEASES
###### Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
And Enteric Viruses
PLANT EXTRACT AND ITS THERAPEUTIC USE
###### Polyamino acid for use as adjuvant
FROZEN STOCKPILING OF INFLUENZA VACCINES
COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION
OF VIRUSES
###### ANTIVIRAL CELL-PENETRATING PEPTIDES
US20090280
507
METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID
PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE,
MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS
NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF
PRODUCING THE MONOCLONAL ANTIBODY
US20090275
###### 666
US20090275
583
US20090275
508
US20090275
###### 016
US20090270
###### 443
US20090270
###### 431
US20090269
367
###### US20090264
653
###### US20090264
509
###### US20090264 444
CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION
AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS OR AS A
TANNIN
###### ANTIVIRAL COMPOUNDS AND USE THEREOF
USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH
PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF
CYTOMEGALOVIRUS INFECTION
ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
IMMUNE RESPONSE
###### 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC
OUTBREAKS USING REPLIKIN COUNT CYCLES
USEFUL INDOLE COMPOUNDS
###### Adenoviral vector-based foot-and-mouth disease vaccine Organic compounds Fauci/COVID-19 Dossier


-----

HEMISPHERx BIOPHARMA
HOPPE UTA
###### Universite De Rouen Sirna Therapeutics, Inc. Pfizer Inc.
ALCARAZ LILIAN
MEDIMMUNE, LLC
###### AstraZeneca AB
ASTRAZENECA AB
TECNOGEN S.P.A.
GOODRUM PATRICIA GAIL RAY
###### Veritron Limited
AKASHI MITSURU
###### Novartis AG
ARAD DORIT
CURRELI FRANCESCA
May03
###### 8Feb06 19Iul-06 15Apr03 15Mar06 6Feb08 253un04 4Oct07 13Apr06 10Mar06 24Apr98
16May08
###### 20Apr05 203U1-06 8Sep05
6May08
11SYSMEX
CORPORATION
###### Oct05
2Aug
###### -07
8Feb
###### -07
193U107
17NOV
###### -08 14Mar -07 4Feb -09
303un
###### -09 3Oct -08 12Apr -07 28Feb -07


-----

###### 160ct
 -08
 iDec
 -08

27:11109
20111107
10Sep

###### -06
5May
###### -09
 noct
 -06

10Dec

###### -09
3Dec
###### -09
3Dec
###### -09
3Dec
###### -09
3Dec
###### -09
3Dec
###### -09
3Dec
###### -09

19NOV

###### -09

19NOV

###### -09

19NOV

###### -09

19NOV

###### -09

19NOV

###### -09

19NOV

###### -09

19NOV

###### -09

12NOV

###### -09

12NOV

###### -09

12NOV

###### -09

17BASF
SE
###### Myriad Genetics, Incorporated
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
###### UNIVERSITY OF ROCHESTER Not Available
THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION
BOGOCH ELENORE S


-----

BARDEN TIMOTHY

GENVEC, INC.
CHOWDHURY SULTAN
CC-BY-NC-SA Dr. David E. Martin
May06
###### 13Oct06
2May06
2May08
###### 2Sep04 19Oct05 23Apr08
16Dec05
10NOV05
###### 20Feb08 28Feb
 -07
 13Apr
 -09
 12Apr
 -07
 IMay
 -09

2Sep

###### -05
 19Oct
 -06
 23Apr
 -09

18Dec

###### -06

8May

###### -08
 20Feb
 -09
5Nov
###### -09
5Nov
###### -09
5Nov
###### -09
5Nov
###### -09
 29Oct09 29Oct09 29Oct09 22Oct09 22Oct09 22Oct09
155

###### US20090264

362
###### US20090264
307
###### US20090264


-----

300
US20090263
352
US20090258
###### 440
US20090258
340
US20090258
###### 074
US20090258
011
US20090257
###### 950
US20090253
###### 714
US20090253
695
US20090252
775
US20090252
###### 646
US20090247
###### 614
US20090247
608
US20090239
848
US20090239
###### 830
US20090239
###### 824
US20090239
###### 814
US20090239
###### 810
US20090235
625
US20090233
965
US20090233
907
US20090233
309
US20090232
###### 844
US20090232
843
US20090232
808
US20090232
748
US20090227
637
###### 4Influenza


-----

###### virus inhibiting peptides
ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE
RESOLUTION
ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF
LARGE LIBRARIES
METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29
CYSTEINE MUTANTS
SURFACE FOR LABEL INDEPENDENT DETECTION AND METHOD
THEREOF
###### Assay for SARS coronavirus by amplification and detection of the replicase sequence
MIXTURES OF TANNINS, THEIR PRODUCTION AND USE IN
MEDICAMENTS OR AS DISINFECTANTS
###### Antibodies against west nile virus and therapeutic and prophylactic uses thereof
Membrane Scaffold Proteins
###### Methods of reducing risk of infection from pathogens Hydroxyalkyl Substituted Imidazonaphthyridines
VIRUCIDAL DISINFECTANT
The Administrators of the Tulane Educational Fund
The Trustees of Princeton University
###### Nuevolution A/S ZymoGenetics, LLC
BUNCH THOMAS A
###### Becton, Dickinson and Company
BASF SE
###### Washington University
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF
###### ILLINOIS Not Available Coley Pharmaceutical Group, Inc,
B. BRAUN MEDICAL AG
###### STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT Invention Factory, LLC Folate Conjugates Targeting Lipids
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA
DESATURASE
###### Treatment of viral infections by modulation of host cell metabolic pathways
HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS
AND METHODS OF USE
###### Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA
DESATURASE
FILTER AND ASSOCIATED METHOD

###### Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors
BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS
AND METHODS
IMMUNOPOTENTIATING COMPOUNDS
###### Identifying and predicting influenza variants and uses thereof
MOLECULES AND CHIMERIC MOLECULES THEREOF


-----

###### Virucidal activities of cetylpyridinium chloride
DIARYL UREAS FOR TREATING VIRUS INFECTIONS
ALNYLAM PHARMACEUTICALS, INC.
ALNYLAM PHARMACEUTICALS, INC.
FOREST LABORATORIES HOLDINGS LIMITED
BENNETT BRYSON
###### Anacor Pharmaceuticals, Inc.
ALNYLAM PHARMACEUTICALS, INC.

###### Forest Laboratories Holdings Limited
GENERAL ELECTRIC COMPANY
NOV03
###### 13Ian06
IDecOS
###### 2Apr04 10Apr08
12Sep03
17May06
###### 213un04
20NOV00
20Aug03
###### 23Feb05 283an05 83an07 4Dec07 4Dec07 20Mar08 13un07 163un03 4Dec07 20Mar08
28Sep07
24ASTRAZENECA
AB
###### Apr06
22ASTRAZENECA
AB
LONGHORN VACCINES & DIAGNOSTICS, LLC
SUTTON 3AMES
NIMAN HENRY L
APOLLO LIFE SCIENCES LIMITED
###### ViraTox, L.L.C.
RIEDL BERND
###### Mar06 lOct07 23Mar06 8-3U105 283an05
7NOV03
ISDecOS
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 17Feb -09


-----

###### 12:an -07 IDec -06

2 IMay
###### -09
3Apr
###### -09
3Feb
###### -09 28Feb -07
6Apr
###### -09 10Oct -07
18Aug
###### -04 22Feb -06
28May
###### -09
28May
###### -09
4Dec
###### -08
4Dec
###### -08 20Mar -09 23un -08
13N0V
###### -08
4Dec
###### -08 20Mar -09
28Sep
###### -07 23Apr -07 20Mar -07 20Apr -09 23Mar -07
ADan
###### -08 273an -06 18Mar -09


-----

6Dec
###### -06
156
###### 22Oct09 22Oct09 22Oct09 22Oct09 15Oct09 15Oct09 15Oct09 15Oct09 15Oct09 8Oct09 8Oct09 8Oct09 8Oct09 lOct09 lOct09
24Sep
###### -09
24Sep
###### -09
24Sep
###### -09
24Sep
###### -09
24Sep
###### -09 24Sep -09
17Sep
###### -09
17Sep
###### -09
17Sep
###### -09
17Sep
###### -09
17Sep
###### -09
17Sep
###### -09
17Sep
###### -09
10Sep
###### -09

US20090227
541
###### US20090227 030
US20090227
###### 005
US20090226
885


-----

US20090222
###### 936
US20090221
653
US20090221
###### 640
US20090221
631
US20090221
###### 624
US20090221
583
US20090221
556
US20090221
551
US20090221
###### 487
US20090220
941
US20090220
937
US20090220
547
US20090220
546
US20090220
545
US20090220
###### 544
US20090220
541
US20090220
530
US20090220
###### 514
US20090220
###### 456
US20090216
###### 860
US20090216
747
US20090215
###### 786 US20090214
663
###### US20090214
590
20BORON-CONTAINING
SMALL MOLECULES
###### Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
 Methods for pathogen detection Nucleic Acid Sequences That Can Be Used As Primers And Probes In


-----

The Amplification And Detection Of Sans Coronavirus
###### Anacor Pharmaceuticals, Inc.
The Trustees of the University of Pennsylvania
###### Searete LLC, a limited liability corporation of the State of Delaware
OVERDIIK MARLIEKE
###### Recombinant Expression of Multiprotein Complexes Using Polygenes BERGER IMRE 7-(2-amino-l-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-onederivatives as beta2 adrenoreceptor agonists Novel Crystal Modifications
IMIDAZOPYRIDINONES
###### 4-AMIN0QUIN0LINE COMPOUNDS FOR TREATING VIRUS-RELATED
CONDITIONS
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA
DESATURASE
HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES
AND METHODS
SUBSTITUTED FUSED[1,2] IMIDAZ0[4,SC] RING COMPOUNDS AND
METHODS
POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1
COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND
###### KITS AND METHODS USING SAME Compositions for Use in Identification of Adventitious Viruses Reducing interference between oil-containing adjuvants and surfactant-containing antigens Adjuvanted influenza vaccines for pediatric use Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen
AD3UVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED
FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE
EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR
AD3UVANTING SPLIT INFLUENZA VACCINES
DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND
METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE
ADAM10 and its Uses Related to Infection
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE
SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
AND COMMUNICATING EVENT RELATED INFORMATION
###### System and method for detecting, collecting, analyzing, and communicating event-related information
NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC
APPLICATIONS
###### Virus coated nanoparticles and uses thereof Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof AstraZeneca AB
ASTRAZENECA AB
###### Not Available
BUSCHER BENIAMIN A
AURIGENE DISCOVERY TECHNOLOGIES LIMITED
###### Pfizer Inc. Pfizer Inc. Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
MND DIAGNOSTIC LTD


-----

###### IBIS BIOSCIENCES, INC.
NOVARTIS VACCINES AND DIAGNOSTICS SRL
GROTH NICOLA
NOVARTIS AG
NOVARTIS VACCINES AND DIAGNOSTICS SRL
NOVARTIS VACCINES AND DIAGNOSTICS SRL
HU HONG-MING
HODGE THOMAS
###### Not Available Georgetown University Georgetown University- OTC
BOISSY GUILLAUME
ALBRECHT THOMAS B
Wayne State University
Dun07
17Dec01
###### 27Mar07 101un03
8NOV05
29Aug05
###### 16Mar06
3Aug07
6May05
###### 213un07
4NOV05
###### 15Mar06
10NOV05
###### 25Oct05
3Mar05
###### 2Aug05 22Feb08 153un06
4NOV05
4NOV05
###### 293U1-05 133an06
28Aug03
###### 25Feb08 25Feb08
5Aug05
###### 26Sep06 8-3U105 193un -08 31Oct -07
28Sep
###### -07
8Mar
###### -04
6NOV
###### -06
28Aug
###### -06


-----

###### 15Mar -07
15May
###### -09
4May
###### -06 233un -08
3Nov
###### -06 14Mar -07
11N0V
###### -06 250ct -06
3Mar
###### -06

2Aug
###### -06 20Feb -09 153un -07
6Nov
###### -06
6Nov
###### -06 273U106 163an -07 llFeb -09
19NOV
###### -08
28Aug
###### -08 263U106 26Mar -09 103U106
10Sep
###### -09
10Sep
###### -09
10Sep
###### -09
10Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep


-----

###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
3Sep
###### -09
27Aug
###### -09
27Aug
###### -09
27Aug
###### -09
27Aug
###### -09
27Aug
###### -09 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
157

###### US20090214

587
###### US20090214
537
###### US20090214
533
###### US20090214


-----

510
###### US20090214 444
US20090209
###### 640
US20090209
555
US20090209
###### 524
US20090209
505
US20090209
###### 458
US20090208
531
US20090205
###### 116
US20090203
753
US20090203
675
US20090203
112
US20090202
995
US20090202
590
US20090197
###### 914
US20090197
###### 894
US20090197
###### 890
US20090197
338
US20090196
921
US20090192
505
US20090192
163
US20090192
153
US20090192
099
US20090192
###### 090
US20090192
081
###### SRecombinant virus and use thereof
Serum Resistance Factors of Gram Positive Bacteria
METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY
###### Broad Spectrum Antiviral Compositions


-----

POLY AROMATIC SODIUM CHANNEL BLOCKERS
###### Prevention of and countermeasures against viral infection
2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR
CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE
###### ACTIVITY IS BENEFICIAL Novel Compounds
PRODRUGS OF HETEROARYL COMPOUNDS
###### Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
 ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA ARTICLE, LAMINATE AND ASSOCIATED METHODS
 7-(2-amino-l-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-onederivatives as beta2 adrenoreceptor agonists Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses Post Genome Institute Co., Ltd.
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
NEW YORK
###### Government of the US as represented by the Secretary, Department of Health and Human Services
PARION SCIENCES, Inc.
CHOKO CO., LTD.
HANSEN PETER
###### AstraZeneca AB Koronis Pharmaceuticals, Incorporated
VANDERBILT UNIVERSITY

###### National Institutes of Health Office of Technology
GENERAL ELECTRIC COMPANY
###### AstraZeneca AB Oct04
13May05
###### 17Aug06 21Feb06 26Feb08
20NOV03
8May06
22NOV07
###### 203un03 4Mar04 16Feb06
30Sep05
29Aug05
6SIGA
TECHNOLOGIES, INC.
D6C04
4VER0
CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION Ricardo Kratje
MOLECULAR CARDIOTOXICOLOGY MODELING
INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO
ALUMINIUM AD3UVANTS

###### Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing


-----

Them
NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC
AGENTS
PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC
AGENTS
###### Method of Increasing the Function of an AAV Vector Compositions Methods and Kits For Enhancing Immune Response To
A Respiratory Condition
###### Method for cryospray ablation Novel Compounds
NOVEL ADENINE COMPOUND
PRODRUGS OF HETEROARYL COMPOUNDS
PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING,
ANTI-INFLAMMATORYj AND ANTI-VIRAL ACTIVITY
###### Casein derived peptides and uses thereof Fauci/COVID-19 Dossier
1OHNSON KORY R
NOVARTIS VACCINES AND DIGNOSTICS SRL
CAGE PETER
XENON PHARMACEUTICALS INC.
XENON PHARMACEUTICALS INC.
The Trustees of teh University of Pennsylvania
The Procter & Gamble Company
###### Reset Medical, Inc.

ASTRAZENECA AB
###### AstraZeneca Aktiebolag A corporation of Sweden Koronis Pharmaceuticals, Incorporated
TAKEDA PHARMACEUTICAL COMPANY LIMITED
SIDELMAN ZVI
CC-BY-NC-SA Dr. David E. Martin
###### octes
26Aug05
4NOV05
###### 7Mar06
21Dec01
###### 301U1-03 7Apr05 6Feb08
5Dec07
###### 6Oct05
22Sep05
###### 203un03 253un03 lMar00 HOct -05
12May
###### -06 17Feb -09 21Feb -07 26Feb -09


-----

###### 15Apr -09
7May
###### -07
20NOV
###### -08
7Apr
###### -09 4Mar -05 16Feb -07
5Dec
###### -08
28Aug
###### -06
6Dec
###### -05 30ct -06
28Aug
###### -06
6Nov
###### -06
6Mar
###### -07 14Apr -09 20Feb -09
7Apr
###### -06
6Feb
###### -09
5Dec
###### -08 50ct -06
21Sep
###### -06
30Mar
###### -09
31Dec
###### -08 310ct -07
158
27Aug
###### -09
27Aug
###### -09
27Aug
###### -09
27Aug


-----

###### -09
27Aug
###### -09
20Aug
###### -09
20Aug
###### -09
20Aug
###### -09
20Aug
###### -09
20Aug
###### -09
20Aug
###### -09
20Aug
###### -09
13Aug
###### -09
13Aug
###### -09
13Aug
###### -09
13Aug
###### -09
13Aug
###### -09
6Aug
###### -09
6Aug
###### -09
6Aug
###### -09
6Aug
###### -09
6Aug
###### -09
303U109
303U109
303U109
303U109
303U109
303U109

###### US20090191
229
US20090186
###### 056
US20090186
041
US20090186
025
US20090186
###### 014 US20090182


-----

133
US20090181
972
US20090181
361
US20090176
821
US20090176
815
US20090176
699
US20090175
948
US20090175
902
US20090170
717
US20090169
###### 636
US20090163
533
US20090163
518
US20090162
831
US20090162
392
US20090162
365
US20090162
320
US20090155
###### 564
US20090149
###### 475
US20090149
###### 448
US20090149
###### 429
US20090131
###### 486
US20090131
###### 459
AD3UVANCY AND IMMUNE POTENTIATING PROPERTIES OF
NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS
15NEW
YORK BLOOD CENTER
COMPOSITIONS AND METHODS FOR PREVENTING INFECTION
###### ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS
 Fusion Protein Comprising an Fc Receptor Binding Polypeptide and
an Antigenic Polypeptide for Mediating an Immune Response
METHOD FOR TREATMENT OF PANCREATITIS
BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL


-----

AGENTS

###### Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications Rapid test for detecting infection Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4Amino-lH-Imidazo[4,5-C] Quinolin-1YL)Butyl]Methanesulfonamides
and Methods
###### Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity Inhibitors Based on Fusion, Hrl and Hr2 Sequences in Bacterial Adhesin
AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTIMICROBIAL
AGENT
###### Immunogenic Substances Comprising A Polyinosinic AcidPolycytidilic Acid Based Adjuvant
RE-SEQUENCING PATHOGEN MICROARRAY
###### Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases Novel Compounds
HUMAN PARVOVIRUS
MUTANT FORMS OF STREPTOLYSIN 0
###### Novel siRNAS and methods of use thereof
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING
###### LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA
VIRUS SPIKE PROTEIN
ARTICLE AND ASSOCIATED METHOD
###### Thioxanthine Derivatives and Their Use as Inhibitors of MPO Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases ANTIVIRAL COMPOUNDS
2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR
CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE
###### ACTIVITY IS BENEFICIAL 2-Thioxanthine Derivatives Acting as MPO-Inhibitors
LA 3OLLA BIOSCIENCES LLC
###### Functional Genetics, Inc. ImmunoBiology Limited Ore Pharmaceuticals Inc. Shanghai Institute of Materia Medica Chinese Academy of Sciences
BOISSY GUILLAUNE
KUMAR ARUN
###### 3un04 8Aug02
15NOV06
###### 22Mar06 10Oct07
29D6C05
8D6C05
###### 141an08


-----

9C0LEY
PHARMACEUTICAL GROUP, INC.
Sep05
ERIKSSON
TOMAS
CHIRON SRL
BRINKER C JEFFREY
###### Not Available
The Government of the United States of America, as
###### represented by the Secretary of the Air Force Not Available
COLEY PHARMACEUTICAL GROUP, INC.
BONNERT ROGER
DELWART ERIC L
NOVARTIS AG
FEINSTEIN ELENA
###### 19JU1-06 6-JU104
30NOV07
###### 13Ian06 2-3U104 24Feb06 lApr05
27May03
###### 24May04
21Dec07
###### 25Oct06
28DNAVEC
###### Corporation Oct05
28GENERAL
ELECTRIC COMPANY
ASTRAZENECA AB
ASTRAZENECA AB
###### Myriad Genetics, Incorporated
HANSEN PETER
ASTRAZENECA AB
Sep07
###### 13Apr06
23NOV04
###### 223un05
8May06
###### 53un06 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 23Mar -09 19Mar -09 18Apr -08 22Mar -07


-----

###### 90ct
 -08
15Dec

###### -06
5Dec
###### -06 MJan
 -08
8Sep
###### -06
16Dan
###### -09
6DU105
26Nov
###### -08 273un -06 10Apr -08 24Feb -07
31Mar
###### -06 4Mar -09
24May
###### -05
19Dec
###### -08 250ct -07 270ct -06
28Sep
###### -07 12Apr -07
22NOV

###### -05 223un
 -06
7May
###### -07 43un -07
303U109
233U109
233U109
233U109
233U109
163U109
163U109
163U109
###### 93ul09


-----

9DU109
9DU109
9DU109
9DU109
2DU109
2DU109
###### 253un09 253un09 253un09 253un09 253un09 253un09 183un09 113un09 113un09 113un09
21May
###### -09
21May
###### -09
159

US20090131
328
US20090130
###### 146
US20090130
138
US20090126
###### 514 US20090124
843
###### US20090124
652
###### US20090124 640 US20090124
611
###### US20090124
596
###### US20090124
512
US20090123
###### 494
US20090123
###### 460
US20090123
###### 417
US20090118
503
US20090118
288
US20090118
263
US20090117


-----

537
US20090117
367
US20090117
123
US20090117
115
US20090117
113
US20090111
828
US20090111
091
US20090105
295
US20090105
212
US20090105
203
US20090105
151
US20090105
092
###### US20090104 226
FURIN INHIBITORS
SMITH 3UDITH
COMBINATION VACCINE
###### Antiviral and antibacterial activity from medicinal mushrooms Devices for collection and preparation of biological agents
HAZARDOUS SUBSTANCE REMOVING METHOD, HAZARDOUS
SUBSTANCE REMOVING MATERIAL USED THEREIN SUCH AS AIR
###### FILTER, MASK, WIPE SHEET, AND THE LIKE, AND STORAGE
METHOD THEREOF

###### Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor Pyrazolopyridine-1,4-Diamines and Analogs Thereof Chemical Compounds 637
DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND
EMERGING STRAINS OF INFLUENZA
MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE
IMMUNOSTIMULATORY COMBINATIONS
RECOMBINANT SUPER-COMPOUND INTERFERON AND USES
THEREOF
FAAH INHIBITORS
###### N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor Novel Adenine Compound
METHOD FOR DETECTING SARS CORONAVIRUS
ARTICLE AND ASSOCIATED METHOD
IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS
###### Binary epitope antibodies and B cell superantigen immune


-----

###### stimulants Immunogenic And Therapeutic Compositions For Streptococcus Pyogenes
L-ALANINE DERIVATIVES
SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS,
AND METHOD FOR DETECTING VIRUS
HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES
NOVEL ADENINE COMPOUND
COMPOUNDS FOR TREATING VIRAL INFECTIONS
AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS
###### ANTIVIRAL AGENTS VIRAL DATABASE METHODS Alphavirus Vectors for Respiratory Pathogen Vaccines
CHIRON BEHRING GMBH & CO. KG
STAMETS PAUL EDWARD
BELGRADER PHIL
###### 231U1-04 8Oct04 63an04
5Sep07
###### 28Not Available Mar03 30Takeda Pharmaceutical Company Limited
ASTRAZENECA AB
###### Coley Pharmaceutical Group, Inc.
BONNERT ROGER VICTOR
REGENTS OF THE UNIVERSITY OF COLORADO
###### FLICK RAMON
3M Innovative Properties Company
WEI GUANGWEN
###### Not Available
ASTRAZENECA AB
ASTRAZENECA AKTIEBOLAG
EIKEN KAGAKU KABUSHIKI KAISHA
GENERAL ELECTRIC COMPANY
###### National Health Research Institutes
NISHIYAMA YASUHIRO
###### Chiron Corporation
ASTRAZENECA AB
SYSMEX CORPORATION
###### Coley Pharmaceutical Group, Inc. AstraZeneca Aktiebolag a corporation of Sweden Myriad Genetics, Incorporated
CHEONG KWANG HO
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
NEW YORK
NOVARTIS VACCINES AND DIAGNOSTICS INC.
D6C04
###### 53un06 lApr05 113an07 183an06


-----

###### 31JU1-07
30Dec02
###### 28Feb01 203un07 213U1-05
22Sep05
###### 273un03
28Sep07
2NOV07
9NOV06
###### 8Oct04
23NOV05
###### 31Oct07
14NOV03
22Sep05
###### 16Oct06 193U1-07
28NOV06
###### 21May04 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
223U105
###### 7Oct -05
24Sep
###### -08
5Sep
###### -07
21NOV
###### -08
28Dec
###### -05 43un -07
31Mar
###### -06 103an -08 ISIan -07 313ul08 17Mar -08 6Oct -08 203un -08 193ul06
20Sep
###### -06 103un -08
28Sep


-----

###### -07 23Sep -08 9l\lov -07 HOct -05 22Nov -06 31Oct -08 12Nov -04 22Sep -06 160ct -07 14JU108
_27NOV_
###### -07
_20May_
###### -05
May
###### -09
21May
###### -09
21May
###### -09
21May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
14May
###### -09
7May
###### -09
7May
###### -09
7May
###### -09


-----

7May
###### -09
7May
###### -09
7May
###### -09
7May
###### -09
7May
###### -09 30Apr09 30Apr09 23Apr09 23Apr09 23Apr09 23Apr09 23Apr09 23Apr09 160
21

###### US20090104 209 US20090104
147
###### US20090099 216 US20090099 161
US20090099
###### 156
US20090099
###### 110
US20090099
###### 043
US20090098
###### 530
US20090098
207
US20090092
962
US20090092
633
US20090092
581
US20090083
865
US20090082
547
US20090082
###### 332 US20090082
287
###### US20090081 675


-----

US20090081
252
US20090081
157
US20090078
263
US20090076
###### 076
US20090075
###### 980 US20090074 810
US20090069
###### 314
US20090068
759
US20090068
665
US20090068
###### 636
US20090068
142
US20090068
095
METHODS OF REDUCING A VIRAL INFECTION AND KITS
THEREFORE
21LABONTE
PATRICK
###### Sialoadhesin-Related Compositions and Methods
NOVEL ADENINE COMPOUND
###### Substituted Imidazoquinolines and Imidazonaphthyridines Heterocyclic Compounds as Ccr2b antagonists Antiviral oligonucleotides Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions Cell Line For Producing Coronaviruses Technology for the Preparation of Microparticles
METHOD FOR DETECTING SARS CORONAVIRUS
###### Polyamino acid for use as adjuvant Interferons of rhesus and cynomolgus origin and uses thereof
DELPUTTE PETER
###### AstraZeneca Aktiebolag A corporation of Sweden Coley Pharmaceutial Group, Inc.
BOWER 3USTIN FAIRFIELD
3UTEAU 3EAN-MARC
ZHU YORK YUAN YUAN
CRUCELL HOLLAND B.V.
###### NexBio, Inc.
EIKEN KAGAKU KABUSHIKI KAISHA
AKASHI MITSURU
CLARK WILLIAM A
###### Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof CHAN TEH-SHENG
COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO
CELLS


-----

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC
DISEASES AND CANCERS
METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL
CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS
AND OSMOLYTES
METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A
MICROORGANISM IN A SAMPLE
DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
INFLUENZA VACCINES
###### Immunostimulatory Combinations for Vaccine Adjuvants Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet,
and the like, and storage method thereof
###### INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE
THEREOF
###### Pyrazolopyridines and Analogs Thereof Modified Adenovirus Hexon Protein and Uses Thereof
IVERSEN PATRICK L
ABBOT PHILIP
PARION SCIENCES, INC.
COLSTON DR BILL W
CHIRON BEHRING GMBH & CO.
###### Not Available
Sep07
###### HMay06
22Sep05
###### llFebOS
24D6C04
13Sep02
###### 23IU1-07 223U1-05 243U1-07 273un03 20Apr05 HApr07 113an06 29Apr03
22Sep05
7Sep06
24Aug07
###### 9Sep04 93an06 2SARAI
3UN-ICHIRO
###### Mar03 13Baylor University Coley Pharmaceutical Group, Inc.
The Trustees of the University of Pennsylvania
###### Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods Coley Pharmaceutical Group, Inc.
REUSABLE DETECTION SURFACES AND METHODS OF USING SAME BioScale, Inc.
METHODS AND KITS FOR IDENTIFYING TARGET NUCLEOTIDES IN
MIXED POPULATIONS


-----

###### VIRAL PROTEIN
COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
INFECTION AND SARS
CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF
USE THEREOF
###### Fauci/COVID-19 Dossier
APPLIED BIOSYSTEMS INC.
CHANG MING-FU
###### Three Rivers Pharmaceuticals LLC
LO AGNES
CC-BY-NC-SA Dr. David E. Martin
Tun07
###### 3Oct03 28Apr06 23Feb05 6Sep07 30Apr04 2Mar04 lApr03
2D6C05
19Sep
###### -08 llMay -07
22Sep
###### -06 10Feb -06
19Dec
###### -05 28Feb -08
21NOV
###### -08 213U106
243U108
###### 103un -08 19Apr -06 llApr -08 Ilian -07
5Nov
###### -08
20Sep
###### -06
7Sep
###### -07
21Aug
###### -08
9Sep
###### -05


-----

###### 9:an -07
21N0V
###### -08 133un -08
31Mar
###### -06 27Apr -07 22Feb -06
5Sep
###### -08
313U108
19Sep
###### -07
293U108
4Dec

###### -06
161
###### 23Apr09 23Apr09 16Apr09 16Apr09 16Apr09 16Apr09 16Apr09 16Apr09 16Apr09 9Apr09 9Apr09 9Apr09 26Mar -09 26Mar -09 26Mar -09 26Mar -09 26Mar -09 26Mar -09 26Mar -09 26Mar -09 19Mar -09 19Mar -09 19Mar


-----

###### -09 12Mar -09 12Mar -09 12Mar -09 12Mar -09 12Mar -09 12Mar -09

US20090062
328
US20090062
272
US20090062
259
US20090062
229
US20090061
027
US20090061
017
US20090060
###### 950 US20090054 413 US20090054
342
US20090053
708
US20090053
299
US20090053
257
US20090053
248
US20090047
665
US20090047
353
US20090047
306
US20090047
272
US20090042
942
US20090042
925
US20090042
858
US20090042


-----

827
US20090042
292
US20090042
###### 274
US20090042
252
US20090041
818
US20090041
803
US20090041
781
US20090036
653
US20090036
535
###### Oxime and Hydroxylamine Substituted Imidazo[4J5-c] Ring
Compounds and Methods
11COLEY
PHARMACEUTICAL GROUP, INC.
IMIDAZOQUINOLINYL SULFONAMIDES
###### Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists
METHOD AND COMPOSITION FOR REDUCING THE EXPRESSION OF
###### ROCK-II Composition For The Prevention and Treatment Of Common Cold Diseases
SHELF STABLE, REDUCED CORROSION, READY TO USE
PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS
###### Method for Producing Viral Vaccines Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease Bioactive peptides and method of using same Method and/or Apparatus of Oligonucleotide Design and/or Nucleic Acid Detection Methods for generating immune response using cationic-liposomemediated nucleic acid delivery REPLIKIN PEPTIDES AND USES THEREOF Compositions and methods for transepithelial molecular transport
BONK 3ASON D
ASTRAZENECA AB
###### Myriad Genetics, Incorporated
PANDALIS GEORGIOS
BESSE MICHAEL
BAXTER HEALTHCARE
###### AstraZeneca AB
AYALON-SOFFER MICHAL
LEE CHARLIE
###### Georgetown University
BOGOCH ELENORE S
Thomas lefferson University
COMPOSITIONS FOR USE IN IDENTIFICATION OF ADENOVIRUSES IBIS BIOSCIENCES, INC.
CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES


-----

WITH ADJUVANTS
ADJUVANT COMPOSITIONS
###### Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases Muscarinic Receptor Antagonists
OXIME SUBSTITUTED IMIDAZOQUINOLINES
LACTAM CONTAINING HCV INHIBITORS
###### ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV
B7-DC Variants

###### Method of Purifying Virus Envelope

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

###### ANTIVIRAL AGENT, AND FABRIC AND ANTIVIRAL MEMBER
SUPPORTING ANTIVIRAL AGENT
###### Dioscorea Extracts
METHODS FOR DETECTING PARVOVIRUS INFECTIONS
###### Methods for the directed expansion of epitopes for use as antibody ligands Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease
NOVARTIS VACCINES AND DIAGNOSTICS SRL
M N L PHARMA LIMITED
APPELBAUM JACOB G
ASTRAZENECA AB
###### Coley pharmaceutical Group, Inc.
BARSANTI PAUL
JUTEAU JEAN-MARC
The Johns Hopkins University
GENOMIDEA INC.
###### Maxygen, Inc. ITO HIROSHI Academia Sinica
The Research Foundation of State University of New York
###### Peptimmune, Inc.
ASTRAZENECA AB
FebOS
30D6C03
###### 14Mar06
20Aug03
###### 24Mar06
30Aug07
28Aug07
###### 3Oct05 18Sep06
12Aug05
###### 9-JU107 6Jun03
31May02
###### HSep03
4NOV05
###### 21Jan04 14Apr04 20Apr05
14NOV03


-----

###### 163un05
13Sep02
###### 133U1-07 273U1-04
18NOV02
12Aug03
###### lDec03
5May03
###### 13Apr06 6Oct05 10Feb -06

23Dec
###### -04
 12Mar -07

6May
###### -08

2Mar
###### -07
30Aug
###### -07
28Aug
###### -08 20ct -06
18Sep
###### -07

8Aug
###### -06 93ul08
103U108
###### 25Mar -08
16Sep
###### -08

6Nov
###### -06 213an -05 14Apr -05 18Apr -06

12N0V
###### -04 163un -06
103U108
###### 11JU108
223U105
###### 30Oct -06

10Aug


-----

###### -04
2Sep
###### -08 160ct -08
7May
###### -08 50ct -06 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
162
5Mar
###### -09
5Mar
###### -09
5Mar
###### -09
5Mar
###### -09
5Mar
###### -09
5Mar
###### -09
5Mar
###### -09 26Feb -09 26Feb -09 26Feb -09 26Feb -09 26Feb -09 26Feb -09 19Feb -09 19Feb -09 19Feb -09 19Feb -09 12Feb -09 12Feb -09 12Feb -09 12Feb


-----

###### -09 12Feb -09 12Feb -09 12Feb -09 12Feb -09 12Feb -09 12Feb -09
5Feb
###### -09
5Feb
###### -09

US20090035
861
US20090035
323
US20090012
###### 280
US20090012
151
US20090012
125
US20090011
###### 465
US20090011
###### 403
US20090005
376
US20090005
371
###### US20090004
643
US20080319
###### 170
US20080318
998
US20080317
702
US20080311
138
US20080311
125
US20080311
042
US20080310
992
US20080305
###### 120
US20080305


-----

119
US20080300
275
US20080300
###### 244
US20080300
191
US20080299
545
US20080299
182
US20080299
###### 070
US20080295
843
US20080293
775
US20080293
742
US20080292
657
US20080292
641
28RNA1
###### Medicine Having No Adverse Effects
IMMUNE RESPONSE MODIFIER CON3UGATES
OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING
NIDOVIRUS INFECTIONS
###### Novel Compounds 951 Piperidine Derivatives., Their Process for Preparation., Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing
Them
INTERFERON-ALPHA POLYPEPTIDES AND CON3UGATES
MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND
ARTICLES THEREOF
###### 1-Alkoxy IH-Imidazo Ring Systems and Methods Substituted Fused [l,2]lmidazo[4,5-C] Ring Compounds and Methods
METHODS FOR CONCURRENT IDENTIFICATION AND
QUANTIFICATION OF AN UNKNOWN BIOAGENT
###### Methods and Uses of Antibodies in the Purification of Interferon
GONDAI TAKUMA
###### Not Available
BESTWICK RICHARD K
BONNERT ROGER VICTOR
CAGE PETER
MAXYGEN, INC.
###### UNIVERSITY OF UTAH RESEARCH FOUNDATION
3M Innovative Properties Company
HEPPNER PHILIP D
###### ISIS Pharmaceuticals, Inc. ViraNative AB Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines COLEY
PHARMACEUTICAL GROUP, INC.


-----

METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS
AGENTS
###### Adjuvant Activity of Gastrointestinal Peptides Scytovirin Domain 1 Related Polypeptides Loop-Variant Pdz Domains as Biotherapeutics, Diagnostics and Research Reagents
EDGINGTON GARRY
###### Not Available Office of Technology Transfer
DELAGRAVE SIMON
APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT VIROFORCE SYSTEMS INC.
###### Immunogenic Compositions Comprising Hmgb 1 Polypeptides Modified Bacteriophage Vectors and Uses Thereof Novel Benzothiazolone Derivatives
NOVEL COMPOUNDS
PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND
THE USE THEREOF
CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS
PURITY
METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY
###### Antiviral Compounds
MEDIMMUNE, INC.
###### UNIVERSITY OF ROCHESTER
ASTRAZENECA AB
###### AstraZeneca AB
CAI SUI XIONG
CLARKE PETER
###### ONISHI ERIC
ENGEL ROBERT
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE HAAS MARCI B
###### Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4
PRIMATE T-LYMPHOTROPIC VIRUSES
###### Antigenic GM-CSF peptides and antibodies to GM-CSF Fauci/COVID-19 Dossier
ASTRAZENECA AB
CHESHIRE DAVID
###### Centers for Disease Control and Prevention Morphotek, Inc.
CC-BY-NC-SA Dr. David E. Martin
DanOS
###### 22Feb06
24D6C03
###### 5-DU107 7Mar06
18NOV02
###### 26May04 2Sep04 llFebOS 18Feb04 12Feb05 9Feb05


-----

###### 193un07 13Dec04
25May05
5Dec05
29NOV06
###### 179un04 29Oct04
9Aug05
###### 14Dec06
6May03
###### 6Mar07 lMar07
30May07
###### 13un07
15Dec05
12D6C05
###### 21Feb05 8Feb06 273an -06 21Feb -07 25Apr -08
33U108
6Mar
###### -07 30Oct -06
17May
###### -05 iSep -05 10Feb -06 17Feb -05 13Feb -06
8Feb
###### -06 19Jun -08
13Dec
###### -05
24May
###### -06
4Dec
###### -06 173un -08 16Jun -05 50ct


-----

###### -05
3Aug
###### -06
13Dec
###### -07
6May
###### -04
6Mar
###### -08 29Feb -08
30May
###### -08 13un -07
12Dec
###### -06 llDec -06 24Feb -07
8Feb
###### -07
5Feb
###### -09
5Feb
###### -09 83an09 83an09 83an09 83an09 83an09 13an09 13an09 13an09
25Dec
###### -08
25Dec
###### -08
25Dec
###### -08
18Dec
###### -08
18Dec
###### -08
18Dec
###### -08
18Dec
###### -08 llDec -08 llDec -08
4Dec


-----

###### -08

4Dec

###### -08

4Dec

###### -08

4Dec

###### -08

4Dec

###### -08

4Dec

###### -08

4Dec

###### -08

27NOV

###### -08

27NOV

###### -08

27NOV

###### -08

27NOV

###### -08

163

US20080287

###### 453
US20080286
###### 756
US20080280
951
US20080279
###### 920
US20080279
891
US20080279
812
US20080279
722
US20080279
721
US20080279
###### 720
US20080275
###### 084 US20080274 140
US20080269
###### 240
US20080269
192
US20080269
###### 156
US20080269
148
US20080269
115


-----

US20080267
997
US20080267
992
US20080267
819
US20080261
258
US20080261
257
US20080260
775
US20080260
773
US20080260
769
US20080260
###### 764
US20080255
###### 150
US20080255
###### 076 US20080254 440 Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING
SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
###### Salt II
21BOWER
DUSTIN FAIRFIELD
Dec05
THE
CHINESE UNIVERSITY OF HONG KONG
ASTRAZENECA AB
###### Compositions For Treating Respiratory Viral Infections and Their Use Intradigm Corporation Viral Adjuvants
DOHNSTON ROBERT E
###### Disease Prevention and Vaccination Prior to Thymic Reactivation Monash University
TRANSPORTABLE DECONTAMINATION UNIT AND
DECONTAMINATION PROCESS
DECONTAMINATION UNIT AND PROCESS
DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION
ENCLOSURE AND DECONTAMINATION PROCESS
###### Piperidines for the Treatment of Chemokine Mediated Diseases Vaccines and Methods for Using the Same Novel Adenine Compound Chiral Fused [lJ2]Imidazo[4J5-C] Ring Compounds Inhibitors of RTP801 and their use in disease treament Modified Small Interfering Rna Molecules and Methods of Use Immunogenic Sars Domain Modified Viral Particles with Immunogenic Properties and Reduced


-----

###### Lipid Content Useful for Treating and Preventing Infectious Diseases Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof^ and Use of Sars Virus S Gene for Preparation of Vaccine
TRANSPORTABLE DECONTAMINATION UNIT AND
DECONTAMINATION PROCESS
Immune Cell Biosensors and Methods of Using Same
###### Fluorescent Proteins and Related Methods and Compounds
New Live Virus Vaccines
###### Saccharide Conjugate Vaccines Polypeptides for Oligomeric Assembly of Antigens REPLIKIN PEPTIDES AND USES THEREOF Novel Compounds Steroid-Derived Pharmaceutical Compositions Anti-Sars Virus Antibody., Hybridoma Producing the Antibody and Immunoassay Reagent Using the Antibody
BACIK MICHAEL A
CENTANNI MICHAEL A
CENTANNI MICHAEL A
ASTRAZENECA AB
KUTZLER MICHELE

###### AstraZeneca Aktiebolag A Corporation of Sweden Coley Pharmaceutical Group, Inc.
FEINSTEIN ELENA
HAN DANG
BEADENKOPF ROBERT 1
###### Lipid Sciences, Inc. 291U1-03 2Aug05
5NOV04
###### 9-JU104
5D6C03
###### 6Mar07 6Mar07 6Mar07
27May05
19NOV04
22Sep05
30D6C04
###### 26Feb07 lOct04 173un04 293un00 4Cancer Center, Sun Yat-Sun University
BACIK MICHAEL A
###### Amaox, Inc. UNIVERSITY OF MASSACHUSETTS
3OHNSON PHILIP R
###### Not Available
CAPECCHI BARBARA
BOGOCH ELENORE S
ASTRAZENECA AB
###### ladoLabs GmbH FU3II NOBUYUKI


-----

Dun04
###### 6Mar07 9-JU104 20Sep04 15Feb05
24D6C04
###### 23:111-04
30May06
5NOV05
###### 293un04 31Oct03
18Dec
###### -06
3Apr
###### -08 313U106
4Nov
###### -05
81U105
###### 19Apr -04 20Feb -08 20Feb -08 20Feb -08
24May
###### -06
18N0V
###### -05
21Sep
###### -06
29Dec
###### -05 26Feb -08
30Sep
###### -05 163un -05
9May
###### -08 43un -04 20Feb -08 11JU105
20Sep
###### -05 15Feb -06
23Dec
###### -05


-----

22DU105
30May
###### -07
 INov
 -06 293un -05 29Oct -04
20NOV
###### -08
20NOV
###### -08
13NOV
###### -08
13NOV
###### -08
13NOV
###### -08
13NOV
###### -08
13NOV
###### -08
13NOV
###### -08
13NOV
###### -08
6Nov
###### -08
6Nov
###### -08 30Oct08 30Oct08 30Oct08 30Oct08 30Oct08 30Oct08 30Oct08 30Oct08 23Oct08 23Oct08 23Oct08 23Oct08 23Oct08 23Oct08 16Oct08 16Oct08 16Oct08 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 164

US20080249

145


-----

US20080249
###### 110
US20080249
097
US20080249
039
US20080248
551
US20080248
043
US20080242
851
US20080242
###### 794
US20080242
649
US20080241
935
US20080241
###### 910
US20080241
909
US20080241
511
US20080241
189
US20080241
###### 000 US20080234
345
###### US20080234
319
US20080233
###### 650
US20080233
570
US20080233
558
US20080233
###### 150
US20080233
128
US20080227
817
US20080227
797
US20080227
219
US20080227
149
US20080226
681
US20080226
597


-----

US20080213
891
US20080213
308
###### 8SaltS
668
###### Novel Substituted 3-Sulfur Indoles
PRODRUGS OF HETEROARYL COMPOUNDS
###### Modified Short Interfering Rna (Modified Sirna)
WHITTOCK ROBERT
BONNERT ROGER
###### Koronis Pharmaceuticals., Incorporation
SANTARIS PHARMA A/S
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES OSORIO 3ORGE E
###### Antibodies to SARS coronavirus
MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET
EFFECTS IN RNA INTERFERENCE
COLOR STABILIZED ANTIMICROBIAL POLYMER COMPOSITES
New Combination 665
###### Methods for pathogen detection Devices for pathogen detection Microfluidic chips for pathogen detection

PRODUCTION OF SILVER SULFATE GRAINS USING INORGANIC
ADDITIVES
###### Sequential Delivery Of Immunogenic Molecules Via Adenovirus And Adeno-Associated Virus-Mediated Administrations Systems for pathogen detection
METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE
DIGESTIVE TRACT
###### Novel Compounds 679 Method for propagating adenoviral vectors encoding inhibitory gene products
Amgen Inc.
DHARMACON, INC.
BLANTON THOMAS N

CADOGAN ELAINE BRIDGET
###### Searete LLC, a limited liability corporation of the State of Delaware
 Searete LLC, a limited liability corporation of the State of Delaware
 Searete LLC, a limited liability corporation of the State of
 Delaware

BLANTON THOMAS N
The Trustees of the University of Pennsylvania
###### Searete LLC, a limited liability corporation of the State of Delaware
Gene Logic Inc.

EBDEN MARK

GENVEC, INC.
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A

###### Inhibitors of viral entry screening method
RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS)
###### Treatment of Viral Infections
New Salt I


-----

###### Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases Electrochemiluminescent assay Interferon-Alpha Polypeptides and Conjugates Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production
EVOLVED INTERFERON-ALPHA POLYPEPTIDES
RNAi Agents Comprising Universal Nucleobases
###### Imidazoquinoline Compounds Medical Research Council
MAHMOOD KUTUB
KRAUSE WERNER
ASTRAZENECA AB
ASTRAZENECA AB
###### Not Available
MAXYGEN, INC.
###### Glycotope GmbH
MAXYGEN, INC.
###### Alnylam Pharmaceuticals, Inc.
CHU DANIEL
Feb07
27May03
###### 201un03 303an04 6Apr07
19May06
###### 2Apr03 30Mar07 8Feb07 27Mar07 27Mar07 27Mar07 30Mar07 28Apr04 27Mar07
8Sep06
###### 22Mar07
10NOV05
###### HSep03 lFeb05
16NOV06
2NOV06
###### 2Aug05 4-3U105
17NOV04
18NOV02
###### 13Feb04
18May05
###### 213U1-04 14Sep04 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
7Feb


-----

###### -08
25May
###### -04
27Dec
###### -06
28Dan
###### -05 4Apr -08
21May
###### -07
19Sep
###### -07
30Mar
###### -07
7Feb
###### -08 27Mar -07 27Mar -07 27Mar -07
30Mar
###### -07 27Apr -05 27Mar -07
7Sep
###### -07 21Mar -08
9May
###### -08
25May
###### -07 lAug -07
16N0V
###### -07 INov -07 313U106
33U106
16NOV
###### -05 250ct -07 14Feb -05
17May
###### -06
6Aug


-----

###### -VI
14Sep
###### -05 165 9Oct08 9Oct08 9Oct08 9Oct08 9Oct08 9Oct08 2Oct08 2Oct08 2Oct08 2Oct08 2Oct08 2Oct08 2Oct08 2Oct08 2Oct08
25Sep
###### -08
25Sep
###### -08
25Sep

###### -08
25Sep

###### -08
25Sep

###### -08
25Sep
###### -08
25Sep
###### -08
18Sep
###### -08
18Sep
###### -08
18Sep
###### -08
18Sep
###### -08
18Sep
###### -08
18Sep
###### -08
4Sep
###### -08
4Sep
###### -08
 US20080213 284
US20080213
125
US20080210


-----

748
US20080207
698
US20080207
688
US20080207
###### 674
US20080207
###### 650
US20080207
597
US20080207
596
US20080207
587
US20080207
573
US20080206
283
US20080206
235
US20080200
505
US20080199
915
US20080199
###### 495
US20080199
###### 491
US20080199
###### 481 US20080194
922
###### US20080194
689
###### US20080194
632
###### US20080194 481 US20080194 422
US20080193
919
US20080193
###### 474
US20080188
513
US20080188
###### 488
US20080187
609
RECEPTOR BINDING POLYPEPTIDES
###### National Health Research Institutes, a Taiwanese corporation


-----

###### Apparatus and Method for Using Ozone as a Disinfectant Systems and methods for receiving pathogen related information
and responding
###### Novel Compounds 569 Novel Piperidine Derivatives
Immune Response Modifier Formulations And Methods
###### Chemical Compounds 636
HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL
FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE
OF SARS CORONAVIRUS
###### Novel compounds 329 Pyridazine Derivatives for Inhibiting Human Stearoyl-CoaDesaturase
COMPOUNDS
FOR TREATING VIRAL INFECTIONS
###### Vaccine Against Sars
COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE
RESPONSE
###### Piperidines for the Treatment of Chemokine Mediated Diseases Methods and Kits For Mass Production Of Dsrna Stimulation of thymus for vaccination development Sustained Release Vaccine Composition
COMPOUNDS
POTENTIATION FOR MEDICAL THERAPIES
###### Disinfectant and Germicidal Agent Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases Albumin Fusion Proteins
PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR
DETECTING SARS-CORONAVIRUS USING THE SAME
###### Systems and methods for receiving pathogen related information
and responding
###### Immunostimulatory Compositions l-(2-Methylpropyl) -1H-Imidazo[4., 5-C] (1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4j5C](I,5]Naphthyridin-4-Amine Methanesulfonate Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors Methods and apparatus to prevent^ treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers Fauci/COVID-19 Dossier Huawei Technologies Co. LTD. Searete LLC, a limited liability corporation of the State of Delaware,
CONNOLLY STEPHEN
ASTRAZENECA AB
###### Coley Pharmaceutical Group, Inc.
BONNERT ROGER VICTOR
SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR
CORPORATE COLLABORATION
MARTIN BARRIE
XENON PHARMACEUTICALS INC.
###### Myriad Genetics, Incorporated
DONG 3OHN Y


-----

Dohns Hopkins University
ASTRAZENECA AB
###### RNA-Line Oy
Monash University
BRANDON MALCOLM
ASTRAZENECA AB
HOLDEN DAMES F
REICHWAGEN SVEN
ASTRAZENECA AB
Human Genome Sciences, Inc.
Dan04
###### 18Mar04
30NOV05
20D6C06
###### 21DU1-05
30D6C04
###### 113an07 22Dec06 193un06 20Sep04 16Oct06 173un03
27D6C06
27May05
2May03
###### 15Apr99 163un04 21Feb07 7Sep05
25May05
###### lAug05
21Dec01
12SAMSUNG
ELECTRONICS CO., LTD.
###### Searete LLC, a limited liability corporation of the State of Delaware
GRAM CHRISTOPHER D
Dec03
30NOV05
###### 25Apr05 30taked Pharmaceutical Company Limited Dec04
20XENON
PHARMACEUTICALS INC.
###### VAIL MARILYN L Sep04 3Apr00
CC-BY-NC-SA
###### Dr. David E. Martin 103an -05 18Mar -05


-----

###### llSep -07
19Dec
###### -07
19DU106
28Dec
###### -05
10Dan
###### -08
20Dec
###### -07 193un -07
20Sep
###### -05
7May
###### -08 17:un -04
27Dec
###### -07
24May
###### -06
2May
###### -03
24May
###### -07 163un -05 19Feb -08
28Sep
###### -07
26May
###### -06 313U106 310ct -07 21Apr -08 223an -08 25Apr -06
28Dec
###### -05
20Sep
###### -05 18Mar -08
Sep
###### -08
4Sep
###### -08


-----

4Sep
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08
28Aug
###### -08

2 lAug
###### -08

2 lAug
###### -08
21Aug
###### -08
21Aug
###### -08
21Aug
###### -08
14Aug
###### -08
14Aug
###### -08
14Aug
###### -08
14Aug
###### -08
14Aug
###### -08
14Aug
###### -08
14Aug
###### -08
7Aug
###### -08
7Aug
###### -08
7Aug
###### -08 166 94


-----

US20080187
528
US20080183
396
US20080182
###### 900
US20080182
###### 874
US20080181
969
US20080176
902
US20080176
841
US20080176
217
US20080175
861
US20080175
832
US20080172
247
US20080171
363
US20080171
###### 066
US20080171
057
US20080170
###### 996
US20080167
332
US20080167
321
US20080167
198
US20080166
793
US20080166
701
US20080166
370
US20080160
###### 010
US20080159
962
US20080156
743
###### US20080154 210
US20080153
###### 850
US20080153
837


-----

US20080152
728
###### ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS Systems and methods for transmitting pathogen related information
and responding
###### ISFunctional Genetics, Inc. Searete LLC, a limited libility corporation of the State of Delaware Method of treatment of virus infections using shikonin compounds WANG FEIXIN Novel Compounds
POLYMER COMPOSITE
###### Salt III
EPOXIDE INHIBITORS OF CYSTEINE PROTEASES
METHOD OF PREDICTING INFLUENZA OUTBREAKS BY
CORRELATING AN INCREASE IN REPLIKIN COUNT IN SHRIMP
WHITE SPOT SYNDROME VIRUS AND/OR TAURA SYNDROME VIRUS
MODIFIED POLYMERASES AND ATTENUATED VIRUSES AND
METHODS OF USE THEREOF
###### Materials and Methods for Prevention and Treatment of RNA Viral Diseases Method to Decrease the Risk of a Vaccine-Induced Chronic Immune Mediated Disorder in Humans With a Family History of the Disorder
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
ASTRAZENECA AB
BARNES CRAIG L
ASTRAZENECA AB
THE BOARD OF TRUSTEES OF THE LELAND STANFORD
JUNIOR UNIVERSITY
BOGOCH ELENORE S
NOV06
30NOV05
###### 21Feb03
30NOV04
###### 31Jan07 2Aug05 13Jun06 24Oct06
22THE
PENN STATE RESEARCH FOUNDATION
BEHERA ARUNA K
CLASSEN IMMUNOTHERAPIES
MAXYGEN, INC.
###### Listeriolysin-Containing Bacillus Spores as Antigen Delivery Agents CUTTING
SIMON
###### Reagents, Devices, and Methods For Proteomic Analysis With Applications Including Diagnostics, Vaccines, Quality Control and Research
NETWORK IMMUNOLOGY INC.
###### Compositions and Methods for Stimulation of Lung Innate Immunity The Board of Regents of the University of Texas System Novel Compounds 243
ELKINS BARRY


-----

###### Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase XENON
PHARMACEUTICALS INC.
###### Filter based detection system
 Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture Immunoassay Method and Immunoassay Kit to Be Used Therein Immunogenic Compositions Comprising Multiple Gonococcal
 Antigens
 Peptide That Elicits Neutralizing Antibodies Targeting the Hiv CoReceptor
Use
###### of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries
HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR
REMOVING HAZARDOUS SUBSTANCES, AND NONWOVEN FABRIC

###### Mixture for Transdermal Delivery of Low and High Molecular Weight
Compounds
###### Adamantyl Derivates as P2x7 Receptor Antagonists
 Novel Fluorene Derivatives, Composition Containing Said Derivatives
and the Use Thereof
###### Noble gas-chlorine mixture effective against micro organisms
COONEY CHRISTOPHER GERARD
The Regents of the University of California
ARKRAY, me.
CHIRON SRL
The Government of the United States of America as
###### IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE

GMBH

###### FUJIFILM Corporation

ORYXE
###### AstraZeneca AB
AVENTIS PHARMA S.A.
GLOBUS ALFRED R
Dec06
###### 30Apr02 6Apr04 19May04 19Feb05 21Apr04 28JU1-06 19JU1-06 20Sep04 4Jan07 4Jan07 25JU1-05 26Jun03 9Apr04
19May05
27D6C06
###### 28May04 30Aug04
19May05
###### 7-JU103 Fauci/COVID-19
 Dossier


-----

15N0V

###### -07 llSep
 -07

26Sep

###### -07

28NOV

###### -05
31Dan
###### -07 313U106 133un
 -07
 240ct
 -07

24Dec

###### -07
 173an
 -08

6Apr

###### -05

14Aug

###### -07
 20Feb
 -06
 19Apr
 -05
303U107
###### 183U107
20Sep

###### -05
 43an
 -07
 43an
 -07
 243U106 253un
 -04
 llApr
 -05

19May

###### -06

27Dec

###### -07

25May

###### -05

29Aug

###### -05

14N0V

###### -07
 25Apr
 -07

CC-BY-NC-SA
###### Dr. David E. Martin


-----

7Aug
###### -08 31JU108 31JU108
313U108
313U108
243U108
243U108
###### 243ul08 243ul08 243ul08
173U108
173U108
173U108
173U108
173U108
103U108
103U108
103U108
103U108
103U108
103U108
###### 33ul08 33ul08 33ul08 263un08 263un08 263un08 263un08
167

US20080152
###### 544
US20080149
###### 100
US20080146
612
US20080146
###### 455
US20080145
847
US20080138
808
US20080132
502
US20080132
###### 480
US20080131
###### 465
US20080131
###### 446
US20080125
###### 434 US20080124
323


-----

###### US20080124
311
###### US20080124
303
###### US20080124
302
US20080118
530
US20080118
517
US20080118
###### 495
US20080118
###### 473 US20080114
019
###### US20080114
002
US20080113
###### 409
US20080113
337
US20080108
629
US20080107
###### 650
US20080103
###### 746
US20080103
149
US20080102
###### 444
US20080096
959
###### 29Building decontamination with vaporous hydrogen peroxide Antiviral Heat Treatment
 Novel Biaromatic Compounds^ Inhibitors of the P2X7-Receptor
STERIS INC.
DE HAAN PETRUS THEODORUS
ASTRAZENECA AB
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A

METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A

METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A

###### 5-Heteroaryl Thiazoles And Their Use As PI3KInhibitors
 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease Group a Streptococcus Crge Protein Vaccine Composition Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors

ARNOULD 3EAN-CLAUDE
###### AstraZeneca AB
MANETTI ANDREA


-----

SANOFI PASTEUR SA
XENON PHARMACEUTICALS INC.
###### Nutritional Composition Comprising Indigestible Oligosaccharides N.V. Nutricia Novel pharmaceutical compositions for the treatment of virus infection and cancer Methods and compositions for treatment of viral infections Uses of Recombinant Super-Compound Interferons Modulation of Replicative Fitness By Deoptimization of Synonymous Codons
Human monoclonal antibodies against interleukin 8 (IL-8)
###### Mammalian Genes Involved in Infection Methods of treating a respiratory condition comprising probiotic treatment Hydroxylamine Substituted Imidazoquinolines Substituted Acids for the Treatment of Respiratory Diseases Transient protein expression methods Method of Examining/ludging Presence of Virus Infection such as HIV or Presence of Prion Infection by Near-Infrared Spectroscopy
and Device Used in Same
###### Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes
METHOD FOR TREATING INFLAMMATORY DISEASES OF THE
DIGESTIVE TRACT
###### Systems and methods for pathogen detection and response
NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR
THERAPEUTIC APPLICATIONS
METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES
###### Durable Biocides and Disinfectants lllumigen Biosciences, Inc. Cavit Sciences, Inc
WEI GUANGWEN
BURNS CARA C
GENMAB A/S
RUBIN DONALD H
###### Alimentary Health Ltd. Coley Pharmaceutical Group, Inc.
ASTRAZENECA AB
HATEBOER GUUS
OSAKA UNIVERSITY
XENON PHARMACEUTICALS INC.
Gene Logic Inc.
###### Searete LLC, a limited liability corporation
Dan04
20D6C06
###### 271an05 HSep03 HSep03 HSep03
9NOV04
###### 24Aug04 27Sep04
17NOV03
###### 20Sep04


-----

###### 24Aug04
23NOV05
12Dec05
###### 9Mar05 8Oct04
16Dec02
###### 27Oct04
1NOV06
12Aug03
###### 8-3U104 15Apr99
12NOV04
###### 20Sep04
8Sep06
30NOV05
30COLLAND
FREDERIC

###### Oct06

FOCUS

###### Technologies, Inc. MITSUI NORIN CO., LTD. 6-3U104 7-3U104
3Mar
###### -08

20Dec

###### -06
 253an
 -06

25May

###### -07

25May

###### -07

25May

###### -07

7NOV

###### -05

22Aug

###### -05

27Sep

###### -05

93an

###### -08

20Sep

###### -05

24Aug

###### -05

17NOV

###### -06

123U107
9Mar

###### -06
 7Oct
 -05


-----

Aewzz
###### 80-
Aewzz
###### 80-
Aewzz
###### 80-
Aewzz
###### 80-
Aewez
###### 80-
Aewez
###### 80-
Aewez
###### 80-
Aewez
###### 80-
Aewez
###### 80uncs 80uncs 80uncs 80uncs 80unc2T 80unc6T 80unc6T 80unc6T 80unc9Z 80unc9Z uTuew -a ptaeq -jq vs-dn-as-dd
J9TSS0Q
###### 6T-aiA0D/'pned
 S0incs £0-

IDOST
###### 90-
13O0E
###### £0-
d9STT
###### £0-
d9S£
S0-
d9S0Z
S0-

AON0T
£0-
uricx
S0inc9

170-
§nvZT

£0-

IDOTE

S0-

###### £0-
uncz.z


-----

###### -08
15May
###### -08
15May
###### -08
15May
###### -08
15May
###### -08
8May
###### -08
8May
###### -08 iMay -08 iMay -08 iMay -08 24Apr08 168
 US20080096 928 US20080096 895
US20080096
###### 186
US20080090
913
###### US20080090 841 US20080090 791 US20080090 229 US20080090 224
US20080085
895
US20080085
873
###### US20080081 047 US20080076 710 US20080076 115
US20080075
###### 740
US20080075
737
US20080075
693
###### US20080071


-----

063
US20080070
907
US20080069
839
US20080069
838
US20080069
###### 836
US20080069
###### 830
US20080069
###### 804 US20080064
105
###### US20080064 080
US20080063
###### 664
US20080058
309
US20080057
513

###### Methods for treating Hepatitis C
AREFOLOV ALEXANDER
###### Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors
PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR
DETECTING SARS-CORONAVIRUS USING THE SAME
###### Sphingolipid-Derived Phamaceutical Compositions
METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL
CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS
AND OSMOLYTES
###### Cystic fibrosis treatment methods Devices for generating detectable polymers Nucleic acid detection Substituted Chiral Fused [l,2]lmidazo[4,5-C] Ring Compounds Disease treatment methods Anti-Sars Monoclonal Antibodies

INTERFERON-ALPHA POLYPEPTIDES AND CON3UGATES
###### Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
 Adeno-Associated Virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29
CYSTEINE MUTANTS
###### Protein Formulations Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods
ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS
OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE


-----

VIRUS
NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY
SYNDROME (SARS) AND USES THEREOF
METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED
IMMUNOGENICITY IN VIVO
Dna Sequences^ Peptides, Antibodies and Vaccines for Prevention
and Treatment of Sars
###### Alphavirus Replicon Packaging Constructs Animal protein-free media for cultivation of cells Animal protein-free media for cultivation of cells High-yield transgenic mammalian expression system for generating virus-like particles Novel Compounds 171
METHOD FOR PRODUCING NUCLEIC ACID PROBES
XENON PHARMACEUTICALS INC.
###### 14JU1-04 20Sep04
12HWANG
1UNG-100
Dec03
29BRAXMEIER
TOBIAS
PARION SCIENCES, Inc.
###### Hollis-Eden Pharmaceuticals, Inc.
ENGELHARD ERIC K
HAI KANG LIFE CORPORATION LIMITED
DANIELSON MICHAEL M
###### Hollis-Eden Pharmaceuticals, Inc.
ANDONOV ANTON
MAXYGEN, INC.
###### GILLIM-ROSS LAURA
The Trustees of the University of Pennsylvania
The Trustees of the University of Pennsylvania
###### ZymoGenetics, Inc. Medlmmune, Inc. Coley Pharmaceutical Group, Inc.
GUAN YI
CHAN KWOK HUNG
and Human Services
HOFFMAN STEPHEN L
PERRI SILVIA
###### Baxter Healthcare Corporation Baxter Healthcare Corporation Academia Sinica
ASTRAZENECA AB
###### Ventana Medical Systems, Inc. 3un04
7Sep06
###### 13Oct06 12Oct06
2May03
30D6C04
28Aug02
5Dec03


-----

19May04
3Nov03
17Dec01
17Dec01
###### 2Apr04 3Feb06 123U1-06
22May03
###### 24Mar04 15ep04 243un03 25May04 29Oct04 29Oct04 5Sep06 273U1-06 15ep06 143U105
20Sep
###### -05
24N0V
###### -04 293un -05

7Sep
###### -07 130ct -06 120ct -06
 30Apr -04
29Dec
###### -05 130ct -06
6Dec
###### -04
4May
###### -07
3Nov
###### -04
 310ct -07

6Sep
###### -07

20Sep
###### -07
2Feb
###### -07
123U107
24May
###### -04
 24Mar


-----

###### -04 26Feb -07
240 un
###### -04
20May
###### -05 30Oct -07 30Oct -07
5Sep
###### -06
263U107
31Aug
###### -07 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
169
###### Apr08 24Apr08 24Apr08 17Apr08 17Apr08 17Apr08 17Apr08 17Apr08 10Apr08 10Apr08 3Apr08 27Mar -08 27Mar -08 27Mar -08 27Mar -08 27Mar -08 20Mar -08 20Mar -08 20Mar -08 20Mar -08 20Mar -08 20Mar -08 20Mar


-----

###### -08 13Mar -08 13Mar -08 13Mar -08
6Mar
###### -08
6Mar
###### -08 24

US20080051
297
US20080050
718
###### US20080044 816 US20080044 814 US20080044 438 US20080044 437 US20080044 426 US20080044 423 US20080044 384 US20080044 378
US20080033
###### 172 US20080031 979
US20080031
877
US20080031
868
US20080031
853
US20080031
###### 770
US20080027
092
US20080027
###### 006
US20080021
038
US20080020
379
US20080015
247


-----

US20080015
###### 230
US20080015
###### 194
US20080015
###### 184 US20080014 204 US20080014
183
US20080009
###### 496
US20080009
###### 040 US20080004 236 US20080004
228
###### Method for determining antigen-specific T cell response in high throughput format Centro di Biotecnologie Avanzate and istituto Giannina Gaslini 123un06 14MethodSj
 Articles., and Compositions for Identifying Oligonucleotides ATKINS 3OHN F Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence Reagents and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus Yeast Cell Particles As Oral Delivery Vehicles For Antigens Encapsidation System for Production of Recombinant Virus-Like Particles Novel Atypical Pneumonia-Causing Virus
COMPOUNDS
###### Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens Methods and Compositions for Protein Production Using Adenoviral Vectors Mutagenic Heterocycles
USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISORDERS
###### Purification of bacterial antigens
HUMAN LYSOZYME MEDICINE, ITS MANUFACTURING METHOD AND
APPLICATION THEREOF
INTERFERON-ALPHA POLYPEPTIDES AND CON3UGATES

###### Apparatus and method for using ozone as a disinfectant 1-Acetic Acid-Indole., -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor CcrS Diagnosis and prognosis of infectious diseases clinical phenotypes
and other physiologic states using host gene expression biomarkers
###### in blood


-----

QUERCETIN-CONTAINING COMPOSITIONS
HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC
AGENTS
METHODS AND COMPOSITIONS OF TARGETED DRUG
DEVELOPMENT
###### Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines Compositions Against Sars-Coronavirus and Uses Thereof Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto
MUTAGENIC HETEROCYCLES
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS
###### High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections
New Expression Tools for Multiprotein Applications
###### Fauci/COVID-19 Dossier
BECTON, DICKINSON AND COMPANY
HIBBERD MARTIN L
OSTROFF GARY R
CHEN QUN
BESTEBROER THEODORUS MARINUS
COCHRANE DUNCAN
Medlmmune Vaccines, Inc.
INTROGEN THERAPEUTICS, INC.
###### Koronis Pharmaceuticals, Incorporated
BODDUPALLI SEKHAR
COVACCI ANTONELLO
AN MI
ROCHE PALO ALTO LLC
BOAST NIGEL
BONNERT ROGER VICTOR
The Regents of the University of Colorado
FAULL ALAN
AGAN BRIAN K
LINES THOMAS C
XENON PHARMACEUTICALS INC.
###### Joseph Errico
3M INNOVATIVE PROPERTIES COMPANY
DE KRUIF CORNELIS A
DNAVEC RESEARCH INC.
###### Koronis Pharmaceuticals, Inc. Baxter Healthcare Corporation
COMPER WAYNE D
BERGER IMRE
CC-BY-NC-SA Dr. David E. Martin
NOV03
12Sep03
###### 21Apr03 17Mar06 2Sep04
18NOV03
###### 23Jun06 25Jun04
15May06


-----

19Dec03
###### 4Aug06 17Feb06 93un05
19May04
2Aug06
26NOV03
###### 12Feb04 243un04
5Nov04
173 ul-06
###### 20Sep04 233an06 143un04
11NOV04
###### 243un04
19Dec03
###### 29Oct04 6Feb04 9Mar04 113un -07

15N0V
###### -04

13Sep
###### -04
 21Apr -04

16Mar
###### -07 iSep -05
18Nov
###### -04 223un -07 243un -05
15May
###### -07

10Dec
###### -04

4Aug

###### -06
 16Feb -07
93un
###### -05
15Aug
###### -07
29l\lov
###### -06
24Nov
###### -04


-----

###### 14Feb -05 20:un -05
7Nov
###### -05
16DU107
20Sep
###### -05 230an -07

143 un
###### -05

10NOV
###### -05 28Apr -05
27Dec
###### -06
20Sep
###### -07
7Feb
###### -05

25NOV
###### -04
 28Feb -08
 28Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
 21Feb -08
7Feb
###### -08
7Feb
###### -08
7Feb
###### -08
7Feb
###### -08
7Feb


-----

###### -08
7Feb
###### -08 31Jan08 31Jan08 243an08 243an08 173an08 173an08 173an08 173an08 173an08 173an08 103an08 103an08 33an08 33an08 170
 US20080004 206
US20080003
###### 236
US20070299
081
US20070298
###### 415
US20070292
###### 453
US20070287
725
US20070287
###### 724
US20070286
872
US20070286
822
US20070281
325
US20070276
009
US20070275
938
US20070275
937
US20070275
883
US20070275
879
US20070275
###### 465
US20070275
091
US20070275
002


-----

###### US20070274 994 US20070274
983
###### US20070274 950 US20070274
922
US20070270
361
US20070270
360
US20070266
957
US20070265
###### 236
US20070265
###### 226
US20070259
###### 914
US20070259
907
###### 21Albumin fusion proteins
BELL ADAM

ADENOVIRUS FIBER SHAFT COMPOSITION AND METHODS OF USE GenVec, Inc.
###### Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase Method of Amplifying Nucleic Acid
RNA virus vaccines and methods
###### Isoxazolej Dihydroisoxazolej And Oxadiazole Substituted Imidazo Ring Compounds And Method Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines Live Attenuated Nidovirus Vaccines

Compounds for the Treatment of Periodontal Disease
COMPOSITIONS AND METHODS FOR ANALYSIS OF TARGET
ANALYTES
###### Compositions and Methods for Viral Inhibition Therapeutic Treatment Methods Therapeutic Treatment Methods 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
Use of Ulinastatin and Its Pharmaceutical Composition for Treating
###### Severe Acute Respiratory Syndrome Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism Compositions And Methods For Improved Mucus Function
Use Of Proteins And Peptides Encoded By The Genome Of A Novel
###### Sars-Associated Coronavirus Strain Virulence-Associated Adhesins
 Nutritional Composition Comprising Immunoglobulins and Oligosaccharides

INTERFERON-ALPHA POLYPEPTIDES AND CON3UGATES


-----

###### Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof
Rna Interference Mediated Inhibition of Severe Acute Respiratory
###### Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid Antipathogenic Domestic Livestock House, Disinfectants for Domestic Livestock House, Disinfectants for Living Organisms, Feedstuffs and Drinking Water for Animals Asthma Treatment Methods Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use Novel Piperidine Derivates as Modulators of Chemokine Receptor CcrS.
ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES
AND THIAZOLONAPHTHYRIDINES
XENON PHARMACEUTICALS INC.
###### Takara Bio Inc.
DITTMER DIRK P
3M INNOVATIVE PROPERTIES COMPANY
3M INNOVATIVE PROPERTIES COMPANY
###### Vanderbilt University
ANACOR PHARMACEUTICALS INC.
DANIELZADEH ROBERT
CHANG BRYAN
AHLEM CLARENCE N
AHLEM CLARENCE N
GOSSELIN GILLES
GUANGDONG TECHPOOL BIOCHEM PHA
###### Alnylam Pharmaceuticals
KING MALCOLM
AZEBI SALIHA
###### Novartis Vaccines and Diagnostics, Inc.
NUTRICIA NV
MAXYGEN INC
FANG HAO
CHOU TE-HUI W
SIRNA THERAPEUTICS, INC.
###### DecOl 18Oct04 20Sep04
10D6C03
14Dec05
###### 183un04 183un04 22Apr03 123un06
17Sep03
###### 15Oct03
28Aug02
28Aug02
###### 283un02
26May03
###### 133un03


-----

###### 30Mar04 2Dec03 263un03 24Aug04
18NOV02
5Sep03
###### 4Aug03 15Apr03
28TAKAHASHI
KAZUO
AHLEM CLARENCE N
###### Anacor Pharmaceuticals
TUCKER HOWARD
PRINCE RYAN B
###### Sep04
28Aug02
2May06
###### 243un04 183un04 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 313ul06 13Apr -07
20Sep
###### -05
6Dec
###### -04
14Dec
###### -06 173un -05 173un -05 22Apr -04 123un -07 203U106 15Oct -04 12Feb -07 12Feb -07
6Sep
###### -06
25May
###### -04
143 un
###### -04
30Mar
###### -05


-----

2Dec
###### -04 253un -04
24Aug
###### -05
19May
###### -04
7Sep
###### -04
4Aug
###### -04 13Apr -04
25Aug
###### -05 160ct -06
2May
###### -07 203un -05 173un -05 33an08 33an08
27Dec
###### -07
27Dec
###### -07
20Dec
###### -07
13Dec
###### -07
13Dec
###### -07
13Dec
###### -07
13Dec
###### -07
6Dec
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07


-----

29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
29NOV
###### -07
22NOV
###### -07
22NOV
###### -07
22NOV
###### -07
15N0V
###### -07
15NOV
###### -07
8NOV
###### -07
8NOV
###### -07
171

###### US20070259
881
###### US20070258 999 US20070254 906 US20070254 329 US20070253 978 US20070253 860
US20070249
###### 686
US20070248
###### 969
US20070248
###### 949 US20070244
133
###### US20070244 044 US20070243
600
###### US20070243 544
US20070243


-----

263
US20070238
681
US20070238
###### 116
US20070231
347
US20070231
###### 344
US20070231
303
US20070231
295
US20070225
303
US20070225
205
US20070225
###### 204 US20070224 700 US20070224 614
US20070219
228
US20070219
211
US20070219
###### 200
US20070219
###### 196
US20070219
149
###### 18Substituted Imidazo Ring Systems and Methods
CELEBI AZIM A
###### Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof THE PUBLIC
HEALTH AGENCY OF CANADA
###### Method of Administration of Dopamine Receptor Agonists Mammalian Genes Involved in Viral Infection and Tumor Suppression
Copy choice recombination and uses thereof
###### Process and device for sterilising ambient air
 Modulators of Crth-2 Receptor Activity for the Treatment of
 Prostaglandin D2 Mediated Diseases
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA
###### Sensitive and Specific Test to Detect Sars Coronavirus Thienopyrimidines and Thiazolopyrimidines for Use in Medicine Antimicrobial Peptides System for performing multi-formatted assays
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA
###### Antiviral Methods
MODULATION OF ACE2 EXPRESSION
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA


-----

###### Immunization Regimen with E4-Deleted Adenovirus Prime and ElDeleted Adenovirus Boost Conjugate vaccines for non-proteinaceous antigens
METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES
FOR SUCH CHIMERIC ADENOVIRUSES
###### Antimicrobial Silicon Oxide Flakes 8-Oxoadenine Compound
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
###### Method and apparatus for analyzing bioprocess fluids
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA
###### Aryl substituted imidazonaphthyridines Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of Stearoyl-Coadesaturase (Scd)
PRODRUGS OF HETEROARYL COMPOUNDS
AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES,
AND IMIDAZONAPHTHYRIDINES
###### Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity Fauci/COVID-19 Dossier DarPharma, Inc.
RUBIN DONALD H
NIMAN HENRY L
SCHRODER WERNER
ASTRAZENECA AB
BLYN LAWRENCE
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
BOWER JUSTIN F
NOVABIOTICS LIMITED
GEN-PROBE INCORPORATED
BLYN LAWRENCE
AglON Technologies, Inc.
BENNETT C F
BLYN LAWRENCE
The Trustees of the University of Pennslyvania
The Brigham and Women's Hospital, Inc.
The Trustees of the University of Pennsylvania
BUJARD PATRICE
HASHIMOTO KAZUKI
MAXYGEN, INC.
MAXYGEN, INC.
###### BioScale, Inc.
BLYN LAWRENCE
AMOS DAVID T
XENON PHARMACEUTICALS INC.
###### Koronos Pharmaceuticals, Incorporated
AMOS DAVID T
###### Japan as Represented by the Director-General of National Institute of Infectious Diseases Jun04 28Apr03 21Jul-04
2May02
###### 2-JU104


-----

###### 18Oct04 5Oct04 HSep03 17Dec03 43un04 18Aug04 10Mar05 HSep03 14Apr06
7NOV06
###### HSep03 28Apr04 28Oct05 203un03 12May04 26Mar04 19May04 19May04
2May05
###### HSep03 183un04 20Sep04 203un03 24Mar04 HAug03
CC-BY-NC-SA
###### Dr. David E. Martin 173un -05 28Apr -04 213U105
2May
###### -03
29Dec
###### -06 18Apr -07 30ct -05 13Mar -07
17Dec
###### -04
31May
###### -05
18Aug
###### -05 10Mar -06 13Mar -07 21Mar -07


-----

7Dec

###### -06 13Mar -07 27Apr -05 30Oct -06 203un -03
2May
###### -05 25Mar -05
14Sep
###### -06
14Sep
###### -06
19Dec
###### -06 7Mar -07 173un -05
20Sep
###### -05
15May
###### -07 24Mar -05
10Aug
###### -04
172
8Nov
###### -07
8Nov
###### -07 INov -07 INov -07 INov -07 INov -07 25Oct07 25Oct07 25Oct07 18Oct07 18Oct07 18Oct07 18Oct07 18Oct07 HOct07


-----

###### HOct07 4Oct07 4Oct07 4Oct07 4Oct07
27Sep
###### -07
27Sep
###### -07
27Sep
###### -07
27Sep
###### -07
27Sep
###### -07
20Sep
###### -07
20Sep
###### -07
20Sep
###### -07
20Sep
###### -07
20Sep
###### -07
 US20070218 536 US20070218 489 US20070218 467 US20070218 001 US20070213
356
US20070213
309
US20070212
###### 770
US20070212
677
US20070208
052
US20070207
526
US20070203
209
US20070203
107
US20070203
###### 082 US20070203 073 US20070203


-----

###### 060
US20070202
###### 492
US20070197
###### 646
US20070197
###### 478
US20070196
818
US20070196
###### 434
US20070196
357
US20070196
333
US20070196
###### 274
US20070192
###### 906
US20070192
905
US20070191
###### 294
US20070190
163
US20070190
071
US20070190
065
###### 28Polyvalent
 Viral Vectors and a System for Production Thereof
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA
###### Methods for rapid identification and quantitation of nucleic acid variants Biotherapeutics, Diagnostics and Research Reagents Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines Sepsis Treatment Methods Oligopeptide-free cell culture media Identifying off-target effects and hidden phenotypes of drugs in
human cells

###### Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines Norovirus and sapovirus antigens Useful indole compounds Pharmaceutical compositions
RNAI Agents For Anti-SARS Coronavirus Therapy
SARS and Ebola inhibitors and use thereof, and methods for their
###### discovery Casein Derived Peptides And Therapeutic Uses Thereof Viral Assay
SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL
INFECTIONS
NOVEL PHARMACEUTICALS


-----

###### Using Nucleic Acids for Clinical Microbiology Testing Methods of preventing or treating sinusitis with oxidative reductive potential water solution
 Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution Composition comprising mixtures of IFN-alpha subtypes Immunoconjugates with improved efficacy for the treatment of diseases Rice plant having vaccine gene transferred thereinto Edible vaccines expressed in soybeans Short interfering rna (sirna) analogues Technology for preparation of macromolecular microspheres 9-Substituted 8-oxoadenine compound Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
GAO GUANGPING
BLYN LAWRENCE
ECKER DAVID 1
BIOTECH STUDIO, LLC
HARALDSON CHAD A
AHLEM CLARENCE N
###### Baxter Healthcare, S.A. Odyssey Thera, Inc.
HEPPNER PHILIP D
COIT DORIS
BARTOLINI WILMIN
###### Hollis-Eden Pharmaceuticals, Inc. Intradigm Corporation
BATES PAUL
SIDELMAN ZVI
###### University Of Warwick ACHILLION PHARMACEUTICALS, INC.
PFIZER LTD
O'HARA STEPHEN
###### Oculus Innovative Sciences, Inc. Oculus Innovative Sciences, Inc.
HUANG SHIR-LY
SUN LE
EBINUMA HIROYASU
The University of North Carolina
SANTARIS PHARMA AS
FANG FANG
###### AstraZeneca Aktiebolag
ALTMEYER RALF
###### Apr04 HSep03 21JU1-05 53an04 153un04
28Aug02
###### 41an06
22NOV04
###### 183un04


-----

**in** **in** **cxi** **m** **in** **^kOkOrnkOkOkOkO** **m** **kO** **kD**
###### OOOOO^'OOOOOOOO^'OOOOl H ©
**>OJOOJOCC®CX)X)+-»CCX)C®+-»CCC®C** **C** i—I **c** **■P** **OJO** **C** **>** **OJO** **-P** **c** **c** **C_Q_Q**
**O^^Q-^ccLdiaioruruairucorururucCL** **os** **zs** **uc^^o^uQ-^CLCLaiai**
**Z<<<nfD<LLLLOnnLLnQ.OSnS** **z<LnS^na5Lnn** **in** **o** **a5^<kDnLnzkO<kDOkr)<^■nkD** o j **kD** **<** **in** l l **u-**
**(NXXLn(\SL^^^^C^OOmO<C^^^^■k0n^OmO^^nOLn** **®kD®n®rd®r^®Cx|®OO®m®kD®rd®LH®^®®®kD**
**CXlrHCXlCXlCXlTHTHCXlrHCXlCXlCXlCXlCXia^THCXlCXlCXimCXl** **I** **rd** **I** **CXI** **I** **rd** **i** **rd** **i** **m** **i** **m** **I** **rd** **i** **CXI** **i** **rd** **i** **rd** **i** **CXI** **i** **CXI** **i** **rd** **i** **rd** **i** **CXI** **i** **rd**


-----

###### -07 220ct -04 22:an -07 22:an -07 23Feb -06 193an -07
8Apr
###### -05 120ct -05 22Mar -04
243 an
###### -07 24Mar -05
4Dec
###### -06
20Sep
###### -07
20Sep
###### -07
20Sep
###### -07
20Sep
###### -07
13Sep
###### -07

13Sep
###### -07
13Sep
###### -07
13Sep
###### -07
6Sep
###### -07
6Sep
###### -07
30Aug
###### -07
30Aug
###### -07
30Aug
###### -07
30Aug
###### -07
30Aug
###### -07
30Aug


-----

###### -07
23Aug
###### -07
23Aug
###### -07
23Aug
###### -07
23Aug
###### -07
23Aug
###### -07
23Aug
###### -07
23Aug
###### -07
16Aug
###### -07
16Aug
###### -07
16Aug
###### -07
16Aug
###### -07
16Aug
###### -07
16Aug
###### -07 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
173

###### US20070190

031
US20070185
###### 044
US20070185
027
###### US20070184 434
US20070178
533
US20070178
505
US20070178
048
US20070173
755
US20070173
###### 481
US20070172
817
US20070172
###### 448
US20070167


-----

###### 476
US20070167
###### 408
US20070166
823
US20070166
###### 784
US20070166
###### 384
US20070166
281
US20070160
981
US20070155
767
US20070155
699
US20070155
683
###### US20070154
348
US20070149
###### 487
US20070148
###### 670
US20070141
597
US20070141
###### 080
US20070141
053
US20070136
###### 890
US20070135
###### 439
 Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv Modulation of ace2 expression ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND
PREVENTION OF INFECTIONS BY CORONAVIRUSES
###### Compositions for use in identification of influenza viruses Method and diagnostic tests based on flow cytometric analysis of antigen-specific t lymphocytes Promoter engineering and genetic control
 Antiviral composition comprising p-menthane-3,8-diol Methods of treating or preventing peritonitis with oxidative reductive potential water solution Compositions and methods for preventing infection
17EGAN
MICHAEL
BENNETT C F
SEQUOIA PHARMACEUTICALS, INC.
ESHOO MARK W
AGRATI CHIARA


-----

ALPER HAL S
CLARKE PAUL D
###### Oculus Innovative Sciences, Inc.
1OLLA BIOSCIENCES LLC

###### Methods of Producing Antibodies for Diagnostics and Therapeutics CHANG XIAO-HA Method for detecting the specificity of activated lymphocyte Piperazine, [l,4]Diazepane, [l,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED
CYTOTOXICITY AND USES THEREOF
###### Methods for detecting parvovirous infections Combination approaches for generating immune responses Methods , composition and preparations for delivery of immune response modifiers Chloroquine coupled antibodies and other proteins with methods for their synthesis VIRAL PROTEASE Sulfone substituted imidazo ring ethers Boron-containing small molecules Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof Supports for assaying analytes and methods of making and using thereof Antiviral Compositions and Methods Methods for detecting conformational changes in bioentities Biomimetic Biodetector of Toxins, Viruses, Bacteria, and Biological Factors Treating severe acute respiratory syndrome Treatment of inflammatory respiratory diseases Expression of a recombinant transgene Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
HU DUN
CELEBI AZIM A
ZENTARIS GmbH
BLUTH MARTIN H
BARNETT SUSAN W
ZARRAGA ISIDRO ANGELO E
KOSAK KENNETH M
CHEN XIN
DELLARIA JOSEPH F DR
###### Anacor Pharmaceuticals
WANG LIVING
FRUTOS ANTHONY G
MAYO FOUNDATION FOR MEDICAL EDUCATION AND
RESEARCH
O'MALLEY SHAWN M
HARMON H 1
HEMISPHERx BIOPHARMA
###### Schering Aktiengesellschaft Board of Trustees Operating Michigan State University
BOISSY GUILLAUME
Dun04
###### 8Mar05


-----

###### 28Apr03 17Oct05
5Aug03
###### 33an06 12Mar04 203an06
20Sep02
###### 8-3U103 8Dec03
29Dec03
19Dec05
5May03
15Sep03
###### 9Apr04 21Aug04 24Oct05 4Dec03
30Dec05
###### 253U1-03
29Dec05
8NOV05
28Dec05
###### 25Oct05
16May03
9May03
###### 3-3ul03 8Dec05 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 153un -05
8Mar
###### -05
9Nov
###### -06 17Oct -06
5Aug
###### -04
33an
###### -07
2Mar
###### -05 223an -07 llDec -06
22NOV
###### -06
7Dec
###### -04
22Dec
###### -04


-----

19Dec
###### -06
5May
###### -04
15Sep
###### -04
8Apr
###### -05 22Feb -07 230ct -06
3Dec
###### -04
16Aug
###### -06
263U104
###### 73un -06
7Nov
###### -06 250ct -06 250ct -06 263an -07
7May
###### -04
23U104
8Dec
###### -05
16Aug
###### -07
9Aug
###### -07
9Aug
###### -07
9Aug
###### -07

2Aug
###### -07

2Aug
###### -07

2Aug
###### -07
263U107
263U107
263U107
263U107
193U107
193U107
193U107
193U107


-----

19DU107
19DU107
12DU107
5DU107
5DU107
5DU107
5DU107
###### 283un07 283un07 21Jun07 21Jun07 21Jun07 143un07 143un07 174

US20070135
367
###### US20070134
695
###### US20070134 694 US20070134
255
###### US20070134 214
US20070123
566
US20070116
785
US20070116
###### 716
US20070116
###### 600
US20070111
309
US20070111
###### 296
US20070111
231
US20070105
193
###### US20070104
808
###### US20070104 686
US20070099
968
US20070099
901
US20070099
855
US20070099
178
US20070098


-----

735
US20070098
719
US20070093
969
US20070092
938
US20070092
###### 936
US20070092
871
US20070087
###### 974
US20070087
341
US20070087
340
US20070087
339

###### Method for controlling sr protein phosphorylation., and antiviral agents whose active ingredients comprise agents that control sr protein activity
Dengue virus detection measured by immunocytometry in a
###### dendritic cell surrogate Method for the measurement of dengue virus binding inhibition
Hmpv treatment with ribavirin and anti-hmpv antibody
###### Inactivated host cell delivery of polynucleotides encoding immunogens Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents
26FUKUHARA
TAKESHI
BURGESS TIMOTHY
BURGESS TIMOTHY
###### ViroNovative B.V.
XU FENG
CHENGDU DIKANG PHARMACEUTICAL INSTITUTE
###### Nitric oxide as an anti-viral agents vaccine and vaccine adjuvant MILLER
CHRISTOPHER C
###### Sars coronavirus s proteins and uses thereof Detection device and methods associated therewith Vero cell line adapted to grow in suspension Methods and Devices for Quantitative Viral Assays Detection of mutations in a gene associated with resistance to viral infection., 0AS2 and 0AS3 Severe acute respiratory syndrome DNA vaccine compositions and methods of use
FIELDING BURTRAM C
COOK RICHARD A
###### DAELLI MARCELO G
SHU YING
###### lllumigen Biosciences., Inc.
 Vical Incorporated


-----

COMPOSITIONS AND METHODS FOR TREATMENT OF RHINOVIRUS THE QUIGLEY CORPORATION
###### Vaccines, immunotherapeutics and methods for using the same Antiviral compounds and methods Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
 Glycyrrhizin or derivatives thereof for for treating or preventing severe acute respiratory syndrome (sars) Method for detecting sars coronavirus Methods for the Elimination of Pathogens and Other Particulate Agents
GITR binding molecules and uses therefor
###### Molecular nephrotoxicology modeling Diagnostics for sars virus Severe acute respiratory syndrome Microarray for pathogen identification
TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS
WITH IMMUNOMODULATOR COMPOUNDS
###### Compositions for use in identification of influenza viruses
 Compositions for use in identification of influenza viruses
 Compositions for use in identification of influenza viruses

CHATTERGOON MICHAEL A
###### Biotron Limited
3M INNOVATIVE PROPERTIES COMPANY
###### lohann Wolfgang Goethe University
EIKEN KAGAKU KABUSHIKI KAISHA
CHANDAWARKAR RAIIV Y
###### TolerRx, Inc.
CASTLE ARTHUR
###### Temasek Life Sciences Laboratory
HAYNES BARTON F
COMBIMATRIX CORP
SCICLONE PHARMACEUTICALS, INC.
ESHOO MARK W
ESHOO MARK W
ESHOO MARK W
Dec03
###### 27Oct05 27Oct05
2May03
13Aug03
15May03
18NOV05
10D6C03
###### 233un05 4Oct05
16NOV05
23Aug05
16May03
###### 6Aug01 133un03 243un04
25NOV03
###### 63un03 273un03


-----

###### 29Oct05 25Mar05
22NOV02
###### 15JU1-03
8May03
###### 20Oct05 14May04 17Oct05 17Oct05 17Oct05
24Dec
###### -04 260ct -06 260ct -06
3May
###### -04
12Aug
###### -04
14May
###### -04
20NOV
###### -06
10Dec
###### -04 233un -06
29Sep
###### -06
16N0V
###### -06
23Aug
###### -06
12May
###### -04 270ct -06
143 un
###### -04
243 un
###### -04
24N0V
###### -04 73un -04 153un -04 30Oct -06 27Mar -06
24N0V
###### -03


-----

###### 4Feb -04
10May
###### -04 20Oct -06
9N0V
###### -06 170ct -06 170ct -06 170ct -06
14Oun07
###### 143un07 14Jun07
14Dun07
###### 14:un07
31May
###### -07
24May
###### -07
24May
###### -07
24May
###### -07
17May
###### -07
17May
###### -07
17May
###### -07
10May
###### -07
10May
###### -07
10May
###### -07
3May
###### -07
3May
###### -07
3May
###### -07
3May
###### -07
3May
###### -07
3May
###### -07 26Apr07 26Apr07 26Apr07


-----

###### 26Apr07 19Apr07 19Apr07 19Apr07 19Apr07 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
175

US20070087

338
US20070087
337
US20070087
336
US20070087
332
US20070087
008
US20070082
971
US20070077
201
US20070072
893
US20070072
202
US20070066
649
US20070066
648
US20070066
639
US20070066
552
US20070065
939
US20070065
###### 407
US20070060
###### 754
US20070060
611
US20070060
535
US20070060
###### 499
US20070059
728
US20070059
###### 686
US20070059
243
###### US20070054


-----

937
###### US20070054 834
US20070053
933
US20070053
###### 920
US20070053
878
US20070048
759
US20070048
747
US20070048
282
###### 17Compositions for use in identification of influenza viruses Compositions for use in identification of influenza viruses Compositions for use in identification of influenza viruses Pulmonary stem cells, related methods and kits of parts
ESHOO MARK W
ESHOO MARK W
ESHOO MARK W
LING THAI-YEN
###### Rab9a, rablla, and modulators thereof related to infectious disease UNIV
VANDERBILT
Use of a plastic composition and a product obtained thereby
Stem cell expansion and uses
###### Substituted imidazo ring systems and methods
Use of chimeric receptors in a screening assay for identifying
###### agonists and antagonists of cell receptors
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
###### Oxime substituted imidazoquinolines Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids Systems for detection and production of respiratory, herpes and enteric viruses Interferon-Alpha Polypeptides and Conjugates
 Alkoxy substituted imidazoquinolines
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
###### Targeted delivery of antiviral compounds through hemoglobin bioconjugates Chloroquine combination drugs and methods for their synthesis
COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER
SYSTEM AND METHOD
###### Materials and methods for the detection of severe acute respiratory syndrome virus (SARS)
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
BRAIN INFLAMMATION AND SEPSIS
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF


-----

BRAIN INFLAMMATION AND SEPSIS
POLYGIENE AB
DOWDING CHARLES
AMOS DAVID T
BATES ELIZABETH E M
###### Not Available
NOZAKI MASAKO
AMOS DAVID T
INTROGEN THERAPEUTICS INC
###### Diagnostic Hybrids, Inc.
MAXYGEN INC
HARALDSON CHAD A
###### Not Available
ADAMSON 1 G
KOSAK KENNETH M
The Government of the US, as represented by the
###### Secretary of the Navy
ERAGEN BIOSCIENCES INC
###### Not Available Not Available Quaternary ammonium halides for treatment of infectious conditions NANOBIO CORP IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL
METHODS OF USING SAME
###### Nematode polypeptide adjuvant Sars
DETECTION OF TARGET MOLECULES WITH LABELED NUCLEIC ACID
DETECTION MOLECULES
###### Methods for assaying analytes Albumin fusion proteins Fauci/COVID-19 Dossier
SHEPPARD PAUL 0
###### Not Available
FOUCHIER RONALDUS A M
###### LI YOUGEN LESLIE THOMAS M
Human Genome Sciences, Inc.
CC-BY-NC-SA Dr. David E. Martin
OctOS
###### 17Oct05 17Oct05 17Oct05 24Feb04 23Feb04 29Sep04
25NOV03
###### 24Mar05
29NOV02
29NOV02
###### 12Aug04 213an05
20Sep05
18NOV02
###### 3Oct03
29NOV02


-----

###### 30Apr98 15Sep05 2-3U104 313an04
29NOV02
29NOV02
###### HApr05 203U1-05 223an03 8Apr03 103un05 lSep05 9Feb04 170ct -06 170ct -06 170ct -06 170ct -05 24Feb -05 273an -05 25Mar -06
24N0V
###### -04 24Mar -06 INov -06 INov -06
12Aug
###### -04 203an -06 28Apr -06 30Oct -06 lOct -04
INOV
###### -06
13NOV
###### -06 22Feb -06 63un -06 28JU106


-----

```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-
```
                                                jbwst

```
£0-

viewzz

£0-

viewzz

£0-

viewzz

£0-

viewzz

£0-

viewzz

£0-

viewzz
£0-

viewez
£0-

viewez
z.0vidvs
£0vldV3T
£0vldV6T
£0vldV6T
£0vldV6T
£0vldV6T
£0vldV6T

9ZT
90-
§nv8

S0-
d9ST

90-
unczT

170-
Jdvg

170-
uecxz
90inC0Z

90-
JdV0T

90-

AONT

90-
AONT


-----

###### -07
8Mar
###### -07
8Mar
###### -07
8Mar
###### -07
8Mar
###### -07
8Mar
###### -07 iMar -07 iMar -07 iMar -07

US20070042
###### 441
US20070042
388
US20070042
381
US20070042
351
US20070042
350
US20070041
941
US20070037
763
US20070037
231
US20070037
142
US20070037
###### 140
US20070036
###### 760
US20070036
###### 744 US20070034
529
US20070032
###### 499
US20070031
923
US20070031
832
US20070031
283
US20070027
306
US20070026


-----

391
US20070026
087
US20070026
###### 014
US20070026
009
US20070025
###### 966
US20070021
###### 439
US20070021
326
US20070020
###### 734
US20070020
235
US20070015
181
###### Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device 2BioScale, Inc.
 Method of probe design and/or of nucleic acids detection
BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY
###### VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES
THEREOF
###### Multi-allelic molecular detection of sars-associated coronavirus Methods and compositions for detecting sars virus and other infectious agents Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same Oligonucleotide compound and method for treating nidovirus infections Methods and apparatus for detecting bacteria using an acoustic device Methods and apparatus for detecting viruses using an acoustic device Methods and compositions for detecting sars virus Adeno-associated virus (aav) clades, sequences, vectors containing
same, and uses therefor
###### Treatment or prevention of respiratory viral infections with alpha thymosin peptides Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode
LEE CHARLIE
May05
12Aug05
###### 16Rosetta Genomics 3an03 22KOSTRIKIS
LEONDIOS G
CHENG 3ING


-----

BOYER DEAN D
###### AVI BIOPHARMA INC BioScale, Inc. BioScale, Inc.
CAPITAL BIOCHIP COMPANY, LTD.
The Trutees of the University of Pennsylvania
###### SciClone Pharmaceuticals, Inc.
BARD ALLEN I
###### Novel cysteine protease inhibitors and their therapeutic applications BOISSY
GUILLAUME
###### Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom Assay cartridges and methods for point of care instruments Albumin fusion proteins Methods and compositions for identifying chemical or biological agents using multiplexed labeling and colocalization detection Anti-coronavirus agent Interferon beta in severe acute respiratory syndrome (sars) Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
###### Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers Composition and its Therapeutic Use
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
CHAM BILL E
###### Phylogica Limited
BLANKFARD MARTIN
HASELTINE WILLIAM A
GHC TECHNOLOGIES INC
###### Toagosei Co., Ltd.
ARES TRADING S.A.
BOGOCH ELENORE S
MAXYGEN, INC.
PARION SCIENCES INC
###### INSIGNION HOLDINGS LTD AND VER
MAXYGEN, INC.
MAXYGEN, INC.
###### System and methods for nucleic acid and polypeptide selection WILLIAMS RICHARD B Aug03 14JU1-03 13Jun03
24D6C03
2May05
2May05
9May03
30Sep03
###### 23Apr03 3Jun05
5Aug05
###### 29Jun00


-----

5May99
###### 233un05 9Feb04 HApr05 16Oct03 17Apr03 27Mar01 19May04 253U1-05
9Aug02
###### 19May04 19May04
19May00
###### Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
2May
###### -06
12Aug
###### -05
26May
###### -04
13Aug
###### -04
143U103
143 un
###### -04
10May
###### -06
2May
###### -06
2May
###### -06
9May
###### -03
30Sep
###### -04 23Apr -04 23un -06
5Aug
###### -05 10Apr -06 20Feb -04 233un -06
8Aug
###### -06
6Apr
###### -06 31Oct


-----

###### -03
6Apr
###### -04 16Feb -06
13Sep
###### -06
253U105
25Sep
###### -06
13Sep
###### -06
13Sep
###### -06
2May
###### -06 22Feb -07 22Feb -07 22Feb -07 22Feb -07 22Feb -07 22Feb -07 15Feb -07 15Feb -07 15Feb -07 15Feb -07 15Feb -07 15Feb -07 15Feb -07
8Feb
###### -07
8Feb
###### -07
8Feb
###### -07
8Feb
###### -07 iFeb -07 IFeb -07


-----

###### IFeb -07 IFeb -07 IFeb -07 IFeb -07
25Dan07
25Dan07
25Dan07
25Dan07
###### 18:an07
177
US20070015

###### 172 US20070014 778 US20070014 719
US20070009
###### 932 US20070009 884 US20070004 028 US20070003
577
###### US20070003
565
###### US20060293
352
###### US20060293

308

###### US20060293
267
###### US20060292 178 US20060292 162 US20060292 151
US20060287
###### 263 US20060286
667
###### US20060286 124 US20060286 121
US20060286
###### 119
US20060281
###### 128


-----

US20060281
072
US20060280
###### 754
US20060280
748
US20060280
723
US20060280
679
US20060276
972
US20060275
841
US20060275
802
US20060275
749
US20060275
515
###### lExpression profiles for microbial infection Endoribonuclease and uses thereof Steroid analogs and characterization and treatment methods Promoter engineering and genetic control Z-BioMedj Inc.
LEE CHOW
DOWDING CHARLES
ALPER HAL S
###### Methods and apparatuses for detecting chemical or biological agents GHC
TECHNOLOGIES INC
###### Signal measuring system for conducting real-time amplification assays Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections
Use of habl8g/cdl47 molecule as target for antiviral antagonists
and thus obtained antiviral antagonist
###### Phenoxiacetic acid derivatives Pyridyl derivatives and their use as therapeutic agents Dual functional oligonucleotides for use as anti-viral agents Proteins encoded by the severe acute respiratory syndrome (SARS) coronavirus and a role in apoptosis Plasma or serum fraction for the treatment or prevention of bacterial infections L-SIGN polymorphisms and methods involving use of same Methods and compositions for inducing antigen-specific immune responses Methods for detection and production of influenza viruses
GEN-PROBE INCORPORATED
CHU KID
CHEN ZHINAN
BONNERT ROGER V
Xenon Pharmaceuticals Inc.
###### UNIVERSITY OF MASSACHUSETTS


-----

###### Agency for Science, Technology and Research
BUCKHEIT ROBERT W HR
GARDNER HASON P
COLEY PHARMACEUTICAL GROUP LTD
###### Diagnostic Hybrids, Inc. Vaccine compositions and methods of treating coronavirus infection ID Biomedical Corporation of Quebec Adenoviral vector-based vaccines Compositions and methods for treatment of chronic and infectious diseases Compositions and methods using lentivirus-based vectors for generating immune responses Agonistic Binding Molecules to the Human 0X40 Receptor Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins Plasma or serum fraction for treatment or prevention of abnormal cell proliferation Interferon for treating or preventing a coronaviral infection Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells Method for determining the amount of an analyte in a sample Assay method and apparatus with reduced sample matrix effects Mutations in 0AS1 genes Compositions for use in identification of orthopoxviruses Antiviral preparations obtained from a natural cinnamon extract Fauci/COVID-19 Dossier
BROUGH DOUGLAS E
###### Biokit S.A.
VIRXSYS CORPORATION
BAKKER ALEXANDER BERTHOLD H
GARRY ROBERT F
BUCKHEIT ROBERT W HR
###### Viragen, Inc
BOWDISH KATHERINE S
###### Gen-Probe Incorporated
BLANKFARD MARTIN
###### FELLIN P C ISIS Pharmaceuticals, Inc.
OVADIA MICHAEL
CC-BY-NC-SA Dr. David E. Martin
Hun05
6Hun05
###### 29Sep04 27Apr05 HApr05 10Mar05
28Hun05
9Hun03
21Aug03
###### 29HU1-03 13Apr05 4Aug04 22Apr05


-----

###### 26Mar04 lSOul-04 24Apr98 303un04 253ul-03 23Dec03
9Sep03
###### 133un02 4Nov03 22Apr05
19May03
###### 4Mar03 10Mar05 20Dec04
4May05
5D6C03
24D6C03
30l\lov
###### -05 53un -06

29Sep
###### -05
 26Apr -06

6Apr
###### -06
10Mar
###### -06 27Jun -06
93un
###### -03
18Aug
###### -04 293ul04 13Apr -06

4Aug
###### -05
 24Apr -06 28Mar -05 183ul05
2 8Apr
###### -06
303un
###### -05 233an -06 6Apr -06

17Aug


-----

###### -06 133un -03
3Nov
###### -04 24Apr -06
19May
###### -04
17Dec
###### -04 10Mar -06
19Dec
###### -05
3May
###### -06
24Aug
###### -05 223un -06
178
###### 183an07 183an07 183an07 113an07 113an07 43an07 43an07 43an07
28Dec
###### -06
28Dec
###### -06
28Dec
###### -06
28Dec
###### -06
28Dec
###### -06
28Dec
###### -06
21Dec
###### -06
21Dec
###### -06
21Dec
###### -06
21Dec
###### -06
21Dec
###### -06
14Dec
###### -06


-----

14Dec
###### -06
14Dec
###### -06
14Dec
###### -06
14Dec
###### -06
14Dec
###### -06
7Dec
###### -06
7Dec
###### -06
7Dec
###### -06
7Dec
###### -06
7Dec
###### -06
 US20060275
317
US20060270
835
US20060270
###### 614
US20060270
041
US20060270
017
US20060269
###### 976
US20060269
###### 936
US20060269
###### 911
US20060269
###### 572
US20060269
###### 538 US20060264 448 US20060264 444 US20060264 435 US20060263
847
###### US20060263 765 US20060259 249 US20060258 611


-----

US20060258
577
US20060257
993
US20060257
992
US20060257
991
US20060257
###### 976
US20060257
945
US20060257
941
US20060257
925
US20060257
###### 866
US20060257
861
US20060257
###### 854
US20060257
852

###### Vaccine compositions for prevention of chronic and infectious diseases 23Biokit S.A. Diagnosis and treatment of Alzheimer disease
Use of chaicones for the treatment of viral disorders
###### Cell lines for production of replication-defective adenovirus Inactivation of a pathogen in a sample by a treatment with formalin
and UV light
METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY
###### Biokit S.A.
BODDUPALLI SEKHAR
HOWE 3OHN A
BARRETT NOEL
###### Biokit S.A. Screening assay for TLR7j TLR8 and TLR9 agonists and antagonists DOLLET SANDRA Antisense antiviral compound and method for treating ssRNA viral infection Accelerated vaccination Serine proteases with altered sensitivity to activity-modulating substances Purine derivatives Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases Novel compounds Compositions and methods for treatment of sever acute respiratory syndrome (sars) Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars) Rapid identification of microbial agents


-----

###### Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
 ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND
PREVENTION OF INFECTIONS BY CORONAVIRUSES
###### Integration of fluids and reagents into self-contained cartridges containing sensor elements Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems Integration of fluids and reagents into self-contained cartridges containing particle-based sensor elements and membrane-based sensor elements
 Methods and kits for propagating and evolving nucleic acids and proteins
 Methods and apparatus for detecting cardiac injury markers using
an acoustic device
###### Integration of fluids and reagents into self-contained cartridges containing particle and membrane sensor elements
 Method for isolating intracellular antibodies able to neutralize protein interactions
 Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay Screening assay for inhibitors of severe acute respiratory syndrome
(SARS) using SELDI-TOF Mass Spectrometry

Membrane assay system including preloaded particles
###### Severe acute respiratory syndrome coronavirus AVI BIOPHARMA INC
GEISBERT THOMAS W
COCO WAYNE M
PFIZER LTD
BONNERT ROGER V
BONNERT ROGER
SIBER GEORGE R
HOUDE MICHEL
ECKER DAVID 1
UNIV HONG KONG
ERICKSON 1OHN W
ANSLYN ERIC
ANSLYN ERIC
ANSLYN ERIC
RNA LINE OY
###### BioScale, Inc.
ANSLYN ERIC
LINE GENOMICS S.P.A.
ALMSTEAD NEIL G
###### Wright State University
BALLARD KARRI L
###### Chiron Corporation
Dec03
23Dec03
24May05
13D6C04
26May05
23D6C03
###### 24Mar05


-----

###### 16Sep04 lAug03
27May05
4May05
18Aug03
###### 7Apr03
20May03
9May03
###### 3Mar04
19May03
###### 28Apr03 27Feb04 27Feb04 27Feb04 63un03
2May05
###### 27Feb04
21NOV02
###### 243U1-02
12May05
###### 27Feb04 10Apr03 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
6Apr
###### -06
6Apr
###### -06
24May
###### -05
12Dec
###### -05
26May
###### -05
5Apr
###### -06 23Mar -06
10May
###### -06 173an -06
26May
###### -06
3May
###### -06
16Aug
###### -04
6Apr
###### -04
20May
###### -04
5May


-----

###### -04
3Mar
###### -05
143 un
###### -06 28Apr -04

22Dec
###### -04

22Dec
###### -04

22Dec
###### -04 73un -04
2May
###### -06

22Dec
###### -04

21N0V
###### -03 243ul03
12May
###### -06

22Dec
###### -04
9Apr
###### -04
7Dec
###### -06
30NOV
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06
30Nov
###### -06

23NOV
###### -06

23NOV
###### -06

23NOV
###### -06


-----

23NOV
###### -06
23NOV
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
16N0V
###### -06
179

###### US20060253 060 US20060252
767
###### US20060246 081 US20060241 546
US20060240
551
###### US20060240 530 US20060240
515
###### US20060240 412 US20060235 350 US20060234 981 US20060234


-----

263
US20060229
356
US20060228
299
US20060223
863
US20060223
847
US20060223
###### 184
US20060223
###### 074
US20060216
702
US20060211
765
US20060211
752
US20060211
###### 130
US20060211
115
US20060210
967
US20060210
###### 433
US20060205
713
US20060205
###### 040 US20060204
997
US20060199
802
###### Method of using oxidative reductive potential water solution in dental applications 2Oculus Innovative Sciences, Inc. Piperazine derivatives and their use as therapeutic agents
 Methods and compositions for polytopic vaccination Method of treating second and third degree burns using oxidative reductive potential water solution Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
XENON PHARMACEUTICALS INC.
DEEM MICHAEL W
###### Oculus Innovative Sciences, Inc.
HE YUXIAN
###### Methods and compositions for infectious cDNA of SARS coronavirus UNIV NORTH
CAROLINA
###### Soluble fragments of the SARS-CoV spike glycoprotein Compositions for use in identification of adenoviruses Method of treating skin ulcers using oxidative reductive potential


-----

###### water solution
 Boron-containing small molecules
 Method for reducing the presence of amplification inhibitors in a reaction receptacle
Use of indomethacin and derivatives as broad-spectrum antiviral
###### drugs and corresponding pharmaceutical compositions Constructs binding to phosphatidylserine and their use in disease treatment Methods for treating Hepatitis C Anti-coronavirus drug Supports useful in incorporating biomolecules into cells and methods of using thereof Spotting compositions and methods of use thereof Virus-like particles, methods of preparation, and immunogenic compositions Novel compounds
Use of phenylmethimazoles, methimazole derivatives, and
###### tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
 Method for continuous mode processing of multiple reaction receptacles in a real-time amplification assay Methods of generating chimeric adenoviruses and uses for such chimeric aden oviruses Re-sequencing pathogen microarray
DIMITROV DIMITER S
BLYN LAWRENCE
###### Oculus Innovative Sciences, Inc. Anacor Pharmaceuticals Gen-Probe Incorporated Universita' Degli Studi Di Roma "Tor Vergata"
PEREGRINE PHARMACEUTICALS INC
AREFOLOV ALEXANDER
###### Arigen, Inc.
FRUTOS ANTHONY G
BUNCH THOMAS A
COMPANS RICHARD W
ASTRAZENECA AB
MayOS
###### 301U1-03 29Apr05 23Mar05 23un04 213U1-03 213U1-03 HSep03 23Mar05 16Feb05 10Mar05
12Aug03
###### 243an05 143U1-04 153U1-03 5Apr05


-----

###### 5Apr05
17May02
###### 7Apr03
16BENAVIDES-PERALTA
URUGUAYSITO
###### Mar04 10Gen-Probe Incorporated
The Trustees of the University of Pennsylvania
AGAN BRIAN K
###### Signal measuring system having a movable signal measuring device GEN-PROBE
INCORPORATED
###### Pyridazine derivatives and their use as therapeutic agents Compositions for use in identification of adventitious viruses Method for performing multi-formatted assays
 Pyridyl derivatives and their use as therapeutic agents
Xenon Pharmaceuticals Inc.
SAMPATH RANGARA3AN
###### Gen-Probe Incorporated
ABREO MELWYN
###### Mar05 201un03 2-3U104 10Mar05 293U1-04
3Mar05
###### 10Mar05 303U1-03
2May

###### -06

293U104
###### 29Apr
 -05
 23Mar
 -06

8Feb

###### -06
 193an
 -06
 193an
 -06
 12Apr
 -06
 23Mar
 -06
 16Feb
 -06
 10Mar
 -06
 HAug
 -04

243 an

###### -06

143U105


-----

###### 140u104
5Apr
###### -05
5 Apr
###### -05 4Apr -06

6 Apr
###### -04
17May
###### -05 10Mar -06
ISOun
###### -04
2OU105
###### 10Mar -06 29Oul04
3Mar
###### -06
10Mar
###### -06
29OU104
9Nov
###### -06
9Nov
###### -06
2Nov
###### -06 26Oct06 26Oct06 26Oct06 26Oct06 26Oct06 19Oct06 19Oct06 19Oct06 12Oct06 12Oct06 5Oct06 5Oct06 5Oct06 5Oct06
28Sep
###### -06
21Sep
###### -06
21Sep
###### -06
21Sep
###### -06
21Sep
###### -06


-----

21Sep

###### -06

21Sep

###### -06

14Sep

###### -06

14Sep

###### -06

14Sep

###### -06

7Sep

###### -06 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E . Martin
###### 180

US20060199

###### 176
US20060195
067
US20060193
745
US20060190
189
US20060189
###### 644
US20060189
571
US20060189
570
US20060189
569
US20060189
568
US20060189
542
US20060188
519
US20060178
341
US20060177
849
US20060177
837
US20060177
813
US20060171
962
US20060171
958
US20060165
723
US20060165
###### 716


-----

US20060163
149
US20060160
109
###### US20060154
243
US20060153
803
US20060147
958
US20060143
719
US20060142
383
US20060142
202
US20060140
971
US20060135
###### 458 Coronavirus S peptides
CHONG PELE C S
###### Delivery of immune response modifier compounds Virucidal disinfectant
 Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research Lipid-modified immune response modifiers

Use of lipid conjugates in the treatment of infection

Use of lipid conjugates in the treatment of infection

Use of lipid conjugates in the treatment of infection

Use of lipid conjugates in the treatment of infection

###### Preventive or therapeutic composition for viral infectious disease Peptides, antibodies, and methods for the diagnosis of SARS Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV)
and transmissible gastroenteritis coronavirus (tgev)
###### Nucleic acid primer set, nucleic acid probe set and method for detecting respiratory disease virus using the primer set and probe set Systems and methods for identifying diagnostic indicators Novel high-throughput screening method of drug for bioactive protein
SARS vaccine
###### Antiviral activity from medicinal mushrooms
 Nucleic acid sequences encoding proteins capable of associating into
a virus-like particle
###### Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae Product for absorption purposes Harnessing network biology to improve drug discovery Antigenic peptides of SARS coronavirus and uses thereof
 Inhibition of sars coronavirus infection with clinically approved antiviral drugs


-----

###### System for detecting polynucleotides
Use of golden hamster as infectivity model of SARS
###### 3D-Structure model of SARS coronavirus 3CL protease and antiSARS drugs Compositions and methods for targeted delivery of immune response modifiers Cell surface expression vector of sars virus antigen and microorganisms transformed thereby Antiviral oligonucleotides Fauci/COVID-19 Dossier
KEDL ROSS M
ARNDT ANDREAS
HOFFMANN GEOFFREY W
WIGHTMAN PAUL D
YEDGAR SAUL
YEDGAR SAUL
O3CIUS DAVID
YEDGAR SAUL
FURUKAWA SATORU
AU MUN Y D
###### 153U1-04
25Aug03
###### 283an05 21Apr04
14Aug03
###### 103an00 103an00 103an00 103an00 223U1-03 143un04
23CHUNG
BONG H
###### 3un03
23HUH
NAM
BOROZAN IVAN
ENDO YAETA
###### Consejo Superior de Investigaciones Cientificas
STAMETS PAUL
###### Fort Dodge Veterinaria S.A.
BAROCCHI MICHELLE
H3ERTEN MARIE-CHRISTINE
###### Odyssey Thera, Inc.
GOUDSMIT 3AAP
STANTON LAWRENCE W
CHOI K Y
CONTAMIN HUGUES
SHANGHAI LEAD DISCOVERY PHARMA
3M INNOVATIVE PROPERTIES CO
CHOI 3AE C
3UTEAU 3EAN-MARC
CC-BY-NC-SA Dr. David E. Martin
###### Dec04


-----

###### 13Aug04 8Sep03
3Sep04
###### 63an04
3Sep04
###### 29JU1-04 133un03
22NOV04
###### 213U1-03 93un03
20May03
###### 18Aug04 43un03
8Dec00
###### 43un03
13Sep02
14311105
25Aug
###### -04 273an -06 16Mar -06
12Aug
###### -04
8Sep
###### -05
8Sep
###### -05
8Sep
###### -05
8Sep
###### -05
223U104
###### 133un -05 233un -04
23Dec
###### -05 ISAug -05
8Sep
###### -04
2Sep
###### -05 22Mar -06
2Sep
###### -05 29JU105 HJun -04
21N0V


-----

###### -05 20:an -06 9:un -04
21N0V
###### -05
16Aug
###### -05
2Dec
###### -05 23Feb -06 43un -04 190ct -05
Sep
###### -06
31Aug
###### -06
31Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
24Aug
###### -06
10Aug
###### -06
10Aug
###### -06
10Aug
###### -06
10Aug
###### -06
3Aug
###### -06
3Aug
###### -06 273U106 273U106 273U106


-----

20DU106
13DU106
###### 133U106 63ul06 293un06 293un06 293un06 293un06 223un06
181
7

US20060135
###### 422 US20060134
753
###### US20060134
609
###### US20060134
397
US20060128
628
US20060123
###### 499
US20060122
368
US20060121
580
US20060121
043
US20060115
875
US20060113
298
US20060111
387
US20060110
803
US20060110
758
US20060110
###### 405
US20060100
232
US20060100
229
US20060099
###### 606
US20060099
573
###### US20060094
105
###### US20060094 104
US20060093


-----

###### 616
US20060089
###### 324
US20060089
323
US20060088
###### 926
US20060088
909
US20060079
###### 485
US20060075
###### 894
US20060070
952
Use of angiotensin receptor blockers (ARBs) to treat diseases
###### associated with excess ACE
17M0SK0WITZ
DAVID W
###### Super-antigen fusion proteins and the use thereof Compositions and methods for determining the presence of SARS coronavirus in a sample
 Microporous materials, methods, and articles for localizing and quantifying analytes
Human tissue antigen-binding peptides and their amino acid
###### sequences Civet animal model system for Severe Acute Respiratory Syndrome
(SARS) coronavirus infection and uses thereof

###### Antigen delivery platform
 Binding molecules against SARS-coronavirus and uses thereof
Use of modulators of EphA2 and EphrinAl for the treatment and
###### prevention of infections Detection, characterization and treatment of viral infection and methods thereof Electromagnetic wave applicator

ARYL SUBSTITUTED IMIDAZOQUINOLINES
###### Antigenic peptides of SARS coronavirus and uses thereof Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof Plasma or serum fraction for treatment and prevention of viral infections and related conditions Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
 Pyrazolopyridines and analogs thereof
 Assay to detect viral uncoating Diagnostic assays Mixed cell diagnostic systems for detection of respiratory, herpes
and enteric viruses

###### Animal protein-free media for cultivation of cells
 Process for vaccinating eucaryotic hosts and for protecting against
SARS-CoV infection
RNAi modulation of RSV, PIV and other respiratory viruses and uses
###### thereof


-----

RNAi modulation of RSV^ PIV and other respiratory viruses and uses
###### thereof Method of removing hazardous substance, and hazardous substance removing material using the same such as air cleaning filter, mask
and wipping sheet, and method of storing the same
###### Virus-like particles, methods of preparation, and immunogenic compositions
Use of lipid conjugates in the treatment of infection
###### Bioagent air filtration systems Charge-based water filtration systems Fauci/COVID-19 Dossier Healthbanks Biotech Co., Ltd.
GETMAN DAMON K
SMITH ROGER E
CHEN SHOW-LI
CHEN BINDING
GOVERNMENT OF THE U S A AS REP
CRUCELL
MEDIMMUNE, INC.
BROWN EARL
ZAIDAN HODIN HANDOTAI KENKYU SHINKOKAI
3M INNOVATIVE PROPERTIES CO
###### Crucell Holland B.V.
UNIV HONG KONG
BUCKHEIT ROBERT W DR
AGARWAL ATUL
BONK DASON D
NARAYAN SHAKTI
MIGUEZ MARIA-DOSE
###### Diagnostic Hybrids, Inc.
DORNER FRIEDRICH
ALTMEYER RALF
BARIK SAILEN
BARIK SAILEN
###### Apr03 21DU1-04 17Apr03
26NOV02
###### 15Dec04
6D6C04
3D6C04
###### 22DU1-03 27Oct04
30Sep03
27NOV02
20D6C02
13Dun03
22NOV04
###### 20Aug04
11NOV04
###### 3Oct03
9D6C03
###### 24Mar04 24Apr98


-----

###### 29Oct04 29Sep04 22Oct04 22Oct04 28DAIKIN
IND LTD
###### Mar03
17C0MPANS
RICHARD W
03CIUS DAVID
###### University of Wyoming Research Corporation d/b/a Western Research Institute University of Wyoming Research Corporation d/b/a
CC-BY-NC-SA Dr. David E. Martin
May02
###### 10Ian00 28Ian03 283an03
31Mar
###### -04
193U105
###### 16Apr -04
20NOV
###### -03
15Dec
###### -04
6Dec
###### -04
2Dec
###### -05 203an -06 27Oct -05 HOct -05
27NOV
###### -03 133an -06
6Dec
###### -05 28Oct -05
22Aug
###### -05
10Nov
###### -05 lApr -05
8Dec
###### -04 24Mar


-----

###### 90-
Aewv

###### 90-
Aewv

###### 90-
Aewv

###### 90-
XewTT

###### 90-
XewTT

###### 90-
XewTT

###### 90-
XewTT

###### 90-
Aewsz

###### 90-
Aewsz

###### 90-
Aewsz

###### 90-
Aewsz
###### 90uncT 90uncT 90unc8 90unc8 90unc8 90unc8 90uncsT 90unc22 90unc22 90unc22 90unc22

170-
###### uecsz

170-
###### uecsz

S0-
d9S8

###### £0-
Xewex

###### V0-

JBW92

S0-
###### uncvx

S0-
###### uncvx

S0-
d9S8Z

170­

###### 13062

S0-
d9S02

###### 90-


-----

###### 27Apr06 27Apr06 27Apr06 27Apr06 13Apr06 13Apr06 6Apr06
182

US20060067
###### 940
US20060063
###### 150
US20060063
149
US20060062
###### 804
US20060057
605
US20060057
161
US20060053
516
US20060051
###### 744
US20060051
###### 374
US20060035
###### 926
US20060035
859
US20060035
853
US20060035
327
###### US20060034
853
###### US20060024
668
###### US20060024
271
US20060019
###### 976
US20060019
967
US20060019
927
US20060019
923
US20060018
923
US20060018
877
###### US20060014 254


-----

US20060009
###### 459
US20060008
###### 810
US20060008
379
US20060006
678
US20060003
941
US20060003
352
US20060003
351

###### Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
 Antisense antiviral compound and method for treating ssRNA viral infection Compositions and methods for detecting pathogen infection SARS-CoV-specific B-cell epitope and applications thereof Compositions for use in identification of viral hemorrhagic fever viruses Detection of coronavirus infection Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against
SARS

###### Feline infectious peritonitis (FTP) and systemic multi-organ coronavirus biomarkers and screening methods Compositions and methods for mucosal vaccination Benzothiazolium compounds Treating severe and acute viral infections Methods for tailoring the immune response to an antigen or
immunogen
###### Recombinant super-compound interferon and uses thereof Novel human virus causing respiratory tract infection and uses thereof Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics Treatments for viral infections using IFN cytokines and ribavirin, alone or in combination Methods for treating Hepatitis C
SARS CoV main protease inhibitors
###### Anti-viral uses of borinic acid complexes Methods and compositions for inducing innate immune responses Novel human virus causing respiratory tract infection and uses thereof
 Intradermal delivery of vacccines and therapeutic agents
 Albumin fusion proteins
 Pyridazine derivatives and their use as therapeutic agents
 Methods and compositions for detecting rhinoviruses

Room decontamination with hydrogen peroxide vapor
###### Door handle cover Peptides and peptidomimetics having immune-modulating, antiinflammatory
and anti-viral activity


-----

Mass tag PCR for mutliplex diagnostics
###### Methods and kits for identifying target nucleotides in mixed populations Fauci/COVID-19 Dossier
21DIAM0ND
MICHAEL
IVERSEN PATRICK L
BERTHET FRANCOIS X
###### National Taiwan University ISIS Pharmaceuticals, Inc.
CHOU CHIH-MING
The University of Hong Kong
AUSTIN KIMBERLY M
3M Innovative Properties Company
LEE SHIOW-3U
HEMISPHERx BIOPHARMA
###### Biomedical Research Models, Inc.
WEI GUANGWEN
CHAN KWOK H
HOEK CORNELIA V D
###### ALIBEK KEN
CHEN GUANGMING
HSIEH HSING-PANG
BELLINGER-KAWAHARA CAROLYN
###### Coley Pharmaceutical Group, Ltd.
CHAN KWOK H
ALARCON 3ASON B
Human Genome Sciences, Inc.
ABREO MELWYN
###### Focus Technologies, Inc.
STERIS INC.
HERRON ROY H DR
KAWABE TAKUMI
BRIESE THOMAS
###### Applera Corporation
CC-BY-NC-SA Dr. David E. Martin
###### 3un04 16Sep04
23D6C03
###### 21Sep04 22Mar04 16Sep04
5Dec03
###### 303un04 28Apr04 13Aug04
16May03
###### 73an04 26Aug04 213U1-04 73an04 153an04 223U1-04 213U1-04


-----

14Dun04
###### 18JU1-04 21JU1-04 293un01 22Dan03 16Mar04 6-3U104 8-3U104 27May04 253un03 29Apr04 30Apr04 213un -05
14Sep
###### -05
6Sep
###### -05
21Sep
###### -04 21Mar -05
16Sep
###### -04
3Dec
###### -04 283un -05 28Apr -05
15Aug
###### -05 60ct -05
73an
###### -05 10Mar -05
16May
###### -05
18Aug
###### -04 133an -05 143U105 203U105
143 un
###### -05 183U105
213U104
###### 29Apr -05 73ul05
9Feb


-----

###### -05
6DU104
8DU104
26May
###### -05 253un -04 28Apr -05 29Apr -05
30Mar
###### -06 23Mar -06 23Mar -06 23Mar -06 16Mar -06 16Mar -06
9Mar
###### -06
9Mar
###### -06
9Mar
###### -06 16Feb -06 16Feb -06 16Feb -06 16Feb -06 16Feb -06
2Feb
###### -06
2Feb
###### -06 263an06 263an06 263an06 263an06 263an06 263an06 193an06 123an06 123an06 123an06 123an06


-----

5Dan06
5Dan06
5Dan06
183

US20060003
340
US20060002
947
US20060002
932
US20050288
###### 866
US20050287
167
US20050287
118
US20050282
279
US20050282
209
US20050282
###### 154
US20050281
828
US20050277
592
US20050277
181
US20050276
818
US20050276
815
US20050271
711
US20050266
550
US20050266
###### 465
US20050266
###### 425
US20050266
397
US20050260
645
US20050255
123
US20050250
677
US20050249
742
US20050249
739
###### US20050244 423


-----

US20050240
353
US20050239
735
US20050239
###### 086
US20050239
047
US20050238
655
###### 22Multi-allelic molecular detection of SARS-associated coronavirus li-key/antigenic epitope hybrid peptide vaccines Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential Polycistronic HIV vector constructs Bacterial plasmid with immunological adjuvant function and uses thereof
 Expression vector encoding coronavirus-like particle
 Variable length probe selection Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells Beta-peptides Compositions and methods for detecting pathogen infection Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMPdependent kinase and a target for SARS therapy
 Antiviral activity from medicinal mushrooms Therapeutic antimicrobial compositions and methods TC-83-derived alphavirus vectors^ particles and methods Interferon-alpha polypeptides and conjugates
 Methods for producing and identifying multispecific antibodies Methods for identification of coronaviruses Comparative genomic resequencing Chimeric ebola virus envelopes and uses therefor Glycopeptide antibiotic derivatives Compositions and methods for modulating a cytotoxic T lymphocyte
immune response

###### Antibodies against SARS-CoV and methods of use thereof Methods for treating viral infection using IL-28 and IL-29 cysteine mutants Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research Enhancement of immune responses
 Multiplex systems, methods, and kits for detecting and identifying nucleic acids
 Methods and devices for determining a cell characteristic, and applications employing the same
 Antiviral activity from medicinal mushrooms
 Fauci/COVID-19 Dossier


-----

BRIESE THOMAS
GIMZEWSKI DAMES K
STAMETS PAUL
CC-BY-NC-SA Dr. David E. Martin
###### Vaccinex, Inc.
BLYN LAWRENCE B
ALBERT THOMAS
The Trustees of the University of Pennsylvania
###### BALZARINI DAN Dana-Farber Cancer Institute, Inc.
MARASCO WAYNE
HENDERSON KATHERINE E
BOWDISH KATHERINE S
###### Yale University
BERTHET FRANCOIS X
GODZIK ADAM
STAMETS PAUL
The Procter & Gamble Company
###### Alphavax, Inc.
HWU PAUL L
ALBERT THOMAS
###### Birch Biomedical Research, LLC
HUMPHREYS ROBERT
Duke University
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
###### Aug03
14Sep99
###### 4Dun04 20DU1-04
5May04
26NOV03
29May03
18Dun04
###### 6Oct03 28Feb04 21Apr04
23D6C04
###### 17May04
6Dan04
###### 26Apr04 18May04 19May04
31D6C03
###### 26Apr03 8Apr04 30Apr02 lSep03
27Dun02
25NOV03
###### 2Apr04 21Apr04
30D6C03
###### 27Apr04
10Sep02


-----

6Dan04
13Aug
###### -04 lUan -05
33un
###### -05
7Feb
###### -05
5May
###### -05
23NOV
###### -04
28May
###### -04 203un -05 50ct -04 lApr -05 21Apr -05 27Apr -05
17May
###### -05 63an -05 25Apr -05
18May
###### -05
18May
###### -05
29Dec
###### -04 22Apr -04
8Apr
###### -05 28Apr -03 iSep -03
22Dec
###### -04
24N0V
###### -04 4Apr -05 4Feb -05
30Dec


-----

###### -04 27Apr -04
9Mar
###### -05 4:an -05
5Dan06
5Dan06
5Dan06
29Dec
###### -05
29Dec
###### -05
29Dec
###### -05
22Dec
###### -05
22Dec
###### -05
22Dec
###### -05
22Dec
###### -05
15Dec
###### -05
15Dec
###### -05
15Dec
###### -05
15Dec
###### -05
8Dec
###### -05 iDec -05 IDec -05 IDec -05 IDec -05
24N0V
###### -05
17N0V
###### -05
10Nov
###### -05
10Nov
###### -05
10NOV
###### -05
3Nov
###### -05


-----

###### 27Oct05 27Oct05 27Oct05 27Oct05 27Oct05 184
 US20050234
122
US20050233
###### 314
US20050232
895
US20050223
###### 427
US20050222
258
US20050220
###### 816
US20050215
###### 494 US20050214 890 US20050214
748
###### US20050214
747
US20050208
###### 066
US20050208
###### 060
US20050208
###### 020
US20050208
019
US20050203
038
US20050203
###### 024
US20050202
###### 415
US20050196
382
US20050196
381
US20050191
###### 620
US20050189
302
US20050187
192
US20050186
575
US20050182
243


-----

US20050181
357
US20050181
075
US20050176
661
US20050171
###### 044
US20050169
885
###### US20050164
167
###### UPrevention of and countermeasures against viral infection Sensitive and quantitative detection of pathogens by real-time nested PCR
 Anti-viral pharmaceutical compositions Modified polynucleotides for reducing off-target effects in RNA interference Pharmaceuticals comprising shikonins as active constituent
 Mutant viral nucleic acids and vaccine containing same
 Baicalin and its derivatives as a treatment for SARS coronavirus infection or other related infections Novel "Cleave-N-Read" system for protease activity assay and methods of use thereof Peptide-based diagnostic reagents for SARS Compositions and methods for analysis of target analytes Recombinant baculovirus and virus-like particle
 Vaccine composition
 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines Uses of interferons with altered spatial structure Modulation of ACE2 expression
 Peptides and methods for inducing cellular resistance to infection Replikin peptides and uses thereof
 Antiviral oligonucleotides targeting viral families
 Lentivirus vector-based approaches for generating an immune response to HIV in humans Particle on membrane assay system
 Viral inactivation using ozone
 Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses Corona-virus-like particles comprising functionally deleted genomes BOSCH BEREND 3.

Membrane scaffold proteins
###### High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) Pharmacological enhancement and manufacturing method of antiviral compound
 Antiviral oligonucleotides Oligonucleotide compound and method for treating nidovirus infections Recombinant super-compound interferon
 Method of discovery and development of broad-spectrum antiviral


-----

###### drugs Fauci/COVID-19 Dossier
BESTWICK RICHARD K.

WEI GUANGWEN
BUSCHER BENIAMIN A.
BAYBURT TIMOTHY H.
CHAN KWOK H.
GONG IIAO
DROPULIC BORO
BALLARD KARRI L.
KEYSER STEVEN A.
BOGOCH ELENORE S.
CHAN KWOK H
BAUDRY MICHEL
CHANG TSENG Y
DANIELZADEH ROBERT
CHAO YU-CHAN
###### Aventis Pasteur S.A.
BRICE GARY T
WEI GUANGWEN
SD Pharmaceuticals, Inc.
###### Dharmacon, Inc.
WANG FEIXIN
CHOKO CO., LTD.
###### Mar04 301un03
10D6C03
###### lApr04 21Feb03 31Mar04
10NOV03
26NOV03
12NOV03
###### 163an04
25NOV03
###### 22Sep04
12NOV03
28Aug03
###### 10Mar04
1D6C03
23D6C03
5Dec02
9Sep03
###### 27Feb04 17Mar04 20Feb04
17May02
###### 183un03 24Mar03
21NOV03
5Dec02
24D6C03
28Aug03
###### 283an04


-----

CC-BY-NC-SA
###### Dr. David E. Martin HMar
 -04 303un
 -04
3Dec

###### -04
22Dec

###### -04
14May

###### -05
31Mar

###### -04
8Nov

###### -04
23NOV

###### -04
8N0V

###### -04
 170ct
 -04
24N0V

###### -04
15N0V

###### -04
10NOV

###### -04
26Aug

###### -04
 10Mar
 -04 IDec
 -04
 43un
 -04 190ct
 -04

9Sep

###### -04
22Dec

###### -04 HOct
 -04 20Feb
 -04
30Dec

###### -03 113an
 -05 24Mar
 -04
21NOV

###### -03


-----

**I-*** **I** **I-*** **I** **NJ** **I** **NJ** **I** **I-*** **I** **I-*** **I** **OOI** **OOI** **NJ** **i** **NJ** **I** **NJ** **I** **NJ** **I** **NJ** **I** **NJ** **I** **NJ** **I** **NJO^O^O^NJNJNJh^i** **N>** **I** **N>** **I** **N>** **I**
**00®00®00®Ln®Ln®lH®lH®LH®lH®Ln®Ln®Ln®N>®N>®N>®N>®'X>®'X>®'X>®'X>OOO®®®00®00®Cri®N>®N>**
**>Ln>Ln>Ln>Ln>Lnrt)** **tn** c d u i c d u i c d **miouiiouiiouiiouiiouiiouiiouiiouiiouiiouiioo** **n** **n** **O** **O** **O** **tn** **।** **^** **>** **^** **□** **w** **7)**
**C** **C** **C** **C** **C** **"O** **"O** **"O** **"O** **CD** **CD** **CD** **CD** **CD** **CD** **CD** **CD** **CD** **CD** **CD** **r+** **r+** **r+** **n** **n** **n** **CD** **C** **CD** **CD**

**CTQ** **CTO** **CTQ** **CTQ** **CTO** **■O'O'O'O'O'O'O'O'O'O'O®®®r+r+r+** **Z3** **era** **n** **"O**

**UI** **UI** **UI** **©** **©** **©**

**UI** **UI** **UI**


-----

###### -05 HAug -05
4Aug
###### -05
4Aug
###### -05
28:11105

US20050163
648
US20050158
###### 411
US20050158
325
US20050153
912
US20050153
310
US20050148
658
US20050147
697
US20050142
536
US20050142
157
US20050139
808
US20050123
563
US20050119
###### 284
US20050119
251
US20050117
187
###### US20050114 910
US20050113
298
US20050112
559
US20050112
558
US20050112
555
US20050112
###### 554
US20050107
###### 324
US20050106
563
US20050101
581


-----

US20050100
885
US20050100
883
US20050100
612
US20050096
259
US20050095
618
US20050095
582

METHOD AND APPARATUS FOR STERILIZING AIR IN LARGE
VOLUMES BY RADIATION OF ULTRAVIOLET RAYS

26LIANG
MICHAEL Y.
###### Methods and apparatus to prevent, treat, and cure the symptoms of nauea caused by chemotherapy treatments of human cancers Immunomodulatory combinations
 Antiviral oligonucleotides targeting viral families
 Luciferase biosensor
 Method for preventing and treating severe acute respiratory syndrome Compositions and methods for reducing the transmissivity of illnesses
 Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS) Oxidative reductive potential water solution and methods of using the same Oxidative reductive potential water solution and process for producing same Lipoparticles comprising proteins, methods of making, and using the
same

###### ANTIVIRAL AGENTS AND METHODS OF USE
 Nicotinamide derivatives and their use as therapeutic agents
 Apparatus for forming nano-grating device Transgenic mice having a human major histocompatibility complex

(MHC) phenotype, experimental uses and applications

###### Receptor binding peptides derived from the SARS S protein Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS) Prognostic PCR assay for severe acute respiratory syndrome (SARS) The Chinese University of Hong Kong Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
 Modulation of CEACAM1 expression
 Epitope profiles of SARS coronavirus Therapeutic treatment methods 2 Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) Peptide-based diagnostic reagents for SARS
 Virucidal activities of cetylpyridinium chloride


-----

###### Neutrophil activation by immune response modifier compounds Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS) Compositions and methods for detecting severe acute respiratory syndrome coronavirus Fauci/COVID-19 Dossier
The Chinese University of Hong Kong
###### Diagnostic Hybrids, Inc.
CC-BY-NC-SA Dr. David E. Martin
AHLEM CLARENCE N.
BAKER BRENDA F.
CHANG TSENG Y.
###### ViraTox, L.L.C.
DEWHURST STEPHEN
HENG XU RUI
BENNETT C. F.
BUTLER BRAEDEN
HENSLEY CHARLES
ROSENBLOOM RICHARD A.
LAUE THOMAS
###### Oculus Innovative Sciences, Inc. Oculus Innovative Sciences, Inc.
DORANZ BENIAMIN J.
###### Wisconsin Alumni Research Foundation -
FINE RICHARD M.
CHEN YUNG-HSIN
AURIAULT CLAUDE
###### VAIL MARILYN L. Ian04
8D6C03
30D6C03
5Dec02
###### 10Oct03 53an04 6Feb03 30Apr03
30D6C03
30D6C03
###### 303U1-03
30Sep03
21Dec01
###### 17Mar04 303U1-03
15Sep03
29Sep03
24Sep03
3Sep03
###### 9-3U104 123U1-03 8Sep03
28Aug02
###### 28Apr03
12NOV03
7NOV03


-----

###### 31Oct03 293U1-03
3NOV03
###### 263an -04
27NOV
###### -04
30D6C
###### -04 12Sep -03 lOct -04 53an -04 14Dec -04 30Apr -04 llAug -04 43un -04 283U104
30Sep
###### -04
 63U104 17Mar -04
 23U104 13Sep -04 29Sep -04 23Sep -04
3Sep
###### -04 93U104 123U104
8Sep
###### -04
SDCC
###### -03 26Apr -04
12NOV
###### -03 10Sep -04
1NOV
###### -04 283U104
3NOV


-----

###### -03 283U105 21JU105
21311105
###### 143U105
143U105
73U105
73U105
###### 303U005 303un05
30311005
93UO05
23UO05
23UO05
23UO05
26May
###### -05
26May
###### -05
26May
###### -05
26May
###### -05
26May
###### -05
26May
###### -05
19May
###### -05
19May
###### -05
12May
###### -05
12May
###### -05
12May
###### -05
12May
###### -05
5May
###### -05
5May
###### -05
5May
###### -05 186
 US20050090
505
US20050085
529
###### US20050080 093 US20050075
307


-----

###### US20050074
743
###### US20050074
359
US20050071
892
US20050070
###### 460
US20050069
911
US20050069
869
US20050069
558
US20050069
555
US20050065
143
US20050059
578
US20050059
576
US20050059
072
US20050058
982
###### US20050054 644 US20050054 640
US20050053
###### 990
US20050051
###### 497
US20050048
###### 473
US20050048
###### 465
US20050048
072
US20050039
###### 220
US20050037
338
US20050036
951
US20050032
222
US20050031
###### 620
US20050031
592
###### 20Methods of reducing risk of infection from pathogens


-----

###### Prenylation inhibitors reduce host cell permissiveness to viral replication Methods of reducing risk of infection from pathogens Modulation of aminopeptidase N expression Method and composition for treating a biological sample Aircraft and passenger decontamination system Techniques and applications of establishment of SARS-CoV primate model
HOPKINS SAMUEL E.
BENNETT C. FRANK
CHAPMAN 1OHN
STERIS INC.
GAO HONG
###### Infection prophylaxis using immune response modifier compounds 3M Innovative Properties Company Proteome epitope tags and methods of use thereof in protein modification analysis
SARS nucleic acids, proteins, antibodies, and uses thereof
###### Crystals and structures of SARS-CoV main protease Thiosemicarbazones as anti-virals and immunopotentiators Pyridazine derivatives and their use as therapeutic agents Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents Targeted delivery of antiviral compounds through hemoglobin bioconjugates Selective modulation of TLR gene expression Modified small interfering RNA molecules and methods of use Hydrolytically-resistant boron-containing therapeutics and methods of use 1-Amino IH-imidazoquinolines Cleavage of RNA by restriction endonucleases Viral inactivation using ozone Enzymatic diagnostic test for SARS and other viral diseases Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer Immunostimulatory combinations and treatments Imageable animal model of SARS infection Method and means for detection of severe acute respiratory syndrome Methods of treating lung diseases Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases Combined cancer treatment methods using selected antibodies to aminophospholipids Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines Fauci/COVID-19 Dossier engeneOS, Inc.
AMBROSINO DONNA
BONANNO JEFFREY B.
BARSANTI PAUL A.
Xenon Pharmaceuticals Inc.
HE UN


-----

ADAMSON J. GORDON

3M Innovative Properties Company
###### Chiron Corporation
AKAMA TSUTOMU
GRIESGRABER GEORGE W.

ROBERTS RICHARD 3.
KEYSER STEVEN A.
ARAD DORIT
###### World Sense Technology Limited
3M Innovative Properties Company
XU MINGXU
TSENG KUO-TANG
###### Arizeke Pharmaceuticals., Inc.
BELLOTTI MARC
HUANG XIANMING
BRICE GARY L.
CC-BY-NC-SA Dr. David E. Martin
HOPKINS SAMUEL E.
###### Aug03 21Oct03 18Aug04 123U1-03 6Oct03 6Oct03 273un03
5Aug03
10May02
###### 4Aug03 253U1-03
27D6C02
###### 293U1-04
15Aug03
###### 30Apr98 17Sep04 253U1-03 153un04
3Sep04
###### 31Aug04 2Aug04 233un04 20Aug04 25Aug04 27May04
14Aug03
###### 93an04 293un00
15Aug03
13NOV03
18Aug
###### -04 21Oct -03
18Aug
###### -04


-----

12DU104
###### 60ct -03 60ct -03 253un -04
5Aug
###### -04
5Feb
###### -04
4Aug
###### -04
233U104
29Dec
###### -03
293U104
15Aug
###### -03
17May
###### -04
17Sep
###### -04
253U103
###### 153un -04
3Sep
###### -04
31Aug
###### -04

2Aug
###### -04 233un -04
20Aug
###### -04
25Aug
###### -04
27May
###### -04
14Aug
###### -03
93an
###### -04 213un -04
15Aug
###### -03
13N0V
###### -03
187
###### 28Apr05 21Apr05 14Apr05


-----

###### 7Apr05 7Apr05 7Apr05
31Mar
###### -05
31Mar
###### -05
31Mar
###### -05
31Mar
###### -05
31Mar
###### -05
31Mar
###### -05
 24Mar
 -05
 17Mar
 -05
 17Mar
 -05
 17Mar
 -05
 17Mar
 -05
 10Mar
 -05
 10Mar
 -05
 10Mar
 -05
 10Mar
 -05
3Mar
###### -05
3Mar
###### -05
3Mar
###### -05
 17Feb
 -05
 17Feb
 -05
 17Feb
 -05
 10Feb
 -05
 10Feb
 -05
 10Feb
 -05

US20050025
788
US20050025


-----

761
US20050020
###### 524
US20050019
###### 756
US20050015
847
###### US20050014 830 US20050014
752
US20050009
###### 110
US20050009
009
US20050008
535
###### US20050004 144 US20050004
071
###### US20050004
063
US20050003
340
US20050002
953
US20050002
941
US20050002
913
US20050002
901
US20040265
879
US20040265
###### 796
US20040265
367
US20040265
351
US20040259
###### 934
US20040259
803
US20040258
698
US20040253
###### 624
US20040253
328
US20040241
842
US20040237


-----

198
US20040235
952
###### Systemic delivery of non-viral vector expressing SARS viral genomic vaccine Anti-viral treatment methods using phosphatidylethanolaminebinding peptides linked to anti-viral agents Hematopoietic stem cell gene therapy Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis Compositions and methods for preventing infection Substances for breaking down conformation of microbes Prodrugs of heteroaryl compounds
 Methods of producing antibodies for diagnostics and therapeutics Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) Noble gas-chlorine mixture effective against micro organisms Combined use of IMPDH inhibitors with toll-like receptor agonists Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
 Assay system and methods for detecting SARS-CV SARS-coronavirus virus-like particles and methods of use Combinations and kits for cancer treatment using selected antibodies to aminophospholipids Hematopoietic stem cell gene therapy Compositions and methods for treating coronavirus infection and
SARS
###### Compositions for enhancing transport of molecules into cells Methods and kits for detecting SARS-associated coronavirus Liposomes coated with selected antibodies that bind to aminophospholipids Methods and compositions for enhancing immune response Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds Disease prevention by reactivation of the thymus Delivery of immune response modifier compounds Microporous materials, methods of making, using, and articles thereof Anti-atypical pneumonia decoction Stimulation of thymus for vaccination development Protecting shield for performing the insertion of a tube during emergency rescuing or anesthesia Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase Fauci/COVID-19 Dossier
4CH0U
GEORGE CHIN-SHENG
###### Board of Regents, The University of Texas System
Monash University
DE MEIRLEIR KENNY
HILDRETH 3AMES E.


-----

CHU SHU FANG
###### Koronis Pharmaceuticals, Incorporated
CHANG XIAO-IIA
CHAN KWOK HUNG
GLOBUS ALFRED R.
REGENTS OF THE UNIVERSITY OF CALIFORNIA
COMPER WAYNE D.
GUAN YI
AsiaGEN Corporation
HEROLD DENS
###### Board of Regents, The University of Texas System
Monash University
BLATT LAWRENCE M.
IVERSEN PATRICK L.
BRIESE THOMAS
HUANG XIANMING
KEDL ROSS M.
CARROLL STEVEN S.
Monash University
DING NAIYONG
DURTSCHI 1ACOB
HU XIN YUAN
Monash University
YANG JUI KUANG
###### Agouron Pharmaceuticals, Inc.
CC-BY-NC-SA Dr. David E. Martin
Dun04
15Aug03
###### 15Apr99 26May04 8Aug03 173U1-03 31Mar04 8-3U103 24Mar04 7-3U103 14Apr04 20Apr04 19May04 1-3U103 4May04
15Aug03
###### 15Apr99 30Mar04 29Apr04 233an04
15Aug03
###### 9Apr04 27Apr04 15Apr99 9Apr04 26May04 133un03 15Apr99


-----

###### 23un03 27Apr04 43un -04
15Aug
###### -03
30Dec
###### -03
26May
###### -04

8Aug
###### -03 43un -04
31Mar
###### -04
83U103
###### 24Mar -04
73U103
###### 14Apr -04 20Apr -04
19May
###### -04
13U103
4May
###### -04
15Aug
###### -03 18Apr -03
30Mar
###### -04 29Apr -04 233an -04
15Aug
###### -03

9Apr
###### -04 27Apr -04
30Dec
###### -03

9Apr
###### -04
26May
###### -04
213U103
30Dec
###### -03


-----

###### 23un -03 27Apr -04 188
3Feb
###### -05 3Feb -05 273an05 273an05 273an05 203an05 203an05 133an05 133an05 133an05 63an05 63an05 63an05 63an05 63an05 63an05 63an05 63an05
30Dec
###### -04
30Dec
###### -04
30Dec
###### -04
30Dec
###### -04
23Dec
###### -04
23Dec
###### -04
23Dec
###### -04
16Dec
###### -04
16Dec
###### -04
2Dec
###### -04
2Dec
###### -04
25NOV
###### -04

US20040235
###### 946 US20040235
047
###### US20040234


-----

###### 457
US20040229
828
US20040229
778
US20040229
219
US20040229
211
US20040220
139
###### US20040219
155
###### US20040214
785
###### US20040214 764 US20040213
779
###### US20040209 844 US20040208
873
###### US20040208
868
###### US20040204 420 US20040202 720 US20040191
833
###### US20040184 950
US20040180
380
US20040176
367
###### US20040175
378
###### US20040171
568
###### US20040171 086
US20040170
###### 965
US20040170
###### 959
US20040170
649
US20040170
###### 620 US20040167
161
###### Organosulphur prodrugs for the prevention and treatment of


-----

###### injectious diseases and pathologenic immune system response Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS)
 Methods of preventing and treating SARS using low pH respiratory tract compositions Antiviral oligonucleotides targeting RSV
 Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
 Method of inhibiting human metapneumovirus and human
 coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS) Sensitive diagnostic testing methodology using multiplex real time
PCR with one dye (MOD) and its use as in severe acute respiratory
###### syndrome (SARS) Inhibiting viral infections Selected immunoconjugates for binding to aminophospholipids Surface sanitizing compositions with improved antimicrobial performance
 Anti-viral treatment methods using phosphatidylethanolaminebinding peptide derivatives
 Methods for treating viral infections using immunoconjugates to aminophospholipids Compositions and methods for preventing infection
Human monoclonal antibodies against interleukin 8 (IL-8)
###### Selected antibody CDRs for binding to aminophospholipids
Compounds for modulating RNA interference
###### Delivery of immune response modifier compounds using metalcontaining particulate support materials Selective activation of cellular activities mediated through a
common toll-like receptor
###### Building decontamination with vaporous hydrogen peroxide Proteome epitope tags and methods of use thereof in protein modification analysis 1-Amino IH-imidazoquinolines Selected antibody compositions and methods for binding to aminophospholipids
 Antiviral oligonucleotides targeting HIV Selective modulation of TLR-mediated biological activity Mixed cell diagnostic systems Methods for identifying antiviral oligonucleotides Method of treating and preventing infectious diseases via creation of
a modified viral particle with immunogenic properties
240TT
DAVID M.
SIBER GEORGE R.
The Procter & Gamble Company
###### Replicor, Inc.
ELMALEH DAVID R.

GALLAHER WILLIAM R.
May04
20May03
###### 2Feb04
12Sep03
13May03


-----

###### 29Apr04
22YEUNG
WAH HIN ALEX
SCEUSA NICHOLAS A.
RAN SOPHIA

###### Xantech Pharmaceuticals, Inc.
HE DIN
RAN SOPHIA
HILDRETH DAMES E.
GENMAB A/S

###### Board of Regents, The University of Texas System
RANA TARIQ M.
3M Innovative Properties Company
3M Innovative Properties Company
STERIS INC.
###### engeneOS, Inc.
3M Innovative Properties Company
###### Board of Regents, The University of Texas System Replicor, Inc.
3M Innovative Properties Company
GOODRUM PATRICIA GAIL RAY
###### Replicor, Inc.
CHAM BILL E.
###### Selected antibody compositions for binding to aminophospholipids RAN SOPHIA Method of treating or inhibiting the development of brain inflammation and sepsis Fauci/COVID-19 Dossier
NOZAKI MASAKO
CC-BY-NC-SA Dr. David E. Martin
###### Aug03
5NOV03
15Aug03
###### 9Mar04
15Aug03
15Aug03
22Sep03
16D6C03
15Aug03
5Aug03
###### 9Apr04 24Mar04 293an04
13NOV03
###### 5Mar04 153U1-03
12Sep03
###### 27Feb04 30Mar04 HSep03 293un00 153U1-03
20May03
24May
###### -04


-----

20May
###### -03
2Feb
###### -04
12Sep
###### -03
13May
###### -03 29Apr -04
22Aug
###### -03
5Nov
###### -03
15Aug
###### -03
9Mar
###### -04
15Aug
###### -03
15Aug
###### -03
22Sep
###### -03
16Dec
###### -03
15Aug
###### -03
5Aug
###### -03
9Apr
###### -04 24Mar -04 293an -04
13N0V
###### -03
5Mar
###### -04
153U103
12Sep
###### -03 27Feb -04
30Mar
###### -04
12Sep
###### -03 203un -03
153U103
26NOV
###### -03


-----

25NOV

###### -04

25NOV

###### -04

25NOV

###### -04

18N0V

###### -04

18N0V

###### -04

18N0V

###### -04

18N0V

###### -04

4N0V

###### -04

4N0V

###### -04
 28Oct04 28Oct04 28Oct04 21Oct04 21Oct04 21Oct04 14Oct04 14Oct04
30Sep
###### -04

23Sep

###### -04

16Sep

###### -04

9Sep

###### -04

9Sep

###### -04

2Sep

###### -04

2Sep

###### -04

2Sep

###### -04

2Sep

###### -04
2Sep

###### -04

2Sep

###### -04

26Aug

###### -04

189

US20040167
073
US20040162


-----

309
US20040162
###### 254
US20040162
253
US20040147
543
US20040147
###### 440
US20040142
852
US20040142
322
US20040141
###### 950
US20040138
187
US20040131
622
US20040131
621
US20040131
###### 610
US20040081
667
US20040077
587
US20040071
757
US20040071
709
US20040067
###### 920
US20040009
943
US20040009
245
US20040009
152
US20040005
998
###### US20030224
353
US10669245
###### iCasein derived peptides and uses thereof Methods and compositions related to IRM compounds and toll-like receptor 8
 Antiviral oligonucleotides targeting HSV and CMV Antiviral oligonucleotides targeting HBV Aryl substituted imidazoquinolines Compositions comprising cell-impermeant duramycin derivatives Composition and its therapeutic use Continuous non-radioactive polymerase assay


-----

###### Immunostimulatory combinations Therapeutic treatment methods Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids Combinations and kits for treating viral infections using antibodies to aminophospholipids Methods for treating viral infections using antibodies to aminophospholipids Compositions and methods for treating and preventing infection 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections Inhalation antiviral patch
Chay 13 Medical Research Group N.V.
3M Innovative Properties Company
###### Replicor, Inc. Replicor, Inc.
3M Innovative Properties Company
###### Board of Regents, The University of Texas System
AL SARI AHMAD M. H.
###### Schering Corporation
3M Innovative Properties Company
AHLEM CLARENCE N.

###### Board of Regents
RAN SOPHIA
RAN SOPHIA
HILDRETH 3AMES E.

LACOLLA PAOLA
ROLF DAVID
###### Corona-virus-like particles comprising functionally deleted genomes BOSCH
BEREND-3AN
###### Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof Pathogen vaccines and methods for using the same
 Methods and apparatus to prevent, treat and cure infections of the
human respiratory system by pathogens causing severe acute
###### respiratory syndrome (SARS)
 Materials and methods for prevention and treatment of RNA viral diseases Method for preparation of large volume batches of poly-lCLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
 Antisense antiviral agent and method for treating ssRNA viral infection Certain (2S)-N-[(IS)-l-cyano-2-phenylethyl]-l,4-oxazepane-2carboxamides dipeptidyl peptidase 1 inhibitors
US10666592 RNA targeting methods and compositions
US10662485 Bioagent detection oligonucleotides
###### US10662464 Methods of analyzing virus-derived therapeutics
US10662423 Compositions for and methods of identifying antigens
###### Mar00 12Feb04
12Sep03
12Sep03


-----

18Dec03
15Aug03
9May02
###### 7Oct03
30Dec03
28Aug03
15Aug03
15Aug03
15Aug03
###### 223ul-03 273un03 103un03
17May01
173OHNSON
KEITH A.
###### 3un03 12Inex Pharmaceuticals Corporation VAIL MARILYN L.
BEHERA ARUNA K.
ONCOVIR, INC.
IVERSEN PATRICK L.
ASTRAZENECA AB
###### Salk Institute for Biological Studies IBIS BIOSCIENCES, INC.
 American International Biotechnology, LLC President and Fellows of Harvard College
May03
2May03
###### 30Apr03 1-3U103 24Apr03 243anl4 22Augl7 27Decll 313U1-15 21Feb06 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### IMar -04 12Feb -04
12Sep
###### -03
12Sep
###### -03
18Dec
###### -03 ISAug -03
29May
###### -03


-----

###### 70ct -03
30Dec
###### -03
28Aug
###### -03 ISAug -03 ISAug -03 ISAug -03
223U103
###### 273un -03 103un -03 14Apr -03 173un -03
12May
###### -03
2May
###### -03 30Apr -03 13ul03 24Apr -03 19Mar -19
31Dec
###### -18 13Apr -18 293ull6 12Feb -18
26Aug
###### -04
19Aug
###### -04
19Aug
###### -04
19Aug
###### -04 293ul04 293ul04 223ul04 223ul04 223ul04
153U104
###### 83ul04


-----

8DU104
8DU104
###### 29Apr04 22Apr04 15Apr04 15Apr04 8Apr04 15:an04 15:an04 15:an04
8Dan04
4Dec

###### -03
 23un20
26May

###### -20

26May

###### -20

26May

###### -20

26May

###### -20
 190
 US10660824
 Devices^ system and method to control the delivery of oral medications to ensure they are efficacious , taken as prescribed^
and to avoid unwanted side effects
US10655108 Cell-derived viral vaccines with low levels of residual cell DNA
US10655099 Animal protein-free media for cultivation of cells
US10654898
US10647998
###### Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof Tissue preferential codon modified expression cassettes^ vectors containing same, and uses thereof
US10647781 Generation of binding molecules
US10647758
US10646563
US10646438
US10641707
###### Compositions comprising AAV expressing dual antibody constructs
and uses thereof

###### Vaccines and immunotherapeutics using IL-28 and compositions and methods of using Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector
US10640788 CRISPR-related methods and compositions with governing gRNAs
US10640785 Virus vectors for highly efficient transgene delivery
US10640776
###### Method for propagating adenoviral vectors encoding inhibitory gene products
US10640763 Molecular indexing of internal sequences


-----

US10633447 Soluble engineered monomeric Fc
US10632133 Anti-viral azide containing compounds
US10626415 Method of increasing the function of an AAV vector
US10626379 Production of viruses in cell culture
###### US10619186 Methods and compositions for library normalization
US10619153 TAL effector-mediated DNA modification
US10617677 Nuclear transport modulators and uses thereof
###### US10614284
US10611827
###### Descriptive measurements and quantification of staining artifacts for in situ hybridization
Non-human primate-derived pan-ebola and pan-filovirus monoclonal
###### antibodies directed against envelope glycoproteins US10610584 Reverse genetics systems
US10610571
###### Cytokine conjugates for the treatment of proliferative and infectious diseases
US10605808 Antibody producing non-human animals
US10604729 Liquid loading composition., method of making and use thereof
###### US10604574 Oncolytic viral delivery of therapeutic polypeptides
US10604561
###### Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10604549 Adenovirus comprising an albumin-binding moiety

###### Fauci/COVID-19 Dossier UNot
 Available Seqirus UK Limited Baxalta GmbH
The United States of America, as represented by the
###### Secretary, Department of Health and Human Serices
The Trustees of the University of Pennsylvania
###### Merus N.V.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
###### Gen-Probe Incorporated
 Editas Medicine, Inc.
The Children's Hospital of Philadelphia
###### GenVec, Inc. Cellular Research, Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services LIFE TECHNOLOGIES CORPORATION

The Trustees of the University of Pennsylvania
###### Commonwealth Scientific and Industrial Research Organisation Cellular Research, Inc. Iowa State University Research Foundation, Inc. Biogen MA Inc.
 Ventana Medical Systems, Inc.

INTEGRATED BIOTHERAPEUTICS, INC.
###### Seqirus UK Limited
SYNTHORX, INC.


-----

###### Merus N.V.
DEVMAR PRODUCTSj LLC
ONCORUS, INC.
###### Agency for Science, Technology and Research

FUNDACIA" INSTITUT D'INVESTIGACIA" BIOMA'DICA DE
BELLVITGE (IDIBELL)
CC-BY-NC-SA Dr. David E. Martin
###### AuglS
1NOV05
###### 29Oct04 201anl5 29Aprl3 26Sepll 13Mayl4 4Apr08 263U1-10 24Febll
7NOV13
22NOV11
10NOV05
###### 31Mayl6 16Marl2 283U1-10 7Apr05
24NOV15
###### USeplS
10D6C09
###### 9Mayl2 26Mayl5 280ctl4 313U1-09 3Augl7 273un08 8Sepl6 303unl6 16Sepl6 30Aprl4 HAug -16
 INov
 -06
 29Oct
 -18
 203an
 -16 203un
 -17

22NOV

###### -17
23U119
###### USep -18

10May

###### -17


-----

**00**

                                 - C i—I                                  - -P -P C -P CL C

**CL** **03** **O** CJ 05 CL -P Z5 O U U C CL 05 U di CL

O n O) 0J kD u I—) o in o hs ^SXOC0^^<LnH
r^T-iLnT-iLnr-iOr-ir^ HHrxHkOrlnHrx

**i** **Rx** **i** **rd** **i** **CH** **i** **i** **CXI** **i** **CXI** **i** **00** **i** **LH** **i** **rd** **CXI** **i** **CXI** **i** **rd** **I** **i** **CXI** **i** **CXI** **i** **CXI** **i** **rd** **I** **m** **i** **rd** **fM** **i** **rd** **।** **’-l** **1**


-----

12May

###### -20

12May

###### -20

12May

###### -20
5May
###### -20
5May
###### -20
5May
###### -20
5May
###### -20
5May
###### -20
 28Apr20 28Apr20 21Apr20 21Apr20 14Apr20 14Apr20 14Apr20 7Apr20 7Apr20 7Apr20 7Apr20
3 IMar
###### -20
3 IMar
###### -20
3 IMar
###### -20
3 IMar
###### -20
3 IMar
###### -20
 US10603356
 Compositions and method for treatment of inflammatory bowel disease
US10603299 Prevention and treatment of viral infections
###### US10597736 Compositions and methods for detecting viruses in a sample US10596264 Peptides with viral infection enhancing properties and their use
US10596197
Red blood cell membrane-derived microparticles and their use for

###### the treatment of lung disease US10591714 Endoscopic apparatus for thermal distribution monitoring
US10590435
###### Adeno-associated virus (AAV) serotype 8 sequences^ vectors
 containing same, and uses therefor
US10590413 Chiral control
US10590112 Dihydropyrimidinyl benzazepine carboxamide compounds
###### US10588966 Methods and compositions for inhibiting Akt3 US10583086 Technology for preparation of macromolecular microspheres


-----

US10577375
###### Derivatives of porphyrins, their process of preparation and their use for treating viral infections US10570416 TC-83-derived alphavirus vectors, particles and methods
US10570209
###### Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies US10564160 Antibody-secreting cell assay
US10564152
###### Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets US10563224 Replication defective adenovirus vector in vaccination US10563154 Disinfecting aqueous foam, process for preparing same and use thereof
US10562861 Carboxylic acid compounds
US10561743 AAV vectors targeted to the central nervous system
US10561722 Methods and compositions for enhancing immune responses
US10561126
###### Genetically modified non-human animals and methods of use thereof US10557136 In vivo delivery of oligonucleotides
US10557119 Erythroid cells comprising phenylalanine ammonia lyase
US10555993 Dimethyl fumarate and vaccination regimens
US10550378
###### US10550174 Composition comprising a gene vector that selectively depletes P16 positive senescent cells
 Amino acid sequences directed against envelope proteins of a virus
and polypeptides comprising the same for the treatment of viral
###### diseases
US10548971 MERS-CoV vaccine
US10548959
###### Compositions and methods for modified dendrimer nanoparticle delivery
2THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA
###### Not Available Washington University Centre National de la Recherche Scientique University of Pittburgha€JJOf the Commonwealth System of Higher Education
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
###### INSTITUTE
The Trustees of the University of Pennsylvania
WAVE LIFE SCIENCES LTD.
###### Hoffmann-La Roche Inc. Augusta University Research Institute, Inc. Ansun Biopharma, Inc.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
ALPHAVAX, INC.
###### GITR, Inc.
MABTECH AB


-----

The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Etubics Corporation
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX
ENERGIES ALTERNATIVES
###### Sumitomo Dainippon Pharma Co., Ltd.
The University of North Carolina at Chapel Hill
###### Bavarian Nordic A/S Institute for Research in Biomedicine (IRB) Oncolmmunin Inc.

RUBIUS THERAPEUTICS, INC.
###### Biogen MA Inc. Kythera Biopharmaceuticals, Inc.
 Ablynx N.V.
 INOVIO PHARMACEUTICALS, INC.
 Massachusetts Institute of Technology
 Junll 21unl6 2913016 30Junll
7NOV13
###### 7Sepl6
17D6C01
###### 131U1-12 93unl7 15Janl6 2413006 30Octl5
18Msy04
###### 25M8r05
28Aug08
###### ISeplS 24Augl2
161U015
###### 18Msyl2
21NOV14
###### 3Sepl4 13Aprl5 12Decll
18NOV13
14M8014
###### 17Aprl2
51UO08
29NOV13
###### 23Sepl6 21Apr
 -16
31U119
###### 27130
 -17
 281uo
 -12
 lluo
 -18


-----

31May
###### -17
26Sep
###### -18 17Mar -17
7Dec
###### -18
6Feb
###### -19
25Sep
###### -17 280ct -16 HAug -16 283un -18
28Aug
###### -09
8Aug
###### -16 15Feb -17 153un -16 230ct -18 133un -19
3Sep
###### -15 16Apr -18
12Dec
###### -12
10May
###### -19 23Apr -19 103un -19 170ct -17 293un -18
23Sep
###### -16 Fauci/COVID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
192
3 IMar
###### -20


-----

3 IMar
###### -20 24Mar -20 24Mar -20 24Mar -20
 17Mar -20
 17Mar -20
 17Mar -20
 17Mar -20
 17Mar -20
 10Mar -20
3Mar
###### -20
 25Feb -20
 25Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 18Feb -20
 llFeb -20 llFeb
 -20 llFeb -20 4Feb -20 4Feb -20 4Feb
 -20


-----

###### 4Feb
 -20
 16US10544405
 Cas9-nucleic acid complexes and uses related thereto
US10544399 Highly efficient influenza matrix (Ml) proteins
US10544193
###### Compositions and methods for treating diseases by inhibiting
exosome release
Emory University
###### Novavax, Inc.
MOREHOUSE SCHOOL OF MEDICINE
US10544108 Hydrazide containing nuclear transport modulators and uses thereof
###### Karyopharm Therapeutics Inc.
US10544102
###### Benzazepine dicarboxamide compounds with secondary amide function
US10543485 Slip chip device and methods
US10543269 hMPV RNA vaccines
US10539488 Sample fixation and stabilisation
US10538558 Inhibition of TCR signaling with peptide variants
###### US10538554 Peptides and uses therefor as antiviral agents
US10533021 Boron-containing small molecules
US10532111
###### Recombinant adeno-associated virus capsids resistant to preexisting
human neutralizing antibodies
###### US10532110 AAV vectors targeted to the central nervous system
US10532107 Modified virus-like particles of CMV
US10532067 Delivery of RNA to trigger multiple immune pathways
US10527551
###### Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use US10526596 Purification of nucleic acids using metal-titanium oxides
US10526295 Nuclear transport modulators and uses thereof
US10526292
###### Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
US10526283 Prodrugs of dithiol mucolytic agents
###### US10525120 Methods and compositions for live attenuated viruses
US10525049 Specific Akt3 inhibitor and uses thereof
US10519130
US10519129
US10519128
US10519127
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
US10517947 Methods for preparing squalene
US10517923 Immunosuppressive agents and their use in therapy
US10517881 Pharmaceutical compositions and methods


-----

US10513508
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
###### Fauci/COVID-19 Dossier Hoffmann-La Roche Inc. University of Chicago ModernaTXj Inc.
RNASSIST LTD.
SIGNABLOK, INC
VIRAMATIX SDN BHD
###### Anacor Pharmaceuticals, Inc.
The Board of Trustees of the Leland Stanford lunior
###### University
The University of North Carolina at Chapel Hill
###### SAIBA GMBH GlaxoSmithKline Biologicals S.A. Baxalta GmbH Abbott Molecular Inc. Karyopharm Therapeutics Inc. Parion Sciences, Inc.
PARION SCIENCES, INC.
TAKEDA VACCINES, INC.
###### Augusta University Research Institute, Inc.
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc.
NOVARTIS AG
###### Norwegian University of Science and Technology
POP TEST ONCOLOGY LLC
FORMA Therapeutics, Inc.
CC-BY-NC-SA Dr. David E. Martin
###### Ianl3 llJul-03 19Decl6 293U1-11 19Mayl7 24Mar09 22Octl5 lMarl3
30Sep09
27NOV15
###### 203un07 16Febl6
21NOV14
###### 220ctl4 6-3U110 30Decl3 143U1-15 31Decl5 29Mayl2 30Aprl5 6Apr07 153anl6


-----

###### 5Febl5 5Febl5 5Febl5 5Febl5 12Mayl0
6NOV13
###### 3Augl5 5Febl5 153an -14 22Mar -18 93ull8
28NOV
###### -18
13N0V
###### -18
25May
###### -16 28Mar -19

14Aug
###### -17 220ct -18
28NOV
###### -16
28Sep
###### -17

18Aug
###### -17

20Nov
###### -15 20Oct -15 50ct -17
18Dec
###### -14 53ull9
30Dec
###### -16
20Dec
###### -17
2May
###### -16 223ull6
20May
###### -19
2Nov
###### -18
2Nov
###### -18
2Nov


-----

###### -18

2Nov

###### -18

14Dec

###### -17

6Nov

###### -14
 Sian
 -19

2Nov

###### -18

193
###### 281an20 281an20 281an20 281an20 281an20 281an20 281an20 211an20 211an20 211an20 141an20 141an20 141an20 141an20 141an20 71an20 71an20 71an20 71an20 71an20 71an20 71an20
31Dec
###### -19
31Dec
###### -19
31Dec
###### -19
31Dec
###### -19
31Dec
###### -19
31Dec
###### -19
31Dec
###### -19

24Dec

###### -19

US10513507

###### US10512684 Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors


-----

###### Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
US10512669 Blockade of inflammatory proteases with cyclic peptides
US10512665 Methods and compositions related to inhibition of viral entry
US10508098
###### Quinazolinones and azaquinazolinones as ubiquitin-specific protease
7 inhibitors
###### US10507244 Anti-TIGIT antigen-binding proteins and methods of use thereof
US10503347
###### System and method for detectings collectings analyzings and communicating event-related information
US10501733 Polypeptide assemblies and methods for the production thereof
US10501527
###### Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US10501507 Griffithsin mutants
US10501412 Conjugates of cell binding molecules with cytotoxic agents
US10500272
###### Manufacture of surfactant-containing compositions with enhanced stability
US10500267 Influenza virus vectors and uses therefor
US10495640
US10494420
US10488353
###### Exosome-mediated diagnosis of hepatitis virus infections and diseases Mast cell stabilizers for treatment of hypercytokinemia and viral infection
 Apparatus and system for performing thermal melt analyses and amplifications 5FORMA Therapeutics, Inc. Bavarian Nordic A/S
The Regents of the University of California
###### UNIVERSITY OF UTAH RESEARCH FOUNDATION
FORMA Therapeutics, Inc.
###### Potenza Therapeutics, Inc. Georgetown University University of Utah Research Foundation
Emerge Therapeutics, Inc.
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
HANGZHOU DAC BIOTECH CO., LTD.
NOVARTIS AG
###### FluGen, Inc.
MOREHOUSE SCHOOL OF MEDICINE
Emerge Therapeutics, Inc.
GEN-PROBE INCORPORATED
###### US10487350 Methods for diagnosing infectious diseases using adsorption media ExThera Medical Corporation
US10487332 Immunisation of large mammals with low doses of RNA
US10487081 Guanidine substituted imidazo[4,5-c] ring compounds
US10485883
###### Adeno-associated virus (AAV) clades, sequences, vectors containing


-----

same, and uses therefor
US10485861 Nanoparticle-based compositions
###### US10485856 Carbon nanotube compositions and methods of use thereof
US10485761 Irradiated biodegradable polymer microparticles
US10479996
###### Antisense antiviral compound and method for treating ss/RNA viral infection
US10479781 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US10476825 RNA targeting methods and compositions
US10472647 Primary mesenchymal stem cells as a vaccine platform
###### US10472420 Immune response modifier conjugates
US10472332 Antiviral compounds and methods
US10471408 Microspotting device
###### GlaxoSmithKline Biologicals SA
3M Innovation Properties Company
The Trustees of the University of Pennsylvania
###### Massachusetts Institute of Technology Yale University
GLAXOSMITHKLINE BIOLOGICALS, S.A.
###### Sarepta Therapeutics, Inc. Neuprozyme Therapeutics APS Salk Institue for Biological Studies
The Administrators of the Tulane Educational Fund
3M Innovative Properties Company
###### Biotron Limited BioFire Diagnostics, LLC FeblS 26Sepl4 23unll 8Feb07 SFeblS lOctlS 25Feb08 27Febl5 8Sepl6 10Febl5 123U1-12 2Decl4 17Marl4 6Oct08 8Sepl6 313U1-12
8NOV13
###### 6-3U110 31Augl5
30Sep03
###### 14Marl3 19Mar08 243anl0 16Sep04 SMarlS 22Augl7 21Decl2 22Feb06


-----

###### 263un03 18Aprl2 Fauci/COVID-19 Dossier llDec -17
25Sep
###### -15 Hun -12 2Iun -16
2NOV
###### -18 19Jun -17 27JU117 29Feb -16
7Sep
###### -17 10Feb -16
123U112
###### 12Mar -19
21Aug
###### -17
13Dec
###### -16
15NOV
###### -18 23Feb -17 16Oct -15
63U111
###### 22Oct -18 15Feb -17 14Mar -14 17Mar -17
16May
###### -18
6NOV
###### -14 4Mar -16 27Mar -18
15NOV


-----

###### -13 203an
 -15
23May
###### -17
53an
###### -17
24Dec
###### -19
24Dec
###### -19
24Dec
###### -19
24Dec
###### -19
17Dec
###### -19
17Dec
###### -19
10Dec
###### -19
10Dec
###### -19
10Dec
###### -19
10Dec
###### -19
10Dec
###### -19
10Dec
###### -19
10Dec
###### -19
3Dec
###### -19
3Dec
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
26NOV
###### -19
19N0V


-----

###### -19

19N0V

###### -19

12N0V

###### -19

12N0V

###### -19

12N0V

###### -19

12N0V

###### -19

12N0V

###### -19

CC-BY-NC-SA
###### Dr. David E. Martin 194

US10471141

US10471140
US10471063
US10466245
###### Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity Composition for enhancing induction of humoral immunity., and vaccine pharmaceutical composition Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist Covalently linked thermostable kinase for decontamination process validation
US10464988 Antibody/T-cell receptor chimeric constructs and uses thereof
US10464975 Stabilized anti-microbial peptides
US10464955 Charged linkers and their uses for conjugation
###### US10464060 Loading vials
US10463723 Methods and compositions for intranasal delivery
US10463615
###### Circulation of components during microfluidization and/or homogenization of emulsions
3NITTO
DENKO CORPORATION
NOTTO DENKO CORPORATION

###### Verona Pharma PLC
The Secretary of State for Health
EUREKA THERAPEUTICSj INC.
###### Dana-Farber Cancer Institute, Inc.
HANGZHOU DAC BIOTECH CO., LTD.
###### BioFare Diagnostics, LLC Shin Nippon Biomedical Laboratories, Ltd.
NOVARTIS AG
###### US10457974 Methods for diagnosing infectious diseases using adsorption media ExThera Medical Corporation
US10457901 Cleaning composition, method of making and use thereof
###### US10456464
US10450620
US10450383
US10443049


-----

###### Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug Cell-free nucleic acids for the analysis of the human microbiome and components thereof Carbonic anhydrase IX (G250) antibodies and methods of use thereof Active low molecular weight variants of angiotensin converting
enzyme 2 (ACE2)
US10442853 Antibodies and processes for preparing the same
US10434158 Combination of vaccination and inhibition of the PD-1 pathway
###### US10434116 Methods of treating coronavirus infection
US10428128
US10428102
US10428083
###### Helix-grafted proteins as inhibitors of disease-relevant proteinprotein interactions
 Glycolipids and pharmaceutical compositions thereof for use in therapy Heterocyclylmethyl-thienouracile as antagonists of the adenosineA2B-receptor
US10428027
###### Sulfinylphenyl or sulfonimidoylphenyl benzazepines
US10426737 Lipids and lipid compositions for the delivery of active agents
US10421991 Rapid epidemiologic typing of bacteria
US10421962
###### Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof DevMar Products^ LLC
NITTO DENKO CORPORATION
The Board of Trustees of the Leland Stanford lunior
###### University
DANA-FARBER CANCER INSTITUTE, INC.
###### Northwestern University
TAIGA BIOTECHNOLOGIES, INC.
###### CureVac AG United States Government as represented by the Secretary, Department of Health and Human Services Colorodo State University Research Foundation
THE UNIVERSITY OF NOTTINGHAM
BAYER PHARMA AKTIENGESELLSCHAFT
###### Hoffmann La-Roche Inc. Novartis AG BioFire Diagnostics, LLC
 Quark Pharmaceuticals, Inc.
US10420837 Vaccine pharmaceutical composition for transdermal administration
NITTO DENKO CORPORATION
US10420685 Mobile clinics
US10416171 Influenza potency assays
US10416161
###### Exosome-mediated diagnosis of hepatitis virus infections and diseases
 Fauci/COVID-19 Dossier Baylor College of Medicine Seqirus UK Limited
MOREHOUSE SCHOOL OF MEDICINE


-----

CC-BY-NC-SA Dr. David E. Martin
###### Sepl4 4Augl4 ISMarlB 20Feb08 230ctl5 2-JU115 28Febl4
10NOV11
###### 15Aprl0
3Dec09
8NOV13
###### 8Sepl6 4Augl4
7NOV13
###### 2Dec05 243anl7
16May08
###### 22Febl3 7Aprl4
7N0V14
###### 4Aprl4 26Marl5 17Sepl5 19Decl3
19May08
###### 12Sepl2 20ctl4
12N0V14
###### 7-JU115 6Oct08
2Sep

###### -15
 18Apr
 - 19
53un
###### - 17 83ull6
4Sep

###### - 18
 1JU116 28Feb
 - 14

9Nov

###### - 12
 14Mar
 - 13 263un
 - 17

2Nov

###### - 16

19Sep

###### - 18

4Aug


-----

###### -15
7Nov
###### -14
9May
###### -17
241 an
###### -18
23Aug
###### -16
7Feb
###### -18
7Apr
###### -15
9Nov
###### -15
7Apr
###### -15 21Mar -16
8Mar
###### -18
17Dec
###### -14
11N0V
###### -15 15Feb -17 lOCt -15
11NOV
###### -15
71U116
20Sep
###### -16
195
12NOV
###### -19
12NOV
###### -19
12NOV
###### -19
5Nov
###### -19
5Nov
###### -19
5Nov
###### -19
5Nov
###### -19
5Nov
###### -19
5Nov
###### -19
5Nov


-----

###### -19
 290ctl9 290ctl9 290ctl9 220ctl9 220ctl9 150ctl9 150ctl9 80ctl9 80ctl9 10ctl9 10ctl9 10ctl9 10ctl9 10ctl9
24Sep

###### -19

24Sep

###### -19

24Sep

###### -19

24Sep

###### -19

17Sep

###### -19

17Sep

###### -19
 3US10414800
 Methods for producing a depsipeptide
US10414779
US10407492
US10407472

Fused [lJ2]imidazo[4J5-C] ring compounds substituted with
###### guanidino groups Amino acid sequences directed against envelope proteins of a virus
and polypeptides comprising the same for the treatment of viral
###### diseases
 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
US10407431 Compounds and compositions as toll-like receptor 7 agonists
US10407405 Nuclear transport modulators and uses thereof
US10406229 Methods and compositions related to inhibition of viral entry
US10406177 Modified cells and methods of therapy
US10406142
###### US10400274 Hydrazino lH-imidazoquinolin-4-amines and conjugates made therefrom
 Fluorogenic probes and their use in quantitative detection of target
RNA sequences
US10400225 TAL effector-mediated DNA modification
###### US10400024
US10399963
###### Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides


-----

###### Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US10399941 Conjugates of cell binding molecules with cytotoxic agents
US10398795 Decontamination device and method using ultrasonic cavitation
US10393633 Sample fixation and stabilisation
US10392613 Purification of nucleic acids using copper-titanium oxides
US10391188 Decontamination device and method using ultrasonic cavitation
US10391167 Mucosal vaccine composition
###### US10391160 Dimethyl fumarate and vaccination regimens
US10385320
US10385119
US10383938
###### Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism Compositions comprising AAV expressing dual antibody constructs
and uses thereof
###### Lipidated immune response modifier compound compositions, formulations, and methods
US10383935 Methods of making and using live attenuated viruses
US10383852 Prevention and treatment of viral infections
###### NovoBiotic Pharmaceuticals, LLC
3M Innovative Properties Company
###### Ablynx N.V.
Spogen Biotech Inc.
###### Novartis AG Karyopharm Therapeutics Inc. UNIVERSITY OF UTAH RESEARCH FOUNDATION Intima Bioscience, Inc.
3M Innovative Properties Company
3an Biotech, Inc.
###### Iowa State University Research Foundation, Inc.
SANQUIN REAGENTS B.V.
###### Karyopharm Therapeutics Inc.
HANGZHOU DAC BIOTECH CO., LTD.
TOMI ENVIRONMENTAL SOLUTIONS, INC.
RNASSIST LTD.

ABBOTT MOLECULAR INC.
TOMI ENVIRONMENTAL SOLUTIONS, INC.
NITTO DENKO CORPORATION
###### Biogen MA Inc.

The Board of Trustees of the Leland Stanford lunior
###### University Trustees of the University of Pennsylvania
3M Innovative Properties Company
###### Regents of the University of Minnesota Not Available
US10378008 Method and apparatus for automated processing of pooled samples GEE
BLUT MBH
US10378002 Replication conditional virus that specifically kills senescent cells
US10377773
###### Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10377767 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
###### Kythera Biopharmaceuticals, Inc.


-----

FORMA Therapeutics., Inc.
FORMA Therapeutics, Inc.
###### Decl2 26Augl6 5Iun08 17Sepl4 lMayl4 21Junl3 28Marll 31JU1-15 33unll 183unl6
10D6C09
###### 63unl4 3-JU113 12JU1-12 29Decl7 !Marl3 143U1-15 29Decl7 30ctl3 14Marl4 2Decl5 13Mayl4 17Augl0 23Sepl5 23unl6 6Augl4 17Aprl2 SFeblS SFeblS Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 153un -16 lAug -17 17Oct -17
14D6C
###### -17 27Feb -18 173U117
2Mar
###### -17
29Aug
###### -16
6Mar
###### -17 163un -17
21Aug


-----

###### -17
5Dun
###### -15
4Dec
###### -17 16Apr -14
29Dec
###### -17
30May
###### -17 13JU116 llSep -18 20ct -14 13Mar -15
2Dec
###### -16 150ct -18 243ull8 310ct -17
27NOV
###### -18
5Aug
###### -15 63ull8 27Feb -18 iMar -18
17Sep
###### -19
17Sep
###### -19
10Sep
###### -19
10Sep
###### -19
10Sep
###### -19
10Sep
###### -19
10Sep
###### -19
10Sep
###### -19
10Sep
###### -19
3Sep
###### -19


-----

3Sep
###### -19
3Sep
###### -19
3Sep
###### -19
3Sep
###### -19
3Sep
###### -19

27Aug

###### -19

27Aug

###### -19

27Aug

###### -19

27Aug

###### -19

27Aug

###### -19

20Aug

###### -19

20Aug

###### -19

20Aug

###### -19

20Aug

###### -19

20Aug

###### -19

13Aug

###### -19

13Aug

###### -19

13Aug

###### -19

13Aug

###### -19
 196
 US10377760
 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
US10370625 Cleaning composition, method of making and use thereof
US10370455
###### Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
30FORMA
###### Therapeutics, Inc.
DEVMAR PRODUCTS, LLC
IMMUNEXT, INC.
US10370338 Benzazepine dicarboxamide compounds with tertiary amide function
###### Hoffmann-La Roche Inc.
US10369219
US10369216


-----

###### Composition for enhancing induction of humoral immunity., and vaccine pharmaceutical composition Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10369205 Immunomodulatory compositions and methods of use thereof
###### US10369204 Molecular vaccines for infectious disease
US10363303 Microneedle compositions and methods of using same
US10363282 Analogs of C5a and methods of using same
US10363247

###### (Sj E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3methylpyrrolidine-l-carbonyl)p henyl-7-(4-fluorophenyl)benzofuran2-yl)methyl)acrylamide for the treatment of cancer
US10358481 Engineered antibody constant domain molecules
US10357568 Adjuvant nanoemulsions with phospholipids
NITTO DENKO CORPORATION
###### CureVac AG Not Available
Dako Denmark A/S
VERNDARIj INC.

###### Board of Regents of The University of Nebraska Decl4 8Sepl6 5Decl4 23Mayl6 4Augl4 lAprl4 73anl4 2Oct08 113anl6 293unl0 ISKaryopharm Therapeutics Inc. AuglS
The
###### United States of America, as represented by the Secretary, Department of Health and Human Services
GLAXOSMITHKLINE BIOLOGICALS S.A.
US10357562 Immunoprotective primary mesenchymal stem cells and methods
###### Autoimmune Technologies, LLC US10357510 Metal nanoclusters and uses thereof
US10351571
###### Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors
US10350255 Polygonum cuspidatum extracts
###### US10344320 Capacitive liquid crystal biosensors
US10344263 Synthetic membrane-receiver complexes
US10344261 Immunomodulatory conjugates
US10344027 Compositions and methods for inhibiting kinases
US10342868 Methods and compositions for inhibiting Akt3
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
FORMA Therapeutics, Inc.
###### PhotoDynamic Inc.
The lohns Hopkins University
RUBIUS THERAPEUTICS, INC.


-----

ASCEND BIOPHARMACEUTICALS LTD
###### Inhibikase Therapeutics, Inc. Augusta University Research Institute, Inc.
US10342825 Solution containing hypochlorous acid and methods of using same
Sonoma Pharmaceuticals, Inc.
US10336725 Chemical compounds
###### AstraZeneca AB US10335484 Methods of generating robust passive and active immune responses
HUMABS BIOMED SA
US10335393 Nuclear transport modulators and uses thereof
US10335372
###### Compositions with modified nucleases targeted to viral nucleic acids
and methods of use for prevention and treatment of viral diseases
US10329531 Synthetic membrane-receiver complexes
###### Biogen MA Inc. lacob G. Appelbaum
RUBIUS THERAPEUTICS, INC.
###### 313an08 24Marll 14Marl3 7Augl4 30Decl4 lOctlS 6Mayl5
18NOV13
9NOV11
###### 23Aprl5 153anl6 153un09 18Marl4 83anl3 9Mayl2 14Apr04
18NOV13
###### 183an -18
6Sep
###### -17
7Dec
###### -15
13NOV
###### -18
4Aug
###### -15 lApr -15 73an -15 2Oct -09
113U118
###### 123an -18
18Aug


-----

###### -16
2Dec
###### -16 23Mar -12
171U115
7Aug
###### -15
24May
###### -18
30Sep
###### -16
5May
###### -16 29Mar -17
9Nov
###### -12 240ct -18 173an -17 153un -10
13Dec
###### -17 83an -14
4Dec
###### -17 10Mar -17 130ct -17
13Aug
###### -19
6Aug
###### -19
6Aug
###### -19

6Aug
###### -19

6Aug
###### -19

6Aug
###### -19

6Aug
###### -19

6Aug
###### -19
303U119
303U119
303U119
233U119


-----

23:11119
233U119
233U119
###### 16JU119 16JU119
9311119
9311119
93U119
93U119
93U119
93U119
23U119
23U119
23U119
23U119
###### 253unl9 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
197

US10329329

US10328157

###### Fusion proteins for promoting an immune response^ nucleic acids encoding same, and methods of making and use thereof
 Acetylenedicarboxyl linkers and their uses in specific conjugation of
a cell-binding molecule
###### US10323074 Cryptic polypeptides and uses thereof US10322104 Disulfur bridge linkers for conjugation of a cell-binding molecule
US10316031 Compositions and methods for inhibiting kinases
US10314893
###### Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders
US10308913
US10308705
###### Chimeric viruses presenting non-native surface proteins and uses thereof Optimized human clotting factor VIII gene expression cassettes and their use
US10308685 Inhibitory peptides of viral infection
US10307475 Methods and compositions for immunization against virus
US10307472 Combination of vaccination and 0X40 agonists
US10307439 Substituted nucleosides, nucleotides and analogs thereof
###### US10307434 Nucleic acid prodrugs and methods of use thereof
US10307391 Disulfur bridge linkers for conjugation of a cell-binding molecule
###### US10307374 Oil-in-water emulsions that contain nucleic acids
US10301650
###### Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor
US10301648 Method of increasing the function of an AAV vector
###### US10301594 Synthetic membrane-receiver complexes
US10301593 Synthetic membrane-receiver complexes
US10301377


-----

###### Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US10300149 Compositions for enhancing transport of molecules into cells
US10300145
###### Synthetic nanoparticles for delivery of immunomodulatory
compounds
US10300127 Immune complex
###### 7UNIVERSITY
OF MIAMI
HANGZHOU DAC BIOTECH CO., LTD.
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
HANGZHOU DAC BIOTECH CO., LTD.
###### Inhibikase Therapeutics, Inc. Sepl2 153ul-15 293anl5 153U1-15 23Aprl5
18The
###### Trustees of the University of Pennsylvania Octl3 2Icahn School of Medicine at Mount Sinai
The University of North Carolina at Chapel Hill
###### UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION Academia Sinica CureVac AG Alios Biopharma, Inc.
WAVE LIFE SCIENCES LTD.
HANGZHOU DAC BIOTECH CO., LTD.
GLAXOSMITHKLINE BIOLOGICALS S.A.
The Trustees of the University of Pennsylvania
The Trustees of the University of Pennsylvania
RUBIUS THERAPEUTICS, INC
RUBIUS THERAPEUTICS, INC.
The United States of America, as Represented by the
###### Secretary, Department of Health and Human Services
SAREPTA THERAPEUTICS, INC.
###### Massachusetts Institute of Technology
The Rockefeller University
###### US10300124 Rodent hepadnavirus cores with reduced carrier-specific antigenicity
VLP BIOTECH, INC.
###### US10294534 Respiratory infection assay
US10294293
Human monoclonal antibody with specificity for dengue virus
###### serotype 1 E protein and uses thereof US10294280 Constrained proteins and uses therefor US10293060 Method for increasing expression of RNA-encoded proteins
US10293055
###### Acetylenedicarboxyl linkers and their uses in specific conjugation of
a cell-binding molecule
###### Fauci/COVID-19 Dossier
THE SECRETARY OF STATE FOR HEALTH
DSO National Laboratories


-----

Monash University
###### CureVac AG
HANGZHOU DAC BIOTECH CO., LTD.
CC-BY-NC-SA Dr. David E. Martin
Dec05
###### GFeblS 17JU1-14 27Mar09 12Marl4 24Iunl4 6-JU109 15JU1-15 6-Julll
17Dec01
###### 7Apr05
18NOV13
18NOV13
###### 24Febl5 29Apr03 153U1-16 20Marl5 15Marl3 9Decll 14Decl0 213U1-14 21Augl4 15JU1-15
28Aug

###### -18
3Feb
###### -17

12Dec

###### -17
5Apr
###### - 17
 240ct
 - 18
 18Apr
 - 16
3Mar
###### - 16
SFeb
###### - 16

25May

###### - 17
 18Feb
 - 14
 12Mar
 - 14

2Feb

###### - 17

27May

###### - 16
5Apr


-----

###### -17 24Apr -17 IMay -17 18Feb -15
19N0V
###### -18 19Mar -18 24Feb -16
lODan
###### -17 14JU117 21Mar -16 14Mar -14
10Dec
###### -12 IDun -16 21JU115 19Feb -16
3Mar
###### -17
198
###### 253unl9 253unl9 183unl9 183unl9 113unl9 113unl9 41unl9 41unl9 41unl9 41unl9 41unl9 41unl9 41unl9 41unl9 41unl9
28May
###### -19
28May
###### -19
28May
###### -19
28May
###### -19
28May


-----

###### -19
28May
###### -19
28May
###### -19
28May
###### -19
28May
###### -19
21May
###### -19
21May
###### -19
21May
###### -19
21May
###### -19
21May
###### -19
US10293039

###### Attenuated Listeria monocytogenes mutant as a vaccine vector for the delivery of exogeneous antigens
US10292978 Specific Akt3 inhibitor and uses thereof
US10292961 Disulfur bridge linkers for conjugation of a cell-binding molecule
US10288601
###### Method of determining, identifying or isolating cell-penetrating peptides 7Montana State University Augusta University Research Institute, Inc.
HANGZHOU DAC BIOTECH CO., LTD.
###### Phylogica Limited US10287576 Enzymatic encoding methods for efficient synthesis of large libraries
NUEVOLUTION A/S
US10287258
US10287253
US10286067
###### Certain (2S)-N-[(IS)-l-cyano-2-phenylethyl]-l,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors Substituted pyrimidines containing acidic groups as TLR7 modulators Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition US10286056 Adjuvant nanoemulsions with crystallisation inhibitors
US10280199 Coronavirus proteins and antigens
US10279029 Immunogenic compositions and uses thereof
US10279028
###### Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
US10279027 Transgenic Vero-CD4/CCR5 cell line
###### US10273454
US10273290
Means and methods for influencing the stability of antibody
###### producing cells


-----

###### Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides US10272150 Combination PIV3/hMPV RNA vaccines
US10272149 Modified bat influenza viruses and their uses
US10266887 CRISPR effector system based diagnostics
###### US10266886 CRISPR effector system based diagnostics
US10266846
US10266545
US10265417
###### Adeno-associated virus (AAV) serotype 8 sequences^ vectors containing same, and uses therefor Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use Adeno-associated virus (AAV) clades, sequences, vectors containing
same, and uses therefor
US10265407 Modular nanodevices for smart adaptable vaccines
US10265395 Adjuvant compositions and related methods
US10265371
###### Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
US10265291 Disulfur bridge linkers for conjugation of a cell-binding molecule
US10260071
US10259865
US10259848
CpG oligonucleotide analogs containing hydrophobic T analogs with
###### enhanced immunostimulatory activity
 Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Compositions and methods comprising hydrocarbon-stapled polypeptides

ASTRAZENECA AB
APROS THERAPEUTICS, INC.

NITTO DENKO CORPORATION
GLAXOSMITHKLINE BIOLOGICALS S.A.
###### Phibro Animal Health Corporation
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
###### Ohio State Innovation Foundation
INTERNATIONAL AIDS VACCINE INITIATIVE

ACADEMISCH MEDISCH CENTRUM BI3 DE UNIVERSITEIT
VAN AMSTERDAM
DANA-FARBER CANCER INSTITUTE, INC.
###### ModernaTX, Inc.
 3. CRAIG VENTER INSTITUTE

MASSACHUSETTS INSTITUTE OF TECHNOLOGY
MASSACHUSETTS INSTITUTED OF TECHNOLOGY
The Trustees of the University of Pennsylvania
###### I-NOVA MEDICINSKA ISTRAZIVAN3A D.O.O.
The Trustees of the University of Pennsylvania
###### Yale University
 Not Available
CENTRO DE INVESTIGACION BIOMEDICA EN RED EN
###### BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER
BBN)
HANGZHOU DAC BIOTECH CO., LTD.


-----

COLEY PHARMACEUTICAL GMBH
ADMA Biologies., Inc.
DANA-FARBER CANCER INSTITUTE, INC.
###### Aprl4
 15Janl6 lSJul-15 23Mayll !Dec05 2413014 5Decl6
 4Augl4 27Janll
7Fet>14
###### 25Marl5 24Aprl2 20ctl5
9Dec05
###### 181un09 220ctl5 5Sepl4 9Decl6 9Decl6
17Dec01
###### 2Febl6
30Sep03
###### 15Feb07 24Marl5 133anll 151U1-15 27Sep06 15Marl7 233an08
7Apr

###### -15
 171an
 -17
 151U115 llDec
 -17

12Dec

###### -16

19Sep

###### -17

4Dec

###### -17

4Aug

###### -15
 271an
 -12

4Aug

###### -16
 27Feb
 -18

14Dec


-----

###### -17
6Apr
###### -17 21un -17
21Sep
###### -17 20JU118
4Sep
###### -15
9Mar
###### -18
9Mar
###### -18 20Oct -16
2Feb
###### -16
3Aug
###### -16
10NOV
###### -14 23Mar -17 103an -17 13Feb -17
26May
###### -16 15Mar -17
4May
###### -16
21May
###### -19
21May
###### -19
21May
###### -19
14May
###### -19
14May
###### -19
14May
###### -19
14May
###### -19
14May
###### -19
14May
###### -19
7May
###### -19


-----

7May
###### -19
7May
###### -19

7May
###### -19 30Aprl9 30Aprl9 30Aprl9 30Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 23Aprl9 16Aprl9 16Aprl9 16Aprl9 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
199

US10258655

###### Synergistic bacterial compositions and methods of production and use thereof US10254204 Membrane-assisted purification
US10253353 Enhanced methods of ribonucleic acid hybridization
US10253318
###### Methods and compositions for the treatment of cancer or other diseases US10253296 Synthetic membrane-receiver complexes
US10253093 Human monoclonal antibodies against interleukin 8 (IL-8)
###### 25Seres Therapeutics, Inc. Accelerate Diagnostics, Inc.
The Broad Institute, Inc.
###### CITY OF HOPE
RUBIUS THERAPEUTICS, INC.
CORMORANT PHARMACEUTICALS AB
###### US10251904 Methods for treating arenaviridae and coronaviridae virus infections
GILEAD SCIENCES, INC.
US10247729
US10246425
US10238739
###### Media elaborated with newly synthesized antibodies (MENSA) and uses thereof 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
 Manufacture of surfactant-containing compositions with enhanced stability


-----

US10238733 Cationic oil-in-water emulsions
###### US10238666 Pharmaceutical compositions and methods
US10238633
###### Methods for treating pulmonary emphysema using substituted 2Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)amides inhibitors of Cathepsin C
US10233429
US10233425
Hand., foot., and mouth vaccines and methods of manufacture and
###### use thereof
CD137 enrichment for efficient tumor infiltrating lymphocyte
###### selection
US10233237 Heterodimeric immunoglobulins
US10233158
US10232051
###### Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel
 blocking compounds
 Acetylenedicarboxyl linkers and their uses in specific conjugation of
a cell-binding molecule
MICROBPLEXj INC.

###### Parion Sciences^ Inc.
NOVARTIS AG
GLAXOSMITHKLINE BIOLOGICALS S.A.

Pop Test Oncology LLC
NOV13
###### 7Marll 6Decl3 263an07
18NOV13
16D6C02
###### 16Sepl5 5Mayl4
17D6C12
###### 2Decl4 6-3U110 3Augl5 14Boehringer Ingelheim International GmbH
 Marl3 7Takeda
 Vaccines, Inc.
The Trustees of the University of Pennsylvania
AMGEN INC.

###### Parion Sciences, Inc.
HANGZHOU DAC BIOTECH CO., LTD.
###### US10227376 Radiolabeled cationic steroid antimicrobials and diagnostic methods
BRIGHAM YOUNG UNIVERSITY
US10227373 Enantiomers of the la€2,6a€2-isomer of neplanocin A
###### Auburn University
US10226449 Heterocyclic modulators of lipid synthesis and combinations thereof
###### 3-V Biosciences, Inc.
 US10226434 Design, synthesis and methods of use of acyclic fleximer nucleoside


-----

###### analogues having anti-coronavirus activity US10222374 B-cell antigen presenting cell assay US10221446 Signal propagation biomolecules, devices and methods
US10220002 Controlled-release peptide compositions and uses thereof
US10213383 Hydrophilic filtration during manufacture of vaccine adjuvants
###### US10209254 Chips, detection systems, and methods for multiplex pneumococcus serology
US10209248 Multiplex immuno screening assay
###### US10206994
RNA virus attenuation by alteration of mutational robustness and
###### sequence space Katholieke Universiteit Leuven/Lieden University Medical Center, RC Leiden Univeersity of Pittsburgha€JJOf the Commonwealth System of Higher Education
STC.UNM
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
NOVARTIS AG
The UAB Research Foundation
###### Institut Pasteur INSTITUT PASTEUR
N0V14
###### 16Sepl3
21NOV12
###### 13Decl3 153U1-15 22Augl4 4Augl4 20Decl3 303anl5 8Aprl0 21Mayl3 2Decll
3Dec09
###### 9Octl3 4Mayl2 283anl5
25Nov
###### -14
3May
###### -17
SDec
###### -14
143 un
###### -17
28NOV
###### -17 30Apr -18
16Sep
###### -16
SMay
###### -15


-----

###### 293un -17
2Dec
###### -15 HMar -16
29NOV
###### -17 63un -17 270ct -17
16Sep
###### -14
21N0V
###### -13 4Apr -18
3Mar
###### -17 19Aug -15
17May
###### -17
19Dec
###### -14
23U118
9Aug
###### -17 30ct -16
30NOV
###### -12
3Dec
###### -10 90ct -14
 19JU117 283an -16 16Aprl9 9Aprl9 9Aprl9 9Aprl9 9Aprl9 9Aprl9 9Aprl9 2Aprl9 2Aprl9 26Mar -19 26Mar -19 26Mar


-----

###### -19
 26Mar
 -19
 19Mar
 -19
 19Mar
 -19
 19Mar
 -19
 19Mar
 -19
 19Mar
 -19
 12Mar
 -19
 12Mar
 -19
 12Mar
 -19
 12Mar
 -19
5Mar
###### -19
5Mar
###### -19
5Mar
###### -19
 26Feb
 -19
 19Feb
 -19
 19Feb
 -19
 19Feb
 -19 Fauci/COVID-19
 Dossier
CC-BY-NC-SA Dr. David E. Martin
###### 200
 US10202640
 Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
The Board of Trustees of the Leland Stanford Junior
###### University
US10202617 Expression cassette for efficient surface display of antigenic
###### proteins Temasek Life Sciences Laboratory Limited
US10202615 Mammalian genes involved in toxicity and infection
US10202578 Chicken cells for improved virus production
US10202367 Heterocyclic compounds and methods of use thereof
US10201198
###### US10190984 Protective masks with coating comprising different electrospun fibers interweaved with each other., formulations forming the same.,
and method of producing thereof


-----

###### Systems and methods for analyzing a sample and for monitoring the performance of an optical signal detector
VANDERBILT UNIVERSITY
THE PIRBRIGHT INSTITUTE
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services Profit Royal Pharmaceutical Limited

GEN-PROBE INCORPORATED
US10190137 CRISPR-related methods and compositions with governing gRNAS Editas
###### Medicine, Inc.
US10190132
###### Recombinant influenza virus-like particles (VLPs) produced in
 transgenic plants expressing hemagglutinin
US10189822 Heterocyclic modulators of lipid synthesis
###### US10189820 Heterocyclic amides useful as protein modulators US10183074 Cationic oil-in-water emulsions
US10179176
###### Recombinant adeno-associated virus capsids resistant to preexisting
human neutralizing antibodies
US10179143 Anti-viral azide containing compounds
MEDICAGO INC.

###### 3-V Biosciences, Inc.
 GlaxoSmithKline Intellectual Property Development Limited
GLAXOSMITHKLINE BIOLOGICALS S.A.
The Board of Trustees of the Leland Stanford lunior
###### University
 Life Technologies Corporation

US10173987 Hydrazide containing nuclear transport modulators and uses thereof
###### Karyopharm Therapeutics Inc.
US10172830
###### Pyrazolone compounds having human neutrophil elastase inhibitory properties US10168336 Quinone methide analog signal amplification
US10167499
US10167333

###### Luminophore-labeled molecules coupled with particles for microarray-based assays Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
US10166283
###### Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
US10166255 Intracellular genomic transplant and methods of therapy
US10160796
###### Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US10159731 Methods and compositions for inhibiting Akt3
US10159729 Antigen and method for production thereof
US10159672
###### Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
US10156562 Assay for detecting Thl and Th2 cell populations
###### US10155980 Compositions and methods for detecting rare sequence variants


-----

###### Chiesi Farmaceutici S.p.A. Ventana Medical Systems, Inc. CAPITALBIO TECHNOLOOGY CORPORATION Not Available 7Mayl4 SFebll 10Decl0 51unl3 12Junl4 23Decl4 31Decl5
7NOV13
###### 213an08 19Marl5 7Aprl6 6-3U111 16Febl6 283U1-10 293U1-11 31Mayl6 24Febl4 5Decl3 163anl4 iSCureVac
AG
###### Febl2 INTIMA
BIOSCIENCE, INC.
Emergo Therapeutics, Inc.

###### Augusta University Research Institute, Inc. Sallpro Biotech AB
PARION SCIENCES, INC.
AMGEN INC.
ACCURAGEN HOLDINGS LIMITED
###### US10155946 Particle-nucleic acid conjugates and therapeutic uses related thereto
Emory University
US10155932
###### Decreasing potential iatrogenic risks associated with influenza vaccines Fauci/COVID-19 Dossier Novartis AG 313U1-15 8Sepl6 153anl6 13Sepl3 273unll 16Mayl4 ISAuglG 253unl2 9Sep04
CC-BY-NC-SA
###### Dr. David E. Martin 30Apr -15


-----

8Feb
###### -12 llDec -11
3Dun
###### -14 123un -15
10Dec
###### -15
23Dec
###### -16
29NOV
###### -17
2Sep
###### -16 15Mar -16
33an
###### -18 23Mar -17 16Feb -17
8Aug
###### -17 213un -17
26May
###### -17
24Aug
###### -16
2Dec
###### -14 153an -15 21Mar -17 293ull6
17N0V
###### -17 20Feb -18
12Sep
###### -14
15Dec
###### -17
15May
###### -15 INov -17 9Oct -17
9May


-----

###### -16

201
###### 12Feb
 -19
 12Feb
 -19
 12Feb
 -19
 12Feb
 -19
 12Feb
 -19
 12Feb
 -19
 291anl9 291anl9 291anl9 291anl9 291anl9 221anl9 15Janl9 15Janl9 81anl9 81anl9 Uanl9 Uanl9 Uanl9 Uanl9 Uanl9
25Dec

###### -18

25Dec

###### -18

25Dec

###### -18

25Dec

###### -18

18Dec

###### -18

18Dec

###### -18

18Dec

###### -18

18Dec

###### -18
 31US10150768
 Guanidine substituted imidazo[4J5-c] ring compounds
US10150743 Carboxylic acid compounds
US10149901 Influenza vaccines with reduced amounts of squalene
US10149859
###### Nucleotide and nucleoside therapeutic compositions and uses related thereto
US10149461 Immunocompromised ungulates
US10144735 Immune response modifier compositions and methods


-----

US10143709 Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
US10143652 Methods for the preparation of liposomes
US10138461 Animal protein-free media for cultivation of cells
US10138295
###### Compositions comprising AAV expressing dual antibody constructs
and uses thereof
###### US10138276 Inhibition of TCR signaling with peptide variants
US10131709
###### US10131704
US10131682
###### Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
 Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
US10130701 Coronavirus
US10125112 Modulators of the relaxin receptor 1
US10125092 Lipids and lipid compositions for the delivery of active agents
US10124065 Lipids and lipid compositions for the delivery of active agents
US10124048 Adenovirus vectors
US10123518
###### Genetically modified non-human animals and methods of use thereof
US10119967 Multiplex immuno screening assay
###### US10119164
US10118925
###### Capture primers and capture sequence linked solid supports for molecular diagnostic tests Imidazo[4,5-c] ring compounds containing substituted guanidine groups
US10118923 Compositions and methods for inhibiting kinases
###### US10117920 Combination of vaccination and inhibition of the PD-1 pathway
US10114011 Antigen presenting cell assay
US10106619
###### Virus vaccination and treatment methods with 0X40 agonist compositions
US10106551 Monothiol mucolytic agents
###### US10105426 Immunostimulatory combinations
US10078083 Detecting targets using mass tags and mass spectrometry
3M Innovative Properties Company
###### Sumitomo Dainippon Pharma Co., Ltd. Seqirus UK Limited
Emory University
###### Revivicor, Inc.
3M Innovative Properties Company
###### Indiana University Research and Technology Corporation CuriRx Inc. Baxalta Gmbh
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
SIGNABLOK, Inc.
ImmunoQure AG
DANA-FARBER CANCER INSTITUTE, INC.
HANGZHOU DAC BIOTECH CO., LTD.


-----

THE PIRBRIGHT INSTITUTE
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF
TRUSTEES
###### Novartis AG Novartis AG Oxford University Innovation Limited
 Institute For Research In Biomedicine (IRB) Institut Pasteur IBIS BIOSCIENCES, INC.
3M Innovative Properties Company
###### Inhibikase Therapeutics, Inc. CureVac AG University of Pittsburgha€JJOf the Commonwealth System of Higher Education

La lolla Institute for Allergy and Immunology
PARION SCIENCES, INC.
TRUSTEES OF DARTMOUTH COLLEGE
###### Ventana Medical Systems, Inc. AuglS
 18Mayl2 10Feb09 HSepl3 27Oct08 22Dec06 6Mayl4
23Sep09
###### 29Oct04 13Mayl4
30Sep09
###### 28Decll 25Aprl4
24NOV12
###### 233U1-14 4Mayl2
 5Sepl4 8Marl3 10Apr07 13Aprl5 4Mayl2
 313U1-09 31Augl5 23Aprl5 22Febl3 8Aprl0 4Oct06
 303anl5
30D6C02
###### 2-3U110
26Aug

###### -16
 HMay
 -16
 273an
 -16


-----

10Sep
###### -14 23Mar -15 253un -18
6May
###### -15
2Aug
###### -16
22Sep
###### -17
13May
###### -15
30Sep
###### -10
7Sep
###### -16 27Apr -15
24N0V
###### -12 233U115
25Aug
###### -16
4Sep
###### -15 6Mar -14
 27Apr -15
 12Apr -16
3May
###### -13

15Aug
###### -16

26Aug
###### -16
7Nov
###### -17
7Feb
###### -18 203ull7 40ct -07 293an -16

10Sep
###### -15
28Dec
###### -15 Fauci/COVID-19 Dossier


-----

CC-BY-NC-SA Dr. David E. Martin
202
###### llDec -18 llDec -18 llDec -18 llDec -18 llDec -18
4Dec
###### -18
4Dec
###### -18
4Dec
###### -18
27NOV
###### -18
27NOV
###### -18
27NOV
###### -18
20Nov
###### -18
20NOV
###### -18
20NOV
###### -18
20NOV
###### -18
13N0V
###### -18
13N0V
###### -18
13N0V
###### -18
13N0V
###### -18
13N0V
###### -18
6Nov
###### -18
6Nov
###### -18
6Nov
###### -18
6Nov
###### -18
6Nov
###### -18 30Octl8 230ctl8


-----

###### 230ctl8 230ctl8
18Sep
###### -18
 US10077427 Means and methods for influencing the stability of cells

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT
VAN AMSTERDAM
US10076491 Vaccine composition
US10072309
###### Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids
NITTO DENKO CORPORATION
###### Not Available US10072064 Composition comprised of antigen linked to a TNF superfamily ligand Not Available
US10072058
###### Chimeric virus-like particles incorporating fusion GPI anchored GMCSF
and IL-4 conjugates
###### US10071976 Small molecule fatty acid synthase inhibitors
US10071970
###### Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
US10071155 Nasal mucosal vaccine composition
###### US10071154 Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same US10071076 Methods of treating cancer and other disorders
US10066238 Methods for producing antibodies
US10066012 Human monoclonal antibodies against interleukin 8 (IL-8)
###### US10064934 Combination PIV3/hMPV RNA vaccines US10064900 Methods of populating a gastrointestinal tract
US10059769 Anti-PD-Ll antibodies and uses thereof
US10059741 Peptidomimetic macrocycles
US10059655 Lipids and lipid compositions for the delivery of active agents
###### US10058624 Recombinant promoters and vectors for protein expression in liver
and use thereof
US10058535 Nuclear transport modulators and uses thereof
US10058516
US10055502
###### Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity System and method for detecting, collecting, analyzing, and communicating event related information
US10053728 High density self-contained biological analysis
US10052398
US10052380
###### Additive compositions for pigmented disinfection and methods thereof
 Lipidated immune response modifier compound compositions, formulations, and methods
US10047375 Artificial nucleic acid molecules
US10047148 Neutralizing GP41 antibodies and their use
US10047147 Neutralizing GP41 antibodies and their use


-----

US10046048
US10040831
US10040828
Homogenous suspension of immunopotentiating compounds and
###### uses thereof Compositions and methods for treating diseases by inhibiting
exosome release
Human respiratory syncytial virus consensus antigens, nucleic acid
###### constructs and vaccines made therefrom, and methods of using
same
###### Fauci/COVID-19 Dossier
 Children's Healthcare of Atlanta, Inc.
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY
###### INSTITUTE Parion Sciences, Inc.
NITTO DENKO CORPORATION
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Wake Forest University Health Sciences
###### UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
CORMORANT PHARMACEUTICALS AB
###### ModernaTX, Inc. Seres Therapeutics, Inc. I-MAB
 Aileron Therapeutics, Inc.
 Novartis AG Children's Healthcare of Atlanta, Inc.
 Biogen MA Inc. Katholieke Universiteit Leuven Georgetown University BioFire Diagnostics, LLC Kinnos Inc.
3M Innovative Properties Company
###### CureVac AG
The United States of America, as represented by the
###### Secretary, Department of Health and Human Services
The United States of American, as represented by the
###### Secretary, Department of Health and Human Services
GLAXOSMITHKLINE BIOLOGICALS S.A.
MOREHOUSE SCHOOL OF MEDICINE
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
CC-BY-NC-SA Dr. David E. Martin
###### MarlS 5Febl3
SMaylS
###### 15Marl3 29Aprl5 7Marl4 17Decl2 30ctl3 4Apr08
12NOV10
###### HFebl3
16D6C02


-----

###### 220ctl5 4Febl3 133unl6 1-JU115 19Decl3 16Aprl5 9Mayl2 303anl5 25Feb08
15NOV06
###### 8Decl4 17Augl0 30Decl4
7N0V11
7N0V11
15Dec09
###### 19Decl6 10Aprl2 26Mar -15 293an -14
6May
###### -16 16Mar -14 29Apr -16
5Mar
###### -15
7Mar
###### -17 20ct -14
6Apr
###### -09 273un -16 llFeb -14 26Apr -16 HAug -17 4Feb -14 133un -17 1JU116
17Dec
###### -14 15Apr -16
243 an


-----

###### -17
28Dan
###### -16
23Sep
###### -16 16JU115
23May
###### -15
27NOV
###### -17 283un -16
8Sep
###### -17
4Aug
###### -14 53ull6
19Dec
###### -16 10Apr -13
Sep
###### -18
18Sep
###### -18 llSep -18 llSep -18 llSep -18 llSep -18 llSep -18 llSep -18 llSep -18 llSep -18
4Sep
###### -18
4Sep
###### -18
4Sep
###### -18
4Sep
###### -18
28Aug
###### -18
28Aug
###### -18
28Aug


-----

###### -18

28Aug

###### -18

28Aug

###### -18

28Aug

###### -18

21Aug

###### -18

21Aug

###### -18

21Aug

###### -18

21Aug

###### -18

14Aug

###### -18

14Aug

###### -18

14Aug

###### -18

14Aug

###### -18

7Aug

###### -18

7Aug

###### -18

203
2618

###### 19US10040820
 Method for the purification of protein complexes
US10039781 Pulse inhalation of nitric oxide for treating respiratory diseases
US10039758
US10034931
###### Compositions and methods for inhibiting bacterial and viral pathogens
Use of EGFR pathway inhibitors to increase immune responses to
###### antigens US10034894 Method of treating inflammation US10031134 Antibody-nanoparticle conjugates and methods for making and using such conjugates US10030250 Edible vaccines expressed in soybeans US10030074 Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies
US10030053 Immunogenic compositions and methods of use thereof
###### US10029016 Immunostimulatory compositions and methods of use thereof
US10028482
###### Disinfecting and deodorizing compositions and methods with novel polymeric binding system
US10023845 Methods of making modified viral genomes
US10023632 Antigenic GM-CSF peptides and antibodies to GM-CSF
US10023558 Compounds


-----

###### US10022436 Microneedle compositions and methods of using same
US10022435 Nucleic acid vaccines
US10022422 Peptidomimetic macrocycles
US10018369 Air curtain device
###### US10017784
US10016498
Gene transfer into airway epithelial stem cell by using lentiviral
###### vector pseudotyped with RNA virus or DNA virus spike protein D-amino acid derivative-modified peptidoglycan and methods of use thereof
US10016497 MERS-CoV vaccine
US10016455
###### Method of preventing or treating influenza with oxidative reductive potential water solution US10013760 Stain-free histopathology by chemical imaging
US10010718 Device to kill micro-organisms inside the respiratory tract
US10010607
US10006862
US10005833
###### Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response Continuous process for performing multiple nucleic acid amplification assays Methods of treating inflammation associated airway diseases and viral infections
US10005772 Immune response modifier compositions and methods
###### US10004764
US10004755
Red blood cell membrane-derived microparticles and their use for
###### the treatment of lung disease Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity Fauci/COVID-19 Dossier Immunobiology Limited
 AIT THERAPEUTICSj INC.
 Keck Graduate Institute of Applied Life Sciences
Emory University
CYTOSORBENTS CORPORATION
###### Ventana Medical Systems^ Inc.
 Not Available GITR, Inc.

Emory University

###### Massachusetts Insitute of Technology OxiScience LLC
The Research Foundation for The State University of New
###### York Morphotek, Inc. CHIESI FARMACEUTICI S.P.A.
VERNDARI, INC.
###### ModernaTX, Inc. Aileron Therapeutics, Inc.

KAWANO GIKEN CO., LTD.
###### ID PHARMA CO., LTD.
The Regents of the University of California


-----

###### INOVIO PHARMACEUTICALSj INC.
Sonoma Pharmaceuticals., Inc.
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
###### Not Available
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA
RECHERCHE MEDICALE)
GEN-PROBE INCORPORATED
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS
SYSTEM
3M Innovative Properties Company
###### University of Pittsburgha€JJOf the Commonwealth System of Higher Education
The University of North Carolina at Chapel Hill
CC-BY-NC-SA Dr. David E. Martin
###### 3un09 24Marl5 240ctl4 23Sepl3 lAprlO 27Aprl0 12Oct04 25Mar05
17Dec07
###### 5Aprl2 28Augl4 30Mar07 8Feb06 31Mayl6 113anl6 23Aprl4 143an09
7AuglS
###### 28Oct05
30NOV12
29NOV13
30D6C03
###### 15Marl3 lAprlG 16Sepl4 10Mar05 23anl5 22Dec06
7NOV13
###### HAprl4 213un -10 24Mar -16 230ct -15
23Sep
###### -14 283un -17


-----

12Sep
###### -16
25Dan
###### -10
7Nov
###### -16
 13Feb -15
2311115
28Aug
###### -15
7Sep
###### -16
 18JU116
22Sep
###### -17 lllan -17 lApr -16

7Apr
###### -16
19N0V
###### -15
17N0V
###### -14
14Sep
###### -17

26NOV
###### -14
9May
###### -17

2Aug
###### -17 28Mar -17
16Sep
###### -15
19May
###### -17
31Dec
###### -15
20Dec
###### -07
6Nov
###### -14
301an
###### -17

7Aug
###### -18

7Aug
###### -18

7Aug
###### -18


-----

###### 31JU118 31JU118
243U118
243U118
243U118
243U118
243U118
243U118
###### 17JU118 17JU118 17JU118 17JU118 17JU118 17JU118 10JU118 10JU118 10JU118 10JU118 10JU118 33ull8 33ull8 33ull8 263unl8 263unl8 263unl8 263unl8 263unl8 204

USRE47838 Inhibitory peptides of viral infection

###### UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
USRE47636 Substituted spirocycles
USRE47493
###### Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
USRE46906 Methods for producing vaccine adjuvants
###### Boehringer Ingelheim International GmbH Boehringer Ingelheim International GmbH
NOVARTIS AG
USRE46873 Multi-targeted RNAi therapeutics for scarless wound healing of skin
###### SirnaomicSj Inc.
USRE46630
###### Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
USRE46441 Circulation of components during homogenization of emulsions
USH2284
USH2283
EP2517720A
1
EP2510946A
1
EP2471938A
2
EP2471937A
2


-----

EP2471936A
2
EP2471551A
2
EP2167534B
1
EP2121732B
1

###### Vaccines for protecting against influenza Vaccines for protecting against influenza Stabilized therapeutic small helical antiviral peptides Conjugates of synthetic tlr agonists and uses therefor Recombinant polyvalent vaccine Recombinant polyvalent vaccine Recombinant polyvalent vaccine Decreasing potential iatrogenic risks associated with influenza vaccines
BIOACTIVE PEPTIDES AND METHOD OF USING SAME
###### COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES Boehringer Ingelhelheim International GmbH
NOVARTIS AG
###### Novartis AG Novartis AG
New York Blood Center^ Inc.
The Regents of The University of California
###### National Institute of Biomedical Innovation National Institute of Biomedical Innovation National Institute of Biomedical Innovation Novartis Vaccines and Diagnostics GmbH
Compugen Ltd.
###### UniversitAHt ZAXrich Prorektorat Forschung 173ul-14 12Sepl4 20Febl4
3Dec09
6NOV07
###### 23Augl2
3D6C09
###### 27Apr09 27Apr09 2Oct07 7Feb08
24NOV05
24NOV05
24NOV05
9Sep05
###### HJul-08
6D6C07
303an
###### -18
30Nov
###### -17
 26Mar


-----

###### -18 130ct
 - 15

26May

###### - 16

18Sep

###### - 15
 130ct
 - 15
 27Apr
 - 10
 27Apr
 - 10 310ct - 12 170ct -12

24N0V

###### - 05

24N0V

###### - 05

24N0V

###### - 05

4311112
4311112
43U112

Feb
###### - 20 80ctl9
93U119
###### 263unl8
29May
###### -18
12Dec
###### -17 203unl7
3Sep
###### - 13
3Sep
###### - 13 310ctl2 170ctl2
43U112
43U112
43U112
43U112
43U112
43U112
###### 4Fauci/C0VID-19 Dossier
CC-BY-NC-SA Dr. David E. Martin
205


-----

###### THE VACCINE DEATH REPORT

 Evidence of millions of deaths and serious adverse events

 resulting from the experimental COVID-19 injections

 PURPOSE

The purpose of this report is to document how all over the world millions of people have died, and

hundreds of millions of serious adverse events have occurred, after injections with the experimental

mRNA gene therapy. We also reveal the real risk of an unprecedented genocide.

###### FACTS

We aim to only present scientific facts and stay away from unfounded claims. The data is clear and

verifiable. Over one hundred references can be found for all presented information, which is provided

as a starting point for further investigation.

###### COMPLICITY

The data suggests that we may currently be witnessing the greatest organized mass murder in the

history of our world. The severity of this situation compels us to ask this critical question: will we rise

to the defense of billions of innocent people? Or will we permit personal profit over justice, and be

complicit? Networks of lawyers all over the world are preparing class-action lawsuits to prosecute all

who are serving this criminal agenda. To all who have been complicit so far, we say: There is still time

to turn and choose the side of truth. Please make the right choice.

###### WORLDWIDE

Although this report focuses on the situation in the United States, it also applies to the rest of the

world, as the same type of experimental injections with similar death rates        - and comparable systems

###### of corruption to hide these numbers - are used worldwide. Therefore we encourage everyone around

the world to share this report. May it be a wake-up call for all of humanity.


-----

###### AT LEAST 5 TIMES MORE DEATHS

CDC WHISTLEBLOWER SIGNS SWORN AFFIDAVIT

VAERS data from the American CDC shows that as of September 17, 2021, already **1,437,273** **people**

suffered adverse events, including stroke, heart failure, blood clots, brain disorders, convulsions,

seizures, inflammations of brain & spinal cord, life-threatening allergic reactions, autoimmune

diseases, arthritis, miscarriage, infertility, rapid-onset muscle weakness, deafness, blindness,

narcolepsy, and cataplexy. Besides the astronomical number of severe side effects, the CDC reports

that **31,470** **people** **died** as a result of receiving the experimental injections. However, a CDC

healthcare fraud detection expert investigated this and came to the shocking discovery that the

number of deaths is at least five times higher than what the CDC is admitting. In fact, in her initial

communications to professor in medicine Dr. Peter McCullough, this whistleblower said that the

number of deaths is ten times higher. The CDC health fraud detection expert signed an affidavit, in

which she stated her findings. She carefully chose the wordings **'...under-reported** **by** **a** **conservative**

**factor** **of** **at** **least** **five',** but as she revealed initially, the factor could also be ten. Here is an excerpt of

the affidavit:1

**'I** **have,** **over** **the** **last** **25** **years,** **developed** **over** **100** **distinct** **healthcare** **fraud** **detection**

**algorithms.** **...** **When** **the** **COVID-19** **vaccine** **clearly** **became** **associated** **with** **patient** **death** **and**

**harm,** **I** **was** **inclined** **to** **investigate** **the** **matter.** **It** **is** **my** **professional** **estimate** **that** **VAERS** **(the**

**Vaccine** **Adverse** **Event** **Reporting** **System)** **database,** **while** **extremely** **useful,** **is** **under-reported**

**by** **a** **conservative** **factor** **of** **at** **least** **5.** **...** **and** **have** **assessed** **that** **the** **deaths** **occurring** **within** **3**

**days** **of** **vaccination** **are** **higher** **than** **those** **reported** **in** **VAERS** **by** **a** **factor** **of** **at** **least** **5.'**

###### According to this CDC health fraud detection expert

 the number of vaccine deaths in the U.S. is not 31,470

 but somewhere between 150,000 and 300,000.

The CDC is also vastly underreporting other adverse events, like severe allergic reactions

(anaphylaxis). The Informed Consent Action Network (ICAN) reported that a study showed how the

actual number of anaphylaxis is **50** **to** **120** **times** **higher** than claimed by the CDC.2-3 On top of that, a

private researcher took a close look at the VAERS database, and tried looking up specific case-ID’s. He

found countless examples where the original death records were deleted, and in some cases, the

numbers have been switched for milder reactions. He says:


-----

**'What** **the** **analysis** **of** **all** **the** **case** **numbers** **is** **telling** **us** **right** **now** **is** **that** **there's** **approximately**

**150,000** **cases** **that** **are** **missing,** **that** **were** **there,** **that** **are** **no** **longer** **there.** **The** **question** **is,** **are**

**they** **all** **deaths?'** **4**

How criminal the CDC is, was also revealed a few years ago, when researchers investigated the link

between vaccines and autism. They found that there indeed is a direct connection. So what did the

CDC do? All the researchers came together and a large dustbin was placed in the middle of the room.

In it they threw all the documents that showed the link between autism and vaccinations. Thus, the

evidence was destroyed. Subsequently, a so-called 'scientific' article was published in Pediatric, stating

that vaccinations do not cause autism. However, a leading scientist within the CDC, William Thompson,

exposed this crime. He publicly admitted:

**'I** **was** **involved** **in** **misleading** **millions** **of** **people** **about** **the** **possible** **negative** **side** **effects** **of**

**vaccines.** **We** **lied** **about** **the** **scientific** **findings.'5**

The worst example of criminal methodology used to hide vaccine deaths is the fact that the CDC

doesn't consider a person vaccinated until two weeks after their second injection. This means that

anyone who dies during the weeks before or the two weeks after the second injection, are considered

unvaccinated deaths, and are therefore not counted as vaccine deaths. By doing this, they can ignore

the vast majority of deaths following the injection. This is the nr 1 method used in nations worldwide

to hide the countless numbers ofvaccine deaths.6-7

###### 300,000 ADVERSE EVENTS

 MODERNA HIDES HUNDREDS OF THOUSANDS OF REPORTS

 A whistleblower from Moderna made a screenshot of an internal company notice labelled

"Confidential         - For internal distribution only", showing there were 300,000 adverse events reported in

only three months:

**'This** **enabled** **the** **team** **to** **effectively** **manage** **approximately** **300,000** **adverse** **event** **reports** **and**

**30,000** **medical** **information** **requests** **in** **a** **three** **month** **span** **to** **support** **the** **global** **launch** **of**

###### their COVID-19 vaccine.'8


-----

###### 50,000 MEDICARE VACCINATED DIED

 U.S. DEATH RATE PROBABLY NEAR 250,000

 Attorney Thomas Renz received information from a whistleblower inside the Centers for Medicare &

Medicaid Service (CMS), which reveals how **48,465** **people** **died** shortly after receiving their injections.

He emphasized that these death numbers are from only 18% of the U.S. population.9 If we apply this

to the entire U.S. population, that would mean a death rate of ± 250,000. Other factors also play a role

###### of course, such as the age of the Medicare patients, and the younger members of the American

people, so we can't simply extrapolate this to the entire U.S. population. But we do see that something

extremely serious is going on.

###### LESS THAN 1% IS REPORTED

 THE ACTUAL NUMBER IS 100X HIGHER

All this information already shows us that the number of adverse events and deaths is a multitude of

what is being told to the public. The situation is however still far worse than most of us can even

imagine. The famous Lazarus report from Harvard Pilgrim Health Care inc. in 2009 revealed that in

general only 1% of adverse events from vaccines is being reported:10

**'Adverse** **events** **from** **drugs** **and** **vaccines** **are** **common,** **but** **underreported.** **Although** **25%** **of**

**ambulatory** **patients** **experience** **an** **adverse** **drug** **event,** **less** **than** **0.3%** **of** **all** **adverse** **drug**

**events** **and** **1-13%** **of** **serious** **events** **are** **reported** **to** **the** **Food** **and** **Drug** **Administration** **(FDA).**

**L** **ikewise,** **fewer** **than** **1%** **ofvaccine** **adverse** **events** **are** **reported.'**

According to this study, numbers of adverse evens and deaths should be multiplied with a factor of

100, in order to understand the true prevalence of serous vaccine injuries.

###### REASONS FOR UNDERREPORTING

 THE POPULATION IS MISINFORMED

The reason that less than 1% of adverse events is reported, is first of all because the majority of the

population is not aware of the existence of reporting systems for vaccine injuries. Secondly, the


-----

pharmaceutical industry has been waging an unrelenting media war over the past decades against all

medical experts, who attempted to inform the public about the dangers of vaccines. One deployed

strategy is name-calling, and the negative label 'anti-vaxxer' was chosen to shame and blame all

scientists, physicians, and nurses who speak out about the devastation caused by vaccinations.

**Because** **of** **this** **criminal** **campaign** **of** **aggressive** **suppression** **of** **adverse** **events** **data,** **the**

**majority** **of** **the** **population** **is** **clueless** **that** **vaccines** **can** **cause** **any** **harm** **at** **all.**

The widespread propaganda by the vaccine companies, who use government agencies as their main

carousel, simply told humanity for decades that adverse events are a very rare occurrence. When

vaccinated people, therefore, suffer from serious adverse events, it doesn't even occur to them that

this could be from previous injections, and naturally don't report it as such.

During the current world crisis the attacks on medical experts who are warning about vaccines, have

gone to an even higher level. Medical experts are now being completely de-platformed from all social

media, their websites are deranked by Google, entire YouTube channels are deleted, many have lost

###### their jobs, and in some countries, medical experts have been arrested in an attempt to suppress the

 truth about the experimental covid injections.

**Several** **countries** **are** **now** **labeling** **scientists** **who** **speak** **out** **against** **vaccines** **'domestic**

**terrorists'.** **It** **is** **clear** **that** **all** **means** **have** **to** **be** **deployed** **by** **the** **criminal** **vaccine** **cartel** **to**

**suppress** **what** **is** **going** **on** **with** **these** **injections.**

As a result, countless medical professionals are afraid to report adverse events, which further

contributes to the underreporting of these side effects. Additionally, the amount of scientific

information warning for these dangerous biological agents, and the number of medical experts

warning humanity, is so overwhelming and almost omnipresent       - despite the aggressive attempts to

silence them         - that it is virtually impossible for any medical professional to not be at least somewhat

aware of the risk they are taking, by administering an untested DNA altering injection, without even

informing their patients of what is being injected into their body. If they then see their patients die or

become disabled for life, they are naturally afraid of being held accountable, and therefore have yet

another motivation for not reporting the adverse events.

Lastly: many medical professionals receive financial incentives to promote the vaccines. In the United

Kingdom for example nurses get £10 per needle they put into a child. That again is a reason for them

to not report adverse events.


-----

###### 250,000 VACCINE COMMENTS

 FACEBOOK REVEALS TSUNAMI OF ADVERSE EVENTS

 A local ABC News Station posted a request on Facebook for people to share their stories of

unvaccinated loved ones that died. They wanted to make a news story on this. What happened was

totally unexpected. In five days time over 250,000 people posted comments, but not about

unvaccinated loved ones. All the comments talk about vaccinated loved ones that died shortly after

being injected, or that are disabled for life. The 250,000 comments reveal a shocking death wave

among the population, and the heart wrenching suffering these injections are causing. The post was

already shared 200,000 times, and counting...11

**✓** **—** **WXYZ-TV** **Channel** **7** **©**

10 September om 13:40 **■** **0**

After the vaccines were available to everyone, did you lose an unvaccinated loved one to
COVID-19? If you're willing to share your family's story, please DM us your contact
information. We may reach out for a story we're working on.

**Adam** **Lee** **Marcus** **©** **■** **Volgen**

I know people who died painfully from the vaccine. Want those stories?

9,2 d.
**Leuk** **■** **Beantwoorden** **-1** d

###### 851 antwoorden

**Cindi** **D.** **Markham**

I had a uncle and cousin die from the jab! My son in laws aunt died from it and 3

# e

more friends died from it.

**Leuk** **Beantwoorden** 2d Bewerkt

**Andrea** **Ashton**
My uncle suffered a stroke due to blood clots and complications days after his
second chot. Would you please do a story about all these reactions?

882
**Leuk** **■** **Beantwoorden** -2d *-

**13** **antwoorden**


-----

**Katie** **Jeroudi**
A friend of a parent went into cardiac arrest almost immediately after receiving
second dose. They were unableto revive her.

I alsoknow of someone who lost a limb due to a blood clot/circulation issue after
being fully vaccinated.
Hm. From the looks of the comments, you might want to change your story topic.

**Leuk** **■** **Beantwoorden** **•** 3 d

**251** **antwoorden**

**Pamela** **Witte**
Yes please please please do a story on all the ones who have died after being
vaccinated, more than anyone will know because no one will tell the truth

. . r, . © 8,3 c
**Leuk** **•** **Beantwoorden** **•** 4 d

***4** **110** **antwoorden**

**Carmen** **Marie**
No we were all fine but almost lost one of my vaccinated family members!

**Leuk** **Beantwoorden** **•** 3 d 15 d.

**117** **antwoorden**

**Lani** **Rose**
My son’s classmate lost her mother from heart complications due to the vaccine.

**Leuk** **■** **Beantwoorden** **•** 3 d W- , 20 d.

**372** **antwoorden**

**Liz** **Lemery** **Joy**
Will you be doing any stories of the people that overcame Covid and have
antibodies? Will you be doing any stories on the thousands that also have
debilitating side effects from the vaccine? Curious if you will be balanced
journalists and media or not- but guessing NO!

**Leuk** **■** **Beantwoorden** **■** 2 d             - Bewerkt vDO **64** **d**

**3.160** **antwoorden**

**Julie-Wilson** **Fogle**
Lost my Mom 10 days after she got her 2nd Pfizer jab. She couldn't swallow or
###### talk correctly the very next day...was hospitalized and basically never "woke up"
again. Was sent home on hospice after 5 days in the hospital and died at home 2
days later.... **Meer** **weergeven**

**Leuk** **Beantwoorden** 3 d

**32** **antwoorden**


-----

**Noelle** **O'Foster**
My dad flatlined after his second dose of Moderna

                                     - •.D* 7,5 d.
**Leuk** **Beantwoorden** 4 d

###### 294 antwoorden

**Angel** **West**

I lost a relative that got the shot, then got Covid, them died in hospital! She
knew she was reacting from the shot and didn't feel well after getting it. Her
husband took her in to hospital and was never allowed to see her again, him
& their daughters. She was a healthy 54 yr old. This was in Abbotsford
Hospital, BC.

**45V** **82**
**Leuk** **Beantwoorden** 9 u

**De** **Ann** **Burk**

I am so sorry for all of us. My husband has been in a terrible health situation after
his second Pfizer vaccination. He passed away for a brief time then brought back
to life. Along w multiple trips to the Er with mini stroke and the latest ct scan
showed a legion growing in his brain and he was told not to drive. Literally it's like
new symptoms keep happening and we are spending all our money on office
visits, specialists and tests. No one and I mean NO ONE DARES to record the
data as a vaccine reaction. So yeah. There's a huge trust issue underneath this
virus and it's vaccine.
**Leuk** **Beantwoorden** **3** **d** **©-‘i** **^8**

###### 36 antwoorden

**I** **Gina** **Coscarart**

**Liz** **Lemery** **Joy** I had a stroke with 2nd vaccine and the doctors can't report
it. Go figure.

**Leuk** **■** **Beantwoorden** -Id                -                - **

**188** **antwoorden**

**Notice** **in** **the** **last** **comment** **how** **the** **lady** **says** **that** **everybody** **in** **the** **hospital** **is** **afraid** **to** **report**

**this** **as** **a** **vaccine** **reaction,** **and** **another** **person** **says** **'the** **doctors** **can't** **report** **it'.**

That is proof of what I explained earlier: Most medical professionals are either too terrified to report

adverse events, or they are simply corrupt. This causes the true prevalence ofvaccine injuries to

remain hidden from the world, which is powerful real life evidence fot what the Lazarus report

revealed: only 1% ofvaccine injuries are reported to the authorities. The 250,000+ comments show

that once people find a place to report suffering caused by the injections, we see a tsunami...


-----

###### VACCINE DEATHS SUMMARY

IT IS FAR WORSE THAN WE THINK

             - VAERS published 1,437,273 adverse events, including 31,470 deaths as of October 7, 2022

           - CDC fraud expert says that number of deaths is at least five times, and possibly ten times higher

            - A whistleblower from the Centers for Medicare & Medicaid Service (CMS) revealed how almost

50,000 people died from the injections. They represent only 20% of the U.S. population, meaning
###### that if this data is applied to the entire population 250,000 have died

                   - 150,000 reports have been rejected or scrubbed by the VAERS system

          - The actual number of anaphylaxis is 50 to 120 times higherthan claimed by the CDC

          - Everyone who dies before two weeks after the second injection, is not considered a vaccine death,
which causes the majority of early vaccine deaths to be ignored

               - Moderna received over 300,000 reports of adverse events in only three months-time

             - The Lazarus Report shows that only 1% of adverse events is being reported by the public

            - The majority of the population is not aware of the existence of systems where they can report

vaccine adverse events

            - Aggressive censorship and propaganda told the public that adverse events are rare, causing
people to not understand how their health problems stem from past injections

           - The shaming and blaming of medical professionals who say anything against the vaccines, cause
many in the medical community to avoid reporting adverse events

          - The fear of being held accountable after administering an injection that killed or disabled patients,
###### further prevents medical personnel from reporting it

            - Having accepted financial incentives to promote, and administer the covid vaccines, also stops
medical personnel from reporting adverse events

             - Profit driven vaccine manufacturers have every reason not to report the destruction their

untested experimental products are causing

                 - 250,000+ Facebook users comment about vaccine deaths and serious injuries


-----

###### MILLIONS OF DEATHS WORLDWIDE

 According to scientific data less than 1% ofvaccine injuries are being reported.
 And from that 1% the majority of reports is even hidden by the authorities.
 They put systems in place to ignore the bulk ofvaccine deaths. Combining
 these facts with the data that is revealed by government whistleblowers, we
 see that in the United States hundreds of thousands have died from the
 injections. As the rest of the world uses the same injections, we know that on

**a** **global** **scale** **the** **number** **ofvaccine** **deaths** **is** **without** **a** **doubt** **millions.**

###### This is only the short term tsunami of adverse events. Bill Gates, the world's

 leading vaccine dealer and a driving force behind the worldwide vaccine push,
 said in an interview with the BBC that most adverse events only show up after two years, which is why vaccine development usually takes many years. This
 means that the waves of deaths and disabilities in the coming years will be

 exponentially greater. Especially because more and more booster shots are

 imposed on the population, and vaccine passports being implemented.

 WORLD EXPERTS WARN HUMANITY

 LEADING SCIENTISTS ISSUE GRAVE WARNINGS

This alarming data leads world experts, like the Nobel Prize Winner in Medicine, Dr. Luc Montagnier,

to issue a grave warning that we are currently facing the greatest risk of worldwide genocide, in the

history of humanity.12 Even the inventor of the mRNA technology, Dr. Robert Malone, warns against

these injections that are using his technology.13-14 The situation is so severe that former Pfizer vice

president and chief scientist Dr. Mike Yeadon came forward to warn humanity for these extremely

dangerous injections. One of his best known videos is titled 'A Final Warning'.15 Another world renown

scientist, Geert Vanden Bossche, former Head ofVaccine Development Office in Germany, and Chief

Scientific Officer at Univac, also risks his name and career, by bravely speaking out against

administration of the covid shots. The vaccine developer warns that the **injections** **can** **compromise**

**the** **immunity** **of** **the** **vaccinated,** **making** **them** **vulnerable** **for** **every** **new** **variant.1617** World War

II holocaust survivors wrote to the European Medicines Agency demanding the injections to be

stopped, which they consider to be a new holocaust.18


-----

###### VACCINE DEATHS WORLDWIDE

 THE SAME GOES FOR NATIONS AROUND THE WORLD

The situation we described in the United States illustrates the destruction caused by these injections.

We will briefly touch upon some other countries, to prove that the situation in America is not unique.

###### EUROPEAN UNION

In the European Union (which consists of only 27 of the 50 European countries) the official reports of

EudraVigilance officially admit as of August 18th 2021 that approx. **22,000** **people** **died** **and** **2** **million**

**suffered** **side** **effects,** **of** **which** **50%** **are** **serious.19-20** What are serious injuries?

'It be classified as 'serious' if it corresponds to a medical occurrence that results in death, is life­

threatening, requires inpatient hospitalisation, results in another medically important condition, or

prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or

is a congenital anomaly/birth defect.1

In The Netherlands, one of the smallest nations in the European Union, an extra parliamentary

research committee set up a platform for citizens to report vaccine adverse events. This is no initiative

from the government and has received no attention in the media. The majority of the Dutch

population is therefore unaware of its existence. Yet, despite its limited influence, this private initiative

has already received reports of **2,625** **deaths** **and** **3,230** **health** **damages,** **often** **permanently**

**disabling** **the** **people.21**

###### UNITED KINGDOM

Shortly before the national vaccination campaign started, the MHRA (Medicines and Healthcare

Products Regulatory Agency) published the following request:

**'The** **MHRA** **urgently** **seeks** **an** **Artificial** **Intelligence** **(Al)** **software** **tool** **to** **process** **the** **_expected_**

**_high_** **_volume_** **_of_** **_COVID-19_** **_vaccine_** **_Adverse_** **_Drug_** **_Reaction_** **(ADRs)** **and** **ensure** **that** **no** **details** **from**

**the** **ADRs'** **reaction** **text** **are** **missed.122**

The British government published a report of the first series of adverse events, including blindness,

strokes, miscarriages, heart failure, paralysis, autoimmune disease, and more. Shortly after the first


-----

wave of immunization over **100,000** **adverse** **events** **were** **reported,** **including** **1260** **cases** **of** **loss** **of**

**eyesight** **(including** **total** **blindness).** The first part of the report praises the vaccines to be the best

way to protect people from COVID-19, and then continues to show the incredible destruction these

vaccines are causing. The hypocrisy is mindboggling.23-24

Also in the U.K. miscarriages increased by 366% in only six weeks, for vaccinated mothers.25

Furthermore the British Office for National Statistics inadvertently revealed that **30,305** **people** **have**

**died** **within** **21** **days** **of** **having** **the** **injection,** during the first 6 months of 2021.26 And a British

scientist with 35 years of experience did an in depth analysis of the British Yellow Card reporting

system and found it to be unreliable.27

'We can conclude that the Yellow Card reporting scheme can provide some limited information that

may be useful for alerting the UK public to possible adverse effects of the COVID-19 vaccines.

However, the initial conception of the scheme as a purely descriptive rather than as an experimental

undertaking means that **it** **cannot** **address** **the** **real** **issues** **that** **are** **of** **crucial** **importance** **to** **the**

**UK** **public.** These issues are whether there are causal relationships between vaccination with the PF

and AZ vaccines and serious adverse effects such as death, and if so, what are the size of these effects.'

###### ISRAEL

The Israeli Peoples Committee is a team of doctors, attorneys, criminologists, epidemiologists and

academic researchers, determined to perform an investigation, inquiry, and exposure for the benefit

###### of the public. Although they are a relatively unknown group, they still received 3754 reports,

**including** **480+** **deaths,** as of August Sth, 2021,28 The IPC states that these numbers represent only 2­

3% of the true prevalence in the population, which means that the number of deaths in Israel is

**around** **48,000** **and** **adverse** **events** **around** **375,400.**

Also in Israel, statistics from Worldometers.info shows a massive spike in deaths when the

vaccinations started. Before the immunizations began, there were hardly any daily covid deaths in

Israel. Once the vaccinations began, the daily death toll rose from **1-3** **to** **75-100** **deaths** **a** **day!**


-----

###### Daily New Deaths in Israel

**Daily** **Deaths**

**Deaths** **per** **Day**
**Data** **as** **of** **0:00** **GMT+8**

12S

**QOJ** 100

Q 75

**nic:** 50
**o**
**o**
**u**

**"oi** 25

**o**
**z** **.** **j.ijiiihiiiLL.** **iii...** **-L+iUiAl**

###### II NliiW d.u....kl -L. I LUI

**/sO*'** **zsCr** **-Or** **-Cr** **«**

**Hr** **T<** Ha **'k** **T/** Ta Ta Ta t V k

**•i’"** q V' **T?'** **..T^'** **T?'** **"V7** /-{V a

**V’*'** **O'-0** **'**

###### • Daily Deaths iy moving average D 7-day moving average D

See also: Daily Cases Graph

###### Another Israeli website reporting vaccine injuries is Seethetruth.club/covid-19-vaccine-victims

where one can see a rapidly growing number of testimonials of people who suffered greatly from the

shot. In the U.S. a similar website called **1000covidstories.com** shows an ever increasing amount of

videos from people who died or had severe reactions to the covid shots. Also the website called

**TheCovidWorld.com** shows the personal stories of a large number of people who died from the

shots. We must understand that nothing like this has ever happened before in history, where

thousands of people come forward to share their suffering following an immunization. The reason

people do this now, is because their adverse reactions are not at all, like the criminal 'health' agencies

say 'headaches, dizziness and flu like symptoms.' The reactions are extremely severe, often disabling

people for life. The injuries are in fact so severe, that people around the world are stepping forward

to warn humanity.

###### BRAZIL

In Brazil the official vaccine death count is **32,000** **during** **a** **5** **month** **period.** The report was published

on uol.com.br, which reportedly has about the same number of pageviews as CNN.com, according to

data from SimilarWeb. Despite these high amounts of deaths following vaccination, the report states:

'Vaccination is still the best way to control the disease.'29


-----

###### SCIENCE PROVES VACCINE DAMAGE

 STROKES, H EART ATTACKS, CANCER,...

**A** study by the University of San Francisco, or Salk Institute, shows that the vaccines turn the human

body into a spike protein factory, making trillions of spikes that cause blood clots, which cause strokes

and heart attacks.30 Another study confirms how the vaccines can cause deadly blood clots, that in

###### turn cause heart attacks and strokes.31-32 The New England Journal of Medicine shows how the jabs

cause heart inflammation,33 and the same journal published a study about the dramatic increase of

miscarriages.34 Several studies prove the reality of antibody dependent enhancement. 35-36-37Also the

occurrence of infertility and reduced sperm count is confirmed.38-39 Lastly a study showed that the

injections cause cancer.40 And these are just a few examples...

###### EXEMPT FROM LIABILITY

NO VACCINE MANUFACTURER TAKES RESPONSIBILITY

In the past decades, several official government agreements were signed, in nations across the world,

###### that provide every vaccine manufacturer with 100% protection from all liability. It doesn't matter how

much destruction their products cause, nobody has any recourse. On top of that, no health insurance

will ever cover the costs resulting from vaccine damage. They simply do not reimburse the vaccinated,

when they get into trouble. Yet... the same governments that refuse to protect you from possible

destruction of your health, life, and beloved ones, mandate these deadly injections and require them

###### for shopping, travel, gatherings, and even banking services.

 DO THE INJECTIONS EVEN WORK?

 HEALTH OFFICIALS SAY THEY ARE NOT EFFECTIVE

World-renowned vaccine developer Geert Vanden Bossche MVD, PhD warns that these injections

destroy the body's immune system, making the vaccinated vulnerable for every new variant of the

disease.41 He also says:


-----

**'Mass** **vaccination** **campaigns** **during** **a** **pandemic** **of** **highly** **infectious** **variants** **fail** **to** **control**

**viral** **transmission.** **Instead** **of** **contributing** **to** **building** **herd** **immunity,** **they** **dramatically** **delay**

**natural** **establishment** **of** **herd** **immunity.** **This** **is** **why** **the** **ongoing** **universal** **vaccination**

**campaigns** **are** **absolutely** **detrimental** **to** **public** **and** **global** **health.'** **42**

The Nobel prize winner in medicine Dr. Luc Montagnier sounds the alarm that these vaccines are

creating dangerous new variants.43 And in Israel the statistics showclearly a dramatic increase in covid

deaths once immunizations started (see earlier in this report). The Israeli prime minister Naftali

Bennet even says that the people who are most at risk now, are those who received two doses of the

vaccine..44

**In** **the** **island** **nation** **Seychelles** **there** **were** **hardly** **any** **covid** **deaths,** **but** **once** **they** **started**

**vaccinating** **the** **population,** **the** **deaths** **increased** **a** **hundred** **fold.**

100 people_________ _

**»** **m,** **most** **vaccinated** **country** **in** **the** **world**

When Seychelles **6^**

**tan•** **ScytMw».** **2021** **1** launched their VAXX

they had a
cumulative 1 death

###### Over 99% of the Covid deaths have been since they launched their on

**Feb** **24.2021** 9th January 2021

Jun 4.2021

Jul 24. 2021

In Australia, a young couple was refused access to their newborn baby for eight days, even though

they were fully vaccinated. The chief health officer from Australia, Dr. Jeannette Young, gave the

following revealing explanation for this inhumane situation: 45

**'Just** **because** **you** **are** **vaccinated,** **doesn't** **mean** **that** **you** **won't** **get** **infected.** **That's** **why** **we**

**could** **not** **allow** **that** **family** **to** **go** **and** **visit** **their** **baby.'**


-----

Anthony Fauci also made it crystal clear: 'the CDC is considering mask mandates for the vaccinated',46

'the vaccinated increasingly test positive for covid, therefor they will need to keep wearing masks',47

'the vaccinated still need to avoid eating in restaurants',48 and 'the vaccinated carry the Delta variant

as much as the unvaccinated'49 So according to Fauci the vaccines do nothing. Yet he insists on

mandating these useless injections for travel.50 The same was publicly stated by the UK's Prime

Minister Borisjohnson, who said:51

**'Can** **I** **now** **meet** **my** **friends** **and** **family** **members** **indoors** **if** **they** **are** **vaccinated?** **There** **I** **am**

**afraid** **the** **answer** **is** **no,** **because** **we're** **not** **yet** **at** **that** **stage,** **we're** **still** **very** **much** **in** **the** **world**

**where** **you** **can** **meet** **friends** **and** **family** **outdoors,** **under** **the** **rule** **of** **six,** **or** **two** **households.** **And**

**even** **if** **your** **friends** **and** **family** **members** **may** **be** **vaccinated,** **the** **vaccines** **are** **not** **giving** **100%**

**protection** **and** **that's** **why** **we** **need** **to** **be** **cautious.'**

A research article published in 'Trends in Internal Medicine' by Dr. J. Bar Classen MD, is titled:52

'US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data

Analyzed Using the Proper Scientific Endpoint, **"All** **Cause** **Severe** **Morbidity"'**

Even the CDC admitted that the injections offer no protection against the Delta variants, and coming

variants, and all covid measures, therefore, need to stay in place.53 Yet they keep insisting that

everybody must be vaccinated. The chief health officer of New South Wales, Australia said we have to

prepare to live with a constant cycle of ongoing covid booster injections for the foreseeable future.54

Moderna's chief medical officer, Dr. Tai Zaks, said that the vaccines do not bring life back to normal.55

This was confirmed by the director of the World Health Organization Tedros Adhanom, who said:56

**'A** **vaccine** **on** **its** **own** **will** **not** **end** **the** **pandemic.** **Surveillance** **will** **need** **to** **continue,** **people** **will**

**still** **need** **to** **be** **tested,** **isolated** **and** **cared** **for.** **Contacts** **will** **still** **need** **to** **be** **traced** **and**

**quarantined,** **communities** **will** **still** **need** **to** **be** **engaged.'**

A study by The Lancet showed that the Delta variant is freely transmitted among the vaccinated.57 This

was confirmed by a study that showed how a in July 2021, following multiple large public events in a

Barnstable County, Massachusetts, town, 469 COVID-19 cases were identified among Massachusetts

residents who had travelled to the town during July 3-17; 346 (74%) occurred in fully vaccinated

persons.58


-----

###### CREATURE WITH TENTACLES

 LIVING ORGANISMS IN THE VACCINES

Dr. Carrie Madej investigated vaccine vials from Moderna and Johnson &Johnson under a microscope

with 400x magnification. What she saw shocked her...

**In** **both** **vials** **there** **was** **a** **living** **organism** **with** **tentacles.** **This** **creature** **moves** **around** **and** **lifts**

**itself** **up.68A**

The sight of this and the thought that these unknown, octopus-like creatures are being injected into

millions of children worldwide, caused Dr. Madej to weep.

###### SELF-ASSEMBLING NANOBOTS

 WHAT IS SECRETLY BEING BUILT INSIDE YOUR BODY?

Dr. Madej also observed pieces of graphene in the vials, as well as self assembling nanoparticles. The

particles moved towards one another, and formed more complex structures. The same was revealed

by Dr. Zandre Botha from South Africa. She studied several vaccine vials using a variety of methods,

and what she found is simply too bizarre for words. Just like Dr. Carrie Madej she saw complex self­

assembling nanobots. 69CLook at the following micrographs...


-----

###### What kind of diabolical agenda is secretly being rolled out, by injecting these kinds of self-assembling

nanobots into the bodies of millions of people? And why are so many news agencies, and so called

fact-checkers doing overtime to deny these apparent, undeniable findings? What is really the purpose

###### of these injections, thar are so forcefully being imposed onto all of humanity? And why are all the

governments worldwide collaborating with this plan? There clearly is a nefarious agenda behind

covertly injecting this kind of nanotechnology into humanity. What is it? Who dares to ask these

questions, and find the answers?


-----

###### DANGEROUS TOXINS

 GRAPHENE ALTERS THE ELECTROMAGNETIC FIELD

The world-renowned biophysicist Andreas Kalcker has discovered that the vaccines contain large

amounts of graphene oxide (up to 95% of the solids).

**He** **warns** **that** **the** **graphene** **oxide** **injected** **into** **humans** **is** **altering** **their** **electromagnetic** **field,**

**which** **disrupts** **the** **normal** **functioning** **of** **their** **organs.65**

'What we are concerned about is the side effects it has. This isn’t described in medicine, but it’s

described in my field, biophysics. What happens? The body needs its electro molecular capabilities to

work. The heart beats because there’s a magnetic field that creates, subsequently, the electricity for

pumping and everything else. Graphene is completely altering our electromagnetic field, something

that has never happened before. What we’re seeing is something 'in vivo' with some dramatic effects.

We have been watching a lot of videos of people who are dying after being vaccinated. You see people

spasming. These spasms have, for example, very specific frequencies, and they are the same in all

kinds of spasms.

**These** **spasms** **indicate** **that** **there** **is** **a** **disruption** **of** **the** **human** **electromagnetic** **fields.1**

The presence of graphene oxide, among other toxic materials like aluminum, LNP capsids, PEG and

parasites in the vaccines was further confirmed by Dr. Robert Young.66-67 The Scientist's Club also

released a report with microphotographic evidence of nanoparticles in the vaccines.

'Major revelations on what is in the CoV-2-19 vaccines, with the use of electron, pHase, dark field,

bright field and other types of microscopy from the original research of Dr. Robert Young and his

scientific team, confirming what the La Quinta Columna researchers found          - **toxic** **nanometallic**

**content** **with** **magneticotoxic,** **cytotoxic** **and** **genotoxic** **effects,** **as** **well** **as** **identified** **life­**

**threatening** **parasites.** In addition, in 2008, Hongjie Dai and colleagues at Stanford University found

graphene oxide.'68


-----

###### DRAMATIC BLOOD CHANGES

RESEARCH REVEALS CHANGES IN BLOOD

Dr. Robert Young also discovered how the blood of vaccinated people changes dramatically, after the

injection with mRNA. The following image reveals the normal healthy state of the red blood cells which

are even in color, even in shape and even in size.69A

The second micrograph taken under Phase Contrast Microscopy reveals the live blood 24 hours after

the mRNA vaccine now containing crystallized red blood cells called Heinz bodies, biological

transformations of red and white blood cells, large symplasts of graphene oxide crystals center and

Orotic acid crystals in the upper right hand corner of the micrograph.


-----

German researchers discovered that the content from vaccine vials formed crystals, after being placed

under a lamp that warms them to about 30° Celcius (85° F). The photo below shows this clearly.69BThe

image to the left shows the original vial content, and the image to the right is what happens after a

few minutes... complex crystals are formed. _What_ _impact_ _does_ _this_ _have_ _on_ _the_ _human_ _body?_

###### PERMANENTLY ALTERED DNA

 THE HUMAN GENOME IS BEING MODIFIED

Dr. Carrie Madej studied vaccines and transhumanism for two decades. In her documentary 'The

Battle For Humanity', produced by Stop World Control, she warned that these injections could

permanently change the human DNA, with potentially disastrous outcomes. Fact-checkers around the

world        - who are often paid by the vaccine industry        - jumped to label it as fake news. Facebook made

it their policy to censor all voices that warned how this gene therapy could potentially alter the human

genome. Until... a Facebook employee recorded and released an insider zoom meeting with Facebook

CEO Mark Zuckerberg, who told his staff that the injections do indeed change the human DNA! These

are his exact words:

**'We** **just** **don't** **know** **the** **long** **term** **side** **effects** **of** **basically** **modifying** **people's** **DNA** **and** **RNA** **to**

**directly** **encode** **in** **a** **person's** **DNA** **and** **RNA,** **basically** **the** **ability** **to** **produce** **those** **antibodies**

**and** **_whether_** **_that_** **_causes_** **_other_** **_mutations_** **_or_** **_other_** **_risks_** **_downstream.'63_**


-----

###### A PATENTED TRANSHUMAN

NO LONGER A HUMAN WITH HUMAN RIGHTS

Dr. Chinda Brandolino is a Latin American physician who has been speaking out about the fact that

once the human genome is altered, that person is no longer considered an original human being, but

has become a transhuman, and therefore loses human rights. Furthermore, she explains that the

altered DNA and RNA can be patented, making that genetically modified person property of the patent

holders. The implications of this are highly alarming.64

###### TRANSHUMAN BABY

 BLACK EYES & ACCELERATED AGING

Scientists in South America are investigating a strange phenomenon: Some newborn babies from

vaccinated parents in Mexico have **black** **eyes,** while normally the eyes of newborns are lightly

colored. It also appears that these babies are **aging** **too** **fast,** as they can stand and even walk at only

three months old.63A The researchers are careful not to make premature statements but will

investigate this further.638


-----

###### DIFFERENT DOSAGES

 WHY DO SOME DIE, WHILE OTHERS ARE FINE?

 Why do some people die, or become disabled for life, while others seem fine after being inoculated?

Dr. Jane Ruby explains that not all vials have the same dosages.688 ClinicalTrials.gov shows that there

are different phases of the vaccination experiment, with different dosages of the mRNA being

administered to different people. An unknown percentage of the injections are even placebos!

**This** **means** **that** **some** **people** **get** **a** **harmless** **substance** **injected,** **while** **others** **get** **a** **shot** **with**

**5,10,** **20,** **or** **30** **micrograms** **of** **mRNA.**

Dr. Ruby warns that in the booster shots some vials contain as much as 100 or even 250 micrograms

###### of mRNA. This explains why in certain areas the vaccinated seem fine, while in other areas people

drop dead after being injected. It's like Russian roulette: nobody knows what is being injected into

###### their body. There is no informed consent. If people however take the boosters, they will get different

dosages. Where previous shots may have been harmless, the next could be lethal.

###### FRAUD WITH COVID DEATHS

 WORLDWIDE FRAUD INFLATED COVID DEATHS

The excuse for murdering millions of people with these injections is that they supposedly prevent

people from dying of covid. The reality is however that the so-called number of covid deaths is the

greatest lie in history. Worldwide it was revealed that over 95% of all covid deaths, were deaths from

other causes. The Italian politician Vittorio Sgarbi exclaimed in the Italian Chamber of Deputies:69

**‘Let's** **not** **make** **this** **the** **chamber** **of** **lies.** **Don't** **lie!** **Tell** **the** **truth.** **Don't** **say** **there's** **25,000** **dead.**

**It's** **not** **true.** **Don't** **use** **the** **dead** **for** **rhetoric** **and** **terrorism.** **Figures** **from** **the** **Higher** **Institute**

###### of Health say 96.3% died of other diseases.'

A magazine in Belgium, De Tijd, wrote how the government claimed that 3,000 elderly people had died

###### of COVID-19. Because of these numbers the entire country was placed on lockdown. However,

research showed that only 3% of the deceased had been tested. Not 3,000 but only 90 people may

have had covid.70


-----

While supposed covid deaths went through the roof, statistics in several countries showed that

suddenly there are no more flu deaths. In the USA alone there are almost 40 million cases of the flu

every year, but since covid hit, this number has dropped to less than 2,000. Where did all the tens of

millions of flu patients go? _They_ _are_ _now_ _all_ _being_ _registered_ _as_ _covid._

###### FLU CASES PLUMMET DURING PANDEMIC

## 1,822 38,000,000

###### 2019-2020 I
 2020 - 2021 FLU SEASON FLU SEASON

**Jl**

A forensic German coroner Prof. Dr. Klaus Puschel examined more than 140 coronadalities in

Hamburg at the start of the pandemic. On German TV he said that the hysteria around the coronavirus

has been gravely exaggerated. All the people who died had underlying disorders and would have died

quickly anyway, with or without the virus, according to Puschel, adding that there is no 'killer virus'.

Healthy people don't have to worry, says Puschel. The coroner also predicted that corona will not even

cause a peak in the annual mortality rate, a prediction that turned out to be accurate.71

**Medical** **professionals** **around** **the** **world** **have** **testified** **of** **being** **pressured** **by** **their** **supervisors**

**to** **report** **all** **patients** **as** **covid,** **and** **register** **every** **death** **-** **no** **matter** **what** **the** **cause** **was** **-** **as** **a**

**covid** **death.** **The** **internet** **has** **been** **flooded** **by** **thousands** **of** **testimonies** **of** **outraged** **people**

**who** **said** **that** **they** **went** **to** **a** **doctor** **or** **hospital** **for** **issues** **unrelated** **to** **COVID-19** **and** **to** **their**

**amazement,** **they** **were** **registered** **as** **a** **covid** **patient.72**

Dr. Elke de Klerk, founder of Doctors for Truth in the Netherlands, testified that she received secret

messages in the dossiers of terminally ill patients, requesting that these people should be registered

as covid deaths.73 Project Veritas called several funeral directors in New York, and they testified how


-----

every dead person was registered as covid, while everybody knew that was not correct.74 Minnesota

senator Scott Jensen, who is also a practicing physician, revealed on Fox News that U.S. hospitals

receive huge financial incentives to register patients as covid. For every person they registered as a

covid death they are paid 39,000 USD. This has been confirmed by medical professionals around the

###### world.75 The technical director of CNN Charlie Chester was secretly filmed by a Project Veritas

undercover journalist, while he admitted that CNN inflated the death rates 'because fear sells'.76

**A** **Zoom** **meeting** **with** **African** **government** **officials** **was** **leaked,** **revealing** **how** **they** **were**

**discussing** **ways** **to** **ramp** **up** **covid** **numbers,** **to** **continue** **the** **lockdowns.77**

National File released a recording of a Zoom conference call between physicians and a marketing

director at Novant Heath New Hanover Regional Medical Center, a group of 20 hospitals, clinics, and

offices that treat patients in North Carolina and South Carolina. In the recording, Mary Rudyk, MD tells

Director of Marketing Carolyn Fisher and another hospital employee that she wants the hospitals to

become more 'scary to the public' by **inflating** **the** **number** **of** **COVID-19** **patients,** and by using

messaging that falsely tells individuals 'if you don’t get vaccinated, you know you're going to die.'78

New York was the epicenter of the COVID-19 pandemic. In the heart of New York is the famous

Elmhurst hospital where supposedly more people died from this virus than anywhere else in the

world. It was the epicenter within the epicenter of the pandemic. For this reason, an experienced

nurse from Florida, Erin Olszewski, decided to go there to help with the crisis. What she saw in this

world-famous hospital, however, filled her with so much horror, that she decided to take a hidden

camera with her to film what was going on.

**Patients** **who** **repeatedly** **tested** **negative** **for** **COVID-19** **are** **still** **registered** **as** **'confirmed** **COVID-**

**19'.** **They** **are** **put** **on** **a** **respirator** **in** **a** **covid** **ward...** **which** **causes** **them** **to** **die.**

In a revealing documentary byJourneyman Pictures, this nurse talks about the crimes she constantly

sees happening in Elmhurst. She shows on her smartphone how a patient indeed tested negative for

COVID-19 twice... and yet was registered as 'confirmed' COVID-19'. She explains that this happens all

the time in Elmhurst: deception and murder resulting in high COVID-19 mortality rates that are

trumpeted by the media.79


-----

###### FUNERAL DIRECTOR SPEAKS OUT

AN UNDERTAKER WITNESSES GOVERNMENT CRIMES

One very revealing eyewitness account comes from a funeral director from the UK, John O'Looney.80

For 10 years he was part of one of the largest funeral companies in the United Kingdom, he worked

with the BBC to document the pandemic, and worked with a government pandemic official. He is

connected to 45 other funeral directors and has therefore a clear overview of what is going on. What

he discloses is shocking. First of all, he testifies that neither he nor any of the other funeral directors

saw an increase in deaths during the so-called pandemic. During March 2020 however, John was

suddenly called night after night, for three weeks, specifically to care homes. All who died were

labelled as covid. He never saw a doctor in attendance, nor a covid test once. At the same time, there

was a 1,000% increase in purchases of Midazolam. A nurse told him how they were instructed to

administer lethal doses of this drug to the elderly, to mass exterminate them. These high numbers of

deaths were then used to promote the narrative of a 'covid pandemic'.

**He** **was** **also** **approached** **by** **a** **government** **pandemic** **official,** **who** **told** **him** **they** **had** **to** **label**

**each** **death** **as** **covid.** **People** **run** **over** **by** **cars,** **heart** **attacks,** **cancer** **patients,** **it** **didn't** **matter**

###### what killed them, they all had to be labelled as covid deaths.

Once the government started mass vaccinating the British population, John says the deaths

skyrocketed. Tve never seen anything like it, as a funeral directorfor fifteen years. And it began exactly

when they began putting needles in their arms. I've never seen a death rate like that again. It was

awful, awful. Those were pandemic numbers, but it was only after they started vaccinating, never

before that point.'John explains that most vaccine deaths were labelled covid deaths.

**'Every** **funeral** **director** **with** **an** **ounce** **of** **honesty** **will** **tell** **you** **that** **all** **those** **who** **are** **dying** **all**

**around** **us** **are** **vaccine** **recipients.** **There** **is** **no** **covid** **pandemic** **and** **I** **am** **living** **proof** **of** **that.** **It's**

**all** **designed** **to** **make** **you** **take** **the** **vaccine.** **In** **my** **network** **of** **funeral** **directors,** **not** **a** **single** **child**

**has** **died** **of** **covid.** **So** **there** **is** **no** **reason** **whatsoever** **to** **put** **these** **gene** **therapies** **into** **children.**

**Here** **we** **have** **a** **depopulation** **agenda.** **It's** **the** **vaccines** **that** **are** **killing** **the** **people,** **and** **I** **am**

**seeing** **that** **firsthand** **as** **a** **funeral** **director.'**

_Watch_ _the_ _entire_ _testimony_ _ofJohn_ _O'Looney_ _online,_ _as_ _he_ _reveals_ _far_ _more_ _than_ _I_ _quote_ _here._ _For_ _example_

_how_ _medical_ _authorities_ _within_ _the_ _NIH_ _told_ _him_ _that_ _the_ _Delta_ _variant_ _is_ _a_ _vaccine_ _injury_ _See_ _it_ _here:_

_Stop_ _WorldControl._ _com/director_


-----

###### COVID FRAUD SUMMARY

 THE WORLD IS BEING DECEIVED LIKE NEVER BEFORE

                  - Health care workers are paid or pressured to register all patients as covid

                     - The hundreds of millions of flu cases every year are now all covid

            - A forensic German coroner examined 140 coronadalities and said they all died of other causes
and there is no killer virus

              - Doctors get hidden messages requiring them to register dying patients as covid deaths

                  - A network of 20 hospitals is caught increasing covid numbers to create fear

           - Innumerable people worldwide are outraged because they were incorrectly registered as covid

                    - Funeral directors admit they see false covid registrations all the time

        - CNN technical director Chester confessed they inflate covid numbers because 'fear sells'

          - An African government official is seen in a Zoom call discussing how to ramp up covid numbers, in
order to continue the lockdowns

               - The Italian politician Vittorio is infuriated because he sees how the chamber is lying:
only a small percentage died of covid!

           - A funeral director witnesses the murder of thousands of elderly, to create so-called covid deaths

          - He and dozens of other funeral directors were instructed by the British government to label every
death as covid

                     - Once the vaccinations started, these funeral directors witnessed

an unprecedented explosion of deaths

###### Many more examples of how the pandemic is being orchestrated can be found in the Full Report at StopWorldControl.com/full


-----

###### ONLY THE VACCINATED DIED

 DURING SPANISH FLU ONLY VACCINE RECIPIENTS DIED

In 1918 a disastrous number of 50          - 100 million people supposedly died of what was called the

'Spanish flu'. An expert eye witness of this event was the medical scientist Eleanor McBean, PhD, N.D.

who wrote a book with her first hand experiences of what was truly going on.81-82 She explains there

wasn't really a flu, but mass vaccinations had been imposed on the population, causing flu-like

symptoms, a host of different illnesses, and massive deaths.

**She** **knew** **of** **not** **a** **single** **unvaccinated** **person** **who** **died** **of** **this** **alleged** **'Spanish** **flu',** **while** **most**

**vaccinated** **lost** **their** **lives.**

'I was an on-the-spot observer of the 1918 influenza epidemic. All the doctors and people who were

living at the time of the 1918 Spanish Influenza epidemic say it was the most terrible disease the world

has ever had. Strong men, hale and hearty one day would be dead the next. The disease had the

characteristics of the black death added to typhoid, diphtheria, pneumonia, smallpox, paralysis, and

all the diseases the people had been vaccinated with immediately following World War 1. Practically

the entire population had been injected 'seeded' with a dozen or more diseases — or toxic serums.

When all those doctor-made diseases started breaking out all at once, it was tragic. That pandemic

dragged on for two years, kept alive with the addition of more poison drugs administered by the

doctors who tried to suppress the symptoms.

**As** **far** **as** **I** **could** **find** **out,** **the** **flu** **hit** **only** **the** **vaccinated.** **Those** **who** **had** **refused** **the** **shots**

**escaped** **the** **flu.**

My family had refused all the vaccinations so we remained well all the time. We knew from the health

teachings of Graham, Trail, Tilden, and others, that people cannot contaminate the body with poisons

###### without causing disease. When the flu was at its peak, all the stores were closed as well as the schools,

businesses — even the hospital, as the doctors and nurses had been vaccinated too and were down

with the flu. No one was on the streets. It was like a ghost town. We [who didn't take any vaccines]

seemed to be the only family which didn't get the flu; so my parents went from house to house doing

what they could to look after the sick, as it was impossible to get a doctor then. If it were possible for

germs, bacteria, viruses, or bacilli to cause disease, they had plenty of opportunities to attack my

parents when they were spending many hours a day in the sick rooms. But they didn't get the flu and

they didn't bring any germs home to attack us children and cause anything. None of our family had

the flu — not even a sniffle— and it was in the winter with deep snow on the ground.


-----

**It** **has** **been** **said** **that** **the** **1918** **flu** **epidemic** **killed** **20,000,000** **people** **throughout** **the** **world.** **But**

**the** **doctors** **killed** **them** **with** **their** **crude** **and** **deadly** **treatments** **and** **drugs.** **This** **is** **a** **harsh**

**accusation** **but** **it** **is** **nevertheless** **true,** **judging** **by** **the** **success** **of** **the** **drugless** **doctors** **in**

**comparison** **with** **that** **of** **the** **medical** **doctors.**

While the medical men and medical hospitals were losing 33% of their flu cases, the non-medical

hospitals such as BATTLE CREEK, KELLOGG and MACFADDEN'S HEALTH-RESTORIUM were getting

almost 100% healings with their water cure, baths, enemas, etc., fasting and certain other simple

healing methods, followed by carefully worked out diets of natural foods. One health doctor didn't

lose a patient in eight years. The very successful health treatment of one of those drugless doctors

who didn't lose any patients will be given in the other part of this book, titled VACCINATION

CONDEMNED, to be published a little later. If the medical doctors had been as advanced as the

drugless doctors, there would not have been those 20 million deaths from the medical flu treatment.

There was seven times more disease among the vaccinated soldiers than among the unvaccinated

civilians, and the diseases were those they had been vaccinated against. One soldier who had returned

from overseas in 1912 told me that the army hospitals were filled with cases of infantile paralysis and

he wondered why grown men should have an infant disease. Now, we know that paralysis is a

common after-effect of vaccine poisoning. Those at home didn't get the paralysis until after the

worldwide vaccination campaign in 1918.'

**'Seven** **men** **dropped** **dead** **in** **a** **doctor's** **office** **after** **being** **vaccinated.** **Letters** **were** **sent** **to** **their**

**families** **that** **they** **had** **been** **killed** **in** **military** **action.'**

_-_ _Eleanor_ _McBean,_ _PhD,_ _N.D._

Her expert medical eye witness account was later confirmed by autopsies, which showed there indeed

wasn't a flu, but the suffering was caused by random dosages of an experimental 'bacterial meningitis

vaccines', which to this day, mimics flu-like symptoms. The massive, multiple assaults with additional

vaccines on the unprepared immune systems of soldiers and civilians created a 'killing field1. Those

that were not vaccinated were not affected.


-----

###### THE SOLUTION: EARLY TREATMENT

 LEADING SCIENTISTS HAVE THE ANSWER

 If the toxic covid injections offer no solution for the COVID-19 disease, how can we then help

humanity? The answer is simple: from the very start of this worldwide health crisis, there were many

###### prominent scientists and medical doctors who exclaimed how they were successfully treating many

thousands of covid patients using existing drugs that are known for their safety and efficacy. There is

###### for example the world-famous French professor Didier Raoult, director of one of the largest research

groups in infectious diseases and microbiology. He is the most cited microbiologist in Europe

according to ISI and has trained more than 457 foreign scientists in his lab since 1998 with more than

1950 articles referred in ISI or Pubmed and is considered the world's foremost expert on infectious

diseases. Professor Raoult started treating covid patients with a medicine that has been around for

over sixty years and is famous for its safety and efficiency in defeating coronaviruses:

hydroxychloroquine.

**Professor** **Raoult** **treated** **over** **four** **thousand** **patients** **with** **hydroxychloroquine** **+ azithromycin**

**and** **virtually** **all** **of** **them** **recovered,** **except** **for** **a** **handful** **of** **very** **elderly** **who** **already** **had** **several**

**morbidities.83**

This incredible success inspired many other medical doctors around the world to start using the same

drug. In The Netherlands, Dr. Rob Elens gave all his covid patients hydroxychloroquine combined with

zinc and saw a 100% recovery rate in an average of four days. Nobody needed to be hospitalized.

Along with 2,700+ other medical professionals, this physician sent a letter to the Dutch government,

asking them to include HCQ into the standard protocol. Dr. Elens and other Dutch medical doctors set

up a 'COVID-19 Self Care' website, with information on howto prevent and overcome COVID-19, using

HCQ and zinc.84

In New York, the family practitioner Dr. Vladimir Zelenko treated over 500 covid patients at the

beginning of the pandemic with hydroxychloroquine + zinc + azithromycin. He also had a 100%

recovery rate, with hardly any side effects, and no hospitalizations.85 As of August 2021 Dr. Zelenko

and his team successfully treated over 6,000 covid patients. He developed a protocol to treat COVID-

19 which became world-famous and is saving the lives of millions of people around the world. The

Zelenko Protocol is used by for example the online telemedicine platform Speakwithanmd.com and

the vast network of 800,000+ members of America's Frontline Doctors.86


-----

**Hundreds** **of** **studies** **confirm** **the** **effectiveness** **of** **HCQ** **in** **treating** **COVID-19** **and** **preventing**

**hospitalization** **and** **death.** **87-88-89**

World leading scientists Dr. Pierre Kory and Dr. Peter McCullough are both the most published medical

experts in their field. Both these physicians and their teams have successfully treated tens of

thousands of covid patients using for example Ivermectin. Dr. Kory and his team of top medical

experts studied the entire medical literature for over nine months and found that Ivermectin proves

to be a miracle drug that effectively prevents and treats COVID-19.

**63** **peer** **reviewed** **studies** **confirm** **the** **effectiveness** **of** **Ivermectin** **in** **treating** **COVID-19.9°-91-92**

Biophysicist Andreas Kalcker used chlorine dioxide to slash the daily death rate of 100 to 0, in Bolivia

and was asked to treat the military, police, and politicians in several Latin American nations. His

worldwide network COMUSAV.com consists of thousands of physicians, academics, scientists, and

lawyers who are promoting this effective treatment.93-94-95

Information about early treatment for covid can be found on the following websites:

**[www.CovidPatientGuide.com](http://www.CovidPatientGuide.com)**

**[www.C19Protocols.com](http://www.C19Protocols.com)**

**[www.TheCovidRemedy.com](http://www.TheCovidRemedy.com)**

**[www.FlemingMethod.com/best-available-published-evidence](http://www.FlemingMethod.com/best-available-published-evidence)**

**[www.StopWorldControl.com/cures](http://www.StopWorldControl.com/cures)**


-----

###### SUPPRESSION OF TREATMENTS

 PHYSICIANS AROUND THE WORLD ARE PERSECUTED

 With several options to successfully treat COVID-19, why is there still such an outcry for a vaccine?

And why is the majority of the population not even aware of the available treatments? The answer is

shocking and shows once more what is going on in our world...

**All** **over** **the** **world** **physicians** **who** **were** **successfully** **treating** **covid** **patients,** **encountered** **the**

**unthinkable:** **they** **were** **intimidated** **and** **shut** **down** **by** **the** **government.**

America's Frontline Doctors informed the world about the safe and effective cures for covid, during

###### their first White Coat Summit in 2020. This broadcast was viewed over twenty million times in a few

hours, butthen they were shut down all across the board: Facebook, Youtube, Twitter, and even their

website was taken down by Squarespace. Dr. David Brownstein from Michigan, a leading holistic

practitioner, had successfully treated over 120 covid patients, but his entire medical blog was

removed. Dr. Rob Elens who successfully treated all his covid patients in the Netherlands was

threatened by the government that he would lose his license if he continued treating these people.

Dr. Joseph Mercola, a leading voice worldwide in healthy living, published information on howto treat

covid and was forced to delete his content after Google had already banned him. Professor Raoult,

who is one of the most respected scientists in the world, is suddenly slandered all over the internet.

Dr. Zelenko who successfully treated over 6,000 patients, among whom two presidents and the Israeli

health minister, is also bashed all over the web, and even had to leave his community because of the

backlash.

**The** **biophysicist** **Andreas** **Kalcker** **was** **de-platformed** **from** **all** **major** **social** **media,** **his** **book** **was**

**removed** **from** **Amazon** **and** **even** **his** **scientific** **account** **on** **ResearchGate** **was** **deleted.**

All these are just a few of the examples of physicians and scientists who successfully treat covid

patients, who faced massive opposition. Never before in the history of mankind has it occurred that

a working and safe drug for an illness has been kept from the world, through such an internationally

coordinated effort. People are not supposed to recover from covid, because the world population

needs to be scared into accepting this lethal injection.

_All_ _the_ _evidence_ _for_ _this_ _censoring_ _ofphysicians_ _can_ _be_ _found_ _here:_ _StopWorldControl._ _com/full_


-----

###### ULTIMATE MIND CONTROL

 CHILEAN PRESIDENT UNVEALS DIABOLICAL PLAN

As we all know, the goal of criminals is to always increase their power and wealth. They are never

satisfied but continually crave more. Ultimately they want to play 'god' over the whole world, where

everybody will be their servant. To keep increasing their power, there is one thing they need: _the_ _blind_

_obedience_ _of_ _the_ _masses._ Only a totally ignorant and utterly obedient population will collaborate with

###### their plans. That's why they have been buying the entire world's mainstream news media, education

systems, health care, and government agencies, etc. so they can use all of that to spread their

brainwashing propaganda to every mind in every corner of the world. Still, they don't stop here, as

they are fully aware that not everybody believes everything on television. Therefore their plan to gain

100% control over the minds of all of humanity has further developed. Recently their agenda has been

voiced loud and clear by the Chilean president Sebastian Pinera. In a public speech, he bluntly

announced to the entire nation:

**'Let's** **hear** **what** **the** **leaders** **of** **the** **world** **launch** **in** **this** **community.** **It** **is** **the** **possibility** **that**

**machines** **can** **read** **our** **thoughts** **and** **can** **even** **insert** **thoughts,** **insert** **feelings.** **5G** **is** **a**

**tremendous** **leap.** **It's** **a** **cosmic** **leap,** **a** **Copernican** **leap,** **because** **really** **what** **5G** **technology** **is**

**going** **to** **mean** **is** **an** **even** **greater** **shift** **in** **our** **lives** **than** **all** **the** **previous** **technologies** **have**

**meant.** **It** **offers** **the** **possibility** **that** **machines** **can** **read** **our** **thoughts** **and** **can** **even** **insert**

**thoughts,** **insert** **feelings.** **That's** **not** **just** **going** **to** **change** **life,** **it's** **going** **to** **transform** **it.** **5G** **in**

**the** **actual** **nervous** **system** **of** **our** **society,** **just** **like** **that.** **It** **is** **to** **modernize** **our** **state,** **to** **be** **a**

**change** **that** **reaches** **every** **home** **in** **our** **country.'96**

After stealing our voices through censorship, stealing our votes through election fraud, stealing our

money through ever-increasing taxes, they will now steal our very own thoughts and feelings through

5G. That will be the summit of their tyranny, as they will be able to impose the desired thoughts and

feelings onto the whole world, so nobody will even be able to divert from their narrative anymore. Is

that why Klaus Schwab so confidently states in his promotional videos about the near future:

**'You** **will** **own** **nothing,** **have** **no** **privacy** **and** **you** **will** **be** **happy.'97**

Could it be that he is referring to an artificially induced state of fake happiness? What does this have

to do with this vaccine report? It could be more than we are aware of right now. For 5G to be able to

modify the thoughts and feelings of the population it requires another element: nanoparticles inside

###### of the brains of people, that receive and transmit the 5G signals.


-----

**It** **turns** **out** **that** **the** **substance** **that** **is** **most** **efficient** **in** **communicating** **with** **5G** **is** **the** **very**

**substance** **that** **is** **massively** **present** **in** **the** **covid** **injections:** **graphene** **oxide.98'99**

No substance on earth communicates better with 5G than graphene oxide100, and no substance in

existence is more efficient in penetrating the human brain and manipulating human thoughts and

feelings, than graphene. One company that has been using graphene to manipulate the human brain,

###### for medical purposes, is IN BRAIN Neuro Electronics. Their website states:

**'We** **use** **graphene,** **the** **thinnest** **material** **known** **to** **man** **to** **build** **the** **new** **generation** **of** **neural**

**interfaces** **for** **brain** **restoration** **to** **help** **patients** **around** **the** **world.'**

The company highlights its technology as being able to 'read' a person's brain, detect specific

neurological patterns, and then control that person's neurology to **alter** **their** **brain** **function.101** It

appears that the intention of INBRAIN is to merely help people with neurological disorders, but the

reason I mention them is to illustrate how graphene is indeed the ideal substance to alter the human

brain. And again, it works better with 5G than anything else. The fact that it is present in the covid

vaccines, is therefore highly disturbing, especially if we know what the agenda is of the world leaders,

as described by the Chilean president:

**'5G** **offers** **the** **possibility** **that** **machines** **can** **read** **our** **thoughts** **and** **can** **even** **insert** **thoughts.**

**insert** **feelings.'**

Another element we have to touch on, is the clear and public agenda of the globalists to end humanity

as we know it and steer all of us into becoming cyborgs. This is clearly explained in the book of Klaus

Schwab 'The Fourth Industrial Revolution'. He strongly believes humans need to become one with

machines, that are fully connected to the cloud, and who are surveilled and controlled by artificial

intelligence. That's why he says nobody will have any form of privacy anymore, yet they will be 'happy'.

How well Schwab masters the skill of deception with cleverly chosen words to hide his true intents, is

seen at the end of his book:

'In the end, it all comes down to people and values. We need to shape a future that works for all of us

by putting people first and empowering them. In its most pessimistic, dehumanized form, the Fourth

Industrial Revolution may indeed have the potential to "robotize" humanity and thus to deprive us of

our heart and soul. But as a complement to the best parts of human nature—creativity, empathy,

stewardship—it can also lift humanity into **a** **new** **collective** **and** **moral** **consciousness** based on a

shared sense of destiny. It is incumbent on us all to make sure the latter prevails.'102


-----

What he says here is that humans need to be empowered and may not be turned into robots, that

have lost their soul. He however goes on to explain the true goal: 'lift humanity into a new collective

and moral consciousness.' What does that mean? It means exactly what it says: every human will think

and feel the same way, we will all share the same 'collective consciousness'.

**This** **means** **total** **brain** **manipulation** **of** **all** **of** **humanity.** **Everyone** **will** **be** **submitted** **to** **the**

**narrative** **that** **the** **world** **leaders** **prescribe.** **Humanity** **will** **have** **a** **new** **collective** **consciousness.**

No longer will Google, Facebook, or Twitter need to censor anybody's voice because the Fourth

Industrial Revolution will ensure that all of humanity is 'lifted into the same mindset'. That's the

ultimate goal of these criminals. The hypocrisy of Schwab is sickening, as this is exactly what he says

should not happen. This is turning humans into robots who can no longer think for themselves, but

who will all be forced to share the same 'mind'.

The agenda is crystal clear: humanity must be connected to artificial intelligence, that will tell everyone

what to think and feel. The key to this is injecting humanity with nanotechnology, which turns every

person into a walking antenna that can receive and transmit all kinds of signals. Could that be the

reason they insist on imposing never-ending injections onto humanity? Is it so they can continually

increase the presence of graphene oxide and other nanotechnology inside of people, shifting them

more and more to the new era of transhumanism? If that wasn't exactly what the World Economic

Forum has been promoting for the past decades, and what is explained in their recent articles, books,

and videos, I would consider this to be the scenario of a bad movie. But it is not a movie. It's in reality

what these psychopaths are cooking up in their insane minds as the future for humanity.

###### NEW WORLD ORDER

 AUSTRALIA NO LONGER HIDES WHAT IS GOING ON

For decades the tyrannical system of worldwide oppression and control, called the New World Order,

was labelled a conspiracy theory. But as it is with all so-called conspiracy theories, after some time

they prove to be more than theories. In Australia, the health officials no longer hide their agenda, and

have been calling their covid tyranny the 'New World Order.' This is what the Chief Health Officer of

New South Wales, Kerry Gai Chant, said during a public broadcast:

**'We** **will** **be** **looking** **at** **what** **contact** **tracing** **looks** **like** **in** **the** **New** **World** **Order.** **Yes,** **it** **will** **be**

**pubs** **and** **clubs** **and** **other** **things** **if** **we** **have** **a** **positive** **case** **there.'103**


-----

Brad Hazard, the Australian Health Minister, said the following words:

**'That's** **just** **the** **way** **it** **is.** **We** **have** **got** **to** **accept** **that** **this** **is** **the** **New** **World** **Order'.104**

An Australian news reporter announced new restrictions with the following words:

**'Also** **the** **New** **World** **Order** **that** **will** **come** **into** **force** **at** **12pm,** **at** **midnight** **tonight,** **new**

**restrictions** **on** **various** **businesses.'105**

Another Australian news broadcast, said it like this:

**'The** **New** **World** **Order,** **our** **army** **comes** **marching** **in,** **partnering** **with** **police,** **to** **help** **enforce**

**the** **countries** **tough** **new** **quarantine** **laws.'106**

The day that the new restrictions came into place, the news reporter said:107

**'Today** **is** **the** **first** **full** **day** **of** **the** **New** **World** **Order.** **Outdoor** **gatherings** **are** **limited** **to** **two**

**people.** **Exercise** **is** **allowed** **but** **no** **further** **than** **a** **10km** **radius** **from** **your** **home.** **Browsing** **in**

**shops** **is** **not** **permitted.** **Only** **one** **person** **per** **household** **may** **leave** **to** **do** **essential** **shopping.**

**And** **from** **tomorrow** **funerals** **are** **limited** **to** **ten** **people.'**

What is the excuse for this inhumane tyranny? 14 supposed covid deaths during the first half of 2021!

While in 2017 over four thousand people died in Australia from influenza and pneumonia.108

###### NO THEORY BUT HISTORY

IS HUMAN HISTORY A CONSPIRAY THEORY?

**If** we know history, then we understand the basic reality that there have always been power-hungry

madmen whose sole desire was to rule the entire world. Think of the Chinese, Persian, Greek, Roman,

Spanish, British world empires, among others. The lust for world domination is as old as the world

itself. That's why it always amazes me when I see people react with mockery when I mention this

historic reality. Even the name of my website StopWorldControl.com is ridiculous to some. 'Hahaha,

world control, what a silly conspiracy theory!' This is alarming, as it shows how far the minds of some

###### of us have been led astray from understanding even the most basic principles of human existence. As


-----

recent as 80 years ago the world was threatened by yet another madman who wanted to rule the

world, with two consecutive world wars as a result. Is that a conspiracy theory too?

**The** **plan** **to** **control** **the** **entire** **world** **has** **always** **existed,** **and** **has** **been** **expressed** **in** **countless**

**forms,** **throughout** **the** **existence** **of** **humanity.**

**All** **throughout** **the** **history** **of** **mankind,** **up** **to** **this** **very** **day,** **there** **have** **been** **cruel** **and** **horrifying**

**practices,** **at** **the** **heart** **of** **certain** **groups** **of** **people.**

Nowadays the public seems to be so severely brainwashed, that when we warn for similar dark forces

in our time, they immediately deny it. But if we want to protect our lives, we must understand how

the same kind of wicked entities that terrorized our world in the past, are still around today. It is these

kinds of evil people who are at the heart of the criminal network that is behind the New World Order.

###### WHO ARE THESE CRIMINALS?

 MEET THE DARK FAMILIES WHO RULE THE WORLD

 Who exactly are these criminals? Do we have some of their names and whereabouts? How do they

operate and what can we do to stop them? An important part of the answer is given in the magnificent

documentary MONOPOLY, which can be viewed on StopWorldControl.com.

**MONOPOLY** **reveals** **in** **great** **detail,** **with** **all** **the** **evidence** **on** **screen,** **how** **virtually** **everything** **in**

**our** **world** **is** **owned** **by** **the** **same** **people,** **and** **it** **shows** **what** **they** **are** **planning** **for** **humanity.**

Because these superrich entities own everything, it's a piece of cake for them to control the world.

They own Apple, Facebook, Twitter, Google, Facebook, and the rest of Big Tech, all the major news

media, the entire travel industry, the whole food industry, the banks, the clothing industry, and so on.


-----

By strategically buying everything, they have gained an unrivaled monopoly worldwide. Something

Julius Ceasar could only dream of... They also own the entire health industry, which allows them to tell

hospitals around the world whatto do and what notto do. They have positioned their political puppets

in governments around the world through election fraud, bribery and blackmailing. Once we

understand this, we can see how they are able to impose tyranny all over the world.

It would take me too far to name all the involved individual entities, but I will reveal a few, that are at

the heart of this network. In Italy there are for example 13 Italian families or bloodlines, called the

'Black Nobility'. I call them _the_ _mafia_ _on_ _steroids._ These families, along with other similar dynasties from

other regions of the earth, consider themselves to be superior over the rest of humanity. They look

upon regular folks as 'bugs', 'cattle', and 'dogs'. That is literally how they write about you and me in

###### their literature.

**They** **believe** **that** **it's** **their** **destiny** **to** **rule** **over** **humanity,** **who** **are** **to** **become** **their** **slaves.**

These families are organized in a pyramidal hierarchy, where ultimately everyone answers to the same

puppet masters at the top. _The_ _key_ _to_ _their_ _power_ _is_ _secrecy,_ _so_ _nobody_ _can_ _touch_ _them._ That's why the

real leaders always stay in the shadows. The world population only sees puppets that operate on the

visible stage of the world scene, like mind-programmed politicians, perverted Hollywood celebrities,

industrial leaders, media personalities, etc. Some better-known puppets are Klaus Schwab, Bill Gates,

George Soros, the Clinton, Bush and Morgan family, etc. Although they are all individually very rich

and powerful, they are submitted to entities that are higher up in the hierarchy, but who make sure

they stay out of the picture. _Secrecy_ _is_ _their_ _strength._

One of their strategies is to set up public 'world' organizations, which are their visible platforms to

work out their agenda. One of these has become very prominent during this organized pandemic and

is called the World Health Organization, which is mostly financed by Bill Gates, a key puppet of this

criminal network. The WHO is dictating to all of humanity         - think about this!         - what we can or cannot

do when it comes to our health. Nobody elected the World Health Organization and nobody wants

them to be around, to bully every physician, nurse, and health practitioner into blind obedience.

**The** **WHO** **forces** **the** **entire** **world** **into** **unquestioning** **submission** **to** **their** **tyrannical** **'guidelines',**

###### that are more often anti-scientific than based on proper science.

The WHO for example told the entire world to use the PCR test to discover covid cases, while this test

cannot discern between different types of pathogens, and produces up to 93% of false positives. This

flawed test is the main tool to tell the world there is a pandemic, while no medical device in history


-----

has ever been so unreliable. Yet this anti-scientific protocol is imposed on the entire world, to promote

the illusion of a global pandemic, which is mainly based on false positives. The hundreds of millions

###### of so-called 'covid cases' are nothing but false positives, resulting from a fatally flawed test. The

actual virus Sars-Cov-2 has never been isolated and purified, therefore it is impossible to test for it.

It's a scam of astronomical proportions.

**That's** **an** **example** **of** **how** **a** **'world** **organization'** **is** **used** **to** **roll** **out** **the** **agenda** **of** **submitting**

**humanity** **to** **tyranny,** **in** **the** **name** **of** **'protecting** **your** **health'.**

A similar organization is the United Nations, which portrays itself as the so-called 'peace keeper' of

this world. Their agenda is however to submit all of humanity to a one-world government. The U.N.

works closely with the European Union and NATO, which are similar carousels for the criminal families

to wipe out the independence of the nations and set up a one-world government.

Another public player is the World Economic Forum, founded by Klaus Schwab. The World Economic

Forum presents itself as a think tank for the rich and powerful of the world, where they'seek solutions

###### for the world's problems'. Their magic word is 'sustainable development' which claims to ensure a

better future for our world. Together with the U.N., they developed the so-called Agenda21, which

claims to offer the ultimate solution for a more sustainable world.

**In** **reality,** **this** **means** **nothing** **less** **than** **seizing** **all** **rights,** **freedoms** **and** **properties** **from** **the**

**entire** **world** **population** **and** **bringing** **it** **all** **in** **the** **hands** **of** **the** **superrich.**

Then there is the banking imperium, which controls all the money in the world. Their job is to bring

about a cashless society where only those who are digitally connected to the system of surveillance

and slavery, will still have access to finances. The Nigerian government has been paid handsomely by

them, to reserve banking services strictly for the vaccinated, an example that will soon be followed by

other countries. A leading entity in the banking imperium is the notorious Rothschild family. They own

the central banks in 165 nations, thus controlling the money flow in most of the world. Since ancient

times this family has dedicated itself to the worship of the darkest of all forces. Another well-known,

equally dark family are the Rockefellers. They published the 'Scenario of the Future' in 2010, in which

they described the current pandemic in great detail, with the desired outcome of establishing a new

world of domination and control.

**Entities** **like** **the** **Rockefeller** **Institute** **present** **themselves** **as** **protectors** **of** **humanity,** **but**

**behind** **this** **humanitarian** **mask** **there** **is** **a** **gruesome** **face** **of** **lust** **for** **power.**


-----

I already mentioned the Black Nobility from Italy. Their most effective strategy has been to hide behind

the beautiful face of Christianity, as they established the Vatican in Rome, as the 'center of Roman

Catholicism'. Behind the monumental architecture of the majestic cathedrals, there however lurks a

world so dark and perverse, that no normal human being could ever comprehend it. The recent

exposure of organized, systematic child abuse in this religious stronghold is only the tiniest tip of an

iceberg so deep, that it would traumatize most of us, if we knew what is going on there. Make no

mistake: there are also good religious people in the Vatican, who are opposing the criminal activities.

**For** **example** **archbishop** **Carlo** **Maria** **Vigano,** **has** **been** **speaking** **out** **against** **what** **he** **calls** **the**

**'Deep** **Church',** **comparing** **it** **to** **the** **'Deep** **State'.**

The Vatican is located inside Vatican City, which is a sovereign state independent from Italy, where no

Italian law has any authority. Because they are not submitted to the laws of any land, not even Italy

that surrounds them, they are able to commit any crime they want. Similar sovereign states inside the

nations are 'The City of London' (an independent state within London that evades all British laws but

controls the British government), 'Washington D.C.' (or the District of Columbia, which is a sovereign

state inside the United States, that rules over the American people). The criminal families have set up

these untouchable 'states within nations' from where they operate.

**Pigna**

**Old**
**Gardens**

**Academy** **of**
**Sciences**

**DamasoSt** *****
**tCourtyacd**

**Gardens**

**Sistine**
**Chapel** **Palace**

**Saint** **Peter's**
**Square**

**Puzza**
**Santa**
**Marta**

**Hall**

**ITALY**
**Rome**


-----

**Vatican** **City** **is** **the** **most** **important** **of** **them** **all,** **and** **it** **is** **here** **that** **the** **highest** **puppet** **masters**

**have** **their** **seat.**

We all know the White Pope, a role that is currently played by Pope Francis. His job is to control the

worldwide Roman Catholic faith community, and steer them towards the New World Order. In several

public messages he calls all believers to get vaccinated112, and goes on to proclaim the New World

Order as the only solution to the world's problems. Here are some of his statements:113

'We can heal injustice by building **a** **new** **world** **order** **...** The path to humanity's salvation passes

through the creation of **a** **new** **model** of development... take care of the Earth, with **radical** **personal**

**and** **political** **choices,...** without **an** **overall** **vision** there will be no future ... we must bring an end to

**short-sighted** **nationalism** **...'**

Besides the White Pope, there is also a lesser known Black Pope who has far more power, but who

works more behind the scenes. The Black Pope however is still submitted to one who sits on a higher

throne: _the_ _Grey_ _Pope._ This supreme puppet master operates entirely in the shadows, from where he

yields enormous power over the world. If you want to understand how all this originated historically,

you have to research the dark spiritual origins of the Jesuits. I will leave it here, for now, as this topic

can easily lead us too far.

Their strategy is however to always hide behind magnificent masks, that show the opposite of who

they are.

**We** **see** **this** **with** **Klaus** **Schwab,** **who** **uses** **eloquent** **rethoric** **to** **bewitch** **the** **minds** **of** **his**

**worldwide** **audience,** **and** **convince** **them** **that** **the** **noblest** **of** **all** **causes** **is** **to** **make** **sure** **that**

**every** **human** **on** **earth** **will** **think** **and** **feel** **the** **exact** **same** **way.** **'Lift** **humanity** **into** **a** **collective**

**consciousness.'**

The way he presents this stark raving mad plan, is however so cunning that most people would give

him a standing ovation, after hearing his speech. The same we see with the White Pope, who speaks

beautifully about caring for the poor, ending injustice, saving the Earth, and other noble causes, while

in fact he simply says: 'The whole word needs to be enslaved to a one world government, where

nobody will have a voice, rights, freedoms, possessions, identity or privacy.' It's the same kind of

hypnosis they use to impose the vaccine mandates: 'The world is attacked by a deadly disease, but we

have a wonderful solution: lifesaving vaccines. Hurray!' That these wonderful vaccines contain living


-----

creatures with tentacles, self assembling nanobots, highly toxic substances, and that millions are killed

by them, is of course not mentioned.

**It's** **all** **about** **hypnotizing** **humanity** **using** **refined** **forms** **of** **hypocrisy** **and** **deception.**

Another way these criminals operate, is by organizing themselves in so-called secret societies, to

establish their hidden influence in every nation. Apart from the completely hidden societies, there are

also more public cults, like Freemasonry. This is one of the better-known spiritual organizations, used

to influence local authorities in virtually every town of every nation. They attract people in authority,

claiming to be an innocent organization that wants to help humanity. Only when members climb to

the higher levels of

**Freemasonry** **focuses** **on** **making** **influential** **people** **in** **every** **community** **their** **members,** **so** **they**

**can** **use** **them** **for** **the** **outworking** **of** **their** **plans.**

Google whistleblower Zach Vorhies109 told me in a personal conversation that in 2016 Google layed

###### out their plans to program humanity in a revealing location: the San Francisco Freemasonry

Headquarters. There Google informed their staff about the company strategy: _mold_ _the_ _mind_ _of_

_mankind._ That illustrates how Freemasonry plays a central role in this worldwide agenda.

The many secret societies work closely with the secret services of the nations, like for example the CIA

and FBI in America. Entities that on the surface fight crime, but in reality are among the worst of all

criminal organizations. The renowned German journalist Udo Ulfkotte, who was murdered for his

confessions, admitted a few years ago that journalists all over the world are paid by secret services,

secret societies, government agencies, billionaires, etc. to **always** **lie** **and** **never** **tell** **the** **truth** **to** **the**

**public.** His important testimony can be seen in the documentary **BUSTED** on StopWorldControl.com.

It is because of the confessions of this brave journalist              - who was editor of one of Europe's largest

newspapers       - that a major awakening is going on in Germany. His book opened the eyes of the

German population, who are now a major force against the New World Order.

Although Vatican City, Washington D.C., and the City of London are the headquarters of the criminal

families, many of their logistics operations have been transferred to Asian countries, because they

plan to use China to overthrow the rest of the world. The oppressive communistic regime of total

slavery and control which they installed in China, must be rolled out now over the rest of the world.

**Our** **enemy** **is** **however** **not** **the** **Chinese** **Communist** **Party,** **since** **they** **are** **also** **mere** **puppets.**

**Those** **calling** **the** **shots** **are** **still** **seated** **in** **Vatican** **City.**


-----

Good news is that there has been a lot of infighting in this criminal network, causing it to fall apart in

several camps, that all compete for world domination. May this confusion among them increase, as

they fall into their own pits, and their plans fail miserably.

Much more can be said aboutall ofthis, as many books have been written aboutthis criminal network,

by researchers who often dedicated their entire lives to expose them. If you want to learn more, you

can find a wealth of quality information compiled by some excellent researchers on the Dutch website

**Ellaster.nl.** Use Google translate to read the articles: ellaster.nl/category/val-van-cabal/cabal

**You** **can** **also** **watch** **the** **docu-series** **'Fall** **of** **Cabal'** **on** **StopWorldControl.com/cabal.** **a**

**masterpiece** **of** **journalism** **that** **explains** **a** **lot** **about** **this** **worldwide** **'cabal'.**

###### THE GREAT AWAKENING

 HUNDREDS OF MILLIONS ARE RISING UP

Is there any hope for humanity? Yes. Although we are witnessing the greatest criminal operation since

the birth of our world, something entirely different is also happening. Hundreds of millions of people

are waking up from the deep sleep of ignorance and deception, and they are letting out a roar of truth,

all over the world. In every nation organizations of medical doctors, lawyers, scientists, and all kinds

###### of professionals are being established, to fight for freedom. They consist of tens of thousands of

educated, influential and passionate professionals who are determined to stop this diabolical scheme.

Brand new media platforms are being born, that grow every day in influence. They are not owned by

the criminal cartel, but work from a heart that wants to defend humanity against the onslaught of

destructive fake news media, that is operated by the cabal.

On top of that, increasingly large numbers of health care workers are refusing the vaccine mandates.

In Canada 35,000 medical professionals protested against the vaccines.59 In New York 83,000 health

care workers refuse the toxic injections.60 Overall in the U.S. 58% of all physicians is not taking the

dangerous shots.61 Also among law enforcement and fire fighters there is increasing protest against

the vaccine mandates. In California 50% of all law enforcement stands up against these criminal

mandates.62

**These** **are** **just** **a** **few** **examples** **of** **the** **mass** **non-compliance** **in** **nations** **around** **the** **world.**


-----

This resistance is about to explode even far more worldwide, as the truth about these injections is

spreading far and wide, despite all the attempts from the _criminal_ _vaccine_ _cartel_        - which includes Big

Tech, Big Pharma, government agencies, news media, etc.        - to suppress this information.

On **StopWorldControl.com** we are about to launch a world map, that will show hundreds of

organizations in nations around the world who are resisting this criminal operation. They represent

hundreds of millions of people who refuse to become slaves of criminals. Among them are large

numbers of physicians, scientists, academics, lawyers, entrepreneurs, politicians, etc. There is an

unprecedented and unstoppable awakening going on, that will only increase in the near future.

It is clear that with every new attempt of the criminals to proceed with their nefarious plan, millions

more people are waking up. The whole climate change hoax for example, which is just another one of

###### their tricks to impose more control and taxes onto the population.

**Every** **informed** **person** **knows** **the** **climate** **is** **100%** **controlled,** **through** **geo-engineering** **or**

**weather** **manipulation.110**

There is no such thing as global warming. What we see is a worldwide system of highly developed

weather manipulation, which is causing all the storms, heat waves, wildfires, earthquakes, extreme

hail and snow storms, floods, and other natural disasters. _Cloud_ _seeding_ is for example a commonly

known practice where big rain storms are created by spraying chemicals in the sky.111 In a separate

report we will provide all the evidence for this. We have official documents and video footage from

the U.S. government and military that clearly state how the weather is not only 100% controlled, but

it has also been _weaponized._ Governments, military and private corporations have been refining their

weather manipulation systems for decades. The criminals constantly cry: 'Global warming!' but their

game is failing, as the truth about weather manipulation, or geo-engineering, is coming out. Hundreds

###### of millions of people who discovered howthe pandemic is orchestrated, also begin to understand that

other attacks on humanity are coming from the same source. Also the imaginary threat of an alien

invasion, is a card up the sleeve of the criminals that we will see thrown on the table in the future.

'The aliens are coming to invade the earth! We need a one world government to protect us!' It will be

amusing to observe how many people will fall for this one.

**The** **strategy** **is** **always** **the** **same:** **create** **a** **problem** **(pandemic,** **climate** **change,** **racism,** **social**

**unrest,** **alien** **threat,** **asteroid** **collision,** **etc.)** **and** **then** **offer** **a** **solution.** **The** **solution** **is** **always**

**the** **same:** **stealing** **rights,** **freedoms** **and** **finances** **from** **the** **people.**


-----

The veil has however been lifted, and no more is everyone buying their lies. The awakening of

hundreds of millions of intelligent people is unstoppable and will become the greatest shift in all of

human history. The insane vaccine mandates are causing the world to wake up as never before.

Freedom will come, as the truth will break through more and more. Courageous heroes of humanity

will rise up in increasing numbers to stop the plans of the madmen, and direct the world into a better

direction. These heroes are medical professionals, lawyers, scientists, politicians and hundreds of

millions of vigilant citizens.

**We** **all** **play** **a** **part** **in** **this** **Great** **Awakening.** **None** **of** **us** **may** **stand** **at** **the** **sidelines** **and** **do**

**nothing.** **That** **is** **complicity.** **Witnessing** **a** **crime** **and** **allowing** **it** **to** **happen** **is** **the** **same** **as**

**supporting** **it.**

Many of us have remained silent, out of fear of losing jobs, finances, position, respect, or friends. We

must understand however that if we don't speak out now, we will lose far more than jobs, finances,

and friends. We will lose our very humanity and become programmed slaves without the ability to

###### think or feel independently. So what can we do? The most important is to inform our fellow humans,

even though they may resist fiercely at first because their minds are so brainwashed by the

propaganda. The initial rejection of truth should not discourage us, but we must resort to all possible

means to awaken the entire world. It's only because of the ignorance of the population that this

criminal network can reign on the earth. Now there is however an unprecedented awakening

happening and all of us have the duty to do all we can, to fan the flames ofthis awakening.

**Everybody** **can** **print** **out** **this** **report** **in** **many** **copies** **and** **distribute** **it** **to** **our** **local** **law**

**enforcement,** **school** **directors** **and** **teachers,** **medical** **personnel,** **friends,** **and** **neighbors.**

We can all upload this PDF to an **online** **printing** **service** and have thousands of copies made, that

we hand out in our community. All of us can send this report as an email attachment to all our

contacts, and people in authority. There is no excuse for any one of us, to do nothing. We need to

inform the world. We have to rise and do what we can. We must spread the truth far and wide. That

takes effort. Please don't sit down and complain, but rise and take action. This report is made with

great effort, to be a tool for awakening the world. _Please_ _use_ _it._

**More** **information** **can** **be** **found** **at** **StopWorldControl.com.** **Make** **sure** **to** **sign** **up** **for** **the** **emails,**

**to** **be** **informed** **and** **empowered,** **so** **you** **can** **defend** **your** **life,** **freedom** **and** **future.**


-----

###### DETOX FROM THE SHOTS

IS THERE HOPE FOR THE VACCINATED?

Stop World Control is investigating proposed solutions to detox from the covid vaccines. We have

found several options that are promising, and we hope to release a **Vaccine** **Detox** **Guide** soon. Sadly

not every damage done by the mRNA shots will be able to be undone, like the altering of the DNA.

That is a switch that cannot be reversed. There are however methods to get rid of the nanotech in

your body, kill the living organisms that are being injected, remove the spike proteins, etc. As

vaccinations continue, and different pathogens will be released, we will keep researching for any new

solutions that will become available. Sign up for the emails of Stop World Control to stay updated on

this research. _If_ _you_ _know_ _of_ _working_ _solutions_ _to_ _detox_ _from_ _these_ _injections,_ _please_ _email_ _us_ _at_

_network&stopworldcontrol._ _com_


-----

###### * FINAL SUMMARY *

 The data shows that millions may have died already from the covid injections,
 and hundreds of millions suffer serious side effects. This is just the short term
 destruction. The real devastation comes after a few years.

 There is graphene oxide in the vaccines, which is the perfect conductor for 5G,
 and also the best substance for brain manipulation. The Chilean president said that 5G will insert thoughts and feelings into everyone. Klaus Schwab adds that humanity will be lifted into one and the same consciousness. This reveals
 an agenda of total mind control. The Australian government calls the covid

 tyranny the New World Order.

 All this is based on worldwide fraud of inflating covid numbers, relabeling
 every death as covid, a PCR test that produces false positives, media scare
 mongering, and government propaganda. The criminal network who is behind
 all this, has been buying the entire health industry, they direct the World

 Health Organization, they own all mainstream media, and control most
 governments. They suppress every treatment for covid, so the world would think a vaccine is the only way out.

 Their power lies in the fact that they operate in the shadows, so the public has
 no clue about their existence. The solution is exposing them. Once enough
 people in the world - especially law enforcement, health care workers, school
 teachers, judges, and local authorities - understand what is going on, the plans of the wicked will fail. Mass awakening will result in mass non-compliance.

 Although most of the judicial system is corrupt, lawyers need to become brave

 warriors to present all the evidence for this crime, and start prosecuting all
 who are complicit. There still remain honest judges, who can turn the tide.

 This can become the greatest awakening of all time, if we all rise up, share truth, and unify as one humanity against these criminals.


-----

###### REFERENCES

 STARTING POINT FOR YOUR OWN RESEARCH

As internet censorship is increasing, because criminals are desperately trying to hide all truth, some

###### of the links below may get deleted. Usually one can however retrieve them, using the internet archive

Archive.org. Simply copy and paste the deleted URL in the search box, and you should see a saved

version of the web page. Personally, I save a PDF version of every important web page, and I download

every critical video, so I build my private database of evidence.

1: [https://renzlaw.godaddysites.com/45k-whistleblower-suit](https://renzlaw.godaddysites.com/45k-whistleblower-suit)

2: [https://www.icandecide.org/wp-content/uploads/2021/03/Letter-to-Dr.-Walensky-re-anaphylaxis.pdf](https://www.icandecide.org/wp-content/uploads/2021/03/Letter-to-Dr.-Walensky-re-anaphylaxis.pdf)

3: [https://jamanetwork.com/journals/jama/fullarticle/2777417](https://jamanetwork.com/journals/jama/fullarticle/2777417)

4: [https://centipedenation.eom/first-column/150k-records-deleted-from-vaers-covid-database/](https://centipedenation.eom/first-column/150k-records-deleted-from-vaers-covid-database/)

5: https://www.forbes.com/sites/emilywillingham/2015/08/06/a-congressman-a-cdc-whisteblower-and-an-

autism-tempest-in-a-trashcan/?sh=47819f145396

6: [https://rumble.com/vm1yrt-wow-vaccine-caused-deaths-reported-as-un-vaxxed-covid-deaths.html](https://rumble.com/vm1yrt-wow-vaccine-caused-deaths-reported-as-un-vaxxed-covid-deaths.html)

7: [https://dissident.one/2021](https://dissident.one/2021) /08/29/18311/

8: [https://alexberenson.substack.eom/p/some-actual-news](https://alexberenson.substack.eom/p/some-actual-news)

9: https://www.lifesitenews.com/news/nearly-50k-medicare-patients-died-soon-after-getting-covid-shot-

whistleblower/

10: [https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011](https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011) .pdf

11: [https://www.facebook.com/80221381134/posts/10158207967261135/?d=n](https://www.facebook.com/80221381134/posts/10158207967261135/?d=n)

12: [https://www.dailymotion.com/video/x81f1y1](https://www.dailymotion.com/video/x81f1y1)

13: [https://video.foxnews.eom/v/6260748415001](https://video.foxnews.eom/v/6260748415001) #sp=show-clips

14: https://childrenshealthdefense.org/defender/censored-dark-horse-podcast-bret-weinstein-robert-malone-

inventor-mrna-vaccine-technology

15: [https://rumble.com/vk894g-dr-michael-yeadon-a-final-warning-to-humanity.html](https://rumble.com/vk894g-dr-michael-yeadon-a-final-warning-to-humanity.html)

16: [https://thehighwire.com/videos/a-coming-covid-catastrophe](https://thehighwire.com/videos/a-coming-covid-catastrophe)

17: [https://www.youtube.com/watch?v=ZJZxiNxYLpc](https://www.youtube.com/watch?v=ZJZxiNxYLpc)

18: [https://doctors4covidethics.org/holocaust-survivors-write-to-the-european-medicines-agency/](https://doctors4covidethics.org/holocaust-survivors-write-to-the-european-medicines-agency/)

19: [https://healthimpactnews.com/2021](https://healthimpactnews.com/2021) /21766-dead-over-2-million-injured-50-serious-reported-in-european-

unions-database-of-adverse-drug-reactions-for-covid-19-shots/

20: [https://www.adrreports.eu/en/index.html](https://www.adrreports.eu/en/index.html)

21: [https://meldpuntvaccinatie.nl/](https://meldpuntvaccinatie.nl/)

[22:https://ted.europa.eu/udl?uri=TED:NOTICE:506291](https://ted.europa.eu/udl?uri=TED:NOTICE:506291) -2020:TEXT:EN:HTIVIL&src=0

23: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-

vaccine-summary-of-yel low-card-reporting

24: [https://dailyexpose.co.uk/2021/02/08/official-data-on-adverse-reactions-to-vaccines](https://dailyexpose.co.uk/2021/02/08/official-data-on-adverse-reactions-to-vaccines)


-----

25: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-

vaccine-summary-of-yellow-card-reporting#annex-1-vaccine-analysis-print

26: [https://theexpose.Uk/2021/09/15/30k-people-died-within-21](https://theexpose.Uk/2021/09/15/30k-people-died-within-21) -days-of-having-a-covid-19-vaccine-in-england/

27: [https://dailysceptic.org/is-the-mhras-yellow-card-reporting-system-safeguarding-the-uk-public](https://dailysceptic.org/is-the-mhras-yellow-card-reporting-system-safeguarding-the-uk-public)

28: [https://www.the-people-committee.com/](https://www.the-people-committee.com/)

29: [https://humansarefree.com/2021/08/32k-people-dead-in-brazil-following-covid-19-vaccines.html](https://humansarefree.com/2021/08/32k-people-dead-in-brazil-following-covid-19-vaccines.html)

30: [https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness/](https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness/)

31: [https://www.ahajournals.Org/doi/10.1161](https://www.ahajournals.Org/doi/10.1161) /CIRCRESAHA.121.318902

32: [https://www.nature.com/articles/s41586-021-03744-4](https://www.nature.com/articles/s41586-021-03744-4)

33: [https://www.nejm.0rg/d0i/full/l](https://www.nejm.0rg/d0i/full/l) 0.1056/NEJMc2109975

34: [https://deeprootsathome.com/a-foreshadowing-buried-82-miscarriage-data-in-new-nejm-study/](https://deeprootsathome.com/a-foreshadowing-buried-82-miscarriage-data-in-new-nejm-study/)

35: [https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733)

36: [https://pubmed.ncbi.nlm.nih.gov/32908214/](https://pubmed.ncbi.nlm.nih.gov/32908214/)

37: [https://citizenfreepress.com/breaking/whoa-fauci-finally-mentions-vaccine-risk-for-ade/](https://citizenfreepress.com/breaking/whoa-fauci-finally-mentions-vaccine-risk-for-ade/)

38: [https://canadianmale.wordpress.eom/2021/04/19/thousands-of-reports-of-menstrual-irregularities-](https://canadianmale.wordpress.eom/2021/04/19/thousands-of-reports-of-menstrual-irregularities-)

reproductive-dysfunction-following-covid-vaccines/

39: https://www.lifesitenews.eom/wp-content/uploads/2021/06/Pfizer-bio-distribution-confidential-document-

translated-to-english.pdf

40: [https://www.nature.com/articles/s41586-018-0465-8](https://www.nature.com/articles/s41586-018-0465-8)

41: [https://thehighwire.com/videos/a-coming-covid-catastrophe](https://thehighwire.com/videos/a-coming-covid-catastrophe)

42: https://nulluslocussinegenio.eom/2021/09/13/why-mass-vaccinations-prolong-and-make-epidemics-

deadlier-real-vaccine-expert-calls-out-flawed-government-pandemic-strategy/

43: [https://rumble.com/vldilx-nobel-prize-winner-professor-luc-montagnier-says-vaccine-is-creating-varian.html](https://rumble.com/vldilx-nobel-prize-winner-professor-luc-montagnier-says-vaccine-is-creating-varian.html)

44: [https://rumble.com/vlme81](https://rumble.com/vlme81) -the-most-vulnerable-population-are-the-ones-who-received-two-vaccine-

doses.html

45: [https://www.bitchute.com/video/3dX3gawfhaEJ/](https://www.bitchute.com/video/3dX3gawfhaEJ/)

46: [https://rumble.com/vkb885-fauci-says-cdc-considering-mask-mandates-for-vaccinated-americans.html](https://rumble.com/vkb885-fauci-says-cdc-considering-mask-mandates-for-vaccinated-americans.html)

47: [https://rumble.com/vkciqv-fauci-vaccinated-wear-a-mask-will-he-ever-be-canceled.html](https://rumble.com/vkciqv-fauci-vaccinated-wear-a-mask-will-he-ever-be-canceled.html)

48: [https://rumble.eom/vflkib-more-fauci-b.s.-vaccinated-americans-still-cant-eat-indoors.html](https://rumble.eom/vflkib-more-fauci-b.s.-vaccinated-americans-still-cant-eat-indoors.html)

49: [https://rumble.com/vlt9b1](https://rumble.com/vlt9b1) -dr.-anthony-fauci-fully-vaccinated-people-carry-as-much-virus-as-

unvaccinat.html

50: [https://rumble.com/vmgq6o-fauci-demands-vaccine-mandate-for-air-travel-and-public-schools.html](https://rumble.com/vmgq6o-fauci-demands-vaccine-mandate-for-air-travel-and-public-schools.html)

51: [https://www.bitchute.com/video/OQBSOIAIrXEa/](https://www.bitchute.com/video/OQBSOIAIrXEa/)

52: [https://www.stopworldcontrol.com/downloads/en/vaccines/vaccines-harm.pdf](https://www.stopworldcontrol.com/downloads/en/vaccines/vaccines-harm.pdf)

53: https://www.nbcnews.com/science/science-news/cdc-warns-internal-document-war-has-changed-

coronavirus-nl 275478

54: [https://rumble.com/vmhl](https://rumble.com/vmhl) er-we-need-to-prepare-to-live-with-covid-boosters-australia.html

55: [https://nypost.eom/2020/11/24/moderna-boss-says-covid-shot-not-proven-to-stop-virus-spread/](https://nypost.eom/2020/11/24/moderna-boss-says-covid-shot-not-proven-to-stop-virus-spread/)

56: [https://rumble.com/vjs9ef-australias-new-world-order-began-july-10-2021](https://rumble.com/vjs9ef-australias-new-world-order-began-july-10-2021) .html

57: [https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733)

58: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7031](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031) e2.htm?s_cid=mm7031 e2_


-----

59: [https://rumble.com/vn5us5-30000-canadian-doctors-protest-vaccine-mandates.html](https://rumble.com/vn5us5-30000-canadian-doctors-protest-vaccine-mandates.html)

60: https://newsnationusa.com/news/usanews/83000-hospital-workers-could-be-fired-as-new-york-covid-

vaccine-mandate-goes-into-effect/

61: [https://www.visiontimes.com/2021/06/25/the-majority-of-american-physicians-remain-unvaccinated.html](https://www.visiontimes.com/2021/06/25/the-majority-of-american-physicians-remain-unvaccinated.html)

62: [https://www.latimes.com/california/story/2021](https://www.latimes.com/california/story/2021) -06-19/vaccination-rates-lag-among-california-public-safety-

workers-drawing-concern

63: [https://rumble.com/vmh8gx-covid-injections-indeed-change-the-human-dna.html](https://rumble.com/vmh8gx-covid-injections-indeed-change-the-human-dna.html)

63A: [https://www.roxytube.com/watch/hybrid-transhuman-black-eyed-baby_Lznw1](https://www.roxytube.com/watch/hybrid-transhuman-black-eyed-baby_Lznw1) XMWmlJWQyZ.html

63B: [https://www.orwell.city/2021/09/black-eyed-babies.html](https://www.orwell.city/2021/09/black-eyed-babies.html)

64: [https://rumble.com/vmk9yn-alarm-humans-with-modified-dna-have-no-rights-and-are-patented.html](https://rumble.com/vmk9yn-alarm-humans-with-modified-dna-have-no-rights-and-are-patented.html)

65: [https://www.bitchute.com/video/hyOI\/lxQK4uQIR/](https://www.bitchute.com/video/hyOI//lxQK4uQIR/)

66: drrobertyoung.com/post/science-team-reveals-graphene-aluminum-lnp-capsids-peg-parasites-in-4-cov-

vaccines

67: drrobertyoung.com/post/transmission-electron-microscopy-reveals-graphene-oxide-in-cov-19-vaccines

68: [https://www.stopworldcontrol.com/downloads/en/vaccines/nanotech-vaccines.pdf](https://www.stopworldcontrol.com/downloads/en/vaccines/nanotech-vaccines.pdf)

68A: [https://rumble.eom/vn482j-dr.-carrie-madej-first-u.s.-lab-examines-vaccine-vials-horrific-findings-re.html](https://rumble.eom/vn482j-dr.-carrie-madej-first-u.s.-lab-examines-vaccine-vials-horrific-findings-re.html)

68B: [https://www.bitchute.com/video/TtgkYxzmsHSJ/](https://www.bitchute.com/video/TtgkYxzmsHSJ/)

69: [https://www.bitchute.com/video/UBFi2Xt4d2oR/](https://www.bitchute.com/video/UBFi2Xt4d2oR/)

69A: https://www.drrobertyoung.com/post/transmission-electron-microscopy-reveals-graphene-oxide-in-cov-

19-vaccines

69B: [https://www.youtube.com/watch?v=s8e06KfDWI\/ll\/l](https://www.youtube.com/watch?v=s8e06KfDWI//ll//l)

69C: https://rumble.com/vnbgal-never-before-seen-blood-doctor-reveals-horrific-findings-after-examining-

vi.html

70: https://www.tijd.be/politiek-economie/belgie/federaal/nieuw-gemor-over-belgische-rapportering-

coronadoden/10220849.html

71: [https://www.bitchute.com/video/iP2eQxEwQI5h](https://www.bitchute.com/video/iP2eQxEwQI5h)

72: [https://www.sto](https://www.sto) pwo rl dco ntro I .co m/fu 11

73: [https://www.stopworldcontrol.com/nl/elke-de-klerk/](https://www.stopworldcontrol.com/nl/elke-de-klerk/)

74: [https://www.youtube.com/watch?v=g5f_6ltv7ol&t=8s](https://www.youtube.com/watch?v=g5f_6ltv7ol&t=8s)

75: [https://www.globalresearch.ca/hospitals-getting-paid-more-label-cause-death-coronavirus/5709720/amp](https://www.globalresearch.ca/hospitals-getting-paid-more-label-cause-death-coronavirus/5709720/amp)

76: [https://www.stopworldcontrol.com/media/](https://www.stopworldcontrol.com/media/)

77: [https://www.stopworldcontrol.com/media/](https://www.stopworldcontrol.com/media/)

78: https://nationalfile.com/doctor-wants-to-be-scary-to-the-public-and-inflate-covid-numbers-if-you-dont-get-

vaccinated-you-know-youre-going-to-die/

79: [https://www.youtube.com/watch?v=UIDsKdeFOmQ](https://www.youtube.com/watch?v=UIDsKdeFOmQ)

80: [https://www.sto](https://www.sto) pwo rl dco ntro I .co m/d i recto r

81: [https://educate-yourself.org/cn/flu1918andnow07feb04.shtml](https://educate-yourself.org/cn/flu1918andnow07feb04.shtml)

82: [https://salmartingano.com/2020/05/the-1918-spanish-flu-only-the-vaccinated-died/](https://salmartingano.com/2020/05/the-1918-spanish-flu-only-the-vaccinated-died/)

83: [https://www.sciencedirect.com/science/article/abs/pii/S1477893920302179?via%3Dihub](https://www.sciencedirect.com/science/article/abs/pii/S1477893920302179?via%253Dihub)

84: [https://artsencollectief.nl](https://artsencollectief.nl) / [https://zelfzorgcovid19.nl/](https://zelfzorgcovid19.nl/)


-----

85: https://techstartups.com/2020/04/05/new-updates-dr-vlaclimir-zelenko-cocktail-hyclroxychloroquine-zinc-

sulfate-azithromycin-showing-phenomenon-results-900-coronavirus-patients-treated-must-watch-video

86: [https://thezelenkoprotocol.com/](https://thezelenkoprotocol.com/)

87: [https://americasfrontlinedoctors.org/treatments/hydroxychloroquine/science-of-hcq](https://americasfrontlinedoctors.org/treatments/hydroxychloroquine/science-of-hcq)

88: [https://www.sciencedirect.com/science/article/pii/S0924857920304258](https://www.sciencedirect.com/science/article/pii/S0924857920304258) /

89: [https://c19hcq.com/](https://c19hcq.com/)

90: [https://ivmmeta.com](https://ivmmeta.com)

91: [https://covid.us.org/2021](https://covid.us.org/2021) /01 /28/ivermectin-safe-effective-covid-19/

92: [https://brandnewtube.com/watch/dr-mccullough-shares-is-hcq-truly-safe-for-covid-](https://brandnewtube.com/watch/dr-mccullough-shares-is-hcq-truly-safe-for-covid-)

19_FoRTpkTw6EKrlz.html

93: [https://www.stopworldcontrol.com/cds](https://www.stopworldcontrol.com/cds)

94: [https://comusav.com](https://comusav.com)

95: [https://andreaskalcker.com](https://andreaskalcker.com)

96: https://www.eldiestro.es/2021/06/del-no-tendras-nada-y-seras-feliz-pasamos-al-las-maquinas-leeran-

nuestros-pensamientos-e-insertaran-incluso-sentimientos-ya-que-eso-es-algo-a-lo-que-aspiramos-todos/

97: https://www.forbes.com/sites/worldeconomicforum/2016/11/10/shopping-i-cant-really-remember-what-

that-is-or-how-differently-well-live-in-2030/amp/?sh=3a2b52dd1735&_twitter_impression=true

98: [https://grolltex.com/the-future-of-graphene-and-5g/](https://grolltex.com/the-future-of-graphene-and-5g/)

99: [https://graphene-flagship.eu/innovation/spearheads/c2-sh01](https://graphene-flagship.eu/innovation/spearheads/c2-sh01) -5g/

100: [https://www.tandfonline.eom/doi/full/10.1080/03602559.2018.1542714](https://www.tandfonline.eom/doi/full/10.1080/03602559.2018.1542714)

101: https://www.naturalnews.com/2021-07-19-graphene-based-neuromodulation-technology-is-real-inbrain-

neuroelectronics.html

102: [https://www.academia.edu/35846430/The_Fourth_lndustrial_Revolution_Klaus_Schwab](https://www.academia.edu/35846430/The_Fourth_lndustrial_Revolution_Klaus_Schwab)

103: https://rumble.com/vmb1vd-new-world-order-announced-by-aussie-health-overlords-then-fact-checkers-

spr.html

104: [https://rumble.com/vmaand-australian-health-official-talks-about-new-world-order.html](https://rumble.com/vmaand-australian-health-official-talks-about-new-world-order.html)

105: [https://rumble.com/vlbbOg-australian-news-says-new-world-order-will-come-into-force-at-midnight.html](https://rumble.com/vlbbOg-australian-news-says-new-world-order-will-come-into-force-at-midnight.html)

106: [https://rumble.com/vlbay8-australian-news-broadcast-declares-new-world-order-in-effect.html](https://rumble.com/vlbay8-australian-news-broadcast-declares-new-world-order-in-effect.html)

107: [https://rumble.com/vjstsv-australia-new-world-order.html](https://rumble.com/vjstsv-australia-new-world-order.html)

[108:https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0-2017~l\/lain%20Features~Deaths](https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%2520Subject/3303.0-2017%7El//lain%2520Features%7EDeaths)

%20due%20to%20influenza~5

109: [https://www.zachvorhies.com/](https://www.zachvorhies.com/)

110: [https://www.geoengineeringwatch.org/](https://www.geoengineeringwatch.org/)

111: [https://patents.google.com/patent/US5357865A/en](https://patents.google.com/patent/US5357865A/en)

112: [https://www.vaticannews.va/en/pope/news/2021](https://www.vaticannews.va/en/pope/news/2021) -08/pope-francis-appeal-covid-19-vaccines-act-of-

love.html

113: https://www.breitbart.eom/national-security/2021/03/15/pope-francis-calls-for-new-world-order-after-the-

pandemic/


-----

**Evidence** **that** **graphene** **oxide** **is** **in** **the** **vaccines:**

[https://stateofthenation.co/?p=70400](https://stateofthenation.co/?p=70400)

[https://rumble.com/vjk0u1](https://rumble.com/vjk0u1) -breaking-astrazeneca-vaccine-vials-examined-by-researchers-confirm-toxic-po.html

[https://rumble.com/vjgmj9-breaking-discovery-the-actual-contents-insicle-pfizer-vials-exposecl.html](https://rumble.com/vjgmj9-breaking-discovery-the-actual-contents-insicle-pfizer-vials-exposecl.html)

[https://rumble.com/vkgdq7-deadly-shots-former-pfizer-employee-confirms-poison-in-covid-vaccine.html](https://rumble.com/vkgdq7-deadly-shots-former-pfizer-employee-confirms-poison-in-covid-vaccine.html)

[https://www.orwell.city/2021/07/andreas-kalcker.html](https://www.orwell.city/2021/07/andreas-kalcker.html)

[https://rumble.com/vk7lap-andreas-kalckers-team-confirms-evidence-of-graphene-oxide-in-vaccines.html](https://rumble.com/vk7lap-andreas-kalckers-team-confirms-evidence-of-graphene-oxide-in-vaccines.html)

[https://www.orwell.city/2021/07/absorption-signal.html](https://www.orwell.city/2021/07/absorption-signal.html)


-----

